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Editorial on the Research Topic
Ethnopharmacology in Central and Eastern Europe in the Context of Global
Research Developments
Historically, medicinal plants have been a key element of healthcare, and are still widely used as
alternative and complementary therapy (mainly in developed countries) or as a primary treatment
(in most developing countries). Moreover, many of the modern pharmaceuticals were developed
from molecules extracted from natural sources, and medicinal plants still today represent an
important pool for the identification of novel drug leads.
The ethnopharmacological tradition in Central and Eastern Europe has a great historical
significance and large parts of the Western world’s knowledge for therapeutic properties of
medicinal plants has its roots in the Greek and Roman cultures (e.g., with a reference to the
influential works of Dioscorides, Pliny the Elder, and Galen). The German-speaking Central
European areas also have played very important roles, with some influential medieval herbal
book editions such as the Mainz Herbal (Herbarius Moguntinus, 1484) and The German Herbal
(1485). Moreover, at the beginning of the nineteenth century modern drug discovery from plants
started to played a key role in Central Europe, most notably the work of the German apothecary
assistant Friedrich Sertürner, who isolated an analgesic and sleep-inducing agent from opium that
was named morphium (morphine) after the Greek god of dreams, Morpheus. At the same time,
it should be noted that on many occasions the rich ethnopharmacological knowledge of some
East European countries and Russia remained localized and did not find its way to integrate with
the Western world of herbal therapy traditions. The focus of this Research Topic is to make a
special contribution to ethnopharmacology rooted in Central and Eastern Europe, on the context
of global research developments in the area of ethnopharmacology, phytochemistry, molecular
pharmacology of natural products, nutrigenomics, and other related disciplines. This special issue
consists of 24 articles covering diverse topics related to the listed research fields.
Advances in screeningmethods and analytical equipment, increasing number of targets available
for testing, and improved possibilities for optimization of natural leads using syntheticmodification
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strategies substantially improved the process of modern
drug discovery from natural sources (Atanasov et al., 2015).
Hypericum is a well-known genus that is used for its medicinal
properties. Tocci et al. evaluated five Hypericum species for
their polyphenolic content, toxicological safety, and antifungal
potential against some sensitive and drug resistant clinical
fungal isolates. The authors have identified 52 compounds
by LC-MS analysis and showed that H. hircinum subsp.
majus infusion exerted broad antifungal activity against
Aspergillus, Penicillium, and non-albicans Candida strains
(Tocci et al.).
Ethnobotany has played an important role in new drug
development and drug discovery (Kayser, 2018). The importance
of the traditional use of medicinal plants on the Greek islands of
the North Aegean Region was summarized in a Brief Research
Report Article by Axiotis et al. In this report the authors present
109 wild plants from 52 families, and enlist their therapeutic uses,
including uses in galenic preparations which were reported by
local medical doctors and pharmacists (Axiotis et al.).
Medicinal plants and natural products are of potential
importance in several age-related disorders, including memory
impairment and dementia (Tewari et al., 2018). In this research
topic Dimpfel et al. assessed the biological activity of some
commercial extracts of the underground parts of Rhodiola rosea
L. and its analytical markers, salidroside and rosavin, using long-
term potentiation of synaptic transmission in hippocampus slices
(a synaptic model of memory).
Loeser et al. evaluated the effect of Casperome R©, an orally
bioavailable soy lecithin-based formulation of standardized
frankincense extract on various systemic parameters and organ
damages that were induced by severe systemic inflammation
caused by intraperitoneal administration of lipopolysaccharides
(a murine model of sepsis). The study revealed that the extract
possesses anti-inflammatory, anti-oxidant, and hepatoprotective
effects (Loeser et al.).
Zielin´ska et al. review older and recent data on pharmacology,
phytochemistry, and clinical studies of Chelidonium majus L.
along with controversies about this herb, its safety, and drug
quality issues.
The study of Wozniak et al. evaluated the effects of
phytochemically characterized extracts of various parts of
traditionally used Syringa vulgaris L. (common lilac) on the
pro-inflammatory functions of neutrophils. The authors also
isolated active compounds, including neooleuropein from the
extracts using bioassay-guided fractionation. It was found that
neooleuropein acts through inhibition of cytokine production by
attenuation of the MAP kinase pathways (Woz´niak et al.).
Smooth muscle cells are a prominent target of diverse natural
products with different bioactivities (Hnatyszyn et al., 2003;
Uhrin et al., 2018). Sándor et al. assessed the relaxant effects
or contracting activity of the hydroethanolic extract, fractions,
phytoconstituents, and essential oil of Roman chamomile on
smoothmuscle preparations. The authors found that the essential
oil of the plant possessed a good smooth muscle-relaxant effect
(Sándor et al.).
Identification of the molecular mechanism of action of
promising natural products is a vital step toward their
clinical application (Butler, 2008; Tewari et al., 2018). In a
mechanistic study, Celin´ska-Janowicz et al. studied the apoptosis-
inducing mechanisms of selected propolis components in tongue
squamous cell carcinoma cells (CAL-27). In another work,
Grienke et al. isolated several flavonoids and rare sesquiterpene
lactones from the ethanolic extract of Centaurea ragusina L., a
plant species endemic to Croatia. For the first time they identified
ragusinin, and hemistepsin A from this genus. The authors
further studied the mechanism underlining the ragusinin activity
in cancer cells (Grienke et al.).
In their review article Kozlowska et al. summarize the herbal
medicines used in the Beskid mountain ranges, which are located
south of Krakow and Lviv, two important medieval centers of
apothecary tradition in the area. In another interesting review
Kunnumakkara et al. summarize potential benefits, traditional
uses, chemistry, biological activities, and clinical trials of “guggul”
from Commiphora and Boswellia.
Berberine is an important phytoconstituent of plants utilized
in different traditional medicine systems, including the Chinese
system of traditional medicine (Huang et al., 2011). In their work
“Berberine: Botanical Occurrence, Traditional Uses, Extraction
Methods, and Relevance in Cardiovascular, Metabolic, Hepatic,
and Renal Disorders” Neag et al. review diverse biomedical
information on berberine, including several chromatographic
techniques for berberine extraction and quantification.
There is great interest of the scientific community toward
the health benefits of food items used in the Mediterranean
diet, which has a variety of health benefits (Sofi et al., 2010).
Wang et al. review recent studies on pomegranate, mainly
focusing on vasculoprotective effects attributed to diverse
pomegranate phytoconstituents, including tannins, especially
ellagitannins, and ellagic acid, among other compounds.
Lycopene is a carotenoid which is responsible for different
pigmentation in tomatoes, grapefruit, and watermelon, and it
represents a compound with a potent antioxidant action (Horvitz
et al., 2004). In their work, Mozos et al. review mechanisms
of action of lycopene on the vascular system considering
substantial epidemiological and experimental data, and
clinical studies.
Breast cancer is the most common cancer in women and
represents a global health burden both in the developed and
developing countries. Hong et al. study apigenin and luteolin to
better understand their mechanism of action in the context of
breast cancer intravasation of the lymphatic barrier. Both of these
natural compounds were evaluated in a three-dimensional assay
system containing MDA-MB231 breast cancer spheroids and
immortalized lymph endothelial cell monolayers (Hong et al.)
Toiu et al. evaluated the chemical composition, antimicrobial,
antioxidant, and in vivo anti-inflammatory activity of various
extracts of the aerial parts of an important plant species with
traditional use in Romanian, Ajuga laxmannii (Murray) Benth.
In their work, Shikov et al. review 70 wild plant species that
are referenced in the 11th edition of the State Pharmacopeia of
the USSR and also discuss their health food value, mainly based
on published Russian literature.
Marchelak et al. present a comprehensive study focused
on extracts of the flowers of Prunus spinosa L. The authors
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profiled the phenolic contents of the extracts through
UHPLC-PDA-ESI-MS3, and also studied several biological
effects with relevance in the context of cardiovascular disease
(Marchelak et al.).
Chowdhury et al. explore the anti-proliferative and anti-
metastatic potential of various extracts of the medicinal plant
colocynth. The authors have found that ethanol and acetone
extracts of colocynth fruit pulp exhibit promising activity in
different cancer cell types, inhibiting viability, and cell migration
in association with the modulation of the expression of diverse
relevant genes and cellular pathways (Chowdhury et al.).
Ononis natrix is a member of the Fabaceae family and is a less-
explored plant species. In their work, Yerlikaya et al. give new
insight on the chemical composition and biological activities of
Ononis natrix subsp. hispanica.
Wang et al. identify and characterize the natural product
falcarindiol as a novel inducer of macrophage cholesterol eﬄux,
a process with a protective effect in atherosclerosis.
In their research paper, Raclariu et al. establish DNA
metabarcoding and HPLC-MS techniques for the authentication
of Veronica officinalis L. herbal products. The authors advocate
for the use of an integrative approach for the detection of
adulteration and substitution in the herbal products (Raclariu
et al.).
López et al. study the effects of lavender essential oil on
pharmacological targets that are involved in anti-depressive and
anxiolytic effects, as well as on in vitromodels of neurotoxicity.
Lewenhofer et al. performed an activity-guided identification
of active principles from Scrophularia lucida L. using cancer cell
models. The authors identified 14 substances including some very
rare iridoids, like scrovalentinoside or koelzioside, and flavonoids
such as nepitrin and homoplantaginin (Lewenhofer et al..)
In conclusion, this Research Topic includes a wide range of
interdisciplinary research work contributing to the ultimate goals
of augmenting the existing knowledge and fostering the scientific
field of ethnopharmacology in Central and Eastern Europe,
as well as globally. This research topic successfully gathered
comprehensive interdisciplinary information in the field of
ethnopharmacology from the field surveys to standardization
and elucidation of molecular mechanisms of action of natural
products. Moreover, with consideration of the existing challenges
in the field of drug discovery formmedicinal plants, this research
topic provides up-to-date snapshot of current knowledge and
paves the way for further chemical and biological assessment of
diverse natural compounds with potential for future therapeutic
development. We hope that this compendiumwill further inspire
scientists from different research fields to make use of the
gathered traditional medical knowledge in the search for superior
future remedies from nature.
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Anamaria Brozovic5* and Marijana Radic´ Stojkovic´6*
1 Department of Pharmacognosy, University of Vienna, Vienna, Austria, 2 Department of Biology, Faculty of Science,
University of Zagreb, Zagreb, Croatia, 3 Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria,
4 Division of Molecular Medicine, Rud¯er Boškovic´ Institute, Zagreb, Croatia, 5 Division of Molecular Biology, Rud¯er Boškovic´
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The endemic Croatian species Centaurea ragusina L., like other species from the genus
Centaurea, has been traditionally used in Croatia as an antibacterial agent and for the
treatment of gastrointestinal and urogenital disorders. In several chromatographic steps,
three flavonoids and three sesquiterpene lactones (STLs) were isolated and identified
from the most active fractions of the ethanol extract. Two STLs, one for which we
created the trivial name ragusinin, and hemistepsin A are here reported for the first
time as constituents of the genus Centaurea. All six compounds were screened for
their effect on several tumor and one normal cell lines. Among them, ragusinin showed
the best bioactivity and high specificity to affect tumor murine SCCVII, human HeLa
and Caco-2 cell lines, but not the viability of normal V79 fibroblasts. Due to these
characteristics the action of ragusinin was investigated in more detail. Since DNA is
the primary target for many drugs with antibacterial and anticancer activity, we studied
its interaction with ragusinin. Rather moderate binding affinity to DNA excluded it as
the primary target of ragusinin. Due to the possibility of STL interaction with glutathione
(GSH), the ubiquitous peptide that traps reactive compounds and other xenobiotics to
prevent damage to vital proteins and nucleic acids, its role in deactivation of ragusinin
was evaluated. Addition of the GSH precursor N-acetyl-cysteine potentiated the viability
of HeLa cells, while the addition of GSH inhibitor L-buthionine sulfoximine decreased
it. Moreover, pre-treatment of HeLa cells with the inhibitor of glutathione-S-transferase
decreased their viability indicating the detoxifying role of GSH in ragusinin treated cells.
Cell death, derived by an accumulation of cells in a G2 phase of the cell cylce, was
shown to be independent of poly (ADP-ribose) polymerase and caspase-3 cleavage
pointing toward an alternative cell death pathway.
Keywords: Centaurea, sesquiterpene lactones, DNA, cell viability, toxicity, glutathione
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INTRODUCTION
The genus Centaurea (Asteraceae) represents an attractive
source for bioactive secondary metabolites such as sesquiterpene
lactones (STLs), flavonoids, lignans, and their glycosides
(Khammar and Djeddi, 2012). A number of therapeutic effects
against microbial infections, gastrointestinal disorders, and
urogenital ailments have been attributed to Centaurea species in
Croatian folk medicine and worldwide (Pahlow, 1989; Ayad et al.,
2012; Politeo et al., 2012).
Our recent study on the phytochemical and bioactive profile
of non-volatile constituents of Centaurea ragusina L., an endemic
Croatian halophytic species (Radic´ et al., 2013), indicated the
strong potential for obtaining bioactive compounds from the leaf
ethanol extract (CRE) (Vujcˇic´ et al., 2017).
In continuation of this previous study, the aim was to
investigate the biological activity of all isolated compounds,
namely the interaction with DNA, the antibacterial activity
against Gram-positive (Staphylococcus aureus) and Gram-
negative bacteria (Acinetobacter baumannii) (Lee et al., 2007;
C´urkovic´-Perica et al., 2015) and anticancer activity against a
panel of murine and human cancer cells.
Due to its high biological significance, DNA is the primary
target for many drugs with antibacterial and anticancer activity.
Small organic molecules can bind to DNA by means of a
non-specific, electrostatic binding along the DNA backbone, a
specific groove binding and intercalation or can form crosslinks
with DNA strands and induce cleavage of the DNA backbone
(Demeunynck et al., 2002; Sangeetha Gowda et al., 2014).
STLs are known to bind covalently to sulfhydryl groups of
enzymes and other functional proteins by Michael type addition
of their electrophilic α, β-unsaturated carbonyl structures. It is
believed that most of STL biological effects are due to their
reaction with biological nucleophiles such as GSH (Kupchan
et al., 1971; Picman, 1986; Schmidt, 1999). Among many roles of
GSH in the cell, the most important one seems to be the removal
of reactive species and elimination of xenobiotic compounds. The
last one can be accomplished through conjugation with GSH
followed by secretion of adducts from the cell (Boyland and
Chasseaud, 1969).
Here, the aim was to study the activity of the most bioactive
compound in more detail, which included the interaction with
DNA as the potential primary target and the interaction with
GSH and its impact on cytotoxicity, cell cycle and cell death.
MATERIALS AND METHODS
All safety precautions were taken when working with chemicals
reagents used in the experiments.
General Experimental Procedures
1D and 2D NMR experiments were performed on an Avance
500 MHz instrument equipped with cryoprobe (Bruker,
Billerica, MA, United States). The samples were measured in
MeOD and DMSO-d6, respectively (calibrated to the residual
non-deuterated solvent signals). HR-ESI-MS analyses were
performed on a maXis HD ESI-Qq-TOF mass spectrometer
(Bruker Daltonics, Bremen, Germany). The ESI ion source was
operated as follows: capillary voltage: 2.0 to 4.5 kV (individually
optimized), nebulizer: 0.4 bar (N2), dry gas flow: 4 L min−1 (N2)
and dry temperature: 200◦C, scanning range, m/z 50–1550. For
each isolated compound, fragment ion spectra of the [M+H]+,
the [M+Na]+ and either the [M-H] − or the [M+HCOO]− ion
were recorded. The sum formulas of the ions were determined
using Bruker Compass DataAnalysis 4.2 based on the mass
accuracy (1m/z ≤ 2 ppm for MS1 and≤ 3 ppm for MS/MS) and
isotopic pattern matching (SmartFormula algorithm).
Column chromatography (CC) was performed using
Merck silica gel 60 (40–63 µm) and Pharmacia Sephadex
LH-20 (20–100 µm). The fractions obtained from all
chromatographic steps were analyzed by TLC (mobile phase:
CH2Cl2-EtOAc (85:15), n-hexane-EtOAc-CH3COOH (6:3:1),
or n-hexane-EtOAc (8:2); stationary phase: Merck silica gel
60 PF254, detected with staining reagents vanillin/H2SO4 at
vis, UV254, and UV366). HPLC was performed on a Shimadzu
UFLC-XR instrument (Kyoto, Japan) with a photodiode array
detector (DAD). LC-parameters: stationary phase: Phenomenex
Gemini-NX (C18), 150 mm × 3.00 mm, 5 µm; temperature:
35◦C; mobile phase: water with 0.1% formic acid (A); acetonitrile
(B); flow rate 0.4 mL/min; UV detection wavelength: 275 nm;
injection volume: 10 µL; gradient: 80/20 A/B in 5 min to 70/30
A/B, then within 20 min to 50/50 A/B and within another 2 min
to 2/98, followed by a 5 min column wash (2A/98B) and a
re-equilibration period of 10 min. All chemicals and solvents
used were of analytical grade.
Plant Material
Centaurea ragusina L. plants (in vegetative phase) were collected
in September, 2016, from two wild habitats – Katalinic´ brig
(43◦30′03′′N, 16◦26′40′′E, 363 m) and Sustipan (43◦30′04′′N,
16◦25′35′′E, 754 m), Split, Croatia and identified by M. Rušcˇic´,
Department of Biology, University of Split, Croatia. A voucher
specimen (FSS-CR112016) is deposited at the above-mentioned
department.
For extract preparation and isolation of pure compounds,
lyophilized leaf materials from both locations were combined
after confirmation of their comparable metabolite profile (Vujcˇic´
et al., 2017).
Extraction and Isolation
The dried ground leaves of C. ragusina L. (804.9 g) were
macerated with 7 L EtOH 96% (at 22◦C for 7 days). For an
exhaustive extraction the procedure was repeated three times.
The dried extract (CRE, 108.9 g) was roughly fractionated by
silica gel CC (Merck silica gel 60 PF254, 510 g; 5.5 cm × 56 cm)
using a step gradient of CH2Cl2-EtOAc-MeOH (CH2Cl2;
CH2Cl2-EtOAc 98:2; 95:5; 90:10; 85:15; 80:20; 75:25; 65:35; 60:40;
55:45; 45:55; 35:65; 25:75; EtOAc; EtOAc-MeOH 80:20; 60:40;
40:60; 20:80; MeOH) to give twelve fractions (A1–12).
Fraction A6 (2.9 g) was further separated using silica gel CC
(Merck silica gel 60 PF254, 213 g; 3 cm× 56 cm) applying again a
gradient system of CH2Cl2-EtOAc-MeOH to yield 25 fractions
(B1–25). Fraction B11 (91.6 mg) was purified via Sephadex
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LH-20 CC (mobile phase: MeOH) yielding eight fractions (C1–8).
Fraction C7 was obtained as 17.5 mg of compound 2 (oroxylin A).
Also Fraction B12 (76.4 mg) was purified via Sephadex LH-20 CC
(mobile phase: MeOH) yielding 14 fractions (D1–14). Fraction
D13 was obtained as 11.8 mg of compound 1 (chrysin).
Fraction B19 (939.8 mg) was subjected to silica gel CC
(Merck silica gel 60 PF254, 310 g; 3.3 cm× 63 cm) eluting with
the isocratic solvent system of n-hexane-EtOAc-CH3COOH
(6:3:1), yielding 14 fractions (E1–14). Fraction E9 (26.9 mg) was
further separated by means of a Sephadex LH-20 column (mobile
phase: MeOH) to give three fractions (F1–3). Fraction F2 was
obtained as 21.8 mg of compound 5 [(3aR,4S,6aR,8S,9aR,9bR)-
[dodecahydro-8-dihydroxy-3,6,9-tris(methylene)-2oxo-2(3H)-
azuleno[4,5-b]furanyl]-3-methyl-butanoate].
Fraction A8 (834.3 mg) was separated via a Sephadex
LH-20 column (mobile phase: MeOH) giving seven fractions
(G1-7). Fraction G7 was obtained as 80.3 mg of compound
3 (hispidulin). Fraction G4 (339.4 mg) was submitted to
passage over a Sephadex LH-20 column (mobile phase: CH2Cl2-
acetone, 85:15) to yield twelve fractions (H1-12). Fraction H10
(251.4 mg) was further separated using silica gel CC (Merck
silica gel 60 PF254, 150 g; 1.5 cm × 56 cm) applying again
a gradient system of n-hexane-EtOAc-CH3COOH (6:3:1 to
4:5:1) to yield ten fractions (I1-10). Fraction I9 (185.8 mg)
was subjected to a Sephadex LH-20 column (mobile phase:
MeOH) resulting in three fractions (J1-3). Fraction J1 (17.8 mg)
was purified by silica gel CC (Merck silica gel 60 PF254,
50 g; 1.5 cm × 35 cm) applying again a gradient system of
CH2Cl2-EtOAc-MeOH to yield two fractions (K1-2). Fraction
K1 was obtained as 3.4 mg of compound 4 (deacylcynaropicrin).
Fraction J2 (153.6 mg) was purified by preparative TLC (Merck
silica gel 60 PF254, 20 cm × 20 cm) and a solvent system
of n-hexane-EtOAc-CH3COOH (5:4:1) to yield three fractions
(L1-3). Fraction L2 (115.7 mg) was separated via a Sephadex
LH-20 column (mobile phase: MeOH) giving two fractions
(M1-2). Fraction M2 was obtained as 12.7 mg of compound 6
(hemistepsin A).
The physical and spectroscopic data of compounds 1 to 6
agreed with those published previously for chrysin, oroxylin
A, hispidulin, deacylcynaropicrin, [3aR,4S,6aR,8S,9aR,9bR)-
[dodecahydro-8-dihydroxy-3,6,9-tris(methylene)-2oxo-2(3H)-
azuleno[4,5-b]furanyl]-3-methyl-butanoate], and hemistepsin A
(Miyase et al., 1985; Zdero et al., 1989; Jang et al., 1999; Nagao
et al., 2002; Marques et al., 2010; Yang et al., 2013). Their purity
was checked using TLC and LC-MS and revealed to be > 98% in
all cases.
Spectroscopic Experiments for the
Determination of ctDNA Interactions
The electronic absorption spectra (UV/Vis) were recorded on a
Varian Cary 100 Bio spectrophotometer (Agilent, Santa Clara,
CA, United States) and circular dichroism (CD) spectra on a
JASCO J815 spectrophotometer (ABL&E Handels GmbH, Wien,
Austria) at 25◦C using appropriate 1 cm path quartz cuvettes
(Eriksson and Nordén, 2001). The calf thymus DNA (ctDNA)
was purchased from Sigma-Aldrich. Isothermal titration
calorimetry (ITC) experiments were performed on a MicroCal
VP-ITC microcalorimeter (MicroCal, Inc., Northampton, MA,
United States) (Chaires, 2006). Origin 7.0 software, supplied
by the manufacturer was used for data analysis. All additional
data of these experiments are provided in the Supplementary
Material.
Antibacterial Assay
Antibacterial activities of C. ragusina L. CRE extract, fractions
and isolated compounds against Gram-negative A. baumannii
Durn (C´urkovic´-Perica et al., 2015) and Gram-positive S. aureus
ATCC 25923 were tested using modified Clinical and Laboratory
Standards Institute (CLSI), broth microdilution (BD) using
2,3,5-triphenyltetrazolium chloride (TTC) (Lee et al., 2007). The
TTC-BD were performed according to the guidelines of the
CLSI using 96-well microplates (Clinical Laboratory Standards
Institute [CLSI], 2007). The bacteria were grown on nutrient
agar (Biolife, Milan, Italy) for 16 h at 36 ± 0.1◦C to obtain
the cultures in log phase of growth. The bacterial biomass was
then suspended in sterile NaCl (0.85% v/v) to give turbidity
equivalent to the McFarland 0.5 standard. Bacterial suspension
(0.1 mL) was transferred to a tube containing 9.1 mL nutrient
broth (Biolife) and 0.8 mL 0.05% TTC to give an inoculum
density of 1 × 106 Colony Forming Units (CFU)/mL. Minimum
inhibitory concentration (MIC) and minimum bactericidal
concentration (MBC) values were determined in triplicates. The
final concentrations for MIC and MBC determination of samples
were 1.9–4000 µg/mL. Other data on antibacterial experiments
are available in the Supplementary Material.
Cytotoxicity Assays and Cell Death
Analysis
Crystal Violet (CV) Assay
Murine melanoma (B16F10) cell lines, human colon carcinoma
(Caco-2) and human breast carcinoma (MCF-7) cell lines were
purchased from American Type Culture Collection (ATCC,
Manassas, VA, United States), murine fibrosarcoma (FsaR) and
murine squamous cell carcinoma (SCCVII) cell lines were
obtained from BC Cancer Research Centre (Vancouver, Canada).
Cells were grown in a humidified atmosphere of 5% CO2,
at 37 ◦C in Roswell Park Memorial Institute (RPMI) 1640
medium supplemented with 10% fetal bovine serum (FBS)
(Sigma-Aldrich, St. Louis, MO, United States). As normal cell
line, the V79 fibroblasts derived from hamster’s lung tissue,
were used. CV protocol (Ivankovic´ et al., 2015) is described in
Supplementary Material.
[3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide] Tetrazolium Reduction (MTT) Assay
Ethacrynic acid (ETA; Sigma-Aldrich) was dissolved in
DMSO (Sigma-Aldrich) and kept at −20◦C. Buthionine
sulfoximine (BSO; Sigma-Aldrich) and N-acetylcysteine (NAC;
Sigma-Aldrich) were dissolved in water, 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide was purchased
by Sigma-Aldrich and dissolved in phosphate-buffered saline
and kept by 4◦C. Human cervical carcinoma HeLa cell line
was obtained from cell culture bank (GIBCO BRL-Invitrogen,
Waltham, MA, United States). The cells were grown as a
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monolayer culture in Dulbecco’s modified Eagle’s medium
(DMEM; Sigma-Aldrich), supplemented with 10% (FBS;
Sigma-Aldrich) in a humidified atmosphere of 5% CO2 at 37◦C
and were sub-cultured every 3–4 days. Cytotoxic activity of the
STL 5 was determined by MTT assay, an assay for assessing cell
viability based on its metabolic activity, modified accordingly
(Mickisch et al., 1990; also in Supplementary Material).
Cell Cycle and Cell Death Analysis
HeLa cells were seeded into tissue culture plates and treated
with different concentrations of the compound during 72 h.
Thereafter, both adherent and floating cells were collected,
washed with PBS and fixed overnight in 70% ethanol at –
20◦C. Fixed cells were treated with RNase A (0.1 mg/mL,
Sigma-Aldrich) for 1 h at room temperature and afterward
stained with propidium iodide (PI; 50 µg/mL, Sigma-Aldrich) for
30 min in the dark. In order to analyze the cell cycle progression,
the DNA content and PI staining were detected by flow cytometry
(FACS Calibur, BD Biosciences, San Jose, CA, United States).
Data were analyzed with ModFit LTTM program (Verity Software
House Inc., Topsham, ME, United States).
Twenty-four hours after the seeding, HeLa cells were treated
with 2, 5, and 10 µM of compound 5. After 48 h, both
adherent and floating cells were collected by centrifugation and
then washed with PBS. The cell suspension was incubated with
Annexin V (BD Biosciences; according to producer’s protocol)
and PI (5 µg/mL, Sigma-Aldrich). Upon 30 min incubation at
room temperature in the dark, the viable, early apoptotic, late
apoptotic/necrotic, and necrotic cell populations were detected
and counted by flow cytometry (BD Biosciences). Data were
analyzed with ModFit LTTM program (Verity Software House
Inc.).
In addition, the specific markers of programmed cell death
were determined, cleavage of Poly (ADP-ribose) polymerase-1
(PARP) and caspase-3, by western blot as described previously
(Brozovic et al., 2013). In short, the 2 h incubation at
room temperature with monoclonal anti-PARP (Santa Cruz
Biotechnology) and polyclonal anti-caspase-3 (anti-Cas-3;
Cell Signaling Technology, Danvers, MA, United States)
antibodies was performed. After washing with 0.01% Tween
20 in PBS and incubation with the corresponding horseradish
peroxidase-coupled secondary antibody (Amersham Pharmacia
Biotech, Munich, Germany), proteins were visualized with
ECL (Amersham Pharmacia Biotech) according to the
manufacturer’s protocol. All membranes were incubated with
anti-extracellular-signal-regulated kinases 1/2 (anti-ERK1/2)
(Santa Cruz Biotechnology) antibody to confirm equal protein
loading. ERK1/2 was used as loading controls since no changes
in total ERK1/2 expression were detected upon exposure of
cells to different drugs (Brozovic et al., 2004; Herraiz et al.,
2011).
Determination of Glutathione Function
The function of intracellular GSH in cell response to STL 5
was investigated by MTT assay. HeLa cells were either pre-
treated overnight with a specific inhibitor, 0.001 mM BSO or
for 2 h with a precursor in GSH synthesis, 5 mM NAC. Both
compounds are frequently used in the manipulation of GSH
level in the cells (Trachootham et al., 2009; Kannan et al.,
2014). Upon pre-treatment with either BSO or NAC, different
concentrations of STL 5 were added and the cytotoxicity effect
of the compounds was determined 72 h later as described
above.
The capacity of GSH to form the detoxification conjugates
through enzymatic reaction with STL 5 was investigated by
pretreatment of HeLa cells with of 5 µg/mL ETA for 2 h and
then with different concentrations of STL 5. The cell survival
was examined 72 h after. The optimal concentrations of used
modulators of GSH synthesis and glutathione S-transferase
reaction were determined previously (Osmak and Eljuga, 1993;
Brozovic et al., 2008; Brozovic et al., 2013).
Statistical Analysis
All results were evaluated using the software package Statistica
12.0 (StatSoft, Tulsa, OK, United States). Results were subjected
to one-way ANOVA for comparison of means and significant
differences were calculated according to Duncan’s multiple range
test. Data were considered statistically significant at P < 0.05.
Different letters indicate significant difference at P < 0.05.
RESULTS
Selection of Plant Material, Extraction,
Fractionation, and First Bioactivity
Assessment
As a starting point for phytochemical investigations, an ethanol
C. ragusina L. leaf extract (CRE) was prepared to obtain a
multicomponent mixture embracing a wide range of secondary
metabolites (Figure 1).
In antibacterial assays, CRE showed moderate antibacterial
effects against S. aureus with MIC of 500 µg/mL and MBC of
2000µg/mL, respectively, and weak activity against A. baumannii
with MIC and MBC values both of > 4000 µg/mL, respectively
(Vujcˇic´ et al., 2017).
In contrast to the moderate antibacterial activity, CRE
exhibited significant effects on all tested murine melanoma
(B16F10), squamous cell carcinoma (SCCVII) fibrosarcoma
(FsaR) cell lines and normal hamster fibroblasts (V79).
At a CRE concentration of 60 µg/mL, the cell survival
relative to the negative control was ≤ 10% for V79 fibroblasts,
SCCVII and FsaR, respectively, and 21% for the B16F10. CRE
did not show selective cytotoxicity between murine cancer and
normal cell lines, which may be a consequence of a cumulative
effect of different bioactive compounds included in the crude
extract.
For a more focused isolation process of the bioactive
constituents of the crude extract, twelve fractions (A1–A12)
obtained by separation of CRE via silica gel chromatography
were retested in the mentioned cell lines, revealing A6 and A8
as fractions with the strongest cytotoxic activity. Both fractions
(60 µg/mL) exhibited stronger cytotoxic activity on B16F10
(< 10% cell survival) and SCCVII (≤ 20% cell survival) cell
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FIGURE 1 | HPLC analysis of the ethanol C. ragusina L. leaf extract (CRE) at 254 nm (for LC parameters see section “Experimental”).
lines compared to the moderate activity observed toward FsaR
and V79 cells (≤ 30% cell survival). Based on these results,
fractions A6 and A8, were selected for further chromatographic
separations.
Isolation and Identification of Pure
Compounds
Six constituents were isolated from CRE fractions A6 and A8 by
separation techniques including CC and preparative thin layer
chromatography.
By using HR-ESI-MS analyses and NMR experiments,
and by comparison with earlier studies (Miyase et al.,
1985; Zdero et al., 1989; Jang et al., 1999; Nagao et al.,
2002; Marques et al., 2010; Yang et al., 2013), the isolates
(Figure 2) were identified as chrysin (1), oroxylin A (2),
hispidulin (3), deacylcynaropicrin (4), (3aR,4S,6aR,8S,9aR,9bR)-
[dodecahydro-8-dihydroxy-3,6,9-tris(methylene)-2oxo-
2(3H)-azuleno[4,5-b]furanyl]-3-methyl-butanoate (5), and
hemistepsin A (6). Instead of using the complicated and long
systematic name for compound 5, we created the trivial
name ragusinin. The flavonoids (1–3) can be classified
as flavones, whereby different substitution patterns with
methoxy or hydroxy groups can be observed on C-6 and
C-4′. Compounds 4–6 are STLs belonging to the subtype of
guajanolides.
FIGURE 2 | Chemical structures of isolated C. ragusina L. leaf constituents.
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Compound 1 is a frequently occurring flavone reported as a
constituent of several Centaurea species (Mouffok et al., 2012).
However, we are reporting here for the first time its isolation
from C. ragusina L. Different bioactivities have been reported
for compound 1. It suppresses inducible nitric oxide synthase,
cyclooxygenase-2 expression and inhibits NF-κB activation,
which altogether leads to anti-inflammatory effects (Feng et al.,
2014). Compound 1 is also reported as a tumor cell growth
arrest compound, arresting C6 glioma cells in the G1 phase of
the cell cycle either through activating p38-MAPK leading to
the accumulation of p21Waf1/Cip1 protein or mediating the
inhibition of proteasome activity (Weng et al., 2005). It also
suppresses tumor growth of anaplastic thyroid cancer ATC cells
both in vitro and in vivo (Yu et al., 2013).
Compound 2 is known as the main component of several
medicinal plants including Oroxylum indicum (Krueger and
Ganzera, 2012) and various Centaurea species. However, so
far it has not been reported for C. ragusina L. Compound 2
was shown to activate caspase-3 and caspase-9 in human colon
carcinoma HCT-116 cells and decrease tumor volume and weight
in immunodeficient mice that were inoculated with HCT-116
cells (Hu et al., 2012). It also exhibits anti-inflammatory effects
by decreasing pro-inflammatory cytokines mediated by estrogen
receptor activity (Wang et al., 2013).
Compound 3 has been isolated from various Centaurea
species, e.g., C. melitensis L. (Negrete et al., 1989), C. aspera L.
(Ferreres et al., 1980), and C. jacea L. (Forgo et al., 2012), but
never from C. ragusina L. It is an important compound used in
traditional Chinese medicine for the treatment of liver carcinoma
(Gao et al., 2014). Besides an apoptotic effect on human liver
cancer HepG2 cells, it was also shown that this effect is mediated
via mitochondrial dysfunction (Gao et al., 2014). Furthermore,
an anti-proliferative effect toward human lung cancer A-549 cells
was reported for compound 3 (Zhang et al., 2012).
Compound 4 has already been reported as a constituent of
C. ragusina L. (Mahmoud et al., 1986) and other Centaurea
species with anti-inflammatory and cytotoxic activity (González
et al., 1977; Sosa et al., 2011).
To the best of our knowledge, guajanolides 5 and 6 have
never been identified as constituents from Centaurea species
before. Whereas for 6 an antibacterial and cytotoxic activity
toward human cell lines in the low µM range has previously
been reported (Jang et al., 1999) compound 5 (ragusinin) with
its isovalerate residue is a rare STL without reports on bioactivity.
Study of Biological Activity (Interactions
With DNA, Antibacterial and Cytotoxic
Activity) of C. ragusina L. Constituents
The DNA binding affinity of compounds is important to explore
since the DNA represents a well-known target of several broadly
used drugs and the binding to DNA is one of the common
causes of cell death (Demeunynck et al., 2002; Sangeetha Gowda
et al., 2014). In order to determine the binding affinity of the
isolated compounds to ctDNA, UV/Vis spectroscopy and ITC
(Bronowska, 2011) were employed (see section “Experimental”
and “Supplementary Material for details”). CD was used for
monitoring of conformational changes of ctDNA induced by
small molecule binding and for gaining information about modes
of interaction (Cantor and Schimmel, 1980; Johnson, 1994).
Among isolated STLs and flavonoids (Supplementary
Material), only 5 exhibited significant changes in CD titrations
(Supplementary Figure S4). Due to that reason, we decided to
characterize the binding of DNA only with compound 5. UV/Vis
spectroscopy was not applicable in the study of DNA-ragusinin
interaction due to absorption of STLs at short wavelengths
(210–220 nm). Therefore, the binding interaction of 5 with
ctDNA was monitored by ITC.
The ITC experiment of 5 with ctDNA resulted in negative
peaks indicating that the binding process was exothermic
(Figure 3). The resulting values were fitted to a single-site binding
model by the non-linear least square method yielding rather
moderate binding constant (log Ka = 4.04). The stoichiometry
(N) was fixed to 0.5 based on results from CD titration with
ctDNA (the saturation of binding sites was reached at the
ratio, r = 0.5, Supplementary Material). The binding of 5 to
ctDNA was characterized by a positive binding entropy (T1rS/kJ
mol−1 = 18.5) accompanied by smaller negative enthalpy
(1rH/kJ mol−1 = -4.6) revealing that its binding is entropically
driven. In many cases, the groove binding is associated with
positive (favorable) binding entropies due to the release of
FIGURE 3 | Calorimetric titration of compound 5 (c = 3 × 10−5 mol dm−3)
with ctDNA (c = 1.5 × 10−3 mol dm−3) in sodium cacodylate buffer (pH 7.0,
I = 0.05 mol dm−3; T = 25◦C; 1rG/kJ mol−1 = -23.0). The top panels
represent the raw data from the single injection of ctDNA into a solution of 5
and the bottom panels show the experimental injection heats while the solid
lines represent the calculated fit of the data.
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FIGURE 4 | Percentage of cell survival of rodent (V79, SCVII, B16F10, and FsaR) and human (Caco-2, HeLa, and MCF-7) cell lines after exposure to isolated
flavonoids (compounds 1–3), at concentrations of 10 µM (gray bars) and 5 µM (white bars). Values represent mean of 3 replicates ± SD. Different letters indicate
significant difference at p < 0.05. The dashed line indicates inhibition of cell growth by 50%. The positive control is 5-fluorouracil and the negative control are cells
without the tested samples.
Frontiers in Pharmacology | www.frontiersin.org August 2018 | Volume 9 | Article 97215
fphar-09-00972 August 21, 2018 Time: 8:18 # 8
Grienke et al. Centaurea ragusina L. Isolates’ Bioactivity
FIGURE 5 | Percentage of cell survival of murine (V79, SCVII, B16F10, and FsaR) and human (Caco-2, HeLa, and MCF-7) cell lines after exposure to
deacylcynaropicrin (4), ragusinin (5) and hemistepsin A (6) at concentrations of 10 µM (gray bars) and 5 µM (white bars). Values represent means of three
replicates ± SD. Different letters indicate significant difference at p < 0.05. The dashed line indicates inhibition of cell growth by 50%. The positive control is
5-fluorouracil and the negative control are cells without the tested samples.
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FIGURE 6 | Survival of HeLa cells following treatment with ragusinin (5). The
cells were treated for 72 h with different doses of 5. The MTT assay was
performed. Each point represents the mean of quadruplicates ± SD. Different
letters indicate significant difference at p < 0.05. The experiment is performed
at least three times.
confined or interfacial water molecules to the bulk (Perozzo et al.,
2004; Chaires, 2006).
Two STLs 5 and 6 were found to be the most active
ones reducing the growth of S. aureus with a MIC value of
31.3 µg/mL (Supplementary Table S1). However, since the
cytotoxic activity of the isolated compounds was more prominent
than the antibacterial, we presented here cytotoxic activity in
more detail while the data on antibacterial activity are available
in the Supplementary Material.
Crystal Violet (CV) bioassay, which measures the DNA mass
of living cells, was used for initial activity screening. The cytotoxic
effect of the isolated compounds 1 to 6 was monitored with the
CV test for 24 h at 5 and 10 µM on a panel of three murine
and three human cancer cell lines. 5-Fluorouracil was used as
a positive control at equimolar concentrations as the studied
compounds (Figures 4, 5). The isolated flavonoids 1 and 2 did
not demonstrate cytotoxic activity against the majority of cancer
cell lines at the applied concentrations. Only compound 3 exerted
a noticeable cytotoxic effect against HeLa cells (Figure 4). Among
the isolated STLs, 5 showed the most prominent cytotoxic
activity. In particular, compound 5 reduced the cell survival of
SCCVII cells to 42% at 10 µM and 50% at 5 µM concentration
(Figure 5). It also exhibited promising activity against Caco-2
cells at 10 µM and HeLa cells at both concentrations applied
(Figure 5). On the other hand, 5 had weak (cell survival was
85% at 10 µM) or no activity (> 95% at 5 µM) against
normal fibroblasts (V79). Moreover, while compound 4 did not
show significant cytotoxic effects on any cell line at the applied
concentrations, compound 6 showed noticeable effects against
SCVII and FsaR cells at 10 µM.
Cytotoxic Activity of Ragusinin (5) in
HeLa Cell Line
In order to determine the biological effect of the most active
compound 5 (Figure 5) in more detail, we used MTT assay and
HeLa cells as experimental model (Cimbora-Zovko et al., 2011).
Ragusinin decreased cell survival of HeLa cells in a
concentration-dependent manner in comparison to untreated
cells (Figure 6). The dose that killed 50% of the cell population
(IC50 value) after 72 h of continuous treatment with 5 was
between 1.8 and 2.3 µM (Figure 6).
To better understand the mechanism underlying the cell
growth impairment by 5, the cell cycle progression was
investigated. HeLa cells were treated with increasing doses of
5 during 48 h. As shown in Figure 7A, compound 5 triggers
the accumulation of HeLa cells in the G2 phase of cell cycle.
Moreover, a compound 5 induced dose-dependent increase of
cells in the Sub G1 population indicates a ragusinin-triggered cell
death (Figure 7A). The same was confirmed by treatment of cells
with 10 µM of 5 during 24–72 h. Time-dependent accumulation
of HeLa cells in the G2 phase is detectable as well as time-increase
of cells in the Sub G1 phase of the cell cycle (Figure 7B).
In order to determine the type of cell death triggered by 5,
the cells were treated with increasing doses of the compound
and 48 h later, FACS-Annexin V/PI staining was performed.
Our results show a ragusinin-induced dose-dependent apoptosis
(Figure 7C). We then performed Western blot analysis of specific
cell death markers, PARP and caspase-3 cleavage, following
treatment with 1.25 and 2.5 µM of 5 for 24–72 h. The
obtained results were interesting since 5 did not induce PARP
(Figure 7D) and caspase-3 cleavage (Figure 7E). The assumed
caspase-independent cell death triggered by 5 was in addition
confirmed by measuring the absence of caspase activity 3/7 by
Caspase-Glo R© 3/7 Assay (data not shown). The occurrence of
caspase and PARP cleavage independent cell death indicates
some alternative cell death pathway described in the literature
to be triggered by a different type of cell stressors (Kroemer and
Martin, 2005; Tait and Green, 2008). This is the first example of
caspase independent cell death described for compound 5.
Role of Glutathione (GSH) in Protection
of Cells From Ragusinin (5)
We were further interested in the possible role of GSH as
a protector of cells in ragusinin-induced cell death. For that
purpose, HeLa cells were either pre-treated with 5 mM NAC,
the precursor for GSH synthesis, for 2 h prior to treatment
with compound 5 or overnight with a specific inhibitor of GSH
synthesis, i.e., 0.001 mM BSO. The conditions used were tested
previously to be effective (Brozovic et al., 2008; Brozovic et al.,
2014). The obtained data showed that an increased level of
GSH protects HeLa cells from ragusinin’s toxicity (Figure 8A).
At the same time, depletion of GSH decreased cell survival of
HeLa cells compared to cells treated with compound 5 only
(Figure 8B).
Due to the fact that GSH instills several vital roles within
a cell including antioxidation, maintenance of the redox state,
modulation of the immune response, and detoxification of
xenobiotics (Balendiran et al., 2004), we discussed first its possible
role as an antioxidant. It is known that the cytotoxicity of the
sesquiterpenes helenalin and cynaropicrin can be affected via
generation of intracellular reactive oxygen species (ROS) (Cho
et al., 2004; Jang et al., 2013). We examined that possibility for
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FIGURE 7 | Cell cycle progression and induction of cell death in HeLa cells following treatment with ragusinin (5). The cells were treated either with 2.5, 5, and
10 µM of compound 5 for 48 h (A) or with 10 µM during 24–72 h (B). Cell cycle analysis was performed by flow cytometry upon cell staining with PI. The
representative data of three independent experiments which yielded similar results are shown. The cells were either non-treated or treated with 2.5, 5, and 10 µM of
5. After 48 h and staining with Annexin V and PI, the cell death was measured by flow cytometry. The representative data of three independent experiments which
yielded similar results are shown. The statistical analysis of data for three independent experiments are presented as means of percentage of viable (V), early
apoptotic (EA), late apoptotic/necrotic (LA/N), and necrotic (N) cell populations ± standard deviation (C). 24–72 h after exposure to 1.25 and 2.5 µM of 5, protein
level of cleaved PARP (D) and activated (i.e., cleaved) caspase-3 (Cas 3) (E) and cleaved PARP was analyzed in whole cell extracts by Western blot analysis. ERK1/2
protein expression was used as internal protein loading control. The representative data of three independent experiments which yielded similar results are shown.
Zero or C, non-treated cells; PM, protein marker PageRuler Prestained Protein Ladder (Thermo Fisher Scientific, United States). FL1-H/Annexin V-FITC,
FL2-H/Propidium iodide.
ragusinin by pre-treating HeLa cells either with tempol or trolox,
two antioxidant compounds (Aliaga et al., 2003). Results showed
that antioxidants, as well as salubrinal (Brozovic et al., 2013), i.e.,
an inhibitor of endoplasmic reticulum stress, had no impact on
ragusinin’s toxicity (Supplementary Material, in Supplementary
Figure S6). Thus, we further explored the capability of 5 to reach
functional protein targets in living cells without being deactivated
by reaction with GSH. The combination treatment of HeLa cells
with the well-known inhibitor of glutathione S-transferase (GST)
ethacrynic acid (Osmak et al., 1998) (c = 5 µg/mL) decreased cell
survival compared to cells treated with 5 only (Figure 9). The data
imply the enzymatically regulated formation of a detoxification
complex between GSH and 5.
DISCUSSION
Among the isolates (1 to 6) from the traditionally used herbal
remedy C. ragusina L. leaves, we discovered an interesting
pharmacological profile for the rare guajanolides ragusinin (5)
and hemistepsin A (6). Compound 5 was only once described as
a constituent from the aerial parts of the Australian Helipterum
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FIGURE 8 | The role of GSH in ragusinin’s (5) toxicity. The cells were either pre-treated for 2 h with 5 mM NAC (A) or overnight with 0.001 mM BSO (B). After that,
the cells were treated with different concentrations of 5. 72 h later, an MTT assay was performed. Bars represent the mean of quadruplicates ± SD. Different letters
indicate significant difference at p < 0.05. All experiments were performed at least three times.
FIGURE 9 | The treatment of HeLa cells with ethacrynic acid (ETA). The cells
were pre-treated with 5 µg/mL ETA. Two hours later the cells were treated
with different concentrations of 5. 72 h later an MTT assay was performed.
Bars represent the mean of quadruplicates ± SD. Different letters indicate
significant difference at p < 0.05. All experiments were performed at least
three times.
maryonii S. Moore (Zdero et al., 1989) and is characterized by
an isovalerate residue in position C-9a; compound 6 has been
described previously as a constituent from leaves and flowers of
Hemisteptia lyrata Bunge (Jang et al., 1999).
Whereas both natural compounds showed no antibacterial
activity against the Gram-negative A. baumannii, they exhibited
moderate inhibitory activity against S. aureus ATTC 25923
(MIC value of 31.3 µg/mL, Supplementary Material). For
comparison, three STLs (13-acetylsolstitialin A, centaurepensin,
and chlorojanerin) isolated from the aerial parts of Centaurea
solstitialis L. ssp. solstitialis showed inhibitory activity against
standard S. aureus with MIC values of 16 µg/mL (Özçelik
et al., 2009). In line with these findings, we focused on a more
prominent cytotoxic activity of the isolated compounds and the
investigation of the mechanism of action of the most active
compound 5.
We investigated the binding of isolated compounds to DNA
since studying the interactions of compounds with potential drug
targets and the knowledge of their antiproliferative activity can
help in forming the hypothesis about the mechanism of action of
novel compounds.
The isolated flavonoids (1–3) exhibited only weak interactions
with DNA which may explain the absence of cytotoxic effects
against the majority of studied cell lines. The somewhat stronger
cytotoxic activity of flavonoids against HeLa cells can be ascribed
to interactions with biological targets other than DNA (Chen
et al., 2012). Compound 3 with the highest number of hydroxy
groups on the flavonoid skeleton exhibited the most pronounced
cytotoxic activity. This finding is in agreement with literature data
(Beutler et al., 1998; Jeong et al., 2007; Csupor-Löﬄer et al., 2009).
While there are numerous reports on DNA binding affinities
with flavonoids (Kanakis et al., 2005; Rusak et al., 2010), there
is little data on DNA binding interactions with sesquiterpenes
(Vujcˇic´ et al., 2007). Regarding the structure of 5 and literature
data (Gates, 2009; Chadwick et al., 2013), the interaction
with DNA can be achieved via noncovalent binding to
double-stranded DNA (dsDNA) or by alkylation of DNA
nucleophiles through reaction with the α-methylene-γ-lactone
group. Several studies on the reactivity of STLs toward OH-
or N-nucleophiles (Atta-ur-Rahman, 2011) and CD changes
which were not consistent with an alkylation effect (Agarwal
et al., 2014) (Supplementary Figure S4) do not support the
latter possibility. In addition, the -SH group was found to be
much more susceptible to alkylation by sesquiterpenes than other
nucleophiles (Gewirtz et al., 2007). A reasonable explanation
based on our results from ITC and CD is noncovalent binding
of 5 most probably inside a hydrophobic interior of the DNA
groove. Due to its rather moderate binding affinity to ctDNA, it
can be concluded that the cellular DNA is not 5’s primary target
in the living cell.
Among the isolated STLs, compound 5 showed the strongest
cytotoxic activity, especially on murine SCVII as well as human
Caco-2 and HeLa cell lines, while no cytotoxic effect on normal
V79 fibroblasts was observed. Similar to the antibacterial activity,
a correlation between the cytotoxic activity and the type and
properties of the substituents on the central ring in the vicinity of
the α-methylene-γ-lactone group was observed. In comparison
to less lipophilic substituents of sesquiterpenes, as observed for
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FIGURE 10 | A summary of the most significant results obtained in this study.
6 and especially 4, the hydrophobic character of the isovalerate
residue of 5 most probably enables better penetration through
the cell membrane and consequently better antibacterial and
cytotoxic activity. In the literature, cytotoxic effects of various
STLs have been explained by selective alkylation of growth
regulatory macromolecules such as enzymes which control cell
division and thus a variety of cellular functions (Lyss et al., 1998;
Rasul et al., 2012).
Since compound 5 (ragusinin) showed the strongest activity
compared to other isolates and since the biological activity
of 5 was not described before we decided to investigate the
mechanism of its toxicity in more details. The IC50 value of
ragusinin was between 1.8 and 2.3 µM (Figure 6). This is
consistent with data from the literature, where compounds of
similar chemical structure, i.e., sesquiterpene lactones such as
helenalin (Gertsch et al., 2003), neoambrosin (Saeed et al.,
2015), and damsin (Villagomez et al., 2013), are reported to
be cytotoxic against various cell lines in the micromolar range.
Further analysis revealed time-dependent accumulation of HeLa
cells upon ragusinin treatment in the G2 phase and Sub G1
phase of the cell cycle (Figure 7B). But, the occurrence of
caspase and PARP cleavage independent cell death indicates
some alternative cell death pathway described in the literature
to be triggered by a different type of cell stressors (Kroemer
and Martin, 2005; Tait and Green, 2008). The phenomenon is
interesting to follow up further, especially because it is known
that helenalin, a STL isolated from Arnica montana, induces
the same atypical form of cell death which does not include
the activation of classical mediators of apoptosis (caspases,
AIF, Omi/HtrA2, and Apaf/apoptosome) (Hoffmann et al.,
2011).
In a series of noteworthy reports on the reactivity and
kinetics of helenalin and helenanolide type STLs with GSH,
it was demonstrated that at physiological pH helenalin reacts
with GSH almost exclusively via its cyclopentenone structure
while the α-methylene-γ-lactone site is less reactive (Schmidt
et al., 1999). Since the guajanolide 5 possesses one reactive
site, i.e., the α-methylene-γ-lactone group that can react
with GSH, we decided to investigate the role of GSH in
deactivation of 5.
From the literature is known that GSH is one of the major
endogenous antioxidants. In the cytoplasm, GSH is used as a
substrate for glutathione peroxidase in the reduction of H2O2
and lipid hydroxyperoxides, a reaction that produces glutathione
disulfide, the so-called oxidative form of GSH. Glutathione
disulfide is rapidly reduced to GSH by glutathione reductase. This
redox cycling of GSH plays a role in the maintenance of cellular
redox homeostasis. GSH binds to endogenous and diverse
xenobiotic electrophilic compounds either catalytically, through
the action of glutathione S-transferase, or non-catalytically
(Townsend and Tew, 2003; Brozovic et al., 2014). The formed
GSH conjugates can be exported from cells, resulting in the loss of
cellular GSH. Our data showed that variation of GSH amount in
the cell induced by a specific precursor in GSH synthesis, NAC or
a specific inhibitor of GSH synthesis, BSO had an impact on HeLa
survival upon treatment with 5 (Figure 8). Similar results were
obtained in human colon tumor cells upon BSO and helenalin
treatment (Jordan et al., 1987). Moreover, we showed that GSH
probably does not play a role as antioxidant (Supplementary
Figure S6) but rather as molecule which form conjugates with 5
increasing in that way the survival of HeLa cells upon treatment
with it (Figure 9).
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CONCLUSION
In this study, the most active compound has shown to
be a sesquiterpene lactone, ragusinin (compound 5) whose
biological activity has not been investigated so far. Currently, our
knowledge about the mechanism of action of STLs is still limited.
Several of them reached clinical trials due to their ability to trigger
cell death in tumor but not in normal cells (Zhou and Zhang,
2008; Kawasaki et al., 2009; Crespo-Ortiz and Wei, 2012).
Here we are showing for the first time the biological activity of
compound 5, ragusinin. Although ITC and CD results suggested
that the cellular DNA is not the primary target of ragusinin in the
living cell, these data represent valuable information since, to the
best of found knowledge, STL−DNA interactions have not been
communicated before.
The variation of the amount of GSH in the cell by using a
specific precursor in GSH synthesis (NAC) or a specific inhibitor
of GSH synthesis (BSO) showed the importance of GSH in the
cell’s response to 5. Moreover, it was shown that formation of
GSH-ragusinin conjugates increased cell survival what implies
the role in GSH detoxification rather than in stabilization of
the cell redox system. Ragusinin induced G2 arrest followed by
caspase-independent cell death.
Though the actual protein targets remain unclear at this
stage of the investigation, we can confirm that compound 5 is
deactivated by GSH resulting in a diminished cytotoxic effect.
A summary of the most significant results obtained in this
study by using specified techniques is presented in Figure 10.
In future studies, it will be interesting to investigate whether
ragusinin-GSH conjugates have a biological activity or whether
they are ejected from cells through so-called GSH pumps such as
MRP1 and MRP2 (Homolya et al., 2003).
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Berberine-containing plants have been traditionally used in different parts of the world for
the treatment of inflammatory disorders, skin diseases, wound healing, reducing fevers,
affections of eyes, treatment of tumors, digestive and respiratory diseases, and microbial
pathologies. The physico-chemical properties of berberine contribute to the high diversity
of extraction and detection methods. Considering its particularities this review describes
various methods mentioned in the literature so far with reference to the most important
factors influencing berberine extraction. Further, the common separation and detection
methods like thin layer chromatography, high performance liquid chromatography, and
mass spectrometry are discussed in order to give a complex overview of the existing
methods. Additionally, many clinical and experimental studies suggest that berberine
has several pharmacological properties, such as immunomodulatory, antioxidative,
cardioprotective, hepatoprotective, and renoprotective effects. This review summarizes
the main information about botanical occurrence, traditional uses, extraction methods,
and pharmacological effects of berberine and berberine-containing plants.
Keywords: berberine, botanical occurrence, traditional uses, extraction methods, biological activities
INTRODUCTION
Berberine
Berberine(5,6-dihydro-9,10-dimethoxybenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium) Figure 1,
is a nonbasic and quaternary benzylisoquinoline alkaloid, a relevant molecule in pharmacology and
medicinal chemistry. Indeed, it is known as a very important natural alkaloid for the synthesis
of several bioactive derivatives by means of condensation, modification, and substitution of
functional groups in strategic positions for the design of new, selective, and powerful drugs
(Chen et al., 2005).
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FIGURE 1 | Berberine structure (according to ChemSpider database).
TRADITIONAL USE OF
BERBERINE-CONTAINING SPECIES
In the Berberidaceae family, the genus Berberis comprises of
∼450–500 species, which represent the main natural source of
berberine. Plants of this genus are used against inflammation,
infectious diseases, diabetes, constipation, and other pathologies
(Singh A. et al., 2010). The oldest evidence of using barberry
fruit (Berberis vulgaris) as a blood purifying agent was written on
the clay tablets in the library of Assyrian emperor Asurbanipal
during 650 BC (Karimov, 1993). In Asia, the extensive use
of the stem, stem bark, roots, and root bark of plants rich
in berberine, particularly Berberis species, has more than 3000
years of history. Moreover, they have been used as raw material
or as an important ingredient in Ayurvedic and traditional
Chinese medicine (Birdsall, 1997; Kirtikar and Basu, 1998; Gupta
and Tandon, 2004; Kulkarni and Dhir, 2010). In Ayurveda,
Berberis species have been traditionally used for the treatment
of a wide range of infections of the ear, eye, and mouth, for
quick healing of wounds, curing hemorrhoids, indigestion and
dysentery, or treatment of uterine and vaginal disorders. It has
also been used to reduce obesity, and as an antidote for the
treatment of scorpion sting or snakebite (Dev, 2006). Berberine
extracts and decoctions are traditionally used for their activities
against a variety of microorganisms including bacteria, viruses,
fungi, protozoa, helminthes, in Ayurvedic, Chinese, and Middle-
Eastern folk medicines (Tang et al., 2009; Gu et al., 2010).
In Yunani medicine, Berberis asiatica has multiple uses,
such as for the treatment of asthma, eye sores, jaundice,
skin pigmentation, and toothache, as well as for favoring the
elimination of inflammation and swelling, and for drying ulcers
(Kirtikar and Basu, 1998). Decoction of the roots, and stem
barks originating from Berberis aristata, B. chitria, and B. lycium
(Indian Berberis species), have been used as domestic treatment
of conjunctivitis or other ophthalmic diseases, enlarged liver
and spleen, hemorrhages, jaundice, and skin diseases like ulcers
(Rajasekaran and Kumar, 2009). On the other hand, the use of
decoction of Indian barberry mixed with honey has also been
reported for the treatment of jaundice. Additionally, it has been
reported the use of decoction of Indian barberry and Emblic
myrobalan mixed with honey in the cure of urinary disorders as
painful micturition (Kirtikar and Basu, 1998). Numerous studies
dealing with its antimicrobial and antiprotozoal activities against
different types of infectious organisms (Vennerstrom et al., 1990;
Stermitz et al., 2000; Bahar et al., 2011) have been assessed so far.
Moreover, it has been used to treat diarrhea (Chen et al., 2014)
and intestinal parasites since ancient times in China (Singh and
Mahajan, 2013), and the Eastern hemisphere, while in China it is
also used for treating diabetes (Li et al., 2004).
Nowadays, a significant number of dietary supplements based
on plants containing berberine (Kataoka et al., 2008) are used
for reducing fever, common cold, respiratory infections, and
influenza (Fabricant and Farnsworth, 2001). Another reported
use for berberine-containing plants is their application as an
astringent agent to lower the tone of the skin. Also, positive
effects were observed on the mucous membranes of the upper
respiratory tract and gastrointestinal system with effects on the
associated ailments (Chen et al., 2014; Yu et al., 2016).
In southern South America leaves and bark of species of the
genus Berberis are used in traditional medicine administered
for mountain sickness, infections, and fever (San Martín, 1983;
Houghton and Manby, 1985; Anesini and Perez, 1993).
Furthermore, there are other genera which contain berberine.
The genus Mahonia comprises of several species that contain
berberine. Within them, M. aquifolium has been traditionally
used for various skin conditions. Due to its main alkaloid
(berberine), is known to be used in Asian medicine for its
antimicrobial activity. Coptidis rhizoma (rhizomes of Coptis
chinensis), another plant which contains berberine, is a famous
herb very frequently used in traditional Chinese medicine for the
elimination of toxins, “damp-heat syndromes”, “purge fire”, and
to “clear heat in the liver” (Tang et al., 2009). Table 1 gathers
a synthesis of the main traditional uses of species containing
berberine.
BOTANICAL SOURCES OF BERBERINE
Berberine has been detected, isolated, and quantified from
various plant families and genera including Annonaceae
(Annickia, Coelocline, Rollinia, and Xylopia), Berberidaceae
(Berberis, Caulophyllum, Jeffersonia, Mahonia, Nandina, and
Sinopodophyllum), Menispermaceae (Tinospora), Papaveraceae
(Argemone, Bocconia, Chelidonium, Corydalis, Eschscholzia,
Glaucium, Hunnemannia, Macleaya, Papaver, and Sanguinaria),
Ranunculaceae (Coptis, Hydrastis, and Xanthorhiza), and
Rutaceae (Evodia, Phellodendron, and Zanthoxyllum) (Table 2).
The genus Berberis is well-known as the most widely distributed
natural source of berberine. The bark of B. vulgaris contains
more than 8% of alkaloids, berberine being the major alkaloid
(about 5%) (Arayne et al., 2007).
Berberine is also widely present in barks, leaves, twigs,
rhizomes, roots, and stems of several medicinal plants species,
including Argemone mexicana (Etminan et al., 2005), Berberis
aristata, B. aquifolium, B. heterophylla, B. beaniana, Coscinium
fenestratum (Rojsanga and Gritsanapan, 2005), C. chinensis,
C. japonica, C. rhizome, Hydratis canadensis (Imanshahidi and
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TABLE 1 | Traditional uses of berberine-containing species.
Family Scientific name Traditional uses References
Annonaceae Annickia chlorantha (Oliv.)
Setten & Maas (ex-Enantia
chlorantha Oliv.)
Treat jaundice, hepatitis A, B, C, and D,
conjunctivitis, leishmaniasis, medicine for cuts
and infected wounds, sores and ulcers,
antipyretic for various fevers, tuberculosis,
vomiting of blood, urinary tract infections,
treatment of fatigue, rheumatism, treat malaria
symptoms, aches, wounds, boils, vomiting,
yellow bitter, chills, sore, spleen in children and
body pains, skin ailments, intercostal pain and
to promote conception, intestinal worms,
intestinal spasms, malaria and sexual asthenia,
treat coughs and wounds; rickettsia fever, treat
of sleeping sickness and dysentery, hemostatic
and rickettsia, treat yellow fever and typhoid
fever, treat diabetes, treat syphilis, and other
infectious diseases, poliomyelitis, treat
hypertension, treat HIV and prostate cancer
Oliver, 1960; Sandberg, 1965; Bouquet, 1969;
Hamonniere et al., 1975; Onwuanibe, 1979;
Burkill, 1985; Gill and Akinwumi, 1986; Gbile
et al., 1988; Vennerstrom and Klayman, 1988;
Vennerstrom et al., 1990; Adjanohoun et al.,
1996; Nguimatsia et al., 1998; Kayode, 2006;
Odugbemi et al., 2007; Ehiagbonare and
Onyibe, 2008; Jiofack et al., 2008, 2009;
Kadiri, 2008; Ogbonna et al., 2008;
Olowokudejo et al., 2008; Betti and Lejoly,
2009; Ndenecho, 2009; Adeyemi et al., 2010;
Noumi, 2010; Noumi and Anguessin, 2010;
Noumi and Yumdinguetmun, 2010; Bele et al.,
2011; Din et al., 2011; Ngono Ngane et al.,
2011; Oladunmoye and Kehinde, 2011;
Gbolade, 2012; Musuyu Muganza et al., 2012;
Tsabang et al., 2012; Betti et al., 2013;
Borokini et al., 2013; Fongod, 2014; Ishola
et al., 2014; Ohemu et al., 2014
Annickia pilosa (Exell) Setten &
Maas (ex-Enantia pilosa Exell)
Medicine for cuts Versteegh and Sosef, 2007
Annickia polycarpa (DC.)
Setten & Maas ex I.M.Turner
(ex-Enantia polycarpa (DC.)
Engl. & Diels)
Treat cuts, antiseptic to treat sores, stomach
ulcers, leprosy and ophthalmia, treatment of
skin infections and sores, treat jaundice, and
treat fever including malaria and to promote
wound healing, against intestinal problems
Irvine, 1961; Bouquet and Debray, 1974; Ajali,
2000; Govindasamy et al., 2007; Versteegh
and Sosef, 2007
Rollinia mucosa (Jacq.) Baill. Treat of tumors Hartwell, 1982
Xylopia polycarpa (DC.) Oliv. Treat wounds, ulcers, leprosy, rheumatism,
stomach and gall-bladder problems, eye
diseases, for conception, diarrhea, malaria,
fevers and sleeping disorders
Neuwinger, 1996
Berberidaceae Berberis actinacantha Mart. Antipyretic San Martín, 1983
Berberis aquifolium Pursh Skin conditions, treat eczema, acne,
conjunctivitis and herpes, alleviate the
symptoms of psoriasis, treat diarrhea and in
higher doses to treat constipation,
improvement of blood flow to the liver,
stimulate intestinal secretions and bile flow,
treat jaundice, hepatitis, cirrhosis and general
digestive problems, treatment of gall bladder
disease, hemorrhages and a few forms of
cancer, fungal infections, dysentery,
anti-inflammatory properties, stomach
problems, sore womb following childbirth
and/or menstruation
King, 1898; Ritch-Krc et al., 1996
Berberis aristata DC. Treat allergies, metabolic disorders,
ophthalmia, and other eye diseases, treat
bleeding piles, anti-osteoporosis, treat skin
diseases, menorrhagia, fever, diarrhea,
dysentery, cholera, jaundice, ear and urinary
tract infections, anti-bacterial, anti-fungal,
anti-inflammatory, analgesic, anti-pyretic,
jaundice, piles, malaria, laxative, anti-scorbutic,
anti-diabetic, and anti-hepatopathic
Bhattacharjee et al., 1980; Duke and
Beckstrom-Sternberg, 1994; Küpeli et al.,
2002; Acharya and Rokaya, 2005; Chhetri
et al., 2005; Kunwar and Adhikari, 2005;
Sharma et al., 2005; Joshi and Joshi, 2007;
Meena et al., 2009; Shahid et al., 2009;
Phondani et al., 2010; Saraf et al., 2010;
Tiwary et al., 2010; Sati and Joshi, 2011;
Yogesh et al., 2011
Berberis asiatica Roxb. ex DC. Jaundice, diabetes mellitus, wound healing,
asthma; drying unhealthy ulcers,
anti-inflammatory, swelling, treat
pneumococcal infections, eye (conjunctivitis)
and ear diseases, rheumatism, fever, stomach
disorders, skin disease (hyperpigmentation),
malarial fever, laxative, teeth problems
(toothache), and headache
Watt, 1883; Kirtikar and Basu, 1933; Samhita,
1963; Hashmi and Hafiz, 1986; Bhandari et al.,
2000; Shah and Khan, 2006; Uniyal et al.,
2006; Uprety et al., 2010; Maithani et al., 2014
(Continued)
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Berberis buxifolia Lam. Treat infections Anesini and Perez, 1993; Mølgaard et al., 2011
Berberis chitria Buch.-Ham.
ex Lindl.
Treat skin disease, jaundice, rheumatism,
affection of eyes (household treatment for
conjunctivitis, ophthalmic, bleeding piles),
ulcers, skin diseases, enlarged liver and spleen
Watt, 1883; Kirtikar and Basu, 1933; Sir and
Chopra, 1958
Berberis darwinii Hook. Antipyrectic, anti-inflammatory, treat stomach
pains, indigestion, and colitis
Montes and Wilkomirsky, 1987
Berberis empetrifolia Lam. Treat mountain sickness San Martín, 1983
Berberis integerrima Bunge. Antipyretic, treat diabetes, bone fractures,
rheumatism, radiculitis, heart pain, stomach
aches, kidney stones, tuberculosis, chest pain,
headaches, constipation, and wound
Khalmatov, 1964; Khodzhimatov, 1989;
Baharvand-Ahmadi et al., 2016
Berberis jaeschkeana C. K.
Schneid.
Treat eye diseases Kala, 2006
Berberis koreana Palib. Antipyretic, treat gastroenteritis, sore throats,
and conjunctivitis
Ahn, 2003
Berberis leschenaultia Wall. ex
Wight & Arn.
Antipyretic, cold and complications during
post-natal period
Rajan and Sethuraman, 1992
Berberis libanotica Ehrenb. ex
C. K. Schneid.
Treat rheumatic and neuralgic diseases,
anti-inflammatory, treat arthritis and muscular
pain
El Beyrouthy et al., 2008; Esseily et al., 2012
Berberis lycium Royle Treat eye diseases, febrifuge, jaundice,
diarrhoea, menorrhagia, piles, backache,
dysentery, earache, fracture, eye ache,
pimples, boils, wound healing, cough and
throat pain, intestinal colic, diabetes, throat
pain, scabies, bone fractures, sun blindness,
against stomachache and intestinal problems
Zaman and Khan, 1970; ul Haq and Hussain,
1993; Bushra et al., 2000; Kaur and Miani,
2001; Hamayun et al., 2003; Ahmed et al.,
2004; Abbasi et al., 2005, 2009, 2010; Shah
and Khan, 2006; Zabihullah et al., 2006;
Hussain et al., 2008; Sood et al., 2010
Berberis microphylla G. Forst.
(ex-Berberis heterophylla
Juss. ex Poir.)
Febrifuge, anti-inflammatory and treat diarrhea Muñoz, 2001
Berberis oblonga (Regel) C. K.
Schneid
Heart tonic, treat neurasthenia, antipyretic,
antidiarrheal, treat rheumatism, eye diseases
and wounds of the mouth, jaundice, stomach
aches, back pain and arthralgia
Khalmatov, 1964; Sezik et al., 2004; Pak, 2005
Berberis petiolaris Wall. ex G.
Don
Treat malarial fever, diarrhea, conjunctivitis, and
jaundice
Karimov, 1993
Berberis pseudumbellata R.
Parker
Diuretic, treat jaundice, intestinal disorders, eye
diseases, oxytocic and throat ache, stomach
problems and ulcers
Kala, 2006; Khan and Khatoon, 2007; Singh
et al., 2009; Khan et al., 2016
Berberis thunbergii DC. Anti-inflammatory Küpeli et al., 2002
Berberis tinctoria Lesch. Antimicrobial for skin disease, jaundice,
affection of eyes, treat menorrhagia, diarrhea,
and rheumatism
Fyson, 1975; Satyavati et al., 1987
Berberis umbellata Wall. ex G.
Don
Treating fever, jaundice, nausea, eye disorders
and skin problems, tonic
Singh et al., 2012
Berberis vulgaris L. Antiarrhythmic, sedative, anticancer, heal
internal injuries, remove kidney stones, treat
sore throat and fever
Tantaquidgeon, 1928; Chaudhury et al., 1980;
Zovko Koncic´ et al., 2010
Caulophyllum thalictroides (L.)
Michaux
Menstrual cramps, relieve the pain of childbirth,
promote prompt delivery, treat colics, cramps,
hysteria, rheumatism, uterine stimulant, inducer
of menstruation, and antispasmodic
Castleman, 1991; Hutchens, 1992
Jeffersonia diphylla (L.) Pers. Antispasmodic, diuretic, emetic, expectorant,
treat diarrhea, dropsy, gravel and urinary
problems, emetic, expectorant, treat sores,
ulcers and inflamed parts
Uphof, 1959; Duke and Ayensu, 1985; Foster
and Duke, 1990; Coffey, 1993; Moerman,
1998; Lust, 2014
(Continued)
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Mahonia fortunei (Lindl.)
Fedde
Anticancer, febrifuge, antiodontalgic, treat
testicular swelling and arthritic pain
Duke and Ayensu, 1985; He and Mu, 2015
Mahonia napaulensis DC. Diuretic, demulcent, treat dysentery and
inflammations of the eyes
Chopra et al., 1986; Manandhar, 2002
Nandina domestica Thunb. Antitussive, astringent, febrifuge, stomachic
and tonic, treat of fever in influenza, acute
bronchitis, whooping cough, indigestion, acute
gastro-enteritis, tooth abscess, pain in the
bones, muscles and traumatic injuries, and
antirheumatic
Kariyone and Koiso, 1971; Duke and Ayensu,
1985; Fogarty, 1990
Sinopodophyllum hexandrum
(Royle) T. S. Ying
Regulate menstruation, promote the circulation
of blood, treat amenorrhea, difficult labor and
retention of dead fetus or placenta
Kong et al., 2010
Menispermaceae Tinospora sinensis (Lour.)
Merr (ex-Tinospora cordifolia
(Willd.) Miers)
Tonic, antiperiodic, anti-spasmodic,
anti-inflammatory, antiarthritic, anti-allergic,
anti-diabetic, improve the immune system,
antistress, anti-leprotic and anti-malarial
activities
Singh et al., 2003
Papaveraceae Argemone albiflora Hornem
(ex-Argemone alba F. Lestib.)
Anthydropic, cathartic, diaphoretic, diuretic,
demulcent, emetic, purgative, treat jaundice,
skin ailments, colds, colics and wounds
Smyth, 1903; Foster and Duke, 1990
Argemone mexicana L. Analgesic, antispasmodic, sedative, treat
warts, cold sores, cutaneous affections, skin
diseases, itches, treat cataracts, treat dropsy,
jaundice, treat chronic skin diseases,
expectorant, treat coughs and chest
complaints, demulcent, emetic, expectorant,
laxative and antidote to snake poisoning
Uphof, 1959; Pesman, 1962; Usher, 1974;
Stuart and Smith, 1977; Emboden, 1979;
Chopra et al., 1986; Coffey, 1993; Chevallier,
1996
Argemone platyceras L. Treat respiratory ailments as asthma, cough,
bronchitis and pneumonia
Emes et al., 1994
Bocconia frutescens L. Treat skin conditions (ulcers and eruptions) and
respiratory tract infections (bronchistis and
tuberculosis)
Martinez, 1977, 1984
Chelidonium majus L. Treat ophthalmic diseases (remove films from
the cornea of the eye), mild sedative,
antispasmodic, relaxing the muscles of the
bronchial tubes and intestines, treat warts,
alterative, anodyne, antispasmodic,
cholagogue, diaphoretic, diuretic, hydrogogue,
narcotic, purgative, treat bronchitis, whooping
cough, asthma, jaundice, gallstones and
gallbladder pains, anticancer, analgesic, treat
stomach ulcer, treat get rid of warts, ringworm
and corns
Launert, 1981; Grieve, 1984; Phillips and Foy,
1990; Phillips and Rix, 1991; Chevallier, 1996;
Lust, 2014
Corydalis solida subsp.
brachylova
Anodyne, antibacterial, antispasmodic,
hallucinogenic, calm the nerves, sedative for
insomnia, CNS stimulant, painkiller, treat painful
menstruation, lowering the blood pressure,
traumatic injury and lumbago
Launert, 1981; Bown, 1995
Corydalis solida subsp.
slivenensis (Velen.) Hayek
(ex-Corydalis slivenensis
Velen.)
Corydalis solida subsp. tauri
cola
Corydalis turtschaninovii
Besser (ex-Corydalis ternata
(Nakai) Nakai)
Treat memory dysfunction, treat gastric,
duodenal ulcer, cardiac arrhythmia disease,
rheumatism and dysmenorrhea
Tang and Eisenbrand, 1992; Kamigauchi and
Iwasa, 1994; Orhan et al., 2004; Houghton
et al., 2006
(Continued)
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Eschscholzia californica
Cham.
Sedative, diuretic, relieve pain, relax spasms,
promote perspiration, treat nervous tension,
anxiety, insomnia, urinary incontinence
(especially in children), narcotic, relieve
toothache, antispasmodic, analgesic and
suppress the flow of milk in lactating women
Coffey, 1993; Bown, 1995; Chevallier, 1996;
Moerman, 1998
Glaucium corniculatum (L.)
Rud. subsp. corniculatum
Reduce warts, antitusive, treat CNS
disturbances, sedative, cooling, and mild
laxative
Al-Douri, 2000; Al-Qura’n, 2009; Hayta et al.,
2014
Macleaya cordata (Willd.)
R.Br.
Analgesic, antioedemic, carminative,
depurative, diuretic, treat insect bites, and
ringworm
Grieve, 1984; Duke and Ayensu, 1985
Macleaya microcarpa
(Maxim.) Fedde
Treat some skin diseases and inflammation Deng and Qin, 2010
Papaver dubium L. Sudorific, diuretic, expectorant and ophthalmia Chopra et al., 1986
Papaver dubium var. lecoquii
Papaver rhoeas L. var.
chelidonioides
Ailments in the elderly and children, mild pain
reliever, treat irritable coughs, reduce nervous
over-activity, anodyne, emollient,
emmenagogue, expectorant, hypnotic, slightly
narcotic, sedative, treat bronchial complaints
and coughs, insomnia, poor digestion, nervous
digestive disorders and minor painful
conditions, treat jaundice, fevers, and
anticancer
Uphof, 1959; Launert, 1981; Grieve, 1984;
Duke and Ayensu, 1985; Phillips and Foy,
1990; Bown, 1995; Chevallier, 1996
Papaver hybridum L. Treat dermatologic diseases, anti-infective,
diuretic, sedative, and antitussive
Rivera Núñez and Obon de Castro, 1996; Ali
et al., 2018
Ranunculaceae Coptis chinensis Franch. Control of bacterial and viral infections, relax
spasms, lower fevers, stimulate the circulation,
treat diabetes mellitus, analgesic, locally
anaesthetic, antibacterial, antipyretic, bitter,
blood tonic, carminative, cholagogue,
digestive, sedative, stomachic, vasodilator,
treat diarrhoea, acute enteritis and dysentery,
treat insomnia, fidget, delirium due to high
fever, leukaemia and otitis media, treat
conjunctivitis, skin problems (acne, boils,
abscesses and burns whilst), mouth, tongue
ulcers, swollen gums, and toothache
Uphof, 1959; Usher, 1974; Duke and Ayensu,
1985; Yeung, 1985; Bown, 1995
Coptis japonica (Thunb.)
Makino
Control of bacterial and viral infections, relax
spasms, lower fevers, stimulate the circulation,
locally analgesic and anaesthetic,
anti-inflammatory, stomachic, treat
conjunctivitis, intestinal catarrh, dysentery,
enteritis, high fevers, inflamed mouth and
tongue
Kariyone and Koiso, 1971; Usher, 1974;
Grieve, 1984; Bown, 1995
Coptis teeta Wall. Control of bacterial and viral infections, relaxes
spasms, lowers fevers and stimulate the
circulation, locally analgesic, anaesthetic,
ophthalmic and pectoral diseases, effective
antibacterial, treat dysentery
Stuart and Smith, 1977; Duke and Ayensu,
1985; Bown, 1995
Hydrastis canadensis L. Treat disorders of the digestive system and
mucous membranes, treat constipation,
antiperiodic, antiseptic, astringent, cholagogue,
diuretic, laxative, stomachic, tonic, treat
disorders affecting the ears, eyes, throat, nose,
stomach, intestines, and vagina
Uphof, 1959; Weiner, 1980; Grieve, 1984; Mills,
1985; Foster and Duke, 1990; Coffey, 1993;
Bown, 1995; Chevallier, 1996; Lust, 2014
Xanthorhiza simplicissima
Marshall
Treat mouth ulcers, stomach ulcers, colds,
jaundice, treat piles, and digestive disorders
Weiner, 1980; Foster and Duke, 1990;
Moerman, 1998
(Continued)
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Rutaceae Phellodendron amurense
Rupr.
Treat gastroenteritis, abdominal pain and
diarrhea, antiinflammator, immunostimulator
and treat cancer (antitumor activities)
Uchiyama et al., 1989; Park et al., 1999
• Phellodendron chinense C.
K. Schneid.
• Phellodendron chinense
var. glabriusculum C. K.
Schneid.
• (ex-Phellodendron wilsonii
Hayata & Kaneh.)
Act strongly on the kidneys, detoxicant for hot
damp conditions, treat meningitis,
conjunctivitis, antibacterial, antirheumatic,
aphrodisiac, bitter stomachic, cholagogue,
diuretic, expectorant, febrifuge, hypoglycaemic,
treat ophtalmia, skin, vasodilator and tonic,
treat acute diarrhoea, dysentery, jaundice,
vaginal infections (with Trichomonas vaginalis),
acute urinary tract infections, enteritis, boils,
abscesses, night sweats and skin diseases,
and expectorant
Kariyone and Koiso, 1971; Usher, 1974; Stuart
and Smith, 1977; Grieve, 1984; Yeung, 1985;
Bown, 1995; Chevallier, 1996
Zanthoxylum monophyllum
Tul.
Treat eye infections and dark vomitus Hirschhorn, 1981; Eric Brussell, 2004
Hosseinzadeh, 2008), Phellodendron amurense, P. chinense,
Tinospora cordifolia (Khan et al., 2011), Xanthorhiza
simplicissima (Bose et al., 1963; Knapp et al., 1967; Sato
and Yamada, 1984; Steffens et al., 1985; Inbaraj et al., 2001; Liu
et al., 2008a; Srinivasan et al., 2008; Vuddanda et al., 2010).
Several researches found that berberine is widely distributed
in the barks, roots, and stems of plants, nevertheless, bark and
roots are richer in berberine compared to other plant parts
(Andola et al., 2010a,b). In the Papaveraceae family, Chelidonium
majus is another important herbal source of berberine (Tomè
and Colombo, 1995). An important number of plants for
medicinal use, such as Coptidis rhizoma and barberry, are the
natural sources with the highest concentration of berberine.
Barberries, such as Berberis aristata, B. aquifolium, B. asiatica,
B. croatica, B. thunbergii, and B. vulgaris, are shrubs grown
mainly in Asia and Europe, and their barks, fruits, leaves, and
roots are often widely used as folk medicines (Imanshahidi
and Hosseinzadeh, 2008; Kosalec et al., 2009; Andola et al.,
2010c; Kulkarni and Dhir, 2010). Different research groups have
reported that maximum berberine concentration accumulates
in root (1.6–4.3%) and in most of the Berberis species, plants
that grow at low altitude contain more berberine compared to
higher altitude plants (Chandra and Purohit, 1980; Mikage and
Mouri, 1999; Andola et al., 2010a). However, a correlation could
not be established within the results of berberine concentration
regarding to species and season of the year (Srivastava et al.,
2006a,c; Andola et al., 2010c; Singh et al., 2012). Comparative
studies of berberine concentration contained in different species
of the same genus have been reported, e.g., higher berberine
content in B. asiatica (4.3%) in comparison to B. lycium (4.0%),
and B. aristata (3.8%). Meanwhile, Srivastava et al. (2004)
documented a higher berberine content in root of B. aristata
(2.8%) compared with B. asiatica (2.4%) (Andola et al., 2010a).
Seasonal variation of berberine concentration has been reported,
e.g., the maximum yield of berberine for B. pseudumbellata was
obtained in the summer harvest, and was 2.8% in the roots and
1.8% for the stem bark, contrary to that reported in the roots of
B. aristata, where the berberine concentration (1.9%) is higher
for the winter harvest (Rashmi et al., 2009). These variations may
be caused to multiple factors, among which stand out: (i) the
intraspecific differences, (ii) location and/or, (iii) the analytical
techniques used. Table 2 gathers a synthesis of the main species
containing berberine.
EXTRACTION METHODS
Berberine, a quaternary protoberberine alkaloid (QPA) is one of
the most widely distributed alkaloid of its class. Current studies
suggest that isolation of the QPA alkaloids from their matrix
can be performed using several methods. The principles behind
these methods consist of the interconversion reaction between
the protoberberine salt and the base. The salts are soluble in
water, stable in acidic, and neutral media, while the base is soluble
in organic solvents. Thus during the extraction procedure, the
protoberberine salts are converted in their specific bases and
further extracted in the organic solvents (Marek et al., 2003;
Grycová et al., 2007).
In the case of berberine, the classical extraction techniques
like maceration, percolation, Soxhlet, cold or hot continuous
extraction are using different solvent systems like methanol,
ethanol, chloroform, aqueous, and/or acidified mixtures.
Berberine’s sensitivity to light and heat is the major challenge
for its extraction. Hence, exposure to high temperature and light
could lead to berberine degradation and thus influencing its
matrix recovery. In his study Babu et al. (2012) demonstrated
that temperature represent a crucial factor in both extraction
and drying treatments prior extraction. The yield of berberine
content in C. fenestratum stem tissue samples was higher in
case of samples dried under the constant shade with 4.6%
weight/weight (w/w) as compared to samples dried in oven
at 65◦C (1.32% w/w) or sun drying (3.21% w/w). As well hot
extraction procedure with methanol or ethanol at 50◦C gave
lower extraction yields when compared with methanol or
ethanol cold extraction at −20◦C. Thus, berberine content in
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Family Scientific name Common name Used part References
Annonaceae Annickia chlorantha (Oliv.) Setten &
Maas (ex-Enantia chlorantha Oliv.)
African whitewood, african yellow
wood Epfoué, Péyé, Nfol, Poyo
Bark Mell, 1929
Annickia pilosa (Exell) Setten & Maas
(ex-Enantia pilosa Exell)
– Bark Buzas and Egnell, 1965
Annickia polycarpa (DC.) Setten &
Maas ex I. M. Turner (ex-Enantia
polycarpa (DC.) Engl. & Diels)
African yellow wood Bark Buzas and Egnell, 1965
Coelocline polycarpa A.DC. Yellow-dye tree of Soudan Bark Henry, 1949
Rollinia mucosa (Jacq.) Baill. Biriba, wild sweet sop, wild
cashina
Fruit Chen et al., 1996
Xylopia macrocarpa A.Chev. Jangkang Stem bark Willaman and Schubert, 1961
Xylopia polycarpa (DC.) Oliv. – Stem bark Willaman and Schubert, 1961
Berberidaceae Berberis aetnensis C.Presl – Roots Bonesi et al., 2013
Leaves Musumeci et al., 2003
Root Henry, 1949
Berberis amurensis Rupr. Barberry Stem & roots Tomita and Kugo, 1956
Berberis aquifolium Pursh Oregon grape Roots Parsons, 1882
Berberis aristata DC. Tree turmeric Bark Chakravarti et al., 1950
Roots Singh A. et al., 2010
Stem
Raw herb Singh R. et al., 2010
Extract
Fruit Kamal et al., 2011
Roots Andola et al., 2010a,c
Roots Rashmi et al., 2009
Roots Singh and Kakkar, 2009
Roots Srivastava et al., 2004
Roots Srivastava et al., 2001
Bark Willaman and Schubert, 1961
Berberis asiatica Roxb. ex DC. Chutro, rasanjan (Nep);
marpyashi (Newa); daruharidra,
darbi (Sans)
Roots Andola et al., 2010b
Roots Andola et al., 2010c
Roots Srivastava et al., 2004
Roots, stem, bark Willaman and Schubert, 1961
Berberis barandana Vidal. – ND Willaman and Schubert, 1961
Berberis beaniana C. K. Schneid. Kang song xiao bo (pinyin, China) – Steffens et al., 1985
Berberis chitria Buch.-Ham. ex Lindl. Chitra, indian barberry Whole plant Hussaini and Shoeb, 1985
Roots Srivastava et al., 2006a,b,c
Berberis concinna Hook.f. Barberry Stem bark Tiwari and Masood, 1979
Berberis congestiflora Gay Michay Leaves and stem Torres et al., 1992
Berberis coriaria Royle ex Lindl. – Stem bark Tiwari and Masood, 1979
Berberis croatica Mart. ex Schult. &
Schult.f.
Croatian barberry Roots Koncˇic´ et al., 2010
Roots Kosalec et al., 2009
Berberis darwinii Hook. Michai, calafate Roots Richert, 1918
Leaves Urzúa et al., 1984
Stem-bark Habtemariam, 2011
Berberis densiflora Raf. – Leaves Khamidov et al., 1997b
Berberis floribunda Wall. ex G.Don Nepal barberry Roots Chatterjee, 1951
Berberis fortunei Lindl. Fortune’s Mahonia Wood Willaman and Schubert, 1961
Berberis guimpelii K. Koch & C. D.
Bouché
– Roots Petcu, 1965a
Berberis heteropoda Schrank – Root bark Willaman and Schubert, 1961
Berberis himalaica Ahrendt – Stem-bark Chatterjee et al., 1952
(Continued)
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Berberis horrida Gay – Leaves and stem Torres et al., 1992
Berberis iliensis Popov – Young shoots Karimov and Shakirov, 1993
Roots Dzhalilov et al., 1963
Berberis integerrima Bunge. – Root Karimov et al., 1993
Leaves Karimov et al., 1993; Khamidov
et al., 1996c, 1997b
Berberis jaeschkeana C. K. Schneid. Jaeschke’s Barberry – Rashid and Malik, 1972
Berberis jamesonii Lindl (ex-Berberis
glauca Benth)
– – Willaman and Schubert, 1961
Berberis japonica R.Br Japanese Mahonia Wood, root Willaman and Schubert, 1961
Berberis kawakamii Hayata – Roots Yang and Lu, 1960a
Berberis koreana Palib. Korean barberry Bark of the stem Petcu, 1965b
Bark of the roots
Seeds
Stem
Roots
– Kostalova et al., 1982
Roots Yoo et al., 1986
Leaves
Berberis lambertii R. Parker – Roots Chatterjee and Banerjee, 1953
Berberis laurina Thunb Laurel barberry Roots Gurguel et al., 1934; Willaman
and Schubert, 1961
Berberis leschenaultii Wall. ex Wight
& Arn (ex-Mahonia leschenaultii (Wall.
ex Wight & Arn.) Takeda)
– Bark Willaman and Schubert, 1961
Berberis libanotica Ehrenb. ex C. K.
Schneid.
– Root Bonesi et al., 2013
Berberis lycium Royle Boxthorn barberry Roots Andola et al., 2010c
Berberis microphylla G. Forst.
(ex-Berberis heterophylla Juss. ex
Poir. Berberis buxifolia Lam.)
Patagonian barberry, magellan
barberry, calafate
Roots Freile et al., 2006
– Rashid and Malik, 1972
Berberis mingetsensis Hayata – Roots Yang and Lu, 1960b
Berberis nummularia Bunge Nummular barberry Young shoots Karimov et al., 1993
Berberis morrisonensis Hayata – Roots Yang, 1960a,b
Stem
–
Berberis nepalensis Spreng.
(ex-Mahonia acanthifolia Wall. ex
G.Don)
– – Willaman and Schubert, 1961
Berberis nervosa Pursh Dwarf Oregon-grape – Willaman and Schubert, 1961
Berberis oblonga (Regel) C. K.
Schneid
Oblong barberry Stem Karimov and Lutfullin, 1986;
Gorval’ and Grishkovets, 1999
Leaves Khamidov et al., 2003
Roots Tadzhibaev et al., 1974
Berberis petiolaris Wall. ex G. Don Chochar Roots Huq and Ikram, 1968
Berberis pseudumbellata R. Parker – Roots Andola et al., 2010b
Stem bark
– Pant et al., 1986
Berberis repens Lindl. Creeping mahonia, creeping
Oregon grape, creeping
barberry, or prostrate barberry
– Willaman and Schubert, 1961
Berberis sargentiana C. K. Schneid. Sankezhen – Liu, 1992
Berberis swaseyi Buckley – – Willaman and Schubert, 1961
Berberis thunbergii DC. Japanese barberry Stem Khamidov et al., 1997a
Leaves Khamidov et al., 1997a
Berberis tinctoria Lesch. Nilgiri barberry Roots Srivastava and Rawat, 2007
(Continued)
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Family Scientific name Common name Used part References
Berberis trifolia (Cham. & Schltdl.)
Schult. & Schult.f.
– Root, stem Willaman and Schubert, 1961
Berberis turcomanica Kar. ex Ledeb. – Leaves Khamidov et al., 1996a,b,c
Berberis umbellata Wall. ex G.Don Himalayan barberry Roots Singh et al., 2012
Berberis vulgaris L. Barberry Stems and roots Imanshahidi and Hosseinzadeh,
2008
Roots Koncˇic´ et al., 2010
Roots Kosalec et al., 2009
Berberis waziristanica Hieron. – Root bark Atta-ur-Rahma and Ahmad,
1992
Caulophyllum thalictroides (L.)
Michaux (ex-Leontice thalictroides L.)
Blue cohosh – Willaman and Schubert, 1961
Jeffersonia diphylla (L.) Pers. Twinleaf – Willaman and Schubert, 1961
Mahonia borealis Takeda – – Willaman and Schubert, 1961
Mahonia fortunei (Lindl.) Fedde Fortune’s Mahonia wood Willaman and Schubert, 1961
Mahonia napaulensis DC. (ex-
Mahonia griffithii; ex-Mahonia
manipurensis Takeda; Mahonia
sikkimensis Takeda)
Nepal Barberry bark Willaman and Schubert, 1961
Mahonia simonsii Takeda – – Willaman and Schubert, 1961
Nandina domestica Thunb. Nandina, heavenly bamboo or
sacred bamboo
bark, root Willaman and Schubert, 1961
Sinopodophyllum hexandrum (Royle)
T.S.Ying
Himalayan May Apple, Indian
may apple
Root, rhizome Willaman and Schubert, 1961
Menispermaceae Tinospora sinensis (Lour.) Merr.
(ex-Tinospora cordifolia) (Willd.) Miers
Gulbel, indian tinospora Stem Srinivasan et al., 2008
– Singh et al., 2003
Papaveraceae Argemone albiflora Hornem.
(ex-Argemone alba F.Lestib.)
White prickly poppy, Bluestem
pricklypoppy
Aerial part and roots Slavikova et al., 1960
Foote, 1932
Israilov and Yunusov, 1986
Argemone hybrida R.Otto & Verloove – Leaves and stem Israilov and Yunusov, 1986
Argemone mexicana L. Prickly poppy Apigeal parts, seeds Haisova and Slavik, 1975;
Israilov and Yunusov, 1986;
Fletcher et al., 1993
Leaves Bapna et al., 2015
Seeds Fletcher et al., 1993
– Singh, 2014
– Majumder et al., 1956; Hakim
et al., 1961; Misra et al., 1961
Superterranean parts Slavikova and Slavik, 1955
Roots
– Santos and Adkilen, 1932; de
Almeida Costa, 1935; Misra
et al., 1961; Doepke et al., 1976;
Abou-Donia and El-Din, 1986;
Monforte-Gonzalez et al., 2012
Roots Pathak et al., 1985; Kukula-Koch
and Mroczek, 2015
Leaves and capsules Schlotterbeck, 1902
Whole plant Bose et al., 1963; Haisova and
Slavik, 1975
Latex Santra and Saoji, 1971
(Continued)
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Argemone ochroleuca Sweet Chicalote Seeds Fletcher et al., 1993
Argemone platyceras L. Chicalote poppy, crested poppy Leaves and stem Israilov and Yunusov, 1986
Argemone subintegrifolia Ownbey – Aerial part Stermitz et al., 1974
Argemone squarrosa Greene Hedgehog pricklypoppy Aerial part Stermitz, 1967
Bocconia frutescens L. Plume poppy, tree poppy, tree
celandine, parrotweed, sea
oxeye daisy, john crow bush
Leaves Slavik and Slavikova, 1975
Roots, stalks, leaves Taborska et al., 1980
Chelidonium majus L. Celandine poppy Roots Jusiak, 1967
Corydalis chaerophylla DC. Fitweed Roots Jha et al., 2009
Corydalis ophiocarpa Hook. f. et
Thoms
Fitweed Manske, 1939
Corydalis solida subsp. brachyloba Fitweed Aerial parts Sener and Temizer, 1988, 1991
Corydalis solida subsp. slivenensis
(Velen.) Hayek (ex-Corydalis
slivenensis Velen.)
Fitweed – Kiryakov et al., 1982a,b
Corydalis solida subsp. tauricola Fitweed – Kiryakov et al., 1982b
Rhizome Sener and Temizer, 1990
Corydalis turtschaninovii Besser.
(ex-Corydalis ternata (Nakai) Nakai)
Fitweed Tubers Lee and Kim, 1999
Eschscholzia californica Cham. Californian poppy Roots Gertig, 1964
Glaucium corniculatum (L.) Rud.
subsp. corniculatum
Blackspot Hornpoppy Aerial parts Doncheva et al., 2014
– Slavik and Slavikova, 1957
Glaucium grandiflorum Boiss. &
A.Huet
Red Horned Poppy,
Grand-flowered Horned Poppy
Aerial part Phillipson et al., 1981
Hunnemannia fumariifolia Sweet Mexican Tulip Poppy, Golden
Cup
Roots Slavikova and Slavik, 1966
Macleaya cordata (Willd.) R.Br. Plume poppy – Kosina et al., 2010
Macleaya microcarpa (Maxim.) Fedde Poppy Roots Peˇncˇíková et al., 2011
Papaver dubium L. Long-Head Poppy Roots Slavik et al., 1989
Papaver dubium var. lecoquii Long-Head Poppy Latex Egels, 1959
Papaver rhoeas L. var. chelidonioides Corn Poppy Roots Slavík, 1978
Papaver hybridum L. Poppy Aerial part Phillipson et al., 1981
Sanguinaria canadensis L. Bloodroot Greathouse, 1939
Ranunculaceae Coptis chinensis Franch. Chinese goldthread Roots Jin and Shan, 1982
Roots Lou et al., 1982
Coptis japonica (Thunb.) Makino Japanese goldthread Rhizome Kubota et al., 1980
Coptis teeta Wall. Gold thread Rhizome Chen and Chen, 1988
Rhizome Zhang et al., 2008
Roots
Hydrastis canadensis L. Goldenseal – Baldazzi et al., 1998
– Leone et al., 1996
Xanthorhiza simplicissima Marshall Yellowroot Root, stem, and leaves Okunade et al., 1994
Rutaceae Evodia meliaefolia (Hance ex Walp.)
Benth.
– Bark Perkin and Hummel, 1895
Phellodendron amurense Rupr. Amur cork tree Bark Chiang et al., 2006
Root bark Zhang et al., 2008
Trunk bark
Perennial Branch bark
Annual branches
Leaves
(Continued)
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Phellodendron chinense C. K.
Schneid.
Chinese cork tree Bark Chan et al., 2007
Phellodendron chinense var.
glabriusculum C. K. Schneid.
(ex-Phellodendron wilsonii Hayata &
Kaneh.)
Chinese cork tree Bark, branch, leaf and
heartwood
Chen, 1981
– Tan et al., 2013
Bark Chen, 1982
Phellodendron lavallei Dode Lavalle corktree Bark Yavich et al., 1993
Zanthoxylum monophyllum (Lam.) P.
Wilson
Palo rubio Stem and branches Stermitz and Sharifi, 1977
Zanthoxylum quinduense Tul. – – Ladino and Suárez, 2010
the shade-dried samples was 4.6% (w/w) for methanolic cold
extraction and 1.29% (w/w) for methanolic hot extraction (Babu
et al., 2012).
Along with extraction temperature, the choice of solvents
is considered a critical step in berberine extraction as well
(Figure 2). As seen in Table 3, methanol, ethanol, aqueous or
acidified methanol or ethanol are the most used extraction
solvents. The acidified solvents (usually with the addition of 0.5%
of inorganic or organic acids) are used to combine with free
base organic alkaloids and transform them in alkaloid salts with
higher solubility (Teng and Choi, 2013). The effect of different
inorganic acids like hydrochloric acid, phosphoric acid, nitric
acid, and sulfuric acid as well as the effect of an organic acid
like acetic acid were tested on berberine content and other
alkaloids in rhizomes of Coptis chinensis Franch by Teng and
Choi (2013). In this case, 0.34% phosphoric acid concentration
was considered optimal. Moreover, when compared to other
classical extraction techniques like reflux and Soxhlet extraction,
the cold acid assisted extraction gave 1.1 times higher berberine
yields.
Large solvent volumes and long extraction time represent
other drawbacks of conventional extraction methods (Mokgadi
et al., 2013). For example, Rojsanga and Gritsanapan (2005)
used maceration process to extract 100 g of C. fenestratum
plant material with a total volume of 3,200mL solvent (80%
ethanol) over a period of 416 h. Furthermore, in a different
study, Rojsanga et al. (2006) used several classical extraction
techniques likemaceration, percolation, and Soxhlet extraction to
extract the berberine from C. fenestratum stems. This time even
if the extracted plant material was in a lower amount than the
previous study (30 vs. 100 g), large solvent volumes (2,000mL
for maceration, 5,000mL for percolation, and 600mL for Soxhlet
extraction) over long time periods (7 days for maceration
and 72 h for Soxhlet extraction) were employed (Rojsanga and
Gritsanapan, 2005; Rojsanga et al., 2006).
Large solvent volumes are characteristic for other
conventional methods too. Shigwan et al. (2013) extracted
berberine from Berberis aristata and B. tinctoria powdered stem
bark (800 g) using hot extraction (50◦C for 3 h) with 2,500mL
methanol (Shigwan et al., 2013).
Even though conventional methods are widely used in
berberine extraction, a number of other different methods have
been developed lately. This led to an improved extraction
efficiency, a decreased extraction time and solvents’ volumes used
in the extraction. Thus, ultrasound assisted solvent extraction
(USE), microwave-assisted solvent extraction (MAE), ultrahigh
pressure extraction (UPE), and supercritical fluid extractions
(SFE), pressurized liquid extraction (PLE) have been successfully
used as alternative extraction techniques with better results when
compared with classical extraction methods.
Ultrasonically and microwave-assisted extraction are
considered green, simple, efficient, and inexpensive techniques
(Alupului et al., 2009).
Teng and Choi (2013) extracted berberine from Rhizome
coptidis by optimized USE. Using response surface methodology,
they identified that the optimal extraction conditions were 59%
ethanol concentration, at 66.22◦C within 46.57min. A decrease
in the extraction time (39.81min) was obtained by Chang (2013).
He used the combination of ionic liquids solutions as green
solvents with USE to extract berberine from Coptis chinensis in
order to apply an environmentally friendly approach (Chang,
2013). Moreover, in their study, Xu et al. (2017) compared
several extraction tehniques like USE, distillation, and Soxhlet
extraction in order to establish an high-efficient method
for phellodendrine, berberine, and palmatine extraction from
fresh Phellodendron bark (Cortex phellodendri). In the case of
berberine, the combination of simple or acidified solvent (water,
ethanol, andmethanol) with the adjustment of the specific setting
characteristics to each extraction type enabled them to determine
the highest extraction yield. They concluded that the use of
USE and hydrochloric acid-acidified methanol were the most
efficient in extracting berberine. The USE extraction yield was
significantly higher when compared to distillation and Soxhlet
extraction, with values of ∼100 mg/g toward 50 and 40 mg/g
berberine, respectively (Xu et al., 2017).
The important reduction in organic solvent and extraction
time determined the increasing interest in MAE, too. Lately,
MAE was used as a green and cost-effective alternative to
conventional methods. Using central composite design, Satija
et al. (2015) successfully optimized the MAE parameters in terms
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FIGURE 2 | Short view on berberine extraction methods.
of irradiation power, time, and solvent concentration to extract
berberine form Tinospora cardifolia. They compared two classical
extraction techniques like maceration and Soxhlet extraction
with MAE under optimized conditions (60% irradiation power,
80% ethanol concentration, and 3min extraction time). The
results showed that MAE extraction had the highest yield
of berberine content with 1.66% (w/w) while Soxhlet and
maceration had 1.04 and 0.28% (w/w), respectively. Their study is
emphasizing the dramatic time reduction in case of MAE (3min)
when compared with Soxhlet extraction (3 h) and maceration (7
days) together with solvent and energy consumption (Satija et al.,
2015).
Another novel extraction technique considered to be
environmentally friendly is UPE. The interest toward this
extraction technique is increasing because it presents several
advantages toward classical extraction techniques like increased
extraction yields, higher quality of extracts, less extraction
time, and decreased solvent consumption (Xi, 2015). These are
achieved at room temperature by applying different pressure
levels (from 100 to 600MPa) between the interior (higher values)
and the exterior of cells (lower values) in order to facilitate the
transfer of the bioactive compounds through the plant matrices
in the extraction solvent (Liu et al., 2006, 2013). In the study
regarding berberine content in Cortex phellodendri, Guoping
et al. (2012) made a comparison between UPE, MAE, USE, and
heat reflux extraction techniques. They observed that the higher
extraction yield and the lower extraction time was obtained in
case of UPE with 7.7 mg/g and 2min extraction time toward
reflux, USE and MAE with 5.35 mg/g and 2 h, 5.61 mg/g and 1 h.
and 6 mg/g and 15min, respectively (Guoping et al., 2012).
Super critical fluid extraction is another environmentally
friendly efficient technique used in phytochemical extraction.
Because the extraction is performed in the absence of light and
oxygen, the degradation of bioactive compounds is reduced. Also,
the inert and non-toxic carbon dioxide used as a main extraction
solvent in combination with various modifiers (e.g., methanol)
and surfactants (e.g., Tween 80) at lower temperatures and
relatively low pressure, allows the efficient extraction of bioactive
compounds (Liu et al., 2006; Farías-Campomanes et al., 2015). In
case of berberine extraction from the powdered rhizome ofCoptis
chinensis Franch, the highest recovery of berberine was obtained
when 1,2-propanediol was used as amodifier of supercritical CO2
(Liu et al., 2006).
Pressurized liquid extraction, also known as pressurized
fluid extraction, pressurized solvent extraction, and accelerated
solvent extraction (ASE) is considered a green technology used
for compounds extraction from plants (Mustafa and Turner,
2011). Compared with conventional methods, PLE increases
the extraction yield, decreases time and solvent consumption,
and protects sensitive compounds. In their study, Schieffer and
Pfeiffer (2001) compared different extraction techniques like
PLE, multiple USE, single USE, and Soxhlet extraction in order
to extract berberine from goldenseal (Hydrastis canadensis).
When compared in terms of extraction yield the results are
comparable,∼42 mg/g berberine, except single USE with slightly
lower content (37 mg/g berberine). Big differences were observed
in the extraction time, PLE requiring only 30min for a single
sample extraction compared to 2 h for multiple extraction
techniques or 6 h for Soxhlet extraction (Schieffer and Pfeiffer,
2001).
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TABLE 3 | Extraction and detection methods for berberine in different herbal and biological matrixes.
Sample (weight) Extraction method Detection method References
Dried stem powder
Coscinium fenestratum
(Gaertn.) (1 g)
Extraction solvents (ES): water, methanol–water (1:1.
v/v), and methanol
Sonication (15min, room temperature)
Centrifugation (2,800 rpm, 15min)
Filtration and evaporation
Extracts resolubilization (methanol:water, 9:1 v/v)
HPLC - DAD Column: ODS, Chromolith, RP-18e,100 ×
4.6mm Mobile Phases: Methanol/Deionized Water
(90:10, v/v) Flow: 0.5 mL/min, Temperature: 25◦C UV
Spectrophotometric Analysis
Akowuah et al., 2014
C. fenestratum
(Gaertn.) (10 g)
ES: methanol
Hot extraction: sample refluxed with ES for 3 h
Filtration and evaporation.
Extracts resolubilization (methanol)
TLC
Adsorbent: Silica Gel GF 254
Solvent system: n-Butanol: Ethyl acetate: Acetic acid
(2.5:1.5:1, v/v/v)
Detection: 254 and 366 nm
Arawwawala and
Wickramaar, 2012
Cold extraction: sample extraction with ES for 24 h
Filtration and evaporation.
Extracts resolubilization (methanol)
Dried C. fenestratum
(0.1 g)
ES: absolute methanol
Cold extraction: sample extraction at −20◦C
Hot extraction: water bath sample extraction at 50◦C
ES: absolute ethanol
Cold extraction sample extraction at −20◦C
Hot extraction: water bath sample extraction at 50◦C
Samples centrifugation (10min at 10◦C after cooling
down)
Samples filtration
HPLC
Column: C18, 250 × 4.6mm, 5µm
Mobile Phases: Acetonitrile/0.1% Trifluro-acetic acid
(50:50, v/v)
Detection: 344 nm
Flow: 0.8 mL/min
Babu et al., 2012
C. fenestratum (1,000g)
Capsules (containing
62.5mg C.
fenestratum)
ES: petroleum ether, chloroform, methanol (1L each)
Soxhlet extraction: with each ES for 3 days at
(30–40◦C)
ES: methanol (10mL)
Extraction for 1 h
Filtration and evaporation
Resolubilisation in methanol (5mL)
HPLC
Column: Luna C18, 150 × 4.6mm, 5µm, Phenomenex
Mobile Phases: (A) Potassium dihydrogen phosphate
(pH −2.5) and (B) Acetonitrile
Detection: 220 nm
Flow: 1 mL/min
HPTLC
Adsorbent: Silica Gel 60F 254
Solvent system: n-Butanol: Glacial acetic acid: Water
(8:1:1, v/v/v)
Detection: 350 nm for all measurements
Jayaprakasam and
Ravi, 2014
Tinospora cordifolia
(Willd.), Tribulus
terrestris (L.), Emblica
officinalis (Gaertn.) (3 g)
ES: chloroform
Dried sample trituration with ammonia solution
Drying at room temperature
Extraction with ES for 1h
Chloroform phase extraction with 5% sulfuric acid (x 3)
Basification of acid extract with sodium carbonate (pH
−9)
Extraction of basified solution with chloroform (X 3)
Evaporation of chloroform phase ( temperature under
50◦C)
Residue solubilization with methanol
UV-VIS
UV absorbance: 348 nm
Joshi and Kanaki, 2013
Cortex phellodendri
(2 g)
Ultrahigh pressure extraction (UPE)
Optimal parameters: ES: ethanol (69.1%), liquid-solid
ratio−31.3, extracting pressure−243.30 MPa, extraction
time−2min
HPLC
Column: Hypersil ODS C18, 250 × 4.6mm, 5µm
Mobile Phases: (A) 0.3% triethanolamine aqueous
solution
(pH − 3.5)
Detection: 265 nm
Temperature: 30◦C
Flow: 1 mL/min
Guoping et al., 2012
Rhizome of Coptis
chinensis Franch (1 g)
Supercritical fluid extraction
Extraction time: up to 3 h
Temperature: 60◦C
Pressure: from 200 to 500 bar
Flow-rate of carbon dioxide (gaseous state): 1 L/min
Flow-rate of modifier: 0.4 mL/min.
Organic solvent modifier systems:
ethanol-modified supercritical carbon dioxide,
methanol-modified supercritical carbon dioxide,
HPLC
Column: Diamonsil C18, 250 × 4.6mm, 5µm
Mobile Phases: 33mM Potassium dihydrogen
phosphate : acetonitrile (70:30, v/v)
Detection: 345 nm
Flow: 1 mL/min
Liu et al., 2006
(Continued)
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Sample (weight) Extraction method Detection method References
1,2-propanediol-modified supercritical carbon dioxide,
5% Tween 80 in methanol-modified supercritical carbon
dioxide, 5% Tween in ethanol-modified supercritical
carbon dioxide
Soxhlet extraction
ES: hydrochloric acid: methanol (1: 100, v/v)
Time: 8 h
Cortex pellodendri
amurensis (1 g)
Ultrahigh pressure extraction
ES: ethanol (50 %), liquid-solid ratio −30: 1, extracting
pressure −400 MPa, extraction time −4min, extraction
temperaturte −40◦C
Ultrasonic extraction
ES: 70% ethanol
Sample soaking for 24 h in 40ml ES
Sonic extraction for 60min at 30◦C
HPLC- DAD
Column: Daisopak SP-120-5-ODS_BP, 250 × 4.6mm,
5µm
Mobile Phases: (A) acetonitrile and (B) phosphoric acid:
water (0.7:100, v/v)
Detection: 345 nm
Temperature: 25◦C
Flow: 1 mL/min
Liu et al., 2013
Heat reflux extraction
ES: 70% ethanol
Sample soaking for 24 h in 40ml ES
Sample extraction for 4 h at boiling state
Soxhlet extraction
ES: 70% ethanol
Sample soaking for 24 h in 40ml ES
Sample extraction: 4 h
Goldenseal (Hydrastis
canadensis L.) (2, 5,
5 g)
Pressurized hot water extraction
ES: water at 140◦C,
Optimal parameters: pressure: 50 bars and flow rate: 1
mL/min, Time: 15min
Reflux extraction
ES: methanol (200mL)
Sonication: 4 h at 80◦C
Ultrasonic extraction
ES: methanol (50mL)
Reflux: 6 h with continuous stirring
HPLC-DAD
Column: Zorbax eclipse Plus C 18, 75 x 4.6mm, 3.5µm
Mobile phases: (A) 0.1 % Formic Acid (pH 2.7) and (B)
methanol
Detection: 242 nm
Temperature: 35◦C
Flow: 1 mL/min
MS
Detection: ESI (+)
Capillary temperature: 200◦C, Sheath gas: 80, Capillary
voltage: 20 V, Tube lens voltage: 5V
Mokgadi et al., 2013
Berberis aristata DC
(1.5 g), Berberis aristata
herb extract (0.1 g),
Ayurvedic form (6 g)
Crude herb reflux extraction
ES: methanol (100mL) for 1 h in a water bath
Filtratio
Reextraction with ES (50mL) for 30min (×2)
Filtrates combination and concentration to 50mL
Herb extracts ultrasonic extraction
ES: methanol (up to 10mL)
Sonication
Filtration
HPLC
Column: Zorbax ODS II, 250 x 4.6mm, 5µm
Mobile phase: potassium hydrogen phosphate buffer
(pH 2.5)/ acetonitrile
Detection: 346 nm
Temperature: 40◦C
Flow: 1 mL/min
Singh R. et al., 2010
Ayrvedic form ultrasonic extraction
ES: methanol (up to 25mL)
Sonication
Berberis aristata DC
root
Soxhlet extraction
ES: ethanol
Berberine isolation
Ethanolic extract concentration to obtain a syrup mass
Dissolvation in hot water and filtration
Acidification (36.5% w/v hydrochloric acid)
Cool: ice bath - 30min, overnight in refrigerator
HPTLC
Stationary phase: precoated silica gel 60GF254
Mobile phases: n-butanol: glacial acetic acid: water
(12:3:4 v/v/v)
Temperature: 33 ± 5◦C
Detection: 350 nm
Patel, 2013
Mahonia manipurensis
(Takeda) stem bark
(100 g)
Cold extraction
ES: 80% methanol (1,000mL)
Stirring at room temperature
Extract concentration
TLC
Stationary phase: precoated silica gel G F254
Mobile phase: hexane: ethyl acetate: methanol (56:20:5)
Fraction purification: positive test using Dragendroff’s
reagent
Further analysis of purified fraction
Mobile phase: chloroform: ethyl acetate: diethylamine:
methanol: 20% ammonium hidroxide (6:24:1.5:6:0.3)
Pfoze et al., 2014
(Continued)
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HPLC
Column: Water Symmetry C18, 250 x 4.6mm, 5µm
Mobile phase: methanol/ formic acid buffer (0.1%, v/v)
Detection: 346 nm
Flow: 1 mL/min
UV-VIS
UV spectra: 200–500 nm
ESI-MS
Coscinium fenestratum
(100 g)
Maceration
ES: 80% ethanol (500ml), 160 h
Shaken: 80 h (200 rpm), stand: 80 h
Reextraction: 48 h, shaken: 24 h, stand: 24 h
Combined extracts concentration
Evaporation to dryness (dry extract)
Resolubilisation in 80% ethanol (10mg dry extract/mL)
TLC
Stationary phase: Silica gel GF254
Mobile phase: ethyl acetate : butanol : formic acid :
water (50:30:12:10);
Detection: 366 nm
Rojsanga and
Gritsanapan, 2005
Argemone mexicana Soxhlet extraction
ES: methanol
Evaporation to dryness
Resolubilisation in methanol (known concentration)
HPTLC
Stationary phase: precoated silica gel 60F254
Mobile phases: toluene: ethyl acetate (9:3, v/v).
Detection: 266 nm
Samal, 2013
Tinospora cordifolia
(20 g)
Microwave assisted extraction (MAE)
ES: 80% ethanol
Irradiation power: 60%, Extraction time: 3min
Soxhlet extraction
ES: ethanol, for 3 h
Filtration
Concentration
HPTLC
Mobile phases: methanol: acetic acid: water (8: 1: 1,
v/v/v).
Detection: 366 nm
Satija et al., 2015
Maceration
ES: ethanol (200mL), 7 days, occasional stirring
Berberis aristata,
Berberis tinctoria
(800 g)
Hot extraction
ES: methanol (2.5 L) (X2)
Extraction time: 3 h
Temperature: 50◦C
Extract concentration under vacuum
HPLC
Column: Unisphere C18, 150 x 4.6mm, 5µm
Mobile phase: (A) 0.1% trifluoroacetic acid and (B)
acetonitrile (60:40, v/v)
Detection: 350 nm
Temperature: 30◦C
Flow: 1 mL/min
Shigwan et al., 2013
Coptis chinensis
Franch. (1g)
Acid assisted extraction
ES: several inorganic acids (hydrochloric acid,
phosphoric acid, nitric acid, and sulfuric acid) and one
organic acid (acetic acid)
Extraction time:1–8 h, Acid concentrations: 0–1%
Solvent to sample ratios: 20–60 mL/g
Maceration at 25◦C
Filtration
Dilution to 100mL final volume
HPLC
Column: XTerra C18, 250 x 4.6mm
Mobile phase: (A) acetonitrile and (B) 25 mmol/L
potassium dihydrogen phosphate,( 27:75, v/v)
Detection: 345 nm
Temperature: 30◦C
Teng and Choi, 2013
Soxhlet extraction
ES: 50% ethanol (100mL), 4 h at 70◦C
Extract evaporation to dryness
Resolubilization in ES (up to 100mL final volume)
Heating reflux extraction
ES: 50% ethanol
Soaked for 1 h
Extraction: 4 h at 70◦C (heated water bath)
Filtration
Dilution (up to 100mL final volume)
Rabbit plasma (100 µl) Mixing 100 µl sample with 3% formic acid in acetonitrile
(200 µl)
Vortex: 30 s
Centrifugation: 10min at 4◦C
Evaporation of supernatant: under nitrogen stream at
40◦C
LC-ESI-MS
HPLC system
Column: Capcell Pakc18 MG, 100 × 2.1mm, 5µm with
Security Guard C18, 4 × 2mm, 5µm
Mobile Phases: (A) 0.4% formic acid solution and (B) 0.2
% formic acid solution in methanol (60:40, v/v)
Liu et al., 2011
(Continued)
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Residue solubilization: in 100 µl of 20% methanol Temperature: 25◦C
Flow: 0.4 mL/min
MS detection:
Source: ESI (+)
Quantification: MRM mode
Rat plasma Solid phase extraction (SPE)
Cartridges: Oasis HLB (1 cc, 30mg)
Pre-conditioning: 2mL methanol
Equilibrtating:
UPLC-MS/MS
UPLC system
Column: 120 EC-C18, 50 × 4.6mm, 2.7µm with
Security Guard C18, 4 × 2mm, 5µm
Mobile Phases: (A) 10mM ammonium acetate in water
(pH- 4.5) and (B) acetonitrile
Temperature: 35◦C
Flow: 0.8 mL/min
MS detection:
Source: ESI (+)
Quantification: MRM mode
Liu M. et al., 2015
Rat plasma
Rat tissue
Rat plasma
ES: methanol
Mixing sample (200 µl) with internal standard (40 µl) and
ES (560 µl)
Vortex: 20 s
Centrifugation: 10min, 12,000x g
Filtration
UPLC-MS/MS
UPLC system
Column: Acquity BEH C18, 50 × 2.1mm, 1.7µm
Mobile Phases: (A) acetonitrile and (B) formic acid: water
(0.1:99.9, v/v)
Flow: 0.25 mL/min
MS detection:
Source: ESI (+)
Quantification: MRM mode
Wang et al., 2016
Rat tissue
Grinding: 3mL physiological saline with 600mg tissue
Centrifugation: 10min, 12,000x g, 4◦C
Mixing supernatant (200 µl) with internal standard (40 µl)
and ES (560 µl)
Vortex: 20 s
Centrifugation: 10min, 12,000x g
Filtration
Rat plasma Evaporation of 10 ul IS in the working tube
Mixing sample (200 µl) with internal evaporated standard
Vortex: 1min
Mixing sample with 10 µl 1% formic acid and 200 µl
acetone
Vortex: 2min
Centrifugation: 10min, 10,000 rpm
Mixing supernatant with 200 µl methanol
Vortexing, centrifugation
Mixing supernatant wit 400 µl acetonitrile
Vortexing, centrifugation
Evaporation to dryness (37◦C, under nitrogen stream)
Resolubilization in methanol
LC-MS/MS
LC system
Column: Zorbax Eclipse XDB-C18, 150 × 2.1mm,
3.5µm
Mobile Phases: (A) acetonitrile and (B) water with 1%
acetic acid and 0.001 mol/L ammonium acetate
Flow: 0.2 mL/min
MS detection:
Source: ESI (+)
Quantification: MRM mode
Xu et al., 2015
Rat plasma ES: 90% methanol
Mixing sample (100 µl) with internal standard (10 µl) and
ES (100 µl)
Vortex: 1min
Centrifugation: 10min, 12,000 rpm, 4◦C
Supernatant evaporation to dryness under nitrogen
stream
Resolubilization (100 µl ES)
UPLC-MS/MS
UPLC system
Column: Acquity UPLC BEH C18, 50 × 2.1mm, 1.7µm
Mobile Phases: (A) formic acid: water (0.1:99.9, v/v) and
(B) acetonitrile
Flow: 0.4 mL/min
MS detection:
Source: ESI
Quantification: MRM mode
Yang et al., 2017
When referring to berberine extraction from biological
samples, the extraction process is relatively simple and
involves several steps like sample mixing with extraction
solvents (e.g., methanol, acetone, acetonitrile), vortex,
centrifugation followed by supernatant evaporation
under nitrogen stream (Table 3). Other extraction
techniques like solid phase extraction (SPE) can also be
applied.
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ANALYTICAL TECHNIQUES
After extraction and purification, the separation and
quantification of berberine are commonly resolved by
chromatographic methods. According to literature studies,
berberine determination in plants was predominantly performed
using methods like UV spectrophotometry (Joshi and Kanaki,
2013), HPLC (Babu et al., 2012; Akowuah et al., 2014), HPTLC
and TLC (Rojsanga and Gritsanapan, 2005; Arawwawala and
Wickramaar, 2012; Samal, 2013), capillary electrophoresis (Du
and Wang, 2010), while berberine content in biological fluids
was mainly achieved by using LC-MS (Deng et al., 2008; Feng
et al., 2010), UPLC-MS (Liu M. et al., 2015; Liu L. et al., 2016),
UHPLC/Q-TOF-MS (Wu et al., 2015).
UV-Vis spectrophotometry can be considered as one of the
most rapid detection methods for berberine quantitative analysis
from plant extracts. Based on the Beer-Lambert law, berberine
concentration can be determined according to its absorption
maxima at 348 nm. Joshi and Kanaki (2013) quantified berberine
in Rasayana churna samples in the range of 2–20 µg/mL, the
interference with other compounds being avoided by the specific
isolation of the alkaloid fraction (Joshi and Kanaki, 2013).
Next, high-performance liquid chromatography (HPLC) is a
versatile, robust, and widely used technique for the qualitative
and quantitative analysis of natural products (Sasidharan et al.,
2011). This approach is widely used in berberine identification
and quantification. Generally, the choices of stationary phase
in berberine separation are variants of C18-based silica column
(Table 3) with a mobile phase consisting of simple or acidified
solvents like water, methanol, or acetonitrile, used as such
or in combination with phosphate buffers. Normally, the
identification and separation of berberine can be accomplished
using either isocratic or gradient elution system. Berberine
identification is further accomplished using high sensitivity UV
or DAD (diode array detectors) detectors. For example, Shigwan
et al. (2013) developed in his study a reverse phase HPLC
method with photodiode array detection (PDA) to quantify
berberine from Berberis aristata and B. tinctoria. They used
a Unisphere-C18 column (5µm, 4.6 × 150mm) with an
isocratic gradient of acidified water (with 0.1% trifluoroacetic
acid) and acetonitrile (60:40, v/v) to elute berberine within
5min. The developed method was reproducible, validated,
precise, and specific for berberine quantification (with a
concentration range between 0.2 and 150µg/mL; Shigwan et al.,
2013).
Two other commonly used techniques in berberine
quantification are thin layer chromatography (TLC) and
high performance thin layer chromatography (HTPLC).
Sometimes, these methods are preferred over HPLC, offering
the possibility of running several samples simultaneously along
with the use of small amount of both samples and mobile phases
(Samal, 2013). For these reasons, Samal (2013) used an HPTLC
method to quantify berberine from A. mexicana L. using toluene
and ethyl acetate (9:3, v/v) as mobile phases, and a silica gel
plate as stationary phase, they developed a simple, rapid, and
cost-effective method for berberine quantification. The LOD
(0.120 µg) and LOQ (0.362 µg) of the method are in accordance
with high-quality requirements.
Following the same principles (small sample volume,
high separation efficiency, and short analysis time), capillary
electrophoresis (CE) was successfully used in berberine
analysis. Du and Wang (2010) used CE with end-column
electrochemiluminescence (ECL) detection for berberine
analysis in both tablets and Rhizoma coptidis. Using a 4min
analysis time, a small sample volume (3.3 nL) and a LOD of (5×
10−9 g/mL), the developed method proved to be highly sensitive
and with good resolution (Du and Wang, 2010).
Besides UV, HPLC, HTPLC, TLC, and CE, other detection
methods like liquid chromatography coupled with mass
spectrometry (LC/MS) are currently employed to quantify
berberine in biological fluids. Generally, it is considered a
powerful technique for the analysis of complex samples because
it offers rapid and accurate information about the structural
composition of the compounds, especially when tandem mass
spectrometry (MSn) is applied. For example, Xu et al. (2015)
developed a sensitive an accurate LC-MS/MS method to
determine berberine and other seven components in rat plasma
using multiple reactions monitoring (MRM) mode. Compounds
separation was optimized using six different types of reverse-
phase columns, and two different mobile phases (methanol–
water and acetonitrile–water with different additives). Additives
like formic acid, acetic acid, and ammonium acetate were added
in different concentrations as follows: 0.1, 0.5, 1, and 2% for
formic acid, 0.1, 0.5, 1, and 2% for acetic acid and 0.0001, 0.001,
0.01 mol/L for ammonium acetate. The method was also tested
in terms of specificity, linearity, lower limit of quantification
(LLOQ), precision, accuracy, and stability (Xu et al., 2015).
ANTIOXIDANT EFFECT
Under normal conditions, the body maintains a balance
between the antioxidant and pro-oxidant agents (reactive oxygen
species—ROS and reactive nitrogen species—RNS; Rahal et al.,
2014).
The imbalance between pro and antioxidants occurs in case of
increased oxidative stress (Bhattacharyya et al., 2014).
The oxidative stress builds up through several mechanisms: an
increase in the production of reactive species, a decrease in the
levels of enzymes involved in blocking the actions of pro-oxidant
compounds, and/or the decrease in free radical scavengers (Pilch
et al., 2014).
An experimental study demonstrated the effect of berberine
on lipid peroxidation after inducing chemical carcinogenesis in
small animals (rats). An increase in LPO (lipid peroxidation) was
observed after carcinogenesis induction, but also its significant
reversal after berberine administration (30 mg/kg). Berberine
shows therefore at least partial antioxidant properties, due to its
effect on lipid peroxidation (Thirupurasundari et al., 2009).
Other mechanisms involved in the antioxidant role of
berberine are: ROS/RNS scavenging, binding of metals leading
to the transformation/oxidation of certain substances, free-
oxygen removal, reducing the destructiveness of superoxide ions
and nitric oxide, or increasing the antioxidant effect of some
endogenous substances. The antioxidant effect of berberine was
comparable with that of vitamin C, a highly-potent antioxidant
(Shirwaikar et al., 2006; Ahmed et al., 2015).
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The increase in blood sugar leads to oxidative stress not
by generating oxygen reactive species but by impairing the
antioxidant mechanisms. Administration of berberine to rats
with diabetes mellitus increased the SOD (superoxide dismutase)
activity and decreased theMDA (malondialdehyde) level (marker
of lipid peroxidation). This antioxidant effect of berberine could
explain the renal function improvement in diabetic nephropathy
(Liu et al., 2008b).
The oxidative stress plays an important role in the
pathogenesis of many diseases. The beneficial effect of berberine
is presumed to reside mostly in its antioxidant role.
CARDIOVASCULAR EFFECTS OF
BERBERINE
Effect on Cardiac Contractility
The beneficial effect of berberine in cardiac failure was
demonstrated in a study on 51 patients diagnosed with NYHA
(New York Heart Association) III/IV cardiac failure with low left
ventricular ejection fraction (LVEF) and premature ventricular
contractions and/or ventricular tachycardia. These patients
received tablets containing 1.2 g berberine/day, together with
conventional therapy (diuretics, ACEI—angiotensin-converting-
enzyme inhibitors, digoxin, nitrates) for 2 weeks. An increase
in LVEF was observed in all patients after this period, but
also a decrease in the frequency and complexity of premature
ventricular contractions. The magnitude of the beneficial effect
was in direct proportion with the plasma concentration of
berberine (Zeng, 1999).
The Cardioprotective Effect During
Ischemia
Berberine can provide cardio-protection in ischemic conditions
by playing various roles at different levels: modulation of
AMPK (AMP—activated kinase) activity, AKT (protein
kinase B) phosphorylation, modulation of the JAK/STAT
(Janus kinase/signal transducers and activators of transcription)
pathway and of GSK3β (glycogen synthase kinase 3β; Chang
et al., 2016). AMPK is an important enzyme playing an essential
role in cellular metabolism and offering protection in ischemic
conditions by adjusting the carbohydrate and lipid metabolism,
the function of cell organelles (mitochondria, endoplasmic
reticulum) and the apoptosis (Zaha et al., 2016).
Berberine activates the PI3K (phosphoinositide 3-
kinase)/AKT pathway which is considered a compensatory
mechanism limiting the pro-inflammatory processes and
apoptotic events in the presence of aggressive factors. The
activation of this pathway is associated with a reduction of the
ischemic injury through the modulation of the TLR4 (toll-like
receptor 4)-mediated signal transduction (Hua et al., 2007).
Several supporting data indicate that the JAK2/STAT3
signaling plays an important role in cardioprotection against
ischemia-reperfusion injury (Mascareno et al., 2001).
GSK3β is a serine/threonine protein-kinase, an enzyme
involved in reactions associated to important processes at the
cellular level: metabolization, differentiation, proliferation, and
apoptosis. Berberine inhibits this kinase, thereby exercising its
cardioprotective effect (Park et al., 2014).
EFFECTS ON THE ENDOTHELIUM
Berberine induces endothelial relaxation by increasing NO
production from arginine through the activity of eNOS
(endothelial nitric oxide synthase) which is considered a key
element in the vasodilation process. Besides increasing the NO
level, it also up-regulates eNOS mRNA. Furthermore, berberine
facilitates the phosphorylation of eNOS and its coupling to
HSP 90 (heat shock proteins), which consequently increases NO
production (Wang et al., 2009).
Moreover, berberine reduces endothelial contraction
by reducing COX-2 expression. Any imbalance in
COX 1 or 2 activity may alter the ratio between
prothrombotic/antithrombotic and vasodilator/vasoconstrictor
effects (Liu L. et al., 2015).
The beneficial effect of berberine on the TNFα-induced
endothelial contraction was also recorded, as well as an increase
in the level of PI3K/AKT/eNOS mRNA (Xiao et al., 2014).
THE ROLE OF BERBERINE IN
ATHEROSCLEROSIS
Atherogenesis is a consequence of high blood lipid levels and
is associated with inflammatory changes in the vascular wall.
Berberine interferes with this process by up-regulating the
expression of SIRT1 (silent information regulator T1) and by
inhibiting the expression of PPARγ (peroxisome proliferator-
activated receptor-γ). SIRT1 is a NAD-dependent deacetylase.
The SIRT1 enzyme has many targets (PPARγ , p53), all playing
different roles in atherogenesis (Chi et al., 2014).
The Role of Berberine in Lipid Metabolism
The effects of berberine on lipid metabolism are also the
consequence of its effects on LDL cholesterol receptors. On one
hand, these receptors are stabilized by an extracellular signal-
regulated kinase (ERK)-dependent pathway, and on the other,
berberine increases the activity of LDL receptors through the JNK
pathway (Cicero and Ertek, 2009).
Moreover, berberine has an effect on ACAT (cholesterol
acyltransferases), a class of enzymes that transform cholesterol
into esters, thus playing an essential role in maintaining
cholesterol homeostasis in different tissues. There are two types
of ACAT enzymes, ACAT1, and ACAT2. ACAT1 is a ubiquitous
enzyme, while ACAT2 can be found only in hepatic cells and
enterocytes. Berberine influences the activity of ACAT2 without
an effect on ACAT1, therefore reducing the intestinal absorption
of cholesterol and decreasing its plasmatic level (Chang et al.,
2009; Wang et al., 2014).
The hypolipidemic effect of berberine is also a result of its
action on PCSK9 (proprotein convertase subtilisin kexin 9). This
enzyme can attach itself to LDL receptors, leading to a decrease in
LDL metabolization and an increase in its blood level (Xiao et al.,
2012).
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In a clinical trial, 63 patients with dyslipidemia were randomly
divided in three groups. The first group was treated with
berberine (1,000 mg/day), the second with simvastatin (20
mg/day) and the third with a combination of berberine and
simvastatin. The authors reported a 23.8% reduction in LDL-C
levels in patients treated with berberine, a 14.3% reduction in
those treated with simvastatin and a 31.8% LDL-C reduction in
the group treated with both simvastatin and berberine. This result
demonstrates that berberine can be used alone or in association
with simvastatin in the treatment of dyslipidemia (Kong et al.,
2008).
THE ROLE OF BERBERINE IN GLUCOSE
METABOLISM
Many studies demonstrated that berberine lowers blood sugar,
through the following mechanisms:
- Inhibition of mitochondrial glucose oxidation and
stimulation of glycolysis, and subsequently increased
glucose metabolization (Yin et al., 2008a).
- Decreased ATP level through the inhibition of mitochondrial
function in the liver, which may be the probable explanation
of gluconeogenesis inhibition by berberine (Xia et al., 2011).
- Inhibition of DPP 4 (dipeptidyl peptidase-4), a ubiquitous
serine protease responsible for cleaving certain peptides, such
as the incretins GLP1 (glucagon-like peptide-1) and GIP
(gastric inhibitory polypeptide); their role is to raise the
insulin level in the context of hyperglycemia. The DPP4
inhibition will prolong the duration of action for these
peptides, therefore improving overall glucose tolerance (Al-
masri et al., 2009; Seino et al., 2010).
Berberine has a beneficial effect in improving insulin resistance
and glucose utilization in tissues by lowering the lipid
(especially triglyceride) and plasma free fatty acids levels
(Chen et al., 2011).
The effect of berberine (1,500mg day) on glucose metabolism
was also demonstrated in a pilot study enrolling 84 patients with
type 2 diabetes mellitus. The effect, including on HbA1c, was
comparable to that of metformin (1,500 mg/day), one of the most
widely used hypoglycemic drugs. In addition, berberine has a
favorable influence on the lipid profile, unlike metformin, which
has barely any effect (Yin et al., 2008b).
HEPATOPROTECTIVE EFFECT OF
BERBERINE
The hepatoprotective effect of berberine was demonstrated
on lab animals (mice), in which hepatotoxicity was induced
by doxorubicin. Pretreatment with berberine significantly
reduced both functional hepatic tests and histological damage
(inflammatory cellular infiltrate, hepatocyte necrosis; Zhao et al.,
2012).
The mechanism by which berberine reduces hepatotoxicity
was also studied on CCl4 (carbon tetrachloride)-induced
hepatotoxicity. Berberine lowers the oxidative and nitrosamine
stress and also modulates the inflammatory response in the
liver, with favorable effects on the changes occurring in the
liver. Berberine prevents the decrease in SOD activity and
the increase in lipid peroxidation and contributes to the
reduction in TNF-α, COX-2, and iNOS (inducible nitric oxide
synthase) levels. The decrease in transaminase levels supports
the hypothesis according to which berberine helps maintain the
integrity of the hepatocellular membrane (Domitrovic´ et al.,
2011).
NEPHROPROTECTIVE EFFECT OF
BERBERINE
The chronic kidney damage occurring in time in patients with
HT (hypertension) and DM (diabetes mellitus) is well known; it
is mainly due to the atherosclerosis of the renal artery, caused
by inflammation and oxidative stress. The protective effect of
berberine on kidneys was studied on 69 patients suffering from
both HT and DM, with blood pressure and blood sugar levels
controlled with conventional medication. The patients received
300mg berberine/day for 24 months, with 2-week interruptions
every 5 months. The authors recorded lower CRP (C-reactive
protein), MDA and SOD levels after treatment, but without
significant changes in creatinine, arterial pressure, or glycaemia
levels. These results support the renal protective effect of
berberine through its anti-inflammatory and antioxidant effects
(Dai et al., 2015).
Another animal study tested the renoprotective effect of
berberine after administration of HgCl2 (mercury chloride).
This substance induces hepato-renal damage by increasing the
oxidative stress (increases lipid peroxidation and NO levels, and
lowers glutathione and SOD levels as well as the activity of other
protective enzymes). Administration of HgCl2 increased the AST
(aspartate aminotransferase), ALT (alanine aminotransferase),
and ALP (alkaline phosphatase) levels, compared to the control
group. However, pretreatment with berberine lowered these
enzymes significantly. In addition, both urea and creatinine levels
were significantly increased in the HgCl2 group vs. the control
group, and again pretreatment with berberine prevented these
changes. Additionally, the authors recorded higher pro-oxidant
and lower antioxidant levels in the intervention group. These
data support the hepatic and renal protective effects of berberine.
Other studies performed on animal models with CCl4−induced
hepatotoxicity demonstrated the same effect (Othman et al.,
2014).
In addition, berberine can lower the nephrotoxicity caused
by cisplatine. In an animal study, berberine was administered
in progressive doses of 1, 2, 3mg/kg, orally, for 2 successive
days, starting 2 days after cisplatine administration. After the
last doses of berberine, the animals were sacrificed and the
kidneys were examined by the pathologist. The results showed
significant histological improvement and a reduction in NF-
kB (nuclear factor kappa-light-chain-enhancer of activated B
cells), TNF α, COX2 an iNOS levels, all of which support
the anti-inflammatory effect of berberine (Domitrovic´ et al.,
2013).
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FIGURE 3 | Therapeutic effects of berberine in vivo. Mechanisms of berberine in regulation of metabolism, immunity and oxidative reactions. Phosphodiesterase
(PDE), cyclic 3′,5′-adenosine monophosphate (cAMP), phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), Janus kinase/signal transducers and activators of
transcription (JAK/STAT), glycogen synthase kinase 3β (GSK3β), superoxide dismutase (SOD), malondialdehyde (MDA), nitric oxide (NO), cholesterol acyltransferases
(ACAT2), dipeptidyl peptidase-4 (DPP 4), proprotein convertase subtilisin kexin 9 (PCSK9).
IMMUNOMODULATORY EFFECT OF
BERBERINE
The immunomodulatory effect of berberine was demonstrated in
many experimental and clinical contexts.
In an experimental autoimmune myocarditis model,
berberine contributed to mitigate the cardiac damage by:
limiting the rise in anticardiac myosin antibodies, modulating
the activity of certain STATs and blocking Th1 and Th2 cell
differentiation, which play an important role in the pathogenesis
of myocarditis (Liu X. et al., 2016).
Experimental autoimmune neuritis is an experimental animal
model equivalent to the Guillain-Barre syndrome in humans.
This neurologic syndrome is characterized by autoimmune
injury of the peripheral nervous system. The beneficial effect
of berberine on this animal model resided in its influence
on cellular and humoral immunity through the inhibition of
lymphocyte proliferation (especially CD4), and the decrease in
pro-inflammatory cytokines (IL-6 and TNF α; Li et al., 2014).
Experimental autoimmune encephalomyelitis is an
established model of multiple sclerosis. Multiple sclerosis is
a one of the most common diseases of the central nervous
system (CNS) and involves neurodegenerative and inflammatory
processes, and autoimmune demyelination (Ransohoff et al.,
2015). The blood-brain barrier permeability and changes in
matrix metalloproteinase (MMP) levels in the cerebrospinal fluid
and brain were studied using this model (Ma et al., 2010). MMPs
may be involved in demyelination and their activity in tissues
depends on the balance between their level and their tissue
inhibitors. MMP2 and MMP9 are the main endoproteinases
involved in the migration of lymphocytes in CNS and in altering
the BBB (blood brain barrier) (Avolio et al., 2003). Berberine has a
beneficial effect in experimental autoimmune encephalomyelitis
by inhibiting the activity of MMP9, reducing BBB permeability
and, consecutively, by decreasing the inflammatory cellular
infiltration of the CNS (Ma et al., 2010).
The current therapy used for inflammatory bowel diseases,
including glucocorticoids and immunosuppressive agents, has
a low level of safety. The effect of berberine was studied
in combination with 5-ASA (5-aminosalicylic acid) vs. 5-ASA
alone using an experimental animal model with DSS (dextran
sulfate sodium)-induced colitis. The authors analyzed the level
Frontiers in Pharmacology | www.frontiersin.org August 2018 | Volume 9 | Article 55744
Neag et al. Berberine: Botanical Occurrence, Traditional Uses, Extraction and Bioactivities
of proinflammatory cytokines in the animal gut. A decrease in
COX2, IL6, and IL23 mRNA levels was observed in animals
treated only with 5-ASA, whereas animals treated with both 5-
ASA and berberine had a reduction in mRNA levels for COX2,
IL6, IL23 as well as for TNF alfa and IL12b. This beneficial effect
could partially be attributed to the inhibition of NF-kB and the
reduction in JAK2 phosphorylation (through the influence on the
JAK/STAT pathway) by both 5-ASA and berberine (Li et al., 2015;
Figure 3).
Another study demonstrated that berberine increases the
corticosteroid level in rats with experimentally-induced colitis.
This engendered the theory that its beneficial effect may also be
attributed to the increase in endogenous glucocorticoid levels,
compounds with well-known therapeutic effect in inflammatory
bowel disease (Minaiyan et al., 2011).
CONCLUSION
A review of the available scientific literature shows that
the traditional medical uses of berberine-containing plants
have been evaluated by modern pharmacological studies.
Different species of berberine-rich plants have multiple
pharmacological and therapeutic actions, such as antioxidant
and immunomodulatory effects, protective action on the
cardiovascular system, liver and kidney, endothelial relaxation,
regulator on glucose metabolism and atherosclerosis, which
can all be explained by the presence of berberine as well
as other phyto constituents (when dealing with berberine-
containing plant extracts). Moreover, the effects of berberine
vary according to its origin (different plants or pharmaceutical
products) and its concentration, depending on the very diverse
extraction and detection techniques already described. Over
time, modern extraction techniques were increasingly preferred
to classical ones. Since classical methods are generally time- and
solvent-consuming processes, modern extraction techniques
such as USE, MAE, UPE, SFE, and PLE are seen as better
alternatives to overcome these limitations. Furthermore,
berberine, due to its antioxidant and anti-inflammatory
effects, has several clinical applications in many disorders,
from inflammatory conditions to the metabolic syndrome.
However, there are some traditional uses that have not yet
been completely elucidated, and further studies are needed.
Therefore, extensive studies on the potential of plants containing
berberine that have shown aforementioned pharmacological
activities should go through additional in vitro and in vivo
studies.
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Extensive research during last 2 decades has revealed that most drugs discovered today,
although costs billions of dollars for discovery, and yet they are highly ineffective in
their clinical response. For instance, the European Medicines Agency has approved 68
anti-cancer drugs, and out of which 39 has reached the market level with no indication
of increased survival nor betterment of quality of life. Even when drugs did improve
survival rate compared to available treatment strategies, most of these were found to be
clinically insignificant. This is a fundamental problem with modern drug discovery which
is based on thinking that most chronic diseases are caused by alteration of a single
gene and thus most therapies are single gene-targeted therapies. However, extensive
research has revealed that most chronic diseases are caused by multiple gene products.
Although most drugs designed by man are mono-targeted therapies, however, those
designed by “mother nature” and have been used for thousands of years, are “multi-
targeted” therapies. In this review, we examine two agents that have been around for
thousands of years, namely “guggul” from Commiphora and Boswellia. Although we are
all familiar with the search engine “google,” this is another type of “guggul” that has been
used for centuries and being explored for its various biological activities. The current
review summarizes the traditional uses, chemistry, in vitro and in vivo biological activities,
molecular targets, and clinical trials performed with these agents.
Keywords: guggul, guggulsterone, boswellia, boswellic acid, cancer, commiphora, chronic diseases
INTRODUCTION
Despite the remarkable advances made in the field of therapies for chronic diseases including
cancer over the last few decades, they still present a major health burden and are the prime cause
of death across the world. Most of the chronic illnesses are caused by the deregulation of multiple
genes; however majority of the drugs approved by Food and Drug Administration (FDA) target
single gene product or pathway only. This displays one of the major drawbacks of these synthetic
drugs. In addition, these drugs are associated with different adverse side effects and hence not
tolerable by patients (Siddiqui et al., 1984; Sarup et al., 2015; Kunnumakkara et al., 2017; Banik
et al., 2018). Therefore, there is an urgent need to identify novel, safe, and multi-targeted agents for
the prevention and treatment of these diseases (Bordoloi et al., 2016; Kunnumakkara et al., 2018).
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It has been well-evidenced that natural products are effective,
multi-targeted, and extremely safe as they are the roots of many
traditional systems of medicine such as Ayurveda, Unani, Siddha,
traditional Chinese medicine etc. (Shishodia et al., 2008; Harsha
et al., 2017). One such medicine of enormous use in Ayurveda is
“Guggul.” Guggul is the gum resin obtained from two different
plants Commiphora and Boswellia, produced by drying the white
sap of 15–20 years old tree for a year (Figure 1; Hanus et al.,
2005).
The history of guggul goes as far back as 1700 BC. Ancient
script on medicine and surgery; Sushrut Samhita, describes that
guggul when taken orally can cure internal tumors, malignant
sores, obesity, liver dysfunction, intestinal worms, leucoderma,
sinus, and edema. It is also used as an Ayurvedic medicine
for the prevention and treatment of various other diseases
such as inflammatory bowel disease (IBD), ulcers, arthritis,
cardiovascular diseases (CVDs), diabetes etc. (Shishodia et al.,
2008). The main ingredients of guggul are guggulsterone (GS)
and boswellic acid (BA) which are obtained from Commiphora
and Boswellia respectively. It also contains a huge number of
lignans and ketosterols, which contributes to the vivid health
beneficiary effects of guggul (Arora et al., 1971, 1972; Kimura
et al., 2001; Zhu et al., 2001; Francis et al., 2004).
According to Pubmed; “google,” there are 449 publications
on Commiphora, 519 on Boswellia, 207 on guggulsterone, 329
on boswellic acid, and 90 on guggul with earliest being in 1960
describing the “Antiarthritic and anti-inflammatory activity of
the gum “guggul”; and in 1969 on “Analgesic effect of the gum
resin from Boswellia serata.” Some of the major species include
Commiphora wightii (guggul), Commiphora mukul, Commiphora
gileadensis, Boswellia serrata (salai guggul), Boswellia carterii,
Boswellia sacra (source of frankincense & gum resin), Boswellia
ovalifoliolata, Boswellia dalzielii, Boswellia frerean, and Boswellia
FIGURE 1 | (A) Commiphora (Mark W. Skinner/www.discoverlife.org) and
Gum guggul (http://www.varionlife.com). (B) Boswellia (Pankaj
Oudhia/www.discoverlife.org) and Salai guggul.
thurifera. What is common among all these plants and their
products is that all of them exhibit anti-inflammatory activities,
although to a variable extent. The current review describes the
traditional uses, chemistry, molecular targets, in vitro, in vivo
and clinical studies of guggul isolated from Commiphora and
Boswellia.
SOURCE AND CHEMICAL CONSTITUENTS
OF COMMIPHORA AND BOSWELLIA
The guggul tree which belongs to the family Burseraceae, is
mainly found in the dry regions of the Indian subcontinent
mainly India, Pakistan and Bangladesh. The oleogum resin
of C. mukul (guggul tree) is a yellowish substance that is
tapped during winter and ∼700–900 g of resin is obtained
from each tree (Deng, 2007; Shishodia et al., 2015; Yamada
and Sugimoto, 2016). The guggul or balsam or the oleo gum
resin is found in the balsam canals in the phloem of the
large veins of leaf and base of the stem. It is a complicated
mixture of minerals, gum, terpenes, sterols (Guggulsterol -I,-II,-
III,-IV,-V), essential oils, sterones (Z-, E-, M-guggulsterone, and
dehydroguggulsterone-M), ferrulates, lignans, and flavanones.
The ethyl acetate soluble fraction also known as guggulipid,
consists of various bioactive components like diterpenoids,
triterpenoids, steroids, lignans, and fatty tetrol esters. Based
on the pH gradient, further fractionation yields 95% neutral,
4% acidic, and 1% basic fractions. The neutral fraction when
subjected to further fractionation produces 88% non-ketonic and
12% ketonic fractions. A large number of steroids including the
two isomers E-(cis-) and Z-(trans-) GS [4, 17(20)-pregnadiene-
3, 16-dione] were obtained from the ketonic fraction. Nearly 5%
guggulipid and 2% gum guggul by weight is present in the GS
(Figure 2A; Deng, 2007; Shishodia et al., 2008, 2015; Sarup et al.,
2015).
Phenolics are common natural products found in plants and
possess substantial antioxidant and anti-inflammatory effects.
Various phenolic compounds such as hydroxybenzoic acid
derivatives such as gallic acid, protocatechuic acid, gentisic
acid, vanillic acid, p-hydroxy benzoic acid, syringic acid, ellagic
acid, and cinnamic acid derivatives which include caffeic acid,
chlorogenic acid, ferulic acid, sinapic acid (SA), and p-coumaric
acid are largely present in plants. These phenolic compounds
are predominantly available in guggul as well, which in part
contributes to its immense biological function against diverse
human chronic diseases (Hazra et al., 2018).
Guggulsterone is the only known antagonist of farnesoid
X receptor (FXR). This FXR, also known as NR1H4 (nuclear
receptor subfamily 1, group H, member 4), is a bile acid receptor
(BAR). Bioinformatics studies (molecular docking simulation)
revealed that GS binds to FXR and nuclear factor-kappa B
(NF-κB) and it docks into two non-canonical binding sites
of FXR, helix 1-loop-helix 2 loop and parts of helix—helix 8
including helix 8-loop-helix 9 (Meyer et al., 2005; Yang et al.,
2014). Different bile acids and chenodeoxycholic acids act as
natural ligand for FXR, whose expression is elevated in the liver
and intestine. When FXR binds to its ligand, it gets activated
Frontiers in Pharmacology | www.frontiersin.org August 2018 | Volume 9 | Article 68655
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FIGURE 2 | Chemical constituents of Commiphora (guggul) and Boswellia (Salai guggul) (A) Commiphora (B) Boswellia.
and reaches the cell nucleus, where it forms a heterodimer
with RXR. This heterodimer binds to the hormone response
elements on DNA and regulates various genes. FXR activation
downregulates cholesterol 7 alpha-hydroxylase (CYP7A1), the
rate-limiting enzyme in bile acid synthesis from cholesterol by
inducing the expression of small heterodimer partner (SHP)
which in turn inhibits the transcription of CYP7A1 gene. While
obeticholic acid, fexaramine, cafestol, and chenodeoxycholic acid
act as agonist of FXR; GS, from the gum resin of guggul has
also been confirmed to inhibit pro-inflammatory signals, together
with transcription factor NF-κB (Sharma and Sharma, 1977;
Urizar et al., 2002; Shishodia et al., 2008; Yamada and Sugimoto,
2016). Another study reported that the inhibitory activity of
NF-κB is due to the binding of GS to the RH domain of NF-κB
precursor protein p105 containing important sequences for DNA
binding and dimerization (Khan et al., 2013).
B. serrata, commonly known as salai guggul, Indian olibanum,
loban, or kundur, belongs to the Burseraceae family and is found
in dry mountainous regions of India, Northern Africa, and the
Middle East. Burseraceae family includes 17 genera and 600
species of plants. The genus Boswellia has 25 different species
distributed throughout the tropical regions. B. serrata is one such
medicinal plant which exhibits immense potential to combat
various chronic disorders. The active pharmacological principle
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of the oleo gum resin from the trees of different Boswellia
species is the BA (Büchele et al., 2003; Du et al., 2015; Roy
et al., 2016). The gum resin of the Boswellia species mainly
consists of mucus, resin acids, and volatile oil with different
quantitative composition from species to species. The gum resin
of salai guggul contains pentacyclic triterpenic acids, namely
α-boswellic acids, β-boswellic acids, γ-boswellic acid, acetyl-β-
boswellic acid, 11-keto-β-boswellic acid (KBA), acetyl-11-keto-
β-boswellic acid (AKBA), and tetracyclic triterpenic acids like
tirucallic acids viz 3-oxotirucallic acid, 3-hydroxytirucallic acid,
and 3-acetoxytirucallic acid (Figure 2B). Other oleo gum resin
compounds which display biological activities are: betulinic
acid, lupenoic acid, epi-lupeol, isoincensole, isoincensole acetate
and 1-ursene-2-diketone-incensole acetate along with few other
terpenes that can be found in volatile oil (Du et al., 2015; Ammon,
2016; Roy et al., 2016).
MOLECULAR TARGETS OF COMMIPHORA
AND BOSWELLIA
GS suppresses the physiological action of the FXR which is
a nuclear hormone receptor that controls the synthesis and
transport of bile acid (Sinal and Gonzalez, 2002; Urizar et al.,
2002). However, it increases the transcription of bile salt export
pump (BSEP) which is majorly involved in hepatic bile acid
transport (Cui et al., 2003). Besides regulating transport of bile
acid, GS is a potent anti-inflammatory agent which suppresses
LPS-induced NO production (Meselhy, 2003). GS has also been
reported to inhibit the activation of NF-κB by suppressing the
levels of receptor activator of NF-κB ligand (RANKL) (Ichikawa
and Aggarwal, 2006). In 2004, Shishodia and group reported
that GS suppressed the activation of NF-κB and IκB-α kinase
and exhibited antiproliferative activity by inhibiting c-Myc and
cyclin D1. Furthermore, GS has also been found to exert anti-
metastatic effect through reducing the levels of MMP-9, COX-
2, and VEGF (Shishodia and Aggarwal, 2004). This group also
reported that GS induced apoptosis bymodulating the expression
of anti-apoptotic genes, IAP1, XIAP, Bcl-2, cFLIP, Bfl-1/A1, and
survivin (Shishodia and Aggarwal, 2004). Further, GS has also
been found to induce tumor cell apoptosis by activating the
apoptotic genes, caspase-3,−8,−9, and inducing the release of
cytochrome c, cleavage of bid and PARP. This was controlled by
activated mitogen-activated protein kinase 4 (MKK4) mediated
upregulation of c-Jun N-terminal kinase (JNK) and suppression
of Akt. The antiproliferative activity of GS was found to be
supported by reduced levels of cyclin D1, cdc2, and simultaneous
upregulation of cyclin-dependent kinase inhibitors p21 and p27
(Figure 3A; Shishodia et al., 2007).
Boswellic acid is known to inhibit leukotriene synthesis by
inhibiting 5-lipoxygenase (5-LOX) (Safayhi et al., 1992, 1995;
Ammon et al., 1993). This 5-LOX inhibitor has also been found
to reduce the activity of human leukocyte elastase (HLE) in vitro
(Safayhi et al., 1997). Suppression of these molecules contributes
to anti-inflammatory action of Boswellia. Boswellia is also known
to induce apoptosis in cancer cells. In 2007, Bhushan and group
reported that a triterpenediol from B. serrata induced apoptosis
in HL-60 cells through both intrinsic and extrinsic pathways
(Bhushan et al., 2007). In the first case, the triterpenediol was
found to disturb the mitochondrial membrane potential, reduce
Bcl-2/Bax ratio and cause release of AIF, Smac/DIABLO, and
cytochrome c from the mitochondria along with suppression
of survivin and upregulation of caspases-3,−8, and−9, thereby
leading to the cleavage of ICAD and PARP while in the second
case, the oxidative stress generated in the cells due to excessive
ROS and NO production triggered the activation of TNF-R1
and DR4 followed by activation of caspase-8. Another study in
multiple myeloma cells also suggested that BA acetate induces
apoptosis by upregulating death receptor proteins, DR4 and DR5
which subsequently leads to the activation of caspase-8 followed
by caspase-3 (Xia et al., 2005). The role of DR5-mediated pathway
which involves activation of CAAT/enhancer binding protein
homologous protein (CHOP) was reported in AKBA-mediated
apoptosis of prostate cancer cells (Lu et al., 2008). Caspase-8
activation has also been reported in other BA-induced apoptosis
studies (Liu et al., 2002a,b). In 2002, Park et al. hypothesized that
AKBA contributed in the process of proliferation and apoptosis
of tumors by inhibiting platelet-derived growth factor (PDGF)-
stimulated extracellular signal-regulated kinase 1 and 2 (ERK-1
and ERK-2) (Park et al., 2002b). BA mediated apoptosis has also
been evident in cancer cells via activation of p21, an important
cell cycle regulator protein (Glaser et al., 1999; Liu et al., 2006).
Apart from this, AKBA has been found to interfere with IL-6-
induced STAT3 signaling via protein tyrosine phosphatase SHP-1
subsequently causing downregulation of cyclin D1, Bcl-2, Bcl-
xL, Mcl-1, and VEGF, thus impeding proliferation, survival and
angiogenesis of multiple myeloma cells (Kunnumakkara et al.,
2009). Moreover, BA has also been found to suppress metastatic
growth factor, basic fibroblast growth factor (bFGF), chemokine
receptor; CXCR4 and angiogenic factor; VEGFR 2 (Singh et al.,
2007; Pang et al., 2009; Park et al., 2011a). Further, in vivo studies
have unveiled that BA regulates proliferation and metastasis of
cancer cells by downregulating other targets like COX-2, c-Myc,
cyclin D1, MMP-9, VEGF, ICAM-1, Bcl-2, Bcl-xL, survivin, and
cellular inhibitor of apoptosis protein 1 (IAP-1) (Park et al.,
2011a,b; Yadav et al., 2012). Most of these genes are regulated by
the transcription factor, NF-κB which is also downregulated by
BA (Syrovets et al., 2005a,b; Takada et al., 2006). Furthermore,
BA has also been shown to regulate the activity of P-glycoprotein
(Pgp) which is an important class of drug transporters (Weber
et al., 2006). It is also an inhibitor of topoisomerases I and II in
cancer cells (Hoernlein et al., 1999; Syrovets et al., 2000; Zhao
et al., 2003). The anticancer activity of this potential compound
also involves regulation of let-7 and miR-200 microRNA family
(Figure 3B; Takahashi et al., 2012).
THERAPEUTIC PROPERTIES OF GUGGUL
Congregate evidences show guggul to be profoundly effective
against diverse chronic diseases such as Alzheimer’s disease,
arthritis, cancer, pancreatitis, IBD, dermatitis, diabetes, infectious
diseases, intestinal metaplasia, otitis media, respiratory
diseases, asthma, psoriasis, gingivitis etc. Besides, it also
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FIGURE 3 | Various molecular targets of guggul from Commiphora and Boswellia (A) Molecular targets of guggul from Commiphora includes Bcl2, B-cell lymphoma
2; CDC 2, cell division cycle kinase 2; c-FLIP, cellular caspase-8 (FLICE)-like inhibitory protein; COX, cyclooxygenase; FXR, farnesoid X receptor; IKK, IκB kinase; IAP,
Inhibitors of apoptosis proteins; JNK, c-Jun N-terminal kinase; MKK4, mitogen-activated protein kinase kinase 4; MMP, matrix metalloproteinase; NF-κB, nuclear
factor-κB; RANKL, Receptor activator of nuclear factor kappa-B ligand; VEGF, vascular endothelial growth factor; XIAP, x-linked inhibitor of apoptosis protein.
(B) Molecular targets of guggul from Boswellia includes Bcl-2, B-cell lymphoma 2; Bcl-xL, B-cell lymphoma-extra-large; CXCR-4, C-X-C chemokine receptor type 4;
DR, Death receptor; 5-LOX, 5-Lipoxygenase; MMP, Matrix metalloproteinase; NF-κB, nuclear factor-κB; Topo, Topoisomerase; ICAM-1, Intercellular adhesion
molecule 1; STAT-3, Signal transducer and activator of transcription 3; IL-6, Interleukin 6; PARP, Poly ADP ribose polymerase; Mcl-1, Myeloid leukemia cell
differentiation protein; bFGF, Basic fibroblast growth factor; ERK-1,-2, Extracellular signal-regulated kinases.
exerts hepatoprotective, neuroprotective, anti-inflammatory,
anti-oxidant, cardioprotective, hypolipidemia, and thyroid
stimulatory effect by targeting multiple signaling pathways
(Table 1; Figure 4).
IN VITRO STUDIES WITH COMMIPHORA
AND BOSWELLIA AND THEIR ROLE IN
DIFFERENT CHRONIC DISEASES
Numerous in vitro studies have indicated the efficiency of guggul
against diverse chronic diseases including cancer (Shishodia et al.,
2007, 2008; Singh S. V. et al., 2007; Shah et al., 2012; Roy et al.,
2016). GS induced apoptosis in cancer cells via inhibition of
NF-κB, activation of JNK and downregulation of Akt and anti-
apoptotic proteins (Shishodia and Aggarwal, 2004; Shishodia
et al., 2007). Treatment with GS led to the inhibition of DNA
synthesis and proliferation of leukemia cells via downregulation
of cyclin D1, cdc2, and upregulation of p21 and p27 (Samudio
et al., 2005; Shishodia et al., 2007). In addition, B. serrata gum
resin displayed cytostatic and apoptosis-inducing effect against
leukemia and brain tumor cells (Hostanska et al., 2002). Further,
GS induced cell death in prostate cancer cells by reactive oxygen
intermediate (ROI)-dependent activation of JNK, p38MAPK and
also activation of ERK1/2 (Singh S. V. et al., 2007; Xiao and
Singh, 2008). Additionally, AKBA inhibited the proliferation and
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TABLE 1 | In vitro biological activities of guggul (Commiphora and Boswellia) against various chronic diseases.
Disease Mechanism of action References
Arthritis ↓RANKL-induced NF-κB activation Ichikawa and Aggarwal, 2006c
↓IRF3 Youn et al., 2009c
↓NF-κB Zhang et al., 2016c
Barrett’s esophagus ↓FXR De Gottardi et al., 2006c
CANCER
Bladder cancer ↑EGR1, ↑ATF3, ↑DDIT3 Frank et al., 2009d
Brain cancer ↑p21 Glaser et al., 1999d
↓Erk-1, ↓Erk-2 Park et al., 2002a,bd
– Hostanska et al., 2002d
Breast cancer ↓MDR Xu et al., 2011c
↓MDR Xu et al., 2012c
↓NF-κB; ↓IGF1-Rβ; ↓ERα Choudhuri et al., 2011c
↓Wnt/β-Catenin; ↓cyclin D1; ↓C-myc Jiang et al., 2013c
↑Ho-1; ↑Nrf-2; ↑ROS & ↑p-Akt Almazari et al., 2012c
↑BCRP; ↓MDR Kong et al., 2015c
Cervical cancer ↑P-gp & MRP1 Nabekura et al., 2008c
↓PARP; ↓NF-κB Qurishi et al., 2012d
Cholangiocarcinoma ↓Survivin; ↓Bcl-2 Zhong et al., 2015c
↓ROS/JNK Zhong et al., 2016c
Colorectal cancer ↓STAT3 & VEGF Kim et al., 2008c
↓NF-κB; ↓IGF1-Rβ; ↓ERα Choudhuri et al., 2011c
↑Caspase-8 Liu et al., 2002bd
↑p21; ↓cyclin D1,-E;↓CDK-2,- 4 Liu et al., 2006d
↓PARP Qurishi et al., 2012d
↑let-7 and miR-200 families Takahashi et al., 2012d
↑SAMD14; ↑ SMPD3, ↓DNMT activity Shen et al., 2012d
Esophageal cancer ↓CdX2 Yamada et al., 2014c
↓NF-κB; ↓COX-2 Yamada et al., 2014c
Gall bladder cancer ↓NF-κB Yang et al., 2012c
Glioma ↓Ras; ↓NFκB Dixit et al., 2013c
↓Topoisomerase I Hoernlein et al., 1999d
Head and Neck ↑JNK; ↓Akt Shishodia et al., 2007c
↓STAT3 Li et al., 2009c
↓Bcl-2; ↓XIAP; ↓cyclin D1; ↓c-myc Macha et al., 2010c
↓PI3K/Akt, Macha et al., 2011bc
↓NF-κB; ↓STAT3 Macha et al., 2011ac
↓p-STAT3; ↓STAT3 Leeman-Neill et al., 2009c
Leukemia ↑JNK; ↓Akt Shishodia et al., 2007c
↓ NF-κB ↓ IKK Shishodia and Aggarwal, 2004c
↓BAR Wu et al., 2002c
↑Externalization of PS Samudio et al., 2005c
↓ P-gp Xu et al., 2012c
– Jing et al., 1999d
– Hostanska et al., 2002d
↑Caspase-8, ↑DR4, ↑DR5 Xia et al., 2005d
↓NF-κB Takada et al., 2006d
↓Topoisomerase I, ↓Topoisomerase II Chashoo et al., 2011d
↓PI3K/Akt/Hsp-90 cascade Khan et al., 2012d
- Shao et al., 1998
- Huang et al., 2000c
↓P-gp; ↓COX-2; ↓Prostaglandin E2 Xu et al., 2014a
(Continued)
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TABLE 1 | Continued
Disease Mechanism of action References
Liver cancer ↓Cox-2; ↓P-gp Xu et al., 2017c
↑CHOP-dependent DR5 Moon et al., 2011c
↓TGF-β1; ↓VEGF Shi et al., 2015c
↓BAR Wu et al., 2002c
↓CYP7A1 Owsley and Chiang, 2003c
↑Caspase-8 Liu et al., 2002ad
Lung cancer ↑JNK; ↓Akt Shishodia et al., 2007c
↓PARP Qurishi et al., 2012d
Melanoma ↓Tyrosinase Koo et al., 2012c
↑JNK; ↓Akt Shishodia et al., 2007c
↓Topoisomerase II, ↓MMPs Zhao et al., 2003d
Meningioma ↓Erk-1, ↓Erk-2 Park et al., 2002ad
Myeloma ↓STAT3 Kunnumakkara et al., 2009d
↓p-STAT3; ↓pJAK2; ↓p-c-Src; ↓SHP-1; Ahn and Youn, 2008c
↓STAT3; ↓Bcl-2; ↓Mcl-1; ↓cyclin D1;
↓VEGF; ↑Caspase-3 and ↓PARP
Pancreatic cancer ↓NF-κB; ↓IGF1-Rβ; ↓ERα Choudhuri et al., 2011c
↓NF-κB Park et al., 2011bd
Prostate cancer ↑JNK Xiao et al., 2011c
↓JAK/STAT Macha et al., 2013c
↑Bax; ↑Bak Singh et al., 2005c
↑PSA Burris et al., 2005c
↑JNK Singh et al., 2007bc
↓NF-κB Syrovets et al., 2005bd
↑Caspase 3 Büchele et al., 2006d
↑DR5, ↑CHOP, ↑caspase-8, ↓PARP Lu et al., 2008d
↓AR, ↑p21, ↓cyclin D1 Yuan et al., 2008d
↓mTOR Morad et al., 2013d
↓MMP, ↓PARP-1 Pathania et al., 2015d
↓VEGF, ↓FGF, ↓G-CSF, ↓MMP-2, Xiao and Singh, 2008c
↓IL-17, ↓VEGF-R2
Neuroblastoma ↓PARP Qurishi et al., 2012d
Cardiotoxicity ↓Caspase-3 Wang et al., 2012c
Chikungunya ↓Entry of CHIKV Env pseudotyped lentiviral vectors von Rhein et al., 2016d
Gastric intestinal metaplasia ↓CdX2 Xu et al., 2010c
Hepatic fibrosis ↓NF-κB Kim et al., 2013c
Kidney injury in systemic
infection
↓NF-κB Kim et al., 2016c
Nephrotoxicity ↓MAPK Lee et al., 2017c
Neuroinflammation ↓IκBα - ↓NF-κB Huang et al., 2016c
Obesity ↑Caspase-3; ↓PPARγ2, ↓C/EBP-α,-β Yang et al., 2008c
Otitis media ↓NF-κB Song et al., 2010c
AR, Androgen receptor; ATF3, Activating transcription factor 3; BAR, Bile acid receptor; BCRP, Breast cancer resistance protein; c, Commiphora; C/EBP, CCAAT/enhancer binding
protein; CDK, Cyclin dependent kinase; CdX2, Caudal-related homeobox 2; CHOP, CAAT/enhancer binding protein homologous protein; COX-2, Cyclooxygenase-2; CYP7A1,
Cholesterol 7alpha-hydroxylase; d, Boswellia; DDIT3, DNA damage inducible transcript 3; DNMT, DNA methyl-transferase; DR, Death receptor; EGR1, Early growth response 1; ERα,
Estrogen receptor alpha; FXR, Farnesoid X receptor; G-CSF, Granulocyte colony-stimulating factor; HO-1, Heme oxygenase-1; Hsp90, Heat shock protein 90; IGF1, Insulin-like growth
factor 1; JNK, c-Jun N-terminal kinase; IL, Interleukin; IRF3, Interferon-regulatory factor 3; MAPK, Mitogen-activated protein kinase; MCL-1, myeloid leukemia cell differentiation protein;
MDR, Multidrug resistance; MMP, Matrix metalloproteinases; MRP, Multidrug resistance protein; mTOR, Mechanistic target of rapamycin; NF-κB, Nuclear factor kappa B; Nrf-2, The
nuclear factor erythroid 2 (NFE2)-related factor 2; PARP, Poly ADP ribose polymerase; PI3K, Phosphatidylinositol-4,5-bisphosphate 3-kinase; PPAR, Peroxisome proliferator activated
receptor; pRb, phosphorylated Retinoblastoma; PS, Phosphatidylserine; PSA, Prostate-specific antigen; RANKL, Receptor activator of nuclear factor kappa-B ligand; ROS, Reactive
oxygen species; SAMD14, Sterile Alpha Motif Domain Containing 14; SHP-1, Src homology region 2 domain-containing phosphatase-1; SMPD3, Sphingomyelin phosphodiesterase 3;
STAT, Signal transducer and activator of transcription 6; STAT3, Signal transducer and activator of transcription 3; TGF, Transforming growth factor; TLR-3, Toll-like receptor-3; TLR-4,
Toll-like receptor-4; VEGF, Vascular endothelial growth factor; VEGFR2, Vascular endothelial growth factor receptor 2; XIAP, X-linked inhibitor of apoptosis protein.
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FIGURE 4 | In vitro, in vivo and clinical studies on the biological activities of guggul against diverse chronic diseases.
induced apoptosis in colon cancer cells through p21 and caspase-
8 dependent pathway (Liu et al., 2002b, 2006). Besides, it also
modulated the expression of let-7, miR-200 families and their
downstream targets in colon cancer cells (Takahashi et al., 2012).
Apart from cancer, the effect of guggul has been well proven
against different inflammatory diseases such as rheumatoid
arthritis, IBD, and various other diseases such as obesity,
otitis media, uveitis etc. For example, treatment with GS
downregulated RANKL induced osteoclastogenesis and blocked
IL-1beta mediated production of chemokines and epithelial
neutrophil activating peptide-78 (ENA-78), MMP-1,-3 via
suppression of NF-κB, nuclear p50, and p65 subunit and IκBα
degradation in rheumatoid arthritis (Ichikawa and Aggarwal,
2006; Kinne et al., 2007; Lee et al., 2008; Ammon, 2016). A
study conducted by Cheon and group on IBD showed that
GS inhibited IL-1beta- or lipopolysaccharide (LPS)- induced
ICAM-1 expression, NF-κB transcription activity and IκB
phosphorylation/degradation in humanCaco-2 cells and rat non-
transformed IEC-18 cells (Cheon et al., 2006). Further, treatment
with GS alone showed increase in apoptosis and lipolysis and
its combination with genistein resulted in increased cleavage
of procaspase-3, PARP, expression of Bax, release of cyt-c and
prevented lipid accumulation in maturing adipocytes resulting in
inhibition of adipogenesis (Yang et al., 2007, 2008). GS exerted
its effect against otitis media, the foremost cause of hearing
impairment in children by inhibiting LPS-induced upregulation
of TNF-α expression, COX-2 production and IκBα degradation
(Ovesen and Ledet, 1992; Barrett et al., 2003; Song et al., 2010).
In case of uveitis, treatment with GS inhibited LPS-induced
expression of inflammatory proteins in human primary non-
pigment ciliary epithelial cells (Kalariya et al., 2010).
As guggul is an FXR antagonist, it is used extensively as a
cholesterol-lowering agent (Rizzo et al., 2006; Shah et al., 2012).
GS eliminated the effect of chenodeoxycholic acid (CDCA), an
FXR agonist on the expression of Cdx2 and MUC2 and thus
prevented bile acid induced gastric intestinal metaplasia and
carcinogenesis (Xu et al., 2010). Oswley and Chiang reported
that GS antagonizes FXR induction of BSEP but activates
pregnane X receptor to inhibit CYP7A1 gene (Owsley and
Chiang, 2003). In addition, Commiphora and Boswellia showed
potent cardioprotective as well as thyroid-stimulatory effects
(Singh et al., 1982; Deng, 2007). For instance, GS inhibited
DOX induced cytotoxicity, reduced apoptosis, and intracellular
ROS and formation of MDA in DOX-treated H9C2 cells (Wang
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et al., 2012). In addition, triterpenes and prenylaromadendrane-
type diterpenes from the gum resin of B. carterii was shown
to exert hepatoprotective effect against d-galactosamine-induced
liver cell damage (Wang et al., 2013, 2016).
IN VIVO STUDIES WITH COMMIPHORA
AND BOSWELLIA AND THEIR ROLE IN
DIFFERENT CHRONIC DISEASES
Promising after effects of Commiphora and Boswellia against
various chronic diseases in the in vitro setting has led to
a handful of in vivo studies where the efficacy of guggul
was evaluated in different experimental models of diverse
chronic diseases such as cancer, inflammatory, cardiovascular,
and metabolic diseases, atherosclerosis, asthma etc. (Table 2;
Figure 4). Recently, several studies have reported the anti-tumor
efficacy of guggul in different cancers such as cancers of breast,
esophagus, head, and neck, pancreas, prostate etc. (An et al.,
2009). For instance, AKBA was found to prevent intestinal
tumorigenesis and exert chemopreventive effect via inhibition
of wnt/β-catenin and NF-κB/COX-2 signaling pathways (Liu
et al., 2013; Wang R. et al., 2014). Another study showed AKBA
to function via modulation of let-7 and miR-200 downstream
genes in colorectal (CRC) tumors (Takahashi et al., 2012).
In case of breast cancer, treatment with GS increased the
chemosensitivity of MCF-7/DOX cells to doxorubicin in vivo
through inhibition of Bcl-2 and Pgp (Xu et al., 2014b). In
addition, GS suppressed esophageal tumor cell viability via
inhibition of FXR and prevented the growth of esophageal
cancer cells significantly in combination with amiloride in vivo
(Guan et al., 2013, 2014). Furthermore, in case of glioma, cyano
enone of methyl boswellates (CEMB), and 3-α-propionyloxy-β-
boswellic acid (POBA) significantly inhibited the tumor growth
in murine models (Ravanan et al., 2011; Qurishi et al., 2013).
Again, topical application of Boswellin (BE); B. serrata gum resin
exudate inhibited skin inflammation, epidermal proliferation,
and tumor promotion induced by 12-O-tetradecanoylphorbol-
13-acetate (TPA) in 7,12-dimethylbenz[a]anthracene (DMBA)-
initiated mice. Additionally, treatment with guggulipid was
shown to cause reduced growth of HNSCC cells in vivo (Leeman-
Neill et al., 2009). Besides, GS enhanced the antitumor efficacy
of gemcitabine in pancreatic cancer via modulation of Akt, NF-
κB, and apoptosis-related proteins (Ahn et al., 2012). In case
of prostate cancer as well, guggul has been found to be highly
effective in vivo (Syrovets et al., 2005b; Büchele et al., 2006;
Pang et al., 2009; Pathania et al., 2015). Oral administration of
guggulsterone prevented in vivo angiogenesis of prostate cancer
cells through suppression of VEGF-VEGF-R2-Akt signaling
(Xiao and Singh, 2008).
Apart from cancer, the efficacy of guggul was well proven in
different inflammatory diseases such as arthritis, colitis, gastritis,
IBD, pancreatitis, uveitis etc. (Sharma et al., 1989; Cheon et al.,
2006; Xiao and Singh, 2008; Mencarelli et al., 2009; Kalariya
et al., 2010; Kim et al., 2010, 2013; Dhaneshwar et al., 2013; Kang
et al., 2013; Wang R. et al., 2014). In case of rheumatoid arthritis,
treatment with guggul decreased the thickness of joint swelling,
reduced the infiltration of leucocytes into the pleural cavity,
suppressed the pro-inflammatory cytokines and increased beta-
glucuronidase activity in vivo (Sharma and Sharma, 1977; Reddy
and Dhar, 1987; Sharma et al., 1989; Fan et al., 2005). In addition,
guggul reduced the severity of IBD via inhibition of LPS- or
IL-1beta-induced ICAM-1 gene expression and NF-κB activity
(Krieglstein et al., 2001; Cheon et al., 2006; Mencarelli et al., 2009;
Kim et al., 2010). Furthermore, administration of GS resulted in
mitigation of histological damage, suppressed serum lipase levels,
inhibition of infiltrations of neutrophils, and macrophages and
decreased cytokine production in pancreatitis (Kim et al., 2015).
Moreover, GS inhibited the expression of endotoxin-induced
uveitis (EIU)-associated inflammatory markers such as MMP-2,
NO, and prostaglandin E2 (PGE2) (Kalariya et al., 2010).
Guggul exhibited profound cardioprotective effects as
well in vivo (Chander et al., 2003). It decreased the lipid
peroxide, creatine phosphokinase, phospholipase, xanthine
oxidase activities, and total cholesterol level in the serum;
increased superoxide dismutase (SOD), myocardial antioxidants,
glutathione peroxidase (GSHPx), catalase (CAT); reduced
glutathione (GSH), creatine-phosphokinase-MB (CK-MB),
and lactate dehydrogenase (LDH) as well as reversed the
cardiac damage induced by isoproterenol (Kaul and Kapoor,
1989; Batra et al., 2000; Ojha et al., 2011). The hypolipidemic
effect of guggul has also been well studied in different animal
models (Khanna et al., 1969; Dixit et al., 1980; Baldwa et al.,
1981; Lata et al., 1991). Guggul diminished hyperlipidemia
via inhibition of FXR activation. In high-fat-diet-fed mice,
treatment with GS improved blood glucose in fasting condition,
plasma insulin level, glucose tolerance, level of harmful lipids,
phosphoenol pyruvate carboxykinase, glucose-6-phosphatase,
and other proteins like glucose transporter-4, PPARc, and TNF-α
(Satyavati et al., 1969; Singh et al., 1990; Urizar et al., 2002;
Cui et al., 2003; Sharma et al., 2009; Tripathi, 2009). Further,
C. opobalsamum, C. mukul, B. serrata, and B. ovalifoliolata
species mitigated hepatic damage and displayed protective
effect against lipid peroxidation and deviated serum enzymatic
variables (Al-Howiriny et al., 2004; Y et al., 2006; Mahesh et al.,
2014). In addition, GS reversed neuronal damage and memory
deficits in mice by increasing glutathione level in the brains,
antiacetylcholine esterase, and antioxidant activities (Saxena
et al., 2007). Apart from these, administration of GS was found to
increase thyroid function by enhancing iodine uptake, improved
the activities of thyroid peroxidase, and protease and ameliorated
hypothyroidism through its ability to increase thyroid hormone
in vivo (Tripathi et al., 1975, 1984; Panda and Kar, 2005).
Taken together, these pre-clinical studies provide substantial
evidence of the enormous potential of guggul as a multi-targeted
agent for the prevention and treatment of different chronic
diseases.
CLINICAL STUDIES WITH COMMIPHORA
AND BOSWELLIA AND THEIR ROLE IN
DIFFERENT CHRONIC DISEASES
Several clinical trials have been conducted to evaluate the
effect of “guggul” from Commiphora and Boswellia on
various chronic disorders. Human studies on guggul has
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TABLE 2 | In vivo biological activities of guggul (Commiphora and Boswellia) against various chronic diseases.
Disease Mechanism of action References
Arthritis ↓Leucocytes Sharma et al., 1989d
– Dhaneshwar et al., 2013d
↓IL-1β; ↓TLR4 Wang Q. et al., 2014d
Asthma ↓pSTAT6; ↓GATA3 Liu et al., 2015d
↓pSTAT6; ↓GATA3 Zhou et al., 2015b
Atherosclerosis ↓NF-κB Cuaz-Pérolin et al., 2008d
CANCER
Breast Cancer ↓PCNA; ↓Ki67 Xu et al., 2014bc
Colon Cancer ↑Caspase−3,−8; ↓cIAP-1,-2; ↓Bcl-2 An et al., 2009c
↓Wnt/β-catenin; ↓NF-κB/COX-2 Liu et al., 2013d
↓Wnt/β-catenin; ↓NF-κB/COX-2 Wang R. et al., 2014d
↑let-7 and miR-200 families Takahashi et al., 2012d
Ehrlich tumor ↓VEGF; ↑caspase-3; ↑Bax Agrawal et al., 2011d
↓NF- κB; ↓PARP Qurishi et al., 2012d
Esophageal Cancer ↓NHE-1 Guan et al., 2014c
↓FXR Guan et al., 2013c
Glioma ↓NO; ↑Caspase–3,–8 Ravanan et al., 2011d
↓ AOM-induced ACF Huang et al., 2000d
↓NF-κB; ↓PARP Qurishi et al., 2013d
Head and Neck ↓STAT-3; ↓HIF-1α Leeman-Neill et al., 2009c
Pancreatic cancer ↓NF-κB; ↓Akt Ahn et al., 2012c
↓NF-κB Park et al., 2011ad
Prostate cancer ↓VEGF-VEGF-R2-Akt signaling Xiao and Singh, 2008c
↓NF-κB Syrovets et al., 2005bd
↑Caspase-3 Büchele et al., 2006d
↓VEGFR-2 Pang et al., 2009d
↓MMP; ↓PARP-1 Pathania et al., 2015d
Colitis ↓NF-κB Kim et al., 2010c
↓ICAM-1; ↓NF-κB Cheon et al., 2006c
Dementia ↓AChE activity; ↓MDA; ↑GSH Saxena et al., 2007c
Depression ↑BDNF signaling; ↑Hippocampal neurogenesis Liu et al., 2017c
Diabetes ↓PPARγ Sharma et al., 2009c
Gastritis ↓NF-κB Kim et al., 2013c
Gastric injury ↑Nrf2; ↑HO-1 Zhang et al., 2016d
Gastric ulcer ↑Prostaglandin; ↓leukotrienes Singh et al., 2008d
Hepatic injury ↓NF-κB; ↓p65; ↓p-JNK; ↓TLR-3,-4; ↓MyD88 Chen et al., 2016d
Hyperlipidemia ↓Oxidative modification of LDL Wang et al., 2004c
– Satyavati et al., 1969c
↑Plasma insulin level; ↓LDL; ↓VLDL Sharma et al., 2009c
Inflammatory bowel diseases ↓NF-κB Kang et al., 2013c
↓IL–2,−4; ↓IFN-γ Mencarelli et al., 2009c
Ischemia reperfusion ↑Nrf2; ↑HO-1 Ding et al., 2014d
↑Nrf2; ↑HO-1 Ding et al., 2015d
Memory impairment ↑CREB-BDNF signaling Chen et al., 2016c
Myocardial ischemia ↓Oxidative degradation of lipids; ↓ROS Chander et al., 2003c
↓Lipid peroxides; ↓XO; ↑SOD Kaul and Kapoor, 1989c
Pancreatitis ↓NF-κB; ↓IL-6; ↓Chemokine-1,-10 Kim et al., 2017 c
Thyroid dysfunction ↑Iodine uptake Tripathi et al., 1975c, 1984c
↑Iodine uptake Panda and Kar, 2005
Uveitis ↓NF-κB; ↓MMP-2; ↓iNOS; ↓COX-2 Kalariya et al., 2010c
ACF, Aberrant crypt foci; AChE, Acetylcholinesterase; AOM, azoxymethane; BCRP, Breast cancer resistance protein; BDNF, Brain-derived neurotrophic factor; c, Commiphora; cIAP, The
cellular inhibitor of apoptosis; COX-2, Cyclooxygenase-2; CREB-BDNF, cAMP-response element binding protein-BDNF d, Boswellia; FXR, Farnesoid X receptor; GSH, Glutathione; HIF-
1a, Hypoxia-inducible factor 1-alpha; HO-1, Heme oxygenase-1; ICAM, Intracellular adhesion molecules; IFN, Interferon; IκB, Nuclear factor of kappa light polypeptide gene enhancer
in B-cells inhibitor IL, Interleukin; IL-1β, Interleukin 1 beta; iNOS, Inducible nitric oxide synthase; LDL, Low density lipoprotein; MDA, Malondialdehyde; MDR, Multidrug resistance; MMP,
Matrix metalloproteinases; MyD88, Myeloid differentiation primary response 88; NF-κB, Nuclear factor kappa B; NHE-1, Na+/H+exchanger-1; NO, Nitric oxide; Nrf-2, The nuclear
factor erythroid 2 (NFE2)-related factor 2; p-JNK, Phosphorylated Jun N-terminal kinases; P-gp, P-glycoprotein; PARP, Poly ADP ribose polymerase; PCNA, Proliferating cell nuclear
antigen; PPAR, Peroxisome proliferator activated receptor; pSTAT6, phosphorylated Signal transducer and activator of transcription 6; ROS, Reactive oxygen species; SOD, Superoxide
Dismutase; STAT, Signal transducer and activator of transcription; TLR, Toll-like receptor; VEGF, Vascular endothelial growth factor; VEGFR2, Vascular endothelial growth factor receptor
2; XO, Xanthine oxidase.
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been found to be effective against different diseases such as
asthma, breast fibroadenoma, chronic kidney disease, colitis,
Crohn’s disease, fascioliasis, hepatitis C, hypercholesterolaemia,
hyperlipidemia, metabolic syndrome, nodulocystic acne,
arthritis, schistosomiasis, stress urinary incontinence etc.
(Table 3; Figure 4).
Arthritis
Arthritis is mainly caused due to inflammation of joints, the
tissues surrounding the joints and other connective tissues.
Osteoarthritis is the most common form of arthritis which
affects a wide range of people across all the places. As guggul
has been reported to exhibit high affectivity against arthritis
pre-clinically; hence, its effect was evaluated in the clinical
setting as well. In one such study, 30 patients with arthritis
were treated with gum guggul for 1 month which resulted
in remarkable improvement in the total scores of Western
Ontario and MacMaster Osteoarthritis Index and condition of
the patients (Singh et al., 2003). Another study was conducted
by Kimmatkar et al., to check the safety, tolerability, and efficacy
of B. serrata extract in 30 patients with knee osteoarthritis. The
patients receiving drug treatment reported a decrease in knee
pain and swelling of the knee joint as well as increased knee
flexion and walking distance (Kimmatkar et al., 2003).
Asthma
Asthma is a chronic multifactorial inflammatory disease of the
respiratory tract and is one of the major health concern. Notably,
Boswellia has been found to be effective in the treatment of this
disease. In a clinical study, 40 patients having 23 males, and 17
females in the age range of 18–75 years, suffering from bronchial
asthma were treated with 300mg of gum resin thrice daily for
a period of 6 weeks. This led to improved prognosis in around
70% of the patients as various signs and symptoms of bronchial
asthma like rhonchi, dyspnoea, and attacks disappeared upon
treatment (Gupta et al., 1998).
Breast Fibroadenomas
Breast fibroadenoma accounts for the majority of breast lumps
in young women. Boswellia was found to exert beneficial
effect against breast fibroadenomas as evinced by a study
conducted by Pasta and group. They showed that treatment
with the combination of Boswellia, betaine, and myo-inositol
resulted in decreased fibroadenoma dimension in young women
without exerting any toxic effects. The combination also resulted
in reduced fibroadenoma volume in 38.8% of the patients
in the experimental group, whereas the same was observed
only in 17.85% patients in the placebo group (Pasta et al.,
2016).
Cardiovascular Diseases (CVDs)
CVDs, a group of diseases which involves the heart and the
blood vessels is one of the most common causes of death
across the globe. Notably, guggul presents a potent remedy for
cardiovascular diseases. For example, Singh and group conducted
a study to evaluate the cardioprotective benefits of guggul by
enrolling 200 patients suffering from ischemic heart disease. The
patients were treated with the combination of gum guggul and
Inula racemosa for 6 months which resulted in the reduced levels
of total cholesterol, triglyceride, and total blood lipids in the
patients. It also restored the normal electrocardiogram (ECG) in
26% of the patients, showed improvement of ECG in 59% of the
patients and lessened the chest pain in 25% of the patients (Singh
et al., 1993).
Chronic Kidney Disease
Chronic kidney disease (CKD) is a progressive disease where
occurs due to enhanced inflammation and oxidative stress
leading to reduced kidney function. Studies have indicated B.
serrata in combination with Curcuma longa as an effective
regimen to obtain reduced inflammation in patients with CKD
which functioned via modulation of prostaglandin E2 (PGE2)
(Shelmadine et al., 2017). Moreover, this regimen was found
to be safe, well tolerated which also enhanced the levels of
inflammatory cytokines in CKD patients (Moreillon et al., 2013).
Diabetes Mellitus
A large population of the world is affected by diabetes mellitus
or type 2 diabetes. Several preclinical studies have shown that
the gum resin of commiphora and boswellia are highly effective
against this disease. In a clinical study conducted byAhangarpour
et al., it was observed that the treatment of patients with
diabetes mellitus with B. serrata gum resin (900mg daily for 6
weeks orally) resulted in decreased risk factors associated with
this disease. Further, the treatment also helped in maintaining
fructosamine levels, hepatic enzyme activities, and to bring lipid
profiles close to normal levels in the patients (Ahangarpour et al.,
2014).
Eczema and Psoriasis
Eczema, also known as dermatitis and psoriasis are causedmainly
due to inflammation of the skin. Boswellia has been found to exert
effectiveness against eczema and psoriasis. A group of scientists
revealed that Boswellia-based cream lessens the use of topical
corticosteroids and can diminish the grade of erythema and
the skin superficial symptoms (Togni et al., 2015). Further, in
a double blind study, the efficacy of a novel formulation of BA
(Bosexil R©) containing B. serrata resin extract and lecithin was
evaluated against both psoriasis and eczema. Improvement in
psoriasis, scales (70% of cases), and erythema (50% of cases) was
observed with Bosexil R© compared to placebo. In addition, when
eczema patients were administrated with Bosexil R© formulation,
it showed improvement in both erythema (60% of cases) and itch
(60% of cases) of the patients without any case of waning (Togni
et al., 2014).
Fascioliasis
Fascioliasis is a parasitic worm infection caused by the
common liver fluke Fasciola hepatica and Fasciola gigantica. The
formulation of myrhh, the gum resisn of Commiphora molmol
was reported to be safe, well tolerated, and effective for the
management of this disease. The formulated drug comprised of
8 parts of resin and 3.5 parts of volatile oils, all extracted from
myrrh. They observed that 7 patients who were passing fasciola
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TABLE 3 | Clinical trials of guggul (Commiphora and Boswellia) against various chronic diseases.
Disease Dose Pts (#) Clinical outcome References
Healthy volunteer 1 gb 10 Diminished efficacy Dalvi et al., 1994
125mg, 2 capsulesd 20 Increased pain threshold & tolerance
force, well -tolerated
Prabhavathi et al., 2014
140 mge 47 Effective Chilelli et al., 2016
2 × 250 mgd 12 High and quick absorption Riva et al., 2016
Asthma 900 mg/d; 6 wkd 40 Improved disease condition Gupta et al., 1998
500 mg/dd 32 Effective Ferrara et al., 2015
Breast fibroadenomas –e 64 Reduction in fibroadenoma mass Pasta et al., 2016
CKD 516 mge 16 Safe and tolerable Moreillon et al., 2013
–b 60 Effective Shelmadine et al., 2017
Colitis 900 mg/d; 6 wkd 30 Safe and effective Gupta et al., 2001
1050 mg/d; 6 wkd – Effective Gupta et al., 1997
Crohn’s disease –d 102 Safe and effective Gerhardt et al., 2001
2,400 mg/d; 52 wkd 108 Well-tolerated Holtmeier et al., 2011
Fascioliasis 12 mg/kg/d; 6 df 7 Safe, well-tolerated and effective Massoud et al., 2001
600 mg/d; 6 df 1019 Safe and effective Abo-Madyan et al., 2004b
Hepatitis C –a 15 Effective Scholtes et al., 2012
HCL 1,500 mg/d; 12 wkb 205 Effective Nityanand et al., 1989
100 mg/d; 24 wkf 61 Mild side effects Singh et al., 1994
1,000, 2,000 mg/d; 3 db103 – Well-tolerated, caused dermatologic
hypersensitivity
Szapary et al., 2003
2,160 mg/d; 12 wkb 43 Clinical magnitude is obscure Nohr et al., 2009
HLD –f – – Verma and Bordia, 1988
75 mg/d; 8 wka – Safe and effective Beg et al., 1996
2 g/d; 8 wkb 59 Effective Vyas et al., 2015
Metabolic syndrome 2 pills/d; 4 mob 78 Effective Patti et al., 2015
Nodulocystic acne 50 mg/d; 3 mob 20 Reduced inflammatory lesions Thappa and Dogra, 1994
Osteoarthritis 2 capsules, every 8 h; 3 m-15 d
wash-out-3 me
42 – Kulkarni et al., 1991
500 mgb 30 Safe and effective Singh et al., 2003
999 mg/d; 8 wkd 30 Well-tolerated Kimmatkar et al., 2003
100 or 250 mg/d; 90 dd 75 Safe and effective Sengupta et al., 2008
1000 mg/de 30 Safe and well-tolerated Kizhakkedath, 2013
6 capsules/d; 24 wke 440 Effective, improved knee function Chopra et al., 2013
Polyarthritis 3600 mg/dd 78 No measurable efficacy Sander et al., 1998
RT-related edema 4200 mg/dd 44 Effective, reduced cerebral edema Kirste et al. , 2011
Schistosomiasis 10 mg/kg/d; 3df 204 Well-tolerated Sheir et al., 2001
600 mg/d; 6 df 1019 Safe and effective Abo-Madyan et al., 2004a
Skin damage in Cream, twice/dd 114 Well-tolerated Togni et al., 2015
MCA
SUI 4 g/d, 8 wke 30 Effective Arkalgud Rangaswamy et al.,
2014
CKD, Chronic kidney disease; d, Day; HCL, Hypercholesterolemia; HLD, Hyperlipidemia; MCA, Mammary carcinoma; mo, Month; wk, Week; RT, Radiotherapy; SUI, Stress urinary
incontinence; a, Gugglusterone; b, Guggul; c, Formulation of guggul; d, Boswellia; e, Formulation of Boswellia; f, Commiphora.
eggs in their stools displayed distinct improvement of the general
condition, drop in the egg count, and improvement of all signs
and symptoms with no adverse side effects after treatment with
the drug (Massoud et al., 2001).
Gingivitis
Gingivitis, the inflammation of gingiva is a very common
form of gum disease. Frankincense extract has been found to
exhibit efficacy against gingivitis. A double blinded randomized
placebo controlled trial was conducted among 75 female patients
aged between 15 and 18 years with moderate plaque-induced
gingivitis. Six groups were randomly formed based on the
administration of 0.1 g of frankincense extract, 0.2 g of its
powder, placebo, and whether the patients have undergone
scaling and root planning (SRP) or not. Gingival index, plaque
index, bleeding index, and probing pocket depth were measured
on the 0, 7th, and 14th days of the study. Detailed analysis
of the data revealed that SRP along with the application of
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frankincense extract or powder might cause significant decrease
in inflammatory indices in comparison to the groups without
drug therapy and SRP (Khosravi Samani et al., 2011).
Inflammatory Bowel Disease
Different clinical studies with guggul have shown its efficacy
against IBDs which include colitis and Crohn’s disease. For
instance, the gum resin of B. serrata was found to be effective
in the treatment of chronic colitis with minimal side effects in
a clinical study conducted by Gupta et al. In this study, the
patients with chronic colitis were treated with gum resin from
B. serrata at a dose of 900mg daily divided in three doses
for 6 weeks. The treatment resulted in the improvement of
stool properties, hemoglobin, serum iron, calcium, phosphorus,
proteins, total leukocytes, and eosinophils in the patients
(Gupta et al., 2001). Further, a double-blind, placebo-controlled,
randomized, parallel study on 82 patients with Crohn’s disease
was conducted where patients were given a new B. serrata
extract; Boswelan. In this trial, remission was observed in 59.9%
of the actively treated patients. Additionally, this study also
confirmed better tolerability of Boswelan in long-term treatment
of Crohn’s disease (Holtmeier et al., 2011). Furthermore,
leukotrienes play an important role in inflammation of the
colon in ulcerative colitis. Sallai guggul gum resin is known
to be specific, non-redox, and non-competitive inhibitors of
5-LOX, a crucial enzyme of leukotriene biosynthesis. Patients
with grade II and III ulcerative colitis were treated with B.
serrata gum resin at a dose of 350mg thrice daily for 6 weeks.
Stool properties, histopathology, and scan microscopy of rectal
biopsies, blood parameters including hemoglobin, serum iron,
calcium, phosphorus, proteins, total leukocytes, and eosinophils
showed slightly better improvement in Boswellia treated patients
(Gupta et al., 1997).
Nodulocystic Acne
Guggulipid is considered to be very effective in topical and oral
complementary as well as an alternative medicine (CAM) for
the treatment of acne (Magin et al., 2006). In a clinical study
conducted by Thappa andDogra, patients with nodulocystic acne
were given guggulipid equivalent to 25mg GS for 3 months,
which resulted in progressive reduction in lesions in majority
of patients. However, patients with oily faces displayed better
response to guggulipid (Thappa and Dogra, 1994).
Thus, these clinical studies well evince the potential effect
of Commiphora and Boswellia on different chronic diseases.
However, more studies are inevitable to establish them as cutting
edge strategy for the treatment of diverse human diseases.
CONCLUSION
Since ancient times, Commiphora and Boswellia are considered
as important traditional medicinal plants which are used for the
treatment of various ailments. Guggul isolated fromCommiphora
and Boswellia have immense therapeutic potential against several
diseases and it has been well established by numerous in vitro,
in vivo, and clinical studies. Guggul was used traditionally
for the treatment of inflammation and hyperlipidemia, but
with the extensive studies on guggul and associated molecular
mechanisms unveiled newer insights of its use for the treatment
of various other chronic diseases as well. Gum resin guggul
possesses multiple pharmacological activities especially
hypolipidemic, antiobesity, anti-inflammatory, anti-tumor
effects, cardioprotective, neuroprotective, hepatoprotective,
thyroid stimulatory effects etc. It effectively regulates different
transcription factors, enzymes, cytokines, and anti-apoptotic
proteins which are involved in inflammation, carcinogenesis, and
other chronic diseases. Further, Commiphora in combination
with other ayurvedic herbs is commercially available and
marketed for the treatment and cure of arthritis, obesity and
associated side effects of the disease. Many patents are also
filed and approved to use guggul as a constituent of polyherbal
formulations and cosmetics. Therefore, taking the medicinal
importance and commercial use of guggul into consideration,
it can be advocated to possess substantial therapeutic potential
against diverse chronic disorders. However, more in vitro, in
vivo, and well-designed clinical studies are required to validate
the clinical usefulness of guggul and to obtain a potent herbal
derived drug with enhanced efficacy, minimal side effects and
strong disease combating properties.
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Rhodiola rosea L. roots and rhizome extracts are active ingredients in adaptogenic
herbal medicinal products (HMP) and dietary supplements for temporary relief of
symptoms of stress, such as fatigue and weakness. R. rosea extract has a stimulating
effect on the CNS, suggesting potential benefits on cognitive functions, memory,
learning, and attention. The reproducible efficacy and quality of preparations of
the underground parts of R. rosea depend on the highly variable content of the
active markers, salidroside and rosavin, which affect the quality of HMP and dietary
supplements. However, it is not clear which analytical markers are important for
assessing the efficacy of R. rosea preparations intended for use in aging-induced mild
cognitive disorders, such as attenuated memory, attention, and learning. Furthermore,
the activity of various commercial R. rosea extracts has not been correlated with their
content. Here, the biological activities of salidroside, rosavin, and seven commercial
extracts of underground parts of R. rosea were assessed using a synaptic model of
memory: long-term potentiation (LTP) of synaptic transmission in hippocampus slices.
A high degree of variation in the content of all active markers was observed. One
extract from China lacked rosavin, and there was even variation in the extracts from
the Altai geographic region. In vitro, rosavin, salidroside and all tested R. rosea extracts
potentiated electric stimulation of an intra-hippocampal electric circuit, which resulted
in higher responses of the pyramidal cells in isolated hippocampus slices. Rosavin
was more active at higher concentrations than salidroside; while, salidroside was more
effective at lower concentrations. The highest content of both active markers was
found in the extracts that were active at the lowest concentrations tested; while, some
extracts contained some other compounds that presumably reduced the efficacy due
to antagonistic interactions. Standardized content of active markers is necessary for
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the quality control of herbal preparations containing R. rosea extracts, but insufficient
for assessment of their potential efficacy. Additional bioassays are needed to assure the
reproducible pharmacological activity of R. rosea extracts; therefore, the LTP of synaptic
transmission in hippocampus slices may serve as a validation tool for the quality control
of R. rosea extracts.
Keywords: Rhodiola rosea, salidroside, rosavin, long-term potentiation, hippocampus, quality control, UPLC
INTRODUCTION
Rhodiola rosea L. [Crassulaceae, syn. Sedum rhodiola - DC. Sedum
rosea - (L.) Scop cop, known as roseroot, rosenroot, golden
root, arctic root, orpin rose, rhodiole rougeâtre] (Currier and
Ampong-Nyarko, 2015) has a long history as a valuable medicinal
plant and has appeared in the Materia Medica of several
European countries (Panossian et al., 2010). Rhodiola rosea L.
roots and rhizome extracts are active ingredients in adaptogenic
herbal medicinal products (HMP) and dietary supplements for
temporary relief of symptoms of stress, such as fatigue and
weakness (Panossian and Wagner, 2005; Panossian and Wikman,
2009, 2010, 2014; EFSA, 2010; Panossian et al., 2010; European
Medicine Authority [EMA], 2011). A growing body of evidence
has indicated the extract’s potential use in the prevention and
treatment of stress- and age-related impairments of cognitive
functions and mental disorders (Panossian et al., 2010, 2014;
Panossian, 2013; Panossian and Gerbarg, 2016; Amsterdam and
Panossian, 2016; Nabavi et al., 2016). The stimulating effects of
R. rosea on the CNS were demonstrated long ago and suggested
there were potential benefits on cognitive functions, memory,
learning, and attention (Saratikov et al., 1965, 1978; Marina and
Alekseeva, 1968; Kurkin and Zapesochnaya, 1986; Petkov et al.,
1986; Marina et al., 1994; Saratikov and Krasnov, 2004). An active
compound, named rhodioloside was isolated and identified as
salidroside (Aksenova et al., 1968; Saratikov et al., 1968). A pilot
study of rhodioloside (syn. salidroside) in 46 healthy human
volunteers showed that 2.5 mg salidroside increased attention
in cognitive tests 1 h after a single dose was administered
in 83% of subjects, compared with 54% of volunteers who
were administered placebo (Aksenova et al., 1968). Further
studies provided evidence that R. rosea and salidroside exhibit
neuroprotective activity (Qu et al., 2009; Panossian et al., 2010,
2012; Jacob et al., 2013; Lee et al., 2013), suggesting they may
be effective in treating neurodegenerative disorders, such as
Alzheimer’s disease (Nabavi et al., 2016).
Along with salidroside and its aglycone tyrosol (Figure 1),
cinnamyl alcohol, glycosides, and rosavins (collective name
of rosavin, rosarin, and rosin) also exhibited stress-protective
(Barnaulov et al., 1986), stimulating, and neurotropic activities in
rodents; reduced sleep induced by barbital, hexanal, and chloral
hydrate in mice (Sokolov et al., 1985, 1990); increased locomotor
activity in mice (Sokolov et al., 1990); and induced anti-
depressant-like effects in animal models of depression (Panossian
et al., 2008). Salidroside is common for all species of Rhodiola,
while phenylpropanoids, rosavin, rosarin, and rosin are specific
only for R. rosea and R. sachalinensis (Kurkin et al., 1985;
Nakamura et al., 2007; Booker et al., 2016b). Many publications
have reported on the neuroprotective and neurotropic activity
of salidroside (Sokolov et al., 1985, 1990; Barnaulov et al., 1986;
Panossian et al., 2008; Cifani et al., 2010; Lee et al., 2013); while,
there is limited evidence supporting the importance of rosavin,
the major active marker (Sokolov et al., 1985, 1990; Panossian
et al., 2008; Cifani et al., 2010; Marchev et al., 2017). Rosavin
was inactive is rats during a behavioral test of binge eating; while,
salidroside dose-dependently reduced or abolished binge eating
for the period in which it was elicited (Cifani et al., 2010). In
another study, salidroside was more effective than rosarin and
rosin in inhibiting the expression of IL-1β, and IL-6 in microglial
cells, while rosavin was not tested (Lee et al., 2013). Rosavin
inhibited the expression of the TNF-related apoptosis-inducing
ligand in concanavalin A activated Jurkat T cells, while salidroside
was inactive and rosarin had an opposite effect (Marchev et al.,
2017).
It is unclear which analytical markers are important for
assessing the quality and efficacy of R. rosea herbal preparations
intended for treating aging-induced mild cognitive disorders,
such as attenuated memory, attention, and learning ability.
Rhodiola preparations are usually standardized for salidroside
(1%) and rosavin (3%). The content of active ingredients in herbal
preparations depends on many factors, such as the geographic
and climate zone it was grown in, which season and under what
conditions it was harvested, and how it was dried, extracted,
and prepared to give the final dosage form. For example, a
high degree of inter-clonal variation was found for all tested
constituents (salidroside, tyrosol, rosavin, rosarin, rosin, and
cinnamyl alcohol) in six samples of R. rosea roots collected in
various regions of Norway. The highest variation was found
for salidroside and tyrosol, showing inter-clonal variations of
92.8 and 87.8%, respectively (Hellum et al., 2010). Therefore,
the preparations obtained by various producers can have quite
different active dose levels. Furthermore, the contribution of
these active markers to the overall activity of the total extracts was
not systematically assessed. It was suggested that these phenolic
compounds (rosavin, rosarin, rosin, salidroside/rhodioloside,
and tyrosol) have no impact on activity of CYP450 enzymes and
do not inhibit CYP3A4, CYP2D6, or CYP1A2 (Hellum et al.,
2010; Xu et al., 2013; Thu et al., 2016a). The presence of minor
amounts of herbacetin rhamnosides (rhodiosin and rhodionin)
may presumably induce inhibition of CYP2D6 (Xu et al., 2013)
in some commercial preparations of Rhodiola (Thu et al., 2016b,
2017).
It is a challenge to obtain reproducible efficacy and quality
of HMP, particularly for preparations of the underground parts
of R. rosea (Panossian et al., 2010; Ioset et al., 2011; Booker
et al., 2016a). There may be unpredictable, complex interactions
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FIGURE 1 | Chemical structures of active markers of R. rosea extracts.
between the active constituents of the R. rosea extracts that
affect the regulation of molecular networks playing an important
role in cellular and physiological functions of human organisms
(Panossian et al., 2014). The pharmacological activity of R. rosea
crude extract is related to many compounds, such as salidroside,
tyrosol, rosavin, and other phenolic compounds (Sokolov et al.,
1985, 1990; Barnaulov et al., 1986; Panossian et al., 2008; Lee
et al., 2013; Marchev et al., 2017). The batch to batch reproducible
content of key active markers and the UPLC fingerprint are
not a guaranty of reproducible efficacy and safety. Additional
bioassays are required to assure reproducible pharmacological
activity of HMP. These bioassays may serve as validation tools
for the quality assurance of complex HMP where the total extract
contains active pharmaceutical ingredients. In this context,
assessment of the correlation between the content of active
markers and pharmacological activity of HMP is important.
Although the dose-response relationship of salidroside and
rosavin and dietary supplements was studied (Cifani et al., 2010;
Lee et al., 2013; Marchev et al., 2017), to the our best of our
knowledge, the correlation between the content and biological
activity of various commercial R. rosea extracts has not been
investigated.
The aim of our study was to assess the biological activity of
a selection of commercial extracts of the underground parts of
R. rosea and their analytical markers, salidroside and rosavin,
in a synaptic model of memory: the long-term potentiation
(LTP) of synaptic transmission in the hippocampus (Bliss and
Collingridge, 1993). An interesting result using this model was
the ability of memantine, a substance used in the treatment
of dementia, to increase the population spike amplitude in
response to single stimuli (SS) and to increase LTP (Dimpfel,
1995). We used this method earlier for characterization of
electrophysiological response of R. rosea in hippocampal slices
and have demonstrated a concentration-dependent increase of
the amplitude of the population spike (Dimpfel et al., 2016b).
These results relate very well to previous clinical results where
neurophysiological effects of R. rosea extract in healthy subjects
were characterized (Dimpfel, 2014).
MATERIALS AND METHODS
Test Samples
Seven dry commercial extracts were obtained from different
suppliers via the Internet. Our selection strategy was to compare
Rhodiola extracts containing glycosides of cinnamyl alcohols
(rosavins) with extracts containing only tyrosol and its glycoside
salidroside. Some of the extracts were from plants grown in
the Altai mountains of Siberia. The samples consisted of bulk
powders, obtained from water. According to the manufacturers’
certificates of analysis and origin, they were hydroalcoholic
extracts of R. rosea roots and rhizome (harvest of 2015). Six
extracts were preparations containing only root and rhizome
powders, while one, SHR-5 contained maltodextrin as a carrier
(for details see Supplementary Data S1 and Table 1). Our
inclusion criteria were that products must be consumed as a
solid dose or soft-gel manufactured item. Our exclusion criteria
included ethanolic tinctures and raw materials including dried
roots, rhizomes, and bulk tinctures. Rhodiola SHR-5 extract has
been previously tested for efficacy and safety (Panossian and
Wikman, 2014) and was included as a control (i.e., registered
or licensed product). The samples of R. rosea L. roots and
rhizomes extracts were identified by thin-layer chromatography
(TLC) and ultra-performance liquid chromatography (UPLC)
using salidroside, tyrosol, rosavin, rosarin, rosin, and cinnamyl
alcohol as reference standards (Supplementary Data S2). The
voucher specimens were deposited in EuroPharma USA Inc.
Reference Standards and Solvents
Salidroside, tyrosol, rosavin, rosarin, rosin, and cinnamyl
alcohol reference standards were purchased from Phytolab
GmbH & Co. KG (Vestenbergsgreuth, Germany) and used for
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standard curve development. The solvents (water, methanol,
and acetonitrile) used for extraction and chromatography
were high performance liquid chromatographic grade (Waters
Corporation, United States and Merck, Darmstadt, Germany).
Preparation of the Analytical and
Reference Standard Samples
Powdered extract (0.3 g) was dissolved in 25 mL of solvent
system water:acetonitrile (90:10) using an ultrasonic bath for
30 min. It was then filtered through a 0.45 µm pore size filter
and analyzed by UPLC. Powdered extract (1 g) was dissolved in
10 mL of methanol using an ultrasonic bath for 30 min through
a 00H filter. The filtrate was applied (10 µL) to high performance
TLC (HPTLC) plates. Stock solutions of the reference standard
(2 mg/mL) in methanol was further diluted with methanol to
200 µg/mL, 20 µg/mL, 2 µg/mL, 200 ng/mL, 20 ng/mL, and
2 ng/mL.
Analytical Methods
The R. rosea extracts were analyzed with two basic
chromatographic techniques – HPTLC and UPLC. Quantitative
analysis of extracts was performed using a UPLC method,
validated for linearity (Correlation coefficient R > 0.999),
repeatability and the levels 50, 100, and 150% (RSD < 5%),
intermediate precision at different days and analysts (RSD< 5%),
accuracy (recovery in the range from 90 to 110%), selectivity
(peak purity angle less than purity threshold with resolution> 2),
range from 80 to 120% and robustness (RSD< 2%). Actual results
are shown in tabulated form in the Supplementary Data S1,
Table 2. The limits of detection (LOD) and quantification (LOQ)
of UPLC methods were evaluated by calculations based upon
the standard deviation of the response (σ) and the slope (S) of
calibration curve and the following formulas: LOD = 3.3 σ/S and
LOQ = 10 σ/S. The specificity, generally defined as the ability
of the UPLC methods to unequivocally assess the sample of
interest in the presence of potential interferences, was evaluated
in accordance with the new regulatory guideline (USP 25). In
addition to the evaluation of the resolution between the sample
peak and the next peak, a peak purity test based on photodiode
array (PDA) detection was tested to demonstrate that the sample
was pure with no co-eluting impurities. Specificity of the TLC
method was based on the colors and Rf value of reference
standards bands on the TLC plates visualized as described below.
UPLC Method
Analytical instrumentation and chromatography details
The UPLC fingerprints of the Rhodiola extracts were analyzed
using a Waters Acquity UPLC system consisting of Quaternary
Pumps Manager, Sample Manager, Column Manager, Photodiode
Detector, and Empower 3 software (Waters Corporation,
Milford, MA, United States). The UPLC column (Waters
ACQUITY UPLC BEH C18, column; 100 mm × 2.1 mm i.d.,
1.8 µm, Waters Corporation, United States) solvent system was
gradually increasing concentrations (2.5 to 100% in 14 min)
of acetonitrile in water with a flow rate of 0.6 mL/min
at 75◦C. The injection volume was 2 µL, detection was at
221 nm (phenylethanoids tyrosol and salidroside) and 252 nm
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TABLE 2 | Effective concentrations (%) of Rhodiola extracts inducing single shock stimulation (SS) and theta burst stimulation (TBS) in the hippocampus slice preparation.
Salidroside % Rosavin % Salidroside + Rosavins,% SS EC50, mg/L TBS EC50, mg/L
Rosavin 100 0.44 0.57
Salidroside 100 0.50 0.49
EPR-7 3.08 ± 0.005 3.67 ± 0.012 8.57 4.81 6.5
Alt-S 1.91 ± 0.002 1.33 ± 0.002 5.34 8.9 7.7
Alt-B 0.91 ± 0.000 1.08 ± 0.001 3.39 15.7 13.8
Alt-X 1.85 ± 0.001 0.03 ± 0.002 3.77 10.7 14.4
Chi-S 1.14 ± 0.002 0.00 1.30 9.8 15.3
SHR-5 2.14 ± 0.036 3.10 ± 0.003 7.06 12.4 16.1
Chi-R 2.53 ± 0.001 1.20 ± 0.002 4.98 14.6 19.5
Rosavins is a collective name of phenylpropanoid glycosides rosavin, rosarin, and rosin.
(phenylpropanoids). All quantitative results were calculated per
dry weight of the extracts.
TLC Method
Test solutions (10 µL) were manually applied on HPTLC
plates by a capillary. The solvent system used for HPTLC
was ethyl acetate:methanol:water:acetic acid, 90:8:1:8. The
bands on the silica gel 60 F254 pre-coated HPTLC plates
were visualized by UV light at 254 nm and in the daylight
after derivatization with anisaldehyde-sulfuric acid reagent
(anisaldehyde:acetic acid:sulfuric acid:methanol, 0.5:10:5:85
v/v/v/v) at 105◦C for 10 min. The plates were documented
using a “Reprostar” TLC/HPTLC imaging and documentation
system for a UV system instrument (CAMAG, Switzerland).
Images were captured under UV light at 254 and 366 nm prior to
derivatization and in the daylight after derivatization.
In Vitro Assay on Hippocampus Slices
Hippocampus slices were obtained from 48 adult male Sprague-
Dawley rats at the age of 40 days (Charles River Wiga,
Sulzbach, Germany). Rats were kept under a reversed day/night
cycle for 2 weeks prior to the start of the experiments to
FIGURE 2 | UPLC-UV fingerprint of the R. rosea rhizome extracts EPR-7 and SHR-5: lower panel – overlay of chromatograms of EPR-7 and SHR-5 detected at
252 nm, middle panel – EPR-7 detected at 221 nm, upper panel – UV spectra of tyrosol, salidroside, rosarin, rosin, rosavin, and cinnamyl alcohol.
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allow recording of in vitro activity from slices during the
active phase of their circadian rhythm (Dimpfel et al., 1994).
Animals were exsanguinated under ether anesthesia, the brain
was removed in total and the hippocampal formation was
isolated under a microstereoscopic vision system. The midsection
of the hippocampus was fixed to the table of a vibrating
microtome (Rhema Labortechnik, Hofheim, Germany) using
a cyanoacrylate adhesive, submerged in chilled bicarbonate-
buffered saline [artificial cerebrospinal fluid (ACSF): NaCl:
124 mM, KCl: 5 mM, CaCl2: 2 mM, MgSO4: 2 mM, NaHCO3:
26 mM, glucose: 10 mM], and cut into slices of 400µm thickness.
All slices were pre-incubated for at least 1 h in Carbogen saturated
ACSF (pH 7.4) in a pre-chamber before use (Dimpfel et al., 1991).
The stimulation of Schaffer Collaterals leads to release of
glutamate, resulting in excitation of the postsynaptic pyramidal
cells. The result of the electrical stimulation is recorded as
a so-called population spike. The amplitude of the resulting
population spike represents the number of recruited pyramidal
cells. The response of the pyramidal cells to electric stimulation
in the form of the amplitude of the population spike indicates
activation as increase of the amplitude as reported earlier for
Sideritis extract (Dimpfel et al., 2016a) or calming and sedating
effects (attenuation of the amplitude). Of special interest is the
response to theta burst stimulation (TBS) resulting in LTP, which
relates to an increase of time- and space-dependent memory.
During the experiment, the slices were held and treated in
a special super-fusion chamber (List Electronics, Darmstadt,
Germany) (Haas et al., 1979) at 35◦C (Schiff and Somjen, 1985).
The preparation was super-fused with ACSF at 180–230 mL/h.
Electrical stimulation (200 µA constant current pulses of 200 µs
pulse width) of the Schaffer Collaterals within the CA2 area and
recording of extracellular field potentials from the pyramidal cell
layer of CA1 (Dimpfel et al., 1991) was performed according to
conventional electrophysiological methods using the “Labteam”
Computer system “NeuroTool” software package (MediSyst
GmbH, Linden, Germany). Measurements were performed at
10 min intervals to avoid potentiation mechanisms. Four
stimulations, each 20 s apart, were averaged for each time
point. After obtaining three stable responses to SS, LTP was
induced by applying a TBS. The mean amplitudes of three
signals were averaged to give the mean of absolute voltage values
(Microvolt) ± standard error (SE) of the mean for four slices for
one of the experimental conditions. Four slices were used per day.
Statistical Analysis
The results are reported as means ± SD (standard deviation) or
±SE for the indicated number of experiments. The significance
of differences between samples and controls was determined
with one-way independent measures ANOVA, followed by the
post hoc Tukey’s test for multiple comparisons. The correlations
were evaluated using F-test. All calculations were performed
using GraphPad (San Diego, CA, United States) Prism software
(version 3.03) for Windows. GraphPad Prism was also used for
supplemental graphs. All statistical tests were two-sided tests with
p-values< 0.05 regarded as significant (Supplementary Data S3).
Wilcoxon–Mann–Whitney U test was also used throughout
all experimental data for comparison to results obtained by
vehicle administration at the particular timing with respect to
electrophysiological data (Supplementary Data S4).
RESULTS
UPLC and HPTLC Metabolite Profiling
Representative UPLC and HPTLC fingerprints of two R. rosea
extracts, EPR-7 and the reference standard SHR-5, are shown
in Figures 2, 3. They are almost identical except for the
peaks corresponding to rosavins, which are higher on the
chromatogram of EPR-7 (Figure 2) and the presence of some
fluorescent compounds in SHR-5, which are absent in EPR-7
(Figure 3).
The contents of all active markers in all studied extracts
(Table 1) were quite different, with a lack of rosavin, rosin, and
rosarin in one extract from China. Even the extracts from the
same geographic region – Altai (Russia) differed; e.g., the content
of rosavin in Alt-X was 100-fold lower (0.03%) compared with
SHR-5 (3.1%) or EPR-7 (3.7%), despite that all other phenyl- and
ethyl propanoids were within common limits. This may have a
significant impact on the activity of the Rhodiola Alt-X extract
in T cell activation and apoptosis (Marchev et al., 2017). Overall,
the highest content of rosavin and salidroside was in the Rhodiola
EPR-7 extract.
Electrophysiological Activity in a
Synaptic Model of Memory:
Hippocampal Long-Term Potentiation
Figure 4 shows the concentration-dependent effects of
salidroside and rosavin on pyramidal cell activity in terms
FIGURE 3 | High performance TLC (HPTLC) fingerprint of extracts exposed to
UV 366 nm, after derivatization with 10% sulfuric acid in methanol. Track A –
EPR-7, track C – SHR-5, track E – Alt-S, track B and D – reference standards
rosarin Rf = 0.28 and salidroside Rf = 0.36. Solvent system:
EtOAc:MeOH:H2O:HCOOH, 77:13:10:2.
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FIGURE 4 | Concentration-dependent effects of salidroside and rosavin on pyramidal cell activity in terms of changes of population spike amplitudes (millivolts).
Results were obtained after a single stimuli (SS) or burst stimuli (TBS). Data represent the mean ± SEM of n = 4 slices (all concentrations). The details of statistical
analysis see in Supplementary Data S3.
FIGURE 5 | Effects of Rhodiola extracts at the lowest active concentration
(5 mg/L) on pyramidal cell activity in terms of changes in population spike
amplitudes (millivoltage). Results are obtained after burst stimuli. Data
represent the mean ± SEM of n = 4 slices (all concentrations). The details of
statistical analysis see in Supplementary Data S3.
of changes of population spike amplitudes (millivolts) in
hippocampus slices. In the presence of salidroside, the amplitudes
of the population spike were enhanced in a concentration-
dependent manner. During SS, amplitudes reached about 2.3 mV
and about 4.3 mV during TBS. At 0.5 mg/L, salidroside was
more effective than rosavin in the TBS test, while at the higher
concentrations of 0.75 and 1.5 mg/L, the effect of rosavin was
superior (Figure 4, upper part).
A comparison of the Rhodiola extract Chi-R, containing
the phenyl ethanoids, tyrosol and salidroside, with the extracts
containing both salidroside and rosavin, e.g., Chi-R vs. Rhodiola
EPR-7, demonstrated that the content of salidroside in both
extracts was almost the same 2.5–3.0%, while the content of
rosavin in EPR-7 was 3.5-fold higher than in Chi-R (Table 1).
That is in line with results where the EPR-7 extract was as active as
Chi-R at a 2.5-fold lower concentration (Figure 4, lower part, and
Figure 5). Figure 5 shows that EPR-7 was the most active extract
at 5 mg/L, which corresponds to a concentration of rosavin of
0.18 mg/L (0.4 µM).
The EC50 values (Table 2) were calculated during SS and
TBS. All results were fitted using a hyperbolic tangent function
to give EC50 values (effective concentration to induce a half-
maximal effect). The lower the EC50 values, the less compound is
needed to exert its pharmacological effect. The lower the effective
concentration, the less side effects are expected. According to this
bioassay, the EPR-7 extract had the lowest EC50 value among
the seven Rhodiola extracts compared in this study (Table 2 and
Figures 5, 6).
DISCUSSION
In this study, we compared the biological activity of various
commercial extracts of R. rosea in a synaptic model of memory:
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FIGURE 6 | Concentration-dependent effects of Rhodiola extracts on pyramidal cell activity in terms of changes in the population spike amplitudes (millivolts).
Results were obtained after a single stimuli (SS) or burst stimuli (TBS). Data represent the mean ± SEM of n = 4 slices (all concentrations). The details of statistical
analysis see in Supplementary Data S3.
the LTP of synaptic transmission in the hippocampus (Bliss and
Collingridge, 1993). Synaptic transmission is critical in learning,
memory, and functioning of the nervous system. As memories
are thought to be determined by alteration of synaptic strength, a
persistent increase in synaptic strength following high-frequency
stimulation of a chemical synapse (LTP) is generally considered
one of the major cellular mechanisms that triggers learning and
memory.
When comparing the content of rosavin and/or salidroside
in seven extracts with their EC50 values (Table 2), one can
conclude that the EPR-7 extract, which has the highest content
of both active markers, was active at the lowest concentrations.
However, this correlation did not apply to other extracts, e.g.,
SHR-5, which presumably contained compounds that reduced
the overall efficacy of the total extracts (Figure 3). Active
compounds other than rosavin or salidroside might account for
the efficacy of the extracts in this bioassay through synergistic
or antagonistic modes of action. In this study, the brain
slice is exposed directly to the samples, circumventing the
blood–brain barrier. However, both preclinical and clinical
studies have proven that Rhodiola extract exerts actions on
the brain, suggesting enough compound passes the blood–brain
barrier.
The efficacy of Rhodiola SHR-5 extract was demonstrated
previously on healthy subjects (Spasov et al., 2000; Shevtsov
et al., 2003; Dimpfel, 2014), subjects experiencing stress and
fatigue (Darbinyan et al., 2000), and patients with chronic
fatigue (Olsson et al., 2009) and major depressive disorder
(Darbinyan et al., 2007; Mao et al., 2015). In a double
blind, placebo-controlled study on 20 healthy subjects, Dimpfel
demonstrated that a single dose administration of two capsules
containing 200 mg R. rosea SHR-5 extract changed the
spectral signature of electric brain activity in a stimulating
way compared with placebo. The effect was regarded as a
safe booster of mental activity during cognitive and emotional
challenges. Rhodiola EPR-7 extract was also studied earlier
in isolated skeletal muscle cells (Hernández-Santana et al.,
2014), animals (Dimpfel et al., 2016b), and healthy human
subjects (Shanely et al., 2014; Ahmed et al., 2015). Oral
administration of 100 mg/kg of R. rosea root extract led to
significant attenuation of α1, α2, β1, β2, δ, and θ waves of the
electropharmacograms, which are associated with the activation
of dopamine, serotonin, glutamate, GABA, acetylcholine, and
norepinephrine-mediated signaling pathways (Dimpfel et al.,
2016b). The most affected were α2 (dopaminergic transmission –
CNS stimulating effect) and β1 (glutaminergic transmission –
CNS stimulating effect) in the frontal cortex. The next strongest
changes were seen in the striatum, and the weakest changes in
the reticular formation. Spectral changes lasted up to 4 h after
administration.
These results are in line with those of our recent publication,
where we evaluated the effects of Rhodiola extract and salidroside
on gene expression profiling in the T98G human neuroglia
cell line (Panossian et al., 2014). The most significantly
affected canonical pathways across the entire dataset, which
contains the 1062 genes deregulated by Rhodiola and salidroside,
were G-protein coupled receptor signaling, glutamate receptor
signaling, ephrin receptor signaling, cAMP-mediated pathways,
and dopamine signaling pathways associated with the expression
of cell survival genes (Panossian et al., 2014). A meta-analysis
on the putative antidepressant action of Rhodiola extract
revealed it was effective on major depressive disorder (146
subjects) and stress-induced mild depression (714 individuals)
(Amsterdam and Panossian, 2016). Rosavin was not included
in that study. The results of our study are in line with
a previous publication where the LTP effect of Rhodiola
extract was tested in vitro in the hippocampal slice (Dimpfel
et al., 2016b). A concentration of 5 mg/L induced a slight
increase in the amplitude of the population spike and
an increase in LTP. Further increases were observed by
increasing the concentration up to 30 mg/L. During TBS,
amplitudes of more than 4 mV were measured, indicating their
effect on LTP.
CONCLUSION
In conclusion, rosavin, salidroside and various R. rosea extracts
potentiated the in vitro electric stimulation of an intra-
hippocampal electric circuit, which resulted in higher responses
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of pyramidal cells in isolated hippocampus slices. Rosavin was
more active in higher concentrations than salidroside; while,
salidroside was more effective at lower concentrations. The
highest content of both active markers was found in the extracts
that were active at the lowest concentrations. Although, this
correlation was not applicable to some extracts containing
other compounds that presumably reduced the efficacy due to
antagonistic interactions. The standardized content of active
markers is necessary for the quality control of herbal preparations
containing Rhodiola extracts, but insufficient for assessment of
their potential efficacy. The application of bioassays should be
required for adequate assessment of the quality and efficacy of
R. rosea extracts.
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Pomegranate (Punica granatum L.), one of the oldest known edible fruits, is nowadays
broadly consumed throughout the world. Its fruits and seeds as well as other anatomical
compartments (e.g., flowers and leaves) are rich in numerous bioactive compounds
and therefore, the scientific interest in this plant has been constantly growing in recent
years. It has been shown that pomegranate and its extracts exhibit potent antioxidative,
antimicrobial, and anticarcinogenic properties. The present review summarizes some
recent studies on pomegranate, highlighting mainly its vasculoprotective role attributed
to the presence of hydrolyzable tannins ellagitannins and ellagic acid, as well as other
compounds (e.g., anthocyanins and flavonoids). These in vitro and in vivo studies
showed that substances derived from pomegranate reduce oxidative stress and platelet
aggregation, diminish lipid uptake by macrophages, positively influence endothelial cell
function, and are involved in blood pressure regulation. Clinical studies demonstrated that
daily intake of pomegranate juice lessens hypertension and attenuates atherosclerosis in
humans. Altogether, the reviewed studies point out the potential benefits of a broader use
of pomegranate and its constituents as dietary supplements or as adjuvants in therapy of
vascular diseases, such as hypertension, coronary artery disease, and peripheral artery
disease.
Keywords: pomegranate, antioxidant, blood pressure, cardiovascular disease, vasculoprotective
INTRODUCTION
Pomegranate (Punica granatum L.), belonging to Punica L. genus, Punicaceae family, is an
ancient fruit native to Central Asia in regions spanning from Iran and Turkmenistan to
northern India as well as in the Mediterranean area and the Middle East (Holland et al.,
2009). Archaeologists have found carbonized pomegranate exocarps originated from the Early
Bronze Age (3000 BC), e.g., in Jericho and from the Late Bronze Age in Cyprus (Ward,
2003; Boncuk, 2014). Pomegranate has been highly appreciated since centuries by different
cultures. For example, in Ancient Egypt it was not only a part of the supply of fruits
for pharaoh’s residence (at around 1600 B.C.), but pomegranate was also painted on walls
and tombs to symbolize life after death (Ward, 2003; Boncuk, 2014). Pomegranate used to
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play an important role in different religions, including
Zoroastrianism, Judaism, Buddhism, Christianity, and Islam
(Langley, 2000; Jurenka, 2008). It was praised, e.g., by the Old
Testament of the Bible as “a sacred fruit conferring powers of
fertility, abundance, and good luck” (Jurenka, 2008). Besides
being a part of the mythology and consumed as a fruit,
pomegranate has been known for its medical use. For example,
the Ebers papyrus originating from about 1550 BC noted that
the roots of the pomegranate tree were used to treat tapeworm
parasites (Svenja, 2018). In addition, pomegranate was employed
to treat diabetes by Indians (Saxena and Vikram, 2004) and to
lessen tapeworm infestation also by Romans (Langley, 2000).
The persisting significance of the medical use of pomegranate
can be illustrated, for example, by the fact that in Great Britain
the coats of arms of three royal colleague and the British Medical
Association are decorated with the figure of this herb (Langley,
2000).
Besides native regions spreading from Iran to northern India
and the Mediterranean area and the Middle East, pomegranate is
nowadays cultivated in subtropical Africa as well as in California,
Arizona, and Mexico, as this plant requires high exposure to
sunlight during summer and temperature not lower than∼12◦C
in winter (Levin, 2006; Holland et al., 2009). The pomegranate
tree is about 2–3m tall, glabrous, with multiple trunks and
bushy appearance. The surface of the leaves is smooth and
hairless, with a glossy appearance on the upper part of the
leaf (Figure 1). The fruit ripens within 5–8 months after it has
begun to form. During this process, the color of the external
part of the fruit changes from yellow, green, or pink to fully
red, pink, or deep purple (Figure 1). An edible juicy layer of
a fruit varies in color from white to deep red (Holland et al.,
2009).
Studies accomplished over the last several decades showed that
pomegranate and its components exhibit potent antioxidative
(Gil et al., 2000; Les et al., 2015), anti-inflammatory (Adams
et al., 2006; Rasheed et al., 2009) as well as antibacterial,
antimicrobial, and antifungal properties (Naz et al., 2007; Fawole
et al., 2012; Elsherbiny et al., 2016; Wafa et al., 2017). In addition
to these in vitro studies, in vivo and in vitro studies showed
that pomegranate exhibits anti-hypertensive (Mohan et al., 2010;
Dos Santos et al., 2016; Arun et al., 2017) and antiproliferative
properties (Albrecht et al., 2004; Malik et al., 2005; Malik and
Mukhtar, 2006). Pomegranate and its constituents have been
tested for their use as adjuvant therapy for treatment of several
forms of oncological diseases, mainly of prostate cancer (Lansky
and Newman, 2007; Paller et al., 2013; Panth et al., 2017; Sharma
et al., 2017). Furthermore, numerous pre-clinical studies have
pointed out the beneficial effects of intake of pomegranate
juice or pomegranate extracts in a variety of conditions. For
example, such treatment improved sperm quality in mice (Türk
et al., 2008), lowered amyloid deposition in a mouse model of
Alzheimer’s disease (Hartman et al., 2006), and lessened neuronal
damage in a mouse neonatal hypoxic-ischemic brain injury
model (Loren et al., 2005). In addition, single intraperitoneal
injection with pomegranate extract applied to fishes that had been
naturally infected with lymphocystis disease virus, stimulated
their innate immune response, and reduced their mortality
due to lymphocystis infection (Harikrishnan et al., 2010). In
humans, oral administration of pomegranate extract enriched
with ellagic acid is beneficial for minimizing ultraviolet-induced
skin damage (Kasai et al., 2006), while hydro-alcoholic extracts
of pomegranate have a significant antibacterial activity and are
therefore useful for treatment of dental plaques (Menezes et al.,
2009). Many studies also demonstrated potent vasculoprotective
effects of pomegranate and its constituents, as presented below.
BIOACTIVE CONSTITUENTS OF
POMEGRANATE
Bioactive substances of pomegranate include, for example,
hydrolyzable tannins (gallotannins and ellagitannins), ellagic
acid and its derivatives, gallic acid, anthocyanins/anthocyanidins,
proanthocyanidins, flavonoids, vitamins, as well as sterols,
lignans, saccharides, fatty acids, organic acids, terpenes, and
terpenoids, among others. Ellagitannins and gallotannins
together with ellagic acid and its derivatives are crucial bioactive
compounds of pomegranate (Amakura et al., 2000a; Gil et al.,
2000; Fischer et al., 2011a; Borges and Crozier, 2012; Brighenti
et al., 2017). Furthermore, ellagitannins and gallotannins are
hydrolyzed to ellagic acid and glucose or gallic acid and glucose,
respectively (Arapitsas, 2012). In addition, pomegranate is
a source of numerous (poly)phenolic compounds (Fischer
et al., 2011a). Anthocyanins present in pomegranate comprise
mainly delphinidin 3-glucoside, delphinidin 3,5-diglucoside,
pelargonidin 3-glucoside, pelargonidin 3,5-diglucoside, cyanidin
3-glucoside, and cyanidin 3,5-diglucoside (Alighourchi et al.,
2008; Fischer et al., 2013; Lantzouraki et al., 2015), and the
characteristic colors of pomegranate fruits are attributed to
them. Pomegranate seeds contain different fatty acids with the
most represented punicic acid (Schubert et al., 1999; Kaufman
and Wiesman, 2007; Pande and Akoh, 2009; Verardo et al.,
2014; Górnas´ and Rudzinska, 2016). Flavol-3-ols, flavonoid
glycosides, phenolic acids, and hydrolyzable tannins represent
main phenolic compounds in pomegranate seed residue
(He et al., 2011). In pomegranate peel, gallic acid is a major
phenolic constituent while kaempferol-3-O-glucoside is the most
represented flavonoid (Ambigaipalan et al., 2016). Triterpenoids
oleanolic acid and ursolic acid are present in pomegranate
flower (Fu et al., 2014). Volatile components of pomegranate
comprise monoterpenes, monoterpenoids, aldehydes, alcohols,
and linear hydrocarbons monoterpenes, especially represented
by alpha-terpinene, alpha-terpineol, and 3-carene (Vázquez-
Araújo et al., 2011; Carbonell-Barrachina et al., 2012). An
overview of compounds identified in pomegranate is outlined in
Table 1.
VASCULOPROTECTIVE EFFECTS OF
VARIOUS PARTS OF POMEGRANATE
REVEALED IN IN VITRO AND IN VIVO
MODELS
Many pomegranate-derived compounds exhibit a wide range
of vasculoprotective effects. Various pomegranate parts
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FIGURE 1 | Fruits, flowers, and leaves of Punica granatum L.
(components) have proven to reduce oxidative stress, lipid
peroxidation, and generation of foam cells, to positively
influence endothelial cell function (by increasing NO levels
and lowering glucose levels), to attenuate platelet aggregation
and diminish hypertension, thus altogether improving vascular
function, as presented below. In addition, pomegranate and its
components are protective against toxicity induced by chemicals
or drugs (Table 2 and the text below).
Pomegranate Juice and Extract
In 2000s, Gil et al. in their pivotal study pointed out the
strong antioxidant properties of pomegranate juice enriched
with tannin punicalagin, anthocyanins, ellagic acid derivatives,
as well as other phenolic substances. Using different analytical
methods, the authors revealed potent antioxidant activities of
pomegranate juice that were three times higher than the well-
known antioxidative properties of red wine or green tea (Gil et al.,
2000). These findings were confirmed by subsequent studies that
additionally pointed to vasculoprotective effects of pomegranate
products, as presented below.
In a study involving mice as well as human volunteers,
pomegranate juice intake attenuated oxidative stress (Aviram
et al., 2000).More specifically, in apolipoprotein E-deficientmice,
food supplementation with pomegranate juice reduced by 44%
the size of atherosclerotic lesions and diminished the number of
foam cells in such lesions (Aviram et al., 2000). In humans, intake
of pomegranate juice diminished the susceptibility of low-density
lipoproteins (LDLs) to aggregate and enhanced by up to 20% the
activity of serum paraoxonase (Aviram et al., 2000), an esterase
that is associated with high-density lipoproteins (HDLs) and
can protect lipids against peroxidation (Chistiakov et al., 2017).
Pomegranate juice also inhibited the oxidized LDL (oxLDL)
uptake and cholesterol biosynthesis in a J774.A1 macrophage-
like cell line (Fuhrman et al., 2005). A study utilizing diabetic
mice model suggested that these protective effects might be due
to the presence of unique complex sugars and/or phenolic sugars
in pomegranate juice (Rozenberg et al., 2006). Another study
involved high and low exercise lifestylemimicking rats (high- and
low-capacity runners) fed with pomegranate juice for 3 weeks
(Rosenblat et al., 2015).While the effects were stronger in a group
of low-capacity runners, the consumption of pomegranate juice
decreased the cellular oxidation and increased the paraoxonase
2 activity in peritoneal macrophages from both animal groups
when compared with non-treated cohorts of animals (Rosenblat
et al., 2015).
In cultured human coronary artery endothelial cells exposed
to high shear stress, pomegranate juice down-regulated the
expression of redox sensitive genes ELK-1 and p-JUN and
increased the expression of endothelial nitric oxide synthase
(eNOS) (De Nigris et al., 2005) that is necessary for the proper
functioning of blood endothelial cells (Vallance and Chan,
2001). In addition, an intake of pomegranate juice by LDL
receptor-deficient mice fed with high-cholesterol diet, lessened
progression of atherogenesis at different stages of the disease (De
Nigris et al., 2005). Another in vitro study using cultured bovine
pulmonary artery endothelial cells showed that the presence of
even very low amounts of pomegranate juice in the cultivation
medium protects the generated nitric oxide (NO) against its
oxidative destruction (via an inhibition of a superoxide anion-
mediated disappearance of NO, leading to an enhancement of
the bioavailability of NO) (Ignarro et al., 2006). Another study of
this group showed that presence of pomegranate juice in human
coronary artery endothelial cells reverts down-regulation of the
expression of eNOS caused by the addition of oxLDL (de Nigris
et al., 2006). In a study accomplished in hypercholesterolemic
mice, an intake of pomegranate juice enriched with punicalagin
increased the eNOS expression and decelerated the progression
of atherosclerosis, as well as enhanced nitrates levels (De Nigris
et al., 2007). In pigs, an intake of the commercial pomegranate
extract Pomanox R© made from dried pomegranate skin or
husk could reduce coronary endothelial dysfunction induced by
hyperlipidemia (Vilahur et al., 2015). These beneficial effects
included an activation of the protein kinase B (Akt)/eNOS
pathway and an attenuation of vascular inflammation as well as of
vascular damage induced by oxidative stress (Vilahur et al., 2015).
Furthermore, pomegranate juice attenuated the aggregation
of human platelets exposed to collagen or arachidonic acid
ex vivo (Aviram et al., 2000; Mattiello et al., 2009), by
attenuating calcium mobilization, thromboxane A2 production,
and hydrogen peroxide formation (Mattiello et al., 2009).
These effects were assigned to the presence of polyphenols
in pomegranate products (Mattiello et al., 2009). It was also
shown that pomegranate fruit extract was active at a 2.0µM
concentration that is possible to be achieved after polyphenol-
rich food intake by humans (Mattiello et al., 2009). On the
other side, pomegranate seed oil inhibited cyclooxygenase (COX)
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TABLE 1 | List of compounds identified in pomegranate (Punica granatum L.).
Pomegranate phytochemicals Pomegranate part References
(1) ALKALOIDS
Caffeine Peel* Elsherbiny et al., 2016
N-(2′,5′-dihydroxyphenyl) pyridium chloride Leaf Nawwar et al., 1994b
Peelletierine Peel, bark Neuhofer et al., 1993; Vidal et al., 2003
(2) ANTHOCYANINS/ANTHOCYANIDINS
Cyanidin glucosides and derivatives Juice, seed, peel Hernandez et al., 1999; Noda et al., 2002;
Alighourchi et al., 2008; Türkyilmaz, 2013;
Ambigaipalan et al., 2016; Wafa et al., 2017
Delphinidin glucosides and derivatives Juice, peel Hernandez et al., 1999; Noda et al., 2002;
Alighourchi et al., 2008; Borges and Crozier, 2012;
Türkyilmaz, 2013; Ambigaipalan et al., 2016; Wafa
et al., 2017
(Epi) afzelchin-delphinidin-3-O-hexoside Seed Ambigaipalan et al., 2017
Malvidin glucosides and derivatives Juice Borges and Crozier, 2012; Pérez-Ramírez et al.,
2018
Pelargonidin glucosides and derivatives Juice, peel Hernandez et al., 1999; Noda et al., 2002;
Alighourchi et al., 2008; Türkyilmaz, 2013; Wafa
et al., 2017
Peonidin-3-O-(6”-O-acetyl)glucoside Juice Borges and Crozier, 2012
Vitisin A Juice Borges and Crozier, 2012
(3) ELLAGIC ACID AND DERIVATIVES
Ellagic acid Juice, peel, seed, flower Amakura et al., 2000b; Gil et al., 2000; Wang et al.,
2004; Jain et al., 2011; Wafa et al., 2017
Ellagic acid glucosides and derivatives Juice, peel Gil et al., 2000; Wafa et al., 2017
(4) FATTY ACIDS
Arachidic acid, behenic acid, docosadienoic acid,
eicosapentaenoic acid, erucic acid, gondoic acid, lignoceric
acid, linoleic acid, linolelaidic acid, linolenic acid, myristic acid,
margaric acid, nervonic acid, oleic acid, palmitic acid,
palmitoleic acid, punicic acid, stearic acid, cis-vaccenic acid
Seed Hopkins and Chisholm, 1968; Schubert et al., 1999;
Kaufman and Wiesman, 2007; Pande and Akoh,
2009; Elfalleh et al., 2011; Verardo et al., 2014;
Siano et al., 2016
(5) FLAVONOIDS AND DERIVATIVES
Acetyl prunin, diosmetin glucoside Juice Fanali et al., 2016
Apigenine Leaf Nawwar et al., 1994b
Apigenin-rhamnoside, chrysin Juice Lantzouraki et al., 2015
Catechin Juice, seed, peel De Pascual-Teresa et al., 2000; Mphahlele et al.,
2014; Ambigaipalan et al., 2016
Datiscetin-hexoside Juice Mena et al., 2012
Dihydroxygallocatechin Peel Ambigaipalan et al., 2016
Epicatechin Juice, peel De Pascual-Teresa et al., 2000; Mphahlele et al.,
2014
Eriodictyol 7-O-β-glucoside Juice Mphahlele et al., 2014
Flavan-3-ol Juice, peel De Pascual-Teresa et al., 2000
Gallocatechin Peel Wafa et al., 2017
Hesperidin Juice Mphahlele et al., 2014
Kaempferol Peel Van Elswijk et al., 2004
Kaempferol glucoside(s) Juice, seed, peel Van Elswijk et al., 2004; Mphahlele et al., 2014;
Lantzouraki et al., 2015; Ambigaipalan et al., 2016
Luteolin Peel, fruit Van Elswijk et al., 2004; Han et al., 2015
Myricetin and its glucoside Juice Naz et al., 2007; Lantzouraki et al., 2015
Naringin Juice, peel Kim et al., 2002; Mphahlele et al., 2014
Phloretin Peel, seed, juice Han et al., 2015
Phloridzin Juice Hmid et al., 2017
Pinocembrin Juice Calani et al., 2013
(Continued)
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TABLE 1 | Continued
Pomegranate phytochemicals Pomegranate part References
Quercetin and its derivatives Juice, seed, peel Artik, 1998; Naz et al., 2007; Borges and Crozier,
2012; Han et al., 2015; Lantzouraki et al., 2015;
Ambigaipalan et al., 2016
Rutin Juice, peel Artik, 1998; Mphahlele et al., 2014
Taxifolin and its glycosides Peel, seed, juice Calani et al., 2013; Han et al., 2015
(6) LIGNANS
Isolariciresinol, matairesinol, medioresinol,
pinoresinol, secoisolariciresinol, syringaresinol
Fruit, seed Bonzanini et al., 2009
(7) ORGANIC ACIDS
Citric acid Juice Poyrazoglu et al., 2002; Carbonell-Barrachina et al.,
2012; Gundogdu and Yilmaz, 2012; Legua et al.,
2012; Lantzouraki et al., 2015
Fumaric acid Juice Poyrazoglu et al., 2002; Gundogdu and Yilmaz,
2012
Lactic acid Juice Gundogdu and Yilmaz, 2012
Malic acid Juice Poyrazoglu et al., 2002; Carbonell-Barrachina et al.,
2012; Lantzouraki et al., 2015
Methylmalonic acid Juice Alper et al., 2011
Oxalic acid Juice Legua et al., 2012
Quinic acid Juice, peel Artik, 1998; Amakura et al., 2000a; Ehling and Cole,
2011
Succinic acid Juice Poyrazoglu et al., 2002; Alper et al., 2011
Tartaric acid Juice Poyrazoglu et al., 2002; Ehling and Cole, 2011;
Legua et al., 2012
Uronic acid Peel Hasnaoui et al., 2014
(8) OTHER PHENOLIC COMPOUNDS
3-Hydroxytyrosol Peel Elsherbiny et al., 2016
Benzaldehyde Peel Hadrich et al., 2014
Benzoic acid Peel Hadrich et al., 2014
Brevifolin carboxylic acid Fruit, juice Fischer et al., 2011a,b
Caffeic acid and its hexoside Juice, peel Artik, 1998; Amakura et al., 2000a; Lantzouraki
et al., 2015
Chlorogenic acid Juice, peel Artik, 1998; Amakura et al., 2000a; Hasnaoui et al.,
2014
Cinnamic acid Juice Lantzouraki et al., 2015
Coniferyl 9-O-[β-d-apiofuranosyl
(1→6)]-O-β-d-glucopyranoside
Seed Wang et al., 2004
Cyanidin-pentoside-hexoside Fruit Fischer et al., 2011a
Ethyl cinnamate Juice Cadwallader et al., 2010
Ferulic acid and its hexoside Juice Lantzouraki et al., 2015
Gallic acid Juice, seed, peel Amakura et al., 2000b; Huang et al., 2005a; Jain
et al., 2011; Mphahlele et al., 2014; Ambigaipalan
et al., 2016; Fanali et al., 2016
Protocatechuic acid Juice, seed, peel Ambigaipalan et al., 2016; Fanali et al., 2016
p-Coumaric acid Juice, peel, seed Artik, 1998; Amakura et al., 2000a; Ambigaipalan
et al., 2017
Salycilic acid Peel Elsherbiny et al., 2016
Sesamin, 4-hydroxysesamin Peel Jiang et al., 2012
Vanillic acid Juice Mena et al., 2012
(9) PROANTHOCYANIDINS
Procyanidin dimer B2 and B3 Peel Ambigaipalan et al., 2016
Arabinose, xylose, galactose, glucose, mannose,
rhamnose
Peel Hasnaoui et al., 2014
(Continued)
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TABLE 1 | Continued
Pomegranate phytochemicals Pomegranate part References
(10) SACCHARIDES
Glucose, fructose, maltose, sucrose Juice Carbonell-Barrachina et al., 2012; Legua et al.,
2012; Vegara et al., 2014; Conidi et al., 2017
(11) STEROLS
β-Sitosteryl acetate Peel Jiang et al., 2012
Avenasterol, 17-avenasterol, campesterol,
cycloartenol, 17-stigmasterol, stigmasterol,
β-sitosterol
Seed Górnas´ and Rudzinska, 2016
Camesterol Seed Abd El Wahab et al., 1998
Daucosterol Seed Wang et al., 2004
Stigmasterol Seed Abd El Wahab et al., 1998
(12) TANNINS (GALLOTANNINS AND ELLAGITANNINS AND THEIR DERIVATIVES)
1,2,3-Tri-O-galloyl-β-4C1-glucose Leaf Nawwar et al., 1994a
2-O-Galloylpunicalin Juice Borges and Crozier, 2012
3,3′-Di-O-methylellagic acid Seed Wang et al., 2004
3,3′,4′-Tri-O-methylellagic acid Seed Wang et al., 2004
Castalagin Juice, peel Fischer et al., 2011a
Castalin Fruit, juice Fischer et al., 2011b
Casuarinin (Galloyl-bis-HHDP-hexoside) Peel Satomi et al., 1993; Ambigaipalan et al., 2016
Corilagin (Galloyl-HHDP-hexoside) Peel, leaf Satomi et al., 1993; Nawwar et al., 1994a;
Ambigaipalan et al., 2016
Epicatechin gallate Peel Ambigaipalan et al., 2016
Flavogallonic acid Peel Jiang et al., 2012
Gallagic acid Peel, juice Tzulker et al., 2007
Gallagyldilacton Peel Satomi et al., 1993; Anibal et al., 2013
Granatin A/B Peel Tanaka et al., 1990; Wafa et al., 2017
Lagerstannin C (Galloyl-HHDP-gluconic) Peel Wafa et al., 2017
Pedunculagin I (bis-HHDP-hexoside) Juice, peel Satomi et al., 1993; Lantzouraki et al., 2015; Wafa
et al., 2017
Pentagalloylglucopyranose Seed He et al., 2011
Punicacortein A, B, C, and D Peel, bark Tanaka et al., 1986a; Anibal et al., 2013
Punicafolin Leaf Nawwar et al., 1994a
Punicalagin (HHDP-gallagyl-hexoside) Juice, peel, leaf Tanaka et al., 1986b; Jain et al., 2011; Anibal et al.,
2013; Lantzouraki et al., 2015
Punicalin α and β Peel, juice, leaf Tanaka et al., 1986b; Tzulker et al., 2007; Jain et al.,
2011; Wafa et al., 2017
Punicatannin C Flower Yuan et al., 2013
Punigluconin (Digalloyl-HHDP-glucoside) Peel Wafa et al., 2017
Tellimagrandin Peel Satomi et al., 1993
Tergallagic acid-O-glucoside Juice Borges and Crozier, 2012
Valoneic acid bilactone Juice Fischer et al., 2011a,b
(13) TERPENES AND TERPENOIDS
3-Carene, α-terpinene, α-terpineol, eugenol Juice Carbonell-Barrachina et al., 2012
Asiatic acid Flower Batta and Rangaswami, 1973
Betulinol, 24-methylenecycloartenol, cycloartenol,
squalene
Seed Verardo et al., 2014
Camphor Peel Hadrich et al., 2014
Eugenol Juice Carbonell-Barrachina et al., 2012
Maslinic acid Flower Batta and Rangaswami, 1973
Oleanolic acid Flower Huang et al., 2005b; Fu et al., 2014
α/β-Pinene, limonene, terpineol, β-farnesene,
β-caryophyllene, bisabolene
Juice Vázquez-Araújo et al., 2011
(Continued)
Frontiers in Pharmacology | www.frontiersin.org May 2018 | Volume 9 | Article 54489
Wang et al. Vasculoprotective Effects of Pomegranate
TABLE 1 | Continued
Pomegranate phytochemicals Pomegranate part References
Punicaone, 1β-hydroxy-3-oxoolean-12-en-28-oic
acid, 3β,24-dihydroxyurs-12-en-28-oic acid,
betulin, betulinic acid, borneol, friedelin, lantanolic
acid, lupeol, oleanic acid
Peel Jiang et al., 2012
Ursolic acid Seed, flower Ahmed et al., 1995; Huang et al., 2005a; Fu et al.,
2014
(14) VITAMINS
Vitamin C Juice Dumlu and Gurkan, 2007
(15) XANTONOIDS
Mangiferin Peel Elsherbiny et al., 2016
*Peel (pericarp, rind, and hull are synonyms).
TABLE 2 | Vasculoprotective effects of pomegranate determined in in vitro and in vivo pre-clinical studies.
Vasculoprotective effects Pomegranate part References
Antioxidative properties in vitro and in vivo Juice, fruit extract, peel extract Gil et al., 2000; Les et al., 2015; Delgado et al.,
2016
Suppression of peroxidation of plasma lipids, induction of serum
paraoxonase activity, lowering lipid uptake by macrophages, and
diminishing development of atherosclerosis in mice
Juice, fruit extract Aviram et al., 2000; Fuhrman et al., 2005; Rosenblat
et al., 2015; Mollazadeh et al., 2016
Improvement of endothelial cell function in vitro, in mice and pigs
[due to an activation of the protein kinase B (Akt)/eNOS pathway,
an inhibition of a superoxide anion-mediated disappearance of
NO, and reduction of vascular inflammation]
Juice, fruit extract De Nigris et al., 2005; de Nigris et al., 2006; De
Nigris et al., 2007; Ignarro et al., 2006; Vilahur et al.,
2015
Reduction the collagen- and arachidonic acid-induced platelet
aggregation ex vivo
Juice, fruit extract Aviram et al., 2000; Mattiello et al., 2009
Reduction in activity of angiotensin-converting enzyme (ACE);
decrease in mean arterial blood pressure in rats
Juice, fruit extract, peel extract Mohan et al., 2010; Dos Santos et al., 2016; Arun
et al., 2017
Lessening cardiac toxicity induced by drugs or smoking
(diminishing lipid peroxidation and increasing levels of antioxidant
enzymes)
Juice, fruit extract Jadeja et al., 2010; Al Hariri et al., 2016
Reduction of blood glucose levels in a variety of mouse and rat
models (effects mediated via upregulation of PPAR-γ leading to an
increase in insulin sensitivity)
Seed-, flower-, and peel-extract Das et al., 2001; Huang et al., 2005a; Li et al.,
2005; Vroegrijk et al., 2011; Salwe et al., 2015
Lowering fatty acid, triglycerides and total cholesterol plasma
levels as well as cardiac triglycerides (in Zucker diabetic fatty rats)
Flower extract Huang et al., 2005b
(Schubert et al., 1999), the key enzyme catalyzing the conversion
of arachidonic acid to prostaglandin (PGI2) (Grosser et al.,
2006). The latter substance is known as a potent vasoprotective
factor inhibiting platelet adhesion and thrombus formation on
endothelium (Weiss and Turitto, 1979). In addition, feeding of
rats with pomegranate extract diminished in colonic mucosa
levels of COX-2, prostaglandin E2 (PGE2) as well as inducible
nitric oxide synthase (iNOS) (Larrosa et al., 2010b).
Some other works investigated how pomegranate affects
arterial hypertension, an important risk factor for cardiovascular
diseases (Pickering, 1972). For example, in a study involved
the use of Wistar rats in which diabetes was induced by
streptozotocin administration, and the animals were additionally
challenged by a subcutaneous administration of angiotensin II to
induce hypertension, a prolonged administration of pomegranate
juice (for 4 weeks) reduced activity of angiotensin converting
enzyme (ACE), as well as decreased mean arterial blood pressure
in comparison with non-treated animals (Mohan et al., 2010).
Pomegranate fruit extracts were also studied regarding their
protective effect against cardiac toxicity induced by drugs or
smoking. For example, detrimental effects of a cardiotoxic drug
isoproterenol (known to cause a cardiac necrosis leading to
a myocardial infarction) were reduced upon pre-treatment of
rats with pomegranate juice for 30 consecutive days before
isoproterenol treatment (Jadeja et al., 2010). Such pre-treatment
significantly lessened an increase in the heart weight, infarction
size, plasma marker enzymes, lipid peroxidation levels as well
as levels of Ca2+ ATPase (Jadeja et al., 2010). The protective
effects of pomegranate juice intake were also demonstrated
in a study using rats in which a cardiac hypertrophy
was induced by cigarette smoke exposure (Al Hariri et al.,
2016).
Frontiers in Pharmacology | www.frontiersin.org May 2018 | Volume 9 | Article 54490
Wang et al. Vasculoprotective Effects of Pomegranate
Pomegranate Seed Oil
Pomegranate seeds comprise about 3% of the pomegranate
weight and contain about 12–20% seed oil (Lansky and Newman,
2007) that is rich in fatty acids and contains mainly punicic acid
(Kaufman and Wiesman, 2007; Verardo et al., 2014; Górnas´ and
Rudzinska, 2016).
In rats with streptozotocin-induced diabetes, oral feeding
with seed extracts significantly reduced blood glucose levels
(Das et al., 2001). In mice, an intake of pomegranate seed
oil counteracted their obesity induced by a high-fat diet by
enhancing peripheral insulin sensitivity (Vroegrijk et al., 2011).
Oral treatment of the above cited diabetic rats with pomegranate
seed oil significantly decreased peroxidation of plasma lipids
(Mollazadeh et al., 2016). In addition, such treatment diminished
malondialdehyde content in homogenates from the heart and
kidney tissues, and reduced triglyceride levels in treated animals
in comparison to the control cohort (Mollazadeh et al.,
2016).
Pomegranate Flower, Peel, and Leaf
Extracts
A 6-week oral administration of pomegranate flower extracts
suppressed plasma glucose levels in Zucker diabetic fatty
rats following their exposure to glucose-loading. In addition,
such treatment in these animals increased cardiac peroxisome
proliferator-activated receptor gamma (PPAR-γ) mRNA
expression as well as restored the down-regulated cardiac glucose
transporter (GLUT)-4 mRNA, altogether improving insulin
sensitivity (Huang et al., 2005a). These beneficial effects were
assigned mainly to the presence of gallic acid (Huang et al.,
2005a). A long-term treatment of Zucker diabetic fatty rats with
pomegranate flower extracts was cardioprotective, as it lowered
their fatty acid-, triglycerides-, and total cholesterol plasma levels
as well as reduced the cardiac triglycerides content (Huang et al.,
2005b). In another study, oral administration of pomegranate
flower extracts decreased plasma glucose levels in non-fasted
diabetic rats (but not in fasted-diabetic rats or in normal rats).
This study also showed that pomegranate flower extracts inhibit
α-glucosidase (a key enzyme for carbohydrate digestion in
intestines) and administration of pomegranate flower extracts
may improve postprandial hyperglycemia in type 2 diabetes, and
altogether diminish the risk of cardiovascular dysfunctions (Li
et al., 2005). In mice fed with a high-fat diet to induce obesity,
treatment with pomegranate leaf extract decreased body weight,
energy intake as well as total cholesterol, triglyceride, and glucose
levels (Lei et al., 2007). Administration of hydroalcoholic peel or
leaf extracts of pomegranate for 28 days decreased blood glucose
levels in aWister rat model of diabetes induced by streptozotocin
(Salwe et al., 2015). Hydroalcoholic peel extracts of pomegranate
were also tested in spontaneously hypertensive ovariectomized
female rats (an animal model for menopause characterized by
an increase in the superoxide anion levels; Delgado et al., 2016).
Such treatment diminished elevation of superoxide anion levels
and lessened oxidative stress in this animal model (Delgado et al.,
2016). Treatment of spontaneously hypertensive rats of different
ages for 30 days with pomegranate peel extracts, significantly
reduced systolic blood pressure, ACE activity, oxidative stress
as well as vascular remodeling (Dos Santos et al., 2016). A
recent in vitro study showed that pomegranate peel methanolic
extracts potently scavenge superoxide and hydroxyl radicals,
protect LDL against oxidation and suppress ACE activity (Arun
et al., 2017). Altogether, these studies demonstrated that also
the non-edible parts of pomegranate—peel and leaves—exhibit
vasculoprotective effects.
VASCULOPROTECTIVE EFFECTS OF
PURE COMPOUNDS DERIVED FROM
POMEGRANATE
Studies presented above showed the numerous vasculoprotective
effects of different parts of the pomegranate. It was suggested
that many of these protective effects are caused by the presence
of hydrolyzable tannins (ellagitannins and gallotannins), their
derivative ellagic acid, or their common metabolites urolithins
(Table 3 and the text below).
Pomegranate ellagitannins and a single high molecular
weight ellagitannin punicalagin, attenuated the inflammatory cell
signaling in colon cancer cells (Adams et al., 2006). Punicalagin
and gallic acid induced in isolated macrophages the expression of
paraoxonase 2 (Shiner et al., 2007). These substances also reduced
oxidative stress in macrophages via activation of transcription
factors PPAR-γ and activator protein 1 (AP-1; Shiner et al.,
2007).
Single components (e.g., punicalin, punicalagin, ellagic acid,
and gallic acid) isolated from pomegranate fruit suppressed
the formation of advanced glycation end products (AGEs,
known to contribute to a number of diseases including
diabetic complications and arteriosclerosis) from bovine
serum albumin and sugar in antiglycation assays in vitro
(Kumagai et al., 2015). Pomegranate fruit extracts also
reduced the accumulation of AGEs in mice fed with a
high-fat and high-sucrose diet (Kumagai et al., 2015).
In addition, punicalagin and ellagic acid inhibited lipid
metabolism in mouse and human adipocytes ex vivo (Les et al.,
2017).
Effects of ellagic acid on reactive oxygen species (ROS)
generation were also investigated in endothelial cells. Pre-
treatment of HUVECs with ellagic acid attenuated ROS
production and prevented eNOS downregulation induced
by oxLDL (Lee et al., 2010; Ou et al., 2010). Ex vivo,
ellagic acid stimulated vasorelaxation of the rat thoracic
aorta via an endothelium-dependent mechanism and an
inhibition of calcium influx (Yilmaz and Usta, 2013).
Nevertheless, as ellagitannins and ellagic acid in vivo
metabolize into urolithins that enter systemic circulation
(Cerdáet al., 2005; Larrosa et al., 2010a), researchers
also studied how these metabolites affect the vascular
function.
The antioxidant properties of different urolithins were
evaluated in a cell-based assay and the results showed that
urolithin C and D were more potent antioxidants than the
parental substance ellagic acid and punicalagin (Bialonska et al.,
Frontiers in Pharmacology | www.frontiersin.org May 2018 | Volume 9 | Article 54491
Wang et al. Vasculoprotective Effects of Pomegranate
TABLE 3 | Vasculoprotective effects of pomegranate-derived substances or their metabolites, as determined in vitro and in vivo pre-clinical studies.
Vasculoprotective effects Vasculoprotective substances References
Induction of paraoxonase 2 and reduction in oxidative
stress in isolated macrophages
Punicalagin, gallic acid Shiner et al., 2007
Attenuation of reactive oxygen species (ROS) generation
and prevention of eNOS downregulation induced by
oxLDL in HUVECs. Stimulation of vasorelaxation of the
rat thoracic aorta ex vivo, via an endothelium-dependent
mechanism and through an inhibition of calcium influx
Ellagic acid Lee et al., 2010; Ou et al., 2010; Yilmaz
and Usta, 2013
Suppression of formation of advanced glycation end
products (AGEs) in vitro and in mice
Punicalin, punicalagin, ellagic acid, gallic acid Kumagai et al., 2015
Inhibition of lipid metabolism in adipocytes Punicalagin, ellagic acid Les et al., 2017
Antioxidative properties in a cell-based assay in vitro Urolithins Bialonska et al., 2009
Inhibition of adhesion of monocytes to endothelial cells,
of secretion of a cellular adhesion molecule (VCAM-1)
and pro-inflammatory cytokine (IL-6). Decrease in the
accumulation of cholesterol in THP-1-derived
macrophages
Ellagic acid, urolithin A glucuronide, other urolithins Gimenez-Bastida et al., 2012; Mele et al.,
2016
Attenuation of endothelial dysfunction induced by oxLDL
in cultured human artery endothelial cells, partly by
counteracting eNOS-dependent decrease in NO
production. Reduction in myocardial
ischemia/reperfusion injury and myocardial infarct size in
vivo
Urolithin A Han et al., 2016; Tang et al., 2017
Anti-hypertensive effects of sweetie juice in humans Naringin Reshef et al., 2005
Amelioration of glucose tolerance and diminishing
obesity-related inflammation via activation of PPAR-γ
and -α
Puninic acid Hontecillas et al., 2009
2009). Nonetheless, although an in vitro antioxidant potential
of urolithin A was relatively low in comparison with other
urolithins, its plasma concentrations was the highest among
them (Bialonska et al., 2009). In a subsequent study, urolithin
A glucuronide inhibited adhesion of monocytes to endothelial
cells in the micromolar range (5–15µM), suggesting that the
beneficial effects of pomegranate intake on the vasculature
might be partly mediated by urolithin A glucuronide (Gimenez-
Bastida et al., 2012). In addition, a recent in vitro study showed
potent anti-atherogenic properties of ellagic acid and some
urolithins (Mele et al., 2016). All these compounds reduced
the adhesion of THP-1 derived macrophages to HUVECs
and diminished secretion of soluble vascular cell adhesion
molecule-1 (VCAM-1) and inflammatory interleukin-6 (IL-6)
(Mele et al., 2016). In a study utilizing cultured human artery
endothelial cells, urolithin A attenuated endothelial dysfunction
induced by oxLDL (Han et al., 2016). These effects were
partly mediated by counteracting eNOS-dependent decrease
in NO production (Han et al., 2016). In addition, urolithin
A reduced the expression of intracellular adhesion molecule-
1 (ICAM-1) and monocyte chemotactic protein 1 (MCP-
1), upon adhesion of THP-1 cells to the endothelial cells.
Urolithin A also suppressed the expression of tumor necrosis
factor-α (TNF-α), IL-6 and endothelin-1, increased PPAR-
γ mRNA expression, and downregulated phosphorylation of
the extracellular signal-regulated protein kinase 1/2 (ERK1/2)
(Han et al., 2016). In another study, urolithin A inhibited
heme peroxidases [myeloperoxidase (MPO) and lactoperoxidase
(LPO)] more effectively than its parent compound ellagic acid
(Saha et al., 2016). Animal experiments using C57BL/6 mice
revealed potent anti-inflammatory properties of urolithin A,
as it efficiently reduced phorbol myristate acetate (PMA)-
induced mouse ear edema formation (Saha et al., 2016).
Urolithin A also lessened myocardial ischemia/reperfusion
injury and reduced myocardial infarct size in mice via the
phosphoinositide 3-kinase/Akt (PI3K/Akt) pathway (Tang et al.,
2017).
Altogether, the studies presented above pointed to beneficial
vascular effects of urolithins and especially metabolite urolithin
A. Additional information on metabolic fate and health
effects of ellagitanins and urolithins can be found in several
recent reviews (Garcia-Muñoz and Vaillant, 2014; Lipinska
et al., 2014; Landete et al., 2016; Tomas-Barberan et al.,
2017).
In addition to the above presented effects of hydrolyzable
tannins (ellagitannins and gallotannins), their derivative
ellagic acid, or their common metabolites urolithins, but
also other substances were shown to contribute to beneficial
effects of pomegranate products. These include (poly)phenolic
compounds anthocyanins (Alighourchi et al., 2008; Fischer
et al., 2011a) and flavonoids (Sudheesh and Vijayalakshmi,
2005; Ricci et al., 2006), as well as fatty acids (Kaufman and
Wiesman, 2007). For example, anthocyanins exhibit anti-
inflammatory activities (Vendrame and Klimis-Zacas, 2015).
Flavonoid naringin abundantly present in pomegranate juice
(Mphahlele et al., 2014) is considered to contribute (together
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with flavonoid naritutin) to the anti-hypertensive effects of
sweetie juice in humans (Reshef et al., 2005). Puninic acid
was shown to ameliorate glucose tolerance and diminish
obesity-related inflammation via an activation of PPAR-γ
and α (Hontecillas et al., 2009). Quercetin present in juice,
seed, and peel of pomegranate (Artik, 1998; Borges and
Crozier, 2012; Ambigaipalan et al., 2016) is known to mediate
endothelium-dependent vasodilatation via stimulation of both
the NO/cyclic guanylyl monophosphate (cGMP) pathway and
endothelium-derived hyperpolarizing factor (EDHF) (Khoo
et al., 2010).
CLINICAL STUDIES ON POMEGRANATE IN
THE CONTEXT OF CARDIOVASCULAR
DISEASES
Many clinical studies investigating the effects of pomegranate in
the context of CVDs were performed in the last two decades.
These works profusely demonstrated the vasculoprotective
properties of pomegranate products (Table 4). Nevertheless,
some of these studies pointed to the fact that when applying
pomegranate for a longer period or in high amounts, certain
possible side effects of such treatment (mainly diarrhea) might
occur (Paller et al., 2013).
In hypertensive patients, daily consumption of pomegranate
juice for 2 weeks reduced the activity of ACE by 36% as
well as diminished systolic blood pressure by 5% (Aviram
and Dornfeld, 2001). The same group also reported that a
long-duration intake of pomegranate juice (for 3 years) by
patients with carotid artery stenosis significantly reduced their
blood pressure, LDL oxidation and common carotid intima-
media thickness (Aviram et al., 2004). A 4-week consumption
of pomegranate juice reduced significantly blood pressure
in a cohort of 51 healthy women (without significantly
changing serum ACE activity; Lynn et al., 2012). Another
study involving 13 hypersensitive men demonstrated that intake
of pomegranate juice lowered blood pressure (Asgary et al.,
2013). However, in these patients the levels of some clinical
parameters, such as serum concentrations of C-reactive protein
(CRP), E-selectin, VCAM-1, ICAM-1, and IL-6 remained
unchanged (Asgary et al., 2013). A subsequent study involving 21
hypertensive patients showed that consumption of pomegranate
juice significantly reduced systolic as well as diastolic blood
pressure (Asgary et al., 2014). In addition, a double blind,
randomized, placebo controlled pilot study revealed that the
pomegranate peel hydroalcoholic extract reduced cardiovascular
risk factors in obese women with dyslipidemia (Haghighian et al.,
2016).
Although a meta-analysis evaluating the effects of
pomegranate consumption on CRP concentrations did not
reveal a significant correlation between these parameters
(Sahebkar et al., 2016), the effects of pomegranate consumption
on blood pressure regulation in accomplished animal and
human studies seem to be clinically relevant. In a recent review
it was concluded that both pomegranate juice and seed oil
can effectively lower blood pressure (Asgary et al., 2017).
Another recently accomplished meta-analysis came to the
same conclusions, as intake of pomegranate juice decreased
levels of systolic blood pressure regardless of the duration
and dose of the juice consumed in the evaluated studies,
whereas doses more than 240 cc (eight ounces) exhibited a
borderline significant effect in reducing of a diastolic blood
pressure (Sahebkar et al., 2017). The authors of this meta-
analysis determined a constant benefit of pomegranate juice
intake on blood pressure, which may be considered clinically
relevant. Additional information of how pomegranate affects
TABLE 4 | Outcome of clinical studies involving intake of pomegranate juice or peel hydro alcoholic extract.
Type of the study/Number of probands Clinical outcome References
Daily consumption of pomegranate juice for 2 weeks by
hypertensive patients (N = 10)
Reduction in ACE activity by 36% and of a systolic blood pressure
by 5%
Aviram and Dornfeld, 2001
A long-duration intake of pomegranate juice (for 3 years) by
patients with carotid artery stenosis (N = 19)
Reduction in systolic blood pressure by 12%, decrease in
common carotid intima-media thickness up to 30%
Aviram et al., 2004
A 4-week consumption of pomegranate juice by healthy
women (N = 51)
A mild, but significant reduction in blood pressure (without
significantly changing serum ACE activity)
Lynn et al., 2012
Intake of pomegranate juice by hypersensitive men (N = 13) Decrease in blood pressure while other parameters (serum
concentrations of CRP, E-selectin, VCAM-1, ICAM-1, and IL-6)
remain unchanged
Asgary et al., 2013
Consumption of pomegranate juice by hypertensive patients
(N = 21)
Significant reduction in systolic as well as diastolic blood pressure Asgary et al., 2014
Intake of pomegranate peel hydro alcoholic extract by obese
women with dyslipidemia (N = 38)
Significant reduction in systolic blood pressure Haghighian et al., 2016
A meta-analysis focusing on effects of pomegranate
consumption on CRP
No significant correlation between pomegranate consumption and
CRP levels
Sahebkar et al., 2016
A meta-analysis focusing on blood pressure lowering effects
of intake of pomegranate juice
Decrease in systolic blood pressure levels (regardless of the
duration and dose of the juice consumed in the evaluated studies).
A borderline significant effect in reducing of diastolic blood
pressure by doses higher than 240 cc (eight ounces)
Sahebkar et al., 2017
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vasculature can be found in some other reviews (Lansky and
Newman, 2007; Aviram and Rosenblat, 2013; Hyson, 2015;
Zheng et al., 2017). In addition to many described beneficial
effects of pomegranete on endothelial function, pomegranate
juice was also found to enhance the inhibitory effect of NO
on vascular smooth muscle cell proliferation (Ignarro et al.,
2006). This aspect might be clinically relevant and a subject
of further studies, as vascular smooth muscle cell proliferation
plays an important role in the development and progression of
atherosclerosis and restenosis (Uhrin et al., 2018; Wang et al.,
2018).
CONCLUSION
Pomegranate, an ancient and highly distinctive fruit, is
a rich source of natural bioactive constituents. Various
studies showed that pomegranate and its products exhibit
protective effects on the cardiovascular system. These
vasculoprotective effects include diminishing of oxidative
stress, positive influencing macrophage-, endothelial cell-,
and platelet function, lowering lipid oxidation, reducing
blood glucose levels, vasodilatory effects as well as decreasing
blood pressure via an inhibition of ACE activity. In light
of the altogether promising outcome of numerous pre-
clinical and clinical studies, pomegranate is advocated
to be used as a dietary supplement for prevention and
treatment of cardiovascular diseases, thus representing a
supplementary non-pharmacological therapy for cardiovascular
diseases.
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Greek islands of the North Aegean Region are a group of nine inhabited islands (Lemnos,
Agios Efstratios, Lesvos, Chios, Psara, Oinousses, Samos, Ikaria, and Fourni) located in
the northern part of the Aegean Sea, close to Asia Minor. Each island of this region
can be considered autonomous in terms of culture and biodiversity. With this work
we try to evaluate the status of the traditional uses of medicinal plants in this region.
Endemic and endangered species such as Sideritis sipylea Boiss., Origanum sipyleum
L., Thymus sipyleus Boiss., Pistacia lentiscus L., Verbascum ikaricum Murb., are still
used by locals to treat different ailments. Moreover, the use of some species for the
treatment of specific diseases has been reported for the first time. We report about 109
wild plants of medicinal importance, from 52 families, listing their uses for therapeutic
purposes and galenic preparations provided by local medical doctors and pharmacists.
The information we include was derived from literature sources and additionally collected
through semi-structured interviews conducted on 200 informants (100 men and 100
women). Additionally, informant consensus factor (FIC) and UV value were calculated
for the medicinal plants in the current study in relation with the diseases treated. This
research confirms the importance of the medicinal plants and the diffusion of their
use in traditional medicine within this region. This ethnopharmacological survey is a
fundamental step for the preservation of the local knowledge both for further scientific
research and for the protection of endangered and endemic medicinal plants.
Keywords: ethnopharmacology, traditional medicine, Near East Greek islands, North Aegean Sea, ethnobotany
INTRODUCTION
Greece holds a unique position with respect to the number of plant species and subspecies
compared to other areas of the globe. This depends on the variety of habitats, as well as on
geological history, climate conditions, and geographical position within the Mediterranean. Thus,
it is noted for its high plant species diversity (5800 species and 1893 subspecies) and endemism
(22.2% of all species present with 1278 species and 452 subspecies) (Davis, 1965–1986; Tutin et al.,
1968–1980; Strid, 1986; Strid and Tan, 1991, 1997, 2002; Georgiou and Delipetrou, 2010).
The Northeast Aegean islands offer a unique ecosystem with significant “hotspots” for various
plant diversification responses and endemism. This depends on the fact that Aegean Sea is
an archipelago of continental islands placed on the conjunction of Europe, Asia, and Africa
(Gogou et al., 2016). The available “ecological space” with “environmental heterogeneity” in
addition with the “land-bridge system” with the continents determined a high floristic diversity
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and endemism (Kallimanis et al., 2011). Several botanical studies
have been conducted on these islands (Christodoulakis, 1986,
1996; Panitsa et al., 1994, 2006; Panitsa and Tzanoudakis,
1998, 2001; Snogerup et al., 2001; Bazos, 2005). However,
there is limited information regarding the medicinal plants and
traditional plant remedies in this area.
Nowadays the use of plants and traditional medicine plays
an important role for the discovery of new pharmacological
agents. Ethnopharmacology represents a multidimensional
approach, shaped by tradition and science that can improve
our knowledge of plant use and local meaning of health and
disease (World Health Organization [WHO], 2002). The aim
of this study is threefold: to present a complete list of the
medicinal plants used in traditional medicine in the islands
of Northeast Aegean Sea, preserve information about their
use and, lastly, highlight the use in traditional medicine of
endemic and endangered plant species, in order to prevent their
extinction.
MATERIALS AND METHODS
Study Area
The current study was conducted on the islands and islets
of the northeast edge of the Aegean Sea and is dominated
by the islands of Lemnos, Agios Efstratios, Lesvos, Chios,
Psara, Oinousses, Samos, Ikaria, and Fournoi (Figure 1). The
geographical coordinates of the islands are represented in
Supplementary Table 4. The region covers an area of 3835 km2
and has approximately 2500 vascular plant species.
The terrain of the islands is 33% mountainous, 35% hilly,
and 32% flat. The surface area and the maximum elevation
ranged from 40 km2 for Psara and Fourni to 1633 km2
for Lesvos and from 0 to 1433 m of height (Kerketea mt,
Samos), respectively (Higgins and Higgins, 1996). The islands
can be grouped in two phytogeographical zones among the
13 existing in Greece (Supplementary Figure 1); the zone of
the Northern Aegean (NAe) with Lemnos and Agios Efstratios
and the zone of the Eastern Aegean (EAe) with Lesvos, Psara,
Chios, Oinousses, Samos, Ikaria and Fournoi, with specific
climatic differences (Rauh, 1949). The palaeography and the
geological events that separated these islands from Anatolian
mainland, certain environmental parameters (temperature and
humidity) and habitat diversity in well-defined fragmented areas,
are among the causes of the high endemism, floral richness
and diversification in quantity and quality of many secondary
metabolites that characterize the pharmacological properties of
many species of the study area (Panitsa et al., 2010).
Methodology
The information summarized in the present paper was compiled
from 15 randomly selected villages from the islands of the
surveyed area (Figure 1). The methodology followed in the
field surveys is based on Fujita et al. (1995). The data was
collected through semi-structured interviews performed with
local people (Martin, 1995). After explaining the purpose of
our research, a questionnaire in Greek was administered to
the informants including questions about their age, education,
and interest in traditional medicine. A total of 200 people
was surveyed, 100 women and 100 men, with an average age
of 40. The informants with knowledge about medicinal plants
were questioned multiple times, and, during the interviews,
local names of the plants, utilized parts, preparation methods
and traditional cultivation techniques were recorded. The
majority of these skillful informants were medical doctors,
pharmacists, and farmers. All the results are summarized in
Supplementary Table 1. The data acquired for each plant includes
family, botanical name, local name in Greek, locality, voucher
number, parts used and their preparation, therapeutic effect and
ailments treated. The plant families were listed in alphabetical
order.
Field trips were conducted with the interviewees to collect
specimens of the plants (with the exception of the endangered
ones). A photographic archive of the observed species was created
to help the identification. The specimens were collected and
herborized by the department’s herbarium with a specific voucher
number. Furthermore, we examined the therapeutic effect and
preparations of each plant based on the informants’ feedback and
on literature records.
For the analysis of the use of the medicinal plants against
specific diseases, we used informant consensus factor (FIC),
summarized in Supplementary Table 3 (Trotter and Logan,
1986; Heinrich, 2000). Moreover, the Use Value (UV) was
calculated to demonstrate the relative importance of the species
known locally, summarized in Supplementary Table 1. The plant
species scientific names were verified according to the Plant List
and to the International Plant Name Index. Information that
was not possible to confirm was not recorded. Moreover, in
Supplementary Table 1, we reported some of the most important
bibliographic references for plant species and ailments treated
that were not mentioned by the informants (Snogerup and
Snogerup, 1987, 1993; Panitsa et al., 1994, 2006, 2010; Snogerup
et al., 2001; Bergmeier et al., 2003; Bazos, 2005; Bourbonnais-
Spear et al., 2006; Saliaris, 2008; Axiotis and Axiotis, 2012; Strid,
2016).
RESULTS AND DISCUSSION
In the context of the current survey numerous medicinal plants
were ethnopharmacologicaly investigated (in Supplementary
Table 1). The interviews indicated that 109 wild plant species
from 52 different families are being used for medicinal purposes.
Lamiaceae family is represented by the highest number of species
(17), such as the endemic and endangered Sideritis sipylea Boiss.
Asteraceae family is represented by 12 species. Brassicaceae and
Rosaceae by 5 species. The rest of the plant families are shown
in Supplementary Figure 2. Most of the plant parts were used to
treat different diseases and they were mostly stored in glass bottles
as homemade dry powders obtained by crushing down well-dried
plant materials; the most frequently used parts are leaves (22,8%),
roots (12,78%), flowers (11,41%), essential oils (7,30%), fruits
(6,84%), and barks (5%). The most common preparation is the
decoction.
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FIGURE 1 | Geographical location of the study area (Islands in red). Collection sites of the information are as follows. (1) Lemnos, (2) Agios Efstratios, (3) Lesvos,
(4) Chios, (5) Psara, (6) Oinousses, (7) Samos, (8) Ikaria, (9) Fourni (http://www.pvaigaiou.gov.gr).
Interestingly, Hypericum perforatum L. and Verbascum
ikaricum Murb. are kept in olive oil and used as solutions for
wounds and sun burns. Pharmacists from Lesvos, Chios and
Samos, still use these preparations as traditional therapy for
skin wound healing in combination with modern treatments.
Furthermore, clinicians from Lesvos use the powder of the
root of Alkanna tinctoria for skin regeneration after injuries.
They observed a combined antibacterial and antipruritic action,
which reduces the healing time of the wound. It is important to
note that Sideritis sipylea Boiss., Origanum sipyleum L., Thymus
sipyleus Boiss., which are endemic and endangered plants are
mostly used by the local people of Lesvos, Chios, and Ikaria
with many curative purposes, especially for the infections of the
respiratory and gastrointestinal tract as indicated from the UV
values (Supplementary Table 1).
Furthermore, the resin of Pistacia lentiscus L., unique product
globally of the Chios island is widely used against diarrhea, as
expectorant and for ulcer healing. The use of the water extract
of the roots of Anthyllis hermanniae L. as an efficient natural
remedy against kidney stones in Lesvos and Lemnos, is reported
here for the first time. It was also observed that local people,
especially farmers, use the same name for different plant species.
For example, Cistus creticus L. and Cistus salvifolius L. are both
called “Aksìstaros”; Origanum vulgare L. and the endemic and
endangered Origanum sipyleum L. are both called “Rìgani.” This
lack of distinction by the local population exacerbates the risks
for the endangered species.
Very interesting is the distribution of ailments treated
versus plant species used. As it is presented in Figure 2,
locals are choosing herbal remedies mainly for antimicrobial
activity, gastrointestinal disorders, respiratory, inflammatory,
cardiovascular diseases, and skin burns. In Supplementary
Table 3, FIC values of categories of ailments are summarized.
Hormonal diseases have the highest FIC value (0,722), while the
lowest belongs to the cardiovascular diseases (0,161). Moreover,
among the species recorded (Supplementary Table 1), the highest
UV were calculated for Matricaria chamomilla L. (0.75) and
Lavandula stoechas L. (0.64). From the endemic species the
highest UV is recorded for Sideritis sipylea Boiss. (0.31).
Essential oils are also common in the region, mainly derived
from aromatic plants of Lamiaceae family and they are produced
by water or steam distillation. The oils are usually used as drops
directly on the skin or in galenic formulations, for skin infections
or burns. In some cases, they are used for stomach pain (Anthemis
sp.) or even for urinary infections (Sideritis sipylea Boiss.). The
most common plants used for producing essential oils are Salvia
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FIGURE 2 | Distribution of ailments treated versus plant species used.
fruticosa Miller, Salvia officinalis L., Origanum vulgare L., Sideritis
sipylea Boiss., and Lavandula stoechas L. Furthermore, it has been
reported a traditional method for the production of rose oil of the
flower petals of Rosa damascena Mill. in a small village of Lesvos.
The oil is used for external burns or skin inflammations.
The pharmacological properties of medicinal plants presented
in the current study has been also verified by published data, in
several cases. For example, the essential oil of Laurus nobilis L.,
used as anti-inflammatory is reported by Sayyah et al. (2003).
The expectorant effect of Cistus creticus L. and the use of Mentha
spicata L. in cases of common cold have been reported by Fakir
et al. (2009). Tonic effects of Rosmarinus officinalis L. and the
diuretic effects of Raphanus raphanistrum L. have been reported
by Bruni et al. (1997). The essential oil of Sideritis species presents
an important antimicrobial and anti-inflammatory activity and it
has been previously reported by Aligiannis et al. (2001).
Generally, these plants are distributed mainly in Lesvos, Chios,
Samos, and Ikaria and the majority are wild. A serious threat for
some of these plants, is that they are collected in large amounts
for the local markets; some of them, such as Sideritis sipylea
Boiss., Origanum sipyleum L., Thymus sipyleus Boiss., are in fact
listed in the book of the Red List of Threatened Species. Many
species, such as Origanum vulgare L. and Paeonia mascula (L.)
Mill. subsp. mascula are not yet listed but their population is in a
critical condition. Endemic medicinal plants of the research area
are also annotated in Supplementary Table 2.
A very important issue is the increased use of medicinal
plants in these islands which has led to heavy pressure on the
native populations of many species. The local population must
acknowledge their endangerment and should cultivate them,
in order to protect their populations from extinction. Sideritis
sipylea Boiss. is one of the over harvested species. Habitat loss and
deforestation in Lesvos, Chios, and Samos resulted in a general
degradation of the ecosystems that could lead to the extinction of
many species.
In conclusion, from this brief report is clear that medicinal
plants are an important element of indigenous medical system
of Northeast Aegean islands. In spite of the fact that the
local population has access to modern medicines, many people
continue to depend, at least for the treatment of some diseases,
on herbal remedies. These therapies represent for many local
doctors a low-cost alternative. The population of many endemic
species such as Sideritis sipylea Boiss., Origanum sipyleum L., are
in a critical condition due to unsustainable harvesting techniques,
habitat destruction, and absence of cultivation. The endemic
species of the area have medicinal properties dependent on the
metabolites which respond to environmental stimuli that may
be absent under culture conditions. Because of this it is very
important to educate local people about respecting their natural
habitats and strengthen the legislation against the illegal trade of
endemic and endangered plants in the local and national market.
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Lycopene is a lipophilic, unsaturated carotenoid, found in red-colored fruits and
vegetables, including tomatoes, watermelon, papaya, red grapefruits, and guava. The
present work provides an up to date overview of mechanisms linking lycopene in the
human diet and vascular changes, considering epidemiological data, clinical studies,
and experimental data. Lycopene may improve vascular function and contributes to the
primary and secondary prevention of cardiovascular disorders. The main activity profile
of lycopene includes antiatherosclerotic, antioxidant, anti-inflammatory, antihypertensive,
antiplatelet, anti-apoptotic, and protective endothelial effects, the ability to improve the
metabolic profile, and reduce arterial stiffness. In this context, lycopene has been shown
in numerous studies to exert a favorable effect in patients with subclinical atherosclerosis,
metabolic syndrome, hypertension, peripheral vascular disease, stroke and several other
cardiovascular disorders, although the obtained results are sometimes inconsistent,
which warrants further studies focusing on its bioactivity.
Keywords: lycopene, arterial stiffness, endothelial function, intima-media thickness, cardiovascular risk
INTRODUCTION
Cardiovascular disorders (CVD) are the leading mortality cause worldwide and prophylactic
measures to combat it deserve special attention. Atherosclerosis is, in most cases, the main
manifestation of CVD, and its progression may be clinical silent for a long time, up to a certain
moment, when it directly leads into a severe adverse event (e.g., heart attack or stroke). Beneficial
lifestyle changes are important and most cost-effective components of prevention or treatment
of cardiovascular disorders. Compounds occurring in plants often display diverse bioactivities
with therapeutic potential and different plants and plant-derived compounds have a long history
of being reported to exhibit effects counteracting CVD (Atanasov et al., 2015; Waltenberger
et al., 2016). Among lifestyle factors, a healthy diet is considered a cornerstone of cardiovascular
disease prevention, and the inclusion of sufficient fruits and vegetables in the diet is regarded as
especially important (Böhm, 2012; Piepoli et al., 2016). The prevalence of cardiovascular disorders
is remarkably unevenly distributed in developed countries, and some areas, e.g., Southern Europe,
seem to be protected by having significantly less prevalence of the disease. This effect has often
been attributed to dietary factors, as e.g., the Mediterranean diet, with a lot of vegetables, including
tomatoes, tomato products, and olive oil (Müller-Nordhorn et al., 2008; Krasinska et al., 2017).
Tomatoes, tomato sauce, and watermelon are important sources of lycopene andmay be a surrogate
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for the Mediterranean diet to some degree (Sesso et al., 2003;
Burton-Freeman and Sesso, 2014; Naz et al., 2014).
Dietary lycopene is considered to confer cardiovascular
benefits, as e.g., consuming at least 7 servings/week of
lycopene-based products significantly decreased cardiovascular
risk within seven years in postmenopausal women, free from
prior cardiovascular disorders and cancer (Sesso et al., 2003).
A negative correlation between serum lycopene concentration
and cardiovascular mortality was also found in a follow-up study
with a large Japanese cohort (Ito et al., 2006). Many studies
about the relationship between lycopene and cardiovascular
risk have been conducted and, although, some of the results
are inconsistent, overall dietary lycopene intake and high-
serum concentration of lycopene, significantly reduced the
risk of major cardiovascular events (Cheng et al., 2017; Song
et al., 2017). Not all outcomes were positive, as exemplified
in the Physicians Health Study, including 499 patients with
cardiovascular disorders, not revealing any association of higher
plasma lycopene and CVD (Müller et al., 2016). Within the
Kuopio Ischaemic Heart Disease Risk Factor (KIHD), no
relationship was reported between low serum lycopene and an
increased CVDmortality and sudden cardiac death, respectively,
in Finnish, middle-aged men (Karppi et al., 2012; Müller et al.,
2016).
Vascular health depends on endothelial function, arterial
stiffness, and the presence of atherosclerotic plaques. The
following section will discuss the different methods to measure
vascular health. Endothelial dysfunction enables development
of the atherosclerotic plaque. The flow mediated dilatation of
the brachial artery was traditionally used to assess endothelial
function for a long period, but forearm plethysmography
and reactive hyperemia—peripheral arterial tonometry have
become the gold standards for assessing endothelial vascular
function (Kim et al., 2011; Gajendragadkar et al., 2014). While
hyperemia—peripheral arterial tonometry is less operator-
dependent and non-invasive, while being as reliable as the
traditional method, forearm plethysmography additionally
provides mechanistic information related to nitric oxide
synthesis, is a marker for cardiovascular risk, and can improve
risk prediction (Kim et al., 2011; Gajendragadkar et al., 2014).
An increased arterial stiffness is one of the first structural
and functional changes of the vessel wall and is mainly caused
by arteriosclerosis, atherosclerosis and vessel wall calcification
(Cavalcante et al., 2011). Arterial stiffness is associated with
cardiovascular risk and predicts cardiovascular disorders and
mortality (Vlachopoulos et al., 2010; Mozos et al., 2017c). Pulse
wave velocity (PWV) and augmentation indices are simple,
noninvasive, inexpensive and validated methods used to assess
arterial stiffness and as screening methods for the detection of
pre-clinical cardiovascular disorders (Vlachopoulos et al., 2010;
Mozos et al., 2017a).
Carotid intima-media thickness (IMT) assessed non-invasively
by B-mode ultrasonography, is a simple, validated and safe
method used to measure the extent of subclinical atherosclerosis
(Dwyer et al., 2004; Wood and Johnson, 2004; Hosseini et al.,
2017; Kim and Youn, 2017). IMT is defined by the measurement
of the dimension of the intima and media of the arterial wall,
whereas a value >0.9mm is considered abnormal (Cooney
et al., 2015; Piepoli et al., 2016). Although IMT has been
considered as a surrogate measure of cardiovascular risk,
predicting cardiovascular events, especiallymyocardial infarction
and stroke (O’Leary et al., 1999; Touboul, 2015; Piepoli et al.,
2016; Hosseini et al., 2017; Pleskovic et al., 2017), both the
American and the European guidelines on cardiovascular disease
prevention do not recommend the systematic measurement of
IMT to improve risk assessment (Goff et al., 2014; Piepoli et al.,
2016). Major concerns of IMT include lack of standardization, its
high variability and low intra-individual reproducibility (Piepoli
et al., 2016). Additionally, a trained sonographer is required
to limit variability of the results due to the patient or medical
equipment (Touboul, 2015). There are also methods available
that can better predict cardiovascular events than IMT, most
prominently MRI (magnetic resonance imaging) that can be used
to monitor atherosclerotic plaques. Several methods are stronger
predictor of myocardial infarction than IMT, such as monitoring
atherosclerotic plaques and exploring the carotid wall by MRI
(because the adventitia is also included in the measurement of
the wall thickness; Zhang et al., 2014). However, the resources
needed to access wall thickness by MRI are manifold higher
than using ultrasonography, but especially for patients with
abnormal findings in IMT screenings, a subsequent MRI scan
might be useful to provide a more accurate description of the
atherosclerotic plaque and the risk of major cardiovascular events
(Zhang et al., 2014).
Despite the inevitable influence of aging, vascular changes are
at least partially reversible, and dietary changes may improve
vascular function. Lycopene has several advantages, such as
almost no adverse reactions, its wide availability and low
cost (Gao et al., 2016). The present review aims to give a
current overview of the mechanisms linking lycopene in the
human diet and vascular changes, considering epidemiological
data, clinical observational, retrospective, intervention and
randomized studies, dietary and biomarker studies, in vitro and
in vivo research and discussing preventive benefits of lycopene
intake in context of cardiovascular disease prevention.
LYCOPENE
Lycopene is a lipophilic, biologically active, unsaturated, acyclic
carotenoid, with the chemical formula C40H56 (Figure 1). In
plants it is considered as an important intermediate of carotenoid
synthesis, but in human nutrition lycopene plays no role as
provitamin A precursor due to the absence of appropriate
enzymes. Plant lycopene is usually present as all-trans isomer.
Isomerization of the all-trans isomer into the more bioavailable
cis-isomer, occurs under acidic conditions (e.g., gastric acid),
due to exposure to light and thermal energy. Lycopene can
be found in tomatoes, watermelon, papaya, red grapefruits,
apricots, and guava, and gives their red color (Kong et al., 2010;
Gajendragadkar et al., 2014; Mozos et al., 2017c). Lycopene
content increases during different stages of ripening of fruits,
e.g., for tomatoes there is a steady increase in lycopene content
from the breaker to the red stage (Saini et al., 2017). Watermelon
Frontiers in Pharmacology | www.frontiersin.org May 2018 | Volume 9 | Article 521106
Mozos et al. Lycopene and Vascular Health
pulp can also be used for lycopene extraction (Oberoi and
Soqi, 2017) and is a rich source of cis-isomeric lycopene,
abundant in higher concentrations than in tomatoes (Naz et al.,
2014). Interestingly also the fungal plant pathogen Blakeslea
trispora has been recognized as a commercial source to produce
lycopene (Mantzouridou and Tsimidou, 2008). Several foods
high in lycopene content are classified as functional foods (Naz
et al., 2014). Tomato juice, paste, puree, ketchup, sauce or soup
represent lycopene sources with improved bioavailability due to
thermal treatment, but also because processing releases lycopene
from the fibrous cell structure matrix (Basu and Imrhan, 2007;
Thies et al., 2012; Burton-Freeman and Sesso, 2014).
Not only lycopene intake counts, but also its serum
concentration may influence cardiovascular risk. Low serum
and adipose tissue lycopene levels were correlated with early
atherosclerosis, and major acute coronary and cerebrovascular
events, and were found to bemore reliable in risk assessment than
the daily intake of lycopene (Agarwal and Rao, 2000; Rissanen
et al., 2001; Kim et al., 2011). Oxidative stress and inflammation
are responsible for a reduced level of antioxidants (Kim et al.,
2010). Smoking is a potent oxidative stressor, able to impair
arterial elasticity and endothelial function (Kim et al., 2010;
Mozos et al., 2017b), and lycopene was the only major serum
carotenoid able to reduce the atherosclerotic risk in current and
former smokers according to the Rotterdam Study (Klipstein-
Grobusch et al., 2000).
CARDIOVASCULAR PROTECTIVE
MECHANISMS
Lycopene has several cardiovascular beneficial effects, such
as an antioxidative, antiinflammatory, anti-atherogenic,
cardioprotective, and antiplatelet effect, improving endothelial
function (nitric oxide bioavailability and blood flow), the
metabolic profile (by impairing cholesterol synthesis) and blood
pressure control (Figure 2) (Klipstein-Grobusch et al., 2000;
Heber and Lu, 2002; Ahuja et al., 2006; Basu and Imrhan, 2007;
Verghese et al., 2008; Kim et al., 2010; Kong et al., 2010; Riccioni
et al., 2010; Ried and Fakler, 2011; Böhm, 2012; Wolak and
Paran, 2013; Gajendragadkar et al., 2014; Naz et al., 2014; Müller
et al., 2016; Cheng et al., 2017; Milani et al., 2017).
Antioxidative and Protective Endothelial
Effects
Lycopene is considered an effective singlet oxygen quencher
in the carotenoids group (Kong et al., 2010; Viuda-Martos
et al., 2014). It is a much more potent antioxidant than alpha-
tocopherol (10×more potent) or beta-carotene (twice as potent)
(Kim et al., 2010; Kong et al., 2010). Lycopene modulates also
the production of antioxidant enzymes, such as superoxide
dismutase and catalase (Böhm, 2012; Pereira et al., 2017).
Lycopene can also scavenge peroxynitrite, resulting oxidized
lycopene products (Pisoschi and Pop, 2015).
Oxidative stress causes endothelial dysfunction due to
uncoupling of the nitric oxide synthase and oxidative injury of
the endothelial cells (Mozos and Luca, 2017). Both are associated
with inflammation. By reducing oxidative stress and reactive
oxygen species, lycopene increases the bioavailability of nitric
oxide (NO), improves endothelium-dependent vasodilation
and reduces protein, lipids, DNA, and mitochondrial damage
(Hollman et al., 2011; Naz et al., 2014; Nakamura et al., 2017;
Abdel-Daim et al., 2018).
Endothelial NO enables vasodilation, inhibits platelet
functions, and adhesion and transmigration of white blood cells,
and reduces smooth muscle cell proliferation (Opatrilova et al.,
2017). Watermelon supplementation, due to L-citrulline content,
increases plasma L-arginine, enabling NO production (Figueroa
et al., 2017), because NO is synthesized from L-arginine by
NO synthase in virtually all cell types (Jobgen et al., 2006).
Lycopene supplementation improved endothelial mediated
vasodilation in cardiovascular disease patients, but not in
healthy controls (Gajendragadkar et al., 2014), suggesting the
importance of lycopene in secondary cardiovascular prevention
(Costa-Rodrigues et al., 2018).
In summary, lycopene scavenges both reactive oxygen
and nitrogen species, increases the production of antioxidant
enzymes and protects the endothelial cells from oxidative
damage.
Anti-inflammatory Effect
Inflammation is related to atherosclerosis, arterial stiffness, and
major cardiovascular events. The anti-inflammatory role of
lycopene was demonstrated by several studies (Hung et al., 2008;
Kim et al., 2010; Xu et al., 2012; He et al., 2016). Hung et al.
revealed that lycopene can inhibit TNF-alpha induced NF-kappa
B activation, expression of intracellular adhesion molecule-1
(ICAM-1), and interaction between monocytes and endothelial
cells, which might explain the cardiovascular benefits of lycopene
(Hung et al., 2008). In a different study with Korean women,
lycopene levels were found to correlate with cytokines, but no
correlation with acute phase reactants was found, probably due
to lycopene’s inhibitory effect on the formation of oxidized
LDL (Kim et al., 2010). Xu et al. found an inverse association
of lycopene with vascular cell adhesion protein 1 (VCAM-1),
which enable adhesion of monocytes to the endothelial cells,
but could not verify any association between serum lycopene
concentration and atherosclerosis in their study as suggested by
earlier studies (Xu et al., 2012). In the same context, Gianetti et al.
reported no significant correlations between plasma lycopene
and soluble adhesion molecules (Gianetti et al., 2002). Lycopene
obtained from red guava exerts several anti-inflammatory
effects besides modulation of inflammatory mediators, such
as inhibition of leukocyte mobilization, stabilization of mast
cells, and inhibition of genes which expression is involved in
inflammation (Vasconcelos et al., 2017).
Lycopene can also reduce the secretion of metalloproteinases
by macrophages and inhibit T lymphocyte activation (Thies
et al., 2017). Recently, lycopene was found as an effective
antiglycation agent, able to reduce the synthesis of advanced
glycation end-products (AGE), downregulating the expression
of their receptors (RAGE), which further contributes to vessel
protection (Tabrez et al., 2015; Thies et al., 2017).
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FIGURE 1 | Chemical structures of lycopene and other carotenoids.
Tomato products reduced oxidative stress related to
postprandial lipemia and the associated inflammatory reaction
in a study including normal weight participants (Burton-
Freeman et al., 2012). He et al. reported the benefits of lycopene
in preventing transplant vasculopathy, demonstrating that
intimal hyperplasia and smooth muscle cell proliferation were
reduced by the administration of lycopene and the infiltration
of inflammatory cells in allograft vessels was reduced in an
animal model (He et al., 2016). Lycopene can ameliorate allograft
atherosclerosis via downregulating Rho-associated kinases and
regulating the expression of key factors through NO/cGMP
pathways (He et al., 2016). On the other hand, the benefits
of the tomato-rich diet were not directly related to the anti-
inflammatory effect according to a randomized study including
103 apparently healthy volunteers, after 300 g tomatoes daily for
1 month or placebo (Blum et al., 2007).
Watermelon was shown to reduce levels of inflammation
by downregulation of the proinflammatory mediator
cyclooxygenase 2 (COX-2), impairing prostaglandin E2 and I2
production, which reduces the progression of cardiovascular
disorders (Sellers et al., 2010; Hong et al., 2015). Watermelon
powder supplementation exerts an anti-inflammatory effect
similar to COX-2 inhibitors or conventional non-steroidal
anti-inflammatory drugs (Hong et al., 2015).
High mobility group box 1 (HMGB1), a non-histone DNA
binding protein, produced by necrotic and immune cells,
exposed to pro-inflammatory signals, has an important pro-
inflammatory effect by attracting and activating inflammatory
cells and mediators and binding to RAGE and toll-like
receptors, related to fatal outcomes (Lee et al., 2012). Lee
et al. demonstrated that lycopene inhibits adhesion molecules
expression, which impair HMGB1—induced monocyte adhesion
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FIGURE 2 | Cardiovascular benefits of lycopene [supported by in vivo (*) and/or in vitro (8) findings].
and transmigration (Lee et al., 2012). Lycopene has been also
shown to inhibit lipopolysaccharide-induced HMGB1 release
and HMGB1-mediated secretion of TNF-alpha and secretory
phospholipase A2 (Lee et al., 2012).
Oxysterols, the result of cholesterol auto-oxidation,
accumulate in the subendothelial arterial layer, exerting
oxidative and pro-inflammatory roles and favoring the
atherosclerotic process (Palozza et al., 2011). Lycopene impairs
oxysterol-induced pro-inflammatory cytokines production in
human macrophages and oxysterol-induced ROS production,
limiting the formation of atherosclerotic plaque (Palozza et al.,
2011).
Lycopene exerts a cardioprotective effect against atrazine
induced cardiac injury due to its anti-inflammatory effect, by
blocking the NF-kappa B pathway and NO production (Li et al.,
2017).
Considering the mentioned anti-inflammatory mechanisms
(Figure 3), including decrease of adhesion molecules, pro-
inflammatory cytokines, inhibition of leukocyte migration
and genes involved in inflammation, impaired monocyte-
endothelium interaction, T lymphocytes activation and synthesis
of AGE and RAGE and downregulation of cyclooxygenase 2,
lycopene can be useful in the therapy for vascular inflammatory
disorders.
Modulation of Lipids
Lycopene is transported in the circulation by lipoproteins and
is actively taken up into adipocytes (McEneny et al., 2013).
Lycopene is a regulator of cholesterol levels by inhibition of
HMG-CoA reductase (like statins) and down-regulation of
proprotein convertase subtilisin/kexin type 9 mRNA synthesis.
These results suggest that lycopene supplementation could be
especially beneficial for patients with statin intolerance (Sultan
Alvi et al., 2017). Changes in hepatic gene expression, such
as reduced expression in fatty acid synthase, responsible for
fatty acid storage, were described after watermelon powder
consumption in rats (Hong et al., 2015). Carbonic anhydrase III
and adenylate kinase 2 were involved in the lipid-lowering and
antioxidant effects of tomatoes (Hsu et al., 2008). On the other
hand, NO stimulates fatty acid oxidation and lipolysis in adipose
cells (Jobgen et al., 2006; Hong et al., 2015).
Lycopene is not able to increase HDL cholesterol, but was
shown to improve the LDL/HDL ratio, HDL functionality and
reduced the accumulation of cholesterol in the rabbit aorta,
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FIGURE 3 | Anti-inflammatory effects of lycopene. MMPs, matrix
metalloproteinases; COX-2, cyclooxigenase 2; AGE, advanced glycation
end-products; RAGE, receptors of AGE.
underlining the beneficial effects of lycopene during initial
stages of atherosclerosis (Lorenz et al., 2012; Thies et al.,
2017). However, a recent meta-analysis found that significant
reductions in total and LDL cholesterol were revealed only at
doses of, at least, 25mg lycopene/day in human subjects, and the
effects were comparable with low-dose statinmedication, without
concomitant side effects (Ried and Fakler, 2011; Lorenz et al.,
2012). Fecal cholesterol excretion increases with levels of dietary
lycopene due to decreased intestinal cholesterol absorption. This
can be explained by the insight that increased fecal excretion
impairs the enterohepatic circuit of bile acids, thus increasing the
conversion of cholesterol to bile acids (Verghese et al., 2008). The
lipid lowering properties of lycopene involve also an increased
activity of LDL receptors in macrophages (Li et al., 2015; Cheng
et al., 2017).
Lycopene can lower synthesis of dysfunctional HDL,
modulating HDL functionality toward an antiatherogenic
phenotype, with a low serum amyloid A level and beneficial
changes of the activity of HDL remodeling enzymes (cholesterol
ester transfer protein and lecithin cholesterol acyl transferase)
(McEneny et al., 2013). A hypotriglyceridemic effect of tomato
juice was seen only in subjects with initial high serum triglyceride
levels (Li et al., 2015).
Lycopen can also regulate the hepatic lipid metabolism and
counteracts the hepatic steatosis induced by a high-fat diet,
due to sirtuins (SIRT1) induction and activation, being able to
suppresses lipogenesis, to stimulate lipid catabolism in the liver
and skeletal muscles and lipid mobilization in the white adipose
tissue (Lomb et al., 2010; Li et al., 2015). Another mechanism able
to ameliorate liver steatosis, by lycopene, was described in mice
and is related to decrease of fatty acid binding protein 7 due to
binding to microRNA-21 (Ahn et al., 2012; Li et al., 2015).
In summary, lycopene has lipid lowering properties, reducing
the total and LDL cholesterol, triglyceride level, LDL oxidation,
and synthesis of dysfunctional HDL.
Anti-aggregative Effect
Platelets are involved in the pathogenesis of the atherosclerotic
plaque, development of acute thrombotic events and restenosis
after endovascular procedures (Krasinska et al., 2017; O’Kennedy
et al., 2017). Another cardiovascular beneficial effect of lycopene,
protecting against myocardial infarction and stroke, is its
antiplatelet activity, which is concentration dependent, and was
demonstrated in vivo and in vitro (Sawardekar et al., 2016).
Several mechanisms were considered in explaining the reversible
antiplatelet effect of lycopene, such as the interaction with
thromboxane, thrombin, collagen, von Willebrand factor, P-
selectin and inflammatory mediators, the influence on calcium
and cyclic guanosine monophosphate signaling and ADP-
mediated aggregation (Sawardekar et al., 2016; Krasinska
et al., 2017). It was noticed that lycopene can potentiate
the antiplatelet effect of aspirin, which requires low lycopene
diet in patients on secondary prophylaxis with aspirin due to
the potential bleeding risk (Sawardekar et al., 2016). On the
other hand, in high cardiovascular risk, aspirin (ASP) resistant
patients, or those with ASP contraindications, high risk of
complications after antiplatelet therapy or hyperactive platelets
(obese, sedentary, hypertensive, diabetic, aging patients, and
smokers), lycopene could have an important contribution in
cardiovascular prophylaxis (Sawardekar et al., 2016; Krasinska
et al., 2017; O’Kennedy et al., 2017).
Antihypertensive Effect
Lycopene has antihypertensive effects due to inhibition of the
angiotensin converting enzyme (ACE) and due to its antioxidant
effect, reducing oxidative stress induced by angiotensin-II
and indirectly enhancing production of nitric oxide in the
endothelium (Li and Xu, 2013; Belovic et al., 2016; Khan
et al., 2016; Han and Liu, 2017). A study including 8,556 adult
overweight and obese participants demonstrated association of
lycopene and lycopene/uric acid ratio with lower prevalence
of hypertension (Han and Liu, 2017). Paran et al. reported
a decrease in both systolic and diastolic blood pressure in
54 patients with moderate hypertension, treated with ACE
inhibitors or calcium channel blockers, after 6 weeks of tomato
extract supplementation, suggesting a cause-effect relationship
(Paran et al., 2009). Li et al. concluded, in a metanalysis,
that lycopene supplementation (more than 12 mg/day) might
significantly reduce systolic, but not diastolic blood pressure, in
prehypertensive or hypertensive patients (Li and Xu, 2013).
Angiotensin II induces, besides direct vasoconstriction and
oxidative stress, also vascular smooth muscle cells phenotypic
transformation and production of inflammatory cytokines (Ren
et al., 2017), and lycopene might impair the mentioned pathways,
as well.
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Anti-atherosclerotic Mechanisms
Besides improving endothelial function, oxidative stress
(preventing oxidation of LDL) and metabolic profile, the anti-
inflammatory and antiplatelet effect, lycopene has several other
anti-atherosclerotic contributions (Figure 4), such as inhibition
of vascular smooth muscle cell (VSMC) proliferation and foam
cell formation (Napolitano et al., 2007; Wang et al., 2014).
In general, not all studies confirm the relationship between
lycopene and early atherosclerosis (Kim et al., 2010).
Contractile VSMC change to a proliferative and migratory
phenotype during the atherosclerotic process, enablingmigration
of VSMC into the intima and production of the extracellular
matrix of the plaque (Karagiannis et al., 2013). Such changes
in phenotype are called “phenotypic modulation” (Manabe and
Nagai, 2003) and play an important role in vascular remodeling,
not only due to atherosclerosis, but also in hypertension and
diabetic macroangiopathy (Ren et al., 2017). Lycopene can
suppress VSMCs proliferation, due to inhibiting G1 phase cells
entry into the S phase of the cell cycle, related to its antioxidative
effect (Chen et al., 2010), and not due to the inhibition of
matrix metalloproteinases (Lo et al., 2007). Minimally-oxidized
LDL can induce phenotypic modulation of VSMC (Karagiannis
et al., 2013), and synthesis of oxidized LDL may be impaired
by lycopene (Kim et al., 2010). Lycopene may block VSMC
migration and proliferation also by direct binding to platelet-
derived growth factor (PDGF) and inhibiting PDGF-signaling
(Lo et al., 2007), or due to it antioxidant effect, considering that
reactive oxygen species accelerate the switch from the contractile
to the synthetic phenotype (Sung et al., 2005).
Lycopene has also barrier integrity activity in the endothelial
membrane, by blocking the activation of CD14 and Toll
FIGURE 4 | Anti-atherosclerotic effect of lycopene. oxLDL, oxidized LDL;
VSMC, vascular smooth muscle cells.
like receptor-4 expression (Bae and Bae, 2011) and impairs
the apoptosis of endothelial cells in vitro, by disrupting the
upregulation of p53 and caspase 3 mRNA (Tang et al., 2009).
Cardioprotective Effects
Recent studies emphasized the cardioprotective effects
of lycopene. An experimental study including rats with
isoproterenol induced myocardial infarction, demonstrated
improved ECG findings (shorter QT and RR intervals and
QRS complexes, reduced ST segment elevation) if lycopene was
previously administrated, related to its cell membrane stabilizing
and antioxidant properties (Aman et al., 2012). Supplementation
of lycopene in the same study also prevented alteration in
hemodynamic parameters (systolic, diastolic, and mean blood
pressure), biochemical and inflammatory markers, apoptotic
changes, and reduced the size of myocardial infarction due to
the antioxidant and anti-inflammatory properties of lycopene
(Aman et al., 2012; Wong et al., 2017).
Tomato and lycopene supplementation attenuated cardiac-
remodeling and improved diastolic dysfunction after myocardial
infarction according to a study including male Wistar rats,
enabled by impairing type I and type III collagen content in
the left ventricle, reduced cardiomyocyte death, expression of
miRNAs and by the anti-inflammatory effect and reduction of
oxidative stress (Pereira et al., 2017). Wang et al. administered
lycopene in infarcted rats for 28 days, revealing an increased
ejection fraction compared to controls, associated with decreased
collagen fraction in the peri-infarct zone, due to inhibition of p38
mitogen-activated protein kinase and matrix metalloproteinase
9 expression (Wang et al., 2014). Lycopene effect on interstitial
collagen accumulation was not confirmed by Anjos Ferreira et al.,
in a study including male Wistar rats and testing the effect of
lycopene on doxorubicin-induced cardiotoxicity (Anjos Ferreira
et al., 2007). The anti-inflammatory effect of lycopene has also
a contribution in reversing ventricular remodeling, by inhibiting
the nuclear factor-κB signaling pathway (He et al., 2015).
Lycopene might also serve as a cardioprotective agent
against several drugs. The cardioprotective effect of lycopene
was demonstrated in the case of tulathromycin, a macrolide
antibiotic, and diclofenac sodium, a non-steroidal anti-
inflammatory drug, by Abdel-Daim et al., in a study including
Swiss albino mice, and was attributed to its antioxidant activity
(Abdel-Daim et al., 2018). Lycopene can also protect against
the cardiotoxicity induced by doxorubicin (Karimi et al., 2005;
Anjos Ferreira et al., 2007; Abushouk et al., 2017), isoproterenol
(Aman et al., 2012; Mohamadin et al., 2012), and atrazine (Li
et al., 2017).
Concluding, lycopene supplementation is beneficial for early
and late prognosis in myocardial infarction. It may reduce
myocardial infarction size and related electrocardiographic,
hemodynamic, and biochemical changes (Aman et al.,
2012). Lycopene also reverses ventricular extracellular matrix
remodeling after an acute coronary event, by inhibiting
myocardial fibrosis and preventing apoptosis and necrosis of
cardiomyocytes, its anti-inflammatory effect and the ability to
increase left ventricular function, preventing development of
heart failure and increasing survival rates (Aman et al., 2012;
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Wang et al., 2014; He et al., 2015). Considering difficulties
and high cost of early revascularization and significant side
effects of cardiovascular drugs, lycopene could represent a safe
and effective option in controlling post infarction ventricular
remodeling (Wang et al., 2014).
Lycopene and Endoplasmic Reticulum
Stress (ERS)
The endoplasmic reticulum has several functions related to
intracellular calcium storage, lipid and protein synthesis, and
modification (Schönthal, 2012). Disturbance of those functions
causes “endoplasmic reticulum stress” (ERS) involved in
myocardial ischemia/reperfusion injury (Gao et al., 2016). The
cell reacts to ERS by initiating an “unfolded protein response,”
including several mechanisms, enabling cellular adaptation and
survival or, in severe cases, apoptosis (Schönthal, 2012).
Lycopene protects the cardiomyocytes by relieving ERS
and preventing apoptosis, through stimulation of adenosine 5-
monophosphate-activated proteinkinase, the transcription factor
CHOP (C/EBP homologous protein), p-JNK and Caspase
pathways (Xu et al., 2015; Gao et al., 2016). However, high
lycopene levels might be toxic to the cardiomyocytes (Gao et al.,
2016).
PRECLINICAL STUDIES
Lycopene supplementation for 4 weeks strongly reduced total
and LDL serum cholesterol and the amount of cholesterol
in the aorta, but the surface lipid accumulation in the aorta
and IMT were not significantly reduced and no impairment
of vasoreactivity or increase of pro-oxidant parameters were
detected in New Zealand White rabbits after either a standard or
a high-cholesterol diet (Lorenz et al., 2012). Although lycopene
suppressed cholesterol uptake and intestinal absorption and
increased fecal cholesterol excretion in rabbits, it did not decrease
the expression of HMG-CoA reductase (Lorenz et al., 2012).
Hu et al. reported anti-atherosclerotic effects for both
lycopene and fluvastatin, in the aorta, in rabbits, after a high-fat
diet (Hu et al., 2008; He et al., 2009). Verghese et al. also revealed
a significant decrease in the atherosclerotic plaque formation
with the consumption of lycopene in a study including New
Zealand male rabbits, receiving a high cholesterol diet. Further
observed effects include an improved serum lipid profile as well
as reduction in total cholesterol, LDL and triglycerides (Verghese
et al., 2008). Hsu reported, besides reduction in total and LDL
cholesterol and plasma malondialdehyde (MDA) levels, also an
increase in HDL cholesterol in hamsters fed a 9% tomato paste
containing 0.2% cholesterol, after 8 weeks (Hsu et al., 2008).
Watanabe Heritable Hyperlipidemic rabbits were used in a
study by Frederiksen et al. demonstrating that lycopene did
not influence cholesterol and triacylglycerol levels, lipoprotein
fractions, oxidation of lipids, and aortic atherosclerosis evaluated
biochemically and by microscopy (Frederiksen et al., 2007).
The lack of response of lycopene in Watanabe Heritable
Hyperlipidemic rabbits is, probably, related to their defective
LDL receptors (Tanazawa et al., 1980; Lorenz et al., 2012),
which would suggest the involvement of these receptors in
the cardiovascular benefits of lycopene (Perera and Yen, 2007).
Considering the bloodstream transport of lycopene in LDL
particles, functional LDL receptors enable cardiovascular benefits
of lycopene (Lorenz et al., 2012). Bansal et al. reported
a beneficial cardioprotective effect of lycopene, due to the
reduction of oxidative stress and myocardial injury, in an
experimental model of myocardial ischemia-reperfusion injury
in adult male albino Wistar rats (Bansal et al., 2006). Lycopene
protects also endothelial progenitor cells, necessary to replace
the injured vascular endothelium and for angiogenesis, in a
microenvironment of advanced glycation end products (AGEs),
which act as damage-causing agents (Zeng et al., 2017). Lycopene
improved cell proliferation and regulated protective mechanisms
of AGEs-induced autophagy in endothelial progenitor cells
from diabetic rats, suggesting that supplementation with this
compound might be a new therapeutic option for diabetic
vascular complications (Zeng et al., 2017).
CLINICAL RESEARCH
Endothelial Function
Both cross-sectional and supplementation studies emphasized
the benefits of tomato products on vascular function, mainly
due to the antioxidative effects of lycopene (Kim et al., 2010;
Thies et al., 2012; Xaplanteris et al., 2012; Gajendragadkar et al.,
2014). However, several articles failed to show improvement of
endothelial function after tomato consumption (Stangl et al.,
2011; Table 1).
Gajendragadkar et al. concluded that lycopene
supplementation can improve endothelial function in patients
with cardiovascular disorders, but not in age-matched healthy
volunteers (Gajendragadkar et al., 2014). Forearm responses
to intraarterial infusions of acetylcholine were assessed using
venous plethysmography, which resulted in an improvement by
53% of endothelium-dependent vasodilatation (EDV) in patients
with cardiovascular disorders post-lycopene (Gajendragadkar
et al., 2014). Endothelial function was improved regardless of
traditional risk factors or inflammatory markers, and, even a
modest increase in serum lycopene, further impaired endothelial
function in atherosclerotic patients (Gajendragadkar et al., 2014).
One conclusion of the mentioned study was that lycopene affects
especially smaller vessels, such as resistance arteries, rather than
larger vessels, as measured arterial stiffness remained unaltered
in all study participants (Gajendragadkar et al., 2014).
Pulse Wave Velocity (PWV)
Kim et al. reported an independent, inverse association between
circulating lycopene and brachial pulse wave velocity in 264
healthy women, regardless of age, body mass index, smoking
and drinking habits, menopause, blood pressure, beta-carotene,
alpha-tocopherol, markers of oxidative stress, and inflammation
(Kim et al., 2010; Table 1). Reduced oxidative LDL changes may
have an important contribution to arterial stiffness reduction
due to lycopene (Kim et al., 2010). Another study, including
126 healthy men revealed the benefits of lycopene on oxidative
stress and endothelial dysfunction, especially in subjects with an
Frontiers in Pharmacology | www.frontiersin.org May 2018 | Volume 9 | Article 521112
Mozos et al. Lycopene and Vascular Health
TABLE 1 | Effects of lycopene on endothelial function and arterial stiffness.
Number of participants Methodology Results, conclusions References
36 statin treated cardiovascular
patients (mean age: 67–68
years) and 36 healthy volunteers
(mean age: 61–68 years)
Double-blind trial: 7mg lycopene or placebo
daily for 2 months.
Lycopene supplementation improved
endothelial function in patients with
cardiovascular disorders on optimal
secondary prevention, but not in healthy
persons.
Gajendragadkar et al.,
2014
225 overweight volunteers, aged
40–65 years
Participants were randomly assigned into 1 of 3
dietary intervention groups: control diet (low
tomato content), a high-tomato-content diet, or
a control diet with addition of lycopene
capsules (10 mg/d) for 12 wk. Collected blood
samples were tested for carotenoid and lipid
profiles and inflammatory markers. Arterial
stiffness and dietary intake were also
monitored.
A relatively high daily consumption of
tomato-based products (32–50mg
lycopene/day) or lycopene supplements
(10 mg/day) was ineffective in reducing
conventional cardiovascular risk markers,
inflammatory markers, markers of insulin
resistance and sensitivity, lipid profile and
arterial stiffness in moderately overweight,
healthy, middle-aged individuals.
Thies et al., 2012
25 study participants, mean age:
27 ± 8 years
Randomized, intervention model, crossover
assignment. The participants consumed
high-fat meals containing processed tomato
products or non-tomato alternative.
Tomato products attenuate postprandial
lipemia-induced oxidative stress and
inflammatory response, with a modest
improved flow-mediated dilatation (FMD).
Burton-Freeman et al.,
2012
19 volunteers, 39 ± 13 years Randomized, single-blind, crossover
assignment.
Daily tomato paste consumption exerts a
beneficial midterm effect on endothelial
function.
Xaplanteris et al., 2012
299 Korean men Subgrouped according to the number of
metabolic syndrome risk factors; brachial-ankle
pulse wave velocity (PWV), oxidative stress and
antioxidants (including lycopene) were
measured.
An inverse correlation was found between
PWV and serum lycopene, considering
blood pressure, insulin resistance and
oxidative stress.
Yeo et al., 2011
19 healthy non-smoking
postmenopausal women
Administration of 70 g tomato puree.
Endothelial-dependent FMD and
endothelial-independent nitro-mediated dilation
of the brachial artery were measured with
high-resolution ultrasound.
Acute and long-term (7 d) intake of tomato
products, despite a significant increase in
plasma lycopene had no effect on
endothelial function.
Stangl et al., 2011
126 healthy men Administration of placebo/6 mg/15mg
lycopene daily for 8 weeks. Endothelial function
was assessed by reactive hyperemia peripheral
arterial tonometry. Plasma superoxide
dismutase was used to assess oxidative stress.
An inverse correlation between serum
lycopene levels and arterial stiffness was
found. An increased serum lycopene
decreases oxidative stress, which might
influence endothelial function.
Kim et al., 2011
264 healthy women, 31–75 years The relationship between serum lycopene and
brachial-ankle pulse wave velocity was
assessed.
An independent, inverse relationship
between circulating lycopene and brachial
PWV was observed.
Kim et al., 2010
impaired endothelial function (Kim et al., 2011). After 15 mg/day
lycopene supplementation, for 8 weeks, Kim et al. reported a
decrease of systolic blood pressure and high sensitivity C reactive
protein (Kim et al., 2011).
The main biological mechanism by which lycopene reduces
the risk and mortality of the metabolic syndrome, include
the antioxidant, anti-inflammatory and antiobesity effects, the
ability to improve endothelial function, glycemic control, insulin
sensitivity and lipid profile (Tsitsimpikou et al., 2014; Li
et al., 2015; Han et al., 2016a,b). An inverse relationship was
found by Yeo et al. between lycopene level and brachial-ankle
pulse wave velocity (Yeo et al., 2011). PWV was significantly
higher in patients with metabolic syndrome, with lower than
median serum lycopene values (≤0.0294 mmol/l) compared to
patients without metabolic syndrome; no statistically significant
differences between the 2 groups were found when lycopene
levels were high (Fantin et al., 2010; Yeo et al., 2011).
Higher serum carotenoid levels were associated not just with
a lower prevalence of the metabolic syndrome, but also with
fewer abnormal metabolic syndrome components. A significant
association between lycopene and the metabolic syndrome was
described only for normal-weight and overweight participants,
but not in obese patients, according to a study enrolling 13,196
subjects, probably related to an increased oxidative stress and
decreased antioxidant ability, due to sequestration of lycopene
in the adipose tissue and more important inflammation in obese
(Han et al., 2016b). On the other hand, daily tomato juice
intake reduced waist circumference, cholesterol, and monocyte
chemotactic protein-1 (inflammatory adipokine) and increased
adiponectin (anti-inflammatory adipokine) levels in 30 young,
healthy Taiwanese females (Li et al., 2015). Lycopene was shown
to impair pro-inflammatory cytokine production, such as IL-
6, IL-1b, and TNF-α, preventing insulin resistance (Gouranton
et al., 2011).
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L-arginine or L-citrulline supplementation modulate the
arginine-NO pathway, enabled by multiple cyclic guanosine-
3′,5′-monophosphate-dependent pathways, with important
prophylactic and therapeutic contributions in the metabolic
syndrome (Jobgen et al., 2006).
A large study, including 225 middle-aged, overweight
volunteers reported no changes of conventional cardiovascular
risk factors, inflammatory tests, insulin resistance and sensitivity,
lipid profile, oxidized LDL, von Willebrand factor, and arterial
stiffness after high daily intake of lycopene, despite good
compliance (Thies et al., 2012). One week of lycopene
supplementation increased plasma lycopene, but not biomarkers
of vascular oxidative stress and inflammation, or biomarkers of
nitric oxide (plasma nitrate/nitrite) in healthy, active subjects,
suggesting that the participants already possessed a robust
antioxidant capacity and lycopene provided no additional benefit
(Denniss et al., 2008).
Intima-Media Thickness (IMT)
Several studies reported an association between serum lycopene
levels and intima-media thickness (Gianetti et al., 2002; Riccioni
et al., 2009, 2011; Karppi et al., 2013; Zou et al., 2014), while
other authors reported no association (Dwyer et al., 2004;
Table 2). Zou et al. revealed a decrease in carotid artery intima-
media thickness (IMT) after 12 months of lutein and lycopene
supplementation (20mg each) in 144 Chinese patients with
subclinical atherosclerosis, demonstrating more effective results
after the intake of both lutein and lycopene compared to lutein
alone (Zou et al., 2014).
High serum levels of lycopene, alpha and beta-carotene were
associated with a slow IMT progression during 7 years in a study
including 840 middle-aged men from Eastern Finland (Karppi
et al., 2013). The association between lycopene level and IMT
was mentioned in the scientific literature also for elderly Finish
subjects (Karppi et al., 2011).
Higher carotenoids levels (lutein, zeaxanthin, and beta-
cryptoxanthin; Figure 1) were correlated with reduced IMT
progression over 18 months, in a study with 573 middle-aged
participants, free of cardiovascular symptoms at baseline. Beta-
carotene and lycopene levels were not significantly associated
with IMT progression (Dwyer et al., 2004).
An inverse correlation was found in women between lycopene
levels and IMT, independent of conventional risk factors, in a
large study including 1,111 subjects (McQuillan et al., 2001).
WHY CONFLICTING RESULTS?
Several studies revealed the anti-atherosclerotic effect of lycopene
(McQuillan et al., 2001; Gianetti et al., 2002; Hu et al., 2008;
Verghese et al., 2008; Riccioni et al., 2009; Kim et al., 2010;
Gajendragadkar et al., 2014), but there are also studies available
that report conflicting results related to the vascular effects of
lycopene (McQuillan et al., 2001; Dwyer et al., 2004; Stangl
et al., 2011; Thies et al., 2012). The possible reasons for this
obvious discrepancy are manifold and include methodological
differences in the study designs, such as different lycopene
sources, the use of food-frequency questionnaires, different
intervention times, the methodology used to assess vascular
function, measurement of blood, adipose or dietary lycopene.
Besides those, the use of unstandardized amounts of tomato
food products, different modes of delivery, misclassification
of overall tomato intake, combination of lycopene with other
antioxidants, different processing procedures or eating behavior
influenced by cultural and temporal patterns among different
individuals, may influence the results (Sesso et al., 2003; Kong
et al., 2010; Thies et al., 2012; Gajendragadkar et al., 2014).
Other carotenoids extracted from tomatoes could be also partially
responsible for the effects attributed to lycopene (Rao, 2002).
This is underlined by a study that could not find beneficial
effects for lycopene supplementation alone, but beneficial effects
upon supplementation with tomato-based products (Sesso et al.,
2003). Some studies did not consider dietary intake at all (Yeo
et al., 2011). The interaction flavanone metabolites—lycopene
is difficult to assess, considering the rapid metabolization of
the mentioned metabolites (Habauzit et al., 2015). Duration of
treatment, dose and bioavailability of lycopene, and vascular
endpoint were also different in the studies published on this
topic and might have influenced obtained results. Several factors
influence the bioavailability of lycopene, such as season, the
processing of tomatoes, their origin, dimensions, shape, and the
way they are consumed (Gajendragadkar et al., 2014; Gammone
et al., 2015). Absorption of lycopene may be reduced by diets rich
in fibers and in elderly people (Kong et al., 2010) and is increased
in the presence of oil.
The isomerization of lycopene is another source of variability.
Fresh tomatoes contain lycopene in all-trans form (Shi and
Le Maguer, 2000). Several factors, including high temperatures,
light, oxygen, acids, and metal ions enable isomerization of
lycopene (Kong et al., 2010). Lycopene degradation occurs during
thermal processing, mainly isomerization of all- trans to cis
forms and oxidation (Shi and Le Maguer, 2000). Dehydrated and
powdered tomatoes have poor lycopene stability, depending of
storage in a hermetically sealed atmosphere, and a significant
increase of cis-isomers, giving the highest bioavailability of
lycopene and higher ability to be incorporated in lipoproteins
(Shi and Le Maguer, 2000; Kong et al., 2010). Uptake of cis
lycopene is significantly higher than all trans-isomers (Kong
et al., 2010).
Lycopene is very bioavailable in the presence of oil, especially
in monounsaturated oils, other dietary fats and processed tomato
products (Shi and Le Maguer, 2000; Basu and Imrhan, 2007;
Kong et al., 2010; Gajendragadkar et al., 2014). Lycopene can
increase the antioxidant properties of vitamin C, E, polyphenols
and beta-carotene in a synergistic way (Kong et al., 2010;
Karppi et al., 2013). Supplementation with tomatoes, containing
lycopene (red tomatoes) or not (yellow tomatoes), showed a
better antioxidant effect than lycopene alone, probably due
to the synergistic effects of naturally occurring secondary
metabolites in tomatoes (Basu and Imrhan, 2007; Gitenay et al.,
2007). Generally, supplementation with whole fruits is often
more beneficial than supplementing single food constituents:
Watermelons contain, besides lycopene, hundreds of different
compounds, including L-citrulline and ascorbic acid, both of
which improve the L-arginine/NOpathway, endothelial function,
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TABLE 2 | Lycopene and intima-media thickness (IMT).
Number of participants Methodology Results, conclusions References
144 subjects, aged 45–68 years,
with subclinical atherosclerosis
20mg lutein (n = 48), 20mg lutein + 20mg
lycopene (n = 48) or placebo (n = 48) were
administrated for 12 months; carotid artery
intima-media thickness (IMT) was measured
using Doppler ultrasonography.
Lutein and lycopene supplementation
significantly increased the serum
concentration of lutein and lycopene with
a decrease in carotid artery IMT.
Zou et al., 2014
840 middle-aged men from
Eastern Finland
Ultrasonography of the common carotid
arteries, serum levels of carotenoids
7-year change in maximum intima media
thickness was inversely associated with
serum levels of lycopene, alpha and
beta-carotene, respectively. Elevated
serum levels of carotenoids may have
anti-atherosclerotic effect.
Karppi et al., 2013
1,212 elderly men from Eastern
Finland
B-mode ultrasound (IMT of the common
carotid artery); plasma levels of carotenoids
High plasma concentrations of lycopene,
alpha-carotene and beta-cryptoxanthin
are related to decreased carotid
atherosclerosis in elderly patients.
Karppi et al., 2011
120 subjects without history of
symptomatic carotid artery
disease
Ultrasonic measurement of common carotid
artery IMT, serum profile analysis of cholesterol
(total and LDL), triglycerides and lycopene.
Carotid atherosclerosis was associated
with lower plasma lycopene levels.
Riccioni et al., 2011
640 participants with
asymptomatic carotid
atherosclerosis
Carotid ultrasound investigation was
performed; medical history and laboratory data
were collected.
Participants with IMT ≥ 0.8mm had
significantly lower concentrations of
vitamin A and E, lycopene, and
beta-carotene compared to participants
with no evidence of carotid
atherosclerosis.
Riccioni et al., 2011
573 middle-aged women and
men from an occupational cohort
Ultrasound examination of the common carotid
arteries was performed, lipid profile and risk
factors were assessed at baseline and
18-month follow-up. Plasma antioxidants were
determined at baseline.
18-month change in IMT was inversely
related to serum levels of some measured
carotenoids, not including lycopene,
regardless of cardiac risk factors and
high-sensitivity C-reactive protein.
Dwyer et al., 2004
11 healthy controls, 11 patients
with uncomplicated
hypertension, 11 with essential
hypertension and peripheral
vascular disease
Patients were matched for age, sex, smoking
habit and body mass index; IMT, adhesion
molecules, LDL and antioxidants (including
lycopene) were measured.
A statistically significant correlation was
found between lycopene and IMT,
independent of LDL, creatinine clearance,
and plasma insulin. No significant
correlation was found between lycopene
and soluble adhesion molecules
Gianetti et al., 2002
1,111 subjects, aged 27–77
years
Dietary vitamin intake, fasting plasma levels of
vitamins (A, C, and E), lycopene, alpha and
beta-carotene, bilateral
There was an inverse association between
carotid artery IMT and plasma lycopene in
women, but not in men.
McQuillan et al., 2001
aortic systolic blood pressure, reduce arterial stiffness, and
improve glycemic control, thus acting synergistic with lycopene
(Wu et al., 2007; Figueroa et al., 2013, 2017). Grapefruits
also include in their composition not just lycopene but also
flavonoids, with several benefits, such as the anti-inflammatory
and anti-atherogenic effect, improving vascular reactivity,
reducing insulin resistance, decreasing arterial stiffness, LDL
cholesterol, and blood pressure (Habauzit et al., 2015). These
synergistic effects hamper assessment of quantitative and
qualitative effects of lycopene as a dietary factor.
Several studies included healthy participants or subjects
with different disorders and cardiovascular risk factors (Kong
et al., 2010; Thies et al., 2012; Gajendragadkar et al., 2014).
Enrolling volunteers with established elevated risk markers
for cardiovascular disorders may increase the probability of
detecting changes, especially in short time studies (Thies et al.,
2012). Also, several other uncontrolled or unidentified lifestyle
factors or dietary constituents associated with cardiovascular
disorders, may provide alternative explanations for the different
study results (Sesso et al., 2003). Genetic factors remain
unconsidered at all in all of the reviewed publications, although
they are reported to strongly influence circulating concentrations
of lycopene in different ethnicities (Zubair et al., 2015).
Furthermore, plasma, adipose, and dietary carotenoids are not
sufficiently correlated to be interchangeably (Sesso et al., 2003).
FUTURE RESEARCH DIRECTIONS
Most of the studies considered only tomatoes and tomato
products as lycopene source. It will be the aim of future
human intervention studies to include other lycopene containing
fruits such as watermelon, papaya, red grapefruits, and guava,
and consider synergistic effects with other components and
their importance in primary and secondary cardiovascular
prophylaxis.
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Benefits of lycopene should be especially considered in
patients with high cardiovascular risk, statin intolerance,
borderline hypertension, aspirin resistance, hyperactive platelets,
vascular inflammatory diseases, metabolic syndrome and
coronary heart disease, and its inclusion in combination
therapies for the mentioned disorders, should be approached.
Further mechanistic research is needed to identify new targets
for prevention and complementary treatment of cardiovascular
disorders.
CONCLUSIONS
The present review supports the importance of lycopene in
improving vascular function and in the primary and secondary
prevention of cardiovascular disorders. The demonstrated effects
of lycopene in view of cardiovascular health comprise its general
antioxidant and anti-inflammatory abilities, the antiplatelet, anti-
apoptotic and antihypertensive properties, the ability to improve
endothelial function, the metabolic profile and ventricular
remodeling, reduction of arterial stiffness as well as reduction
of size of atherosclerotic plaque. Lycopene exerts favorable
effects in patients with subclinical atherosclerosis, metabolic
syndrome, hypertension, peripheral vascular disease, and several
other cardiovascular disorders, but sometimes conflicting results
were obtained. Clearly, more and better-designed studies will be
necessary to improve our understanding of the positive effects
of lycopene on vascular health and to elucidate the involved
mechanisms on a molecular level.
Future cardiovascular disease prevention strategies might
include lycopene-enriched products, lycopene supplementation
and new combinations including lycopene. Future studies
focused on dietary lycopene and its synergistic effects with
other dietary components in different study populations, with
elevated cardiovascular risk, are highly warranted and might
enable development of functional foods useful in prevention and
complementary treatment of cardiovascular disorders.
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Introduction: Despite recent advances in critical care, sepsis remains a crucial cause
of morbidity and mortality in intensive care units. Therefore, the identification of new
therapeutic strategies is of great importance. Since ancient times, frankincense is
used in traditional medicine for the treatment of chronic inflammatory disorders such
as rheumatoid arthritis. Thus, the present study intends to evaluate if Casperome R©
(Casp), an orally bioavailable soy lecithin-based formulation of standardized frankincense
extract, is able to ameliorate systemic effects and organ damages induced by severe
systemic inflammation using a murine model of sepsis, i.e., intraperitoneal administration
of lipopolysaccharides (LPS).
Methods: Male 60-day-old mice were assigned to six treatment groups: (1) control,
(2) LPS, (3) soy lecithin (blank lecithin without frankincense extract), (4) Casp, (5) soy
lecithin plus LPS, or (6) Casp plus LPS. Soy lecithin and Casp were given 3 h prior
to LPS treatment; 24 h after LPS administration, animals were sacrificed and health
status and serum cytokine levels were evaluated. Additionally, parameters representing
liver damage or liver function and indicating oxidative stress in different organs were
determined. Furthermore, markers for apoptosis and immune cell redistribution were
assessed by immunohistochemistry in liver and spleen.
Results: LPS treatment caused a decrease in body temperature, blood glucose levels,
liver glycogen content, and biotransformation capacity along with an increase in serum
cytokine levels and oxidative stress in various organs. Additionally, apoptotic processes
were increased in spleen besides a pronounced immune cell infiltration in both liver
and spleen. Pretreatment with Casp significantly improved health status, blood glucose
values, and body temperature of the animals, while serum levels of pro-inflammatory
cytokines and oxidative stress in all organs tested were significantly diminished. Finally,
apoptotic processes in spleen, liver glycogen loss, and immune cell infiltration in liver
and spleen were distinctly reduced. Casp also appears to induce various cytochrome
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P450 isoforms, thus causing re-establishment of liver biotransformation capacity in LPS-
treated mice.
Conclusion: Casp displayed anti-inflammatory, anti-oxidative, and hepatoprotective
effects. Thus, orally bioavailable frankincense extracts may serve as a new supportive
treatment option in acute systemic inflammation and accompanied liver dysfunction.
Keywords: frankincense, lipopolysaccharides, systemic inflammation, cytokines, oxidative stress, liver function
INTRODUCTION
Despite recent advances in critical care, sepsis, septic shock, and
subsequent multi-organ failure remain an important cause of
morbidity and mortality in intensive care units (Engel et al.,
2007; Martin, 2012; Gaieski et al., 2013). About 20–25% of
patients with sepsis and associated organ failure display early
impaired liver function, which in severe cases can result in acute
liver failure (Kramer et al., 2007; Koch et al., 2011; Nesseler
et al., 2012; Horvatits et al., 2013; Yan et al., 2014). Such liver
dysfunction seems to be mediated to a considerable extent by
pro-inflammatory cytokines such as TNF-α, IL-6, and IL-8 that
are liberated by resident macrophages of the liver, the so-called
Kupffer cells (Nesseler et al., 2012; Yan et al., 2014). Moreover,
it has been shown that the severity of liver damage (even more
than the impairment of lung or kidney function) is of major
consequence for overall patient outcome (Kramer et al., 2007;
Koch et al., 2011; Nesseler et al., 2012; Horvatits et al., 2013; Yan
et al., 2014). However, although extensive research efforts have
been made, no specific therapy exists so far for the treatment of
sepsis and of sepsis-associated liver dysfunction (Nesseler et al.,
2012; Horvatits et al., 2013). Therefore, the identification of new
therapeutic strategies is of great clinical importance (Yan et al.,
2014).
Extracts of frankincense gum resins from different Boswellia
species have been used for centuries in traditional medicine,
e.g., in Indian Ayurveda medicine, in China, and in several
African countries, to treat infectious diseases and chronic
inflammatory disorders. But also in Europe, frankincense
extracts are commonly and increasingly used, and several
clinical trials have been conducted to demonstrate their
therapeutic benefit (Abdel-Tawab et al., 2011). Recent data
from both animal experiments and clinical trials revealed
that gum resin extracts from Boswellia species not only exert
beneficial effects in various inflammatory conditions such as, e.g.,
rheumatoid arthritis, osteoarthritis, ulcerative colitis, Crohn’s
disease, multiple sclerosis, or bronchial asthma, but also in
hyperlipidemia, obesity, and cancer (see e.g., Poeckel and Werz,
2006; Moussaieff and Mechoulam, 2009; Abdel-Tawab et al.,
Abbreviations: ALAT, alanine aminotransferase; BROD, benzyloxyresorufin-
O-debenzylation; b.wt., body weight; Casp, Casperome R©; CD, cluster
of differentiation; COX, cyclooxygenase; CSS, clinical severity score;
CYP, cytochrome P450; ECOD, ethoxycoumarin-O-deethylation; EMND,
ethylmorphine-N-demethylation; EROD, ethoxyresorufin-O-deethylation; GSH,
reduced glutathione; GSSG, oxidized glutathione; IL, interleukin; iNOS, inducible
nitric oxide synthase; LPO, lipid peroxides; LPS, lipopolysaccharides; MROD,
methoxyresorufin-O-demethylation; NO, nitric oxide; Phyto, soy lecithin;
PROD, pentoxyresorufin-O-depentylation; TBARS, thiobarbituric acid reactive
substances; TNF, tumor necrosis factor.
2011; Du et al., 2015; Stürner et al., 2017). Additionally, in
2002 the European Medicines Agency classified Boswellia serrata
extract as an “orphan drug” for the treatment of peritumoral
brain edema. The main active principles of these extracts are
pentacyclic triterpenes, termed boswellic acids, which are unique
to Boswellia species (Ammon, 2006). Among others, there are
four important β-configurated boswellic acid derivatives: 3-O-
acetyl-11-keto-β-boswellic acid (AKBA), 3-O-acetyl-β-boswellic
acid (AβBA), 11-keto-β-boswellic acid (KBA), and β-boswellic
acid (β-BA).
The exact molecular basis for the pharmacological actions
of boswellic acids in chronic inflammatory conditions still
remains to be resolved. As possible target structures microsomal
prostaglandin E2 synthase-1, 5-lipoxygenase, human leukocyte
elastase, cathepsin G, topoisomerase I and II, as well as members
of the IκB kinase/NFκB and MAPK signaling pathways have been
identified (Syrovets et al., 2005; Poeckel and Werz, 2006; Takada
et al., 2006; Cuaz-Pérolin et al., 2008; Moussaieff and Mechoulam,
2009; Siemoneit et al., 2009, 2011; Ammon, 2010; Abdel-Tawab
et al., 2011). Additionally, using precipitation experiments with
immobilized boswellic acids, LPS has recently been identified as a
possible direct molecular interaction partner of distinct boswellic
acids and their synthetic derivatives (Henkel et al., 2012). The
authors were also able to show that distinct boswellic acids are
able to inhibit LPS-mediated effects in a series of cell-based
assays via direct binding to LPS. The experiments revealed clear-
cut structure–activity relationships and β-BA was found to be
the most potent derivative. These findings are further supported
by the fact that boswellic acids as well as frankincense resin
extracts reduce LPS-induced NO and proinflammatory cytokine
production in macrophages both in vitro and in vivo (Syrovets
et al., 2000; Pandey et al., 2005; Gayathri et al., 2007; Sharma
et al., 2016), thereby exerting hepato- and renoprotective effects
(Pandey et al., 2005).
To the best of our knowledge, neither individual boswellic
acids nor frankincense extracts have been evaluated for their
effects in acute systemic inflammatory conditions before.
Therefore, the aim of the present study was to investigate
for the first time the impact of Casp, an orally bioavailable
soy lecithin-based delivery form of standardized frankincense
extract, in a murine model of acute systemic inflammation,
i.e., the intraperitoneal administration of LPS. The LPS model
was chosen based on the assumption of a direct interaction
between boswellic acids, especially β-BA and LPS (Henkel
et al., 2012). Additionally, in comparison to other sepsis animal
models such as peritoneal contamination and infection with
(human) stool bacteria (PCI) or cecal ligation and puncture
(CLP), the LPS model has several essential advantages such
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as technical ease and high reproducibility (Seemann et al.,
2017; Stortz et al., 2017). Furthermore, the LPS model has
been proven to be most suitable for studying effects of new
therapies on acute systemic inflammation (Seemann et al.,
2017). Casp is composed of Boswellia serrata extract and soy
lecithin in a 1:1 ratio, with about half part of microcrystalline
cellulose added to improve physical stability. The formulation
is standardized to contain ≥25% of triterpenoic acids by
HPLC. Compared with poorly bioavailable non-formulated
frankincense extracts, Casp provides a quicker absorption as
well as considerably higher plasma and tissue levels of the
most important boswellic acids, including β-BA (Hüsch et al.,
2013; Riva et al., 2016). Since in rats maximum plasma levels
were reached after 180 min (Hüsch et al., 2013), in the
present study Casp was administered to the mice 3 h before
LPS challenge; 24 h after LPS administration, animals of the
different treatment groups (soy lecithin alone; Casp alone; soy
lecithin plus LPS; Casp plus LPS) were evaluated in comparison
to control mice and to LPS-only-treated animals with regard
to general condition, body temperature, blood glucose values,
and serum cytokine concentrations. Additionally, parameters of
oxidative stress were determined in different organs and immune
cell distribution in two organs decisively involved in sepsis
pathogenesis, the liver and spleen. Since liver function is of
importance for overall patient outcome, liver glycogen content
and biotransformation capacity, representing two important
liver function parameters, were also assessed. Finally, to further
substantiate the animal studies, cell-based experiments using
human peripheral blood mononuclear cells (PBMCs) were
performed to confirm the suppressive effect of Casp on cytokine
release in vitro.
MATERIALS AND METHODS
Animals and Experimental Procedure
The study was conducted under the license of the Thuringian
Animal Protection Committee (approval number: 02-011/12).
The principles of laboratory animal care and the German Law on
the Protection of Animals as well as the Directive 2010/63/EU
were followed. Male adult C57BL/6N mice (60-days-old, b.wt.
25–30 g; Charles River Laboratories, Sulzfeld, Germany) were
used and the animals were housed in plastic cages under
standardized conditions (light–dark cycle 12/12 h, temperature
22 ± 2◦C, humidity 50 ± 10%, pellet diet Altromin 1316, water
ad libitum).
A total of 48 mice were randomly divided into six groups
(n = 8 each): control (vehicle-treated animals; 0.9% NaCl, used
for dissolution of LPS), LPS, soy lecithin, Casp, soy lecithin
plus LPS, and Casp plus LPS. LPS (Escherichia coli 0111:B4,
Sigma-Aldrich, Steinheim, Germany) was dissolved in 0.9%
NaCl and injected intraperitoneally at a dosage of 5 mg/kg
b.wt. With this dosage, a medium-grade non-lethal systemic
inflammation was intended to allow for detection of possible
beneficial effects of co-administered drugs (Seemann and Lupp,
2015, 2016; Seemann et al., 2017). Thus, no antibiotic treatment
or fluid resuscitation of the animals was necessary. Soy lecithin
and Casp (kindly donated by Indena S.p.A., Milano, Italy)
were given orally at a dosage of 80 mg/kg b.wt. (equivalent to
the proportion of soy lecithin in Casp) or 240 mg/kg b.wt.,
respectively, 3 h before LPS challenge to ensure maximum
plasma levels of boswellic acids at the time of LPS challenge
(Hüsch et al., 2013). Based on previous findings (Seemann
et al., 2017), animals were sacrificed 24 h after LPS challenge
when plasma levels of pro-inflammatory cytokines are still
elevated and changes in immune cell distribution and liver
function are already detectable. Twenty-four hours after LPS
treatment, body temperature was measured and the mice’s health
status was assessed by using the CSS described previously
(Gonnert et al., 2011). Afterward, mice were sacrificed with
an overdose of isoflurane, decapitated, and bled completely.
Whole blood was collected in a tube (S Monovette R© 1.2 ml
Z Clotting Activator/Serum, Sarstedt, Nümbrecht, Germany)
for clotting. Blood glucose levels were determined using a
droplet of the whole blood with a commercially available blood
glucose meter and respective test strips (BG Star R©, Sanofi-
Aventis, Frankfurt, Germany). After 30 min, clotted blood was
centrifuged at 2000 × g for 10 min to obtain serum which
was used for ELISA and enzymatic activity measurements.
Additionally, brain, thymus, heart, lung, spleen, kidneys, liver,
and adrenals were removed, weighed, and either fixed in 10%
buffered formaldehyde or snap-frozen in liquid nitrogen for
biochemical analysis. For histological analyses, formalin-fixed
organ samples were embedded in paraffin blocks (n = 8 animals
for each treatment group).
Interleukin (IL)-6, IL-10, Tumor Necrosis
Factor (TNF)-α, and Alanine
Aminotransferase (ALAT) Assays
Serum levels of inflammatory and liver damage markers
were quantified with the following commercially available
reagents: mouse TNF-α Quantikine ELISA Kit (R&D Systems,
Minneapolis, MN, United States), IL-6 Mouse ELISA Kit
(Thermo Scientific, Rockford, IL, United States), IL-10 Mouse
ELISA Kit (Thermo Scientific), and EnzyChromTM Alanine
Transaminase Assay Kit (BioAssay Systems, Hayward, CA,
United States).
Oxidative Status in the Tissues
To determine tissue content of GSH and GSSG, samples were
homogenized with 11 volumes of 0.2 M sodium phosphate buffer
[5 mM ethylenediaminetetraacetic acid (EDTA); pH 8.0] and
4 volumes of 25% metaphosphoric acid. After centrifugation
(12,000 × g, 4◦C, 30 min), GSH was measured photometrically
in the supernatants (Ellman, 1959) and GSSG fluorometrically
(Hissin and Hilf, 1976). To assess the tissue content of LPO as
TBARS, tissue samples were homogenized with 19 volumes of ice-
cold saline and analyzed fluorometrically, as previously described
(Yagi, 1987).
Liver Biotransformation Capacity
Biotransformation capacity was assessed in the 9000 × g
supernatants of the livers. To obtain 9000× g supernatants, livers
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were homogenized with 0.1 M sodium phosphate buffer (pH 7.4)
(1:3, w/v) and subsequently centrifuged at 9000 × g for 20 min
at 4◦C. The protein content of these fractions was determined
using a modified Biuret method (Klinger and Müller, 1974). For
determination of CYP enzyme activities, the following model
reactions for different CYP isoforms were performed: ECOD
[CYP1A, 2A, 2B, 2C, 2E (Aitio, 1978)], EROD [CYP1A (Pohl
and Fouts, 1980)], MROD [CYP1A2 (Lubet et al., 1985)], PROD
[CYP2B (Lubet et al., 1985)], BROD [CYP2A, 2B, 2C, 3A (Lubet
et al., 1985)], and EMND [CYP3A (Kleeberg and Klinger, 1982)].
The amount of metabolite formed in these model reactions was
normalized to the protein content of the respective 9000 × g
supernatants and expressed as (pmol×mg protein−1 ×min−1).
Histopathology and Immunohistochemistry
Samples for histopathology and immunohistochemistry were
prepared by cutting 4-µm sections from the paraffin blocks and
floating these onto positively charged slides. Immunostaining
was performed by an indirect peroxidase-labeling method, as
described previously (Kaemmerer et al., 2017). Briefly, sections
were de-waxed, microwaved in 10 mM citric acid (pH 6.0) for
16 min at 600 W, and incubated with the respective primary
antibodies (Table 1) at 4◦C overnight. Detection of the primary
antibodies was performed using either biotinylated goat anti-
rabbit, horse anti-mouse or rabbit anti-goat IgGs, followed
by incubation with peroxidase-conjugated avidin (Vector
ABC “Elite” Kit, Vector, Burlingame, CA, United States).
Binding of the primary antibody was visualized using
3-amino-9-ethylcarbazole (AEC) in acetate buffer (BioGenex,
San Ramon, CA, United States). Sections were then rinsed,
counterstained with Mayer’s hematoxylin (Sigma-Aldrich,
Steinheim, Germany), and mounted in VectaMountTM
Mounting Medium (Vector Laboratories, Burlingame, CA,
United States). All immunohistochemical stainings were
evaluated by two independent blinded investigators. To detect
liver glycogen content, periodic-acid-Schiff staining (PAS;
periodic acid, Schiff ’s reagent: Sigma-Aldrich, Steinheim,
Germany) was performed, and to obtain a histological overview,
hematoxylin and eosin staining (HE) of livers and spleens was
conducted, using standard protocols (McManus, 1948; Fischer
et al., 2008). Identification of the specific cell types was based on
their microscopic features along with the relative location of the
cells in the respective tissues.
Cell Culture Experiments
Cells
Peripheral blood (Institute for Transfusion Medicine, Jena
University Hospital, Jena, Germany) was collected from healthy
adult donors who had not taken any anti-inflammatory drugs
during the last 10 days. The protocols for experiments with
human monocytes were approved by the ethical committee
of the Friedrich Schiller University Jena, Jena, Germany, on
March 19, 2014; approval number: 4025-02/14. All methods
were performed in accordance with the relevant guidelines and
regulations. Leukocyte concentrates were centrifuged (4000 × g,
20 min, 20◦C) and PBMCs were freshly isolated by dextran
sedimentation and centrifugation on lymphocyte separation
medium (Histopaque R©-1077, Sigma-Aldrich, Steinheim,
Germany). Resulting PBMCs were seeded in RPMI 1640
(Sigma-Aldrich, Steinheim, Germany) supplemented with 10%
heat inactivated FCS, 100 U/ml penicillin, and 100 µg/ml
streptomycin in cell culture flasks (Greiner Bio-one, Nuertingen,
Germany) for 1–1.5 h at 37◦C, 5% CO2. Adherent monocytes
were washed twice with PBS and finally harvested by cell
scraping.
Cytokine Measurement
In order to determine the effect of Casp on cytokine release,
1.5 × 106 monocytes/ml in RPMI 1640 (supplemented with
5% heat inactivated FCS, 100 U/ml penicillin, and 100 µg/ml
streptomycin) were pre-incubated for 30 min with vehicle
(0.2% DMSO) or 30 µg/ml Casp after allowing for monocyte
adhesion for 1.5 h at 37◦C and 5% CO2. Cells were stimulated
with 10 ng/ml LPS for distinct intervals (TNF-α, IL-8: 4 h;
IL-6, IL-10: 18 h), and cytokines released into the medium
were measured using specific Quantikine ELISA Kits (R&D
Systems, Minneapolis, MN, United States). The glucocorticoid
dexamethasone (1µM; Sigma-Aldrich, Steinheim, Germany) was
used as positive control.
MTT Assay
To exclude cytotoxic effects of Casp, monocytes were diluted
to 2 × 106/ml in RPMI 1640 (containing 5% heat inactivated
FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin) and
seeded in a 96-well plate. Monocytes were allowed to adhere
for 1.5 h at 37◦C and 5% CO2 prior to treatment with vehicle
(0.5% DMSO) or extract (30 µg/ml) in 100 µl of medium
for 24 h. Afterward, cells were incubated with thiazolyl blue
tetrazolium bromide solution (MTT, 5 mg/ml PBS; Sigma-
Aldrich, Steinheim, Germany) until blue staining of the control.
Formazan formation was stopped by adding 100 µl SDS-lysis
buffer (10%, w/v in 20 mM HCl, pH 4.5) and the well plates
were shaken at room temperature overnight. Finally, absorbance
was measured at 570 nm with a MultiskanTM microplate
spectrophotometer (Thermo Scientific, Ulm, Germany). The
pan-protein kinase inhibitor staurosporine (1 µM; Calbiochem,
La Jolla, CA, United States) was used as positive (cytotoxic)
control.
Statistical Analysis
For statistical analysis, the IBM SPSS statistics program (version
22.0) was used. In all cases, animal experiments were performed
with eight mice per treatment group. Statistical significance was
determined by using the non-parametric Kruskal–Wallis test,
followed by the Mann–Whitney U-test with Holm–Bonferroni
correction. A p-value ≤ 0.05 was considered statistically
significant. Data are given as mean± standard error of the mean
(SEM).
Cell culture experiments were conducted in triplicate. Data
are given as means ± SEM. Statistically significant differences in
comparison to LPS-stimulated control cells were determined by
one-way ANOVA plus Bonferroni post hoc test and are denoted
as follows: ∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001.
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TABLE 1 | Primary antibodies used for immunohistochemistry.
Antibody Type, Catalog-No. Manufacturer Dilution Host
CD3 Monoclonal, ab16669 Abcam 1:400 Rabbit
CD68 Monoclonal, ab955 Abcam 1:500 Mouse
Cleaved caspase-3 Monoclonal, 9661 Cell Signaling Technology 1:600 Rabbit
CYP1A Polyclonal Daiichi Pure Chemicals 1:5000 Goat
CYP2B Polyclonal Daiichi Pure Chemicals 1:5000 Goat
CYP3A Polyclonal Daiichi Pure Chemicals 1:5000 Goat
F4/80 Monoclonal, MCA497G Bio-Rad Laboratories 1:200 Rat
iNOS Polyclonal, sc-651 Santa Cruz Biotechnology 1:500 Rabbit
TNF-α Monoclonal, sc-52746 Santa Cruz Biotechnology 1:500 Mouse
RESULTS
Health Status, Body Temperature, and
Blood Glucose Values
To examine the systemic influence of Casp on LPS-induced
systemic inflammation, health status as assessed by the CSS, body
temperature, blood sugar level, and body and organ weight was
determined. Twenty-four hours after treatment, the health status
of LPS-challenged mice was distinctly impaired (Figure 1A).
Additionally, body temperature was significantly decreased by
an average of 2.6◦C (mean control value: 37.2◦C). Blood glucose
levels were even diminished by more than 50% when compared
with control animals (Figures 1B,C). In all cases, Casp was able to
significantly ameliorate LPS-induced effects, whereas soy lecithin
(solvent control, devoid of frankincense) showed no protective
impact. Mice receiving soy lecithin or Casp alone displayed no
relevant differences to the control group.
In comparison to controls, LPS challenge caused an average
decrease in b.wt. by 14% (Figure 1D) and in liver and thymus
weights by 12 and 25%, respectively, whereas spleen and adrenal
weights were increased by 23% (Figures 1E,F). Weights of brain,
kidney, and heart, in contrast, remained unaffected (data not
shown). Treatment with soy lecithin or Casp alone caused a
decrease in spleen weights by 15 and 22% (p = 0.071; p = 0.007)
and in thymus weights by 21 and 29% (p = 0.066; p = 0.016),
respectively (Figure 1E), with no overt histological changes in
these organs. While administration of soy lecithin had no effect
on LPS-mediated changes in body and organ weights, Casp was
able to significantly return the LPS-induced increase in spleen
and adrenal weights to control values (Figures 1E,F). Thymus
weights, in contrast, remained significantly reduced not only by
additional soy lecithin treatment, but also by co-administration
of Casp by 39 and 34% (p = 0.006; p = 0.007), respectively, which
was not statistically different from the weight reduction observed
after sole LPS treatment (p = 0.167; p = 0.264; data not shown).
Serum Cytokine and ALAT Levels
To evaluate the impact of Casp on LPS-induced alterations in
circulating cytokine levels, serum concentrations of the pro-
inflammatory cytokines TNF-α and IL-6 as well as of the
anti-inflammatory cytokine IL-10 were measured at sacrifice
(Figures 2A–C). Compared to control animals, administration of
LPS caused an elevation of serum TNF-α, IL-6, and IL-10 values
by about 120, 670, and 70%, respectively, whereas sole treatment
with soy lecithin or Casp had no effect. Co-administration of
Casp was able to reduce the LPS-induced increase in serum TNF-
α and IL-6 levels by about 30 and 50%, respectively, whereas IL-10
values were slightly further elevated. Co-administration of soy
lecithin, in contrast, had no influence on LPS effects.
As a parameter indicating liver damage, serum ALAT levels
were determined (Figure 2D). Here, LPS treatment caused a
distinct increase by about 140% compared to controls. Sole soy
lecithin or Casp administration, in contrast, had no influence
on serum ALAT concentration and no effect of soy lecithin co-
treatment on LPS-induced liver damage was noted. In contrast,
after co-administration of Casp significantly lower ALAT values
were observed compared to LPS-only-treated mice.
Oxidative Stress in Different Organs
Since oxidative stress plays a major role in systemic inflammation,
the impact of Casp on LPS-induced changes in the oxidative
status was evaluated in different organs. For this purpose, tissue
levels of lipid peroxidation products as well as the tissue content
of GSH and GSSG were determined. After LPS challenge, tissue
content of lipid peroxidation products was increased by 12,
20, 24, 45, 60, and 170% in brain, heart, lung, spleen, kidney,
and liver, respectively, suggesting considerably elevated oxidative
stress in these organs (Figures 3A–E). Soy lecithin administration
alone caused a decrease in LPO levels only in liver by about 30%,
compared to control levels. Similarly, only in heart LPO were
decreased by about 20% after sole Casp treatment. Compared
to LPS-only-treated animals, combined soy lecithin and LPS
administration reduced LPO levels in lung, heart, and spleen,
but increased the values in liver. In contrast, co-treatment with
Casp significantly attenuated LPS-mediated elevation of LPO
toward control in all organs investigated, thus indicating a
noticeable additional antioxidant capacity of Boswellia serrata
extract (Figures 3A–E). Regarding glutathione status, increases
in GSH, GSSG, and total glutathione concentrations by about 10,
20, and 60% were noticed in kidney, lung, and spleen after LPS
treatment (Figure 3F), respectively, while liver levels decreased
by 10% (representing the primary organ of glutathione synthesis;
data not shown). There was, however, no major change in the
GSH/GSSG ratio in all tissues. In brain and heart, no influence of
LPS administration on glutathione concentrations was observed.
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FIGURE 1 | Clinical severity score (A), blood glucose values (B), changes in body temperatures (C), changes in b.wt. (D), spleen (E), and adrenal weights (F). Mice
were administered either vehicle (control), soy lecithin (Phyto), Casp, LPS (control + LPS), soy lecithin + LPS, or Casp plus LPS (Casp + LPS). Data are given as
means ± SEM, n = 8 for each group. ∗, significantly different from controls; +, significantly different from LPS-treated animals; o, significantly different from soy
lecithin plus LPS-treated animals (p ≤ 0.05; Mann–Whitney U-test followed by Holm–Bonferroni correction).
After additional administration of Casp to LPS-treated animals
only in spleens a normalization of the glutathione status could be
achieved (Figure 3F). In all other organs no relevant significant
impact of either soy lecithin or Casp on LPS-mediated effects on
tissue glutathione levels was observed.
Spleen: Apoptosis, Immune Cell
Redistribution, and TNF-α Expression
Since apoptotic processes are of substantial importance in the
course of systemic inflammation and spleen function is crucial
for the removal of damaged red and white blood cells and of
bacteria from the blood stream, cleaved caspase-3 expression
was assessed in spleens by means of immunohistochemistry
as a marker of apoptotic processes. Examination of spleens
from LPS-only-treated mice revealed a markedly enhanced
expression of cleaved caspase-3, especially in the white pulp,
compared to controls and to soy lecithin R©- or Casp-only-
treated animals (Figures 4A,B). Besides being increasingly
present in spleno- and lymphocytes, strong immunostaining
was noticed especially in tingible body macrophages, which
were much more frequently present in the white pulp of
spleens from LPS-challenged mice than in the other treatment
groups (arrowheads in Figure 4B). While no difference in
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FIGURE 2 | Serum concentrations of TNF-α (A), IL-6 (B), IL-10 (C), and ALAT (D). Mice were administered either vehicle (control), soy lecithin (Phyto), Casp, LPS
(control + LPS), soy lecithin + LPS, or Casp plus LPS (Casp + LPS). Data are given as means ± SEM, n = 8 for each group. ∗, significantly different from controls; +,
significantly different from LPS-treated animals; o, significantly different from soy lecithin plus LPS-treated animals (p ≤ 0.05; Mann–Whitney U-test followed by
Holm–Bonferroni correction).
cleaved caspase-3 expression was detected between LPS-only and
soy lecithin-plus-LPS-treated mice, co-administration of Casp
yielded a clear-cut reduction in cleaved-casepase-3 expression
in spleen, thus indicating an anti-apoptotic effect (Figure 4C;
NB: in Figure 4 and Figures 5–8 photomicrographs from soy
lecithin- or Casp-only-treated mice and from soy lecithin
plus LPS-treated mice are not depicted separately since they
did not differ from controls or from LPS-only-treated mice,
respectively).
To assess the effects of Casp on LPS-induced changes in
immune cell distribution in the spleen, immunostainings
for CD3 and CD68 as markers for T-lymphocytes and
monocytes/macrophages, respectively, were performed. In
control animals and in soy lecithin- or Casp-only-treated
mice, CD3+ cells were abundantly present in the periarteriolar
sheaths of the white pulp (Figure 4D). In contrast, after LPS
challenge the splenic tissue was nearly devoid of CD3+ cells
(Figure 4E). This effect was partially reversed after co-treatment
with Casp (Figure 4F), but not with soy lecithin, indicating a
specific immunomodulatory action of the frankincense extract.
In contrast to the massive emigration of CD3+ positive cells
from the splenic tissue after LPS administration, a considerable
immigration of CD68+ cells was detected in spleens after LPS
treatment of the animals when compared to controls or to soy
lecithin- or Casp-only-treated mice (Figures 4G,H). These
cells were mainly observed in the red pulp, but an increased
infiltration of CD68+ cells was also noticed in the white
pulp. Again, this effect was nearly completely reversed after
co-administration of Casp, but not of soy lecithin (Figure 4I).
Tumor necrosis factor-α is mainly secreted by macrophages.
Due to the massive immigration of CD68+ cells into the spleens
after LPS treatment, TNF-α expression was additionally assessed
in spleen tissue by immunohistochemistry. These investigations
revealed TNF-α expression patterns, which were very similar
to those seen in the CD68 immunostaining: In comparison
to control or to soy lecithin- or Casp-only treatment, LPS-
challenge caused a massive immigration of TNF-α-positive cells
into the splenic tissue, which was almost completely abolished
by co-treatment of the mice with Casp (Figures 5A–C), whereas
co-administration of soy lecithin showed no effect.
Not only LPS, but also pro-inflammatory cytokines such
as TNF-α are known to induce iNOS expression in immune
cells such as neutrophils and monocytes/macrophages via the
NFκB pathway. Besides giving rise to cytotoxic peroxynitrite,
excess NO production is critically involved in the course of
systemic inflammation, since it contributes to hypotension,
cardiodepression, vascular hyporeactivity, and ultimately septic
shock. Therefore, in the present investigation, iNOS expression
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FIGURE 3 | Tissue content of LPO in hearts (A), lungs (B), kidneys (C), livers (D), and spleens (E), and concentration of GSH in spleen tissue (F) as a measure of
oxidative stress in the organs. Mice were administered either vehicle (control), soy lecithin (Phyto), Casp, LPS (control + LPS), soy lecithin + LPS, or Casp plus LPS
(Casp + LPS). Data are given as means ± SEM, n = 8 for each group. ∗, significantly different from controls; +, significantly different from LPS-treated animals; o,
significantly different from soy lecithin plus LPS-treated animals (p ≤ 0.05; Mann–Whitney U-test followed by Holm–Bonferroni correction).
was also assessed in spleen and liver tissue. Following LPS
treatment, a massive immigration of iNOS-positive neutrophils
(and occasionally also of macrophages) was detected in the red
and occasionally also in the white pulp of the spleens from
LPS-only-treated animals in comparison to control and soy
lecithin- or Casp-only-treated mice (Figures 5D,E). Also here,
co-administration of Casp, but not of soy lecithin, distinctly
ameliorated this effect (Figure 5F).
Liver: Immune Cell Immigration,
Glycogen Content, and
Biotransformation Capacity
In parallel to the investigations in the spleens, immunostainings
for different immune cell markers and for TNF-α and iNOS
were also performed in the livers. Here, in contrast to the
spleens, an increased presence of CD3+ T-lymphocytes was
observed after LPS treatment of the animals (Figures 6A,B).
Additionally, liver expression of the macrophage marker
F4/80 was distinctly higher in LPS-challenged mice in
comparison to controls, soy lecithin- or Casp-only-treated
animals (Figures 6D,E). Likewise, TNF-α expression was
strongly enhanced in monocytes/macrophages and also
in sinusoidal endothelial cells after LPS administration
(Figures 7D,E). Additionally, and as in the spleens, LPS
challenge yielded a massive appearance of iNOS-positive
neutrophils in the livers (Figures 7A,B). All these effects were
significantly less pronounced after pre-administration of Casp
(Figures 6C,F, 7C,F), whereas soy lecithin had no impact on
LPS-induced changes.
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FIGURE 4 | Cleaved caspase-3 (A–C), CD3 (D–F), and CD68 (G–I) expression in the spleens of control (A,D,G), LPS (B,E,H), or Casp plus LPS (C,F,I)-treated
mice. Mice were administered either vehicle (control), soy lecithin, Casp, LPS (control + LPS), soy lecithin + LPS, or Casp plus LPS (Casp + LPS). Representative
photomicrographs from one of eight different tissue samples from control mice, LPS-treated, and LPS plus Casp-treated animals are shown. Photomicrographs from
soy lecithin- or Casp-only-treated mice and from soy lecithin plus LPS-treated mice are not depicted separately since they did not differ from controls or
LPS-only-treated mice, respectively. Immunohistochemistry (red–brown color), counterstaining with hematoxylin; original magnification: ×400. Arrows in B and C
mark cleaved caspase-3-positive apoptotic cells, arrowheads indicate tingible body macrophages; arrows in G, H, and I mark CD68-positive
monocytes/macrophages.
Since liver function is crucial for overall patient outcome
in severe systemic inflammation, liver glycogen content and
biotransformation capacity were assessed as representative
parameters. In comparison to livers from control, soy lecithin- or
Casp-only-treated mice, LPS-challenge caused almost complete
glycogen depletion. This effect was partially reversed by
additional administration of Casp but not of soy lecithin
(Figures 7G–I).
Biotransformation capacity was evaluated by assessing the
expression levels of three different CYP isoforms and by
measuring CYP-dependent monooxygenase activities by means
of specific model reactions. All three CYP isoforms (CYP1A1,
CYP2B1, and CYP3A2) assessed were predominantly expressed
in the hepatocytes located around the central veins (Figure 8).
In comparison to controls and soy lecithin-only-treated mice,
LPS administration produced a strong reduction in CYP
isoforms expression. In Casp-only-treated animals, in contrast,
a strong increase in CYP expression was observed, which
was most clearly visible in the pericentral regions of the
liver lobules. Whereas co-administration of soy lecithin did
not show any visible influence on LPS-mediated effects,
additional treatment with Casp was able to restore CYP
expression levels completely (Figure 8). Also in the CYP
model reactions a distinct decrease in enzyme activities
was observed after LPS administration in comparison to
controls (Figure 9). In contrast, after sole soy lecithin and
especially after sole Casp treatment distinct increases in CYP
activities were observed, suggesting a noticeable CYP-inducing
capacity of Casp (Figure 9). Whereas additional soy lecithin
treatment in some instances slightly ameliorated the LPS
effects, biotransformation capacity was completely restored back
to control values after supplementary Casp administration
(Figure 9).
Effects of Casperome R© in Human Primary
Monocytes
In order to investigate anti-inflammatory effects of Casp in
a human in vitro model, the influence of the extract on
LPS-induced cytokine release from human monocytes was
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FIGURE 5 | TNF-α (A–C) and iNOS (D–F) expression in the spleens of control (A,D), LPS (B,E), or Casp plus LPS (C,F)-treated mice. Mice were administered either
vehicle (control), soy lecithin, Casp, LPS (control + LPS), soy lecithin + LPS, or Casp plus LPS (Casp + LPS). Representative photomicrographs from one of eight
different tissue samples from control mice, LPS-treated, and LPS plus Casp-treated animals are shown. Photomicrographs from soy lecithin- or Casp-only-treated
mice and soy lecithin plus LPS-treated mice are not depicted separately since they did not differ from controls or LPS-only-treated mice, respectively.
Immunohistochemistry (red–brown color), counterstaining with hematoxylin; original magnification: ×400. Arrows in A–C mark TNF-α-positive
monocytes/macrophages, arrows in E and F indicate iNOS-positive neutrophils, respectively.
FIGURE 6 | CD3 (A–C) and F4/80 (D–F) expression in the spleens of control (A,D), LPS (B,E), or Casp plus LPS (C,F)-treated mice. Mice were administered either
vehicle (control), soy lecithin, Casp, LPS (control + LPS), soy lecithin + LPS, or Casp plus LPS (Casp + LPS). Representative photomicrographs from one of eight
different tissue samples from control mice, LPS-treated, and LPS plus Casp-treated animals are shown. Photomicrographs from soy lecithin- or Casp-only-treated
mice and soy lecithin plus LPS-treated mice are not depicted separately since they did not differ from controls or LPS-only-treated mice, respectively.
Immunohistochemistry (red–brown color), counterstaining with hematoxylin; original magnification: ×400. Arrows in A–C mark CD3-positive T-lymphocytes, arrows
in D–F indicate F4/80-positive macrophages, respectively.
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FIGURE 7 | iNOS (A–C), TNF-α expression (D–F), and glycogen content (G–I) in the livers of control (A,D,G), LPS (B,E,H), or Casp plus LPS (C,F,I)-treated mice.
Mice were administered either vehicle (control), soy lecithin, Casp, LPS (control + LPS), soy lecithin + LPS, or Casp plus LPS (Casp + LPS). Representative
photomicrographs from one of eight different tissue samples from control mice, LPS-treated, and LPS plus Casp-treated animals are shown. Photomicrographs from
soy lecithin- or Casp-only-treated mice and soy lecithin plus LPS-treated mice are not depicted separately since they did not differ from controls or LPS-only-treated
mice, respectively. A–F: Immunohistochemistry (red–brown color), counterstaining with hematoxylin; G–I: periodic acid-Schiff staining; original magnification: ×400.
Arrows in B mark iNOS-positive neutrophils, arrows in E and F indicate TNF-α-positive monocytes/macrophages.
tested in comparison to the glucocorticoid dexamethasone.
After pre-incubation with the test compounds, freshly isolated
human primary monocytes were stimulated with 10 ng/ml
LPS to elicit cytokine release (assessed by ELISA). At a
concentration of 30 µg/ml, Casp decreased the levels of all
pro-inflammatory cytokines measured. Thus, TNF-α release was
reduced by 32% with similar efficiency as for dexamethasone
(30% reduction). Even stronger effects of Casp were detected
for release of IL-6 and the chemokine IL-8 (Figure 10A).
Additionally, Casp and dexamethasone blocked the release
of the anti-inflammatory cytokine IL-10. To exclude any
cytotoxicity being responsible for diminished cytokine release,
Casp was evaluated in a cell viability (MTT) assay. As shown
in Figure 10B, 30 µg/ml Casp produced no detrimental impact
on monocyte viability after 24 h incubation in comparison
to control, whereas staurosporine reduced cell viability to
about 54% of control values. Thus, these data support
Casp as a potent anti-inflammatory agent without cytotoxic
effects.
DISCUSSION
Since the beneficial effects of frankincense in the treatment
of chronic inflammatory diseases have already been well
documented (see e.g., Poeckel and Werz, 2006; Moussaieff and
Mechoulam, 2009; Abdel-Tawab et al., 2011; Du et al., 2015), the
aim of the present study was to assess possible protective effects
of frankincense on acute systemic inflammation for the first time.
Because of the well-documented influence of the boswellic acids
on cytokine production by monocytes/macrophages (Syrovets
et al., 2000; Pandey et al., 2005; Gayathri et al., 2007; Sharma
et al., 2016), we focused on cytokine plasma levels, immune
cell redistribution, and oxidative stress as well as liver function.
The latter parameter is known to be critical for overall patient
outcome during systemic inflammation and has been shown to be
negatively influenced by pro-inflammatory cytokines (Morgan,
2001; Novotny et al., 2007; Jacob et al., 2009; Nesseler et al., 2012).
After LPS challenge, reduced b.wt. of the animals, decreased
blood glucose levels, and almost complete glycogen depletion of
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FIGURE 8 | CYP 1A1 (A–C), CYP2B1 (D–F), and CYP3A2 (G–I) expression in the livers of control (A,D,G), LPS (B,E,H), or Casp plus LPS (C,F,I)-treated mice.
Mice were administered either vehicle (control), soy lecithin, Casp, LPS (control + LPS), soy lecithin + LPS, or Casp plus LPS (Casp + LPS). Representative
photomicrographs from one of eight different tissue samples from control mice, LPS-treated, and LPS plus Casp-treated animals are shown. Photomicrographs from
soy lecithin- or Casp-only-treated mice and soy lecithin plus LPS-treated mice are not depicted separately since they did not differ from controls or LPS-only-treated
mice, respectively. Immunohistochemistry (red–brown color), counterstaining with hematoxylin; original magnification: ×400. CYP expression was mainly confined to
the hepatocytes around the central veins (asterisks).
the livers were observed, which is in line with literature data
(Raetzsch et al., 2009; Santos et al., 2013; Seemann and Lupp,
2015, 2016; Seemann et al., 2017). On the one hand, these effects
could be explained by the distinctly reduced health status of
the animals, mirrored by low CSS scores, which may have led
to reduced food intake. On the other hand, it has been shown
that (partially mediated via increased TNF-α expression) LPS
is able to reduce gluconeogenesis (Goto et al., 2001; Raetzsch
et al., 2009; Santos et al., 2013) and to increase glycogenolysis
(Casteleijn et al., 1988). Presumably by direct binding of the
boswellic acids to LPS and thus blunting TLR4, MyD88, and
NFκB signaling (and, consequently, TNF-α release and COX-2
induction), but probably also by a direct interaction with NFκB
and COX-2, co-administration of Casp significantly increased
blood glucose values and liver glycogen content compared to
the LPS-only treatment group. Additionally, general health status
of the animals was significantly improved after co-treatment
with Casp with increased food consumption, lower levels of
circulating pro-inflammatory cytokines, a lower severity of
the inflammatory processes, and a normalization of the body
temperatures, compared to the LPS-only-treated animals.
In the present investigation, markedly increased serum
levels of the pro-inflammatory cytokines TNF-α and IL-6 were
observed in LPS-treated animals, as expected from literature data
(Seemann and Lupp, 2015, 2016; Seemann et al., 2017). These
increased levels were distinctly reduced after Casp co-treatment
of the mice. Thus, the reported suppression of pro-inflammatory
cytokine release from monocytes/macrophages by boswellic
acids (Syrovets et al., 2000; Pandey et al., 2005; Gayathri
et al., 2007; Sharma et al., 2016) could be reproduced also
with the frankincense extract Casp in vivo in acute systemic
inflammation. These results were further confirmed by cell-
based assays using human primary monocytes, which revealed
a distinct reduction of the LPS-induced TNF-α, IL-6, and IL-8
release after Casp treatment. In contrast to the suppressive
effects on pro-inflammatory cytokines, murine serum levels of
the anti-inflammatory IL-10 were slightly enhanced by Casp
co-treatment, whereas in the cell-based assay IL-10 release was
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FIGURE 9 | Biotransformation capacity as determined by a panel of model reactions for different CYP isoforms. Mice were administered either vehicle (control), soy
lecithin (Phyto), Casp, LPS (control + LPS), soy lecithin + LPS, or Casp plus LPS (Casp + LPS). ECOD (A), BROD (B), EROD (C), MROD (D), PROD (E), and EMND
(F) were determined in the 9000 × g supernatants of the livers. Data are given as means ± SEM, n = 8 for each group. ∗, significantly different from controls; +,
significantly different from LPS-treated animals; o, significantly different from soy lecithin plus LPS-treated animals (p ≤ 0.05; Mann–Whitney U-test followed by
Holm–Bonferroni correction).
strongly decreased. This discrepancy may be due to the fact that
in vivo IL-10 is not only released by monocytes/macrophages
but also by many other immune cells such as TH2- or Treg-
lymphocytes. IL-10 released from these cells has a central role in
limiting immune responses to pathogens to protect the organism
from damage due to exaggerated inflammatory processes (Saraiva
and O’Garra, 2010). Thus, in addition to the inhibitory effects
seen on cytokine production by monocytes and macrophages,
stimulation of IL-10 release from these other immune cells may
have also contributed to the overall better outcome observed after
co-treatment with Casp, compared to LPS-only-treated mice.
In parallel to the influence of Casp on pro-inflammatory
and anti-inflammatory cytokines, also immune cell redistribution
was distinctly reduced by the frankincense extract. In spleens,
LPS caused a massive appearance of iNOS-positive neutrophils
and of CD68/iNOS/TNF-α-positive monocytes/macrophages,
but a depletion of CD3+ T-lymphocytes, whereas in livers
immigration of iNOS positive neutrophils as well as CD3+
cells was observed. All these effects were distinctly ameliorated
after co-administration of Casp. Especially the influence on
iNOS expression may be of importance, since increased iNOS
expression and, most importantly, immigration of iNOS-positive
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FIGURE 10 | Effect of Casp on cytokine release and cytotoxicity in human monocytes. (A) Human primary monocytes were pre-incubated with vehicle or
compounds (Casp; dexamethasone, dex) for 30 min prior to stimulation with LPS for 4 (TNF-α, IL-8) or 18 h (IL-6, IL-10). Formed cytokines were measured by
ELISA. Data are means ± SEM; n = 3; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05; inhibitor vs. stimulated control (100%), one-way ANOVA plus Bonferroni test. (B) Effect
of Casp on cell viability. Intact human monocytes were incubated with compounds (Casp; staurosporine, stsp) or vehicle for 24 h and cell viability was analyzed by
MTT assay. Data are means ± SEM; n = 3; ∗p < 0.05; inhibitor vs. vehicle control (100%), one-way ANOVA plus Bonferroni test.
neutrophils, but also of iNOS-positive macrophages, into the
tissues has been shown to be critical for the course of the disease
and overall outcome (Kirkeboen and Strand, 1999; Tsukahara
et al., 2001; Farley et al., 2006; Wang et al., 2012). Finally,
in parallel to the positive influence on TNF-α serum values,
Casp was also able to ameliorate LPS-induced increases in
TNF-α expression by monocytes/macrophages and sinusoidal
endothelial cells in liver tissue.
In contrast to average b.wt., spleen weights were distinctly
enhanced after LPS treatment. The occurrence of splenomegaly
in response to severe systemic inflammation has been shown
also in humans (Arismendi-Morillo et al., 2004) and has been
correlated with, among others, TNF-α- and IL-6-mediated
elevation of serum high-mobility group box 1 (HMGB1) levels
in spleen tissue (Valdés-Ferrer et al., 2013). The increase in
volume has been demonstrated for both red and white pulp
and has been shown to be due to hyperemia and enhanced
immigration of white blood cells into the splenic tissue, especially
neutrophils and macrophages (Valdés-Ferrer et al., 2013;
Seemann et al., 2017). As mentioned above, an increased presence
of iNOS-positive neutrophils and CD68/iNOS/TNF-α-positive
monocytes/macrophages was observed in the spleens after LPS
challenge also in the present investigation. Additionally, a distinct
rise in apoptotic processes was also noted, demonstrated by
increased cleaved caspase-3 stainings, and mirrored by increased
presence of tingible body macrophages in spleens after LPS
treatment. Probably, there is an increased need for degradation
of nonfunctional erythrocytes and white blood cells as a result
of systemic inflammation. In contrast to these processes, massive
emigration of CD3+ T-lymphocytes from spleens was observed
after LPS challenge, which is in line with previous investigations
(Valdés-Ferrer et al., 2013; Seemann et al., 2017). Since the
present investigation demonstrated increased immigration of
CD3+ cells into liver tissue, these cells may leave the spleen
to enter other organs in response to systemic inflammation.
Probably by suppressing increased levels of pro-inflammatory
cytokines, spleen weights were significantly decreased back to
normal values after co-administration of Casp. Additionally,
less neutrophils and macrophages were present in spleen tissue
while apoptotic processes as well as presence of tingible body
macrophages were distinctly reduced in comparison to LPS-only-
treated animals. Furthermore, emigration of CD3+ cells from
spleen into other organs was significantly attenuated, suggesting a
noticeable immunomodulatory and anti-inflammatory action of
the frankincense extract.
Lipopolysaccharides-only-treated animals also showed
adrenal hypertrophy, which may be explained by activation of
the hypothalamic–pituitary–adrenocortical axis in response to
the inflammatory event (Prigent et al., 2004; Yang et al., 2007;
Zhang et al., 2014), but also by stimulation of adrenal medullary
catecholamine synthesis to stabilize cardiovascular function
(Flierl et al., 2008). Probably by decreasing pro-inflammatory
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cytokine levels, thus exerting anti-inflammatory effects, Casp
was evidently able to counteract these effects, since adrenal
weights were significantly returned back to normal values in our
investigation.
In contrast to spleen and adrenals, thymus weights were
distinctly reduced after LPS treatment. As in spleen, this effect
may be due to a massive emigration of T-lymphocytes into other
organs, but also to increased apoptotic processes as has been
shown in other sepsis animal experiments before (Hiramatsu
et al., 1997, Seemann and Lupp, 2015). There was, however, also
a comparable decrease in thymus weights and also a reduction
in spleen weights after sole soy lecithin or Casp treatment. These
effects remain unclear since no overt histological changes were
noticed in the histological stainings of both organs after sole
soy lecithin or Casp administration. The effects of Casp on the
weights of these two immune organs could be, however, an
expression of the known immunomodulatory properties of the
boswellic acids (see e.g., Poeckel and Werz, 2006; Moussaieff
and Mechoulam, 2009; Abdel-Tawab et al., 2011; Stürner et al.,
2017), which in our mouse model evidently helped the animals to
better cope with the LPS-induced systemic inflammation. After
combined treatment with LPS, clear-cut protective effects were
seen on all parameters tested, including spleen weights, plasma
levels of pro- and anti-inflammatory cytokines, and immune cell
redistribution, and there was no additional negative influence on
thymus weights. Nevertheless, in future experiments, the effects
of Casp (but also of soy lecithin) on the immune system in
systemic inflammation should be elaborated in more detail in
order to elucidate the underlying mechanisms of the protective
findings of the present investigation more precisely and to
exclude any adverse effects.
Lipopolysaccharides can lead to enhanced generation of
reactive oxygen (ROS) and nitrogen species (RNS), both directly
and via increased pro-inflammatory cytokine expression. ROS are
the result of elevated NADPH-oxidase expression in neutrophils
and monocytes/macrophages after LPS challenge (Kim et al.,
2007), but may also be caused by increased mitochondrial leakage
(Shoji et al., 1995; Galley, 2011). RNSs are generated both via
enhanced NADPH-oxidase and iNOS expression in neutrophils
and monocytes/macrophages. ROS/RNS are neutralized, among
others, by the glutathione system, which represents an important
anti-oxidative mechanism of the body to protect cellular
macromolecules such as DNA, lipids, and proteins from chemical
damage and degradation (Hayes and McLellan, 1999). In the
present investigation, a distinct decrease in glutathione content
in livers was observed after LPS treatment of the animals. This
glutathione loss may either be caused by LPS-induced liver
cell damage, as indicated by increased serum ALAT values,
and subsequent impairment of glutathione synthesis, but may
also be caused by intensified export to other organs, such as
kidneys, lungs, and spleens. This latter hypothesis is supported
by the observation that in these organs, and in contrast to
liver, an increase in glutathione content was observed after
LPS treatment. Lipid peroxidation products are the result of
excessive oxidative stress which has overwhelmed the overall
anti-oxidative capacity of the body and has led to a degradation of
membrane lipids (Ayala et al., 2014). In the present investigation,
corresponding to elevated ALAT values, a strong increase
in lipid peroxidation products was seen especially in livers
after LPS treatment, but also in all other organs tested. Casp
caused a marked reduction in hepatic LPO content when given
in addition to LPS, presumably by direct binding to LPS,
thereby preventing increased expression of NADPH-oxidase,
iNOS, and pro-inflammatory cytokines, but probably also due
to a direct radical scavenging capacity (Afsar et al., 2012; Al-
Harrasi et al., 2013). In all other organs investigated, levels were
even reverted back to normal values. Altogether, these effects
suggest a noticeable anti-oxidative capacity of the frankincense
extract.
Biotransformation capacity is of essential importance for the
detoxification and elimination of endogenous substances, as well
as exogenously administered therapies, and the CYP system
represents one of the key enzyme systems involved in phase I
metabolism of xenobiotics (Nebert and Russell, 2002). It is well
known from the literature that the pro-inflammatory cytokines
TNF-α, IL-1β, IL-6, interferon-α, and interferon-γ, as well as NO
cause a strong downregulation especially of the CYP system but
also of other biotransformation enzymes (Morgan, 2001; Aitken
et al., 2006). Consequently, in sepsis patients CYP-mediated drug
metabolism is markedly impaired (Carcillo et al., 2003; Jacob
et al., 2009). Since sepsis patients usually are concomitantly
treated with several drugs, such as, e.g., antibiotics, reduction in
CYP activity may lead to an accumulation of these substances
and enhanced side effects of these multiple medications, which
may have additional negative impact on the health status of
these patients (Carcillo et al., 2003). In the present investigation,
Casp turned out to be a strong inducer of all CYP enzymes
tested. Since no other comparable in vivo data are available so
far for either the frankincense extract or individual boswellic
acids, this effect remains to be further elucidated. In the only
in vitro study performed so far on liver microsomes, an inhibitory
action of frankincense extract and various boswellic acids on
different CYP enzymes has been shown (Frank and Unger, 2006).
However, in vitro experiments using microsomes do not allow for
prediction of potential drug effects as CYP inducer or inhibitor
in vivo beyond a mere interaction, since for CYP induction
intact cells are required. Based on the CYP-inducing capacity and
the decreased levels of pro-inflammatory cytokines and NO, we
postulate that Casp may be able to restore both CYP enzymes
expression and activities back to normal values, which would
suggest a therapeutic use of frankincense extract in the treatment
of sepsis patients.
Besides the distinct beneficial effects of Casp on most of
the parameters tested, in some instances a significant protective
influence on LPS-mediated changes was also observed with
the phospholipid soy lecithin. Thus, soy lecithin was able
to cause a slight reduction in elevated LPO levels in lungs,
hearts, and spleens and an improvement of CYP-mediated
biotransformation capacity in some of the model reactions.
However, in all these cases, the effect of Casp (i.e., the
combination of soy lecithin and frankincense extract) exceeded
that of soy lecithin alone. Protective effects of phospholipid-
rich lipid solutions in sepsis have been reported both in
humans and in animal experiments (Read et al., 1995;
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Goldfarb et al., 2003; Gordon et al., 2005). The exact mechanism
underlying these effects still remains to be elucidated. However,
an increased binding of LPS by lipoproteins generated from these
lipids and thus prevention of interaction of the LPS/LPS-binding
protein complex with Toll-like receptors has been suggested
(Read et al., 1995; Goldfarb et al., 2003; Gordon et al., 2005).
CONCLUSION
In summary, the present investigation shows for the first time
that the orally bioavailable frankincense extract Casp is able to
prevent acute LPS-induced systemic inflammation in mice by
exerting anti-inflammatory, anti-oxidative, and hepatoprotective
effects. Casp may therefore serve as a new prophylactically
acting supportive treatment option in systemic inflammatory
conditions, especially when accompanied by impaired liver
function. It would be of further interest to determine whether
Casp also exerts protective effects when given later in the course
of the disease and/or using other sepsis models. Additionally,
individual boswellic acids should be tested to find out, which of
the different components of frankincense extract may indeed be
responsible for the beneficial effects of Casp in acute systemic
inflammation.
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During the last two decades incidences of fungal infections dramatically increased and
the often accompanying failure of available antifungal therapies represents a substantial
clinical problem. The urgent need for novel antimycotics called particular attention to the
study of natural products. The genus Hypericum includes many species that are used
in the traditional medicine to treat pathological states like inflammations and infections
caused by fungi. However, despite the diffused use of Hypericum-based products the
antifungal potential of the genus is still poorly investigated. In this study five Hypericum
species autochthonous of Central and Eastern Europe were evaluated regarding their
polyphenolic content, their toxicological safety and their antifungal potential against a
broad panel of clinical fungal isolates. LC-MS analysis led to the identification and
quantification of 52 compounds, revealing that Hypericum extracts are rich sources
of flavonols, benzoates and cinnamates, and of flavan-3-ols. An in-depth screen of
the biological activity of crude extracts clearly unveiled H. hircinum subsp. majus as a
promising candidate species for the search of novel antifungals. H. hircinum is diffused
in the Mediterranean basin from Spain to Turkey where it is traditionally used to prepare a
herbal tea indicated for the treatment of respiratory tract disorders, several of which are
caused by fungi. Noteworthy, the infusion of H. hircinum subsp. majus excreted broad
antifungal activity against Penicillium, Aspergillus and non-albicans Candida isolates
comprising strains both sensitive and resistant to fluconazole. Additionally, it showed
no cytotoxicity on human cells and the chemical characterization of the H. hircinum
subsp. majus infusion revealed high amounts of the metabolite hyperoside. These results
scientifically support the traditional use of H. hircinum extracts for the treatment of
respiratory tract infections and suggest the presence of exploitable antifungal principles
for further investigations aimed at developing novel antifungal therapies.
Keywords: Hypericum, antifungal, Candida, cytotoxicity, LC-MS, phenolic compounds
Abbreviations: CFU, colony forming units; GM, geometric mean; LC-MS, liquid chromatography-mass spectrometry;
MIC, minimal inhibitory concentration.
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INTRODUCTION
The rising incidence of fungal infections is an emerging serious
health problem, especially in cases of immune compromised
patients caused either by diseases like AIDS, or by cancer
therapies and prolonged antibiotic treatments (Lass-Flörl, 2009;
Weil et al., 2017). Estimates of global mortality rates suggest that
fungi are responsible for more deaths than either tuberculosis
or malaria (Brown et al., 2012). Millions more suffer from
severe illness caused by chronic or allergic fungal infections.
Candidiasis is the most prevalent fungal disease worldwide
difficult and extremely costly to treat (World Health Organization
[WHO], 2014). The available antifungal drugs like polyenes,
pyrimidines, azoles, and echinocandins often provoke significant
toxicity including fever, nausea and vomiting, dose-limiting
nephrotoxicity, liver toxicity, and controversial interactions with
co-administered drugs (Dismukes, 2000; Zager, 2000). Another
crucial problem is represented by the increasing rate of drug
resistance that invalidates the clinical treatments. The alarming
gap in the anti-fungal pipeline makes the discovery of new
active compounds a priority for the scientific community. The
strong request of new classes of compounds has renewed
the interest in the screening of natural products (Abreu
et al., 2012; Atanasov et al., 2016). Especially, ethnobotany
represents an important guide in the search of novel antifungal
agents. Due to their ability to synthesize a limitless variety
of chemical structures, plants have represented a source of
bioactive remedies for centuries (Arif et al., 2009). Despite of
this, it is estimated that only a small proportion of plants
are used by humans. Therefore, bioactivity screening programs
and research on new plant-derived compounds are of prime
importance for the search of novel leads. Plants belonging
to the genus Hypericum, are characteristic components of the
European flora. In particular, Europe and the Mediterranean
basin represent a hot spot of diversity for Hypericum species
(Nürk and Crockett, 2011). The best characterized species is
H. perforatum L., which was already described by Hippocrates
as a remedy against possession in the Ancient Greece (Dugoua
et al., 2006). During the centuries it has been used for
the treatment of various pathological states, like neurological
disorders, wounds, inflammations, and infections. The use
of H. perforatum extracts is so popular that this species is
considered the most important medicinal plant of the 20th
century (Gurib-Fakim, 2006). The German Commission E
approved its usage for several indications, including treatment
and post-therapy of acute and contused injuries, myalgia and
first-degree burns as well as dyspeptic complaints (Arsic et al.,
2010). In the Balkan Countries it is considered as one of
the oldest remedies and in the Serbian folk medicine it is
indicated for the treatment of cuts, burns, hemorrhoids and
also as an antiseptic, for liver and stomach complaints, diarrhea,
and gastric ulcers. Its sale represents a huge part of the
overall herbal market (Crockett et al., 2011), exceeding $570
million/annum worldwide (Ayan et al., 2006). Regarding its
antifungal potential, inhibitory properties against Candida spp.,
(Tocci et al., 2013) and fungal plant pathogens (Crockett et al.,
2011) have been reported. Nevertheless, a growing number of
scientific evidences underlines the importance to investigate
other Hypericum species that might exert a more promising
antifungal activity (Radulovic´ et al., 2007; Stojanovic et al., 2013).
In this regard the species H. carinatum, H. myrianthum, H.
linoides (Barros et al., 2013), H. garciae (Tocci et al., 2018a) have
been shown to have the potential to inhibit the growth of Candida
spp. Cryptococcus neoformans and Rhodotorula mucilaginosa
growth.
In Central and Eastern Europe several different Hypericum
species co-occur and the area is considered a significant source of
plant material for the market of herbal products (Raclariu et al.,
2017).
Amongst others, H. maculatum Crantz subsp. maculatum,
H. hircinum L. s. lat., H. hirsutum L., and H. montanum
L., as plants used to treat wounds, skin inflammations and
burns (Menkovic et al., 2011), as well as infections of the
respiratory (Sagratini et al., 2008) and urinary tract (Saric´-
Kundalic´ et al., 2010). These pathologies are often caused
by fungi, with Candida as the main causative agent and by
dermatophytes in the case of external infections (Borgers et al.,
2005; Johnson, 2012; Ritchie and Eltahawy, 2014). To screen for
new candidates suitable for the development of novel antimycotic
solutions, we studied extracts deriving from the aerial parts
of several Hypericum taxa (H. perforatum L., H. maculatum
Crantz subsp. maculatum, H. hircinum L. s.lat., H. hirsutum L.,
and H. montanum L.) with respect to their chemical profile,
their antifungal activity against a broad panel of clinical fungal
isolates of the human gut and their toxicological safety on
human skin fibroblasts and peripheral blood mononuclear cells
(PBMCs).
MATERIALS AND METHODS
Plant Material
Samples of H. hirsutum subsp. hirsutum, H. hircinum subsp.
majus, H. maculatum, H. montanum, and H. perforatum
have been collected during spring-summer of 2015 in the
Alpine region (Northern-Eastern Italy). Species were identified
according to the most recent Flora of Italy (Pignatti, 1982,
2017), nomenclature follows Bartolucci et al. (2018) and
type specimens were deposited in the Department of Food
Quality and Nutrition at the Fondazione Edmund Mach
in San Michele all’Adige, Trento, Italy (Reference number:
NT0001 H. perforatum, NT0002 H. montanum, NT0003
H. maculatum, NT0004 H. hirsutum, NT0005 H. hircinum subsp.
majus).
Preparation of Crude Plant Extracts
For each species, 500 mg of dried plant biomass, represented
by stems and leaves, were powdered by grinding and extracted
in the dark with methanol (drug/solvent ratio = 1:20 w/v) by
maceration (3 × 24 h). H. hircinum subsp. majus was also
subjected to extractions with boiling water (100◦C) for 20 min,
and ethanol 80% by maceration for 24 h. The obtained extracts
were evaporated to dryness, weighed and stored at −20◦C until
analysis.
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Preparation of Samples for Chemical
Analysis
Prior to analysis methanolic extracts were resuspended in
50% methanol/water and filtered using sterile (0.2 µm) PTFE
filters.
LC-MS Analysis
Analysis of phenolic metabolites was performed using a
Waters Acquity UPLC system (Milford, MA, United States)
which consists of a binary pump, an online vacuum degasser,
an autosampler and a column compartment as previously
described (Vrhovsek et al., 2012). Phenolic compounds were
separated at a temperature of 40◦C on a Waters Acquity
HSS T3 column 1.8 µm, 150 mm × 2.1 mm (Milford,
MA, United States). The mobile phase was composed of
component A (0.1% formic acid in water) and component B
(0.1% formic acid in acetonitrile). Acetonitrile was of LC-MS
grade and was purchased from Sigma–Aldrich (St. Louis, MO,
United States). Pure standards of hypericin from Hypericum
perforatum ∼95% (HPLC), hyperoside and hyperforin were
purchased from Sigma-Aldrich (St. Louis, MO, United States).
Milli-Q water was used for the chromatography. The flow
was set to 0.4 mL/min, and the gradient profile was: 0 min,
5% B; from 0 to 3 min, linear gradient to 20% B; from
3 to 4.3 min, isocratic 20% B; from 4.3 to 9 min, linear
gradient to 45% B; from 9 to 11 min, linear gradient to
100% B; from 11 to 13 min, wash at 100% B; from 13.01
to 15 min, the re-equilibrated to the initial conditions of
5% B. Analysis of hypericin, hyperforin and hyperoside was
performed using the same Waters Acquity UPLC system
(Milford, MA, United States) and conditions, by means of a
different gradient. The gradient profile in this case was: 0 min,
10% B; from 0 to 4,5 min, linear gradient to 100% B; from
4,5 to 12 min, isocratic 100% B; finally the column was re-
equilibrated to the initial conditions of 10% B for 4 min.
MRM transitions for hypericin, hyperforin and hyperoside are
reported in Supplementary Table S1. Each sample was analyzed
in triplicate. Samples were kept at 6◦C during the analysis. Mass
spectrometry detection for both methods was performed on a
Waters Xevo TQMS (Milford, MA, United States) instrument
equipped with an electrospray (ESI) source. Capillary voltage
was 3.5 kV in positive mode and −2.5 kV in negative mode;
the source was kept at 150◦C; the desolvation temperature
was 500◦C; cone gas flow, 50 L/h; and desolvation gas flow,
800 L/h. Further MS parameters are reported in Vrhovsek et al.,
2012.
Data Analysis
Quantification was done using Waters MassLynx 4.1 and
TargetLynx software.
Microorganisms and Media
For antifungal susceptibility testing, the reference strain
C. albicans ATCC MYA-2876 from the American Type Culture
Collection (ATCC), Rockville, MD, United States was used. The
human gut clinical isolates, C. albicans YN7, C. parapsilosis YB1,
C. parapsilosis YB3 (Di Paola et al., unpublished), C. albicans
YHS254, C. albicans YHS89, C. lusitaniae YHS217, C. lusitaniae
YHS72, C. parapsilosis YHS133, C. parapsilosis YHS312,
C. parapsilosis YHS301, Aspergillus glaucus YHS165, Penicillium
paneum YHS245 (Strati et al., 2016), C. glabrata MFB004,
C. tropicalis MFB035-1, C. tropicalis RTT037-3 (Strati et al.,
unpublished) were tested for their susceptibility against the
applied drugs. All strains were grown on Sabouraud agarized
medium for 48 h at 30◦C before testing.
Antifungal Susceptibility Testing
Candida strains were tested for their susceptibility to
Hypericum spp. extracts (7 dilution series, ranging from
500 to 8 µg/ml) following the European Committee for
Antimicrobial Susceptibility Testing protocol (EUCAST
DEFINITIVE DOCUMENT EDef 7.2 Revision; European
Committee for Antimicrobial Susceptibility Testing, 2012).
Briefly, cells were grown in RPMI1640 medium supplied with
2.0% glucose, counted and inoculated at a concentration
of 1–5 × 105 CFU/ml. MIC50 and MIC90 values were
determined at 530 nm using a spectrophotometer, as the
lowest concentration of the drug that resulted in ≥50% and
≥90% inhibition of growth relative to the growth control after
48 h incubation.
PBMC Isolation
Peripheral blood mononuclear cells were obtained from
buffy coat of healthy donors (as approved by the Ethical
Committee of the local health centre, Azienda Provinciale
per I Servizi Sanitari, Provincia Autonoma di Trento)
within 4 h from sample collection. PBMC isolation was
performed using Lympholite (CEDARLANE) density gradient
(1.077 g/liter, pH 6,9), according to manufacturer’s instructions,
and incubated in complete nutrient RPMI 1640 medium
(Euroclone) supplemented with glutamine (2 mol/L), 10%
fetal calf serum (FCS) and antibiotics (10000 U/ml Penicillin,
10000 µg/ml Streptomycin) (Biological Industries), at 37◦C and
5% CO2.
Cytotoxicity Assay
The cytotoxicity of H. hircinum subsp. majus infusion,
methanolic and hydro-alcoholic extracts was tested using the
WST-8 (4-[3-(2-methoxy-4-nitrophenyl)-2-(4-nitrophenyl)-2H-
5-tetrazolio]-1,3-benzene disulfonate sodium salt) conversion
assay. The cytotoxicity of the extracts was evaluated on
two normal cell lines, namely PBMC and human foreskin
fibroblast Hs27. Cells were seeded in 96-well culture plates
at concentration of 5000 cells/well and incubated for 24 h
before treatment with H. hircinum subsp. majus extracts.
Plant extracts were diluted in DMSO and added to a final
concentration of 500 µg/ml (final volume of DMSO 0,5%
v/v). To measure the cytotoxic effects 10 µl of Cell Counting
Kit-8 (Sigma-Aldrich) (containing the WST-8 solution) were
added to each well and incubated for 2–4 h for fibroblasts and
PBMCs, respectively, at 37◦C before reading the absorbance at
450 nm.
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TABLE 1 | Analysis of phenolic compounds in the crude extracts of Hypericum species.
H. hirc majus H. hirs H. mac H. mont H. perf
µg/g extract
Benzoates and cinnamates 427,04 ± 47,1 45,9 ± 3,65 243,22 ± 1,14 390,72 ± 6,17 112,6 ± 10,5
2,6-di-OH-benzoic acid nd∗ nd∗ nd∗ nd∗ nd∗
3,5-dihydroxybenzoic acid 1,78 ± 0,013 1,98 ± 0,012 1,47 ± 0,013 0,98 ± 0,009 0,96 ± 0,016
Caffeic acid nd∗ nd∗ nd∗ nd∗ nd∗
Cinnamic acid nd∗ nd∗ nd∗ nd∗ nd∗
Ellagic acid 5,83 ± 0,073 3,29 ± 0,088 7,22 ± 0,114 6,25 ± 0,10 2,18 ± 0,054
Ferulic acid 0,06 ± 0,003 0,38 ± 0,003 0,54 ± 0,012 nd∗ 0,26 ± 0,006
Gallic acid 0,70 ± 0,028 1,07 ± 0,008 0,51 ± 0,013 0,73 ± 0,032 0,42 ± 0,0013
p-coumaric acid 0,08 ± 0,001 0,6 ± 0,019 0,26 ± 0,009 0,25 ± 0,002 0,23 ± 0,007
p-OH-benzoic acid nd∗ nd∗ nd∗ nd∗ nd∗
Vanillic acid nd∗ nd∗ nd∗ nd∗ nd∗
Chlorogenic acid 323,03 ± 4,946 8,51 ± 0,450 nd∗ nd∗ 18,92 ± 0,949
Cryptochlorogenic acid 0,58 ± 0,009 0,12 ± 0,007 1,32 ± 0,048 4,44 ± 0,025 0,72 ± 0,01
Neochlorogenic acid 95,07 ± 0,194 29,95 ± 0,032 231,90 ± 0,112 378,07 ± 0,449 88,91 ± 0,204
Flavonols 9393,64 ± 50,3 7470,05 ± 28,01 6555,52 ± 30,21 5284,31 ± 13,25 7189,19 ± 47,26
Hyperoside 9306 ± 385 7430 ± 211 6240 ± 488 4940 ± 66,3 6880 ± 469
Quercetin 2,28 ± 0,043 9,67 ± 0,063 45,44 ± 0,159 14,35 ± 0,085 5,13 ± 0,011
Quercetin-3-arabinoside nd∗ 0,19 ± 0,005 32,40 ± 0,099 23,19 ± 0,047 132,86 ± 1,522
Quercetin-3-glucoside 43,56 ± 0,536 18,12 ± 0,529 226,89 ± 1,948 235,33 ± 1,712 14,28 ± 0,479
Quercetin-3-glucuronide 28,77 ± 0,212 nd∗ nd∗ nd∗ 2,54 ± 0,02
Quercetin-3-sulfate 11,91 ± 0,026 2,22 ± 0,018 4,64 ± 0,024 0,69 ± 0,004 34,82 ± 0,024
Rutin nd∗ 2,47 ± 0,031 3,19 ± 0,015 0,86 ± 0,006 118,89 ± 0,197
Kaempferol 0,025 ± 0,001 1,73 ± 0,007 0,43 ± 0,005 0,11 ± 0,001 0,19 ± 0,001
Kaempferol-3-glucuronide 0,48 ± 0,0151 nd∗ nd∗ nd∗ 0,05 ± 0,001
Kaempferol -3-glucoside 0,38 ± 0,012 2,38 ± 0,071 2,16 ± 0,038 1,18 ± 0,031 0,33 ± 0,009
Syringetin-3-glucoside nd∗ nd∗ nd∗ nd∗ nd∗
Iso-rhamnetin nd∗ nd∗ 0,13 ± 0,003 nd∗ nd∗
Iso-rhamnetine-3-glucoside nd∗ 0,08 ± 0,004 nd∗ nd∗ nd∗
Myricetin 0,23 ± 0,004 3,19 ± 0,014 0,24 ± 0,003 0,29 ± 0,004 0,10 ± 0,002
Flavones 0,65 ± 0,036 2,215 ± 0,016 1,175 ± 0,006 3,035 ± 0,014 0,45 ± 0,010
Luteolin trace 1,93 ± 0,011 0,79 ± 0,004 2,52 ± 0,009 0,22 ± 0,006
Luteolin 7-O-glucoside 0,65 ± 0,036 0,28 ± 0,005 0,38 ± 0,002 0,51 ± 0,005 0,18 ± 0,004
Flavanones 0,44 ± 0,009 1,43 ± 0,031 0,58 ± 0,018 2,3 ± 0,009 0,82 ± 0,016
sNaringenin 0,05 ± 0,004 0,18 ± 0,006 nd∗ 0,07 ± 0,002 0,10 ± 0,004
Naringenin-7-glucoside 0,39 ± 0,005 1,25 ± 0,025 0,58 ± 0,018 2,23 ± 0,007 0,72 ± 0,012
Chalcones 0,11 ± 0,006 0,42 ± 0,005 0,32 ± 0,008 nd∗ 0,31 ± 0,005
Phlorizin 0,11 ± 0,006 0,42 ± 0,005 0,32 ± 0,008 nd∗ 0,31 ± 0,005
Coumarins 0,23 ± 0,0032 0,07 ± 0,002 0,14 ± 0,004 0,55 ± 0,005 0,22 ± 0,002
Esculin 0,23 ± 0,0032 0,07 ± 0,002 0,14 ± 0,004 0,55 ± 0,005 0,22 ± 0,002
Flavan-3-ols 53,12 ± 1,24 74,12 ± 3,12 100,09 ± 4,81 58,28 ± 1,53 59,47 ± 2,47
Catechin 21,94 ± 0,609 5,25 ± 0,034 3,68 ± 0,114 1,79 ± 0,048 4,21 ± 0,161
Epicatechin 19,28 ± 0,212 40,21 ± 0,258 68,52 ± 0,029 53,61 ± 0,166 43,76 ± 0,17
Epigallocatechin 3,31 ± 0,030 0,42 ± 0,014 0,52 ± 0,008 1,44 ± 0,031 0,82 ± 0,025
Gallocatechin 2,21 ± 0,032 nd∗ nd∗ nd∗ nd∗
Procyanidin B1 1,37 ± 0,007 0,94 ± 0,025 0,89 ± 0,018 nd∗ 0,42 ± 0,005
Procyanidin B2 5,01 ± 0,091 27,3 ± 0,521 26,48 ± 0,770 1,44 ± 0,287 10,26 ± 0,111
Stilbenoids 0,06 ± 0,001 0,91 ± 0,015 2,24 ± 0,009 0,99 ± 0,008 3,32 ± 0,052
cis-piceid 0,06 ± 0,001 0,91 ± 0,015 2,24 ± 0,009 0,99 ± 0,008 3,32 ± 0,052
Phloroglucinols nd∗ nd∗ nd∗ 20 ± 1,91 8050 ± 565
Hyperforin nd∗ nd∗ nd∗ 20 ± 1,91 8050 ± 565
Naphtodianthrones nd∗ 30 ± 1,79 20 ± 1,71 40 ± 2,67 150 ± 25,1
Hypericin nd∗ 30 ± 1,79 20 ± 1,71 40 ± 2,67 150 ± 25,1
H. hirs majus, H. hircinum subsp. majus; H. hirs, H. hirsutum; H. mac, H. maculatum; H. mon, H. montanum; H. perf, H. perforatum. ∗nd, not detected.
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The results were analyzed by Student’s t-test. The data are
expressed as the percentage of viability and standard error of the
mean.
Microscopy
To estimate the impact of plant extracts on cell morphology and
health, cultures were visualized and recorded using an inverted
microscope Motic AE31 equipped with a camera Moticam 580
5.0 MP.
RESULTS
Extract Composition
The extracts have been chemically characterized by the
identification and quantification of 52 low molecular weight
polyphenols belonging to the classes: flavonols, benzoates
and cinnamates, chalcones, flavan-3-ols, flavones, stilbens,
coumarins, phloroglucinols, and naphtodianthrones (Table 1).
LC-MS analysis revealed that species were characterized by
different content of the detected metabolites, yet in all of the
extracts, quercetin derivatives represented the most prevalent
group of compounds.
Quercetin and quercetin glycosides ranged from 5,21 mg/g
in H. montanum to 9,4 mg/g in H. hircinum subsp. majus,
with hyperoside being the major compounds in the extracts
representing the 45,48% of the detected compounds in
H. perforatum and more than the 99% in the other Hypericum
species. Quercetin-3-glucoside was abundant in H. maculatum
and in H. montanum, while quercetin 3-rhamnoside was highly
present in H. perforatum (132,9 µg/g). Quercetin-3-glucuronide
only occurred in H. hircinum subsp. majus (28,8 µg/g) and
in H. perforatum (10-fold less concentrated). Chlorogenic
acid derivatives (chlorogenic acid, neochlorogenic acid, and
cryptochlorogenic acid) ranged from 38 µg/g for H. hirsutum
and H. perforatum to 456,7 µg/g in H. hircinum subsp. majus.
Also the flavan-3-ols were relatively abundant ranging from
53,12 µg/g in H. hircinum subsp. majus to 100,12 µg/g in
H. maculatum, with epicatechin being the principal compound
of this class (from 19 µg/g in H. hircinum subsp. majus up to
68,5 µg/g in H. maculatum).
Antifungal Activity of Hypericum Crude
Extracts
Hypericum extracts were screened against a panel of clinical
Candida isolates (Table 2 and Supplementary Table S2) and the
results are hereafter given as GM of MIC values. The screening
unveiled that H. hircinum subsp. majus crude methanolic extract
had a strong anti-Candida activity against all tested fungal
strains, with inhibition properties against C. parapsilosis (MIC50
53,5 µg/ml) in the same magnitude of fluconazole (MIC50
22,63 µg/ml).
All extracts exerted antifungal properties against C. albicans
and C. lusitaniae while only H. hircinum subsp. majus was also
active against C. tropicalis and C. glabrata (MIC50 353,55 and
16 µg/ml, respectively).
Also, with respect to the to the MIC90 values, H. hircinum
subsp.majus extract showed higher inhibitory properties than the
other tested extracts (Supplementary Table S2).
TABLE 2 | Antifungal activity of Hypericum species.
Species (strain no.) H. hircinum H. maculatum H. montanum H. perforatum H. hirsutum Fluconazole
MIC50 Range MIC50 Range MIC50 Range MIC50 Range MIC50 Range MIC50 Range
C. albicans (2) 63,25 32–125 250 250 500 500 353,3 250–500 500 500 0,35 0,125–1
C. parapsilosis (2) 32 32 500 500 >500 >500 >125 125–500 >500 500 48 32–64
C. tropicalis (2) 353,55 >500 >500 >500 >500 >500 >500 >500 >500 >500 >64 >64
C. lusitaniae (1) 16 125 64 64 125 125 125 125 64 64 0,5 0,5
C. glabrata (1) 250 >500 >500 >500 >500 >500 >500 >500 >500 >500 0,13 0,13
Data are expressed as GM in µg/ml.
TABLE 3 | Antifungal activity of H. hircinum subsp. majus.
Species (strain no.) Methanol Ethanol 80% Infusion Fluconazole
MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90
C. albicans (4) 31,81 ≥149,5 75,21 >420,4 63,25 >250 4 ≥9,5
C. tropicalis (2) 353,55 >500 353,55 >500 177 >500 >64 >64
C. parapsilosis (5) 53,5 ≥250 250 ≥500 95,18 ≥300 ≥60 >64
C. lusitaniae (2) 16 89,4 63,25 250 32 177 0,35 1,5
C. glabrata (1) 16 64 64 250 64 250 0,13 1
Aspergillus glaucus (1) >500 >500 >500 >500 250 >500 0,25 16
Penicillium paneum (1) >500 >500 >500 >500 64 500 0,13 4
Data are expressed as GM in µg/ml.
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Antifungal Activity of H. hircinum subsp.
majus Extracts
The antifungal activity of H. hircinum subsp. majus was further
investigated against a broader panel of Candida, including
fluconazole resistant strains, and other fungi (Table 3 and
Supplementary Table S3). In addition to crude methanolic
extract, infusion and hydroalcoholic extracts have been tested.
Notably, all H. hircinum subsp. majus extracts showed antifungal
properties and, in particular a remarkable activity against
fluconazole resistant C. parapsilosis and C. tropicalis strains.
The methanolic extract showed the most pronounced cytotoxic
properties. Yet, in general the antifungal activity of the infusion
outcompeted those of the hydroalcoholic extract, also with
respect to the MIC90 values.
Cytotoxicity of H. hircinum subsp. majus
Extracts
The cytototoxicity ofH. hircinum subsp.majus extracts was tested
on PBMC and human skin fibroblast Hs27 cell lines by using
the WST-8 conversion assay. The extracts were tested at a dose
of 500 µg/ml, which corresponds to a 1- (for C. tropicalis) to
10-fold higher concentration than those showing inhibition of
50% of Candida growth. As shown in Figure 1, only the plant
infusion showed no cytotoxic effect on both human cell lines,
while treatment with methanolic and hydroalcoholic extracts
inhibited cell viability by 50% for Hs27 cell line and by 65–70%
for PBMCs.
The effect of H. hircinum subsp. majus on human cells was also
observed microscopically (Figure 2). The imagines confirmed the
cytotoxicity data. Fibroblast treated with plant infusion showed
a normal phenotype, while under treatment with methanolic
and hydro-alcoholic extracts the cell morphology was markedly
altered. The same alteration was observed for PBMCs (data not
shown).
Chemical Composition of H. hircinum
susbps. majus Infusion
The chemical composition of the aqueous extract of H. hircinum
subsp. majus is reported in Table 4. The analysis revealed that
the infusion process allowed the extraction of higher amounts
of phenols in comparison to the extraction by maceration
in methanol. The aqueous extract was mainly characterized
by derivatives of quercetin (24,18 mg/g), of chlorogenic acid
(4,51 mg/g) and by flavan-3-ols (2,26 mg/g). Hyperoside was
the most abundant compound, representing the 2,23% of the
extract. Abundant were also quercetin-3-glucoside (1,65 mg/g),
neochlorogenic acid (2,61 mg/g), chlorogenic acid (1,68 mg/g),
procyanidin B2 (0,89 mg/g), epicatechin (0,59 mg/g) and
procyanidin B1(0,40 mg/g).
DISCUSSION
Plant-based treatments of the traditional medicine could bring
forth new solutions for antifungal therapies. In particular
polyphenol-rich plants represent an import source of bioactive
products for human health (Marchelak et al., 2017) including
antifungal treatments. Among polyphenols, flavan-3-ols,
flavonols and tannins show a high antimicrobial potential
(Daglia, 2012). Flavan-3-ols isolated from green and black tea
exert important anti-Candida activity (Hirasawa and Takada,
2004; Sitheeque et al., 2009), ellagitannins obtained from Punica
granatum inhibit the growth of plant pathogenic fungi (Glazer
et al., 2012), the flavonols myricitrin and fisetin are considered
effective agents against Candida glabrata and Cryptococcus
neoformans, respectively (Salazar-Aranda et al., 2015; Reis et al.,
2016). The mechanisms of action of phenols against Candida
have been intensively studied and include inactivation of
enzyme production (Evensen and Braun, 2009) and anti-biofilm
effects (Evensen and Braun, 2009; Shahzad et al., 2014). Species
FIGURE 1 | Cytotoxicity of H. hircinum subsp. majus extracts (measured
using the WST-8 conversion assay). The metabolic activity is given as the
endpoint of toxicity in human peripheral mononucleate cells (PBMC) and
human skin fibroblast cell line (Hs27), following 24 h exposure to H. hircinum
subsp. majus extracts. Values represent standard error of the mean (n = 3);
Asterisks denote statistically significant differences from control (∗p < 0.05
and ∗∗p < 0.01).
FIGURE 2 | Morphology change of normal fibroblast Hs27 after 24 h
treatment with H. hircinum subsp. majus extracts (observed under inverted
microscope, magnification 100×): (A) control (DMSO), (B) methanolic extract,
(C) hydroalcoholic extract, and (D) infusion.
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belonging to the Hypericum genus are able to synthesize a broad
array of such bioactive phenolic compounds, mainly as products
of the polyketide metabolism (Tocci et al., 2018b), and therefore
might contain novel antifungal remedies.
Here we report new data on the inhibitory activity of extracts
deriving from H. montanum, H. maculatum, H. hirsutum,
and H. hircinum subsp. majus and additional data on the
activity of H. perforatum on the growth of clinical isolates of
Candida spp. The crude extracts obtained from H. maculatum,
H. montanum, H. hirsutum, and H. perforatum showed a
moderate antifungal activity against C. albicans, in the range
of 250–500 µg/ml, good activity against C. lusitaniae (64–
125 µg/ml) and no or only weak activity against C. parapsilosis,
C. tropicalis and C. glabrata. Our data are in accordance
with those of Radulovic´ et al., 2007, showing that extracts
of H. hirsutum, H. maculatum, and H. perforatum exerted
comparable antifungal activity against C. albicans using the
disk diffusion method assay. Discordant data are reported
in Cecchini et al., 2007 which found no activity of extracts
obtained from H. hirsutum or H. montanum against C. albicans.
Most interesting, the antifungal screening of crude extracts
unveiled the promising anti-Candida properties of H. hircinum
subsp. majus. The test showed that extracts obtained from
this species are able to inhibit 50% of growth of C. albicans
at concentrations that are fourfold to eightfold lower than
other Hypericum extracts and with a more pronounced activity
against C. parapsilosis and C. lusitaniae. Moreover H. hircinum
methanolic extract was the only treatment able to inhibit the
growth of C. tropicalis and C. glabrata. These results are
important especially in the light of the increasing incidence
of infections caused by emerging Candida pathogens like
C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei, which
are less susceptible to the commonly used antifungal drugs
(Tortorano et al., 2006; Papon et al., 2013). Previous data on
the antifungal activity of H. hircinum are scarce and limited
to susceptibility tests against just a single reference strain
of C. albicans. Using the disk diffusion test method Pistelli
et al., 2000 found no antifungal activity against the tested
strain, while Cecchini et al., 2007 reported a higher activity of
H. hircinum subsp. majus in comparison to other Hypericum
species.
From a chemical point of view, the extracts applied as
treatments in our tests have been deeply characterized by
investigating the presence of 52 phenolic compounds. In
general, the most abundant classes of detected compounds
were flavonols, benzoate and cinnamates (chlorogenic acid
and neochlorogenic acid), and flavan-3-ols. The major
metabolite in all the extracts was the flavonol hyperoside,
ranging from 4940 ± 66,3 µg/g in H. montanum to
9306 ± 385 µg/g in H. hircinum subsp. majus, and very
abundant were the neochlorogenic acid and the flavan-3-ol
epicatechin. Hyperoside is known for its anticancer, anti-
inflammatory and antimicrobial properties (Ogawa et al.,
2014). The extract of H. hircinum subsp. majus, showed
several chemical peculiarities. It contained the highest
amount of hyperoside, higher amounts of chlorogenic
acid, quercetin-3-glucuronide, kampferol-3-glucuronide,
catechin, epigallogatechin, gallocatechin, and no traces of
the phloroglucinol hyperforin and of the naphtodianthrone
hypericin.
In the light of its pronounced growth inhibition properties
against Candida spp. and considering the ethnobotanical
knowledge available for this species, H. hircinum subsp. majus
has been further subjected to a deeper antifungal screen.
TABLE 4 | Analysis of phenolic compounds in the infusion of H. hircinum subsp. majus.
Compound Amount (µg/g extract) Compound Amount (µg/g extract)
2,6-di-OH-benzoic acid nd∗∗ Kaempferol 1,08 ± 0,15
3,5-dihydroxybenzoic acid 7,08 ± 0,79 Kaempferol -3-glucoside 7,89 ± 1,09
Caffeic acid 44,62 ± 4,97 Kaempferol-3-glucuronide 104,41 ± 14,49
Coniferyl alcohol nd∗ Iso-rhamnetin 0,78 ± 0,11
Gallic acid 15,74 ± 2,18 Iso-rhamnetine-3-glucoside nd∗
Cinnamic acid 6,10 ± 0,85 Syringetin-3-glucoside 3,39 ± 0,46
p-coumaric acid nd∗ Myricetin 7,68 ± 1,07
p-OH-benzoic acid 8,97 ± 1,24 Luteolin 3,51 ± 0,22
Vanillic acid 1,29 ± 0,18 Luteolin 7-O-glucoside 1,77 ± 0,24
Cryptochlorogenic acid 229,7 ± 31,88 Naringenin nd∗
Chlorogenic acid 1683 ± 233,7 Esculin 21,28 ± 2,95
Neochlorogenic acid 2615 ± 362,9 Phlorizin 6,57 ± 0,91
Hyperoside 22203 ± 380 Catechin 282,2 ± 2,71
Quercetin 164,38 ± 15,52 Epicatechin 586,51 ± 68,05
Quercetin-3-arabinoside nd∗ Epigallocatechin 55,77 ± 7,74
Quercetin-3-glucoside 1647 ± 65,03 Gallocatechin 48,92 ± 9,72
Quercetin-3-glucuronide 104,41 ± 14,92 Procyanidin B1 401,6 ± 55,74
Quercetin-3-sulfate nd∗ Procyanidin B2 886,16 ± 108,77
Rutin nd∗ cis-piceid 1,37 ± 0,19
Data are means of three independent experiments, ∗nd, not detected.
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H. hircinum is a shrub native to the areas of the Mediterranean
Basin comprising Greece and Turkey (Euro+Med, 2006).
The infusion of its aerial part is applied in the traditional
medicine to treat chronic catarrhal affections, asthma, sore
throats and cough (Pieroni et al., 2004). Recent scientific
evidences indicate that fungi of the phyla Basidiomycetes
and Ascomycetes (e.g., Bjerkandera, Aspergillus, Candida, and
Saccharomyces) are causative agents of these pathologies (Raza
et al., 2017).
To investigate whether the beneficial effect of H. hircinum
treatments may be attributed to its antifungal activity, we studied,
for the first time, the activity of extracts obtained from the
aerial parts of the plant with a hydroalcoholic solution and,
in accordance with the traditional preparations, by infusion
in boiling water. Additionally, we characterized the chemical
profile. The assay was performed on a broad panel of clinical
Candida strains, a strain of Aspergillus glaucus and a strain
of Penicillium paneum (Table 3 and Supplementary Table S3).
The extract obtained from the herbal tea inhibited 50% of
the growth of all tested fungi, showing strong activity against
both fluconazole sensitive and resistant Candida strains and
moderate activity against Aspergillus and Penicillium strains.
The chemical profile revealed an enrichment in the polyphenol
content in comparison with the crude methanolic extract.
Particularly abundant (content higher than 40 µg/g extract) were
caffeic acid, chlorogenic, neochlorogenic and cryptochlorogenic
acid, quercetin, quercetin-3-glucoside, quercetin-3-glucuronide,
kaempferol-3-glucuronide, all the flavan-3-ols investigated and
extraordinary high levels of hyperoside were detected. Even
if the bioactivity may be due to the synergistic action of
the phytocomplex, it appears reasonable to exclude caffeic
acid, chlorogenic acid, quercetin-3-glucuronide, kaempferol-3-
glucuronide, and gallocatechin as secondary metabolites to
which the antifungal activity may be attributed, since these
compounds are not present in the other Hypericum extracts
showing growth inhibitory properties on Candida strains.
Also, cryptochlorogenic acid, neochlorogenic acid quercetin,
quercetin-3-glucoside, epicatechin, have been detected in all
the crude extract, but they were less present in H. hircinum
subsp. majus and thus their presence cannot be considered
correlated to the bioactivity. According to our data a positive
correlation between the amount of catechin, epigallocatechin,
procyanidin B1 and hyperoside and the antifungal activity exerted
can be individuated. The anti-Candida properties of flavan-3-
ols, and in particular of catechin and epigallocatechin, are well
known and documented (Hirasawa and Takada, 2004; Saito
et al., 2013). Nevertheless, our data suggest that the hyperoside,
being detected in such high amounts in the extract obtained by
the infusion of H. hircinum subsp. majus in water, may play
a fundamental role in the observed fungal growth inhibition
properties. The hypothesis is supported by studies proposing
hyperoside as a lead for the development of new fungicides (Li
et al., 2005).
Finally, the aqueous extract of H. hircinum subsp. majus
showed another promising characteristic exploitable for the
development of a new antifungal therapy. When tested at high
concentrations on human PBMCs and human skin fibroblast
Hs27cell lines, no cytotoxicity was detected.
CONCLUSION
Our work reports a comprehensive phenolic profile of five
European Hypericum species, highlighting the presence of
important exploitable bioactive metabolites. The infusion of
H. hircinum subsp. majus used in the popular medicine for the
treatment of respiratory tract affections has been chemically and
biologically investigated for the first time. The chemical analysis
unveiled a new source of the bioactive metabolite hyperoside
that might be involved in the observed bioactivity of the extract.
The biological tests suggest that the beneficial effects of the
traditional remedies based on H. hircinum could be attributed to
its antiseptic, and in particular to its antifungal properties against
fungal pathogens of the respiratory tract. Moreover, the lack of
cytotoxicity indicates the presence of exploitable and promising
antimycotic principles for the development of an antifungal
therapy with limited cytotoxic side effects. Hence it encourages
future studies to assess the effective therapeutic properties of
H. hircinum subsp. majus with particular attention to the
treatment of fungal-associated pathologies of the respiratory
tract.
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Aim of the study: The aim of the present study was to investigate the effects of
phytochemically characterized extracts connected with the traditional use (infusions
and ethanolic extracts) of different parts of Syringa vulgaris (common lilac) on the
pro-inflammatory functions of neutrophils. Active compounds were isolated from the
most promising extract(s) using bioassay-guided fractionation, and their activity and
molecular mechanisms of action were determined.
Methods: The extracts were characterized using a HPLC-DAD- MSn method.
The effects on ROS, MMP-9, TNF-α, IL-8, and MCP-1 production by neutrophils
were measured using luminol-dependent chemiluminescence and enzyme-linked
immunosorbent assay (ELISA) methods. The effects on p38MAPK, ERK1/2, JNK
phosphorylation, and NF-kB p65 translocation were determined using western blots.
Results: The major compounds detected in the extracts and infusions belong
to structural groups, including caffeic acid derivatives, flavonoids, and iridoids.
All extracts and infusions were able to significantly reduce ROS and IL-8
production. Bioassay-guided fractionation led to the isolation of the following
secoiridoids: 2′′-epiframeroside, oleonuezhenide, oleuropein, ligstroside, neooleuropein,
hydroxyframoside, and framoside. Neooleuropein appeared to be the most active
compound in the inhibition of cytokine production by attenuating the MAP kinase
pathways.
Conclusion: The present study demonstrated that common lilac, which is a traditionally
used medicinal plant in Europe, is a valuable source of active compounds, especially
neooleuropein.
Keywords: Syringa vulgaris, Oleaceae, secoiridoids, neooleuropein, pro-inflammatory mediators, neutrophils
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INTRODUCTION
The Oleaceae family encompasses 25 genera and ∼600 species.
Members of this family include trees, shrubs, or woody climbers
with almost worldwide distribution from northern temperate
to southern subtropical regions, with the exception of the
Antarctic. Genera include Olea (20 spp.), Forsythia (7–11 spp.),
Fraxinus (40–70 spp.), Syringa (20–30 spp.), Osmanthus (15–
30 spp.), Jasminum (200–300 spp.), Chionanthus (80–100 spp.),
and Ligustrum (40–50 spp.) (Jensen et al., 2002; Evans, 2009).
In Central-Eastern Europe, only a few representatives of the
Oleaceae family are found: Fraxinus exelsior L., Ligustrum
vulgare L., Syringa vulgaris L., and Forsythia sp. Moreover,
Olea (leaves) and Fraxinus (leaves) have monographs in the
European Pharmacopoeia as well as European Agency EMEA
monographs. The Syringa genus is distributed in Eurasia, which
is subdivided into western (Central and Southeast Europe) and
eastern zones (Central to East Asia) (Wallander and Albert,
2000). Most of the species are found in Asia, while only S.
vulgaris and S. josikaea are found in Europe (Jensen et al., 2002;
Lendvay et al., 2016). S. vulgaris L., known as the common
lilac, is native to the Balkan peninsula and is widely cultivated
as an ornamental plant in Europe. In Poland, it has been
naturalized since the sixteenth century, where it is cultivated
but also found in the wild (Witkowska-Zuk, 2013). In European
ethnopharmacology, the common lilac inflorescence or leaves
in the form of an infusion or alcoholic extract were used to
treat gout, rheumatism and muscle/joint aches (Fournier, 1948;
Hanlidou et al., 2010; Jaric´ et al., 2015; Sõukand and Pieroni,
2016). In Poland, Bulgaria, Italy, and Greece, the flowers, leaves,
bark, or fruits in the forms of infusions, decoctions, or alcoholic
extracts were used as antipyretics and to treat cold, cough, etc.
(Fournier, 1948; Kuznicka, 1986; Kuzniewski and Augustyn-
Puziewicz, 1986; Anioł-Kwiatkowska et al., 1993; Leporatti
and Ivancheva, 2003; Hanlidou et al., 2010). Locally, different
parts of the plant are used to treat toothaches, gastrointestinal
disorders, skin wounds, and other ailments (Kuznicka, 1986;
Kuzniewski and Augustyn-Puziewicz, 1986; Anioł-Kwiatkowska
et al., 1993; Agelet and Vallès, 2003; Hanlidou et al., 2010;
Papp et al., 2014). Interestingly, in North American materia
medica (pharmacognosy) textbooks, the antipyretic use of the
leaves, flowers, and fruits of the common lilac was mentioned
(Lyle, 1897; Remington andWoods, 1918), and native Americans
used to chew the bark or leaves for treating a sore mouth
(Moerman, 1998). The Asian species are also used in traditional
medicine to treat bronchial disease [Syringa reticulata (Blume)
H. Hara leaves], lung and heart diseases (Syringa pinnatifolia
Hemsl. stem), tooth pain (Syringa vetulina Kom. Bark), and
as antipyretics (Syringa afghanica C.K. Schneid. leaves) (Park
et al., 1999; Takenaka et al., 2002; Machida et al., 2009; Su et al.,
2016).
Scientific data supporting the traditional use of S. vulgaris
are connected with its antioxidant, anti-inflammatory, anti-
nociceptive and antipyretic properties (Bálinet, 1971; Tóth et al.,
2015, 2016; Dudek et al., 2017). Moreover, information about
the single compounds responsible for each of these activities is
scarce.
The aim of the present study was to investigate the effects
of phytochemically characterized (HPLC-DAD-MSn) extracts
connected with the traditional use (infusions and ethanolic
extracts) of different parts of the common lilac (bark, fruits,
leaves and flowers) on the pro-inflammatory functions of
neutrophils, such as reactive oxygen species (ROS) production,
metalloproteinase-9 (MMP-9), interleukin 8 (IL-8), and tumor
necrosis factor (TNF-α) release. We isolated active compounds
from the most promising extracts using bioassay-guided
fractionation. Finally, we focused on the activity and molecular
mechanisms of action of the isolated compounds that were able
to regulate neutrophil inflammation. The biological activities
of single compounds were compared with oleuropein and
ligstroside, characteristic compounds from the Oleacea family
(Jensen et al., 2002), and with positive control clarithromycin,
a macrolide antibiotic, which has been shown to inhibit the
pro-inflammatory function of neutrophils (Simpson et al., 2008;
Cervin et al., 2009).
MATERIALS AND METHODS
Chemicals and General Experimental
Procedures
Hanks’ balanced salt solution (HBSS), RPMI 1640, f-MLP
(formyl-Met-Leu-Phenylalanine), LPS (from Escherichia coli
0111:B4), HEPES solution, and L-glutamine were purchased
from Sigma–Aldrich Chemie GmbH (Germany). Fetal bovine
serum (FBS) and phosphate-buffered saline (PBS) were
purchased from Gibco (USA). Ficoll Hypaque gradient (LSM
1077) was obtained from PAA Laboratories, GmbH (Austria).
Human Quantikine ELISA Kits were purchased from R&D
System (USA). Anti- pp38 (#9211), ppJNK (#9251), pJNK
(#9252), pERK1/2 (#9102), NFκB(p65) (#8242S), and β-
actin (#4967) antibodies were purchased from Cell Signaling
Technology (USA). Anti- ppERK1/2 (#V8031) was purchased
from Promega (USA) and anti-p38 (#SC-535) from Santa Cruz
Biotechnology (USA). Propidium iodide was purchased from BD
Biosciences (USA).
NMR spectra were recorded on a Bruker Advance III 600
MHz spectrometer (Bruker Biospin, Germany) in methanol-
d4. Preparative HPLC was performed with a Shimadzu LC-
20AP instrument (Japan) using a Zorbax SB-C18 column
(150 × 21.2mm, 5µm) (Agilent, USA) at a flow rate of
20.0 mL/min. TLC was performed on Merck silica gel 60 F
254 (0.25mm) plates with a dichloromethane/methanol/formic
acid/water (80:25:1.5:4; v/v/v/v) solvent system. Chromatograms
were visualized by spraying with sulfuric acid (5% in methanol)
followed by heating at 105◦C for 10min. All solvents used
for chromatography were of gradient grade. HPLC-DAD-MSn
analysis was performed on a UHPLC-3000 RS system (Dionex,
Germany) with DAD detection and an AmaZon SL ion trap mass
spectrometer with an ESI interface (Bruker Daltonik GmbH,
Germany). Separation was performed on a Zorbax SB-C18
column (150 × 2.1mm, 1.9µm) (Agilent, USA). The mobile
phase consisted of 0.1%HCOOH in water (A) and 0.1%HCOOH
in MeCN (B) using the following gradients: 0–60min, 5–40%
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B. The LC eluate was introduced into the ESI interface without
splitting, and compounds were analyzed in negative ion mode
with the following settings: nebulizer pressure of 40 psi; drying
gas flow rate of 9 L/min; nitrogen gas temperature of 300◦C; and
a capillary voltage of 4.5 kV. The mass scan ranged from 100 to
2,200m/z. UV spectra were recorded in the range of 200–400 nm.
The absorbance and luminescence were measured using
a BioTek microplate reader (Highland Park, USA). Flow
cytometry was performed using a BD FACSCalibur apparatus
(BD Biosciences, USA).
Plant Material
Bark from the branches, leaves, flowers, and fruits of S. vulgaris
L. were collected in May and August (fruits) 2016, from a
native plant growing in Legionowo, Mazovian district, Poland
(52◦ 23′ 17.647′′ N; 20◦ 55′ 53.171′′ E). The plant material was
authenticated according to Flora Europaea (Tutin et al., 1972)
by Anna K. Kiss. A voucher specimen (no. SV052015) has been
deposited in the Plant Collection, Department of Pharmacognosy
and Molecular Basis of Phytotherapy, Medical University of
Warsaw, Poland (Figure 1S).
Extract Preparation and Phytochemical
Characterization by HPLC-DAD-MS/MS
Infusions (Aqueous Extracts)
Air-dried plant materials (5 g) were poured with boiling water
(250mL), covered, and allowed to stand for 15min. Extracts were
then filtered and lyophilized, resulting in the following aqueous
extract masses: bark- 0.52 g, fruit- 0.48 g, flower- 1.69 g, and leaf-
1.04 g.
Ethanolic Extracts
The air-dried plant materials (2 g) were extracted with 60%
ethanol (v/v, 1:20) in a water bath (70◦C) for 1 h. Then, extracts
were filtered, the ethanol was evaporated, and the water residues
were lyophilized, resulting in the following ethanolic extract
masses: bark- 0.25 g, fruit- 0.21 g, flower- 0.58 g and leaf- 0.51 g.
The extracts were characterized using an HPLC-DAD-MS/MS
method. The presence of substances in extracts was confirmed
by comparing the retention times and spectra (UV, MS, MS/MS)
with standards and/or published data.
Bioassay-Guided Isolation of Active
Compounds From Leaf Extract
The air-dried plant material (100 g) was crushed and extracted
three times with 75% methanol (1:10) at 70◦C for 1 h each time
(3 times). The methanol from combined extracts was evaporated
under reduced pressure, and the aqueous residue was lyophilized
to yield 40 g of extract. The crude extract was subjected to Diaion
HP-20 (Supelco) column chromatography (45× 5 cm) and eluted
with an H2O-MeOH gradient (100:0→ 0:100, v/v) in 5 steps of
1.5 L each to obtain 35 fractions, which were pooled into 6 main
fractions (F1-F6) based on their TLC and HPLC profiles. The
activity of the fractions toward the inhibition of IL-8 and TNF-
α was tested at a concentration of 50µg/mL. Active fraction F6
(2.5 g) was subjected to further separation on a Sephadex LH-
20 (Pharmacia) column (25 × 3 cm) with H2O-MeOH (50:50,
v/v) to obtain 20 fractions of 50mL each, which were pooled into
6 main fractions (F6_1–F6_6) based on their TLC and HPLC
profiles. From fraction F6_2 (235mg), compounds I (75mg; Rt
= 11.3–12.3min.) and II (13mg; Rt = 13.4–13.9); from fraction
F6_3 (633mg), compounds III (78mg; Rt = 8.3–8.9min) and
IV (90mg; Rt = 11.9–12.7min), from fraction F6_4 (243mg),
compounds V (5mg; Rt= 12.0–12.3min), VI (23mg; Rt= 15.4-
16.0min) andVII (7mg; Rt= 19.0–19.5min) were isolated using
preparative HPLC with a gradient of 0.1%HCOOH in H2O-0.1%
HCOOH in MeCN (80:20→ 40:60) over 60min.
Preparation of Solutions of Extracts,
Fractions, and Compounds for Bioassay
Tested extracts were dissolved in PBS or HBSS (1 mg/mL).
Fractions and compounds were dissolved in DMSO (10 mg/mL
or 10mM stock solutions) and then diluted with RPMI 1640
medium. The extracts were tested in a concentration range of
25–100µg/mL. Compounds were tested at concentrations of
10-50µM. The concentration of DMSO used (<0.1%) did not
influence the assays.
Isolation of Human Neutrophils
Peripheral venous blood was taken from healthy human donors
(18–35 years old) in theWarsaw Blood Donation Centre. Donors
did not smoke or take any medications. They were clinically
recognized to be healthy and a routine laboratory tests showed
all values to be within the normal ranges. The study conformed
to the principles of the Declaration of Helsinki.
Neutrophils were isolated by dextran sedimentation and
centrifugation in a Ficoll Hypaque gradient (Böyum, 1968) and
then re-suspended in HBSS buffer or RPMI 1640 medium.
Cytotoxicity
Cytotoxicity was determined by a standard flow cytometric probe
using propidium iodide (PI) staining. After 24 h of incubation
with extracts/compounds, the neutrophils were harvested and
centrifuged (1500 RPM; 10min; 4◦C), washed once with cold
PBS and re-suspended in 400 µL of PBS. Five microliters of PI
(50µg/mL) solution was added to the cell suspensions. After
15min of incubation at room temperature, cells were analyzed
by flow cytometry, and 10,000 events were recorded per sample.
Cells that displayed high permeability to PI were expressed as a
percentage of PI(+) cells.
ROS Production
Neutrophils (3.5 × 105) were incubated in HBSS buffer with
50 µL of the tested extracts and 50 µL of luminol (20mM) in
a 96-well plate. ROS production was initiated by the addition
of f-MLP (0.1µg/mL) to obtain a total volume of 200 µL/well.
Chemiluminescence changes were measured over 40min at
intervals of 2min in a microplate reader. The background
chemiluminescence produced by non-stimulated cells was also
determined. The percentage of inhibition was calculated by
comparison to the control without the tested extracts at the
maximum luminescence.
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IL-8, MMP-9, MCP-1, and TNF-α
Production
Neutrophils (2 × 106) were cultured in 24-well plates in RPMI
1640 medium with 10% FBS, 10mM HEPES, and 2mM L-
glutamine in the presence or absence of LPS (100 ng/mL) for
24 h at 37◦C with 5% CO2 in the presence or absence of
test extracts/fractions/compounds. After 24 h, the neutrophils
were harvested and centrifuged (2000 RPM; 10min; 4◦C). The
amount of released cytokines was measured by enzyme-linked
immunosorbent assay (ELISA) following the manufacturer’s
instructions (BD Biosciences, USA). The effects on IL-8, MMP-
9, MCP-1, and TNF-α production were calculated by comparing
the percentages of the released agents to the stimulated control,
which lacked the test extracts/fractions/compounds.
Western Blotting
Neutrophils (4 × 106) were suspended in RPMI 1640 medium
and incubated for 40min at 37◦C in the presence or absence
of LPS (100 ng/mL) and in the presence or absence of the
test compounds. They were then centrifuged at 1500 RPM for
10min at 4◦C. Cells were lysed in ice-cold buffer containing
PBS, 5mM EDTA, 1% Triton X-100, phosphatase and protease
inhibitors, and the resulting lysates were centrifuged at 8,000
RPM for 15min at 4◦C. The proteins were separated by 12%
SDS-PAGE. Proteins were transferred to nitrocellulose filters and
immunoblotted with rabbit anti-p38MAPK, anti-ERK1/2, and
anti-JNK at 1:1000 dilutions and a rabbit anti-actin polyclonal
antibody at a 1:2000 dilution. Peroxidase-conjugated affinipure
goat anti-rabbit antibody was used as a secondary antibody at
a dilution of 1:10000. Finally, the blots were incubated with
chemiluminescent substrate for the detection of HRP (Thermo-
Scientific, USA) for 10–15min. Western blots were quantified
using the ImageJ 1.38 software after densitometric scanning of
the bands.
Statistical Analysis
The results were expressed as the mean ± SEM of three
independent experiments performed at least in duplicate. All
analyses were performed using Statistica 9 software. The
statistical significance of the differences between means was
established by ANOVA with Dunnett’s or Tukey’s post hoc test.
P-values below 0.05 were considered statistically significant.
RESULTS
Phytochemical Characterization and
Comparison of S. vulgaris From Bark, Fruit,
Flower and Leaf Infusions and Ethanolic
Extracts
The phytochemical analysis of S. vulgaris bark, fruit, flower
and leaf infusions and ethanolic extracts was performed
using a HPLC-DAD-MS/MS method, which allowed for the
identification or partial identification of 64 compounds (Table 1
and Figure 1) from the following groups: phenylethanoids
(compounds 27, 31, 36, 39, and 42), rare phenylethanoids
esterified with an oleoside 11-methyl ester (compounds 43, 49,
50, and 61), flavonoids (compounds 32, 33, and 35), other
phenolic compounds (1–3, 5–14, 17, 18, and 24), lignans
(compounds 21 and 37), iridoids (compounds 34 and 41),
secoiridoids (compounds 4, 15, 16, 20, 26, 28-30, 38, 40, 44–
46, 48, 51–57, 60, 62, and 63), together with eight unknown
compounds. Compounds 1, 2, 5, 7, 14–16, 27–29, 34, 36, 38,
41, 43–46, 48–50, 52–54, 61 were previously isolated as pure
compounds from S. vulgaris leaves, flowers, and bark (Kurkin
et al., 1989, 1990; Damtoft et al., 1995; Kikuchi et al., 2010;
Dudek et al., 2017). However, this is a first comprehensive
phytochemical analysis of a broad range of compounds from
different parts of the plant. Significant differences were observed
in the phytochemical profiles of different plant parts (Table 1 and
Figure 1). In bark extracts, themajor compounds were as follows:
syringin (14; Rt = 16.9min, m/z 417 [M-H+HCOOH]−),
demethyloleuropein (28; Rt = 28.2min, m/z 525 [M-H]−),
forsythoside B (31; Rt = 30.0min, m/z 755 [M-H]−), acteoside
(36; Rt = 31.4min, m/z 623 [M-H]−) and oleuropein (46;
Rt = 38.3min, m/z 539 [M-H]−). In fruit extracts, the major
compounds were as follows: nuzhenide (38; Rt = 33.0min, m/z
685 [M-H]−) and an oleonuezhenide isomer (55; Rt = 43.3min,
m/z 1071 [M-H]−). In flower extracts, the major compounds
were as follows: caffeoylglucaric acid (5; Rt= 10.1min, m/z 371
[M-H]−), quercetin rutinoside (32; Rt = 30.1min, m/z 609 [M-
H]−), acteoside (36; Rt= 31.4min,m/z 623 [M-H]−), oleuropein
(46; Rt = 38.3min, m/z 539 [M-H]−), oleoacteoside (49; Rt
= 40.1min, m/z 1009 [M-H]−) and oleonuezhenide (60; Rt
= 45.4min, m/z 1071 [M-H]−). In leaf extracts, the major
compounds were as follows: secologanoside (16; Rt= 17.3min,
m/z 389 [M-H]−), quercetin rutinoside (32; Rt= 30.1min, m/z
609 [M-H]−), syringalactone B (34; Rt = 30.5min, m/z 525 [M-
H]−), oleuropein (46; Rt = 38.3min, m/z 539 [M-H]−), 2′′-epi-
frameroside (53; Rt= 42.6min,m/z 601 [M-H]−), and ligstroside
(54; Rt = 43.1min, m/z 523 [M-H]−). The phytochemical
profiles of the infusions and ethanolic extracts were similar, and
only quantitative differences were observed.
Effect of Bark, Fruit, Flower and Leaf
Infusions and Ethanolic Extracts of
S. vulgaris on the Pro-inflammatory
Function of Stimulated Neutrophils
In all concentrations of the tested extracts, no significant
reduction in membrane integrity was observed in comparison
to the control using a propidium iodide assay (Figures 2A,B).
Activation of neutrophils by f-MLP results in degranulation and
a significant release of ROS compared to the untreated control
(Figures 2C,D). Additionally, stimulation with LPS resulted in
a significant release of proteinase MMP-9, chemokine IL-8, and
cytokine TNF-α (Figure 3). Incubation of stimulated neutrophils
with extracts at concentration ranges of 25–100µg/mL resulted
in a statistically significant and dose dependent reduction of ROS
production by all extracts over all tested concentrations. There
was no statistically significant difference between infusions and
ethanolic extracts (Figures 2C,D).
All infusions and extracts were able to inhibit the release
of IL-8 in a dose-dependent manner (Figures 3A,B). The effect
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TABLE 1 | Retention time, UV, and MS/MS data of the compounds present in extracts and infusions from S. vulgaris.
Compound RT (min) UV (nm) [M-H]− m/z Ion
fragmentation
BE BA FrE FrA FLE FLA LE LA References
1 Caffeoylglucaric acid (I) 5.5 326 371 353, 209, 190 − − − − + + + + Dudek et al.,
2017
2 Caffeoylglucaric acid (II) 8.3 325 371 353, 209, 190 − − − − + + + + Dudek et al.,
2017
3 Hydroxytyrosol hexoside 8.7 280 315 135 + + − − − − − − Bi et al., 2011
4 Oleoside 9.8 227 389 345, 227, 209,
183, 165, 121
+ + − − − − + + Li et al., 2017
5 Caffeoylglucaric acid (III) 10.1 325 371 353, 209, 190 − − + + + + + + Dudek et al.,
2017
6 p-coumaroylhexaric acid
(I)
11.5 313 355 337, 209, 190 − − − − + + − − Dudek et al.,
2017
7 Caffeoylglucaric acid (IV) 12.9 325 371 353; 209, 190 − − − − + + + + Dudek et al.,
2017
8 Caffeic acid hexoside (I) 13.3 325 341 251, 203, 179,
161, 135
− − − − + + − − Fusani et al.,
2016
9 Caffeic acid
hexo–rhamnoside
14.1 335 487 179, 135 + − − − − − − − Sanz et al., 2012
10 p-coumaroylhexaric acid
(II)
14.2 315 355 337, 209, 190 − − + + + + − − Dudek et al.,
2017
11 Caffeic acid hexoside (II) 14.6 332 341 179 + − − − − − − − Fusani et al.,
2016
12 Feruloylhexaric acid (I) 15.5 326 385 367, 209, 190 − − − − + + − − −
13 Feruloylhexaric acid (II) 16.5 326 385 367, 209, 190 − − − − + + − − −
14 Syringin 16.9 265 417* 371, 209 + + + + − − − − Tóth et al., 2016
15 Oleoside/secologanoside
11-methyl ester
17.0 225 403 371, 223, 179 − − − − + + + + Li et al., 2017
16 Secologanoside 17.3 233 389 345, 209, 183,
165, 121
+ + + + + + + + Li et al., 2017
17 Coniferaldehyde 18.9 343 177 − + + − − − − − − Sanz et al., 2012
18 Ferulic acid hexoside 19.5 325 355 217, 193 − − − − + − − − −
19 Unknown 19.8 233 447* 401 − − − − + + − − −
20 Oleoside/secologanoside
11-methyl ester
19.9 236 403 371, 223, 179 − − + + − − + + Li et al., 2017
21 Olivil hexoside 21.1 278 583* 537, 345, 375,
195, 179
+ − − − − − − − Sanz et al., 2012
22 Unknown 21.3 212 377 197, 153 − − − − + − − − −
23 Unknown 22.2 312 687 315 − − − − + + − − −
24 Caffeic acid derivative 23.2 325 335 179, 135 − − − − + + − − −
25 Unknown 24.3 215 375 357, 191, 129 − − − + + + + + −
26 Safghanoside C 25.1 222 671 491, 371, 299,
281, 191
+ − − − + + − − Takenaka et al.,
2002
27 Echinacoside 25.8 328 785 623, 477, 461 + − − − + + + − Tóth et al., 2016
28 Demethyloleuropein 28.2 215 525 481, 389, 195 + + − − + + + + Dudek et al.,
2017
29 Oleoside dimethyl ester 28.6 320 463* 417, 255, 185 − − − − + + + − −
30 10-hydroxyoleuropein 29.0 235 555 537, 403, 393,
322
− − + + − − − + Tóth et al., 2016
31 Forsythoside B 30.0 330 755 593, 461, 447,
315
+ + − − − − − − Guo et al., 2007
(Continued)
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TABLE 1 | Continued
Compound RT (min) UV (nm) [M-H]− m/z Ion
fragmentation
BE BA FrE FrA FLE FLA LE LA References
32 Quercetin rutinoside 30.1 256, 355 609 301 + + + + + + + + Li et al., 2017
33 Kaempferol rutinoside 30.2 265, 341 593 285 − − − − + + − − Guo et al., 2007
34 Syringalactone B 30.5 228, 280 525 363, 249 + + − + + + + + Dudek et al.,
2017
35 Quercetin hexoside 30.9 255, 353 463 301 + + − − + − + + −
36 Acteoside 31.4 330 623 461, 315, 161,
135
+ + − − + + + − Tóth et al., 2016
37 Pinoresinol hexoside 32.9 278 519 357 + − − − − − − Kicel et al., 2015
38 Nuzhenide 33.0 223 685 523, 453, 299 + − + + + + + − Dudek et al.,
2017
39 Acteoside isomer 33.7 335 623 461, 315 + + − − + − + − −
40 Nuzhenide isomer 34.8 275 685 523, 453, 299 + + − − − − − − −
41 Syringalactone A 35.1 223 509 347, 233, 207,
165
+ − − − − + + + Dudek et al.,
2017
42 Lipedoside A 35.2 324 607 461, 443, 315,
161, 135
+ + − − + − + + He et al., 1994
43 Oleoechinacoside 35.4 334 1172 1009, 997, 785,
623
− − − − + + − − Dudek et al.,
2017
44 Demethyloleoneonuezhenide35.7 231 1074 701, 539 − − − − + − − − Dudek et al.,
2017
45 Neonuezhenide 37.5 217 701 377, 307, 275 + − − − − − + − Dudek et al.,
2017
46 Oleuropein 38.3 280 539 377, 307, 275,
191
+ + + + + + + + Dudek et al.,
2017
47 Unknown 38.7 280 461 419, 363, 307 − − − − − − + − −
48 Demethyloleonuezhenide 39.1 215 1057 685, 523, 453 + + − − + + − − Dudek et al.,
2017
49 Oleoacteoside 40.1 330 1009 847, 745, 665,
623, 461
+ + − − + + + − Dudek et al.,
2017
50 Isooleoakteoside 41.4 330 1009 847, 745, 665,
623, 461
+ + − − − − + − Dudek et al.,
2017
51 Lucidumoside C 41.4 275 583 537, 403, 223 − − + − − − − − Li et al., 2017
52 Oleoneonuezhenide 41.6 222 1087 701, 539 − − − − + + − − Dudek et al.,
2017
53 2′′-epi-frameroside 42.6 235 601 403, 197 + + − + + + + + Takenaka et al.,
2002
54 Ligstroside 43.1 275 523 361, 291, 259 + + + − + − + − Dudek et al.,
2017
55 Oleonuezhenide isomer 43.3 234 1071 773, 687, 523 − − + + − − − − −
56 Neooleuropein 43.5 215 661 429, 345 + − − − + + + − Kuwajima et al.,
1992
57 Isoligustroside 43.6 275 523 361, 291 − − − − − − + + Kikuchi et al.,
1987
58 Unknown 44.5 320 1167 − + − − − − − − − −
59 Unknown 45.1 218 347 233, 209, 139 − − − − − − + − −
60 Oleonuezhenide 45.4 217 1071 1041, 771, 685 + + + + + + + − Dudek et al.,
2017
61 Syringaoleoacteoside 46.2 334 1395 1051, 1009, 565 − − − − + + + − Dudek et al.,
2017
62 Hydroxyframoside 48.1 275 645 483, 413, 345,
275
+ − − − + + + + Iossifova et al.,
1998;
63 Framoside 49.8 280 629 491, 329 − − − − − − + − Tanahashi et al.,
1992
64 Unknown 50.9 217 271 177, 151 − − − − + − − − −
*[M-H+HCOOH]−
E, ethanolic extract; A, infusion; B, bark; Fr, fruit; FL, flower; L, leaf. Bold, most abundant fragmentation ion.
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FIGURE 1 | HPLC-DAD chromatograms of the ethanolic extracts of S. vulgaris bark (A); fruit (B); flower (C); leaf (D) recorded at 240 nm.
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FIGURE 2 | Effect of S. vulgaris ethanolic extracts (A) and infusions (B) at concentrations of 25–100µg/mL on neutrophil membrane integrity {[%] of propidium iodide
positive cells IP (+)}; effect of S. vulgaris ethanolic extracts (C) and infusions (D) at concentrations of 25–100µg/mL on ROS production by stimulated neutrophils [%].
Data were expressed as the mean ± SEM; at least three independent experiments were conducted, and they were assayed in duplicate. Experiments were performed
using cells from different donors. Statistical significance #P < 0.01 compared to the non-stimulated control; *P < 0.05, **P < 0.01, ***P < 0.001 decrease compared
to the stimulated control.
was significant (p < 0.001) for all concentrations tested of the
flower infusion and flower and leaf extracts. The effect on TNF-
α production/release was less pronounced and was statically
significant only at the highest concentration of 100µg/mL
for bark and leaf ethanolic extracts and the flower infusion
(Figures 3C,D). MMP-9 release was inhibited the most by bark
and fruit ethanolic extracts (Figures 3E,F). In general, ethanolic
extracts were slightly more active than infusions, and flower
and leaf preparations were more active than bark and fruit
preparations. In a previous study, we isolated 29 compounds
that were hydroxycinnamoyl and secoiridoid derivatives (Dudek
et al., 2017) from the flower extract with moderate anti-
inflammatory activity. In this study, we performed a bioassay-
guided isolation of active compounds from the leaf extract.
Bioassay-Guided Isolation of Active
Compounds From Leaf Extract
The crude alcoholic leaf extract was fractionated using a
Diaion HP-20 and eluted with a 5-step H2O-MeOH gradient
(100:0 → 0:100) to obtain six main fractions (F1-F6) based
on their TLC and HPLC profiles. The activities of the
fractions were evaluated based on IL-8 inhibition and TNF-
α release. Only fraction F6 inhibited the IL-8 release at a
concentration of 50µg/mL in a statistically significant manner
(p < 0.001). Interestingly, fraction F2 stimulated TNF-α
production, while fractions F5 and F6 decreased the production
of this cytokine (Figure 4). Fraction 5 was rich in oleuropein.
Fraction 6, which contained several compounds, was subject
to further fractionation on a Sephadex LH-20 with H2O-
MeOH (50:50) and then preparative chromatography was used
to isolate the following seven compounds: 2′′-epiframeroside
(I), oleonuezhenide (II), oleuropein (III), ligstroside (IV),
neooleuropein (V), hydroxyframoside (VI), and framoside (VII)
(Figure 4). The structures of these compounds (Figure 5) were
confirmed based on their 1H and 13C NMR spectra, which
were compared with reference data (Fukuyama et al., 1987;
Damtoft et al., 1992; Kuwajima et al., 1992; Tanahashi et al., 1992;
Iossifova et al., 1998; Konno et al., 1998; Takenaka et al., 2002).
Analysis of the extracted ion intensity for single compounds in
each extract confirmed that 2′′-epiframeroside (I), oleuropein
(III), ligstroside (IV), neooleuropein (V), hydroxyframoside
(VI), and framoside (VII) were the major compounds present
in leaf extract. Only oleonuezhenide (II) was present in a higher
concentration in the flower extract (Figure 2S).
Effect on Cytokine/Chemokine Production,
MAP Kinases and NF-kB Activation
Lipopolysaccharide stimulation of human neutrophils resulted
in the induction of the production/release of chemokines IL-
8 (neutrophil chemotactic factor) and MCP-1 (monocyte
chemoattractant protein 1) along with cytokine TNF-α
in comparison to cells that were not stimulated. Isolated
compounds I, II, V, VI, and VII were tested at concentrations
of 10, 25, and 50µM, and their activity was compared with
oleuropein and ligstroside, the characteristic compounds of
the Oleacea family that were also isolated from active fraction
F6, and with the positive control clarithromycin, a macrolide
antibiotic which has been shown to inhibit the pro-inflammatory
function of neutrophils. At all concentrations of the tested
compounds, no significant reduction in membrane integrity
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FIGURE 3 | Effect of S. vulgaris ethanolic extracts (A) and infusions (B) at concentrations of 25–100µg/mL on IL-8 production by stimulated neutrophils [%]; effect of
S. vulgaris ethanolic extracts (C) and infusions (D) at concentrations of 25–100µg/mL on TNF-α production by stimulated neutrophils [%]; effect of S. vulgaris
ethanolic extracts (E) and infusions (F) at concentrations of 25–100µg/mL on MMP-9 production by stimulated neutrophils [%]; Data were expressed as the mean ±
SEM; at least three independent experiments were conducted, and they were assayed in duplicate. Experiments were performed using cells from different donors.
Statistical significance #P < 0.01 compared to the non-stimulated control; *P < 0.05, **P < 0.01, ***P < 0.001 decrease compared to the stimulated control.
was observed in comparison to the control using a propidium
iodide assay (Figure 6A). Neooleuropein was the most active
compound toward inhibiting IL-8 secretion (Figure 6B); at
concentrations of 25 and 50µM, the release was reduced to
50.2% (p < 0.001) and 31.4% (p < 0.001) in comparison with
LPS-stimulated cells (100% of release), respectively. The effect
of neooleuropein at 50µM was more significant than the effects
of 2′′-epiframeroside (p < 0.001), oleonuezhenide (p < 0.001),
ligstroside (p < 0.001), and oleuropein (p < 0.001) at the
same concentration. Framoside and neooleuropein were the
most active in reduction of TNF-α release at all concentrations
tested (Figure 6C). The effect of framoside at 50µM was more
significant than the effect of 2′′-epiframeroside (p < 0.001),
oleonuezhenide (p < 0.001), and ligstroside (p < 0.001) at the
same concentration. Additionally, neooleuropein was statistically
more active than the positive control clarithromycin (p < 0.05).
All isolated compounds except oleonuezhenide significantly
inhibited the release of MCP-1 from stimulated neutrophils
(Figure 6D). However, only neooleuropein was active at all
concentrations tested (Figure 6D). The effect of neooleuropein
at 10µM was more significant than the effects of framoside
(p < 0.05) and hydroxyframoside (p < 0.05); at 25µM, the
effect was more significant than the effects of framoside (p <
0.01), hydroxyframoside (p < 0.01) and oleonuezhenide (p <
0.01), while at 50µM, the effect was more significant than the
effect of oleonuezhenide (p < 0.001) and the positive control
clarithromycin (p < 0.01) at the same concentration. In general,
neooleuropein was as effective or more effective in comparison
with oleuropein and clarithromycin in reducing the release of
pro-inflammatory agents.
The molecular mechanism of the observed effect was related
to MAP kinases and NF-kB activation. Lipopolysaccharide
stimulation of human neutrophils resulted in the rapid
phosphorylation of proteins, including p38 MAPK, p42/44
extracellular signal-regulated kinase (ERK), and c-Jun NH2-
terminal kinase (JNK), as well as the translocation of NF-kB-
p65 from the cytoplasm to the nucleus. Our data show that
the LPS-induced phosphorylation of p38 MAPK and ERK1/2
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FIGURE 4 | Effect of S. vulgaris leaf extract fractions on IL-8 production by stimulated neutrophils [%] (A) on TNF-α production by stimulated neutrophils [%] (B);
scheme of fractionation and compounds isolation from leaf extract (C). Data were expressed as the mean ± SEM; at least three independent experiments were
conducted, and they were assayed in duplicate. Experiments were performed using cells from different donors. Statistical significance #P < 0.01 compared to the
non-stimulated control; *P < 0.05, **P < 0.01, ***P < 0.001 decrease compared to the stimulated control.
was decreased by neooleuropein and oleuropein, while JNK
phosphorylation was decreased by all tested compounds at
50µM (Figure 7A). The inhibition of the translocation of
NF-kB-p65 from the cytoplasm to the nucleus was observed
most significantly for oleuropein; however, the activity of
neooleuropein was evident but more modest (Figure 7B).
DISCUSSION
S. vulgaris preparations have been traditionally used in Europe to
treat several ailments connected with inflammation and, together
with Asian Syringa sp., appear to be an interesting source of
diverse bioactive structures (Su et al., 2015). The aim of the
present study was to investigate the effects of phytochemically
characterized (HPLC-DAD-MSn) extracts that have been used
in traditional medicine (infusions and ethanolic extracts) from
different parts of the common lilac (bark, fruits, leaves, and
flowers) on the pro-inflammatory functions of neutrophils and
to isolate the most active compounds using bioassay-guided
fractionation. Finally, we focused on the activity and molecular
mechanisms of action of the isolated compounds able to regulate
neutrophil inflammation.
For the first time, we provided a comprehensive
phytochemical analysis of common lilac and a comparison
of different parts such as bark, fruit, flower, and leaf
infusions/extracts (Table 1, Figure 1). We were able to identify
or partially identify 64 compounds, and we also demonstrated
significant differences in the phytochemical profiles of different
parts of the plant (Figure 1). In general, the major compounds in
S. vulgaris are as follows: caffeoylglucaric acid (5), syringin (14),
secologanoside (15), demethyloleuropein (28), forsythoside B
(31), quercetin rutinoside (32), syringalactone B (34), acteoside
(36), nuzhenide (38), oleuropein (46), oleoacteoside (49),
2′′-epi-frameroside (53), ligstroside (54), oleonuezhenide isomer
(55), and oleonuezhenide (60). The presence of phenyl ethanoids
31, 36, 49, and secoiridoids 28, 38, 46, 53, 54, 55, 60 as major
compounds seems to be specific to this species, while lignans
are more characteristic of S. pinnatifolia (Su et al., 2016), and
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FIGURE 5 | Structures of isolated compounds.
FIGURE 6 | Effects of isolated compounds at concentrations of 10–50µM, ligstroside (ligs), oleuropein (oleu) and a positive control clarithromycin (clari) at 50 µM: (A)
membrane integrity {[%] of propidium iodide positive cells IP (+)}; (B) inhibition of IL-8 production from stimulated neutrophils [%]; (C) inhibition of TNF-α production
from stimulated neutrophils [%]; (D) inhibition of MCP-1 production from stimulated neutrophils [%]; Data are expressed as the mean ± SEM; at least three
independent experiments were performed, and they were assayed in duplicate. Experiments were performed using cells from different donors. Statistical significance
#P < 0.01 compared to the non-stimulated control; *P < 0.05, **P < 0.01, ***P < 0.001 decrease compared to the stimulated control (LPS).
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FIGURE 7 | Effects of compounds at 50µM on the phosphorylation of p38 MAPK, p42/44 ERK and JNK in LPS-activated human neutrophils (A); and NF-kB p65
translocation to the nucleus (B). Phosphorylation of p38, p42/44 ERK and JNK, and NF-kB p65 translocation were analyzed by an immunoblot assay using antibodies
against the phosphorylated form and based on total protein. Representative images are shown (left A,B). Western blots for p38 MAPK, p42/44 ERK and JNK were
quantified using the ImageJ 1.38 software after densitometric scanning of the bands of at least two independent experiments. Statistical significance **P < 0.01,
***P < 0.001 decrease compared to the stimulated control (right A). NST- not stimulated cells, LPS- stimulated cells, neooleuropein (NOL), 2′′-epiframeroside (EFR),
hydroxyframoside (HFR), framoside (FR), oleuropein (OLE).
secoiridoids named safghanosides are more characteristic of S.
afghanica (Takenaka et al., 2002). S. reticulata contains similar
phenyl ethanoids and secoiridoids as S. vulgaris; however, the
presence of the iridoid syringapicroside and its derivatives in S.
reticulatamay distinguish both species phytochemically (Kikuchi
et al., 1989; Machida et al., 2002).
In the neutrophil model of the pro-inflammatory state,
all extracts and infusions were able to significantly reduce
ROS production (Figures 2C,D). This is probably related
to the presence of compounds that contain caffeic acid, p-
coumaric acid, hydroxytyrosol or tyrosol phenolic moieties,
which display antioxidant properties (Bi et al., 2011; Dudek
et al., 2017). All extracts and infusions were especially active
in decreasing IL-8 production (Figures 3A,B) and, to a lesser
extent, MMP-9 and TNFα release (Figures 3C–F). However,
the leaf extract fractionation revealed that fraction F2 increased
TNFα production, while fractions F5 and F6 significantly
decreased the production of this cytokine (Figure 4). A similar
phenomenon was observed for Echinacea purpurea extracts
(Todd et al., 2015). Further bioassay-guided fractionation of
fraction F6 led to the isolation of the following secoiridoids:
2′′-epiframeroside, oleonuezhenide, oleuropein, ligstroside,
neooleuropein, hydroxyframoside, and framoside (Figure 5). We
compared the anti-inflammatory activity of 2′′-epiframeroside,
oleonuezhenide, neooleuropein, hydroxyframoside, and
framoside with oleuropein and ligstroside, two well-known
compounds that are widespread in the Oleaceae family
(Jensen et al., 2002). Apart from oleonuezhenide, a dimeric
secoiridoid, all compounds exhibited significant inhibition of
pro-inflammatory cytokine and chemokine release/production.
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2′′-epiframeroside primarily inhibited MCP-1 release, while
neooleuropein appeared as themost active compound (Figure 6).
Neooleuropein inhibited the secretion of IL-8 more significantly
than oleuropein (Figure 6B) and secretion of TNF-α and MCP-1
more significantly than the positive control clarithromycin
(Figures 6C,D).
The mechanism of LPS stimulation of human neutrophils
is connected with a functional response through the activation
of mitogen-activated protein kinases (MAPKs): p38 kinase,
p42/44 extracellular signal-regulated kinase (ERK) and c-Jun
NH2-terminal kinases (JNKs) (Nick et al., 1999; Arndt et al.,
2004; Simard et al., 2015). Neooleuropein and oleuropein
significantly inhibited the phosphorylation of the MAP kinases
ERK1/2, p38 and JNK after LPS stimulation (Figure 7A), as well
as the translocation of NF-kB p65 to the nucleus (Figure 7B).
Neooleuropein was more active toward the inhibition of p38
phosphorylation, while oleuropein more significantly inhibited
NF-kB p65 translocation, and all tested compounds inhibited
JNK phosphorylation (Figures 7A,B). The activation of p38
MAPK in neutrophils is connected with the synthesis of TNF-
α and IL-8 (Nick et al., 1999). ERK activation also led to the
elevated expression of pro-inflammatory cytokines in human
neutrophils (Simard et al., 2015). In our study, neooleuropein was
the most active compound in inhibiting p38 phosphorylation,
which correlated with a significant inhibition of IL-8 production.
However, oleuropein was more active in NF-kB inhibition,
which has been shown to affect cytokine gene expression in
human neutrophils, although it has a less marked effect on
IL-8 gene expression (Cloutier et al., 2007). The inhibition
of MCP-1 production by all tested compounds was correlated
with the inhibition of JNK phosphorylation, which has been
strictly correlated with MCP-1 expression but not IL-8 or TNF-
α expression (Arndt et al., 2004). Interestingly, framoside was
able to significantly decrease the TNF-α and IL-8 secretion
(Figures 6B,C) without affecting MAPKs nor NF-kB activation
(Figure 7). It appears that framoside, the most lipophilic
compounds, displays a different mode of action. As in human
neutrophils other pathways such as PI3K are also involved in IL-
8 production and acts downstream of p38 MAPK (Fortin et al.,
2011).
The observed significant inhibition of TNF-α and chemokine
(IL-8 and MCP-1) production is of special interest for treating
inflammatory diseases such as rheumatic arthritis, respiratory
diseases, and arteriosclerosis. The pro-inflammatory effect of
TNF-α mainly results from its capacity to stimulate the
expression of adhesive molecules in endothelial cells and
promote neutrophil attachment to the vascular endothelium
in addition to their degranulation and pro-oxidative activity
(Witko-Sarsat et al., 2000). MCP-1 (CCL2) is able to stimulate
chemotaxis of monocytes and cellular events associated with
chemotaxis and integrin expression. At high concentrations,
MCP-1 elicits a respiratory burst leading to the generation of
ROS (Palomino and Marti, 2015). IL-8 (CXCL8), one of the
most important cytokines produced by neutrophils, mediates
chemotaxis, releases granule enzymes, and promotes integrin
expression and adhesion to endothelial cells (Gabrilovich, 2013).
Although the anti-inflammatory and antioxidant activity of
oleuropein and ligstroside was intensively studied, this is the first
report concerning the biological activity of 2′′-epiframeroside,
neooleuropein, hydroxyframoside, and framoside. In particular,
neooleuropein appears to an interesting compound for further in
vitro and in vivo study.
CONCLUSIONS
The present study demonstrated that the common lilac, which
has been traditionally used in Europe as a medicinal plant, is a
valuable source of active compounds, especially neooleuropein,
for further research regarding their use in treating inflammatory
diseases that result from the excessive activation of neutrophils.
The observed decreases in the production of cytokines, such
as TNF-α, IL-8, MCP-1, depend on the inhibition of the
phosphorylation of MAP kinases.
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As antique as Dioscorides era are the first records on using Chelidonium as a remedy to
several sicknesses. Inspired by the “signatura rerum” principle and an apparent ancient
folk tradition, various indications were given, such as anti-jaundice and cholagogue,
pain-relieving, and quite often mentioned—ophthalmological problems. Central and
Eastern European folk medicine has always been using this herb extensively. In this
region, the plant is known under many unique vernacular names, especially in Slavonic
languages, associated or not with old Greek relation to “chelidon”—the swallow. Typically
for Papaveroidae subfamily, yellow-colored latex is produced in abundance and leaks
intensely upon injury. Major pharmacologically relevant components, most of which were
first isolated over a century ago, are isoquinoline alkaloids—berberine, chelerythrine,
chelidonine, coptisine, sanguinarine. Modern pharmacology took interest in this herb
but it has not ended up in gaining an officially approved and evidence-based herbal
medicine status. On the contrary, the number of relevant studies and publications
tended to drop. Recently, some controversial reports and sometimes insufficiently
proven studies appeared, suggesting anticancer properties. Anticancer potential was
in line with anecdotical knowledge spread in East European countries, however, in the
absence of directly-acting cytostatic compounds, some other mechanisms might be
involved. Other properties that could boost the interest in this herb are antimicrobial
and antiviral activities. Being a common synanthropic weed or ruderal plant, C. majus
spreads in all temperate Eurasia and acclimates well to North America. Little is known
about the natural variation of bioactive metabolites, including several aforementioned
isoquinoline alkaloids. In this review, we put together older and recent literature data
on phytochemistry, pharmacology, and clinical studies on C. majus aiming at a critical
evaluation of state-of-the-art from the viewpoint of historical and folk indications. The
controversies around this herb, the safety and drug quality issues and a prospective role
in phytotherapy are discussed as well.
Keywords: isoquinoline alkaloids, chelidonine, chelerythrine, cytotoxic, anti-inflammatory, anti-microbial
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INTRODUCTION
“No less extraordinary is the property of the herb Celandine;
which, it is said, if any man shall have this herb, with the heart
of a Mole, he shall overcome all his enemies, all matters in suit,
and shall put away all debate,” and “if before named herb be
put upon the head of a sick man, if he shall die, he shall sing
anon with a loud voice, if not, he shall weep”; and “it bringeth
the business begun to an end,” so wrote Albertus Magnus in
thirteenth century A.D. (Best and Brightman, 1999). Nowadays,
mankind would definitely benefit from such a miraculous
remedy. Unfortunately, such claims about Chelidonium majus
L.—the Greater Celandine, have not been verified according to
the modern evidence-based approach (but no data on rigorous
testing toward such properties actually exist in the literature).
However, through years of investigations, many other properties
ascribed to this inconspicuous but characteristic plant have been
confirmed or re-discovered. Several others could not be positively
confirmed. Despite the widespread use in folk medicine and in
official phytotherapy, both in Europe and in Traditional Chinese
Medicine, the celandine herb did not join themost popular herbal
remedies such as chamomile, valerian, St. John’s wort or ginseng.
It has been listed in pharmacopeias and sold in pharmacies
in parallel to the spontaneous collection by people seeking
drugs against gastrointestinal disorders, cancer, infections, but
especially against warts and any skin protuberances. This was
the reason to combine the available historical and ethnobotanical
data with the state-of-the art in pharmacology of C. majus and
its components in the present review (Supplementary Figure 1).
To date, only a couple of papers have provided review of
pharmacological and phytochemical knowledge with the EMA
assessment report from 2011 (European Medicines Agency,
2011) and the review (Gilca et al., 2010), being the most
recent and comprehensive ones. Biswas (2013) has published
a short review with overview of selected bioactivities but
only covering a fraction of available literature and suggesting
future directions of research. Similar approach to review the
C. majus properties was used by Arora and Sharma (2013) who
summarized some activities based on selected literature and
included pharmacognostic characteristics. Gilca et al. (2010) has
classified the pharmacological evidence into the categories related
to traditional usage, also from the viewpoint of the TCM, such as
anti-infectious, spasmolytic, gastric and hepatic, and anticancer.
They also listed traditional indications that had not been
confirmed by modern research, such as diuretic, anti-edema,
expectorant and antitussive, pulmonary, and ophthalmological
diseases. Some current information is also available in herbal
books and compendia (Wichtl, 2004) or in the Internet. The latter
source is of course difficult to verify.
Therefore, we chose to include a possibly high number of
available literature, by selecting records from database search
(PubMed, Scopus, Google Scholar) with the term “chelidonium”
or “celandine” and manually eliminating papers pertaining to
field botany, ecology and other aspects not relevant to medicinal
use of this plant. Some references that have been reviewed earlier
(e.g., in Colombo and Bosisio, 1996) were also not cited directly
if the information was redundant. Some information about the
historical applications and folk medicine in Central and Eastern
Europe were obtained from sources available in local libraries. In
particular, we describe the phytochemical composition of various
parts of the plant, the methods used for obtaining extracts and
analysis of the herbal material. Further, we critically summarize
the most credible research on bioactivity and clinical efficacy of
various products and substances from C. majus. In addition, the
highly debated and controversial issue of the patented, apparently
semi-synthetic drug NSC-631570 (Ukrain R©) promotedmainly as
a cancer cure was discussed (Ernst and Schmidt, 2005). With this
review, we hope to encourage more research and attract interest
to this quite common but not always adequately respected weed.
BOTANICAL DESCRIPTION
C. majus L. (Papaveraceae1) is a short-lived hemicryptophyte. It
has up to 1m high stem, branched and sparsely pubescent. The
alternately placed leaves are light bluish at the bottom and green
at the top. The basal leaves are long-petioled, with the obovated
in contour, pinnatosected leaflets with 5–7 lobed segments. The
apical leaves are short-petioled, with 3-lobed leaflet. From April
to October the plant produces umbellate inflorescences with 2–
6 flowers, which have 4 bright yellow petals and two whitish,
early dropping sepals. The fruit is an elongated (3 cm), pod-
shaped, multiseeded capsule, dehiscent with two valves. The
seeds are shiny, ovate and dark brown or black, with elaiosomes.
The underground part is a short tap root with numerous and
elongated lateral roots. The whole plant contains yellow to orange
latex.C. majus grows in the lowlands and foothills in leafy forests,
in brushwood, parks, gardens, on the roadsides and around
buildings. It prefers moist soils rich in nitrogen and organic
matter (Zarzycki et al., 2002).
Distribution Area
C. majus is native in Europe, western and central part of Asia
and in northern Africa. It occurs from Portugal in the West, to
Central, Eastern to Northern Europe. The Asian range covers
Turkey, Iran, Kazakhstan, Mongolia, Caucasus, and Siberia. In
North America it is an introduced plant.
Taxonomy and Nomenclature
Until the mid-twentieth century the genus Chelidonium L.
was monotypic with C. majus L. as the only species. In 1982
Krahulcowa based on cytotaxonomic study of C. majus L.
sensu lato, proposed to divide the genus into two microspecies.
She proposed C. majus L. (2n = 12) distributed in Europe,
Siberia, and China and a new species C. asiaticum (Hara)
Krahulcova (2n = 10), an East Asian vicariant (Krahulcová,
1982). Aside from the difference in chromosome numbers and
distribution area, C. asiaticum slightly differs morphologically
from C. majus. It is more hairy, with narrower and sharper leaf
lobes. Within C. majus she distinguished European C. majus L.
subsp. majus with more laciniate lobes of leaves, and C. majus.
1The Plant List. Available online at: http://www.theplantlist.org/1.1/browse/A/
Papaveraceae/Chelidonium/ (Accessed Sept 29, 2017).
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subsp. grandiflorum (DC.) Printz, in South Siberia and China
(Krahulcová, 1982).
(Krahulcová, 1982) Name of the genus derives from Greek
(χελιδóνιoν) with chelidon (χελιδóν) meaning swallow (a bird)
for the plant usually blooms simultaneously with arrival of these
birds. The specific epithetmajus in Latin means bigger.
Common English name: Greater celandine.
The name celandine originates from Medieval Latin word
celidonia, a phonetic variant of Latin chelidonia, which was
recorded by Pliny. Similarly, the German name, Schöllkraut,
comes from Schellkraut (Bauhin, 1651), which is derived from
Latin-Greek chelidonium (Waniakowa, 2015).
Common and Folk Names in Some European
Languages
Albanian—latrapeci, bar saraleku; Belarussian—padtynnik,
barodaunik (wart herb); Bosnian—rosopas; Bulgarian—zmiysko
mlako; Croatian—zmijino mlijeko, rosopas; Czech—
vlaštovicˇník, celadona, celduneˇ, cen dalie, dravnicovina,
hadí mlícˇ, krkavník; Dutch—stinkende gouwe; English—
Tetterwort, devils’s milk, rock poppy; French—grande
chélidoine Éclair, herbe aux boucs, herbe a l’hirondelle;
German—Schöllkraut, Gilbkraut, Goldwurz, Schwalbenkraut,
Warzenkraut; Italian—celidonia, cinerognola, Montenegrin—
rusopas, rusa; Polish—glistnik jaskólcze-ziele, celidonia,
cyndalia, cencylja, glistewnik, glis´nik, niebospad, złoty groszek,
złotnik, zółte ziele, zółte kwiatki, roztopas´c´; Ukrainian—
hladyshnyk, hnystnyk, zhovtyi molochay, smetannyk, chystotil;
Romanian: rostopasca˘; Russian—chistotel; Rusyn—rostopast’;
Serbian—rusopas, rusa, rusomacˇa; Spanish—Golondrinera,
Hierba de las verrugas (wart herb).
Chelidonium majus IN FOLK MEDICINE
History of Usage
C. majus has been known as medicinal species since the very
Antiquity. Medicinal properties of C. majus were described
by Dioscorides and Pliny the Elder in the first century AD.
Dioscorides in De Materia Medica states that celandine begins
to blossom when the swallows arrive and withers when they
depart. He also refers to a lore saying that swallows restore sight
to their blind nestlings with use of celandine (Osbaldeston and
Wood, 2000). Pliny the Elder repeats these accounts in Naturalis
Historiae (Jones, 1966).
The foremost medicinal use of celandine, described since the
ancient times until the sixteenth century, was treating visual
impairment and eye diseases. For such conditions, Dioscorides
advised to use herb juice, boiled with honey in a brass vessel.
The juice could also be dried in the shade and the resulting small
pellets were ingredients of other medicinal products. According
to Dioscurides celandine soaked in wine together with anise
fruits was helpful in treating jaundice and dermatologic disorders
such as herpes. Besides, chewing on a root relieved toothache
(Osbaldeston and Wood, 2000). Pliny advised a kind of eye
lotion, which takes its name, chelidonia, from the name of the
plant (Jones, 1966).
Celandine was an admired medicinal plant during the Middle
Ages, mostly used to cure eye diseases, for throat cleansing,
treatment of ulcers and skin eczema as well as against colic
and jaundice (Mayer et al., 2003). In 1080, French monk
and physician Odo Magdunensis wrote De viribus herbarum,
also known as Macer floridus, a botanical poem describing
medical effects of 77 plants. One of the chapters of M.
floridus deals with medicinal application of celandine in “visual
impairment as well as skin and liver conditions” (Mayer et al.,
2003). Hildegard of Bingen wrote about celandine in her work
Liber subtilitatum diversarum naturarum creaturarum created
during 1150–1160A.D. and finally published in 1533. Hildegard
recommended celandine juice to enhance sight and juice mixed
with tallow as a cure for skin ulcer (Mayer et al., 2003).
Moreover, celandine would be a strong aphrodisiacum, but
causing infertility on ladies. Breathing the smell of the plant by
spouses prevents arguments. Celandine was also recommended
by to treat jaundice and against hair overgrowth (Czekan´ski,
2007).
Since the sixteenth century, according to Paracelsus’s
signature doctrine, celandine was used to treat jaundice and
liver diseases (Rostanski, 1997). C. majus was described in
comprehensive botanical medical works of scholars such as:
Joannes Minoritanus, Marcello Vergili, Hieronymus Bock,
Leonhard Fuchs, Pierandrea Matthioli, and Adam Lonicer.
The authors refer to antique sources and recommend using
celandine to treat eye and skin conditions. According to Lonicer,
to cure various dermatologic diseases, known in those days as
“leprosy,” the juice of the root of celandine had to be applied on
the skin, conjointly with drinking the juice mixed with syrup of
common fumitory (Fumaria officinalis) twice a day for 9 days
(Mayer et al., 2003). At the turn of the sixteenth and seventeenth
century two large works on herbs and their applications were
written in Poland. The first is Herbarz Polski by Marcin of
Urz ¸edowo, printed in 1595 and the second is Herbal by Simon
Syrenius, published in 1613. Marcin of Urz ¸edowo described,
based on works of Dioscorides, uses of celandine to treat eye
diseases, jaundice, wounds, toothache, and colic. To cure sight
impairment, herb juice boiled with honey or pellets made of
juice dried in shade should be used. Cataract, on the other hand,
should be treated with juice draining from a broken stem or
root of the plant. In case of jaundice, root of celandine should
be boiled in white wine and the decoction should be drunk for
a few days. The crashed root with wine was drunk to treat colic
and applied on wounds. Applying a piece of root of celandine to
an aching tooth, relieved the pain (Marcin of Urz ¸edowo, 1595).
Simon Syrenius, described celandine-based recipes used in
eye diseases. The main ingredient of such medicines is fresh
celandine juice. As one of the few authors, Syrenius considered
the juice irritative and therefore recommended mixing it with
small amounts of vinegar, milk, or rose water. He also advised
drinking a decoction of celandine roots cooked in wine with
anise or a mixture of powdered root with vinegar before bedtime
to treat jaundice, colic, and stomach ache. In case of toothache
he advised to rub teeth with powdered root with vinegar. Body
ulcers and scabs on the head skin can be cured with a salve of
powdered rootmixedwith pork fat and vinegar. Alternatively, the
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powdered root alone could be put directly on the ulcers. Syrenius
also describes the diaphoretic and diuretic effects of the herb
along with the roots or the root itself. The root boiled in wine has
a diuretic effect. As diaphoretic remedy Syrenius recommended
taking dry bath of celandine herb, which would cause extensive
sweating and expulsion of excess water from the body as well
as drinking decoction from roots boiled in rose vinegar or
white wine with great water dock (Rumex hydrolapathum). In
addition, the celandine could be used to dye the hair yellow,
and to lighten the freckles and hyperpigmentation on the face
(Syrenius, 1613).The British Flora Medica (Barton and Castle,
1845) cites the traditional applications of C. majus in treatment
of jaundice, visceral obstructions, fevers, dropsies, scrofula,
syphilitic aﬄiction, gout, cataract, ophtalmia, and specks as
described previously by Dioscorides and Galen.
In countries, where C. majus is the native species, it became
one of the most widespread drug of folk herbal medicine. The
scope of its applications in folk medicine shows high similarity
among many regions of Central and Eastern Europe. It is worth
to mention its prevalent application to treat warts, eczema
and other skin diseases, gastrointestinal parasites, jaundice, and
liver complaints, inflammatory eye infections and other diseases,
including cancer.
Skin Diseases
In folk medicine, C. majus was most commonly used to remove
warts. Herb juice or latex were used most frequently for this
purpose, however, use of leaves and flowers was also noted. In
Poland it was common to rub the fresh juice from the broken
stem of the celandine onto warts (DeVerdmon, 1936; Kuz´niewski
and Augustyn-Puziewicz, 1999; Kujawska et al., 2016). In the
Bieszczady Mountains and in the Podkarpacie Region (S-E
Poland) the juice was used directly on warts, or they were first
scrubbed off and then the juice was applied on the wound (Szary,
2013). A cataplasm made of flowers that was supposed to be
changed every few days was used in the Kielce Region (Central
Poland) (Szot-Radziszewska, 2012). Occasionally, fresh leaves
were also used (Kujawska et al., 2016). The juice of the aerial
part of the plant was used in the Ukrainian Carpathians (Szary,
2010, 2013) and in Russia (Zevin et al., 1997). The herb juice
was applied to treat warts also in the Balkan countries (Redžicˇ,
2007; Ti ¸ta et al., 2009; Menkovic´ et al., 2011; Mustafa et al.,
2012; Koleva et al., 2015) as well as in Central Italy (Menale
et al., 2006) and Great Britain (Barton and Castle, 1845). Other
dermatologic conditions were also treated. All around Poland
it was common to apply fresh leaves or juice on wounds. In
Podolia (Ukraine) corns were treated by rubbing with a root
of celandine and by application of fresh leaves. After a week,
corns softened and ruptured. A salve from celandine, olive oil,
fir resin and beeswax was a remedy for pustules (Kujawska et al.,
2016). In the Bieszczady mountains (Polish-Slovakian-Ukrainian
frontier), juice of celandine was applied to eczema and cuts, and
decoction of root was used for baths and rinse for dermatologic
conditions (Szary, 2013). In the Rzeszowszczyzna (S-E Poland)
region leaves were applied to ulcers to stimulate picking up and
rupture (Wdowiak and Bielecka-Grzela, 2013). The juice was also
used to lighten freckles (Kuz´niewski and Augustyn-Puziewicz,
1999). In Russia the juice of aerial parts was used in the treatment
of skin wounds, skin irritation, allergic rashes and dermatitis,
leaves, and flowers in the treatment of boils (Mamedov et al.,
2004). The aerial parts of the plant were used by the people of
Montenegro to cure blisters, rashes, and scabies (Menkovic´ et al.,
2011). In Central Serbia, juice was applied directly on skin in skin
eruptions, psoriasis and eczema (Jaric´ et al., 2007).
Liver Diseases
C. majus is one of the best-known folk medicine remedy
for jaundice and liver diseases, such as inflammation, spastic
conditions, and gallstones. In Poland, infusion made of young
celandine leaves was used as a cholagogue and to regulate action
of the digestive tract (Kuz´niewski and Augustyn-Puziewicz,
1999). Jacques (De Verdmon, 1936) in case of jaundice advised
infusion made of half of a teaspoon celandine per cup. All
around Poland it was common to bath children with jaundice
in celandine and to give celandine infusion to drink (Kujawska
et al., 2016). In the Bieszczady and in the Ukrainian Carpathians,
herb infusion was drunk to relieve liver conditions (Szary, 2010).
In Western Ukraine, infusion was used as relaxant in colic
attacks (Szot-Radziszewska, 2007). Also in Balkan countries,
celandine was employed in the treatment of liver disorders. In the
Albanian Alps to treat hepatitis a decoction of fresh aerial parts
has been drunk with sugar in small portions—half coffee cup
(Pieroni et al., 2005). In Serbia celandine was used internally for
inflammation of the gallbladder, bile duct, jaundice, and hepatitis
(Jaric´ et al., 2007; Šavikin et al., 2013). The use of celandine is
similar in Gollak region in Kosovo (Mustafa et al., 2012), in the
Prokletije Mountains (Menkovic´ et al., 2011) and in Zagori in
Epirus, North-West Greece (Vokou et al., 1993).
Against Digestive Tract Parasites
Polish name of C. majus “glistnik” (roundworm herb) comes
from a common traditional usage of this plant to expel
roundworms. For this reason decoction of the herb had to
be drunk for 12 days (De Verdmon, 1936). In the Bieszczady
Mountains children were bathed in decoction of the celandine
herb and were given celandine infusion to drink (Szary, 2013).
Decoction of seeds was also used in the Kielce Region (Szot-
Radziszewska, 2012). In western Ukraine, infusion of the herb
was prepared (Szot-Radziszewska, 2007).
Eye Diseases
Contrary to ancient phytotherapy, celandine was rarely used to
treat eye conditions in folk medicine. Wdowiak (2015) reports
that in the Podolia Region (Ukraine) drops of celandine juice
mixed with vodka were put into eyes. In west Ukraine a tincture
made from celandine was applied. Moreover, a popular belief
among people of the Podolia Region, as well as the Lubelszczyzna
and Podkarpacie Regions (Eastern Poland) said that feces of a
swallow can cause sight loss, if they fall into the eye, which can
be only cured by C. majus. In the small town Giby, of Polish-
Lithuanian-Belarusian borderland, the celandine pollen was used
against eye infections (Kujawska et al., 2017).
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Other Usage
People of S-W Romania and Zagori in Greece were applying
celandine as diuretic (Vokou et al., 1993; Ti ¸ta et al., 2009).
In the central Serbia and in Podolia (Ukraine), celandine was
considered a remedy for gout. Occasionally, it was used as
tonic and stimulant of cardiac functions, also increasing blood
pressure (Vokou et al., 1993). In the Bieszczady Mountains
people incensed aching teeth with the smoke from the burning
herb (Szary, 2015). In Poland, juice was used internally to cure
hydropsy (Kujawska et al., 2016). In Romania it was esteemed
as an antidote for snake venom (Ti ¸ta et al., 2009). People
of Russian descent, called Russlanddeutschen, living in S-W
Germany used celandine as depurative (Pieroni and Gray, 2008).
Among the Hutsuls living on the Ukrainian side of Bukovina (S-
W Ukraine), tea from aerial parts of celandine was employed in
the treatment of cancer (Soˇukand and Pieroni, 2016). In Bosnia
and Herzegovina it was used to cure cancer of lungs (Redžicˇ,
2007). In veterinary treatments, herb decoction was given to cows
suffering from inflammation of the udder, in case of dermatologic
conditions animals were rubbed with leaves. Furthermore, cows
were given root to eat to cause vomit to relieve bloat. Besides,
herb overcooked in milk was applied to ulcers (Kujawska et al.,
2016). In the Bieszczady Mountains celandine was a symbol of
purification of living world from threatening death, it was used as
talismans to protect from demons (Szary, 2015). Dried herb was
used to incense the interiors of huts to deter flies and mosquitos
as well as during plague and other epidemics. Grains soaked in
celandine juice were used as fish and bird poison (Szary, 2013).
PHYTOCHEMISTRY
For the therapeutic purposes, dried herb of C. majus is used
(European Pharmacopeia). In some regions (Central and Eastern
Europe) roots are also exploited. European Pharmacopeia
calls for total alkaloid content as chelidonine [1], assayed
spectrophotometrically with additional TLC screening and
microscopic authentication.
Alkaloids
Pharmacologically relevant substances of C. majus are
isoquinoline alkaloids (Figures 1–7, Table 1). These are the
components of latex produced in all plant parts, but flowers.
Latex is stored in special secretory cells called laticifers. Presence
of articulate laticifers with yellowish content is also used as
an authentication microscopic mark in powdered herb by
pharmacopoeial monographs. The composition of latex is plant
organ specific (Tome¯ and Colombo, 1995; Sowa et al., 2018).
Generally, five groups of alkaloids were found in C. majus. These
are the derivatives of phenanthridine (3,4-benzoisoquinoline),
protoberberine, protopine [37], quinolizidine, aporphine (Kadan
et al., 1990, 1992; Pavao and Pinto, 1995; Táborská et al., 1995;
Petruczynik et al., 2002; Necˇas et al., 2005; Sa¯rközi et al., 2006;
Zhou et al., 2012; K ¸edzia et al., 2013; Grosso et al., 2014;
Poormazaheri et al., 2017). More than forty alkaloids of different
types were isolated and identified from C. majus (Figures 1–7).
Major phenanthridine derivatives that were found in aerial and
underground parts are (+)-chelidonine [1], chelerythrine [9],
(Kadan et al., 1990; Sa¯rközi et al., 2006; Zhou et al., 2012).
Protoberberine derivatives that accumulate in higher amounts
are coptisine [31], berberine [28], stylopine [33] (Slavik
and Slavikowa, 1977; Fulde and Wichtl, 1994; Shafiee and
Jafarabadi, 1998; Sa¯rközi et al., 2006). Aporphine alkaloids
like corydine [39] also appear (Slavik and Slavikowa, 1977;
Shafiee and Jafarabadi, 1998; Kopytko et al., 2005). Two
protopines were found in C. majus, allocryptopine [36]
and protopine [37] (Fulde and Wichtl, 1994; Shafiee and
Jafarabadi, 1998; Kopytko et al., 2005). Sparteine [38] is the
only representative of quinolizidine alkaloids (Kopytko et al.,
2005) but no other publications report its presence. Moreover,
new unusual turkiyenine-type alkaloid named (–)-turkiyenine
[42] was found in C. majus from Turkey (Kadan et al.,
1990).
Alkaloid content in different plant organs was found to
be unstable (Kustrak et al., 1982; Tome¯ and Colombo, 1995).
Daily variations were probably due to the alkaloid degradation
rather than translocation, because of similar time-course of the
compounds accumulation in all plant parts. Significant increase
of sanguinarine [12], chelerythrine [9], chelidonine [1], and
coptisine [31] was observed during the day, with the highest
content in the evening, whereupon the alkaloids diminished
during the night (Tome¯ and Colombo, 1995). Day light seems to
be the crucial factor influencing alkaloid biosynthesis in C. majus,
especially in underground parts of the plants (Kustrak et al.,
1982; Tome¯ and Colombo, 1995). Diurnal changes of alkaloid
content seem to be less dependent on temperature, what was
observed during winter time, when the alkaloid content was low
and stable, due to the reduced metabolism and the senescence of
the aerial parts. According to Tome¯ and Colombo (1995) total
content of alkaloids in leaves was lower than in underground
parts. In latex the content was 32 times higher than in leaves
and 9 times higher than in roots. These results suggest that the
amount of alkaloids in plant organs depend on the number of
laticifers in which they are stored. Moreover, the number of
laticifers is probably organ specific. Laticifers in C. majus are
unbranched (without anastomoses), articulated with perforated
transverse cells (Hagel et al., 2008). Articulated laticifers develop
from multiple cells. The structures form longitudinal rows
composed of series of superimposed cells with perforated end
walls. The type of laticifers can differ even within the same
plant family. In another Papaveraceae species—opium poppy, the
perforation of lateral walls leads to the formation of anastomoses
(connections) between adjacent laticifer elements, unlike that of
Greater celandine (Hagel et al., 2008). From wounded laticifers, a
matrix emerges with various organic substances suspended in it.
This excretion is called latex and depending on the plant species,
it contains proteins, organic acids, alkaloids, sterols, tannins, and
mucilage. The growth and development of laticifers runs close to
the surrounding phloem, which affects the composition of latex.
Amajor site of alkaloid accumulation in the protoplast of laticifer
cells are vesicular organelles, that had been found in opium poppy
between early 70’s and 80’s of the last century (Dickenson and
Fairbairn, 1975; Roberts et al., 1983). Unfortunately, research
on the site of alkaloid biosynthesis in Greater celandine has
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FIGURE 1 | Structures of phenanthridine (3,4-benzoisoquinoline) alkaloids—chelidonine [1] derivatives.
not been continued since then. Recent reports concern protein
determination in latex and confirm its complex composition
(for more information see the separate “Protein subsection”
underneath).
The presence and number of laticifers is due to the
physiological functions of aerial parts and underground parts of
the plant, such as responses to environmental factors, defense
against herbivory, metabolic reserves, and energy store (Agrawal
and Konno, 2009). Coptisine [31] was found mostly in fruits
and herb (Sa¯rközi et al., 2006; K ¸edzia et al., 2013; Sowa et al.,
2018), whereas berberine [28] showed no significant difference
between aerial parts and roots (Tome¯ and Colombo, 1995).
Larger amounts of phenanthridine alkaloids like chelidonine [1],
chelerythrine [9], sanguinarine [12] were observed in roots rather
Frontiers in Pharmacology | www.frontiersin.org April 2018 | Volume 9 | Article 299169
Zielin´ska et al. Medicinal Uses of Chelidonium majus
FIGURE 2 | Further structures of phenanthridine (3,4-benzoisoquinoline) alkaloids—chelerythrine [9] and sanguinarine [12] derivatives.
than in aerial parts of the plants (Tome¯ and Colombo, 1995; Sowa
et al., 2018).
Total alkaloid content (%) in in vitro shoots and embryos
expressed as chelidonine [1] was 1.53 and 1.58%, respectively
(Ciric´ et al., 2008).
Phenolic Compounds
Several flavonoids were found in aerial parts of
C. majus in low amounts. Four diglycosides and five
monoglycosides were identified as derivatives of kaempferol,
quercetin, and isorhamnetin (kaempferol-3-O-rutinoside,
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FIGURE 3 | Further structures of minor phenanthridine (3,4-benzoisoquinoline) alkaloids.
quercetin-3-O-rutinoside, isorhamnetin-3-O-glucoside). The
identification was based on the mass spectra of the compounds
(Grosso et al., 2014). In stems, leaves, and flowers, 5
′
-methoxy-
flavonol [43] and 6′- methoxy-flavonol [44] were also detected
(Stancic-Rotaru et al., 2003).
Hydroxycinnamic acids (caffeic, p-coumaric, ferulic) and
their derivatives ((–)-2-(E)-caffeoyl-D-glyceric acid [46], (–)-4-
(E)-caffeoyl-L-threonic acid [47], (–)-2-(E)-caffeoyl-L-threonic
acid lactone, (+)-(E)-caffeoyl-L-malic acid [48]), as well as
hydroxybenzoic acids (genistic, p-hydroxybenzoic) were
identified in aerial parts (Hahn and Nahrstedt, 1993; Wojdyło
et al., 2007). Later, another three hydroxycinnamic acids were
identified using HPLC-DAD-ESI/MS: caffeoyl threonic acid,
caffeoyl glyceric acid, caffeoylmalic acid (Grosso et al., 2014), that
have been detected previously by Hahn and Nahrstedt (1993).
Two caffeoyl acid derivatives isomers with precursor ions at m/s
359 corresponding to rosmarinic acid were also found in aerial
parts (Grosso et al., 2014).
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FIGURE 4 | Further structures of minor phenanthridine (3,4-benzoisoquinoline) alkaloids.
Proteins
A phytocystatin—chelidocystatin was one of the first proteins
isolated from latex and characterized (Rogelja et al., 1998).
Cystatins, a class of thiol protease inhibitors are involved
in defense and stress-response mechanisms and could also
contribute to the antimicrobial and antiviral activity of C. majus
latex (Benchabane et al., 2010). Whether or not the presence
of cystatin is relevant to the medicinal properties and such
traditional folk uses as anti-warts is yet to be found out.
In a series of papers, Nawrot et al. (2007a,b, 2008, 2013,
2014, 2016, 2017a,b) described a number of proteins from root
and leaf latex. Proteomic analysis using LC-ESI-MS/MS system
revealed the presence of three categories of proteins according
to their functions: proteins involved in disease and defenses
responses (i.e., superoxide dismutases, lactoylglutathione lyases),
nucleic acid binding proteins (i.e., glycine-rich proteins, nucleic
acid binding, DNA-binding, or RNA-binding proteins), and
these that are involved in general metabolism (acyl-CoA
binding protein, malate dehydrogenase, flavodoxin-like quinone
reductase, ubiquitin, polyubiquitin, serine/threonine protein
kinases, rubber elongation factor). A total of 21 proteins were
identified in C. majus latex, although in several cases the
identification was based on correlation between experimental
and the theoretical pI/molecular mass, due to their low score
results. The results shown less complexity of latex proteins in
this species compared to opium poppy. Their contribution to the
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FIGURE 5 | Structures of protoberberine alkaloids.
traditional use of C. majus as antiviral and antimicrobial remedy
has to be further explored and may, in combination with highly
active alkaloids, render unique synergistic effects providing a
multifaceted tool for combat against troublesome infections.
In living plants, these proteins are probably also serving as
a chemical defense against pathogens (Nawrot et al., 2007a,b,
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FIGURE 6 | Structures of aporphine, protopine alkaloids, and non-isoquinoline alkaloids.
2014, 2017a,b). Protein-bound polysaccharide (CM-AIa) bearing
immunomodulatory and cytotoxic activity was isolated by Song
et al. (2002).
Other Compounds
Organic acids: chelidonic [45], malic, citric, succinic, (Kopytko
et al., 2005); Biogenic amines: histamine, methyloamine,
tyramine (Kwasniewski, 1958); choline in fruits (Kwasniewski,
1958); essential oil constituents (Hansel et al., 1992; Kohlmünzer,
2000) triterpenoids (Hahn and Nahrstedt, 1993; Deng et al.,
2016); saponins (Kwasniewski, 1958; Kopytko et al., 2005); Resin
(Hahn and Nahrstedt, 1993); vitamins A, C, nicotinic acid (Hahn
and Nahrstedt, 1993; Kopytko et al., 2005).
Flowers contain xanthophyll pigments like lutein,
violaxanthin, flavoxanthin, chrysanthemoxanthin (Horváth
et al., 2010).
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FIGURE 7 | Structures of miscellaneous compounds.
METHODS FOR ANALYSIS OF ACTIVE
COMPONENTS FROM Chelidonium majus
Alkaloids
First isolation of Chelidonium alkaloids was achieved in
nineteenth century with an important contribution from Mr.
Emanuel Merck’s company at Darmstadt (Henschke, 1888;
Schmidt, 1888) and obtaining and characterization of pure
compounds (chelidonine [1], chelerythrine [9], protopine [37])
was successful in the following years (Selle, 1890; Wintgen and
Schmidt, 1901). Alkaloids of C. majus occur as salts or bases
depending on pH of medium; thus, their extraction was mostly
carried out in acidic condition to convert all compounds to
water-soluble salts. Methanol or ethanol often with addition
of water (Bugatti et al., 1987; Han et al., 1991; Koriem et al.,
2013) and hydrochloric (Kursinszki et al., 2006; Gu et al., 2010)
or acetic acid (Paulsen et al., 2015) were used as extractants.
The isolation from plant material was also achieved with the
use of pure acidified water; further, the solution was alkalized
with ammonia or sodium hydroxide to obtain base forms
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TABLE 1 | Content [%] of pharmacologically relevant constituents in aerial parts and roots of Chelidonium majus.
Compound Content [% of dry mass] References
Aerial parts Roots
Chelidonine Bugatti et al., 1987; Fulde and Wichtl, 1994; Niu and He, 1994; Kedzia et al., 2003; Sa¯rközi et al.,
2006; Gañán et al., 2016; Sowa et al., 2018
t – 0.3 t – 1.51
Chelerythrine t – 0.3 t – 0.77 Bugatti et al., 1987; Fulde and Wichtl, 1994; Niu and He, 1994; Shafiee and Jafarabadi, 1998;
Sa¯rközi et al., 2006; Gañán et al., 2016; Sowa et al., 2018
Sanguinarine t – 0.1 0.1 – 0.4 Bugatti et al., 1987; Fulde and Wichtl, 1994; Kedzia et al., 2003; Sa¯rközi et al., 2006; Sowa et al.,
2018
Berberine t – 0.1 t−0.1 Bugatti et al., 1987; Fulde and Wichtl, 1994; Kedzia et al., 2003; Sa¯rközi et al., 2006; Sowa et al.,
2018
Coptisine t – 1.0 t−0.3 Fulde and Wichtl, 1994; Kedzia et al., 2003; Sa¯rközi et al., 2006; Sowa et al., 2018
Flavonols (quercetin,
kaempferol and
isorhamnetin
glycosides)
0.8 Grosso et al., 2014
hydroxycinnamic acids 0.03 Grosso et al., 2014
xanthophylls 0.03; 1.36 (flowers) Horváth et al., 2010
t, traces (<0.08%).
followed by liquid-liquid extraction with organic solvents such
as dichloromethane, butanol or chloroform (Sa¯rközi et al.,
2006; Sárközi et al., 2007; Migas et al., 2012; Jesionek et al.,
2016; Bogucka-Kocka and Zalewski, 2017). The isolation was
conducted by percolation (Capistrano et al., 2015), maceration
(Koriem et al., 2013; Borghini et al., 2015), heating under reflux
(Gu et al., 2010; Yao et al., 2011; Seidler-Łozykowska et al.,
2016), in water bath (Sa¯rközi et al., 2006) or Soxhlet apparatus
(Bugatti et al., 1987; Stuppner and Ganzera, 1995) as well as
ultrasound assisted (UAE) (Kursinszki et al., 2006; Sárközi et al.,
2007; Paulsen et al., 2015; Jesionek et al., 2016) or microwave
energy (MAE) (Then et al., 2000; Zhou et al., 2012). Supercritical
fluid extraction (SFE) (Then et al., 2000) or SFE combined with
enhanced solvent extraction (ESE) and low pressure solvent
extraction with water (LPSE) (Gañán et al., 2016) was also
applied. Moreover, in situ solvent formation microextraction
(ISFME) with the use of ion-pairing agent (KPF6) and a
water-miscible ionic liquid ([C6MIM][Br]) which formed a
hydrophobic ionic liquid extraction phase ([C6MIM]PF6) for
the pre-concentration of sanguinarine [12] and chelerythrine
[9] was elaborated by Wu and Du (2012). After extraction, the
solution was usually filtrated through a 0.22-µm membrane (Gu
et al., 2010) or additionally purified using solid phase extraction
(SPE) on C18 cartridge (Stuppner and Ganzera, 1995; Kursinszki
et al., 2006; Sa¯rközi et al., 2006). Sa¯rközi et al. (2006) developed
ion-pair SPE with n-heptanesulfonic acid (HS). Dried residue
obtained after extraction was dissolved in methanol with 0.05M
hydrochloric acid, diluted with 0.05M aqueous solution of HS
and loaded on an SPE C18 microcolumn. Further, 70% HS
(0.05M) in methanol was used to remove the matrix and 5%
HS (0.05M) in methanol to elute analytes. The examples of
conditions used to isolate alkaloids from C. majus are presented
in Supplementary Table 1.
Thin Layer Chromatography (TLC)
TLC was mostly employed for screening purposes or for
qualitative analysis of alkaloid composition in C. majus extracts.
This technique has been largely limited to the screening and
multiple sample fingerprinting, but usually does not enable high-
sensitivity or high-resolution insight into the minor components
of the phytochemical profile. Despite of being less intensively
modernized in comparison to column-based techniques like
(U)HPLC, this method is still favored when cost-effectiveness
and simplicity of sample preparation is important, for example in
herbal industries and educational use. Some recent developments
in mass spectrometry hyphenation in form of matrix transfer
or DART (direct analysis in real time) used already in studying
of other species (Móricz et al., 2018) should be useful also for
C. majus alkaloids.
Silica was the most common stationary phase, often
impregnated with salts (Ni, Zn, Cr, Co) to improve the selectivity
(Wagner et al., 1984; Then et al., 2000; Waksmundzka-Hajnos
et al., 2000; Sa¯rközi et al., 2006; Sárközi et al., 2007; Petruczynik
et al., 2008; Jesionek et al., 2016) Silica modified with octadecyl
(C-18) and cyanopropyl (CN) groups and aqueous solutions of
methanol or isopropanol with ammonia or diethylamine which
prevented tailing of chromatographic bands were sporadically
applied (Petruczynik et al., 2007). Petruczynik et al. (2008)
combined various types of stationary phases e.g., cyanopropyl
silica with silica or octadecyl silica to obtain adsorbent gradient.
Apart from the routine isocratic elution with solvent
mixtures, using different modes of gradient elution improved the
separation, e.g., as a two-dimensional or unidimensional multiple
development (Szumiło and Flieger, 1999; Waksmundzka-Hajnos
et al., 2000; Migas et al., 2012), bivariant multiple development
(Bogucka-Kocka and Zalewski, 2017), or stepwise gradient
elution (Matysik and Jusiak, 1990; Waksmundzka-Hajnos et al.,
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2000; Bogucka-Kocka and Zalewski, 2017). TLC separation of
alkaloids was supported by use of magnetic field (Malinowska
et al., 2017) or forced flow of mobile phase (OPLC—
overpressure layer chromatography or optimum performance
laminar chromatography; Pothier et al., 1993; Malinowska et al.,
2005).
TLC was also applied for direct bioautography (TLC-DB) to
test the antibacterial activity of C. majus extracts (Sárközi et al.,
2007; Móricz et al., 2015; Jesionek et al., 2016) combined with
densitometry for quantitative analysis (Then et al., 2000; Sa¯rközi
et al., 2006) and it proved useful as preparative technique for
isolation of alkaloids (Waksmundzka-Hajnos et al., 2002; Koriem
et al., 2013).
High Performance Liquid Chromatography
(HPLC)
High performance liquid chromatography (HPLC) and ultra-
fast liquid chromatography (UFLC) have been the most often
applied analytical techniques. For many years, separation of
C. majus extracts was mostly carried out in reversed phase
(RP) system using long (150 or 250mm) C18 columns with
4.6mm of diameter and 5µm of particle size (Niu and He, 1994;
Petruczynik et al., 2002; Kursinszki et al., 2006; Borghini et al.,
2015; Paulsen et al., 2015; Gañán et al., 2016). More recently,
adsorbents with smaller particles (≤3µm) or shorter columns
(Prosen and Pendry, 2016; Seidler-Łozykowska et al., 2016) were
also applied to achieve shorter separation and saving solvents.
Mobile phases are usually composed of water and acetonitrile
or/and methanol with various additives e.g., ammonium
formate/acetate (Borghini et al., 2015; Seidler-Łozykowska et al.,
2016), organic amines (triethyl-, tetrabutylamine) (Paulsen et al.,
2015), ion-pair reagents (sodiumdodecylsulfate, alkylsulfonic
acids) (Gañán et al., 2016). The additives were necessary to reduce
peak tailing forming as a results of interaction of alkaloid cationic
forms with residual silanol group of stationary phase. Eluents
were acidified with acetic or formic acid to pH < 4 to avoid the
co-occurrence of ionic and uncharged forms.
Normal-phase (NP) chromatography set ups were used rather
seldom in analysis of alkaloids. Here, silica columns was eluted
with sodium acetate in methanol, dioxane and acetic acid
mixture (Bugatti et al., 1987) or chloroform and methanol with
trifluoroacetic acid (Rey et al., 1993) Also, cyanopropyl stationary
phase was eluted with acetonitrile, tetrahydrofuran, dioxane
or methanol with phosphate buffer and octane-1-sulfonic acid
sodium salt or di-(2-ethyl hexyl) orthophosphoric acid (HDEHP)
(Petruczynik et al., 2002).
Alkaloids have a strong absorption in UV region and
have ability to fluorescence; thus both spectrophotometric
and fluorescence detector (Wu and Du, 2012) were applied.
Additionally, ESI-MS and/or NMR were coupled with HPLC to
confirm the identity and structure elucidation of new alkaloids
(Paulsen et al., 2015). Moreover, preparative separation of
particular alkaloids from C. majus extract using silica gel and
sequentially elution with petroleum ether, ethyl acetate and
methanol (Yao et al., 2011) or CaCO3 and different compositions
of toluene-hexane and acetone-hexane mixtures (Horváth et al.,
2010) was performed with use of LC system.
Capillary Electrophoresis CE
CE method with spectrophotometric (DAD) and fluorescence
detection (UV-LEDIF ultraviolet light-emitting diode-induced
native fluorescence or LED-fluorescence) was also used for
C. majus analysis (Stuppner and Ganzera, 1995; Ševcˇik et al.,
2000; Kulp et al., 2011; Zhou et al., 2012; Kulp and Bragina, 2013);
however, this technique has not yet won high popularity and it is
also limited to charged or polar compounds. Recently, Sun et al.
(2015) elaborated the microchip variant of CE with laser-induced
fluorescence detection and 50% formamide as a run buffer and
this technique was applied for separation of chelerythrine [9] and
sanguinarine [12]. The examples of application the separation
techniques in analysis of alkaloids from C. majus are presented
in Supplementary Table 2.
Spectrophotometry
Spectrophotometric method given in European Pharmacopeia
(monograph of Greater celandine) may be useful to estimate of
total alkaloids in C. majus extract. The sample is mixed with
sulphuric and chromotropic acid, and heated 10min. at 100◦C
in water-bath. After cooling to 20◦C, the absorption of sample
is measured at 570 nm and the amount of alkaloid is expressed
as chelidonine [1]. This approach was applied by (Then et al.,
2000; Seidler-Łozykowska et al., 2016). However, for research
purposes, a total-content approach should be discouraged as too
inaccurate and sometimes misleading about contribution of each
component of an actual alkaloid profile.
In summary, most of the published preparative and analytical
approaches were rather routine and typical for phytochemical
studies. However, the efficiency of standard methods often
appeared to be insufficient. The properties that influenced the
separation and analysis processes depend mostly on the tertiary
or quaternary character, oxygenation and secondary cyclization
pattern. Among the most important features are thermo- and
photo-sensitivity, so the procedures should be carried out
in mild conditions which has not always been considered.
Thus, due to the diversity in physicochemical properties, even
among compounds from a single subclass, various specialized
modifications were applied which in most cases significantly
improved the separation.
Another issue that should be addressed in future analytical
studies is that numerous minor alkaloids have been frequently
missed or overlooked whereas some of them have profound
activity. The focus should be on comprehensive qualitative
and quantitative profiling under non-destructive conditions that
would reveal the full phytochemical complexity and allow to
understand the intraspecific and environmental variation of
C. majus.
Other Components
Carotenoids
Carotenoids were determined in aerial parts (Varzaru et al.,
2015) and flowers (Horváth et al., 2010) of greater celandine.
The components were hydrolyzed with alcoholic solution of
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potassium hydroxide and extracts were analyzed on RP-HPLC
using C18 column in isocratic mode using 13% of water in
acetone (Varzaru et al., 2015) or in gradient mode with mixture
of three eluents: 12% (v/v) water in methanol (A), methanol (B),
and 50% (v/v) acetone in methanol (C) in different proportions
(Horváth et al., 2010).
Phenolic Compounds
Grosso et al. (2014) tested different combinations: time,
temperature type of extraction, and eluent composition and
used Box–Behnken design to establish the effective extraction
conditions for phenolic compounds. 76.8% of methanol,
150.0min and 60◦C were found to be optimal. Further,
hydroxycinnamic acids and flavonoids were characterized by
HPLC-DAD-ESI/MSn (C18 column: 150 × 1.0mm, 3µm) and
quantified using RP-HPLC DAD (C18 column: 250 × 4.6mm,
5µm). For both methods, gradient elution with mobile phase
composed of 1% acetic acid in water and methanol was applied
(Grosso et al., 2014). Hence, the method for phenolic analysis is
similar to some which were used for alkaloids and there would be
reasonable to include phenolic compounds in any future HPLC
or LC-MS profiling of this herb.
Proteins
The composition of proteins in C. majus milky sap was studied
by Nawrot et al. (2007a,b, 2014, 2017a,b). The compounds were
pre-separated using two-dimensional gel electrophoresis and
further, HPLC on BEH C18 column (100mm × 100µm, 1.7µm
particle diameter) (Nawrot et al., 2017b) or nano-HPLC on
75µm analytical column (Nawrot et al., 2007a, 2014, 2017a) and
gradient elution with mobile phase containing 0.1% (v/v) formic
acid in water and in acetonitrile were performed. Proteins were
identified by tandem mass spectrometry (MS/MS).
Micro and Macro-elements
Mineral composition of greater celandine herb and root, aqueous
solutions (infusion, decoction) and alcoholic extracts were
determined with the use of inductively coupled plasma atomic
emission spectrometry (Then et al., 2000; Sárközi et al., 2005).
PHARMACOLOGICAL ACTIVITIES AND
CLINICAL EVIDENCE
Obviously enough, the great majority of published
pharmacological properties of C. majus pertains to the
complex mixture or individual alkaloids. Recently, more
and more attention has been also paid to proteins from latex, that
could significantly contribute to the observed activities. Other
compounds, such as various phenolics and chelidonic acid were
rarely considered. The versatile pharmacological activities of
coptisine [31], one of the major constituents of C. majus as well
as the less abundant berberine [28], have been widely described
in the literature but usually as compounds obtained from other
sources, such as Coptis (Ranunculaceae) (Tan et al., 2016) or
Berberidaceae (Imanshahidi and Hosseinzadeh, 2008).
However, these compounds are also contributing significantly
to many of the pharmacological properties of C. majus.
From the growing evidence obtained both in vitro and
in vivo, with several examples of ex vivo studies on isolated
organs, it is clear that four types of medicinal properties are
predominating: antimicrobial and antiviral, hepatic and gastric,
anti-inflammatory, and finally anticancer. Several other activites
have been also reported but less extensively.
Activites in Vitro and in Vivo
Antibacterial and Antifungal
The antimicrobial activity of C. majus is attributed mostly to
the alkaloids and flavonoids (Zuo et al., 2008). This kind of
activity was reported already in the early research on chelidonium
alkaloids, e.g., by Stickl (1928) who proved the bactericidal
properties against Gram-positive strains (Staphylococcus aureus
and Bacillus anthracis) with chelerythrine [9] and sanguinarine
[12] being more potent than chelidonine [1] and berberine [28].
In experiments with multidrug resistant bacteria existing
in surgical wounds and infections of critically ill patients,
C. majus ethanol extract affected Gram-positive bacteria.
Ethanolic extracts of C. majus also showed antimicrobial activity
against Bacillus cereus, E. coli, Pseudomonas aeruginosa, S. aureus,
(Kokoska et al., 2002). The complex composition of alkaloids
can manifest wide spectrum of antimicrobial activity, arising
from different chemical structures of the compounds. Hence,
antimicrobial activity of C. majus was also tested with a use of
different solvent extraction. Antibacterial and antifungal tests
were performed using 96% methanol extracts from leaves and
petioles of plants grown in nature as well as in vitro shoots
and embryos (Ciric´ et al., 2008). Methanolic extracts were
examined against Gram-positive (Bacillus subtilis, Micrococcus
luteus, Sarcinia lutea, and S. aureus), Gram-negative bacteria (E.
coli, Proteus mirabilis, Salmonella enteritidis), plant pathogens—
Agrobacterium rhizogenes, A. tumefaciens), and clinically isolated
C. albicans. Both, in vivo and in vitro derived plant material
extracts showed similar bioactivity, with a slight advantage of in
vitro shoots. Only few extracts were equally active (80 mg/ml)
against E. coli, S. enteritidis, and C. albicans, when compared
to the commercially available antibacterial and antifungal drugs
(streptomycin, bifonazole, respectively), while the rest of them
showed low or no activity (Ciric´ et al., 2008).
Apart from plant extracts, as it was previously summarized
by Kedzia and Hołderna-Kedzia (2013), individually
tested compounds showed different antimicrobial activity.
Chelerythrine [9] and sanguinarine [12] were significantly more
potent than chelidonine [1] against Gram-positive (S. aureus,
S. epidermidis, B. subtilis, B. anthracis), Gram-negative (P.
aeruginosa, E. coli,Klebsiella pneumoniae, Salmonella gallinarum,
S. typhi, S. paratyphi, Proteus vulgaris, Shigella flexneri), and acid-
fast mycobacteria (Mycobacterium tuberculosis, M. smegmatis).
Moreover, chelerythrine [9] exhibited antimicrobial activity
against S. aureus and M. smegmatis, while chelerythrine
[9] derivatives: 8-hydroxydihydrosanguinarine [14a], 8-
hydroxydihydrochelerythrine [10a], dihydrosanguinarine
[10], and dihydrochelerythrine [14] were active against
methicillin-resistant S. aureus (MIC50 = 0.49, 0.98, 23.4,
46.9µg/ml, respectively). The strongest activity was presented
by 8-hydroxydihydrosanguinarine at MIC90 = 1.95µg/ml,
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comparable to that of vancomycin (2.23µg/ml) (Zuo et al.,
2008). In the ethanol extract of C. majus aerial parts there are
several other alkaloids that show potent antimicrobial inhibitory
effect. For instance, berberine [28] was effective against Gram-
negative bacteria—Vibrio cholerae and E. coli. It damaged
bacterial fimbria, thereby inhibited adhesion to the mucosal
surface (Imanshahidi and Hosseinzadeh, 2008; Wongbutdee,
2009).
Enzymes included in latex, like extracellular peroxidases,
DNases, and lectin-like-active glycoproteins can also exhibit
antimicrobial activity. Moreover, chelidocystatines protect plant
against pests and are among the components of latex which
presumably contribute to removal of warts resulting from human
papilloma virus infection (Rogelja et al., 1998; Song et al., 2002;
Gerencˇer et al., 2006; Nawrot et al., 2007b; Ciric´ et al., 2008).
The antifungal activity was tested with the use of plant
latex, and different solvent extracts from aerial and underground
parts like ethanol/methanol ether, chloroform, acetone, and
water (Kokoska et al., 2002; Kedzia et al., 2003). Chelerythrine
[9], sanguinarine [12], chelidonine [1], and their derivatives
were also individually tested against large number of human
and plant pathogenic fungi, i.e., Aspergillus fumigatus, A. niger,
Candida sp. Cladosporium herbarum, Cryptococcus neoformans,
Epidermophyton floccosum, Fusarium sp. Keratinomyces ajelloi,
Microsporum sp. Penicillium notatum, Rhodotorula rubra,
Scopulariopsis brevicaulis, Torlopsis utilis, Trichophyton sp. The
effect of C. majus extracts on pathogenic fungi was significantly
weaker compared to the effect on pathogenic bacteria. For
example, the MIC of ethanol and methanol extracts was ranging
between 1.5 and 8 mg/ml against the most resistant bacteria,
whereas the MIC of ethanol herb extract against the most
pathogenic fungi was 20–40 mg/ml (Pepeljnjak et al., 2003).
Chelerythrine [9], sanguinarine [12] and their derivatives (e.g.,
8-hydroxydihydrochelerythrine [10a]) were up to several times
stronger than chelidonine [1] (Ma et al., 2000; Meng et al., 2009;
Kedzia and Hołderna-Kedzia, 2013). Chelerythrine [9] was also
able to inhibit spore germination of several plant pathogenic
fungi: Sphaerulina juglandis, Septoria microspora, Fusarium
oxysporum, and Curvularia lunata. It suggests the actual
biological—antipathogenic function of isoquinoline alkaloids in
the plant (Wei et al., 2017). However, no particular structural
feature seems to be pinpointed as a determinant of antimicrobial
potency despite some variation in activity toward different strains
between individual alkaloids. It is rather the combination of
them and other compounds targeting multiple sites of action
that result in the observed final effect. This hypothesis still
needs experimental verification for potential synergies or other
interactions.
Antiviral
The glycosaminoglycan present in the latex inhibits intracellular
human immunodeficiency virus HIV viral migration and
blocks reverse transcriptase (Gerencˇer et al., 2006). Moreover,
individually tested five C. majus alkaloids: chelidonine [1],
chelerythrine [9], sanguinarine [12], coptisine [31], and
berberine [28] were able to inhibit the development of HIV-
1. The first two decreased the activity of the virus reverse
transcriptase at the concentrations 150–200µg/ml, while
sanguinarine [12], berberine [28], and coptisine [31] were
already active at concentrations of 50–150µg/ml (Tan et al.,
1991).
The chloroform extract in the concentration of 35µg/ml
decreased the number of adenoviruses responsible for
inducing acute fevelitis of the upper respiratory tract and
conjunctiva in humans (Kéry et al., 1987). The experiments
with animals showed that ethanol extract of C. majus inhibited
encephalomyocarditis virus in 45% of experimental mice,
whereas berberine [28] tested in the concentration range
between 20 and 125µg/ml inhibited influenza virus type A and
B in chicken embryos with 33–99.97% efficiency (data previously
reviewed by Kedzia et al., 2003). These results were presented
only once, and from that time have never been confirmed or
repeated.
Antiprotozoal
Herb and root water extracts, as well as sanguinarine [12] (2–
4µg/ml) were highly effective in the treatment of trichomoniasis
caused by Trichomonas vaginalis. After 8–10 days of treatment
there was no protozoa detected in genitals of nearly 64% young
girl patients. Sanguinarine [12] was also found to inhibit the
development of Entamoeba histolytica, responsible for the hepatic
abscess (Kozicka and Radomanski, 1963; Vychkanova et al.,
1969).
Liver and Biliary Tract
One of the most widespread and repeatedly mentioned
indications of C. majus, both in European/Mediterranean and
East Asian (TCM) tradition, was for various liver complaints.
It may date back to “signatura rerum” rule from coloration of
the latex and flowers but obviously must have been verified by
observations. Nowadays, even though this indication has been
supported by just a few in vitro and in vivo studies, caution is
necessary for alleged hepatotoxicity. Also, clinical evidence is
not sufficient to ultimately recommend this herb and galenic
preparations thereof (European Medicines Agency, 2011).
Some of the hepatoprotective and choleretic/cholagogue
activity could be more aptly attributed to the presence of
hydroxycinnamic (caffeic) acids esters which have been quite
frequently overlooked in alkaloid-focused studies (Weiskirchen,
2016).
The question whether the supposed stimulation of bile flow
is caused only by cholagogue activity or also by increasing bile
production or excretion was first addressed by Rentz (1947).
Comparison of guinea pigs and rats (that do not have gall
bladder and did not respond to the treatment) reaction to
C. majus tincture suggested only cholecystokinetic mechanism
of action, attributed by the author to the stimulation of
smooth musculature by berberine [28]. However, the tincture
composition was unknown.
Vahlensieck et al. (1995) indicated using isolated rat livers
that beside the earlier reports on cholecystokinetic action, also
increase of bile production contributes to the final outcome. The
activity was not very high, reaching 20% increase by perfusion
with C. majus extract. The activity of alkaloid and polyphenol
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fractions separately were only about half of that. It suggests an
additive action of the complex mixture of all active constituents.
The antispasmodic activity of C. majus extract was tested
in trials based on acetylcholine (ACh)-induced contraction in
isolated rat ileal smooth muscle (Boegge et al., 1996). The extract
was found to be moderate antagonist (12.7%; 2.0 × 10−4 g/ml
organ bath) against (ACh)-induced contraction compared to
caffeoylmalic acid [48] (6.9%; 2.5 × 10−5 g/ml) and coptisine
[31] (16.5%; 1.0 × 10−5 g/ml). Also, individual alkaloids, i.e.,
chelidonine [1], stylopine [33], and coptisine [31] have been
tested for relaxant activity on ileum smooth muscles (Hiller
et al., 1998). Among them, chelidonine [1] and stylopine [33]
showed papaverine-like musculotropic action, whereas coptisine
[31] was ineffective in BaCl2 stimulation model. In carbachol
and electric field induced contractions, all three alkaloids and
ethanolic extracts were effective.
In a different contraction model—isolated and perfused
porcine uterus, the commercial alcoholic extract exhibited two-
phase response, initially stimulating very strong contractions
followed by a longer relaxation period (Kuenzel et al., 2013).
These properties were suggested as potentially useful in
supporting artificial insemination or facilitating fertilization
by acceleration of sperm movement toward fallopian tubes.
However, this indication was rather unknown in traditional usage
and would be a novel application of C. majus.
Cytoprotective
The macerated ethanol extract from juice expressed from
pulped fresh plant material (according to the homeopathic
recipes) was able to counteract carbon tetrachloride induced
hepatotoxicity (Mitra et al., 1996). The effects of extract
administration included reduced cell necrosis, absence of fibrosis,
and lower lipid accumulation. Here again, no reliable data on
the composition of the tested extract was available. C. majus
primary tincture (German Homeopathic Pharmacopeia), diluted
100x and 1,000x was significantly effective against cadmium-
induced hepatoxicity in HepG2 and primary rat hepatocyte
models (Gebhardt, 2009). The activity was stronger than
the proprietary compound preparation and similar to the
recognized hepatoprotective herb—Silybum marianum. The
putative mechanisms of cytoprotective activity was associated
to oxidative stress relieve as demonstrated by improvement
of several parameters such as lipid peroxidation, intracellular
Reactive Oxygen Species, reduced glutathione (GSH) level, as
well as diminished apoptosis symptoms (nuclei fragmentation,
cytochrome C release, caspase 3 activation). Hepatotoxicity
caused by cadmium was also ameliorated in vivo in mice and ex
vivo in hepatocyte cultures. In mice, administration of 50 or 75
mg/kg body weight chelidonine [1], also in form of nanocapsules,
improved histopathological picture of livers damaged by Cd
treatment. Also, biochemical parameters such as ALT, AST, and
ALP activities were lowered to the levels intermediate between
control animals and Cd treated ones. Moreover, the expression of
cell death related genes Bax and Bcl-2 was modulated to the levels
closer to the Cd untreated animals. In all tested hepatotoxicity
parameters, nanoencapsulated chelidonine [1] wasmore efficient.
It was corroborated with the ca. 1/3 higher distribution of
chelidonine [1] from nanoformulation into the liver tissues.
The putative mechanisms relate to alleviation of oxidative stress
as revealed by improvement of antioxidant status (lower lipid
peroxidation, higher GSH level, and SOD and CAT activities) and
various cell death and inflammation markers (decreased protein
level of TNF-α, IL-6, NFκB, p65, cas-3, iNOS) (Paul et al., 2013).
Notwithstanding, the literature evidence supporting beneficial
properties in hepatobiliary disorders from both in vitro, in vivo,
or ex vivo studies is still less abundant than case reports on
liver toxicity. This, quite surprising disparity, should motivate
pharmacologists and clinical researchers to do further and more
insightful studies to explain the mechanisms of action and
pinpoint the most active constituents or their combinations.
Antiproliferative, Pro-apoptotic, and Cytotoxicity to
Cancer Cell Lines
As in case of liver and biliary tract disorders, the antitumor
properties have been indicated since antiquity. Today, this kind
of activity belongs to the most intensely investigated. Unlike
the hepatoprotective properties, this kind of properties has been
quite well-documented in a high number of studies. Mostly,
some of the major alkaloids are expected to be able to cause
cell death or stop proliferation of cancerous cells. This is based
on the ability of berberine [28], chelerythrine [9], sanguinarine
[12], and to some extent also other alkaloids to intercalate
DNA that should interfere with replication and cell division
(Philchenkov et al., 2008; Basu et al., 2013; Noureini et al., 2017).
However, other mechanisms have been also discovered, albeit
most studies used in vitro experiments on cell lines. Chelidonine
[1] appeared to exert its cytostatic activity through interactions
with microtubules and thereby causing cell cycle arrest (Panzer
et al., 2001; Havelek et al., 2016a).
The selected examples of cell line-based studies on cytotoxic
properties of C. majus and its major alkaloids are summarized in
Table 2.
In more detail, quite many different, but mostly human cell
lines were used as model systems (for references see Table 2),
representing leukemias (Jurkat with several modifications to
study certain cell death mechanisms), Raji, MT-4, MOLT-4, HL-
60, U-937, HEL-92.1.7, CCRF/CEM, CCRF/ADR5000), colon
carcinomas (Caco-2, HT-29, HCT116, SW480), breast cancer
(MCF-7, MDA-MB231), pancreatic cancer (human PANC-
1, murine PANC02), lung cancer ((A549, H460), prostate
cancer (DU-145), cervical cancer (HeLa), ovarian carcinoma
(A2780), liver cancer (HepG2), gastric cancer (SGC-7901),
vulvar squamous cell carcinoma (A431), oesophageal squamous
carcinoma (WHCO5), and mouse melanoma (B16F10). Non-
cancerous lines, such as lung fibroblasts (MRC-5, WI-38), skin
fibroblasts (Hs27) immortalized cells from mice (3T3), green
monkey (Vero), humans (293N3S, HS-27, HaCaT), or SV-40
transformed bronchial epithelium (BEAS-2B) were also used.
From most of the published mechanistic studies a clear
distinction can be established between mechanisms of
action of chelidonine [1] and sanguinarine [12]/berberine
[28]/chelerythrine [9].
Sanguinarine [12], chelerythrine [9], and berberine [28]
possess strong affinity to binding G-quadruplex in telomeres
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TABLE 2 | Influence of C. majus and its alkaloids on various cell lines in vitro.
Cell line Tested extracts/compounds Main observed outcome/response References
HaCaT—human keratinocyte Dry extract-−0.68% alkaloids, pure
berberine [28], chelidonine [1],
chelerythrine [9], hydrastinine,
sanguinarine [12]
Antiproliferative activity with IC50 lowest for sanguinarine
(2.26µM), extract (as chelidonine) ca. 5.68µM, chelidonine and
chelerythrine ca. 28µM, low activity of berberine and hydrastinine;
Vavrecˇková
et al., 1996
WHCO5 -squamous esophageal
cancer, HeLa, Vero, 293Graham,
HS-27 -transformed human foreskin
fibroblasts
Chelidonine [1] 10-134µM Cytotoxic to all types of cell lines, little specific to malignant cells
(HeLa, WHCO5), mitotic arrest, slippage, upregulated cyclin B1
and cdc2 activity, activation of SAPK/JNK cascade, disruption of
tubular network;
Panzer et al.,
2001
DU-145—human prostate carcinoma
from brain metastasis,
MCF-7—human breast
adenocarcinoma, A549—human lung
carcinoma, HepG2—human
hepatocellular carcinoma, HT-29
human rectosigmoid adenocarcinoma
Chelidonine [1] and stylopine [33] Chelidonine cytotoxic to DU-145, MCF-7, and HT-29 (IC50 18.4,
8.30, 5.90µM, respectively) whereas stylopine active against
DU-145 and MCF-7 only (IC50 13.9 and 16.6µM, respectively);
Lee et al.,
2007
Raji—human lymphoma C. majus 40% ethanol (vodka) extract
10–200µg/ml, equimolar mix of
chelerythrine [9] and sanguinarine [12]
0.2–10µg/ml
Complete cell kill by extract above 10µg/ml (strongest among 61
tested traditional Russian and Siberian medicinal plant species)
and by alkaloid mix above 5µg/ml
Spiridonov
et al., 2005
Murine Nk/Ly lymphoma Chelidonine [1], chelerythrine [9],
coptisine [31], sanguinarine [12]
1-40µg/ml
Chelerythrine and sanguinarine strong cytotoxic (LD50 4, 25 and
6.2µM, respectively), low activity of chelidonine and coptisine;
strong correlation to DNA intercalation and genotoxicity (Comet
assay)
Kaminskyy
et al., 2006
Murine (L1210) and human (HL-60)
leukemia
MeOH extract, 10–100µg/ml Cytotoxicity by apoptosis induction (DAPI staining), HL-60 cells
more susceptible with 100% growth inhibition at 75µg/ml (ca.
70% in L1210);
Nadova et al.,
2008
Human T cell lymphoblastic leukemia Chelidonine [1], sanguinarine [12]
1–10µg/mL
Sanguinarine stronger cytotoxic (IC50 ca. 2.5µM, 100% reached
at 1.5µM) than chelidonine (maximum 60% cell toxicity at a
highest dose). Apoptosis induction comparable in two alkaloids
(microscopy and cas-3 and Bax expression), but low genotoxicity
of chelidonine; chelidonine but not sangunarine induced G2/M
arrest;
Philchenkov
et al., 2008
HL-60 Chelerythrine [9] Cytotoxicity with IC50 of 2.6µM, cell cycle arrest in G1, apoptosis
induction (annexin, cas-8 activity) and necrosis;
Vrba et al.,
2008
HepG2 Chelidonine [1] 0.1–100µM ca. 50% cell toxicity, dose independent; apoptosis and autophagy
induction; decrease of telomerase activity and expression of
hTERT subunit of telomerase (at 0.1µM); long term treatment with
0.1µM induced senescence.
Noureini and
Wink, 2009
HeLa (human cervical cancer), PBMC
(peripheral blood mononuclear cells)
Chelidonine [1] from ethanole extract
isolated via MTT cytotoxicity guides
chromatography, test conc.
22.5–37.5µg/ml
Selectively cytotoxic to HeLa cells (LD50 ca. 85µM); apoptosis
induction (microscopy, annexin staining), cell cycle arrest (G0-G1),
upregulation of p38, p53, cas-3, cas-9, Bax, APAF-1,
down-regulation of PI3K, AKT, JAK3, STAT3, Bcl proteins,
corroborating with RT-PCR;
Paul et al.,
2013
HepG2, PBMC Chelidonine [1], nano-encapsulated
chelidonine [1]
HepG2 selective apoptosis promotion and cell cycle arrest (G2/M),
modulation of apoptosis-associated genes transcription and
protein levels; stronger effect of chelidonine in nanoformulation
(e.g., IC50 in MTT assay was 2.91 vs. 5.45µM), supported by its
higher bioavailability in mice;
Paul et al.,
2013
B16F10–murine melanoma, MCF-7-,
3T3—murine embryonal fibroblasts
Mixture of allocryptopine, chelidonine
[1], protopine, sanguinarine [12],
stylopine [33] (all 3.3µg/ml)
Cytotoxic (up to 55%) to all lines, slightly selective to mouse
melanoma; changes in alkaloid conc. in the medium and cell
lysated was measured but no correlation of the cellular uptake to
the toxicity was found;
Kulp et al.,
2011; Kulp
and Bragina,
2013
HeLa, HepG2, Caco2—human colon
adenocarcinoma, human T cell
leukemia—standard CCRF-CEM and
multidrug resistant CCRF/ADR5000
MeOH extract from Ch. herba (HPLC
tested) 5–4,000µg/ml and pure
chelidonine [1] 5–500µM
(concentrations of extract and
chelidonine [1] didn’t match in the
experiments)
Cytotoxicity selective against some lines (most susceptible
CCRF-CEM, moderate HepG2 and HeLa, resistant Caco2 and
CCRF-ADR5000 to extract but not chelidonine) and apoptosis
promotion; chelidonine much more effective than extract;
enhanced doxorubicine toxicity in resistant cells, inhibition of ABC
transporters; a number of cell death, efflux pumps, metabolism
related genes were modulated—down regulation of MDR,
upregulation of cell death and cell cycle control genes;
El-Readi
et al., 2013
(Continued)
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TABLE 2 | Continued
Cell line Tested extracts/compounds Main observed outcome/response References
MCF-7 Chelidonine [1] 0.25–250µM,
berberine [28] 1–1,000µM
Strong chelidonine cytotoxicity (LD50 ca. 8 vs. 54µM berberine);
apoptosis dominating at lower (<5µM) and autophagy at higher
conc.; senescence induction at 0.05µM for 33 days; telomerase
suppression by chelidonine via down regulation of hTERT
expression and inhibition of enzyme activity—interaction with
G-DNA excluded;
Noureini
et al., 2017
HepG2 Dichloromathane, ethanol, 50%
ethanol, water extracts from C. herba
(characterized by NMR and HPLC),
diluted 1:501
Inhibition of cell proliferation, highest by ethanolic extract, followed
by dichloromethane (no activity of water extract); activation of
genes (whole genome microarray) related to drug metabolism,
oxidative stress and cellular damage; no correlation to the alkaloid
content;
Orland et al.,
2014
PANC-1—human pancreatic cancer,
PANC02—mouse pacreas cancer,
HT-29—colon cancer,
MDA-MB-231—human mammary
gland cancer, BEAS-28—human
bronchial eppithelium
(non-cancerous), 3T3,
PC-EM—primary endometrial cancer
cultures (from surgery)
80% ethanol extract and n-hexane
defatted ethanol extract
1–1,000µg/ml (standardized by
HPLC), Ukrain®
Cytotoxic to cancer lines (IC50 19.4–57.8µg/ml), with
MDA-MB-231 significantly more resistant than other lines; lower
cytotoxicity in 3T3 and PC-EM cells; pilot in vivo results of
anti-metastatic effect against transplanted PANC02 in mice but no
significant effect on tumor growth;
Capistrano
et al., 2015
MDA-MB-231 Chelidonine [1] 0.3–10µM Inhibition of collagen-stimulated cell migration and invasion (but
not fibronectin-induced); mechanisms include suppression of actin
cytoskeleton reorganization, inhibition of integrin signaling via
suppression of ILK association with other components of IPP
complex essential for adhesion;
Kim et al.,
2015
A431—human squamous cells
epidermoid carcinoma
C. majus (parts used undefined) water
extract, no standardization,
50–500µg/ml
Increase of cas-3 activity, three-fold increase of apoptotic cells;
modulation of cell death related genes—mRNA down regulation of
Bcl-2, survivin and Mcl-1, upregulation of p21 and Bax; increase
of p38, MEK, and ERK phosphorylation (activation), inhibition of
NFκB activation;
Park et al.,
2011
Human lung carcinoma (A549, H460),
colon carcinoma (HCT116, SW480),
breast (MCF-7, MDA-MB231), PBMC
C. majus whole plants, dried ethanol
extract, standardized for alkaloids
and polyphenols, 16–500µg/ml
Selectively and differently toxic to cancerous cells, non-toxic to
PBMC. IC50 between 44 and 143µg/ml, depending on cell line,
also synergistic activity with doxorubicin in its lower (1–2µM)
concentrations, antagonistic in higher dox doses; apoptosis
induction (annexin, microscopy); G2/M arrest; inhibition of cell
migration by scratch assay;
Deljanin et al.,
2016
Jurkat E6.1 mutant—human T cell
leukemia, MOLT4—human T cell
lymphoblastic leukemia,
U937—human histiocytic lymphoma,
HEL92.1.7—human erythroleukemia,
Raji—human Burkitt lymphoma,
HL-60, A2780—human ovarian
endometrioid adenocarcinoma, A549,
human primary lung fibroblast
(MRC-5 and WI-38), PBMC
Chelidonine [1], homochelidonine [1],
1–20µM
Cytotoxic effect differing between cell lines (IC50 1.8–5.0µM),
chelidonine stronger than homochelidonine, strongest effect
toward MRC-5, and mutated Jurkat cells; induction of apoptosis
with involvement of mitochondrial pathway; biphasic cell cycle
arrest (G1, G2/M) by homochelidonine, but only G2/M by
chelidonine; increase in H3 histone phosphorylation, activation of
checkpoint kinases, inhibition of cell adhesion, interference with
tubular skeleton, nuclei fragmentation;
Havelek et al.,
2016a,b
SGC-7901 human gastric carcinoma Chelidonine [1] 5–160µM Cytotoxic with IC50 at 23.13µM; apoptosis inducing
(microscopy); increase of histone H3 phosphorylation,
time-dependent regulation of mitotic slippage associated protein
levels—BubR1 (a checkpoint kinase), Cdk-1, cyclin B1; increase
of cas-3 expression; G2/M arrest; microtubule polymerization
inhibition causing mitotic catestrophe;
Qu et al.,
2016
MCF-7 Berberine [28]-−50–500µM,
chelerythrine [9]-−2–25µM,
chelidonine [1]-−5–100µM,
papaverine, sanguinarine
[12]-−2–25µM
Different toxicity (IC50 = 2.5, 3.0, 8.0, 54.0, and 120.0µM for
chelerythrine, sanguinarine, chelidonie, berberine, and
papaverine); strong inhibition of telomerase and hTERT expression
by chelerythrine and sanguinarine, but only of hTERT expression
by chelidonine; strong binding of chelerythrine and sanguinarine to
telomeric G quadruplex, confirmed by docking;
Noureini
et al., 2017
(Continued)
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TABLE 2 | Continued
Cell line Tested extracts/compounds Main observed outcome/response References
REPORTS WHERE UKRAIN® WAS USED AS AN ACTIVE SUBSTANCE
Jurkat - various modifications (A3,
J16, Cas-9 DN expressing, cas-8 and
FADD-negative, CD95/TRAIL
resistant A3, Bcl-2 overexpressing,
cFLIP-L expressing)
Ukrain® (5–50µg/ml) and alkaloid
standards
Ukrain® disproved from being a derivative—just mixture of native
alkaloids by mass spectrometry; strong apoptosis induction by
Ukrain® and activation of caspases (3 and 8); apoptosis mediated
by mitochondrial pathway; similar activity observed for
chelidonine, chelerythrine, and sanguinarine;
Habermehl
et al., 2006
Ewing sarcoma cell lines
(CADO-ES-1, VH-64, STA-ET-1,
STA-ET-2.1)
Ukrain® 0.05–50µM, C. majus
alcohol extract (commercial,
standardized to 1.2 mg/g chelidonine
[1])-−0.5–500µM chelidonine [1]
Different cytostatic activity depending on the target line: STA-ET-1
and VH64 more sensitive (mean GI50 was 11.9µM for Ukrain
®
and 12.3µM for extract)
Lanvers-
Kaminsky
et al., 2006
human glioblastoma T60, T63 Ukrain® Significant inhibition of cell proliferation at 10µM, aopoptosis
induction, increase of glial fibrillary acidic protein—crucial for lower
malignancy adn tumor growth suppression;
Gagliano
et al., 2006,
2007
Caki-1, ACHN—renal clear cell
(Caki-1, ACHN) and papillary (Caki-2)
renal metastatic carcinoma
Ukrain® Reduced cell proliferation (10µM), modulation of malignant
phenotype and invasiveness, by inhibition of MMP activity and
downregulation of secreted and upregulation of intracellular
SPARC protein levels;
Gagliano
et al., 2011
Pancreatic ductal adenocarcinoma
(HPAF-II, HPAC, PL45)
Ukrain® Reduced cell proliferation (10µM), retaining of epithelial
phenotype; decreased invasiveness by inhibition of MMP activity
and downregulation of secreted and upregulation of intracellular
SPARC protein levels; modification of mitotic spindle microtubules;
Funel et al.,
2010;
Gagliano
et al., 2012
Murine (4T07, TUBO) or human
(SKBR-3) breast cancer, 3T3
Ukrain® Moderate (13–30%) cell death induction specific for cancerous
lines. Inhibition of proliferation regain potential; induction of
apoptosis (annexin, caspase-3 activity); verified by an in vivo
experiment—diminished tumor growth in mice;
Bozeman
et al., 2012
4T1—murine mammary gland cancer,
B16F10
Ukrain®, in combination with several
cytostatic drugs
IC50 was 40µM (4T1) and 76µM (B16F10), synergistic effect with
bortezomid;
Savran et al.,
2014
which leads to blocking telomerase activity in fast proliferating
cells (Noureini et al., 2017).
Unlike the quarternary alkaloids, chelidonine [1] is only
a weak DNA intercalating agent and does not induce lethal
mutations or DNA damage. Its mechanism of action is suggested
to rely on interactions with spindle microtubules leading to
cell cyle arrest and mitotic catastrophe, inhibition of ABC
transporters thus abolishing multidrug resistance and finally
modulation of gene transcription (telomerase, cell death-related,
cell cycle-controlling). These properties combined with the
stronger-acting intercalating alkaloids can make the whole
alkaloid fraction a unique multifaceted agent targeting cancer
cells.
For example, El-Readi et al. (2013) demonstrated complex
interaction of chelidonine [1] and alkaloid-rich extract with
several signaling pathways, including those responsible for cell
cycle, cell death, and proliferation. Using microarrays confirmed
by RT-PCR data, it was shown that a set of genes associated
with multidrug resistance (e.g., ABC transporters and CYP) were
significantly downregulated (from 50% in case of CYP3A4 to
99% in ABCG2). On the other hand, caspase-3 and 8 genes
were upregulated (up to 27-fold). These results explain the
strong augmenting of doxorubicin toxicity to resistant Caco-
2 and CCRF/ADR5000 cells. Upon low-dose treatment with
chelidonine [1] (20µM), the LC50 decreased from 3.67µM
(Caco-2) and 32.16µM (CCRF/ADR5000) to 0.42 and 7.4µM,
respectively. Similar results were obtained with an adequate
concentration of extract (5µg/ml) containing (in decreasing
order) chelidonine [1], coptisine [31], stylopine [33], and
protopine [37] as four major compounds and smaller amounts
of other alkaloids. In the more resistant CCRF/ADR5000 cells
the effect of extract was even stronger than pure chelidonine [1],
suggesting that some of the other alkaloids are more efficient P-
gp inhibitors. Induction of apoptosis was the major mechanism
of cytotoxicity, also supported by increase of caspase activity and
annexin staining.
These results support the potential of chelidonine [1] (and at
least some other C. majus alkaloids) as ideal agents to overcome
MDR as targeting both transport proteins, metabolic enzymes
and pro-apoptotic pathways.
The interference of chelidonine [1] with the cell proliferation
apparatus was also demonstrated using planarian stem cell model
(Isolani et al., 2012) in which the gene expression of mcm2
(essential DNA replication factor) or inx-11 (a gap-junction
protein essential for regeneration) was decreased by 20µM of
the alkaloid. The stem cells were affected but not differentiated
populations such as neuronal or intestinal.
Quite a particular story pertains to the mentioned earlier
patented product referred to as a semisynthetic derivative of
alkaloids—a trimeric structure with thiophosphoric acid moiety
connecting alkaloid molecules. It has been mentioned in the
literature as NSC-631570 or Ukrain R©. However, one of the
major doubts regarding this product is its chemical identity
(Panzer et al., 2000; Habermehl et al., 2006; Jesionek et al.,
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2016). Despite the earlier manufacturer claims, it couldn’t be
positively confirmed that it is indeed a thiophosphoric acid
complex and at least in some batches, it appeared as a rich
mixture of native alkaloids, that have been identified using
reliable chromatographic and spectroscopic methods.
Several papers additionally report cytotoxic activity of
Ukrain R© on other cell lines such as prostate cancer (LNCaP,
PC-3), glioblastoma (T60, T63, primary cancer line), pancreatic
ductal adenocarcinoma (HPAF-II, HPAC, PL45, renal clear cell or
papillary cell-derived lines (Caki-1, Caki-2, ACHN), melanoma
(B16F10) and murine (TUBO, 4T1) or human (SKBR-3) breast
cancer (see Table 2 for respective references).
However, due to the conflicting data about the chemical
identity of this product, the previous results would have to be
repeated or reinterpreted. If indeed Ukrain R© is just a version
of alkaloid mix, all the research done using it as an active
substance would extend the scope of anticancer properties of
C. majus native alkaloids. One of the early interesting findings
is radiosensitizing influence of Ukrain R© (Cordes et al., 2002,
2003) and it should be verified using non-modified alkaloid-rich
extract and individual compounds to find out which of them
or a combination would be responsible for this property. Also,
other studies reporting Ukrain
R©
as an active principle need re-
evaluation with native alkaloids as probably constituting major
component in the patented preparation. Moreover, Ukrain R©
remains the only preparation from C. majus that has a vast
literature documenting its anti-cancer and also other properties
in clinical (see the respective section in the present paper),
pre-clinical and in vivo studies.
Anti-inflammatory and Immunomodulating
Some of the versatile traditional uses of C. majus can be
explained, as inmany other herbs, by anti-inflammatory potential
targeting various pathways in the organism as well as modulation
of immune response. Both have been confirmed in many studies
using in vitro cellular models, as well as in vivo.
The ability to inhibit inflammation or, in some cases, to
stimulate immune response and mitigate excessive reactiveness
can contribute to the postulated anticancer properties and
improve symptoms of gastric disorders as well.
Schneider et al. (2016) used human colon cell line (NCM460)
to check anti-inflammatory action of composite preparations
containing C. majusmarketed and popular in Europe and any of
the individual components. C. majus extract was among the most
potent in a couple of checked parameters, such as inhibition of
IL-8, MCP, and I-TAC secretion, thus contributing significantly
to the overall and apparently synergistic combination of active
principles. This activity was likely to influence the clinical
outcome mentioned below (Abdel-Aziz et al., 2017).
Mostly, the total extracts or isolated alkaloids were tested,
but in our opinion, other components such as hydroxycinnamic
derivatives, flavonoids and chelidonic acid are likely to contribute
significantly. Chelidonic acid [45] was efficient in mouse models
of ovoalbumin-elicited allergic rhinitis (Oh et al., 2011) and
ulcerative colitis (Kim et al., 2012). This compound also
attenuated inflammatory responses by reducing levels and gene
expression of several mediators and enzymes in colon tissues
(COX-2, HIF1α, PGE2) and in allergic mice (IL-4, IL-1β, COX-2,
caspase-1, and increase of IFN-γ). In human mast cell line
HMC-1 stimulated for inflammatory response by the phorbol
ester (TPA) and calcium ionophore A23187, chelidonic acid [45]
inhibited IL-6 expression by blocking NFκB (Shin et al., 2011).
Stylopine [33] added to the cell culture of in
lipopolysaccharide-stimulated RAW264.7 macrophages was
inhibiting production of several proinflammatory molecules
such as nitric oxide, PGE2, TNF-α, IL-1β, and IL-6 (Jang et al.,
2004). Also, iNOS and COX-2 protein levels were lowered.
However, the cyclooxygenase activity inhibition was not
selective. Chelidonine [1] and 8-hydroxydihydrosanguinarine
[14a] in the same model inhibited NO production and iNOS
and COX-2 gene transcription (Park et al., 2011). These
results suggest the underlying inhibition of NFκB as potential
mechanism but it wasn’t investigated in this study. However, in
HCT-1 colon cancer cell line treated with chelidonine [1], the
NFκB activation was blocked by inhibition of IκBα degradation
and nuclear translocation of p65 (an NFκB subunit) as well as
mitogen-activated protein kinase pathway activation by blocking
c-Jun N-terminal kinase and p38 phosphorylation (Zhang et al.,
2018).
Alkaloid fraction and sanguinarine [12] were efficient against
carrageenan-induced rat paw edema but chelerythrine [9]
showed lower activity (Lanfeld et al., 1981). However, in the later
study by Mikołajczak et al. (2015), various fractions of water
extract at relatively high doses of 200 mg/kg body weight failed to
alleviate the inflammation in the similar model. The crude water
extract treatment actually aggravated the paw inflammation.
Conversely, the extracts containing mainly coptisine [31] and
chelidonine [1] were effective in hot plate test for antinociceptive
properties that suggests a supramedullary way of action.
Chelerythrine [9] inhibited inflammatory and pain reaction in
several in vivo and cell models employed by Niu et al. (2011).
In vivo, i.p administration of the alkaloid (1–5 mg/kg) alleviated
mouse ear edema, rat paw edema, and abdominal constriction
(pain reaction). Also, the isolated peritoneal macrophages upon
treatment with 0.0001–1µg/ml chelerythrine [9] had dose
dependently reduced PGE2 and COX-2 expression.
In NC/Nga mice model for atopic dermatitis induced by
DNCB (1-chloro-2,4-dinitrobenzene), the hydroethanolic extract
from aerial parts alleviated several measures of dermatitis
such as itching behavior and skin severity (Yang et al., 2011).
Interestingly, the oral administration at doses of 200mg and 400
mg/kg were even more efficient than topical application as 1
and 2% smear. The IgE levels were put back to control values
upon the higher dose oral administration and reduced by about
50% after topical treatment. Also, IL-4 and TNF-α serum levels
were significantly reduced but remained higher than in control
animals.
In an animal model of ovoalbumine-provoked asthma,
chelidonine [1] suppressed eosinophile-mediated inflammation.
The activity at the doses of 1 and 5 mg/kg body weight was
similar to 0.5 mg/kg body weight dexamethasone. Among the
several monitored parameters such as different pro-inflammatory
cell population counts in bronchoalveolar lovage fluid and lungs,
IgE, and cytokine protein and transcripts levels, some were
inhibited even stronger than by dexamethasone (total BALF cells,
Gr-1+/CD11b+ cells, IL-4), whereas others were inhibited either
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similarly or weaker than the standard drug. It suggests a specific
mechanism involving STAT6 and Foxp3 transcription pathways
(Kim et al., 2015).Yet another inflammation-based condition
absent from list of traditional indications, in which C. majus was
found to be efficient is arthritis (Lee et al., 2007). In the mice
model of collagen-induced arthritis, aqueous-methanol extract
at the oral doses of 40 and 400 mg/kg body weight, suppressed
progress of joint damage as well as a set of studied inflammation-
related cellular and biochemical parameters. In the higher dose
regime, the incidence of arthritis decreased from 100 to <40%
during 4 weeks. Cell invasion into lymph nodes, spleen, thymus
and synovial fluid was inhibited in all organs, but most marked
effect was in lymph nodes and joints. Among the tested T
cells populations, there was an insignificant decrease of CD4+,
CD8+, and CD3e+ cells, but a quite remarkable decrease of
CD19+ B cells, almost to the level of non-arthritic animals.
On the other hand, the number of regulatory CD4+CD25+
T cells increased significantly that suggests mobilizing adaptive
response of the immune system to counteract and balance the
excessive inflammatory processes. Suppression of inflammation
mediators such as IL-6, TNFα, IFNγ was observed as well as
lowered level of IgG and IgM but the latter only upon the higher
dose treatment. However, the extract was not standardized an no
particular compound or phytochemical class could be pinpointed
as determining this potent anti-arthritic action.
A couple of reports indicate a potential of C. majus
against Alzheimer’s progression due to significant inhibition
of acetylcholinesterase (AChE) without influence on
butyrylcholinesterase (BuChE), which is a desired profile
for potential drug-likeliness. The extract inhibited AChE in vitro
by 98% at a concentration of 200µg/ml and BuChE by only 13%.
The isolated alkaloid 8-hydroxydihydrochelerythrine [10a] was
the most active and AChE-selective (IC50 0.61µM and selectivity
index 56.7) (Cho et al., 2006). In another study, chelidonine
[1] and other active alkaloids were completely unselective with
similar IC50 values against AChE and BuChE (Cahlíková et al.,
2010). Interestingly, the specific AChE inhibiting activity by
coptisine [31]-rich extract was discovered in vivo in a herbivore
insect Lymantria dispar in which this activity contributes to
killing the pest (Zou et al., 2017). By this property the plant is
protecting itself from herbivore attack and it would be a feasible
biological explanation of the therapeutic potential existence in
the wild growing species.
The analgetic properties of alkaloids, mentioned before
(Mikołajczak et al., 2015) can be explained by the observations
of interaction with glycine transporters (Shin et al., 2003;
Jursky and Baliova, 2011). The water extract inhibited the
glycine-activated and enhanced glutamate-activated ion current
in isolated rat periaqueductal gray (PAG) neurons studied by
patch-clamp technique (Shin et al., 2003). Chelerythrine [9] and
sanguinarine [12] selectively inhibited GlyT1 (but not GlyT2)
in the micromolar concentrations (5–10µM) while berberine
[28] showed no inhibition in transfected HEK293T cells. GlyT1
inhibition was time-dependent, noncompetitive and increased
with glycine concentration. Interestingly, chelerythrine [9] effect
was reversible while sanguinarine [12] persisted through washing
out (Jursky and Baliova, 2011).
Clinical Studies
Quite typically for many traditionally used medicinal plants, the
clinical evidence of efficacy remains scarce and C. majus is no
exception. Therefore, the relatively numerous pharmacological
studies need rigorous verification by properly designed and
supervised clinical studies. At present, most of the allegedly
curative properties toward some important complaints remain
unconfirmed, even if there is strong pre-clinical evidence. The
millennia long tradition of use becomes confirmed in a significant
part even if some mythical indications turned out to be invalid
or perhaps have been misunderstood or distorted when passed
through generations of practitioners and authors.
Several clinical studies exist on the compound preparation
STW-5 containing 10% of C. majus herb extract (Drug-to-
Extract Ratio = 1:3) as one of nine ingredients. The gastric
disorders are the main indications and was evidenced both
clinically and pharmacologically (Von Arnim et al., 2007; Abdel-
Aziz et al., 2017). Certainly, there is no proof that C. majus was
the essential ingredient in this preparation but the functional
dyspepsia/postprandial distress syndrome it seems to be one
of the most active (Abdel-Aziz et al., 2017) influencing acid
regulation and antrum contraction as well asmoderatemitigation
of inflammatory reactions. The mechanisms behind these effects
were also studied in vitro using cell lines showing anti-
inflammatory activity (Schneider et al., 2016). IFN-γ dependent
stat1 phosphorylation was postulated as a putative mechanism of
action in which C. majus extract was among the averagely active,
but apparently the whole composition had superior properties
suggesting synergistic rather than additive effect.
A series of older clinical trials were performed on a
product containing C. majus extract to test the efficacy in
patients with bile tract and gall bladder complaints and gall
stones. These studies, reviewed in detail in the EMA report,
suggest significant improvement of many clinical parameters.
These included: subjective complaints (pain attacks, feeling
of fullness), physician’s examination (sonography of gall
bladder and liver, liver palpation, meteorism, jaundice) and
laboratory tests (bilirubin, transaminases, blood sedimentation).
The patient conditions in which the preparation containing
C. majus alkaloids (in daily doses of ca. 0.2mg alkaloid sum
as chelidonine [1]) was administered with positive outcome
were for example: cholelithiasis, cholangitis/cholecystitis, post-
cholecystectomy, and alcohol toxic liver damage. In the entire
area of gastrointestinal/hepatic complaints, one can estimate the
number of human subjects involved in to date published clinical
literature as exceeding 1,500.
An impressive number of studies suggest antitumor properties
of the apparently semisynthetic product—Ukrain
R©
that showed
efficiency in several in vitro studies on an assortment of neoplastic
and non-transformed cell lines (Capistrano et al., 2015) but it by
large failed to demonstrate clinically relevant activity in humans.
Several case reports have been published that suggest its beneficial
action in a range of malignancies, such as melanoma, metastatic
breast cancer, various carcinomas.
The randomized clinical trials (RCTs) using Ukrain R© were
reviewed over a decade ago (Ernst and Schmidt, 2005) with a
conclusion that despite the intensive publishing activity of several
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groups testing Ukrain R© against miscellaneous malignacies with
very promising outcome, most of these data are full of
shortcomings that prevent unequivocal credibility. Since then,
only a few more studies have been realized but it is still far from
definite resolving of this issue, especially in the situation that the
chemical analyses, some of which were even co-authored by the
inventor (Jesionek et al., 2016) proved that it is not the compound
which was initially claimed.
Most of the RTCs published were full of inconsistencies or
even appeared unreliable due to the insufficient information
regarding the methodology. Despite the spectacular results in
such malignancies as pancreatic or terminal colorectal cancer,
serious doubts remain about the evidence provided in some of
these trials. Some of the studies are so poorly documented that it
would undermine the validity of the results. For example, missing
or suspect randomization method, missing methods for tumor
dimensions measuring, unclear protocols, subjective outcome
evaluation, lack of proper statistics. Also, a great majority of the
clinical trials and case reports were published in one journal.
Nonetheless, these few reports on Ukrain R© remain the only
available clinical data focusing specifically on C. majus and
strongly suggesting extraordinary antitumor potential.
Since the potential conflicts of interest, reliability of the
clinical and chemical data of this product have been disputed
repeatedly (Farrugia and Slevin, 2000, 2001; Nowicky, 2001; Ernst
and Schmidt, 2005), more studies are indeed mandatory also in
this aspect of C. majus as a source of highly potent substances
with multidirectional mechanisms of action. Nonetheless, it
should be borne in mind that approval of an extract/mixture
based drug for clinical practice in such a sensitive field as
oncology is highly improbable at the moment, and most likely
it would remain so in the near future. Thus, further studies are
mandatory that would focus on using individual alkaloids as
lead structures for drugs that would target multiple anticancer
mechanisms. On the other hand, clinical data on efficacy of
various C. majus products used in complementary or adjuvant
therapy may facilitate the tedious process of drug development
without changing the existing paradigm of chemotherapy
based on combination of chemically defined substances. Quite
differently from the relatively safe (with limitations described
below) gastrointestinal and cutaneous indications, the cautious
policies of EMA and other agencies demonstrated in case
of declared anticancer actions are reasonable and should be
continued.
Toxicology and Safety Issues
Repeatedly, studies and case reports occur that suggest hepatic
injury/hepatotoxicity. It is especially important because one of
the main indications of C. majus relates to liver and biliary
tract disorders due to its cholagogue and hepatoprotective
activities. The incidence of hepatotoxic cases and the possible
clinical importance and safety issues have been reviewed
recently (Pantano et al., 2017). Specifically, the results from
animal studies are ambiguous and suggest a rather complex
mixture of various mechanisms, such as inducing or alleviating
oxidative stress or modulation of hepatic enzymes such as
MAO and SOD, or slowing down mitochondrial respiration.
The mitochondrial toxicity was related to DNA intercalating
properties of sanguinarine [12] and chelerythrine [9].
In humans, numerous reports have been recorded since the
1990’s. The main symptoms included cholestasis and mild to
severe liver impairments with quite well documented causality in
a majority of cases. In total, over 50 such cases have been reported
from Europe, mostly from Germany (Etxenagusia et al., 2000;
Stickel et al., 2003).
However, no certain constituent has been directly linked to the
toxicity of the herb. On the contrary, it has been suggested that
drug interactions rather than intrinsic toxicity are responsible for
reported cases. Also, individual hypersensitivity or allergy has to
be considered. Latex contained in the fresh plant is also possibly
more toxic or allergenic than the dried material (EMA report,
2011).
In an in vitro study on HepG2 cells treated with various
solvent extracts (Orland et al., 2014), the biotransformation
and toxicity-related gene expression was enhanced, but
the dichloromethane extract richest in chelidonine [1] and
total alkaloids was the weakest inducer and least cytotoxic,
whereas ethanolic extracts containing more coptisine [31] and
sanguinarine [12] were more cytotoxic. However, the in vivo
relevance of these results is uncertain. In rats, the high doses (up
to 3g/kg body weight; Mazzanti et al., 2009) did not elicit any
symptoms of hepatic injury and did not alter liver function.
Despite proven interaction of sanguinarine [12] and other
alkaloids with DNA, no genotoxicity was observed using well
established methods such as Ames tests or in vivo DNA damage
(EMA report, 2011).
Nonetheless, uncontrolled internal use of unstandardized
preparations should be discouraged and appropriate
pharmacovigilance measures should be implemented to prevent
unnecessary complications following C. majus administration.
The comprehensive pharmacotoxicological investigation is also
needed and should encompass establishing toxic doses range of
various forms and preparations as well as individual constituents.
The European Medicine Agency therefore published the
following recommendation:
“Two possible therapeutic indications were proposed for the
monograph:
Traditional herbal medicinal product:
1) For symptomatic relief of digestive disorders such as
dyspepsia and flatulence (oral intake)
2) For treatment of warts, callus and corns (cutaneous use)”
(EMA, 2011).
However, based on the reported undesirable effects, including
cases of liver damage, special precautions are necessary, especially
during pregnancy and lactation, people suffering from liver
diseases or taking liver-damaging drugs.
CONCLUSIONS AND FUTURE OUTLOOKS
Much effort has been put into the recognition of bioactive
compounds contained in the extracts of C. majus and the
mechanisms of their action. Numerous reports have been
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published about its effectiveness in treatment of different medical
complaints, such as gastrointenstinal and hepatobiliary disorders
or cutaneous ailments caused by a microbial or viral infection.
Next to the huge number of scientific reports indicating the
beneficial effect of C. majus, information about its potential
toxic properties emerged. The use of herbal remedy carries
the risk of adverse effects, which is why it is important to
know the raw material. Official recommendations do not exclude
the use of C. majus as traditional herbal medicinal product.
Therefore, further research on the mechanisms of action during
treatment should be carried out. It is also important to control
the phytochemical composition of the raw material both in
conventional growing conditions and in vitro cultures. The more
so, because the potential risk of carcinogenesis and hepatotoxicity
is still not well documented.
Finally, we conclude that the millenia long history of
Chelidonium in folk, traditional, and official medicine is far from
coming to the end. On the contrary, recent years witnessed a
revival of advanced pharmacological andmechanistic approaches
using both native complexes and individual components in
discovery of the therapeutic potential of this herb. We are
quite convinced that in the near future, at least some of
the already known and evidence-based properties should and
would find their place in officially recognized therapeutic
procedures. Moreover, new discoveries should broaden the scope
of traditional usage and deliver better preparations, especially
combining different classes of active molecules such as proteins,
alkaloids, chelidonic acid, and perhaps also polyphenols. To
achieve it, much more joined and interdisciplinary efforts are
necessary. Further, the plant’s diversity on different levels must be
thoroughly evaluated and optimal combination of the complex
profile should be established for various target applications. As
one of the oldest proverbs from Aristotle’s book, also referring
to C. majus original Greek name, “one swallow does not
make a spring,” even if we observe a lot of “first swallows,”
we urgently need more, to ensure rational exploitation of
the huge potential hidden in the inconspicuous and common
weed.
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The dried flowers of Chamaemelum nobile (L.) All. have been used in traditional medicine
for different conditions related to the spasm of the gastrointestinal system. However,
there have been no experimental studies to support the smooth muscle relaxant effect
of this plant. The aim of our research was to assess the effects of the hydroethanolic
extract of Roman chamomile, its fractions, four of its flavonoids (apigenin, luteolin,
hispidulin, and eupafolin), and its essential oil on smooth muscles. The phytochemical
compositions of the extract and its fractions were characterized and quantified by
HPLC-DAD, the essential oil was characterized by GC and GC-MS. Neuronally mediated
and smooth muscle effects were tested in isolated organ bath experiments on guinea
pig, rat, and human smooth muscle preparations. The crude herbal extract induced an
immediate, moderate, and transient contraction of guinea pig ileum via the activation
of cholinergic neurons of the gut wall. Purinoceptor and serotonin receptor antagonists
did not influence this effect. The more sustained relaxant effect of the extract, measured
after pre-contraction of the preparations, was remarkable and was not affected by an
adrenergic beta receptor antagonist. The smooth muscle-relaxant activity was found to
be associated with the flavonoid content of the fractions. The essential oil showed only
the relaxant effect, but no contracting activity. The smooth muscle-relaxant effect was
also detected on rat gastrointestinal tissues, as well as on strip preparations of human
small intestine. These results suggest that Roman chamomile extract has a direct and
prolonged smooth muscle-relaxant effect on guinea pig ileum which is related to its
flavonoid content. In some preparations, a transient stimulation of enteric cholinergic
motoneurons was also detected. The essential oil also had a remarkable smooth muscle
relaxant effect in this setting. Similar relaxant effects were also detected on other visceral
preparations, including human jejunum. This is the first report on the activity of Roman
chamomile on smooth muscles that may reassure the rationale of the traditional use of
this plant in spasmodic gastrointestinal disorders.
Keywords: Roman chamomile, Chamaemelum nobile, Asteraceae, organ bath experiment, gastrointestinal
preparations, spasmolytic effect, contractile action
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INTRODUCTION
Chamaemelum nobile (L.) All. (Asteraceae), widely known
as Roman chamomile, is a perennial herb native to South-
Western Europe, but it is cultivated as a medicinal plant
all over Europe and in Africa as well. Dried flowers of the
cultivated, double-flowered variety of the species are official in
the European Pharmacopoeia (European Pharmacopoeia, 2008).
Incorporating the plant in traditional herbal medicinal products
has been acknowledged by the European Medicines Agency. The
comminuted herbal substance (as tea) and a liquid extract of
the plant (extraction solvent: ethanol 70% v/v) may be used for
the symptomatic treatment of mild, spasmodic gastrointestinal
complaints including bloating and flatulence. The British Herbal
Pharmacopoeia indicates its use as carminative, anti-emetic,
antispasmodic, and sedative (British Herbal Pharmacopoeia,
1971).
Roman chamomile (RC) has been used as a medicinal plant
from the middle ages. The cultivation of the plant started in
England in the 16th century (Hiller and Melzig, 1999). The
double variety of the flower, which now serves as the main
commercial drug, has certainly been known since the 18th
century (Evans, 1989). The plant gained the name “nobile”
(Latin, noble) to illustrate its superior therapeutic efficacy over
Matricaria recutita L. (German chamomile) (Hiller and Melzig,
1999). The plant was first listed in the Pharmacopoeia of
Württemberg (1741) as a carminative, painkiller, diuretic, and
digestive aid (Lukacs, 1990). In the folk medicine of different
regions of Europe, RC has been used for numerous conditions,
including dyspepsia, flatulence, nausea and vomiting, anorexia,
vomiting of pregnancy, dysmenorrhoea, and specifically for
gastrointestinal cramps and flatulent dyspepsia associated with
mental stress (Augustin et al., 1948; Rápóti and Romváry, 1974;
Melegari et al., 1988; Rossi et al., 1988; Bradley, 1992). In
the Mediterranean region, RC tea is consumed to improve
appetite and also after meal to prevent indigestion (Rivera and
Obon, 1995; Menendez-Baceta et al., 2014; Alarcün et al., 2015).
Traditional use of RC is largely related to its supposed smooth
muscle-relaxant activity.
The majority of the secondary metabolites described from the
plant belong to the aliphatic esters (essential oil) (Fauconnier
et al., 1996), sesquiterpene lactones (Bisset, 1994) and flavonoids
(Herisset et al., 1971, 1973; Abou-Zied and Rizk, 1973; Pietta
et al., 1991). The polysaccharide content of the dried flower
is noteworthy, 3.9% (Lukacs, 1990). The supposed smooth
muscle-relaxant activity of the plant might be attributed to its
flavonoid content. Apigenin and luteolin possess remarkable
smooth muscle relaxant effects on guinea pig ileum (Lemmens-
Gruber et al., 2006).
Although several studies on the bioactivities of RC are
available, the majority of these studies were carried out using
the essential oil, which is not used medicinally, or the observed
activities are not related to the traditional use of the plant. Several
studies demonstrate the antimicrobial effects of RC essential oil
against different bacterial and fungal strains (Hänsel et al., 1993;
Piccaglia et al., 1993; Chao et al., 2000; Bail et al., 2009), and
antifungal activity was demonstrated also for the aqueous extracts
of RC (Magro et al., 2006). The anti-inflammatory capacity and
heat shock protein modulating effects of the flavonoids apigenin
and quercetin, as well as the anti-inflammatory activities of
α-bisabolol, guajazulene, and chamazulene have been reported
in preclinical studies (Viola et al., 1995; Baghalian et al., 2008,
2011; Hernández-Ceruelos et al., 2010). The polysaccharides of
RC exerted antiphlogistic effect in vivo (Lukacs, 1990).
Although the use of RC extract for gastrointestinal problems
seems to be related to its presumptive smooth muscle-relaxant
effect, interestingly no in vitro or in vivo studies have been
carried out so far to assess this bioactivity. However, in an
in vitro study an aqueous extract of C. nobile was demonstrated
to induce a vasorelaxant effect through the NO-cGMP pathway or
possibly through a combination of Ca2+ channel inhibition plus
NO-modulating and phosphodiesterase inhibitory mechanisms.
After the oral administration of RC aqueous extract, significant
hypotensive effect was observed in an animal study on
spontaneously hypertensive rats (Zeggwagh et al., 2009), which
may be related to the flavonoid content of the plant (Jouad et al.,
2001). The clinical efficacy of orally applied preparations has not
been studied yet, only the effects of external application (Schrader
et al., 1997) and aromatherapeutic use (Wilkinson et al., 1999)
have been reported.
The aim of the current study was to assess the effects of
a hydroethanolic RC extract, its fractions and essential oil
on gastrointestinal and urogenital smooth muscles, including
preparations of human jejunum, in order to clarify the rationale
for the use of this plant for smooth muscle relaxation.
Experiments were carried out with an extract conforming to the
monograph of the European Medicines Agency (see in section
“Preparation of Herbal Extracts and Isolation of Reference
Standards”), and also with the fractions of this extract and with
the essential oil of the plant.
MATERIALS AND METHODS
Plant Material
Roman chamomile flowers were purchased from Pál Bobvos
(Hungary). The identity of the plant material was confirmed
according to the requirements of the European Pharmacopoeia.
A voucher specimen is stored for verification purposes in the
herbarium of the Department of Pharmacognosy, University
of Szeged. RC essential oil was purchased from Aromax Ltd.
(Hungary).
Chemicals
For the pharmacological experiments the following drugs were
used: atropine sulfate (Sigma), α,β-methylene ATP lithium
salt (Tocris), capsaicin, histamine dihydrochloride, indo-
methacin, isoprenaline hydrochloride, NG-nitro-L-arginine,
papaverine hydrochloride, prostaglandin F2α (Sigma),
methysergide (Sandoz), (±)-propranolol hydrochloride
(Sigma), pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid
tetrasodium salt (PPADS), tetrodotoxin (Tocris), 8-amino
-7-chloro-2,3-dihydro-1,4-benzodioxan-5-carboxylic acid,1′-
butyl-4′-piperidinylmethyl ester (SB204070), N-(1-azabicyclo
Frontiers in Pharmacology | www.frontiersin.org April 2018 | Volume 9 | Article 323194
fphar-09-00323 April 4, 2018 Time: 18:30 # 3
Sándor et al. Spasmolytic Effect of Roman Chamomile
[2.2.2]oct-3-yl)-6-chloro-4-methyl-3-oxo-3,4-dihydro-2H-1,4-
benzoxazine-8-carboxamide hydrochloride (Y25130) (all from
Tocris). For dissolving and diluting of these drugs the following
solvents were used: 96% ethanol for capsaicin, indomethacin,
and prostaglandin F2α, DMSO for SB204070 and isotonic NaCl
solution for the rest of the drugs. Solutions in organic solvents
were administered at a maximum of 1 µl/ml, aqueous solutions
at 1 or 3 µl/ml bathing solution.
Millipore Direct-Q UV3 clarifier (Molsheim, France) was used
to produce purified water for the HPLC measurements. Methanol
and ethanol (LiChrosolv R© HPLC grade) was obtained from
Merck (Darmstadt, Germany). For chromatographic separation,
polyamide (ICN Polyamide for Column Chromatography),
Sephadex LH-20 (25–100 µm, Pharmacia Fine Chemicals), SiO2
(Silica gel 60 G, 15 µm, Merck), and SiO2 plates (20 cm × 20 cm
Silica gel 60 F254, Merck) were used.
Preparation of Herbal Extracts and
Isolation of Reference Standards
For the pharmacological experiments, RC crude extract was
prepared according to the description of the European Medicines
Agency monograph (EMA-HMPC, 2012). Ten grams of plant
material was extracted with 70% EtOH (3× 100 ml) via ultrasonic
bath, evaporated in vacuum and lyophilized (yield, 3.169%). Part
of the RC crude extract was fractionated to gain RC extract
fractions with different compositions for further experiments.
Vacuum liquid chromatography on polyamide with elution by
MeOH-H2O (20:80, 40:60, 60:40, 80:20, 100:0) was used to gain
fractions from the crude extract as follows: F20, F40, F60, F80,
and F100.
From the methanolic extract of 200 g RC flowers, four marker
compounds (used as reference standards in further experiments)
were isolated using medium pressure liquid chromatography
(SiO2 as stationary phase), gel chromatography (Sephadex
LH-20), preparative HPLC (RP), and preparative TLC (SiO2).
The purity and identity of these compounds were analyzed
by NMR. NMR spectra were recorded in MeOD on a Bruker
Avance DRX 500 spectrometer (Bruker, Fallanden, Switzerland)
at 500 MHz (1H) or 125 MHz (13C).
HPLC Experiments
HPLC experiments were carried out on a Shimadzu LC-20AD
Liquid Chromatograph (SPD-M20A diode array detector,
CBM-20A controller, SIL-20ACHT autosampler, DGU-20A5R
degasser unit, CTO-20AC column oven) using a Kinetex 5 µm
C-18 100A (150 mm × 4.6 mm) with a gradient of 0,01%
trifluoroacetic acid in H2O (A) and acetonitrile (B) as follows:
0–5 min 25% B, 14 min 28% B, 15 min 70% B, 16 min
70% B, 16.5 min 25% B, and 20 min 25% B. The flow was
1.2 ml/min, column oven temperature was 55◦C. Detection was
carried out within the range of 190–800 nm. For quantification,
chromatograms were integrated at 344 nm. The reference
standards and the evaporated extracts were dissolved in MeOH,
filtered through a PTFE syringe filter and injected in volumes of
5 or 10 µl. Calibration curves were established for all the four
reference standards.
GC and GC-MS Experiments
The GC analysis was carried out with an HP 5890 Series II gas
chromatograph (FID), using a 30 m × 0.35 mm × 0.25 µm
HP-5 fused silica capillary column. The temperature program
ranged from 60◦C to 210◦C at 3◦C min−1, and from 210◦C to
250◦C (2 min hold) at 5◦C min−1. The detector and injector
temperature was set to 250◦C and the carrier gas was N2,
with split sample introduction. Quantities of the individual
components of the essential oil were expressed as the percent of
the peak area relative to the total peak area from the GC/FID
analysis.
The GC-MS analysis was performed with a Finninan GCQ
ion trap bench-top mass spectrometer. All conditions were
as above except that the carrier gas was He at a linear
velocity of 31.9 cm s−1 and the capillary column was DB-5MS
(30 m × 0.25 mm × 0.25 µm). The positive ion electron
ionization mode was used, with ionization energy of 70 eV, and
the mass range of 40–400 amu.
Identification of the compounds was based on comparisons
with published MS data (Adams, 2007) and with a computer
library search (the database was delivered together with the
instrument) and also by comparing their retention indices
with literature values (Adams, 2007). Retention indices were
calculated against C8–C32 n-alkanes on a CB-5 MS column
(Kovats, 1965). A mixture of aliphatic hydrocarbons was injected
in hexane (Sigma-Aldrich, St. Louis, MO, United States) by using
the same temperature program that was used for analyzing the
essential oil.
Guinea Pig and Rat Preparations
Guinea pigs (short-haired, colored, 350–450 g) or Wistar rats
(220–300 g) of either sex were killed by a blow to the head and
exsanguination. Three centimeter segments of the ileum or distal
colon were placed into the organ bath in a vertical position, under
a constant tension of 7 mN. Longitudinal strip preparations
(approximately 2–3 cm in length) of guinea pig urinary bladder
or rat gastric fundus were fixed under a tension of 5 mN.
This study was carried out in accordance with University
guidelines. The protocol was approved by the Animal Welfare
Committee, University of Pécs (registration number, BA02/2000-
1/2012) with the understanding that isolated organ studies after
stunning the animal cannot be regarded as animal experiments.
Organ Bath Experiments
Smooth muscle preparations were used in a traditional organ
bath arrangement. The preparations were suspended in Krebs–
Henseleit solution of 5 or 7 ml, kept at 37◦C, and aerated with
a mixture of 95% O2 and 5% CO2. The solution contained
119 mM NaCl, 25 mM NaHCO3, 2.5 mM KCl, 1.5 mM
MgSO4, 2.5 mM CaCl2, 1.2 mM KH2PO4, and 11 mM glucose
(pH = 7.4). Movements of the preparations were recorded with
isotonic transducers (Hugo Sachs Elektronik-Harvard Apparatus,
March, Germany) on ink writers or stored online on a personal
computer.
The guinea pig ileum is a preparation of a low spontaneous
tone. In part of the experiments the effects of RC extract,
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its fractions, essential oil, or flavonoids were studied at basal
tone. All experiments commenced with determining the maximal
longitudinal spasm by adding histamine (10 µM) to the organ
bath for 2 min. This response served as reference for determining
the relative amplitude of any contractile effect that the samples to
be tested might have had.
In another set of experiments the possible relaxant effect of the
materials was tested. For this reason, a tonic, approximately half-
maximal contraction of the ileum was provoked by a moderate
concentration of histamine (0.5 µM, added for 15 min). In
preliminary experiments, no pretreatment was used. In the bulk
of the experiments, however, the muscarinic receptor antagonist
atropine, as well as tetrodotoxin, an inhibitor of nerve axonal
conduction (blocker of voltage-sensitive Na+ channels) was
added prior to the histamine administration. This was done to
avoid the interference with a possible contractile effect of the
material to be examined, i.e., to create a methodologically clear
situation.
All experiments commenced after an equilibration period
of 45 min. Relaxant effects were studied on pre-contracted
preparations (see below). Maximal spasm of the tissue was evoked
to serve as a basis for the comparisons to evaluate the responses
obtained by our test materials. The materials examined were
administered in a single concentration (i.e., in a non-cumulative
manner).
Human Jejunal Preparations
Macroscopically intact segments of human jejunum, removed
during the surgical treatment of pancreatic cancer were used.
Strips of either longitudinal or circular orientation were prepared
(the mucosa and submucosa were removed) and fixed as
described above, under a tension of 10 mN. Freeze-dried extracts
of RC, as well as the essential oil of the plant were mixed in and
further diluted with DMSO. The amounts of DMSO administered
to the jejunum preparations are indicated in the Section “Results”.
This study was carried out in accordance with the Declaration
of Helsinki and the guidelines set by the Research Ethics
Committee, Scientific Council of the Ministry of Health,
Hungary. This Committee agreed to the use of discarded
human tissue for the experimental work. The protocol was
approved by the ETT-TUKEB (Scientific Council of the Ministry
of Health, Research Ethical Committee) [No. 17861-0/2010-
1018EKU (749/PI/10)]. All subjects gave written informed
consent in accordance with the Declaration of Helsinki.
Statistical Analysis
Results of the pharmacological experiments are given as
mean ± SEM, with N denoting the number of preparations
used for testing efficacy. At most 2 preparations from the
same animal were used for each type of experiment. Results
are provided in relative values, where 100% contraction means
maximal spasm of the preparations from the basal tone and, in
pre-contracted preparations, 100% relaxation means relaxation
of the preparation to the level before adding the precontracting
agent. The Mann–Whitney U test was used for the comparisons
of two independent groups, more than two independent samples
were compared by the Kruskal–Wallis test, and two dependent
samples were compared by the Wilcoxon test. The statistical
program GraphPad Prism 5 was used throughout. A probability
of P < 0.05 or less indicated statistical significance.
RESULTS
Chemical Characterization of RC
Extracts
In the HPLC retention time range of 4–9 min, four characteristic
peaks were detected in the crude RC extract and its fractions
F40–F100. The corresponding components were isolated from
the plant material and were identified as the flavonoids
apigenin, eupafolin, hispidulin, and luteolin by 1H and 13C
NMR experiments (see Supplementary Figures S1–S6). These
compounds were further used as reference standards to
characterize the RC extracts. The identification of reference
compounds in different extracts was based on matching the
retention times and UV spectra. Retention times of luteolin,
eupafolin, apigenin, and hispidulin were 4.5, 5.0, 7.5, and
8.5 min, respectively (Figure 1). The baseline separation of
these compounds allowed their reliable quantification in different
extracts.
The crude RC extract contained eupafolin as the main
flavonoid, followed by luteolin, hispidulin, and apigenin
(Table 1). The fractionation on polyamide resulted in
subfractions F20–F100 with different compositions, as
demonstrated by the differences in their flavonoid content.
In F20, the quantities of flavonoids were below the level of
quantification. The flavonoid content of the fractions increased
with increasing MeOH content of the eluting solvent. The
highest flavonoid levels were measured in F80, except for luteolin
and apigenin, which were mainly concentrated in F100.
Chemical Characterization of RC
Essential Oil
Based on their retention times and mass spectrometric data,
methallyl angelate, 3-methyl pentyl angelate, and 3-methylamyl
isobutyrate were identified as the major constituents of RC
essential oil (19.0, 18.2, and 10.4%, respectively) (Table 2).
The identified components comprised 97% of the essential
oil. Previous articles reported isobutyl angelate as the major
constituent of RC essential oil (21.6–38.5%), followed by
2-methylbutyl angelate (11.6–20.3%) (Antonelli and Fabbri, 1998;
Farkas et al., 2003; Omidbaigi et al., 2003, 2004; Bail et al., 2009),
and propyl tiglate (10.8–13.1%) (Omidbaigi et al., 2003, 2004)
or isobutyl isobutyrate (3.3%) (Bail et al., 2009) or 2-butenyl
angelate (7.9–8.4%) (Antonelli and Fabbri, 1998) or 2-methyl-2-
propenyl angelate (9.1%) (Farkas et al., 2003). However, several
commercial samples have similar compositions to the sample
analyzed by us, with methallyl angelate and 3-methyl pentyl
angelate as the major components.
Effects on Guinea Pig Ileum
The crude RC extract induced a transient longitudinal
contraction on guinea pig ileum preparations (Figure 2).
Frontiers in Pharmacology | www.frontiersin.org April 2018 | Volume 9 | Article 323196
fphar-09-00323 April 4, 2018 Time: 18:30 # 5
Sándor et al. Spasmolytic Effect of Roman Chamomile
FIGURE 1 | HPLC chromatogram of the crude RC extract with the peaks of luteolin (1), eupafolin (2), apigenin (3), and hispidulin (4) (344 nm).
TABLE 1 | Flavonoid content of RC crude extract and its fractions as determined by HPLC.
Sample Luteolin (mg/g extract) Eupafolin (mg/g extract) Apigenin (mg/g extract) Hispidulin (mg/g extract)
Crude extract 4.617 ± 0.616 18.756 ± 2.121 0.298 ± 0.027 1.584 ± 0.181
F20 Not detected Not detected Not detected Not detected
F40 0.578 ± 0.001 1.800 ± 0.001 0.179 ± 0.001 0.231 ±< 0.001
F60 1.904 ± 0.001 62.591 ± 0.025 0.151 ±< 0.001 5.951 ± 0.004
F80 22.605 ± 0.001 223.488 ± 0.036 0.859 ±< 0.001 17.060 ± 0.006
F100 55.305 ± 0.002 150.206 ± 0.005 2.055 ±< 0.001 4.983 ±< 0.001
The amplitudes of the contractions were related to the maximal
longitudinal spasm evoked with 10 µM of histamine at the
beginning of the experiments. The threshold concentration
for this effect was equal to or below 20 µg/ml of the extract
(which was the lowest concentration tested) and reached a
plateau with 60 and 200 µg/ml. Quantitative results were as
follows (expressed as % of the maximal spasm): 18.8 ± 3.1%
at 20 µg/ml (N = 6), 40.1 ± 3.3% at 60 µg/ml (N = 11), and
36.3 ± 4.9% at 200 µg/ml (N = 7). A second administration
of the same concentration after a 40-min washout period
usually had a qualitatively similar effect. Yet, because of
variable reproducibility, we examined the effects on separate
preparations with only one administration of the extract.
The solvent of the extract (DMSO; 0.3 or 1 µl/ml) caused no
or minimal contraction (on average, 0 and 2%, respectively;
N = 12).
The 60 µg/ml concentration of the extract was used for
pharmacological analysis. Both atropine (0.5 µM), an antagonist
of acetylcholine at the muscarinic receptors and tetrodotoxin
(0.5 µM), an inhibitor of voltage-sensitive Na+ channels (hence,
of neuronal axonal conduction) inhibited the contractile effect
of RC crude extract. In contrast, the purinoceptor antagonist
PPADS (50 µM) or a combination of serotonin (5-HT) receptor
antagonists methysergide (0.3 µM), SB204070 (1 µM) and
Y25130 (1 µM) failed to influence the contractile effect of
the extract (Table 3). This combination of 5-HT antagonists is
suitable for blocking the contractile effect of 5-HT (Sandor et al.,
2016).
The functional blockade of capsaicin-sensitive neurons did
not inhibit the contractile effect of the RC extract (Barthó et al.,
2004) as compared to time-matched, solvent-treated controls
(Table 3). The cyclooxygenase inhibitor indomethacin (3 µM)
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TABLE 2 | Chemical composition of RC essential oil.
Compoundsa RIb % in samples
Methyl tiglate 867 tr
n-Hexanol 875 1.1
2-Methylbutyl acetate 897 0.4
Isobutyl isobutyrate 925 0.8
Acetonyl acetone 932 0.7
α-Pinene 935 2.4
Camphene + allyl methacrylate 958 0.6
Thuja-2,4(10)-diene 960 1.1
Isoamyl propionate 966 tr
β-Pinene 969 0.3
Myrcene 973 0.6
Propyl angelate 993 1.1
Isobutyl 2-methylbutyrate 998 tr
Isoamyl isobutyrate 1,004 1.5
2-Methylbutyl isobutyrate 1,006 2.7
1,8-Cineol 1,035 tr
Isoamyl methacrylate 1,037 1.1
Isobutyl angelate 1,058 4.9
Methallyl angelate 1,068 19.0
2-Butenyl angelate 1,119 tr
3-Methylamyl isobutyrate 1,122 10.4
3-Methylamyl methacrylate 1,150 6.6
trans-Pinocarveol + isoamyl angelate 1,153 8.6
2-Methylbutyl angelate 1,168 8.3
Pinocarvone 1,177 3.9
Prenyl angelate 1,213 1.5
Myrtenal 1,217 1.2
3-Methyl pentyl angelate 1,264 18.2
Identified components 97.0
aCompounds listed in sequence of elution from a DB-5 MS column. bRetention
indices calculated against C8 to C32 n-alkanes on a DB-5MS column. tr, in traces.
moderately but significantly inhibited the contraction in response
to the RC extract.
Fractions of the RC extract were also tested for contracting
activity. Fraction F20 induced a moderate contraction
(approximately 20% of the maximum) (Table 4). Similar
results were obtained with F40, F60, F80, and F100, although the
extent of contraction tended to decline with F60, F80, and F100.
Our experiments revealed the smooth muscle relaxing activity
of RC extract, fractions and essential oil in this experimental
setting. On histamine-precontracted preparations (treated with
0.5 µM histamine for 15 min, in the presence of atropine
and tetrodotoxin, both 0.5 µM), concentration-dependent
relaxation was observed in response to treatment with RC crude
extract (60–200 µg/ml) (Figure 3 and Table 5). The highest
concentration tested induced full relaxation. The relaxation
detected with the 20µg/ml test sample did not exceed the changes
evoked by the solvent itself (1 µl/ml DMSO; see below). In several
cases the relaxation was preceded by a little contraction. The
relaxation induced by the 60 µg/ml extract was not significantly
altered by the adrenergic β-receptor antagonist propranolol
(1 µM; 51.3 ± 7.8% relaxation, N = 6) or by the NO synthase
inhibitor NG-nitro-L-arginine (100 µM; 47.4 ± 7.4% relaxation,
FIGURE 2 | Contractile effect of RC extract (60 µg/ml, added at the square
symbol) on the guinea pig ileum. Calibrations, vertical: 50% of the maximal
longitudinal spasm evoked by histamine (10 µM), horizontal: 1 min.
TABLE 3 | Effects of drugs on the contractile response to RC crude extract
(60 µg/ml) on guinea pig small intestine (mean ± SEM).
Pretreatment Contraction (% of maximal spasm) N
No pretreatment (control) 40.1 ± 3.3 11
Tetrodotoxin (0.5 µM) 15.0 ± 1.8∗ 6
Atropine (0.5 µM) 8.2 ± 2.0∗ 6
PPADS (50 µM) 49.7 ± 2.7 9
5-HT receptor antagonists# 52.1 ± 3.0 11
Solvent for capsaicin 51.1 ± 5.2 7
Capsaicin& 46.9 ± 6.0 9
Solvent for indomethacin 46.4 ± 4.0 6
Indomethacin (3 µM) 31.2 ± 5.6∗ 10
Values significantly different from the respective control group are indicated by
asterisks (∗). #methysergide (0.3 µM), SB204070 (1 µM) and Y25130 (1 µM).
&10 µM of capsaicin for 10 min, followed by a 60-min washout period.
N = 10) (both compared with the group indicated in Table 5).
The solvent DMSO (0.3 or 1 µl/ml) had a slight relaxant effect in
this experimental arrangement (histamine-precontracted ileum
pretreated with atropine and tetrodotoxin); it amounted to
3.0 ± 1.6% at 0.3 µl/ml and 7.9 ± 1.4% at 1 µl/ml; N = 11 and
17, respectively.
On histamine-precontracted, atropine- and tetrodotoxin-
treated ileum, different fractions of RC extract showed
distinct relaxant effects (Table 6). F20 and F40 (60 or
200 µg/ml) practically produced no relaxation (N = 5 for
both concentrations). This observation refers to the potential
role of flavonoids in the relaxant effect, and experiments with
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FIGURE 3 | Long-lasting relaxant effect of RC extract (60 µg/ml, added at the
square symbol) on the pre-contracted guinea pig ileum, in the presence of
tetrodotoxin and atropine (0.5 µM each). Calibrations, vertical: 100%
relaxation from the pre-contracted baseline, horizontal: 1 min.
TABLE 4 | Contractile effects of RC extract fractions on guinea pig ileum
(longitudinally oriented preparations, mean ± SEM).
Bath concentration Contraction (% of the maximal spasm) N
F20
2 µg/ml 5.2 ± 2.4% 5
20 µg/ml 18.2 ± 6.1% 5
60 µg/ml 18.5 ± 4.4% 6
200 µg/ml 22.2 ± 3.1%∗ 5
F40
2 µg/ml 2.5 ± 1.2% 5
20 µg/ml 18.2 ± 5.9% 5
60 µg/ml 15.5 ± 3.3% 5
200 µg/ml 22.8 ± 8.4%∗ 5
F60
2 µg/ml 8.4 ± 1.3% 6
20 µg/ml 21.8 ± 6.4%∗ 5
60 µg/ml 20.9 ± 8.2%∗ 5
200 µg/ml 4.0 ± 2.7% 6
F80
2 µg/ml 0.4 ± 0.4% 5
20 µg/ml 13.0 ± 3.2% 5
60 µg/ml 12.0 ± 4.0% 5
200 µg/ml 2.5 ± 1.5% 5
F100
20 µg/ml 12.4 ± 2.1% 6
60 µg/ml 26.4 ± 5.8%∗ 5
200 µg/ml 15.1 ± 2.7% 6
Asterisks denote values significantly different from a pooled group of solvent effects
(Kruskal–Wallis test for several unrelated samples).
four flavonoids isolated from the plant material reassured
this hypothesis. All the flavonoids exerted a dual effect on the
guinea pig ileum, i.e., a short-lived contraction at basal tone
and a long-lasting relaxation on the histamine-pre-contracted,
atropine- and tetrodotoxin-pretreated preparations (Table 7). At
TABLE 5 | Relaxing effect of RC crude extract and essential oil on the
pre-contracted ileum.
Bath concentration of
RC crude extract
Relaxation (% of the maximum) N
20 µg/ml 18 ± 5.2% 6
60 µg/ml 76.2 ± 8.5%∗ 9
200 µg/ml 100%∗ 5
Bath concentration of
RC essential oil
Relaxation % N
0.1 µg/ml 12.8 ± 3.5% 6
1 µg/ml 30.8 ± 5.9%∗ 9
10 µg/ml 69.7 ± 5.6%∗ 6
Atropine and tetrodotoxin (0.5 µM each) were present in the medium in order to
inhibit the contractile effect of the RC extract. Tonic submaximal contraction was
evoked with histamine (0.5 µM for 15 min). Values are given in %, where 100%
means full relaxation reaching the pre-histamine values (mean ± SEM). Asterisks
denote values significantly different from a pooled group of solvent effects (0.3 or
1 µl/ml of DMSO, see text) (Kruskal–Wallis test for several unrelated samples).
TABLE 6 | Relaxant effects of RC extract fractions on pre-contracted guinea pig
ileum (mean ± SEM).
Bath concentration Relaxation % N
F60
20 µg/ml 18.7 ± 5.7% 5
60 µg/ml 96.0 ± 3.0%∗ 6
200 µg/ml 93.5 ± 4.9%∗ 6
F80
20 µg/ml 47.2 ± 7.7% 5
60 µg/ml 93.0 ± 5.9%∗ 6
200 µg/ml 100%∗ 4
F100
6 µg/ml 12.5% 4
20 µg/ml 61 ± 13.7% 5
60 µg/ml 69.4 ± 7.5%∗ 6
200 µg/ml 100%∗ 4
100% relaxation denotes that tone returns to baseline. Asterisks denote values
significantly different from a pooled group of solvent effects (0.3 or 1 µl/ml DMSO)
(Kruskal–Wallis test for several unrelated samples).
a concentration of 1 µM, the flavonoids did not exert contractile
activities, however, at 10 µM, a slight effect (34.6 ± 7.4% for
hispidulin, 32.0 ± 3.1% for luteolin, 27.1 ± 4.2% for eupafolin,
and 20.5 ± 5.1% for apigenin, N = 5 each) was observed. The
relaxant activities at 2 µM ranged between 18.2 ± 5.4% and
24.2 ± 3.7%, whereas at 20 µM between 64.5 ± 4.1% and
81.9± 5.3%.
The essential oil of RC (0.1, 1, 10, or 30 µg/ml) showed no
contractile effect on the ileum (N = 6–8). RC oil (1 or 10 µg/ml)
induced considerable relaxation on histamine-precontracted,
atropine- and tetrodotoxin-pretreated preparations (Table 5).
Similar results were obtained on preparations without atropine
and tetrodotoxin pretreatment (N = 6–8, data not shown).
Papaverine was used as positive control. As with other
experiments for studying relaxation, the drug was administered
to histamine-precontracted, atropine- and tetrodotoxin-treated
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TABLE 7 | Relaxant effects of flavonoids on pre-contracted guinea pig ileum
(mean ± SEM).
Bath concentration Relaxation % N
Hispidulin
2 µM 19.4 ± 3.5% 5
20 µM 64.5 ± 4.1% 6
Luteolin
2 µM 19.6 ± 1.6% 5
20 µM 80.0 ± −4.5% 6
Eupafolin
2 µM 18.2 ± 5.4% 5
20 µM 68.7 ± 6.8% 6
Apigenin
2 µM 24.2 ± 3.7% 5
20 µM 81.9 ± 5.3% 6
100% relaxation denotes that tone returns to baseline. The solvent contained a
maximum of 10% DMSO and had no relaxant effect in the volumes used.
TABLE 8 | Contractile effect of RC extract on guinea pig urinary bladder strip,
without pretreatment and following treatment with capsaicin or its solvent
(mean ± SEM).
Bath concentration of
RC crude extract
Contraction (% of the maximal spasm) N
20 µg/ml No pretreatment 8.0 ± 4.2% 7
200 µg/ml No pretreatment 20.0 ± 5.1% 7
200 µg/ml Ethanol
pretreatment#
21.6 ± 4.9% 8
200 µg/ml Capsaicin
(10 µM) pretreatment&
9.1 ± 1.3%∗ 8
#Solvent and time control for capsaicin. &Capsaicin was added and incubated for
10 min. This was followed by a 90-min washout period. ∗Significantly different from
the ethanol control.
ileum preparations, in a non-cumulative manner. The relaxant
responses obtained were as follows, 0.3 µM: 19.7± 4.7% (N = 6);
1 µM: 29.1 ± 3.5% (N = 6); 3 µM: 30.1 ± 4.8% (N = 7); 10 µM:
92.9 ± 4.2% (N = 6), where, as also elsewhere in this paper,
relaxation to the pre-histamine baseline was taken as 100%.
Effects on Guinea Pig Urinary Bladder
The effects of the RC extract and the essential oil were tested on
guinea pig urinary bladder strips as well. RC crude extract evoked
concentration-dependent contraction at 20 and 200 µg/ml
(Table 8 and Figure 4 for 200 µg/ml). The solvent of the extract
had no contractile effect on the bladder (N = 4). The effect of
the 200 µg/ml extract was diminished (approximately halved) by
in vitro capsaicin pretreatment (Table 8). Contractile responses
were compared to the maximal spasm evoked by 100 mM of KCl
at the end of the experiment.
To study the relaxant effect of the crude extract, the
bladder strips were sub-maximally pre-contracted with histamine
(1–3 µM). Atropine and tetrodotoxin were present in the bathing
fluid. Since excitatory purinergic mechanisms are present in the
bladder, α,β-methylene ATP desensitization (10 + 10 µM for
10 min each) was also performed. RC crude extract had no
FIGURE 4 | Contraction, in response to 200 µg/ml RC extract (added at the
square symbol), on the guinea pig urinary bladder detrusor strip. Calibrations,
vertical: 50% of the maximal spasm in response to 100 mM KCl, horizontal:
1 min.
effect at a concentration of 20 µg/ml, whereas a concentration
of 200 µg/ml induced 58.3 ± 4.6% relaxation (N = 7 and 8,
respectively). The solvent itself (1 µl/ml DMSO) exerted no
effect.
Roman chamomile essential oil caused no contraction in
a concentration of 10 µg/ml. Similarly to the extract, RC oil
exerted a moderate relaxing effect on the pre-contracted bladder:
17.9 ± 6.1% and 34.1 ± 5.8% relaxation was evoked with 1 and
10 µg/ml, N = 7 and 6, respectively.
Effects on Rat Gastrointestinal
Preparations
The relaxant effect of RC essential oil was confirmed on
longitudinally oriented preparations of the rat gastrointestinal
tract. Rat whole ileum and distal colon preparations are
characterized by high intrinsic tone, therefore no pre-
contraction was needed. RC oil (10 µg/ml) induced relaxation
(41.4 ± 7.4% and 21.8 ± 3.7%, N = 7 and 10, respectively,
on these preparations, where 100% means the relaxant
response to 3 µM isoprenaline, given at the end of the
experiment). A concentration of 1 µg/ml was barely effective.
No contractile effect was observed. Rat stomach fundus strips
were pre-contracted with 0.1–0.3 µM acetylcholine. RC oil
produced relaxation (on average 44 and 70.3% relaxation
in response to concentrations of 1 and 10 µl/ml, N = 4
each, where 100% means relaxation to the pre-acetylcholine
level).
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Effects on Human Jejunal Preparations
In untreated longitudinally oriented human jejunal preparations
RC crude extract induced transient contraction amounting to
12.4± 3.5% and 30.5± 0.6% at 20 and 200 µg/ml concentrations,
respectively (N = 8). Atropine- and tetrodotoxin-pretreated
preparations were pre-contracted with PGF2α (1 or 2 µM).
RC extract showed a concentration-dependent relaxant effect
(25.8 ± 4.3% at 20 µg/ml, N = 8; 68.5 ± 8.5% at 60 µg/ml,
N = 7; 50.8 ± 3.7% at 200 µg/ml, N = 9). RC essential oil
produced no contraction. A lasting relaxant effect was detected
on pre-contracted preparations (in the presence of atropine and
tetrodotoxin). The relaxant effect reached 26.9± 5.2% at 1 µg/ml
and 81.4 ± 8.2% at 10 µg/ml concentrations (N = 8 and 7,
respectively).
In untreated circularly oriented human jejunal preparations
the RC crude extract evoked transient contraction (43.4 ± 10%
at 200 µg/ml, N = 5), while the 20 µg/ml concentration sample
had a negligible effect (2.8% contraction on 5 preparations). RC
extract induced relaxation in PGF2α-precontracted preparations
(in the presence of atropine and tetrodotoxin). This effect reached
45% with 60 µg/ml concentration (N = 4), while a concentration
of 200 µg/ml produced full relaxation (N = 6), where a relaxation
to the pre-prostaglandin level was taken as 100%.
The solvent itself (1 µl/ml DMSO) did not evoke either
contraction or relaxation on this preparation (N = 4–6).
DISCUSSION
The experiments presented here have been carried out with RC,
which has been used traditionally for the symptomatic treatment
of mild, spasmodic and other gastrointestinal complaints,
however, the presumed smooth muscle-relaxant effect has not
been confirmed experimentally. The aim of our study was to
investigate the effect of a traditionally used extract of the plant,
its fractions and the essential oil of the plant, as well as of four of
its flavonoid components.
The phytochemical analysis of the extract revealed the
presence of flavonoids in the plant, four of which (apigenin,
luteolin, eupafolin, and hispidulin) were isolated and identified.
The hydroethanolic extract was fractionated on polyamide
to gain fractions with different flavonoid content in order
to examine the role of these compounds in the effect on
smooth muscles. The flavonoid content of the extract and
fractions was analyzed by HPLC. The flavonoid content of the
extract was fractionated successfully, fractions F80, F100 (and
to some extent F60) containing higher amounts of flavonoids
than the crude extracts. The flavonoid pattern of fractions
also differed. The essential oil analyzed by us belongs to the
chemotype characterized by the predominance of methallyl
angelate.
Pharmacological experiments were carried out with the
hydroethanolic extract, its fractions (F20, F40, F60, F80, and
F100), four flavonoids (apigenin, eupafolin, hispidulin, and
luteolin) and the essential oil of the plant on different
smooth muscles in vitro. The hydroethanolic extract of RC
has both stimulatory and relaxant effects on guinea pig
ileum. The moderate, transient stimulatory activity results
from the activation of cholinergic neurons, as confirmed
by its inhibition by tetrodotoxin (an inhibitor of neuronal
voltage-sensitive Na+ channels) and atropine (antagonist on
muscarinic receptors for acetylcholine). Although capsaicin,
a stimulant of a certain class of sensory receptors (through
which it evokes a “local efferent” response) shows a similar
cholinergic, neurogenic effect in guinea pig small intestine
preparations (see Barthó et al., 2004 for review), a functional
blockade of capsaicin-sensitive nerve endings by capsaicin
pretreatment failed to inhibit the contractile action of RC
extract. The contractile action of RC extract was moderately,
yet significantly reduced by the cyclooxygenase inhibitor
indomethacin, which may indicate a modulatory role of
endogenous prostanoids. Other pharmacological inhibitors
tested had no contraction-reducing effect, therefore it is
proposed that neither endogenous serotonin, nor PPADS-
sensitive purinergic mechanisms play a role in the excitatory
action of RC extract. It should be noted that both serotonin and
ATP or the P2X receptor agonist α,β-methylene ATP are able
to evoke cholinergic contractions in guinea pig ileum (Benko
et al., 2005; Barthó et al., 2006; Sandor et al., 2016 for recent
data).
Following the transient and mild-to-moderate stimulant
effect, the RC crude extract exhibited a sustained relaxant
effect on the guinea pig ileum in the presence of tetrodotoxin
and atropine, and preliminary experiments indicated a similar
relaxant effect also in the absence of atropine and tetrodotoxin.
Yet, atropine and tetrodotoxin were included into these
experiments for creating a methodologically clear situation,
where an initial, neuronally mediated excitatory action would
hardly interfere with the relaxant one. The concentrations
of the extract causing relaxation were roughly the same as
those causing contraction. Based on these data we propose
that the site of action for the relaxant effect of RC is on
the smooth muscle itself. Neither the adrenergic β-receptor
antagonist propranolol nor the NO synthase inhibitor NG-
nitro-L-arginine significantly reduced the relaxant effect of
the RC extract, hence, no evidence was found for these
mechanisms to be involved in the relaxant response. In fact,
a direct relaxant effect of the extract was demonstrated on all
gastrointestinal preparations tested, including human and rat
gastrointestinal preparations, as well as in guinea pig bladder.
In preparations with high intrinsic tone (rat ileum and rat
colon), relaxant activity was practically the only response to be
seen.
Different RC extract fractions evoked both contraction and
relaxation on guinea pig ileum. While there was a clear-cut
tendency correlation between the flavonoid content and the
relaxant effect, in case of contractile action such correlation was
not observed (on the contrary, fractions with lower flavonoid
content exerted slightly higher contractile activities). Fractions
with high flavonoid content (F60, F80, and F100) had remarkable
relaxant effects, whereas fractions with no (F20) or low (F40)
flavonoid content exerted no such activity. The pure flavonoids
of the extract showed dual effects in the guinea pig ileum, much
similarly to the crude extract. Moreover, there was no substantial
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difference between the potencies of the flavonoids. This means
that any of these flavonoids may contribute to the sustained
relaxant and the transient contractile effect of the extract. The
essential oil of RC caused no contraction on the test preparations;
nevertheless, a consistent relaxant effect was detected. This seems
to indicate that (i) chemical components responsible for the
stimulant effect may be absent in the essential oil; (ii) it may
be that several types of compounds present in the extract are
responsible for the smooth muscle-relaxant action. This point
needs to be clarified in subsequent experiments.
The contraction of guinea pig bladder in response to the
RC extract proved to be special, in that it was reduced by half
following in vitro capsaicin pretreatment. This indicates that
capsaicin-sensitive sensory nerves of the bladder wall are in some
way involved in the excitatory effect of the RC extract (see Barthó
et al., 2004). Nevertheless, the RC extract and oil also induced
bladder relaxation in pre-contracted preparations.
Roman chamomile extract was effective in human jejunal
preparations as well. Both an excitatory and a tetrodotoxin-
and atropine-resistant relaxing effect were demonstrated, again,
the smooth muscle relaxant one being more sustained than the
excitatory one. Preliminary experiments have shown that this
early contraction is reduced by atropine. Due to limited access
to human tissue, no further analysis of these responses could be
performed.
In terms of possible medical uses it may be noted
that a combination of nerve-mediated, mild-to moderate
excitatory effect and a smooth muscle-relaxant action may
even be advantageous for some gastrointestinal problems, e.g.,
diminished peristaltic activity, while for spasms in the stomach or
large intestine it is obviously the smooth muscle relaxing activity
that offers benefits.
CONCLUSION
Our results support the overall smooth muscle relaxant effect of
a hydroethanolic RC extract and of the essential oil of RC. The
predominant effect of the extract, its fractions and flavonoids is
relaxation, being more sustained than the transient contraction
observed in some cases. This activity is in correlation with
the flavonoid content of the extract. Since the components
of the essential oil are partly extracted with alcohols, the
constituents of the oil also contribute to the overall effect
of the hydroethanolic RC extract. The extract used in our
experiments was prepared in accordance with the European
Medicines Agency monograph for this plant, therefore our study
contributes to the body of evidence relating the traditional use of
this plant.
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Propolis evokes several therapeutic properties, including anticancer activity. These
activities are attributed to the action of polyphenols. Previously it has been
demonstrated, that one of the most abundant polyphenolic compounds in ethanolic
extracts of propolis are chrysin, caffeic acid, p-coumaric acid, and ferulic acid.
Although their pro-apoptotic activity on human tongue squamous cell carcinoma
cells (CAL-27) was established previously, the detailed mechanism of this process
remains unclear. Considering the crucial role of proline metabolism and proline
dehydrogenase/proline oxidase (PRODH/POX) in the regulation of cancer cell
survival/apoptosis, we studied these processes in polyphenol-treated CAL-27 cells.
All studied polyphenols evoked anti-proliferative activity, accompanied by increased
PRODH/POX, P53, active caspases-3 and -9 expressions and decreased collagen
biosynthesis, prolidase activity and proline concentration in CAL-27 cells. These data
suggest that polyphenols of propolis induce PRODH/POX-dependent apoptosis through
up-regulation of mitochondrial proline degradation and down-regulation of proline
utilization for collagen biosynthesis.
Keywords: proline, proline oxidase, propolis, flavonoids, phenolic acids, collagen, SCC
INTRODUCTION
Historically, propolis has been a key element of healthcare, and it products are still widely used as
an alternative and complementary therapy or often as a primary treatment. Ethnopharmacology
proved that propolis has medicinal properties , setting out directions for further research.
Studies on the biological activity of propolis conducted in recent years revealed a wide spectrum
of its activities. Propolis has many therapeutic properties, including antibacterial, antifungal,
antiviral, cytotoxic, antioxidant, anti-inflammatory as well as immunomodulatory activity
(Bankova et al., 2014).
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The chemical composition of propolis is related to its
region of origin, however, some compounds occur in a
comparable amount in all propolis samples (Popova et al.,
2015, 2017a,b; Graikou et al., 2016). To broadly known
propolis components belong among others: diterpenes, lignans,
sesquiterpenes, acetophenones (Bankova, 2005), flavonoids and
phenolic acid esters (Bankova et al., 2000) which are responsible
for numerous of its biological activities (Kubiliene et al., 2015;
Turan et al., 2015; Yildirim et al., 2016).
Recently, the interest is focused on anticancer properties of
propolis. In cancer cells treated with propolis significant changes
in various intracellular amino acids and their metabolites were
found, among which proline was proved to significantly affect
cell viability. The increase in proline concentration was observed
in numerous cancer cell lines. The phenomenon was related
to cancer survival (Surazynski et al., 2008a) and poor patient
prognosis. However, proline degradation by PRODH/POX was
found to induce apoptosis in several cancer cell lines (Sadowska
et al., 2013; Kononczuk et al., 2015a). Therefore, compounds
that modulate intracellular proline metabolism are of great
importance as potential anticancer factors.
An important source of proline is collagen. The final products
of collagen degradation in lysosomes are imidodipeptides
(containing C-terminal proline) that are further hydrolyzed
to amino acids by cytoplasmic imidodipeptidase–prolidase
[E.C. 3.4.13.9]. Therefore, prolidase plays an important role
in the regulation of proline-dependent functions. One of
the regulatory role of prolidase is providing proline for
collagen re-synthesis. Alternatively, proline is degraded
into pyrroline-5-carboxylic acid (P5C) in mitochondria
by PRODH/POX. The conversion generates superoxide
anion that may contribute to ROS-dependent induction of
apoptosis (Liu et al., 2006; Phang et al., 2008a,b). Several
studies established the function of PRODH/POX as a tumor
suppressor gene. Therefore, the inhibition of its activity is
correlated with a cancer progression. In several cancer cells, as
cancer of kidney or cancers of digestive tract, the expression
of PRODH/POX is very low or not detected (Phang and Liu,
2012).
Proline can be also synthesized either from ornithine by
ornithine aminotransferase (OAT) or from glutamic acid by
P5C synthase, then P5C might be converted to proline by P5C
reductase (PYCR), leading to increase in proline concentration.
These pathways are therefore considered in studied on proline-
dependent responses of cancer cells.
The squamous cell carcinoma (SCC) is one of the most
frequent cancers of the oral cavity cancer [oral squamous
cell carcinoma (OSCC)]. It is characterized as highly invasive
with the ability to give early and extensive lymph nodes
metastases (Carvalho et al., 2004). The cancer treatment is
primarily focused on the resection of a tumor. Afterward,
the radiotherapy and the chemotherapy are followed. Up
to date, therapeutic protocols do not offer to the patients
with advanced SCC, effective therapeutic options. The
lack of any advanced alternative pharmacotherapy of SCC
is a problem of modern medicine (Pilch and Bouquot,
2005).
Several studies revealed the connection between the
overexpression of oral cancer overexpressed 1 protein
(ORAOV1) and the occurrence of more aggressive tumors
in esophagus (Zhai et al., 2014). Additionally, ORAOV-1-
overexpressed cell lines, among others CAL-27 cell line, are
marked with a higher intracellular proline concentration and
stronger resistance on treatment (Jiang et al., 2008, 2010). It
was confirmed that ORAOV1 influences PYCR activity. Hence,
the increase in intracellular proline level was observed and
consequently the promotion of tumor progression (Togashi
et al., 2014). Hence, the effect of chosen polyphenols on proline
metabolism may be a relevant issue in the apoptosis induction
(Phang et al., 2012).
The purpose of the study was to identify mechanisms of
cytotoxic activity of selected propolis components considering
their effect on the proline metabolism in CAL-27 cell line.
Previous analysis of the commercially available, standardized
preparations of propolis allowed to identify a few of the most
abundant polyphenols as chrysin, caffeic acid, p-coumaric acid,
and ferulic acid (Maciejewicz et al., 2001; Markiewicz-Z˙ukowska
et al., 2012; Czyz˙ewska et al., 2015, 2016). The study revealed
the proapoptotic effect of these compounds on CAL-27 cell line
(Czyz˙ewska et al., 2016), however, its molecular mechanism still
remains unclear. In this report, we present their effect on the
apoptosis in tongue squamous cell carcinoma (CAL-27) and the
mechanism of the activity.
MATERIALS AND METHODS
Cell Culture
The studies were performed on tongue squamous cell line (CAL-
27). The cell line was purchased in ATCC (CRL-2095 TM,
American Type Culture Collection, Manassas, VA, United States).
Cell culture was maintained in Dulbecco’s modified Eagle’s
medium (Gibco, United States) with 10% fetal bovine serum
(FBS) (Gibco, United States) and 50 U/mL penicillin, 50 µg/mL
streptomycin (Gibco, United States) and incubated at 37◦C in
5% CO2.
Polyphenols Solutions
Chrysin was purchased from Roth (Karlsruhe, Germany),
p-coumaric acid, caffeic acid, and ferulic acid were purchased
from Sigma-Aldrich (Steinheim, Germany). All chemicals
and reagents used in this study were of analytical grade
(purity ≥ 99%). Solutions were prepared directly before adding
to cell cultures in appropriate concentrations.
Cell Viability Assay
Cytotoxicity effects of studied polyphenols on CAL-27 cells
was determined using methyl thiazolyl tetrazolium (MTT)
according to modified Carmichael’s method. MTT assay bases
on the conversion of yellow tetrazolium bromide MTT solution
to the purple formazan derivatives, by the mitochondrial
enzyme succinate dehydrogenase,occurred in viable cells. Cells
(105/mL) were cultured on 96-well plates to obtain 70% of
confluency. Then cells were incubated with studied polyphenols
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for 24 h. Polyphenolic compounds were added as DMSO solution
prepared directly before assay. The final concentration of DMSO
did not exceed 0.1% in each well. The tested polyphenols
were used at the following concentrations: chrysin – 5, 25,
50, 80 µg/mL; ferulic acid – 50, 100, 150 µg/mL, caffeic
acid – 65, 130, 190 µg/mL; and p-coumaric acid – 70, 140,
210 µg/mL. The concentrations correspond to the following
molar concentrations: chrysin – 0.020, 0.098, 0.216, 0.315 mM;
caffeic acid – 0.361, 0.722, 1.055 mM; ferulic acid – 0.257, 0.515,
0.772 mM; and p-coumaric acid – 0.426, 0.853, 1.279 mM.
Cisplatin (CDDP) (Sigma-Aldrich, Germany) (10 µM) was used
as a positive control. The selection of polyphenols concentration
was made on the grounds of previously received data (Czyz˙ewska
et al., 2016). Then followed the incubation for 24 h, then the
liquid was removed and cells were washed with PBS. Afterward,
50 µL of MTT solution (1.0 mg of MTT per 1 mL of PBS)
was added to each well and incubated for 1 h. To dissolve
formazan derivatives dimethyl sulfoxide was added after MTT
solution removing. The absorbance was measured at 570 nm
wavelength using an Asys UVN 340 microplate reader (Biogenet,
Józefów, Poland). For the treated cells, amount of viable cells was
expressed as the percentage of control.
Proliferation Assay
The proliferation of studied cells was evaluated as [methyl-
3H]thymidine (Hartman Analytic GmbH, Braunschweig,
Germany) incorporation into DNA of cells treated with studied
polyphenols. In 24-well tissue culture dishes, cells were plated
at 1 × 105 cells/well, using 1 mL of growth medium in each
well. Various concentrations of polyphenols were added to the
culture wells. Cisplatin (10 µM) was used as a positive control.
After incubation for 24 h at 37◦C, 0.5 µCi/mL of [methyl-
3H]thymidine (6.7 Ci/mmol) was added to the wells and cultures
were incubated at 37◦C for 4 h. Thereafter, the cells were washed
with 0.05 M Tris-HCl and with 5% TCA. Then followed cell lysis
in 0.1 M NaOH containing 1% sodium dodecyl sulfate (SDS).
Radioactivity was measured in Liquid Scintillation Analyzer
Tri-Carb 2810 TR (Perkin-Elmer, United States) after adjustment
of 2 mL of scintillation liquid (Ultima Gold XR, Perkin-Elmer,
Waltham, MA, United States) to each sample.
Western Immunoblot
To determine the expression of proteins involved in apoptosis
process and proline metabolism western immunoblot
was performed. Goat monoclonal anti-PRODH/POX
antibody (#EB11136) was purchased from EverestBiotech
(United Kingdom). Rabbit anti-caspase-3 (#9665), rabbit
anti-cleaved-caspase-3 (#9664), rabbit anti-caspase-9 (#9508),
and mouse anti-cleaved-caspase-9 (#7237) antibodies were
purchased from Cell Signaling (United States). Purified mouse
anti-p53 antibody (#554169) was acquired from Becton,
Dickinson and Company (B&D) (United States). Monoclonal
anti-β-actin antibody produced in mouse was obtained from
Sigma-Aldrich (#A2228, United States). Secondary polyclonal
anti-goat, anti-rabbit and anti-mouse antibodies labeled with
horseradish peroxidase were purchased in Sigma-Aldrich, Corp.
(United States).
The Laemmli method was used to perform SDS-PAGE
electrophoresis (Laemmli, 1970). The equal amounts of cell
supernatants (15 µg of protein) were analyzed. Semi-dry
electrotransfer was performed after electrophoresis. For this
procedure, Multiphor II Electrophoresis System Multiphor (GE
Healthcare Bio-Sciences AB, Sweden) was used. Subsequently,
the sequence of incubation with primary and secondary
antibodies and were performed. Afterward, membranes were
incubated with Amersham ECL Western Blotting Detection
Reagent (GE Healthcare Life Science, United Kingdom), and
chemiluminescence was analyzed with BioSpectrum Imaging
System UVP (UltraViolet Products, Ltd., United Kingdom). The
densitometry of bands was quantified by ImageJ software.
Intracellular Proline Concentration
After 24 h incubation with chosen polyphenols, cells were
scratched and suspended in a cold mixture of water and methanol
(v/v 80:20). After then a cycle of frost and defrost followed.
Lastly, the cell solution was sonicated and preserved at −80◦C
until further analysis. The used method allowed to determine
intracellular concentration of proline and to compare treated cells
with untreated ones.
The intracellular level of proline was determined using HPLC
system (Agilent Technologies, Germany) connected to QTOF
mass spectrometry detector (Agilent Technologies, Germany).
Electrospray ionization (ESI) was used as an ion source. The
analysis was performed on a HILIC column (Luna HILIC,
Phenomenex, United States). Samples were injected in a volume
of 2 µL. The procedure required maintenance at 40◦C. The
system was operated in both positive and negative mode at
flow rate 1 mL/min with solvent A – water with 10 mM
ammonium formate, and solvent B – acetonitrile/water (9:1,
v:v) with 10 mM ammonium formate. A mobile phase was as
follows: 100% B during 1.5 min in isocratic mode, at 1.5 min
the gradient mode started from 100% B to 70% B in 5.5 min,
then 40% B in 6.0 min, maintained 40% B during 1 min
and returned to starting conditions in 0.5 min, keeping the
re-equilibration until 10 min. The detector operated in full
scan mode. During analyses, reference masses were delivered
continuously to obtain accurate mass measurements. Reference
masses were at m/z 121.0509 (protonated purine) and m/z
922.0098 [HP-921]. Compound identification was performed
monitoring monoisotopic ions of proline and the internal
standard (Proline-d3, #791261, Sigma-Aldrich, United States).
The concentration range of proline to which calibration curve
was registered was as followed: 6.32–101.12 [µM]. Each of
sample was analyzed in triplicates. To further calculations the
average value of signals was used. Obtained concentrations were
normalized to the internal standard and to the amount of protein
in a sample.
Vitality Assay
Vitality assay describes changes in the intracellular level of
(reduced) thiols such as glutathione which exists in two
forms: reduced – GSH and – oxidized state (GSSG). The
decrease in GSH levels is an early signal of cell death caused
either by the direct GSH oxidation promoted by radicals or
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by the export of GSH through an ATP-dependent plasma
membrane transport system. The assay was performed using
NucleoCounter R© NC-3000TM system (ChemoMetec, Denmark)
according to manufacturer’s protocol. Cells incubated with
studied concentrations of polyphenols were detached from the
plates, washed and stained with Solution 5 (containing three
various reagents: VitaBright-48, propidium iodide, and acridine
orange). Cisplatin (10 µM) was used as a positive control.
Thereafter, the intensity of fluorescence was measured using
NucleoCounter R© NC-3000TM.
Determination of Prolidase Activity
The activity of prolidase was determined according to the
method of Myara et al. (1982). It is colorimetric assay
using Chinard’s reagent. To perform the assay cells were
detached and scraped off using Cell Lysis Buffer (Cell
Signaling, United States). N-Benzyloxycarbonyl-L-proline (Cbz-
Pro) (Bachem, United States) (5 mM) was used as a positive
control. Then samples were sonicated for 3 s × 10 s at 0◦C
and then centrifuged at 16000 × g for 15 min. Afterward, the
cell pellet was discarded. Supernatants were used for protein
determination according to Lowry method and evaluation of
prolidase activity. The activation of prolidase requires incubation
of cell extract supernatant with Mn (II), due to this fact
the 100 µL of each sample was mixed with 100 µL of
50 mM HEPES (pH 7.8) containing MnCl2 to achieve the
final concentration 1 mM of MnCl2. Incubation lasts for 24 h
at 37◦C then the prolidase reaction was initiated by adding
100 µL of the activation mixture which was 94 mM glycyl-proline
(Gly-Pro). After adding of Gly-Pro samples were incubated
for 1 h at 37◦C. The reaction was terminated by addition
1 mL of 0.45 M trichloroacetic acid. Parallel blank tubes
contained trichloroacetic acid was added at time “zero.” After
the samples centrifugation (10.000 × g for 15 min) the amount
of released proline was determined by adding trichloroacetic
acid/supernatant to the mixture of glacial acetic acid: Chinard’s
reagent. Then followed incubation for 10 min at 90◦C. The
determination of proline was based on the measurement of
absorbance at 515 nm. Prolidase activity was expressed as
nanomoles of proline released per minute per milligram of
protein.
Collagen Biosynthesis
Collagen biosynthesis was measured as the incorporation of
radioactive proline into proteins. CAL-27 were incubated with
various concentrations of polyphenols and with the 5 µCi/mL
of 5[3H]-proline (Hartman Analytic GmbH, Germany) for
24 h. 2-Metoxyestradiol (MOE) (Sigma-Aldrich, United States)
(10 µM) was used as a positive control. The amount of
incorporated 5[3H]-proline into collagen was detected after
its digesting by Clostridium histolyticum collagenase (Sigma-
Aldrich, United States) according to the method of Peterkofsky
and Diegelmann (1971).
Statistical Analysis
Statistical analysis was conducted using GraphPad PRISM v.
5 (GraphPad Software, Inc., San Diego, CA, United States).
For results from all experiments, the mean values for at least
six measuring points ± standard error of the mean (SEM)
were determined. The statistical significances were calculated
using one-way ANOVA with Dunnett’s multiple comparison
tests. Differences at p < 0.001 were accepted as statistically
significant.
RESULTS
Studied Polyphenols Significantly
Reduce the Viability of CAL-27 Cancer
Cells
The influence of chosen polyphenols (chrysin, caffeic acid,
p-coumaric acid, ferulic acid) on the viability of human
tongue squamous cell carcinoma cell line (CAL-27) was
determined with MTT assay. The studied polyphenols ability
to induce the cytotoxic effect in CAL-27 was observed for
all polyphenolic compounds (Figure 1). The use of chrysin
resulted in a reduction of cell survival to 82, 62, 32, and
29%. In the case of caffeic acid, decreased CAL-27 cells
survival to 81, 62, and 61% was observed. The use of ferulic
acid decreased cell survival to 85, 65, and 50% compared to
controls whereas in the case of p-coumaric acid, the viability
of CAL-27 cells was reduced to 82, 80, and 73% compared to
controls (100%). To evaluate whether polyphenols cytotoxicity
was a result of their influence on cell DNA biosynthesis
the capability of intracellular thymidine incorporation was
assessed.
The Inhibition of DNA Biosynthesis After
Polyphenols Application
The effects of chrysin, caffeic acid, p-coumaric acid, ferulic acid
on DNA biosynthesis in CAL-27 cells were evaluated as [3H]-
thymidine incorporation into viable cells. The downregulation
of DNA biosynthesis in CAL-27 cells was observed for all
polyphenolic compounds (Figure 2). The obtained results show
that the addition of chrysin resulted in a reduction in DNA
biosynthesis by 46, 80, 83, and 83% whereas the application of
caffeic acid leads to a reduction of DNA biosynthesis by 14,
31, and 52%. Moreover, the similar situation was observed after
adding ferulic acid where the DNA biosynthesis was reduced
by 16, 46, 53, and 71%. In the case of using p-coumaric
acid, DNA biosynthesis was also reduced by 67, 78, and 83%.
These findings of indicate that all polyphenols are inhibitors
of DNA biosynthesis in CAL-27 SCC cells, and the intensity
of this process depends on the concentration of the compound
used.
To evaluate whether chosen compounds lead to the cell death
through the apoptosis pathway involved proline metabolism
regulation the western immunoblot assay was performed.
For further analysis polyphenols were used at the lowest
doses that contributed to noticeable cytotoxic effects. Applied
concentrations were as follows: chrysin – 5 µg/mL, caffeic acid –
65 µg/mL, ferulic acid – 50 µg/mL, and p-coumaric acid –
70 µg/mL.
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FIGURE 1 | The cytotoxic effects of polyphenolic compounds on CAL-27 cells. The cells were treated with a specified concentration [µg/mL] of respective
components for 24 h and cytotoxic effects were determined by MTT assay. Cisplatin (CDDP) (10 µM) was used as a positive control. The values represent
mean ± SEM of two independent experiments conducted six times (n = 12). The stars indicate that value were significantly different (∗p < 0.001) compared with
control.
Selected Polyphenols Activate p53,
PRODH/POX, Caspase 9 and 3 in CAL-27
Cell Line
The study was conducted applying Western Immunoblot method
described in chapter 2.5. CAL-27 cells were subjected to 24 h
exposure to selected concentrations of polyphenols: chrysin
(5 µg/mL), caffeic acid (65 µg/mL), ferulic acid (50 µg/mL),
and p-coumaric acid (70 µg/mL). To evaluate the course of
apoptosis process the caspases expression were assessed. The
findings showed the reduction of expression of total caspase 3 in
CAL-27 cells incubated with all of the tested polyphenols. The
largest reduction in the expression of the total caspase 3 form
compared to the control was observed in cells incubated with
chrysin (5 µg/mL) and ferulic acid (50 µg/mL) (Figure 3A).
Additionally, the obtained data showed reduced expression of
total caspase 9 in CAL-27 cells incubated with all polyphenols
tested. The most significant reduction in the expression of the
total caspase 9 form was observed in cells incubated with chrysin
(5 µg/mL) and ferulic acid (50 µg/mL) (Figure 3C). Moreover,
obtained results revealed an increase in cleaved caspases 9 and 3
expressions in CAL-27 cells after incubation with each of used
polyphenols (Figure 3). The highest increase in expression of
active caspase 9 compared to control was observed in CAL-
27 cells exposed to caffeic acid (65 µg/mL) and p-coumaric
acid (70 µg/mL) (Figure 3D). Furthermore, the data revealed
increased expression of the active form of caspase 3 in CAL-27
cells incubated with each of the polyphenols tested. The most
noticeable increase in expression of active caspase 3 in relation
to control was observed in the case of CAL-27 cells exposed to
chrysin (5 µg/mL) and p-coumaric acid (70 µg/mL) (Figure 3B).
The following results confirm the pro-apoptotic effect of the
polyphenols. These compounds stimulate the expression of the
active forms of the initiator caspase 9 involved in the activation
of the intrinsic pathway of apoptosis and the executive caspase
3. The initiation of apoptosis through the activation of the p53
protein is accompanied by the induction of proline oxidase
(PRODH/POX) expression. It is a mitochondrial enzyme that
catalyzes the conversion of proline to pyrroline-5-carboxylate
while transferring free electrons to cytochrome c resulting in
Frontiers in Pharmacology | www.frontiersin.org April 2018 | Volume 9 | Article 336208
fphar-09-00336 April 3, 2018 Time: 17:22 # 6
Celin´ska-Janowicz et al. Propolis Polyphenols Induce PRODH/POX-Dependent Apoptosis
FIGURE 2 | Decreasing effects of polyphenolic compounds on DNA biosynthesis in CAL-27 cells. The cells were incubated with specified concentration [µg/mL] of
respective polyphenols for 24 h and [3H]-thymidine incorporation into CAL-27 was measured in scintillation counter. Cisplatin (10 µM) was used as a positive control.
The values represent mean ± SEM of two independent experiments conducted three times (n = 6). The stars indicate that value were significantly different
(∗p < 0.001) compared with control.
apoptosis. Therefore, to further examination whether observed
apoptosis involved the changes in PRODH/POX activity, the
western immunoblot for PRODH/POX and p53 (the most potent
inducer of this protein expression) was conducted. Received
outcomes demonstrated the increase in PRODH/POX expression
in all studied cases (Figure 3F). The obtained results coincide
with the p53 expression that was increased in all samples.
Nonetheless, the lowest increase was observed in CAL-27 cells
previously incubated with ferulic acid (Figures 3E,F).
The Proapoptotic Effect of Chrysin,
Caffeic Acid, p-Coumaric Acid, and
Ferulic Acid
To confirm induction of apoptosis by the polyphenols the vitality
assay was performed. The cells were subjected to 24 h exposure
to tested polyphenols in the following concentrations: chrysin
(5 µg/mL), caffeic acid (65 µg/mL), ferulic acid (50 µg/mL), and
p-coumaric acid (70 µg/mL). The obtained outcomes revealed a
significant decrease in cellular GSH concentration in treated cells
compared to untreated control (Figure 4). The most noticeable
increase in the cell population with the low level of GSH was
observed in CAL-27 cells treated with chrysin. The loss of
GSH is broadly known to be directly related to the apoptosis
progression and the assay confirmed our data received from MTT
assay.
The performed assays confirmed the apoptosis induction in
treated cells. To estimate whether chosen compounds leads to
apoptosis through the disruption of proline metabolism, further
studies were conducted.
Chrysin, Caffeic Acid, p-Coumaric Acid,
and Ferulic Acid Affect the Cellular
Metabolism of Proline
Proline transformations affect the regulation of cellular
metabolism and apoptosis. The effect of proline on the
metabolism of tumor cells seems to be particularly important,
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FIGURE 3 | Expression of un-cleaved caspase-3 (A), cleaved-caspase-3 (B), un-cleaved caspase-9 (C), cleaved-caspase-9 (D), PRODH/POX (F) and p53 (E), in
CAL-27 cells and the effect of: p-coumaric acid, chrysin, ferulic acid, and caffeic acid on the process. β-Actin was used as a control (data contained in
Supplementary Presentation 1). The values represent mean ± SEM of six pooled cell homogenates extracts from three independent experiments (n = 18). The stars
indicate which values were significantly different (∗p < 0.001) compared with control.
where a significant increase in the concentration of this
amino acid is observed in comparison with normal cells.
The high concentration of intracellular proline is associated
with an enhanced ability of tumor cells to metastasize. The
performed studies showed the pro-apoptotic activity of all tested
polyphenols. The next stage of the study was to determine
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FIGURE 4 | The analysis of cellular reduced glutathione (GSH) levels in CAL-27 cells after 24 h exposure to tested polyphenols in following concentrations: (C)
chrysin – 5 µg/mL, (B) caffeic acid – 65 µg/mL, (A) ferulic acid – 50 µg/mL, and (D) p-coumaric acid – 70 µg/mL. Cisplatin (10 µM) was used as a positive control.
M1 represents the cells with a high GSH levels (high vitality); M2 represents the cells with low GSH levels (low vitality). The graphs present mean values ± SEM from
three experiments done in duplicates. The asterisks determine values significantly different from control samples (∗p < 0.001).
the effect of the tested polyphenols on the proline level in
CAL-27 SCC cells. For evaluation, if discerned changes might
induce the adjustments in proline metabolism and hence in
its intracellular concentration, the HPLC-QTOF system was
used. Data acquired after chromatographic analysis displayed
a significant decrease in the intracellular proline concentration
in case of CAL-27 cells treated with all studied polyphenols
(Figure 5).
Frontiers in Pharmacology | www.frontiersin.org April 2018 | Volume 9 | Article 336211
fphar-09-00336 April 3, 2018 Time: 17:22 # 9
Celin´ska-Janowicz et al. Propolis Polyphenols Induce PRODH/POX-Dependent Apoptosis
FIGURE 5 | The effect of 24 h exposure to p-coumaric acid (70 µg/mL),
chrysin (5 µg/mL), ferulic acid (50 µg/mL), and caffeic acid (65 µg/mL) on
intracellular proline concentration in CAL-27 cell culture. The mean
values ± SEM from three experiments done in duplicates are presented
(n = 6). The stars indicate which values were significantly different (∗p < 0.001)
compared with control.
FIGURE 6 | Collagen biosynthesis measured as 5[3H]-proline incorporation
into proteins susceptible to the action of bacterial collagenase in CAL-27 cell
culture incubated for 24 h with polyphenols in following concentrations:
chrysin – 5 µg/mL, caffeic acid – 65 µg/mL, ferulic acid – 50 µg/mL, and
p-coumaric acid – 70 µg/mL. 2-Metoxyestradiol (MOE) (10 µM) was used as
a positive control. The values represent mean ± SEM of two independent
experiments conducted three times (n = 6). The stars indicate values
significantly different from control (∗p < 0.001).
The Decline of Collagen Biosynthesis in
the Cells Treated With Polyphenols
Collagen is a most abundant protein in the extracellular
matrix (ECM), where in addition to supporting functions, it
participates in the modulation of cellular signals by interacting
with integrin receptors. It affects a number of cell processes,
including regulation of gene expression, growth, differentiation,
and metabolism of cells. It has been observed that in cancer
cells, this mechanism is disrupted due to the increased activity
of metalloproteinases (MMPs), contributing to the increased
degradation of collagen. The biosynthesis level of this protein
may reflect changes in metabolic processes in living cells. Since
FIGURE 7 | Prolidase activity in CAL-27 cells treated for 24 h with chosen
polyphenols (chrysin – 5 µg/mL, caffeic acid – 65 µg/mL, ferulic acid –
50 µg/mL, and p-coumaric acid – 70 µg/mL). N-Benzyloxycarbonyl-L-proline
(Cbz-Pro) (5 mM) was used as a positive control. The mean values ± SEM
from three experiments done in duplicates (n = 6) are presented. Asterisks
indicate differences between studied cells compared to control untreated cells
at ∗p < 0.001.
collagen is reported to be the essential source of proline further
experiment was designed to assess the possible disorders of
collagen biosynthesis after exposure to studied polyphenols. The
assay was performed according to the Peterkofsky’s method.
Obtained data revealed the decline of collagen biosynthesis in the
cells treated with all tested compounds (Figure 6). The reduction
of collagen biosynthesis by 36% – p-coumaric acid, 95% – chrysin,
44% – ferulic acid, and 43% – caffeic acid, compared to control
(100%) was observed. The most noticeable decrease in collagen
biosynthesis was observed in the cells incubated with chrysin.
Inhibition of Prolidase Activity by Tested
Polyphenols
Prolidase [E.C. 3.4.13.9] is a key enzyme involved in the
process of collagen biosynthesis. This enzyme is involved in the
breakdown of imidopeptides that are degradation products of
collagen fibers. In the last stage of collagen degradation, prolidase
catalyzes the reaction of the release of proline and hydroxyproline
imidopeptides. The released proline can then be included in the
collagen biosynthesis or other metabolic pathways, e.g., related
to the process of apoptosis or the neoangiogenesis process. Since
proline is the major constituent of collagen (it represents the
main source of the aminoacids), their metabolism is directly
connected. Due to this fact, prolidase plays a crucial role in the
recycling of proline for collagen biosynthesis. In CAL-27 cells
incubated with test polyphenols (chrysin – 5µg/mL, caffeic acid –
65µg/mL, ferulic acid – 50µg/mL, p-coumaric acid – 70µg/mL),
a reduction in the activity of prolidase was observed, by 81% –
p-coumaric acid, 78% – chrysin, 77% – ferulic acid, 66% – caffeic
acid in relation to the control (Figure 7).
DISCUSSION
The SCC is one of the most frequent cancers of the oral cavity.
It is associated with high invasiveness and ability to induce
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early and extensive lymph nodes metastases (Carvalho et al.,
2004). The lack of advanced pharmacotherapy of SCC requires
searching for new effective pharmacological strategies (Pilch and
Bouquot, 2005). In this study, we found that selected polyphenols
of propolis induced apoptosis in CAL-27 cells through up-
regulation of proline metabolism.
Recent studies revealed the enhanced progression of the
SCC due to up-regulation of proline level induced by amplified
genes expression of ORAOV1 and P5C-reductase (Togashi et al.,
2014). Therefore, we considered proline metabolism as a target
for potential treatment of SCC. In fact, proline bearing reducing
potential is considered as a stress molecule. Its metabolism
plays an important role in maintaining energetic and redox
balance in cells. Free cytoplasmic proline may up-regulate
transcriptional activity of HIF-1α that is considered as pro-
survival and inflammatory transcription factor since it induces
expression of COX-2, VEGF, TNF-α, IL-1, NF-κB (Surazynski
et al., 2008a).
Proline could be removed from the cytoplasm by
incorporation into collagen. Collagen biosynthesis may
serve as a sink for proline. Up-regulation of collagen
biosynthesis can remove reducing potential, but it may
contribute to tissue cirrhosis usually accompanying prolonged
inflammation (Priest and Davies, 1969; Davis and Cowie,
1990). Interesting is a fact of significant alterations in collagen
content in SCC tissue. Agarwal and Ballabh indicated a definite
alteration in the distribution of collagen type IV with its
significant loss in poorly-differentiated SCC tissue (Agarwal
and Ballabh, 2013), related to increased metastasis. On the
other hand, proline is generated from imidodipeptides (derived
from collagen degradation products) by imidopeptidase –
prolidase. Therefore, the enzyme activity represents an
important factor in the regulation of intracellular proline
concentration. However, other mechanisms that contribute to
generation as well as, utilization of intracellular proline are as
well-important.
A critical pathway of proline utilization is mitochondrial
degradation by proline oxidase – PRODH/POX. During this
process ROS and/or ATP are generated. PRODH/POX is
widely distributed in living organisms and is responsible for
a number of regulatory processes such as redox homeostasis,
osmotic adaptation, cell signaling, and oxidative stress. Recent
data provided evidence that enzyme plays a crucial role in
inhibition of carcinogenesis and tumor growth. It may induce
apoptosis in both intrinsic and extrinsic ways in cancer
cells (Zareba and Palka, 2016). Unfortunately, the enzyme
is often down-regulated in cancer cells leading to inhibited
apoptosis (Kononczuk et al., 2015a). Our results indicated
almost undetectable expression of PRODH/POX in CAL-27
cells. Therefore, we analyzed propolis compounds as factors
inducing PRODH/POX expression and decreasing proline level.
We suggest that polyphenols contained in propolis induced the
enzyme activity, leading to induction of apoptosis in CAL-27
cells.
We found that studied polyphenols decreased in a dose-
dependent manner the viability of CAL-27 cells. Moreover,
the treatment inhibited DNA biosynthesis in these cells. The
decrease in cell number was related to induction of apoptosis.
We observed a significant increase in expression of active/cleaved
caspases -3 and -9 and increase in the amount of the cells with
low level of reduced glutathione (GSH) in polyphenol-treated
CAL-27 cells. Considering the important role of PRODH/POX
in apoptosis (Phang, 2017), its expression was evaluated. The
polyphenols induced expression of PRODH/POX in CAL-27
cells. Cell growth arrest related to apoptosis is induced by
p53. The transcription factor is the most potent inducer of
PRODH/POX expression (Nagano et al., 2017). In fact, p53
expression was also induced by studied polyphenols in SCC
cells.
PRODH/POX-dependent utilization of proline in polyphenol-
treated CAL-27 cells was confirmed by LC–MS analysis of
proline concentration. Since proline could be utilized in
collagen, the biosynthesis of this protein was determined.
All tested compounds significantly inhibited the process. It
suggests that observed decrease in proline concentration was
related to its metabolism by PRODH/POX. The decrease
of collagen biosynthesis in polyphenol-treated CAL-27 cells
may result from inhibition of prolidase by polyphenols. The
enzyme plays an important role in collagen biosynthesis
(Palka and Phang, 1997; Surazynski et al., 2008b; Kononczuk
et al., 2015a). We observed inhibition of prolidase activity
in the cells treated with studied compounds (however to
various degree). We suggest, that decrease in proline level
by propolis compounds result from proline degradation
in mitochondria by induced PRODH/POX and not by
utilization of this amino acid for collagen biosynthesis. The
significant role of PRODH/POX in apoptosis induction we
described previously (Kononczuk et al., 2015b). Stimulation
of PRODH/POX expression by Eptifibatide, αIIbβ3-integrin
inhibitor, lead to strong proapoptotic effect in MCF-7 breast
cancer cells.
The present study provides for the first time evidence that
compounds of propolis (chrysin, caffeic acid, p-coumaric acid,
and ferulic acid, of which the most potential effect on CAL-
27 cells growth inhibition was attributed to chrysin) contribute
to the induction of PRODH/POX-dependent apoptosis in
CAL-27 cells. Therefore, PRODH/POX may represent a novel
target for the propolis-induced anticancer activity in SCC
cells.
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Plants were an essential part of foraging for food and health, and for centuries remained
the only medicines available to people from the remote mountain regions. Their correct
botanical provenance is an essential basis for understanding the ethnic cultures, as
well as for chemical identification of the novel bioactive molecules with therapeutic
effects. This work describes the use of herbal medicines in the Beskid mountain ranges
located south of Krakow and Lviv, two influential medieval centers of apothecary tradition
in the region. Local botanical remedies shared by Boyko, Lemko, and Gorale ethnic
groups were a part of the medieval European system of medicine, used according to
their Dioscoridean and Galenic qualities. Within the context of ethnic plant medicine
and botanical classification, this review identified strong preferences for local use of
St John’s-wort (Hypericum perforatum L.), wormwood (Artemisia absinthium L.), garlic
(Allium sativum L.), gentian (Gentiana lutea L.), lovage (Levisticum officinaleW.D.J. Koch),
and lesser periwinkle (Vinca minor L.). While Ukrainian ethnic groups favored the use of
guilder-rose (Viburnum opulus L.) and yarrow (Achillea millefolium L.), Polish inhabitants
especially valued angelica (Angelica archangelica L.) and carline thistle (Carlina acaulis
L.). The region also holds a strong potential for collection, cultivation, and manufacture
of medicinal plants and plant-based natural specialty ingredients for the food, health
and cosmetic industries, in part due to high degree of biodiversity and ecological
preservation. Many of these products, including whole food nutritional supplements, will
soon complement conventional medicines in prevention and treatment of diseases, while
adding value to agriculture and local economies.
Keywords: ethnobotany, traditional knowledge, herbal texts, bioactive compounds, functional foods, folk
remedies
INTRODUCTION
The terms Beskids or Beskid Mountains (Beschad Alpes Poloniae) denote the Carpathian mountain
ranges that historically separated kingdoms of Poland from Ruthenia (Ukraine) and Hungary as
described in the 1269 Hungarian deed (Papee, 1891). The Beskids are approximately 600 km in
length stretching from Moravian Gate in the west (Czech Republic) to Vyshkovsky Pass in the
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east (Ukraine) along the modern Polish-Slovak border, but are
rather narrow (50–70 km in width). Gorale, Lemko, Boyko, and
Rusyn ethnic groups of mixed Slavic, Vlah (Aromanian) and
Thraco-Celtic origins primarily populate these areas (Figure 1).
During tenth–fourteenth centuries, Beskids formed a transborder
region of limited political and economic affiliation, defined by
a line of defensive border settlements (La: ultra indagines, Ua:
zasiky, Pl: bron) advancing slowly toward the mountain ridges
along the Spis-Borzhava axis in the south and Myslenice-Sanok-
Dolyna axis in the north (Halaga, 1961). Turka on the route to
Uzhok Pass and Wietrzno-Bobrka on the route to Dukla Pass
were typical examples of such defensive hillforts (Ua: gorodysche,
Pl: grodzisko). In the fourteenth century, continuous colonization
of the Beskids was described as of Ruthenus, Ruthenus-Valachus,
Ruthenos seu Valachos, or Valachus origin (Hoshko, 1983).
The ongoing debate whether these terms identified a proper
ethnic affiliation of the migrants or their rustic (agricultural) vs.
valachian (pastoral) background has not been settled (Stavrovsky,
1967). The transborder status, however, combined with severe
geographical and socioeconomic isolation, resulted in self-
treatment as a primary choice of both medicinal and spiritual
healing. Even at the beginning of the twentieth century, one
medical doctor served on average 9,000–17,000 inhabitants
(Otchet, 1915), and a doctor’s reputation and recognition was
well below that of a local pharmacist or a traditional healer.
The use of plants and their preparations in European
medicine, drawing upon the traditions of both the classical and
Arab civilizations, was formalized by works of Hippocrates of
Kos (Corpus Hippocraticum), Dioscorides (De Materia Medica),
Pliny (Naturalis Historiae), Avicenna (Liber Canonis), and
Galen of Pergamon (Hidden Drugs, survived only in Arabic
translation as Al-Adwiya al-Maktuma) as the science of using
fresh plants and dry herbs to improve human health (Cruse,
1999). Prior to 900–1200 AD, however, no written records
described traditional herbal treatments used by Celtic, Slavic,
and Germanic tribes that bordered the Roman Empire. First
medieval manuscripts that partially documented the use of
herbs in these areas were largely translations from earlier
FIGURE 1 | Study area that includes Beskin ridges of the Carpathin Mountains: (A) Schematic map of the mountain region that serves as a border between Ukraine,
Poland, Slovakia, Hungary, and Romania, and (B) Schematic mountain areas inhibited by Gorale, Lemko, Boyko, Rusyn, and Hutsul ethinc groups.
Latin works that incorporated local variations in methods of
collection, preparation, and use (Singer, 1927), including Bald’s
Leechbook andOld English herbals (Anglo-Saxon, tenth–eleventh
century), Regimen Sanitatis (Italian, tenth century), Physicians
of Myddvai (Welsh, fourteenth century), and various editions
of [H]ortus Sanitatis (1491) based on the German Herbarius
Maguntie impressus of 1484 and Herbarius zu Teutsch of 1485.
The latter monographs were intended to treat of cheap and
homely remedies for the use of the poor, as most herbs listed in
these books were native or garden plants, while very few exotic
remedies were described in details.
A glimpse of medieval Slavic herbal tradition could be
found in the tenth–eleventh century manuscripts Izborniki
(Anthologies, transcribed in 1073 and 1076 for Prince
Svyatoslav of Kyiv from manuscripts that had belonged to
Tsar Simeon of Bulgaria) that described medicinal uses of
several plants, including henbane (Hyoscyamus niger), hemlock
(Conium maculatum), and wormwood (Artemisia absinthium).
Subsequent herbal manuscripts (Ua: travnyk, zilejnyk, vertograd,
Pl: zielnik) from sixteenth to eighteenth centuries often combined
traditional herbal medicines with irrational magical applications.
For example, while the seventeenth century vertograd described
management of fever and pain with cabbage (Brassica oleracea)
and beet (Beta vulgaris) leaves, and infection diseases with onion
(Allium cepa) and garlic (Allium sativum), it also prescribed a
mixture of horse and goat manure to cure alopecia in 3 days
(Krylov, 1985). Nonetheless, these manuscripts served during
the late Middle Ages as veritable manuals of practical herbal
medicine. Their text and images were usually mechanically
transcribed from earlier works of the most varied provenance,
while the successive owners often enriched the contents with
personal observations and experiences.
OLDEST HERBALS PRINTED IN THE
CARPATHIAN FORELAND
Foundation of Prague University in 1348 and Krakow University
in 1364 provided diverse educational opportunities for wealthy
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local families of Polish and Ruthenian descent, and led to the
expansion of local medicinal and apothecary tradition. Krakow,
and later Lviv, quickly developed into two influential medieval
centers of apothecary, with former also serving as an important
publishing site of printed herbal texts.
Here, six major monographs describing the use of medicinal
plants were published between 1532 and 1613 (Table 1). The
first one was a Latin reprint of De Herbarum Virtutibus (Naples,
1477) with plants names translated into Polish for the first time
by Simon de Lowicz in 1532. Its significance lies in the fact
that it was the first document of such length to indicate a
renewed interest on this subject and to reveal direct influence
of Dioscorides and Pliny. Even though there was no evidence
of experimentation, and whether or not the author actually ever
attempted to use any of the herbs of which he wrote, this herbal
had a tremendous influence on medical and botanical literature
from the early Middle Ages (Flood, 1976). One testimonial
to the wider influence Macer had on subsequent medical and
botanical commentators was a large number of translations of
the herbal into vernacular languages and dialects. Its popularity
was likely partially due to the selection of predominantly native
European plants (39) or medicinal herbs cultivated in the
gardens (25) over the exotic plants (13) that were difficult to
procure.
Stefan Falimirz (Falimir, a Ruthenian courtier to Jan
Tenczynski, the Duke of Podola in Krasnik) compiled various
Latin [H]ortus Sanitatismanuscripts, translated them into Polish,
and released a first popular encyclopedia of traditional medicines
entitled O ziolach i o mocy ich (On herbs and their power)
in Krakow (1534). The subjects covered herbs and herbal
medicines (including the first use of Polish term wodkameaning
“little water” to describe high proof spirit distilled from grain),
medicinal properties of animals and minerals, obstetrics, surgery,
and were profusely illustrated with over 550 mostly original
woodcuts. Plants were described in a set of 261 articles on
European and 69 exotic herbal remedies. Descriptions of plants
and their use, however, were mostly translations from the
previous sources and likely unknown to the author (Elbanowski,
2014). This became very clear when compared to other chapters
describing animals, where Stefan provided extensive and original
details on local fishes, a subject apparently of great familiarity
to the author. Specifically, Stefan stated, “Because we live in
Poland, there is a need to know characteristics and use of Polish
fishes, as we use them regularly. The ones that help, the ones that
harm, the good, the better, and the worst.” This statement for the
first time indicated the emerging perception of inadequacy of
contemporary Latinmanuscripts that lacked local knowledge and
tradition.
HieronimSpiczynski ofWielun (a wealthy Polish councilman
in Krakow) attempted an adaptation of Stefan Falimirz’s work by
publishing O ziolach tutecznych y zamorskich y o mocy ich (On
local and overseas herbs and their power, 1542) with improved
woodcuts. The monograph contained similar and often identical
descriptions of several medical guides to practical use of herbal
remedies. The catalog of herbs was focused on local plants listed
under Polish and Latin names, with a shorter list of exotic plants
identified only in Latin. Compared to other herbals, it contained
narrower descriptions of plant species with no mention of their
origin or occurrence.
Marcin Siennik (Merten Heüwrecher, a wealthy merchant
of German origin in Krakow) compiled another adaptation of
Falimirz’s herbal 26 years later as Herbarz to jest ziol tutecznych,
postronnych i zamorskich opisanie (Herbal as description of
local, foreign and overseas plants, 1568). Quick comparison
among these editions revealed minor changes in the order of
the chapters, woodcuts, and plant names. Siennik held neither a
professional title nor a degree, and seemingly edited books solely
to make income in accordance with publisher’s instructions. The
only freedom that he enjoyed was expanding the list of plant
nicknames, to which he contributed many new names, however
both descriptions and uses of various remedies were transcribed
intact, together with all previous errors and omissions. The
TABLE 1 | Medieval herbals printed in the Carpathian foothills in the fifteenth–seventeenth centuries.
Front page
Author Simon de Lowicz
(-1538)
Stefan Falimirz
(-1550)
Hieronymus Spiczynski
(-1550)
Marcin Siennik
(-1588)
Marcin de Urzedow
(-1573)
Simon Syrenius
(-1611)
Title Aemilius Macer, De
herbarum virtutibus
(Krakow, 1532)
Hortus sanitatis,
O ziolach i o mocy ich
(Krakow, 1534)
O ziolach tutecznych i
zamorskich i o mocy
ich
(Krakow, 1542)
Herbarz to jest zioł
tutecznych,
postronnych i
zamorskich opisanie...
(Krakow, 1568)
Herbarz polski, to jest o
przyrodzeniu ziol i dzew
rozmaitych...
(Krakow, 1595)
Zielnik herbarzem z
iezyka lacinskiego
zowia...
(Krakow, 1613)
Notes 2,756 verse lines
77 plants
13 exotic
Added Polish names
433 pages
329 plants
69 exotic
Translated to Polish
Adapted from Falimirz
Sorted by Polish names
Adapted from Falimirz
Added German names
488 pages
477 plants total
105 exotic
New compilation
1,540 pages
765 plants total
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resulting monograph was published under a new name, with
modified woodcuts and an expanded index including German
names (Rostafinski, 1888).
Marcin deUrzedow (a Polish Catholic priest born inUrzedow
near Lublin, and a graduate of Krakow University) compiled
Herbarz polski, to jest o przyrodzeniu ziol i dzew rozmaitych
(Polish Herbal, 1595) that was printed after his death and
included descriptions of 372 local plant remedies and 105 exotic
herbs. Plants were listed in Latin alphabetical order and were
heavily influenced by independent translations from Dioscorides
Materia medica and Fuchs Cometraii insignes. Among those,
only 259 chapters described wild native plants characteristic of
the Polish countryside. The woodcuts, however, were the same
ones used in Siennik herbal to depict 240 local herbs–and for
this reason, the rest of the herbal remedies were illustrated
by woodcuts that were repeated or omitted altogether. The
individual reports lacked a particular order of presentation, with
some chapters organized by location, description and use, while
others discussed herbal properties prior to their looks and origins
(Rostafinski, 1888).
Szymon Syrenius (Syreniusz, Syrenski) of Oswiencim, a
graduate of Krakow and Padua Universities, moved to Lviv
and established his medical office there in 1578. He spent next
30 years collecting botanical flora from the northern slopes of
Beskids mountain ranges, including trips to more distant regions
of Podolia and Pokuttya. Here he compiled the most extensive
Polish herbal to date–Zielnik herbarzem z iezyka lacinskiego zowia
(Polish herbal, 1613), printed 2 years subsequent to his death.
Similarly to previously described monographs, this volume was
largely based on translations of Dioscorides Materia medica
and its adaptation by Petri Matthioli, known as Senensis midici,
commentarii in sex libros (1565), including the original woodcuts
from Matthioli’s work (Rostanski, 1997). The volume provided
detailed records of 765 plants, mostly from Southern and Central
Europe. The information was presented in a systematic way,
including plant description, area of distribution, collection and
processing techniques, and medicinal properties, followed by an
index of Latin, Polish, and German names.
Finally, a fairly unknown Old-Eastern-Yiddish remedy book
(refue-bukh) with the Hebrew title of Seyfer derekh ets ha-khayim
was printed in Poland in 1613. While the exact printing place of
the book is unknown, as is the name of the author, Krakow was
one of the possible places of its origin (Geller, 2009). Apart from a
richly decorated title page, the book contains no illustrations, so
technically it was not an herbal but rather a self-help botanical
guide. It described 87 remedies of plant, animal, and mineral
origin, with many Polish words used to identify plant names.
Most botanical terms and folk remedies were referenced to the
tradition of Hippocrates, Dioscorides, and Avicenna, therefore
it is not clear whether this book was an original compilation
of the classical sources, or a more recent adaptation of one
of the herbals similar to those listed above. To this point, we
would like to highlight the unknown author’s experience at the
Padua medical school to which he refers in the beginning of
his book (Geller, 2009)–a striking parallel to the educational
background of his contemporaries Marcin de Urzedow and
Szymon Syrenius. This may suggest a Padua-Krakow axis as
a primary route for introduction and adaptation of antique
botanical knowledge into the Carpathian region. Indeed, over the
course of the sixteenth century, approximately 1,400 Polish and
Ruthenian students, including nearly all physicians to the Polish
royal family, attended Padua University (Theodorescu, 1989).
Jan Zamoyski, Polsih Crown Chancellor and graduate of Padua
University, founded Zamojski Academy in 1594 and shortly after
that, a Jesuit Collegium was founded in Lviv (1608), which later
became Lviv Academy (1661). Together with Krakow University,
these institutions rapidly became the major centers of intellectual
and spiritual life in the region.
ON RELEVANCE OF PRINTED HERBALS
TO TRADITIONAL BOTANICAL
KNOWLEDGE
The sixteenth century scholars discovered a critical obstacle
in sorting and presenting botanical knowledge that had
accumulated over the centuries in antique natural and medical
literature, and had been translated to various languages on
multiple independent occasions. The same plants were often
given different names based on the place of their origin. To make
things worse, the ancient texts and names of old herbal remedies
were often distorted due to evolution of the language and
inadequate translation or transcribing, especially when detailed
descriptions of target plants were absent from the original texts.
This notion did not escape the attention of herbal editors, as
stated by Marcin de Urzedow in the introduction to his work:
“We are no longer satisfied by knowledge of garden and field plants,
but search for new ones in the wild, in forests, on mountains and
cliffs, and even places where mountain goats reached seldom.” For
this particular reason, it was very difficult to define and isolate
local traditional knowledge in these monographs, as medicinal
use of many ancient herbs was fully adopted and integrated
into local folk knowledge. There was, however, a speculative
evidence of an opposite flow of knowledge aboutmedicinal plants
from Slavic into Greco-Roman tradition: Slavic knowledge of
medicinal plants supported the hypothesis of Tomaschek that
the majority of so-called Dacian synonyms interpolated into the
Dioscorides text from the Viennese codex are of Slavic origin
(Grmek, 1959).
PHARMACOPEIAS THAT REGULATED
APOTHECARY TRADITION IN THE REGION
(FIFTEENTH–NINETEENTH CENTURIES)
The official Polish and Polish-Latin scientific literature concerned
with herbal medicines became comparatively extensive between
fifteenth and seventeenth centuries. The first place among
earlier manuscripts from the region belongs to the volume
entitled Antidotarium seu Vocabularium medicum, passim cum
nominibus herbarum Germanis et Polonis rubro adscriptis (1419),
currently kept at the Jagiellonian Library in Krakow. It was
likely written by an unknown physician or monk of German
origin who worked in Poland and had first hand knowledge of
Polish plants (Magowska, 2004). This pharmacological work was
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a direct adaptation from Antidotarium parvum, a pharmacopeia-
like manuscript written by an unknown author in Salerno
between eleventh and thirteenth centuries. Different editions of
this work included 110–170 recipes from antiquity and early
medieval writers, which were annotated with German and Polish
names. We also cannot rule out the possibility that some chapters
were borrowed from Antidotarium magnum, another work of
unclear origin from the twelfth century, which may have been
initiated by Constantinus Africanus and contained 1,200 recipes
(Prioreschi, 2003).
Jan Stanko (Johannes Stanconis) of Luban near Wroclaw, a
graduate of Padua University and a royal physician to Polish King
Kazimierz Jagiellonczyk (Lisowski, 2007), compiled a botanical
and medical glossary entitled Incipit Antibolomenum Benedicti
Parthi in 1472 (now kept at the Archives of the Krakow Cathedral
Chapter). He listed 20,000 scientific andmedicinal terms of Latin,
Greek, Arabic, Italian and other origins, translated into German,
Polish, and Czech languages. The Antibolomenum served as an
apothecary index identifying 433 domestic and 90 foreign plants,
219 domestic species of animals and the minerals used as the
ingredients of the apothecary remedies. While useful for quick
identification of medicinal ingredients and their equivalents, the
manuscript was never published, and had nomajor impact on the
development of the natural sciences at the time.
The first printed pharmacopeia that had significant impact
on the apothecary tradition of Poland was compiled by
a German physician Johann Placotomus (Breitschneider)
under the title of Pharmacopoeia in compendium redacta and
published in 1560. This book was developed on the basis of
Dispensatorium written by Valerius Cordus (1546). The work
included information on individual materia medica (simples)
and complex recipes for powders, pills, syrups, decoctions,
ointments, and oils. It also included recipes and instructions
for preparation of theriacs–panacea-type medical concoctions
as general antidotes against poisons and infectious diseases.
Another pharmacopeia was compiled by Polish physician and
apothecary in Krakow, Jan Woyna of Jasienica under the
title of Pharmacopoea Cracoviensis and published in 1683, in
compilation with two other works, Experemintorum medico-
chymicorum and Observationes medicochirurgico by Daniel
Matthia. This monograph was rather short; although it listed
circa 1,500 apothecary ingredients in alphabetical order, the
descriptions were very brief or nonexistent. Instead, multiple
cross-references to other, mostly foreign pharmacopeias and
dispensatoria, were provided. The only exceptions were made
for new recipes developed by the author, in which case
more detailed information on ingredients and methods of
preparation were given. Certain new recipes were very complex,
for example a novel preparation named Spiritus Castorei
Cracoviensis consisted of four herbs, Castorei (locally sourced
Castor fiber), Anacardini (American Anacardium occidentale),
Asa (Asa foetida from Persia or Afghanistan), and Storacis
(Styrax liquidum from Asia Minor). All four monographs,
however, were private publications without any official character
or certification.
In spite of the fact that unification and standardization of
apothecary tradition in Europe were long overdue, the first
legally enforced government pharmacopeia was published only
in 1698 as Dispensatorium Brandenburgicum. This monograph
was released in Latin language, contained descriptions of over
1,000 apothecary ingredients, including 906 complex mixtures.
The most demanding recipe was that of Theriaca Andromachi
that comprised a mixture of 71 individual components. Duke
of Warsaw Frederick Augustus I made Dispensatorium a
required apothecary regulatory document for all Polish lands
in 1714 under a modified title. Following the first partition
of Poland, the Carpathian foothills were divided between
Poland and Austria, and two new pharmcopeias were published
to regulate the apothecary practices including Pharmacopoea
Regni Poloniae (1817) and Phаrmасороеа Austrica (1820)
(Table 2). These monographs contained descriptive notes on
prescribedmedicines and were intended to register approved and
established remedies (for the physician), and to provide formula
and appropriate methods of preparation (for the pharmacist).
HANDWRITTEN HERBAL MANUSCRIPTS
FROM THE REGION
(SIXTEENTH–EIGHTEENTH CENTURIES)
The beginning of the seventeenth century marked a turning
point in the use of botanicals for medicine and folk healing. The
practices of trained physicians and apothecaries became chiefly
summarized and regulated by pharmacopeias, while the local
knowledge of healers and witchcraft practitioners was mainly
restricted to oral tradition and handwritten manuscripts. While
the second sources often originated from the first, they were
much less consistent. Thesemanuscripts typically borrowed from
multiple printed sources, original or translated, and accreted
with remarks and personal observations of the successive
owners. Thus, while printed herbals recommended carline thistle
(Carlina acaulis) to protect children from the evil enchantments
of the “old women,” the same “old women” often used this plant
to aid in apotropaic and love magic (Ostling, 2014).
One of the earliest examples of such manuscripts, recorded
somewhere in Grand Duchy of Lithuania and self-described as “a
translation from Latin and Polish books,” was created in the mid
sixteenth century (designated here as Pushkarev). If the dating is
correct, this manuscript was translated at the same time asHortus
sanitatis books known as “vertograds” were printed in Moscow
(1534) and Kolomna (1588) (Novoselski and Pushkarev, 1977).
The section of the manuscript that describes herbal tradition is
entitled Knigi lechebnya ot mnogih lekarev sobranye o koreniah i
o zeliah (Medicinal books collected from many doctors). Other
sections contained discussions on hygiene, Galenic commentary
on Hippocrates, notes and quotations from Avicenna and other
medieval physicians, exerts from the pseudo-Aristotle tractates,
descriptions of commonmedicinal practices such as bloodletting,
and magical spells. Large numbers of spelling errors, incorrect
interpretations and misrepresentations, all point to the fact that
the manuscript was written not for personal use, but rather for
sale by a professional transcriber with little knowledge on the
subject. Extensive references to old Ruthenian terms zhuravly
(cranes), zubry (buffalo), tryascia (malaria), tsybula (onion),
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TABLE 2 | Pharmacopeias that regulated regional apothecary practices in the sixteenth–nineteenth centuries.
Front page
Author Johann Placotomus
(1514–1574)
Jan Woyna
(1605–1693)
Prussian Magistrate Polish Supreme
Health Council
Austrian Pharmaceutical
College
Title Pharmacopoea in
compendium redacta per
Johannem Placotomum
(Antwerp, 1560)
Pharmacopoea
Cracoviensis (Frankfurt
am Main, 1683)
Dispensatorium Regium et
Electo-rale Borusso-
Brandenburgicum
(1714)
Pharmacopoea Regni
Poloniae (1817)
Pharmacopoea Austrica
(1820)
Notes 256 pages
502 plants total
147 pages
1,500 recipes
305 ingredients
357 mixtures
pevne (probably), and many other words suggested Volhynia or
Carpathian forelands as possible places of its origin.
The compilation of such manuscripts with no reference
to the original sources was very common among Eastern
Slavic groups during sixteenth–eighteenth centuries. In his
Russkije vrachebniki work, a bibliographer of the history of
Russian medicine listed 186 such manuscripts, most from
the seventeenth century (Zmejev, 1895). As these manuscripts
were transcribed in time, each subsequent version underwent
a complex change based on the local needs and traditions,
with a progressively shifting emphasis onto local and easily
collectible plants, and away from their exotic and expensive
alternatives. It is therefore critical in future works to establish
which particular plants and beliefs were incorporated into
Slavic folk healing manuscripts from European sources, which
knowledge specifically reflects oral local tradition that was fixated
in these works, and which part of the tradition was an original
contribution of local ethnic groups. To achieve this goal, we
would need to determine and investigate independent parts
of handwritten herbal manuscripts (i.e., chapter groups) that
originated from the common source. Another prevalent feature
of these manuscripts that separated them from printed herbals
was the lack of plant illustrations or prints. Otherwise, the plant
uses described in these manuscripts were correct and targeted
either a function of the human body (medicine), social life
(relationships and feelings), household issues, or superstition
beliefs (Ippolitova, 2008). With time, these descriptions became
a part of the oral local tradition, and many of medicinal
prescriptions and uses were eventually transferred to other
unrelated plants.
A Ruthenian handwritten manuscript from the late sixteenth
century, also likely a translation from a Polish source, was found
in the State Archive of Bucharest (Syrku, 1883) (designated
here as Syrku). Some of the plant descriptions from this
manuscript, for example, plantain (Plantagomajor), St. Benedict’s
thistle (Cnicus benedictus), Norwegian angelica (Archangelica
officinalis), and lesser burnet (Pimpinella saxifraga) were very
close if not identical to other subsequent manuscripts, showing
continuation of handwritten tradition in time (Nimchuk, 1976).
One of them, a Ruthenian herbal manuscript Kniha lechebnaya o
mnogih lekarstv, dated to the mid seventeenth century, survived
in the Swidzinski collection from Sanok area (Peredrijenko,
1984) (designated here as Swidzinski). This manuscript was
a compilation of various texts, legends, poems, and prayers
in addition to herbal tradition. The territory to which the
manuscript was localized, had formed a border line between two
ethnic groups of Ruthenian origin, Boyko in the east and Lemko
in the west (Falkowski and Pasznycki, 1935). Both ethnic groups
still maintain a deep tradition in collecting and consuming a
variety of wild plants. Among those, berries, mushrooms and
hazelnuts are most popular. Several reorganizations, including
the deletions of nonessential magical sections, and additions of
important material about the habitat and preparation of the
plant, were evident from this manuscript. We must therefore
postulate, that the original knowledge about the medicinal
properties of the herbs that was fixated in the earlier printed
herbals, became amorphous and open to interpretation when
it entered oral and written tradition of common people in the
seventeenth-eighteenth centuries.
ETHNOGRAPHIC STUDIES OF THE
CARPATHIAN FOOTHILLS
(NINETEENTH–TWENTIETH CENTURIES)
While political and economic transformations took place at the
lowlands of Poland and Ukraine, the people who inhabited the
Carpathian ridges of the Beskid Mountains saw little change and
dependedmostly on cheap and readily available traditional herbal
medicines for the poorest. By that time, the combined knowledge
of printed herbals and handwritten manuscripts was deeply
rooted in the oral tradition of folk remedies (Figure 2). This
fusion was so profound, that most of the ethnographic studies
of the region that took place in nineteenth and early twentieth
century recorded and transcribed traditional folk medicines as
a part of local cultural and ethnographic “heritage.” The rise
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FIGURE 2 | Major historical and publishing milestones that define development of regional herbal texts and botanical manuscripts. Black squares indicate the
emergence of handwritten herbal mauscripts including Pushkarev (1) and Swidzinski (2), as well as ethnobotanical surveys of Rostafinski (3) and Fisher (4) discussed
in this study.
of alternative medicines in these areas could be interpreted
as one of many signs of poor development and often of an
economic decline of the region. The inaccessibility and sometime
active rejection of medicine, the acceptance of simplistic medical
notions, and the reliance on imaginary observations indicated
a loss of confidence in empirical observations and a pessimistic
view of the capacity of men to overcome external difficulties by
reason (Prioreschi, 2000).
Early ethnographic studies in the region were general
descriptive compilations of oral traditional medicines recorded
by Ukrainian and Polish enthusiasts without further analysis or
comparison to the previous written works on the subject.Danylo
Chomych Lepki described Boyko women from mountain
areas who treated skin disorders in babies with herbal baths
that included a mixture of pasqueflower (Pulsatilla patens),
cornflower (Centaurea cyanus), rue (Ruta graveolens) and lesser
periwinkle (Vinca minor), as well as the use of infusions
from the bark of rowan (Sorbus aucuparia) and mezereon
(Daphne mezereum) in love magic (Lepkij, 1884). Oskar
Kolberg, a Polish ethnographer, observed the traditional use of
thyme (Thymus serpyllum), milk thistle (Silybum marianum),
scentless chamomile (Anthemis arvensis), chamomile (Matricaria
chamomilla), wormwood (Artemisia absinthium), galipot (Picea
alba), a mixture of water and burned aspen (Populus tremula)
for treatment of osteomyelitis, and a fermented mixture of
oat hulls and goose feces for treatment of abscesses among
the inhabitants of the Carpathian foothills (Kolberg, 1888).
Ivan Kuziw, a Greek-Catholic priest from Boyko villages Likot
and Dydiowa, noted an unusual method of making infusions
of valerian roots. They were placed in glass bottle, covered
with alcohol, and baked inside a breadloaf (Kuziw, 1889).
Julian Talko-Hryncewicz described 360 medicinal plants used
in Ukrainian lowlands (Talko-Hryncewicz, 1893). Ivan Franko,
an Ukrainian poet and ethnographer of Boyko origin, published
several collections of his ethnographic observations of Boyko
people, including their use of herbal medicines in magic and
protection (Franko, 1898), including blessed chalk, salt, field
poppy (Papaver rhoeas), zillya troyan (a mixture of Levisticum
officinale, Vinca minor, and Ocimum basilicum), and garlic
mustard (Alliaria petiolata).
Volodymyr Szuchewycz, an Ukrainian ethnographer and
teacher residing in Lviv, observed extensive use of traditional
herbal medicines by Hutsuls (a neighboring ethnic group of
Ruthenian origin to the east of Boykos) and described some of
the remedies in the 5th volume of his monograph (Szuchewycz,
1908), including the widely used comfrey (Symphytum officinale),
yarrow (Achillea millefolium), marsh woundwort (Stachys
palustris), mistletoe (Viscum album), and yellow gentian
(Gentiana lutea). Josef Schneider, a Polish ethnographer
born in Stebnyk, documented the use of herbal remedies by
Boyko people from the Dolyna region (Schneider, 1912). He
noted use of bath prepared with aspen (Populus tremula)
and periwinkle (Vinca minor) for treatment of various skin
disorders, baked onion (Allium cepa) for alleviation of abscess,
green cones from spruce (Picea abies) for syphilis, flower
petals for leg pain, and decoction of beet (Beta vulgaris)
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leaves for ringworm. Jan Falkowski, a Polish ethnographer,
described treatment of the Polish plait (plica polonica, irreversibly
entangled moist damaged hair) with chorne zillya (Pulsatilla
vulgaris). Tinctures made with yellow gentian (Gentiana lutea)
were a popular remedy against cholera. Special attention was
paid to ashes of burned medicinal plants. Cataracts were
treated by burning periwinkle (Vinca minor) and using the
ashes to wash the eyes. Burn wounds were treated with
ashes from burned wool or black ligules of sedge (Schoenus
nigricans). Open cut wounds were treated with juice from yarrow
(Achillea millefolium) (Falkowski and Pasznycki, 1935). Several
more recent ethnographical monographs provided comparative
analysis of previously published traditional knowledge and
cultural differences of Boyko people, including limited data on
Boyko herbal remedies. As such, they are not discussed here
(Kyrchiv, 1978; Boltarovych, 1980; Hoshko, 1983). Throughout
the twentieth century, there was a steady growth of published
books on Ukrainian medicinal plants that also contained
fragmented information on the topic from Beskids. Three of
them had a particular influence on the folk knowledge of the
local medicinal plants (Nosal and Nosal, 1962; Komedar, 1971;
Tovstuha, 1990).
Gorale from Silesian Beskids used sap from crushed goldmoss
stonecrop (Sedum acre) to treat ulcers. Crude, crushed herb was
applied for heel pain or, if mixed with fat, into the ear to reduce
earache. In Sacz Beskids it was also used internally to treat flu
or urinary tract diseases. Its relaxant and emetic properties were
used in food poisoning. Sedum maximum leaves were applied
externally crude or crushed on ulcers, bruises or edema. Sap of its
leaves was mixed with barley flour and as a plaster applied to slow
healing wounds (Tylkowa, 1989). On the border of Sandomierz
Basin and Central Beskidian Piedmont, wound healing properties
of Sedum were also known. It was applied in cataplasms or
ointments, when fried with Thymus serpyllum in unsalted pork
fat. Additionally, Gorale used its decoction in mouth rinsing
as a gum strengthening agent or as a remedy to “destroy the
scurvy impurities.” Among Gorales, several different plants had
the dialect name “nine forces” but the most famous one was
carline thistle (Carlina acaulis). The Silesian Beskids inhabitants
used it both internally and externally. Its root boiled with milk
or water and drank once a day on empty stomach was used in
kidney and bladder disease. Leaves were put on ulcers because
of its properties of getting pus out. Moreover, herb infusion was
used internally to treat colic and stitching pain (Tylkowa, 1989).
It is critical to note that historical handwritten manuscripts
and ethnographic studies reported equal if not larger use
of verbal spells (Ua: zagovor, Pl: zamawianie), charm heals,
and whispering prayers to treat diseases and cast magical
incantations (Figure 3A). This knowledge was often culture
and language specific, and most likely truly represented the
original healing tradition that predated Roman and Greek
therapies. The herbal remedies, however, were either substituted
in their entirety by the knowledge gathered from translation
of mostly Roman medicine, directly or via Italy and Germany,
or were so similar that they could not be distinguished. This
overlap though was never complete due to endemic plant
species in the region, which were unknown to Greeks and
Romans, and therefore could provide an exciting opportunity
to observe pre-Christian folk healing traditions from the
Carpathian Mountains. Guelder rose (Viburnum opulus) could
be of particular interest in this matter as it was largely unused
by the Western cultures. Similarly, the endemic species of
Arran whitebeam (Sorbus arranensis), unknown in Roman
healing tradition, was used as an antimicrobial remedy in the
Scottish Highlands (Wagner et al., 2017). Previously, it was
reported that the Bulgarian flora comprises 3,900 species, 12.8%
of which are endemics (Petrova, 2005). Assuming a similar
ratio of endemic plant species in the Ukrainian flora (6,086
FIGURE 3 | Botanical provenance of medicinal plants from the Carpathian Mountains: (A) Traditional healer from Eastern Carpathians as documented by Henryk
Gasiorowski at the beginning of the twentieth century, and botanical profiles of major (B) imported and (C) exported medicinal plants from Ukraine in 2014 (after
Nykytyuk, 2015).
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species), we could expect at least 600 endemic species, of
which at least 200 species could potentially contain biologically
active components and be used medicinally (Konischuk et al.,
2016).
SURVEYS THAT DOCUMENTED
TRADITIONAL USES OF PLANTS IN THE
REGION
Apart from the observational ethnographic studies, we are also
aware of two attempts to collect and analyze ethnographical
data on local use of herbal remedies in the Beskid region
by mailed or published questionnaires of Rostafinski in 1883
(Köhler, 2015) and Fischer in 1929–1934 (Kujawska et al.,
2015), both addressed to Polish speakers. Nearly 370 individuals
replied to the first enquiry and 290 filecards were collected in
the second call from the geographical region of our interest.
Rostafinski’s informants returned nearly 800 records of plants
used by traditional societies for medical purposes. The most
extensive version consisted of 70 questions concerning about
130 species. It was formulated in greater detail and asked
specifically what names people used for cultivated plants,
medicinal remedies (curative, ceremonial and magic plants),
mushrooms, and timber. The information on the medical use
of various plants obtained by Rostafinski showed that traditional
homemade remedies had not yet been substituted by chemical
medicines prepared by pharmacists at the time of the survey
(Köhler, 2015).
Fischer’s survey reported 179 plant taxa from the Galicia
region. However, only 87 (49%) of them were used as medicines
and targeted predominantly respiratory (24), digestive (24), and
skin (23) illnesses. The remaining herbs (53 or 30%) were
used for blessing during various religious ceremonies (Kujawska
et al., 2015). The species that achieved the highest use were
yarrow (Achillea millefolium), garlic (Allium sativum), periwinkle
(Vinca minor), St. John’s wort (Hypericum perforatum), and
juniper (Juniperus communis), which was strictly in line with
previous observations across various centuries. Two plants,
yarrow (Achillea millefolium) and coltsfoot (Tussilago farfara)
were also recognized as the most versatile remedies with multiple
pharmacological indications.
COMPARATIVE ANALYSIS OF MEDICINAL
PLANTS FOR WOUND AND SKIN
APPLICATIONS
To illustrate our assumption that the original Carpathian herbal
remedies were either substituted by knowledge gathered from
classical medicinal monographs or were identical to them,
we attempted a direct comparison of descriptions of herbal
medicines used to treat wounds among printed herbals and
subsequent traditional folk knowledge in the region. Falimirz’s
herbal (1534) listed 63 plants that were used for wound
healing out of 246 plants shown in Table 3 (25%). Among
the herbal references analyzed, Falimirz’s plant list matches
70% of plants described in the Welsh (Celtic) Physicians of
Myddvai manuscript, even though both works are separated by
a hundred years and 2,000 km–suggesting that both authors
used similar, if not identical, sources for transcribing these
monographs. This striking similarity could be explained in part
by the fact that medieval Celtic physicians (Scottish, Irish, and
Welsh) often received education at the University of Padua,
similar to their Ruthenian and Polish counterparts (Scottish
Historical review, 1906). Subsequent handwritten manuscripts
and surveys reported both smaller numbers of total medicinal
plants, as well as those used for wound healing. Only 3 plant
species are recommended to treat wounds across all 6 sources
studied, including derevij (Achillea millefolium), babka (Plantago
maior) and shalvia (Salvia officinalis), but at least 14 plants
are shared among the majority of the sources. Comfrey root
(Symphytum officinale) was used on multiple occasions to heal
wounds associated with bone fractures, minced in animal fat. The
type of fat used in this ointment varied depending on the location:
in Silesian Beskids, pork fat was preffered, in Zywiec Beskids,
goose lard was believed to possess the best curative properties,
while in Sacz Beskids they were both considered as effective.
Another treatment that remained largerly uniform among the
discussed regions was application of galipot of conifer trees to
wound healing ointments after heating it with bee wax and
butter.
MODERN PRODUCTION AND USE OF
MEDICINAL HERBS IN THE REGION
Worldwide, around 20,000 plant species are used for their
medicinal properties, including 180 herbs that are recognized
as medicinal by modern medicine. The annual market need
for herbal and botanical raw materials is estimated at 600,000
tons, with sales reaching $7.5 billion in the United States
alone, and $60 billion worlwide. Cultivation of medicinal plants
remains a fast growing and sustainable section of agriculture,
with profits margins exceeding those of grains and other
food crops 2 to 50-fold due to development of value-addded
products and parallel processing streams of raw materials and
waste products. Low costs of intitial investment into growing,
processing, and packaging medicinal herbs in Eastern Europe
(<$ 10,000) is also a very attractive factor, however it is
partially offset by lack of modern cultivation practices and
delayed returns due to intial 2 to 3-year establishment of
annual crop harvest (Mirzoyeva, 2013). Russia remains the
largest producer of medicinal plants in the region, with Poland
(cultivated herbs) and Bulgaria (wild collected herbs) in the
second place. Ukrainian market of medicinal plants is rather
small, with annual exports (averaging 3,000 tons) exceeding
imports (averaging 2,000 tons) in most years (Nykytyuk,
2015). Botanical imports are largerly dominated by chamomile
(Matricaria chamomilla) and senna (Senna alexandrina), while
chestnut (Castanea sativa), buckthorn (Frangula alnus), and
milk thistle (Silybum marianum) are leading exports in recent
years (Figures 3B,C). This is a drastic difference from 1920s,
when the same region was one of the world leaders in growing,
processing, and exporting medicinal plants, predominantly for
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TABLE 3 | Medicinal plants listed in Falimirz’s Herbal recipes (1534) and their occurrences in manuscripts and regional surveys, including Myddvai (M, 1382), Lowicz (L,
1532), Pushkarev (P, ∼1550), Swidzinski (S, ∼1650), Talko-Hrynkiewicz (T, 1893), and Fischer (F, 1934).
Plant name Appears in
Old latin (Falimirz) Botanical English Ukrainian Polish (Falimirz) M L P S T F
Branca ursina Acanthus mollis L. Bear’s breech Aкaнт Barszcz˙, akant x
Platanus Acer pseudoplatanus L. Sycamore Явiр Jawor
Millesolium Achillea millefolium L. Yarrow Деревiй, рaнник, серпник Krwawnik x x x x x x
Napellus Aconitum lycoctonum L. Wolfsbane Aконiт, вовкобiй, терлич Omieg, tojad x x
Acorus, Calamus Acorus calamus L. Calamus Aїр, лепехa, шувaр Miecz˙yk, tatarak x x
Capillus veneris Adiantum capillus-veneris L. Maidenhair fern Aдiaнт венерин волос Włoski, niekropien´ x
Agrimonia Agrimonia eupatoria L. Agrimony Пaрило, реп’яшки, зрад,
сметaнник
Rzepik x x x
Gith Agrostemma githago L. Corncockle Кукiль Kakol x x x
Porrum Allium ampeloprasum L. Leek Цибуля порa, порей Luk, por x x x x x
Cepe, Cepa Allium cepa L. Onion Цибуля Cebula x x x x x
Allium Allium sativum L. Garlic Чaсник Czosnek x x x x x x
Althaea, Altea Althaea officinalis L. Marshmallow Aлтея, слиз Slaz wysoki x x x x
Carui Ammi majus L. Bishop’s weed Aмми Polny kmin,
aminek
Morsus galline Anagallis arvensis L. Red pimpernel Курячi окa, мокрець Kurzys´lad, krze
ziele
x x
Buglossa Anchusa azurea P.Mill. Anchusa Воловик Wołowy ie˛zyk x x
Cinoglossa Anchusa officinalis L. Bugloss Воловик, медуниця Psi ie˛zyk,
farbownik
x
Anctum, Anethum Anethum graveolens L. Dill Крiп Koper x x x x x
Cotula setida Anthemis cotula L. Stinking chamomile Pомaн собaчий Rumien psi
Cerifolium Anthriscus cerefolium Hoff. Chervil Бугилa Trybula x x x
Fistula pastoris Anthriscus sylvestris Hoff. Cow parsley Бугилa Bzdziucha, trybula x
Apium Apium graveolens L. Celery Селерa Selery x x
Tela araneo Aranea telam* Spider web Пaвутинa Palecz˙yna, nic
predna
Aristologia Aristolochia longa L. Smearwort Хвилiвник Smolnik x x x
Aristologia Aristolochia rotunda L. Smearwort Paсць, конопенкa, снiгур Kokornak x x x x
Radix Armoracia rusticana G.Gart. Horseradish Хрiн Chrzan x x
Abrotanum Artemisia abrotanum L. Southernwood Полин, боже деревце Boz˙e drzewko x x x x x x
Absinthcum Artemisia absinthium L. Absinthe Полин гiркий Piołun x x x x x x
Piretrum Artemisia dracunculus L. Tarragon Тaрхун, естрaгон Draganek,
estragon
x x x
Iarus Arum maculatum L. Snakeshead Aрум Kołorzyk, obrazki
Asarum Asarum europaeum L. Asarabacca Копитняк, пiдлистник Kopytnik x x x
Sparagus Asparagus officinalis L. Asparagus Холодок Gromkowe
korzenie
x x
Scolopendria Asplenium scolopendrium L. Hart’s tongue fern Костенець Jeleni ie˛zyk,
jezycznik
x
Atriplex Atriplex hortensis L. Saltbush, orach Лободa, лутигa Łoboda x x x
Berberus Berberis vulgaris L. Barberry Бaрбaрис, кислиця, квaсниця Berberys, piwnik x x
Bleta Beta vulgaris L. Beet Буряк Cwikła x x x
Borago Borago officinalis L. Borage Огiрочник Borag x x x
Eruca Brassica eruca Mill. Arugula Pуколa Rokietta x x
Caulis Brassica oleracea L. Cabbage Кaпустa Kapusta x x x x
Rapa Brassica rapa L. Field mustard Piпa Rzepa x x x x x
Brionia Bryonia alba L. Bryony Переступень Przestep x x x
Herba umbilicorum Bupleurum rotundifolium L. Hare’s ear Лaскaвець Pepownik
Kalendula, Calendula Calendula officinalis L. Marigold Нaгiдки, крокиш Nogietek x x x
(Continued)
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TABLE 3 | Continued
Plant name Appears in
Old latin (Falimirz) Botanical English Ukrainian Polish (Falimirz) M L P S T F
Soldanella Calystegia soldanella R.Br. Morning glory Плетухa Urdzik
Canapus Cannabis sativa L. Hemp Конопля Konop´ x x x x x
Bursa pastoris Capsella bursa-pastoris Md. Shepherd’s purse Грицики, зозульник, рiжух Tobołki, tasznik x x
Herba victorialis Carlina acaulis L. Carlina Дев’ятисил, вiдклaсник Dziewe˛sił x x x
Cartamus Carthamus tinctorius L. Safflower Сaфлор, шaфрaн Krokosz x
Scabiesa Centaurea scabiosa L. Knapweed Волошкa, блевит, сонце Dryjak, chaber,
blawatek
x x
Centaurea Centaurium erythraea Rafn. Centaury Золототисячник, цинторiя Centuria,
tysia˛cznik
x x x x x
Os de corde cervi Cervus elaphus* Red deer bone Кiсткa оленя Kosc´ z serca
jeleniego
Celidonis, Chelidonia Chelidonium majus L. Celandine Чистотiл, глaдишник Złotnik, glistnik,
jaskolcze
x x x x
Gira solis Chondrilla juncea L. Devil’s grass Хондрилa ситниковиднa Skocz˙ek
Cicorea Cichorium intybus L. Chicory Цикорiй, петровi бaтоги,
стaрiвник
Podroz˙nik x
Kamphora Cinnamomum camphora J.P. Camphor laurel Кaмфорний лaвр Balsamowiec x
Calamentum Clinopodium nepeta Kuntze Lesser calamint Кaлaмiнт Mie˛tka kamienna x
Pes corinnus Clinopodium vulgare L. Wild basil Пaхучкa Sturzesz, czyscica
Hermodactilus Colchicum autumnale L. Autumn crocus Пiзньоцвiт, зимовник Paluchy, zimowit
Cicuta Conium maculatum L. Hemlock Болиголов, блекот, булaв Swinia wesz,
szczwół
x x x
Lilium convalium Convallaria majalis L. Lily of the valley Конвaлiя Lanka, konwalia x x
Coriandrum Coriandrum sativum L. Coriander Корiaндр Koriander,
kolendra
x x x
Pallacium leporis Crepis tectorum L. Hawksbeard Скердa Pałac zaie˛czi,
pepawa
x
Melon Cucumis melo L. Maskmelon Диня Melon x x
Cucumer Cucumis sativus L. Cucumber Огiрок Ogurek x x x
Cucurbita Cucurbita pepo L. Squash Гaрбуз Bania, dynia x
Amcos, Cyminum Cuminum cyminum L. Cumin Кмин Kmin x x x
Cuscuta, Epitimum Cuscuta epilinum Weihe Flax dodder Повитиця, перстенець Kania prze˛dza,
kanianka
Panis porcinus Cyclamen purpurascens Mil. Alpine cyclamen Циклaмен Obraski x
Squinantum Cymbopogon schonanthus S. Camel grass Цимбопогон Palczatka
Ciperus, Cyperus Cyperus longus L. Galilgale Смикaвець Cibora x x
Laurcola Daphne mezereum L. February Daphne Вовчi ягоди Wilcz˙e łyko,
wawrzynek
x x
Pastinaca, Daucus Daucus carota L. Carrot Mорквa Marchew x x x x
Staphisagria Delphinium consolida Gray Larkspur Дельфiнiй, сокирки Ostróz˙ka x x
Gariosili Dianthus caryophyllus L. Carnation Гвоздикa Gwozdzika x
Filius ante patrem Dianthus deltoides L. Maiden pink Гвоздикa Goz´dzik x
Virga pastoris Dipsacus fullonum L. Wild teasel Ворсянкa, будяк, чишaки Polna szcz˙ec´,
drapacz
x x
Poligonia Dipsacus sylvestris L. Fuller’s teasel Ворсянкa, будяки Szcz˙otki, szczec´ x
Squilla Drimia maritima (L.) Stearn Squill Дримiя Czebula zamorzka
Filix Dryopteris filix-mas Schott Fern Щитник, пaпороть Paproc´ x
Cauda equina Equisetum arvense L. Horsetail Хвощ, пaдиволос Przesika, skrzyp x
Iringus Eryngium campestre L. Eryngo Mиколaйчики Mikołaiek x x
Eupatorium Eupatorium cannabinum L. Hemp-agrimony Сiдaч, дaвник, вовчки Szadziecz x x x
Esula minor Euphorbia esula L. Green spurge Mолочaй гострий Sosnka mniejsza
Titimallus Euphorbia helioscopia L. Sun spurge Mолочaй, сaмозелень Romanowo ziele
(Continued)
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TABLE 3 | Continued
Plant name Appears in
Old latin (Falimirz) Botanical English Ukrainian Polish (Falimirz) M L P S T F
Catapucia Euphorbia lathyris L. Spurge Mолочaй Skocz˙ek,
ostromlecz
x x
Eufrasia Euphrasia rostkoviana Hayn Eyebright Очaнкa Swiecz˙ki x
Stercus Feces* Feces Кaл Layno, vykal x
Elitropium Filipendula ulmaria Maxim. Meadowsweet Гaдючник Wia˛zówka x
Filipendula Filipendula vulgaris Moen. Dropwort Лaбaзник, бaлaбaн Orzeszki,
wia˛zówka
x
Feniculus Foeniculum vulgare Mill. Fennel Фенхель Włoski kopr, fenkuł x x
Fragaria Fragaria vesca L. Strawberry Суницi, ягодa Pozimki, poziomka x x
Frarimus Fraxinus excelsior L. Ash Ясен Jesion x x
Fumus terre Fumaria officinalis L. Fumitory Pуткa, сплaвник Dymnica x x
Fungus Fungi generaliter* Mushroom Гриб Grzyb x
Camepiteos Galium mollugo L. Hedge bedstraw Пiдмaренник, брочник Przytulia x
Genesta Genista pilosa L. Broom Дрiк Janowiec x
Genciana Gentiana punctate L. Spotted gentian Тирлич, горичкa Goricz˙ka x x x
Pes columbinus Geranium columbinum L. Longstalk cranesbill Герaнь, кучеряве Gołe˛bia noga x
Gariossilata Geum urbanum L. Herb Bennet Грaвiлaт, ребник, чистець,
пiдоймa
Kuklik x x x
Edera terrestris Glechoma hederacea L. Ground ivy Pозхiдник, собaчa м’ятa Bluszcz x
Liquiricium Glycyrrhiza glabra L. Liquorice Локриця Lakricija x x
Gramen Gramen generaliter Hay Ciно Trawa x
Palma christi Gymnadenia conopsea R.Br. Fragrant orchid Билинець комaрниковий Dłon´ Kristowa,
golka
x
Sticados citrinum Helichrysum arenarium L. Dwarf everlast Цмин, жовтяниця Koczenki, kocanki x
Sticados arabicum Helichrysum stoechas L. Shrubby everlast Цмин aрaбський Koczenki z Arabiji
Elleborus niger Helleborus niger L. Black hellebore Чемерник Cz˙emierzycza x x x x
Samsucus Hibiscus syriacus L. Hibiscus Гiбiскус Wielki slaz
Auricula, Pilosella Hieracium pilosella L. Mousear hawkweed Нечуйвiтер, волосник Niedospiałek,
kosmaczek
x x
Luppulus, Velubilis Humulus lupulus L. Hops Хмiль Chmiel, pawey x
Iusquiamus Hyoscyamus niger L. Golden henbane Блекотa, люлян, немиця Bielon, lulek x x x
Iperico Hypericum perforatum L. St John’s wort Звiробiй, кровкa Jana ziele,
dziurawiec
x x x x
Isopus Hyssopus officinalis L. Hyssop Гiсоп, юсипок Izop, hyzop x x x x
Enula campana Inula helenium L. Elecampane Омaн, дивосил, ґaлaґaн, велике Oman x x x x x
Ircos Iris germanica L. Iris Пiвники Kosaciecz
Iris illirica Iris illyrica Tomm. Illyrian iris Пiвники Fijołkowy korzen´ x
Gladiollus Iris pseudacorus L. Yellow iris Пiвники, косaтень Miecz˙yk x x
Sandix Isatis tinctoria L. Woad Вaйдa Urzet
Iuniperus Juniperus communis L. Juniper Ялiвець Jałowiecz x x x x
Savina, Sabina Juniperus sabina L. Savin juniper Ялiвець, женепин Sawina, jałowiec x x x
Lactuca Lactuca sativa L. Lettuce Сaлaт Sałata x x x
Siler montanum Laserpitium siler L. Laserwort Pозрив-трaвa Czarnogłow
Lavendula Lavandula angustifolia Mill. Lavender Лaвaндa Lavenda x x
Lenticula Lemna minor L. Duckweed Pяскa Rza˛sa x x
Lens Lens culinaris Medikus Lentil Сочевиця Socz˙owicza x
Nasturtium ortulanum Lepidium sativum L. Garden cress Жерухa, хрiниця Rzez˙ucha,
pieprzyca
x x x
Oculus bouis Leucanthemum vulgare Lam. Ox-eye daisy Королиця Jastrun, zlocen x x
Ligusticum, Leuisticus Levisticum officinale Koch Lovage Любисток Lubczyk x x x x
(Continued)
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TABLE 3 | Continued
Plant name Appears in
Old latin (Falimirz) Botanical English Ukrainian Polish (Falimirz) M L P S T F
Lilium Lilium candidum L. Madonna lily Лiлiя бiлa Lilija x x x x
Assodillus, Narciscus Lilium martagon L. Martagon Lily Лiлiя лiсовa, мaслянкa Złotogłow,
powojek
Linaria Linaria vulgaris Mill. Toadflax Льонок, медовики, чистець Matki Boz˙ey len,
lnica
x
Grana solis Lithospermum officinale L. Gromwell Горобейник Wroble proso,
nawrot
x x
Matrisilva Lonicera caprifolium L. Italian honeysuckle Жимолость, козий листок Marsylia, powoj x x
Spica celtica Lycopodium clavatum L. Clubmoss Плaвун, диреч Widłak, babimur x x x
Kantarides,
Cantharides
Lytta vesicatoria L. Spanish fly Шпaнськa мушкa Pryszczel
Malva Malva sylvestris L. Mallow Кaлaчики, проскурник,
слизiвник
Slaz x x x x x
Mandragora Mandragora officinarum L. Mandrakes Maндрaгорa Pokrzyk x
Epatica Marchantia polymorpha L. Liverwort Maршaнцiя (мох) Watrobnt ziele x
Maiorana Marrubium vulgare L. Horehound Шaндрa Szanta x x
Camomilla Matricaria chamomilla L. Chamomile Pомaшкa, ромaн, рум’янок Rumien, rumianek x x x x
Paritaria Melampyrum pretense L. Broomrape Перестрiч, брaтики Nocz y dzien´,
pszeniec
x x x
Mellilotum Melilotus officinalis (L.) Pall. Melilot Буркун Nostrzyk, melot x x
Mellisa Melissa officinalis L. Lemon balm Mелiсa, мaточник, медовник Miodunka,
rojownik
x x x x
Piperita Mentha balsamea Wild. Peppermint M’ятa перцевa Pieprzycz˙ka x
Menta Mentha spicata L. Spearmint M’ятa Mie˛tka x x x x x
Pulegium Mentha pulegium L. Pennyroyal M’ятa блошинa Mieta poley x x x x x
Mercurialis Mercurialis annua L. Mercury Перелiскa Szcz˙yr x x
Spicanardi Nardostachys jatamansi DC. Spikenard Нaрд Nard
Nasturcium aquaticum Nasturtium officinale Aiton. Watercress Нaстурцiя, жерухa Wodna rzez˙ucha,
rukiew
x x x
Nigella Nigella sativa L. Black caraway Чорнушкa Kakolica,
czarnuszka
x x x
Ungula cababellina Nuphar lutea (L.) Sm. Yellow waterlily Глечики жовтi Kon´skie kopyto,
grazel
Nenufar Nymphaea alba L. Water Lily Лaтaття Grzybienie x x
Baselicon Ocimum basilicum L. Basil Вaсильки, бaзил´iк Bazylia x x
Turbit Operculina turpethum Mans Turpeth Крученi пaничi Wilec
Satirion Orchis morio et mascula L. Military orchid Зозулинець Lisie jayka,
storczyk
x x
Diptamus Origanum dictamnus L. Cretan dittany Maтеринкa, ясинець Trzemdała x x x
Origanum Origanum vulgare L. Oregano Maтеринкa, душинкa Lebiodka,
majeranek
x x x x x x
Os mundi Osmunda regalis L. Royal fern Осмундa Stnisowe proso,
dlugosz
x
Pionia Paeonia officinalis L. Peony Пiвонiя Piwonija x x x x
Opium, papaver Papaver somniferum L. Opium poppy Maк опiйний Mak lekarski x x x x x
Oculus corvi Paris quadrifolia L. True lover’s knot Вороняче око, рaнник, бешезникWronie oko,
czworolist
x
Pastinaca domestica Pastinaca sativa L. Parsnip Пaстернaк, пaстярник Pasternak x x x x
Serpentaria Persicaria bistorta Samp. Bistort Гiрчaк, рaковi шийки We˛zownik, rdest x x x x
Persicaria Persicaria maculosa Gray Lady’s thumb Гiрчaк, реплик Rdest x x
Petrosilinum Petroselinum sativum Fuss Parsley Петрушкa Piotruszka x x x x x
Paucedamum Peucedanum officinale L. Hog’s fennel Смовдь руськa Wszywy kopr,
gorysz
x
(Continued)
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TABLE 3 | Continued
Plant name Appears in
Old latin (Falimirz) Botanical English Ukrainian Polish (Falimirz) M L P S T F
Ostrus ostrucium Peucedanum ostruthium Koch Masterwort Смовдь Gorysz x
Meu Peucedanum palustre Monch Milk parsley Горичник Olesznik, gorysz
Alkakenge Physalis alkekengi L. Bladder cherry Фiзaлiс, сердечник Michunki,
zydowska wisznia
x
Pipinella Pimpinella saxifraga L. Saxifrage Бедринець, бедрич Biedrzeniecz x x x x
Pinea Pinus silvestris L. Pine Соснa Sosna x x x
Pistacca sistica Pistacia terebinthus L. Pistacia Терпентинне дерево Pistacja, terebint
Pes milui Plantago coronopus L. Miinutina Подорожник перистий Kania noga x
Amoglossa, Psilium Plantago maior L. Plantain Бaбкa, припутник Babka x x x x x x
Lingua avis Polygala vulgaris L. Tufted milkwort Китятки Krzyz˙ownica
Lingua passerina Polygonum aviculare L. Knotgrass Спориш Sporzysz, rdest x
Aaron Polygonum bistorta Samp. Bistort Гiрчaк змiїний, рaчки, криве We˛z˙ownik, rakowe
szyjki
x x
Polipodium Polypodium vulgare L. Polypody Бaгaтонiжкa, слодишкa Paprotka x x
Populus Populus nigra L. Black poplar Тополя Topola x
Portulata Portulaca oleracea L. Purslane Портулaк Kurza noga,
portulaka
x x x
Consolida, Tormentilla Potentilla erecta Uspen. Tormentil, septfoil Перстaч, кaлгaн Pie˛ciornik, kurze
ziele
x x x x
Pentassilon Potentilla reptans L. Cinquefoil Перстaч Pie˛ciornik x
Herba paralisis Primula veris L. Cowslip Первоцвiт, бaрaнцi Paraliz˙owe,
pierwiosnek
x x
Simphicum Prunella vulgaris L. Self-heal Суховершки Sylfion, glowienka x x
Persicus Prunus persica (L.) Batsch Peach Персик Brzoskiwia x x
Pulicari Pulicaria vulgaris Gaertn. Fleabane Блошниця Płesznik x
Pirula Pyrola minor L. Lesser wintergreen Грушaнкa Gruszyczka x
Lilialis Pyrola rotundifolia L. Wintergreen Грушaнкa Gruszyczka x
Galla Galla* Oak (galls) Чорнильнi горiшки Gallas x x
Quercus Quercus robur L. Oak Дуб Da˛b x x x
Flammula Ranunculus flammula L. Spearwort Жовтець Jaskier x
Raffanus Raphanus raphanistrum L. Radish Pедькa Rzodkiew x x x
Rosa Rosa canina L. Rose Шипшинa, свербивус Roz˙a x x x x x
Rozmarinus Rosmarinus officinalis L. Rosemary Pозмaрин Rozmarin x x
Rubea tinctorum Rubia tinctorum L. Madder Maренa Marzana x x
Rubus Rubus plicatus Weihe Blackberry Ожинa Jez˙yny x x
Ribes Rubus idaeus L. Raspberry Maлинa Maliny x x
Acetoja, Lapathum Rumex acetosa L. Sorrel, dock Щaвель Szcz˙aw x x x x x
Lappacium acutum Rumex confertus Wild. Bitter dock Щaвель кiнський Kobyliszcz˙aw x x
Ruta Ruta graveolens L. Rue Pутa Ruta x x x x x
Salix Salix alba L. Willow Вербa Wirzba x x x x
Ambrosiana Salvia viridisL. Annual clary Шaвлiя Szałwia x x
Salvia Salvia officinalis L. Sage Шaвлiя Szałwija x x x x x x
Galletricum Salvia sclarea L. Clary sage Шaвлiя мускaтнa Szałwia
muszkatołowa
x
Sambucus Sambucus ebulus L. Elderberry Бузинa, хобзa Bez x x x
Ebulus Sambucus nigra L. Elderberry Бузинa Chebd, bez czarny x x
Sapo Saponaria officinalis L. Soapwart Mильнянкa Mydło, mydlnica x
Saturegia Satureja hortensis L. Savory Чaбер Cza˛br x x
Costus Saussurea costus Lipsch. Costus Сосюрея Saussurea x
Saxifraga Saxifraga granulata L. Saxifrage Ломикaмiнь Lamikamien´,
skalnica
x x
(Continued)
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TABLE 3 | Continued
Plant name Appears in
Old latin (Falimirz) Botanical English Ukrainian Polish (Falimirz) M L P S T F
Febrifuga Scrophularia nodosa L. Figwort Paнник, стaровинa Tre˛downik x x
Pellicinus Securigera varia Lassen Crownvetch В’язiль Wilcz˙y groch
Semperviva Sedum acre L. Stonecrop Очиток, оливник Roschodnik x x x x
Senecion Senecio vulgaris L. Groundsel Жовтозiлля, дiдик Przymiot, starzec x x
Herba sulonum Serratula tinctoria L. Saw-wort Серпухa Jeleni trunk,
sierpik
x
Sinapis Sinapis alba L. Mustard Гiрчиця Gorcz˙ycza x x x x
Olus Smyrnium olusatrum L. Alexanders Смирня Gir, przewłoka x
Perfeliata Smyrnium perfoliatum L. Perfoliate Alexanders Смирня Pepkowe ziele x
Solatrum Solanum nigrum L. Black nightshade Пaслiн, нaтинник Psianki x
Virga aurea Solidago virgaurea L. Goldenrod Золотушник We˛z˙owe ziele,
nawloc
x
Endivia Sonchus oleraceus L. Sowthistle Жовтий осот Mlecz˙ x x
Spinachia Spinacia oleracea L. Spinach Шпинaт Szpinak
Spongia marina Spongia officinalis L. Bath sponge Губкa Morzkie bdły
Betonica Stachys officinalis Trevis. Betony Буквиця, чистець Bukwica x x x x x
Premorsa Succisa pratensis Moench Devil’s bit Комонник Cartowo ziobro,
komonica
x
Consolida maior minor Symphytum officinale L. Comfrey Живокiст, гaвйиз Kostywał,
zywokost
x x x
Tenacetum Tanacetum vulgare L. Tansy Пижмо Wrotycz˙ x x x
Rostrum porcinum Taraxacum officinale L. Dandelion Кульбaбa Pepawa, mniszek x x
Edera arborea Taxus baccata L. English yew Тис, негнiй-дерево Cis x x
Serpillum Thymus serpyllum L. Thyme Чебрець, мaтеринкa Macierza duszka x x x x
Timus Thymus vulgaris L. Thyme Maтеринкa Dzie˛cielina,
macierzanka
x
Tribulus Tribulus terrestris L. Goats-head Якiрцi Oseth,
buzdyganek
Trifolium Trifolium pretense L. Red clover Конюшинa, троян Konik, chwast x x x
Matricaria Triplerospermum inodorum L. False mayweed Триреберник Maruna
Spatula fetida Typha latifolia L. Cattail Pогiз Pałki x
Urtica Urtica dioica L. Nettle Кропивa Pokrzywa x x x x x x
Usnea Usnea barbata L. Olds man beard Уснея (лишaйник) Mech, porost
Moracelsi Vaccinium oxycoccos L. Cranberry Журaвлинa Zorawiny x
Valeriana Valeriana officinalis L. Valerian Вaлер’янa, оделен Kozłek x x x
Elleborus albus Veratrum album L. White hellebore Чемериця Czemierzycza x x x x
Tapsus barbatus Verbascum thapsus L. Mullein Дивинa Dziewanna x x x x
Verbena Verbena officinalis L. Vervain Вербенa Koszyszcz˙ko,
werbena
x x x x
Camedreos Veronica chamaedrys L. Speedwell Веронiкa Przetacznik x x
Viole Viola odorata L. Violet Фiaлкa Fijołki x x x x x x
Viscus Viscum album L. Mistletoe Омелa Jemioła x x
Agnus castus Vitex agnus-castus L. Chaste tree Витекс Włoska wirzba x
Passula (uva) Vitis vinifera L. Raisins Pодзинки Greckie wino,
rozynka
x
*Natural substances of non-botanical origin.
German markets (Onipko, 2010). A current well-demonstrated,
long-term trend toward natural medicine and consumers is
indicative of increasing interest in botanical products that
support whole-body health rather than focus on a specific
health condition, representing a key opportunity to adequately
tap the potential of agriculture- and forest-grown medicinal
and aromatic plants of the Carpathian Mountains and their
foreland.
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CONCLUSIONS
The first printed herbals published in the Carpathian forelands
were early compilations of transcribed Greek and Roman works
on the subject, and set a continuous trend of ethnic use of
local botanical remedies according to their Dioscorides and
Galenic qualities. The Padua-Krakow axis was identified as
a key putative factor in introduction of this knowledge to
Ruthenian and Polish medical students during the fifteenth–
sixteenth centuries. Subsequently, this tradition was incorporated
into oral and written legacy of Boyko, Lemko, and Gorale
ethnic groups, and fused with Slavic use of charm and prayer
heals to treat diseases and cast magical incantations. However,
the traditional use of several endemic plant species in the
region could provide an exciting opportunity to observe pre-
Christian folk healing traditions from the Beskid Mountains.
The study also highlighted the vast potential for growing
and processing medicinal plants in the region, and cited low
awareness among farming communities, inadequate processing
capacities, price risks, and non-availability of planting material as
critical constraints that need to be addressed.
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A detannified methanolic extract of Scrophularia lucida L. attenuated the formation
of cancer cell-induced circular chemorepellent induced defects (CCIDs) in the lymph
endothelial cell barrier, which resemble entry ports for the intravasating tumor into the
vasculature as a prerequisite for lymph node metastasis. Therefore, the composition of
this extract was studied in an activity-guided approach. Since no data on the secondary
metabolites of this plant were available, first phytochemical data were collected in the
course of the fractionation of the extract. The study resulted in the identification of 14
substances, among them very rare iridoids, such as scrovalentinoside or koelzioside,
and several flavonoids (e.g., nepitrin and homoplantaginin). One of the latter group,
2′′-O-acetyl-homoplantaginin, is a new natural compound. In the most active fraction,
the flavonoid hispidulin was identified as major component and the assay of the
pure compound confirmed a contribution of hispidulin to the CCID-inhibitory effects
of S. lucida. The activity of the two major iridoids in this assay was less compared to
hispidulin.
Keywords: Scrophularia lucida L., iridoids, phenolic compounds, 2′′-O-acetyl-homoplantaginin, hispidulin,
intravasation, circular chemorepellent-induced defects (CCID) assay
INTRODUCTION
Species of the genus Scrophularia have been applied for centuries in traditional medicine.
The most important one among those, Scrophularia ningpoensis Hemsl., is widely used in
traditional Chinese medicine for a broad spectrum of inflammatory diseases (De Santos
Galíndez et al., 2002; Tong et al., 2006; Li et al., 2009) and listed in the Chinese
Pharmacopeia against febrile diseases with excessive thirst or eruptions, constipation, cough
due to exhaustion, conjunctivits, skin disorders, and others (Stöger, 2017). The use in the
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treatment of inflammatory disorders, wound healing, skin
ailments, and health disturbances has been reported for
numerous species such as Scrophularia auriculata L. or
Scrophularia canina L. from the Mediterranean area (Giner et al.,
2000; Guarrera and Lucia, 2007; Passalacqua et al., 2007) as well as
for Scrophularia variegata M. Bieb. and Scrophularia striata Boiss.
in traditional Iranian medicine (Azadmehr et al., 2013, 2015).
A traditional use as an antipyretic and anti-inflammatory agent
was described for Scrophularia oldhamii Oliv. and as a diuretic for
Scrophularia grossheimii Schischkin (De Santos Galíndez et al.,
2002). In Turkish traditional medicine, the species Scrophularia
nodosa L. is well-known as a diuretic, to treat hemorrhoids, and
also for wound healing, eruptive skin diseases, eczema, psoriasis,
and pruritus (Baytop, 1999; Stevenson et al., 2002; Crisan et al.,
2009). A use in these indications is also conveyed for the Turkish
species Scrophularia depauperata Boiss., Scrophularia cryptophila
Boiss. et. Heldr. Boiss., and Scrophularia floribunda Boiss. et. Bal.
(Ozbilgin et al., 2014).
Recently, the activity of various extracts from several
Scrophularia species has been studied in different cancer models:
weak cytotoxic activity of an ethanolic extract from S. striata
via induction of apoptosis and G2/M phase arrest was shown
in Jurkat human leukemia cells (Azadmehr et al., 2013). In
WEHI 164 fibrosarcoma cells, a methanolic extract of this plant
exhibited a significant and dose-dependent reduction of the
activity of matrix metalloproteinases (Hajiaghaee et al., 2007),
which play a role in tissue remodeling and tumor invasion.
An apolar fraction from a methanolic extract of Scrophularia
orientalis L. significantly reduced the viability of neuroblastoma
cells due to a loss of mitochondrial membrane integrity (Lange
et al., 2016). In MCF-7 breast cancer cells, weak cytotoxicity of an
ethanolic extract from S. variegata was reported (Azadmehr et al.,
2015). A dichloromethane extract from Scrophularia oxysepala
caused significant cytotoxic and apoptotic effects in MCF-7 cells
by influencing the expression of p53, caspase 3, and c-myc, and
the cleavage of PARP (Valiyari et al., 2013). The anti-tumor
activity of S. oxysepala in breast cancer was confirmed in vivo in
an allograft model in mice inoculated with mammary carcinoma
4T1 cells. Animals treated with 50 or 100 mg/kg of an ethanolic
extract developed significantly smaller tumors in size and weight
(Baradaran et al., 2017). In a study of five Scrophularia species,
S. floribunda and Scrophularia lucida L. displayed the highest
cytotoxic activity against HL-60 promyeloic leukemia cells. These
extracts were also tested in a three-dimensional co-culture cell
model consisting of MCF-7 breast cancer spheroids placed on top
of telomerase-immortalized human lymph endothelial cell (LEC)
monolayers. There, tumor spheroids cause the formation of large
cell-free areas in the lymph endothelial barrier, so-called “circular
chemorepellent induced defects” (CCIDs), through which tumor
cells penetrate the vasculature. This assay mimics intravasation
which is an early step within the metastatic cascade resembling
the pathological situation in rodents and humans (Madlener
et al., 2010; Vonach et al., 2011; Viola et al., 2013). A detannified
methanolic extract of S. lucida L. was the most active one in
suppressing CCID formation (Giessrigl et al., 2012).
The lack of any information about the chemical composition
of S. lucida prompted us to perform an activity-guided search for
the active principle of this species contributing to the inhibitory
effect in the CCID assay.
EXPERIMENTAL
General Experimental Procedures
Hispidulin was obtained from Sigma–Aldrich. All other
flavonoids for dereplication were on stock at the Department of
Pharmacognosy, University of Vienna.
For TLC, silica gel plates or HPTLC plates RP-8 (Merck,
Germany) and the mobile phases (1) CHCl3–CH3COOHconc.–
MeOH–H2O (60:32:12:18), (2) EtOAc–HCOOHconc.–CH3
COOHconc.–H2O (100:11:11:20), (3) EtOAc–MeOH–
HCOOHconc.–H2O (75:15:4:4), or (4) MeOH–H2O (90:10)
were used.
A Shimadzu LC-20AD pump, an SPD M20A diode array
detector, a CTO-20AC column oven, and a SIL 20AC HT
auto-sampler (Kyoto, Japan) served for analytical HPLC on a
Luna 5 µ C-18 (250 mm × 4.6 mm) column (Phenomenex,
United States) at 25◦C and a flow rate of 1 mL/min. Mobile
phase 1 consisted of (A) aqueous formic acid (pH 3) and (B)
acetonitrile-aqueous formic acid (pH 3; 80+2) and the gradient
program 1 was 5% B (0 min), 20% B (15 min), 20% B (25 min),
50% B (65 min), and 95% B (80 min). Mobile phase 2 was (A)
aqueous formic acid (pH 3) and (B) acetonitrile and the gradient
2 increased from 5% B (0 min) to 95% B (60 min). UV data
were recorded from 190 to 400 nm. All solvents of analytical or
HPLC-grade (acetonitrile, Chromanorm; methanol, LiChrosolv)
were obtained from VWR International (West Chester, PA,
United States) and CH3COOHconc. (Rotichrom) from Carl Roth
(Karlsruhe, Germany).
NMR spectra were recorded on an Avance III 600 MHz
NMR spectrometer (Bruker BioSpin, Germany) using a 5 mm
broadband observe probe (BBFO Smart probe) with z-axis
gradients and automatic tuning and matching accessory;
resonance frequency for 1H NMR: 600.13 MHz, for 13C NMR:
150.90 MHz. The measurements were performed for solutions
in fully deuterated DMSO or methanol at 298 K. Standard
1D and 2D experiments like double quantum filtered COSY,
TOCSY, NOESY, HSQC, and HMBC were used as supplied by
the manufacturer. Chemical shifts were referenced internally to
the residual, non-deuterated solvent signal for 1H (δ = 2.50 ppm
for DMSO, δ = 3.31 ppm for methanol) or to the carbon signal
of the solvent for 13C (δ = 39.52 for DMSO, δ = 49.00 ppm for
methanol). The analysis of the 1H NMR multiplett structures
was assisted by spin simulations using DAISY within the Topspin
Software (Bruker BioSpin).
LC–MS analyses were carried out on an UltiMate 3000 RSLC-
series system (Dionex, Germering, Germany) coupled to a 3D
quadrupole ion trap mass spectrometer via an orthogonal ESI
source (HCT, Bruker Daltonics, Bremen, Germany). The HPLC
parameters were as described above. The eluate flow was split
1:4 before entering the ESI ion source, which was operated as
follows: capillary voltage: +3.5/−3.7 kV, nebulizer: 26 psi (N2),
dry gas flow: 9 L/min (N2), and dry temperature: 340◦C. Positive
and negative ion mode multistage mass spectra up to MS4 were
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obtained in automated data-dependent acquisition mode using
helium as collision gas, an isolation window of 1m/z = 4, and
a fragmentation amplitude of 1.0 V. In addition, compounds
13 and 14 were measured on the HCT instrument by direct
infusion after addition of ammonium acetate as additive to
generate [M+NH4]+ ions. HRESIMS spectra of compound 3
were recorded on a maXis HD ESI-Qq-TOF mass spectrometer
(Bruker Daltonics) by direct infusion. The sum formulas of
the detected ions were determined using Bruker Compass
DataAnalysis 4.2 based on the mass accuracy (1m/z ≤ 2 ppm)
and isotopic pattern matching (SmartFormula algorithm).
Plant Material
Aerial parts of S. lucida were collected on April 20th 2012, along
the Mediterranean coast east of Dalyan and south of Ortaca
(latitude: 36.808838, longitude: 28.735583). The material was
authenticated by Dr. Özkan Eren, Department of Biology, Adnan
Menderes University, using the serial “Flora of Turkey and the
East Aegean Islands” (Davis, 1968–1985). Voucher specimen
(Herbarium code: AYDN No.: 2601) in duplicates was deposited
in the herbarium of Department of Biology, Adnan Menderes
University.
Extraction and Isolation
The freeze-dried and pulverized material of S. lucida (1.8 kg) was
extracted with methanol at the ratio of 1:10 at room temperature
by maceration on a shaker overnight. The combined solutions
were evaporated at 40◦C resulting in 158 g crude methanol
extract; 140 g of the extract were fractionated in four portions,
whereby each portion was dissolved in 300 mL MeOH–H2O
(10:1) and partitioned three times with 300 mL petroleum
ether, each, to remove chlorophyll, waxes, and fatty matters.
The MeOH–H2O phase was then diluted with 300 mL H2O
and partitioned with three times 600 mL chloroform. After
washing the organic layer with 1% aqueous NaCl solution and
evaporation, 15.6 g chloroform fraction (CF) was obtained. From
the remaining MeOH–H2O fraction, MeOH was removed and
the aqueous residue partitioned with three times 280 mL ethyl
acetate, resulting in 12.3 g ethyl acetate fraction (EF) and 110.2 g
aqueous fraction (AF) after evaporation.
Ten grams of EF were separated by column chromatography
(CC; 3 cm× 60 cm) on Sephadex LH-20 under elution with 50%
MeOH yielding 15 combined fractions (a–o). In fractions k and
l, compound 1 was identified by TLC and LC-DAD. Fractions
e (1 g) and g (580 mg) were further fractionated on the same
stationary phase under elution with 30% MeOH, resulting in
fractions e1–e22 and g1–g19. From fraction e18, 46.5 mg of
compound 2 precipitated. Solid phase extraction (Megabond Elut
C18 cartridge; 12 mL; Agilent, Santa Clara, CA, United States;
sequential elution with 20, 30, 40, and 50% MeOH) of fraction
e22 resulted in the isolation of compound 3 (7 mg) and the
identification of compound 4. A major component from fraction
g6 (63.2 mg) was finally purified by another CC on Sephadex
LH-20 under elution with H2O to yield 27 mg compound 5. In
fraction g10, compounds 6 and 7 were identified, and in fraction
g19, compound 8 was confirmed.
FIGURE 1 | MCF-7 spheroids pre-treated for 30 min with solvent (Co) or
indicated concentration of different fractions, placed on top of LEC
monolayers, and co-cultivated for 4 h when CCIDs were analyzed. Three
independent experiments with at least 15 replicates were analyzed. Error bars
indicate means ± SEM and asterisks significance (t-test).
A portion of CF (3.9 g) was submitted to CC on silica
and elution with CHCl3–MeOH–H2O (75:15:1.5), resulting in
25 fractions, five of which (A–E) were further investigated. In
fraction A (62.5 mg), compound 9 was identified as the major
component. In fraction B (150.8 mg), three major compounds
(10–12) besides 8 were detected and tentatively identified by
LC–MS. From fraction C (150.9 mg), compound 13 (144.7 mg)
and from fraction D (630.5 mg), compound 14 (532 mg) were
obtained. Fraction E (125.9 mg) contained a complex mixture of
easy decomposable substances and attempts to isolate those by
CC were not successful.
Astragalin (1): Rf in TLC: system 1 = 0.50; system 2 = 0.74.
Homoplantaginin (2): yellowish amorphous
powder;1H-NMR and 13C-NMR data: see Table 1;
+ESIMS m/z 463.1 [M+H]+; +ESIMS2 (463.1→)
m/z 301.3 (100); +ESIMS3 (463.1 → 301.3 →) m/z 286.3
(100); +ESIMS4 (463.1 → 301.3 → 286.3 →) m/z 240.1 (10),
186.2 (28), 168.3 (100), 167.1 (11), 121.5 (25), and 120.5 (14);
−ESIMS m/z 461.0 [M−H]−; −ESIMS2 (461.0 →) m/z 446.2
(45), 299.2 (100), 298.2 (17), 297.2 (16), 285.2 (20), 284.2 (73),
and 283.2 (57); −ESIMS3 (461.0→ 299.2→) m/z 284.2 (100);
and −ESIMS3 (461.0→ 284.2→) m/z 255.2 (100), 239.1 (10),
227.1 (51), 211.1 (21), 183.1 (11), and 137.2 (11).
2′′-O-acetyl-homoplantaginin (3): yellowish amorphous
powder;1H-NMR and 13C-NMR data: see Table 1; +ESIMS m/z
505.0 [M+H]+; +ESIMS2 (505.0→) m/z 301.3 (100); +ESIMS3
(505.0→ 301.3→) m/z 286.3 (100); +ESIMS4 (505.0→ 301.3
→ 286.3→) m/z 186.1 (18), 168.3 (100), 140.2 (20), and 121.4
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FIGURE 2 | MCF-7 spheroids pre-treated for 30 min with solvent (Co) or
indicated concentration of different subfractions, placed on top of LEC
monolayers, and co-cultivated for 4 h when CCIDs were analyzed. Three
independent experiments with at least 15 replicates were analyzed. Error bars
indicate means ± SEM and asterisks significance (t-test).
(11); −ESIMS m/z 503.0 [M−H]−; −ESIMS2 (503.0 →) m/z
488.2 (9), 443.2 (10), 299.2 (100), 298.3 (20), 297.3 (20), 284.2
(45), and 283.2 (36); −ESIMS3 (503.0→ 299.2) m/z 284.2 (100);
and −ESIMS4 (503.0 → 299.2 → 284.2 →) m/z 256.1 (59),
255.1 (100), 239.1 (24), 229.0 (28), 228.1 (20), 227.1 (23), 216.0
(27), 211.2 (23), 200.2 (24), 199.2 (38), 183.0 (12), 166.1 (17),
163.1 (13), 150.2 (13), and 141.2 (13). +HRESIMS m/z 505.1340
[M+H]+ (calcd for C24H25O12+, m/z 505.1341, 1 = 0.2 ppm),
527.1159 [M+Na]+ (calcd for C24H24O12Na+, m/z 527.1160,
1 = 0.2 ppm).
Nepitrin (4): Rf in TLC: system 2 = 0.63. LC-DAD data: see
Supplementary Material.
Verbascoside (5): whitish amorphous powder; LC-DAD-data:
see Supplementary Material; +ESIMS m/z 642.2 [M+NH4]+,
625.1 [M+H]+; +ESIMS2 (642.2→) m/z 479.1 (18), 471.1 (74),
and 325.0 (100); +ESIMS3 (642.2→ 471.1→) m/z 453.2 (11),
325.0 (100), 309.0 (11), and 162.9 (54);+ESIMS3 (642.2→ 325.0
→) m/z 162.9 (100); +ESIMS4 (642.2 → 325.0 → 162.9 →)
m/z 162.9 (16), 144.9 (100), and 134.9 (23); −ESIMS m/z 623.2
[M−H]−; −ESIMS2 (623.2→) m/z 461.1 (100); and −ESIMS3
(623.2→ 461.1→) m/z 315.0 (43), 160.8 (12), and 134.9 (100).
Kaempferol-3-O-rutinoside (6): Rf in TLC: system 2 = 0.55.
LC-DAD data: see Supplementary Material.
Rutin (7): Rf in TLC: system 2 = 0.48. LC-DAD data: see
Supplementary Material.
Luteolin-7-O-glucoside (8): Rf in TLC: system 2 = 0.71. LC-
DAD data: see Supplementary Material.
Hispidulin (9): yellowish amorphous powder; LC-DAD data:
see Supplementary Material; +ESIMS m/z 301.1 [M+H]+;
+ESIMS2 (301.1 →) m/z 286.0 (100); +ESIMS3 (301.1 →
286.0→) m/z 256.8 (16), 185.9 (17), 167.9 (100), 140.0 (14), 122.0
(38), 120.9 (30), 119.0 (24), and 112.0 (23); −ESIMS m/z 299.0
[M−H]−; −ESIMS2 (299.0→) m/z 283.9 (100); and −ESIMS3
(299.0→ 283.9→) m/z 266.8 (17), 255.8 (56), 254.9 (29), 238.8
(22), 227.7 (64), 226.8 (74), 213.8 (43), 211.8 (55), 210.8 (18),
199.8 (77), 198.9 (10), 198.0 (10), 185.7 (32), 183.7 (28), 182.9
(17), 177.7 (11), 163.8 (24), 149.7 (21), 136.8 (100), and 129.8 (11).
Buergeriside C1 isomer (10): +ESIMS m/z 307.1
[M−H2O+H]+, 347.1 [M+Na]+; +ESIMS2 (307.1 →)
m/z 160.9 (100); +ESIMS3 (307.1 → 160.9 →) m/z 132.9
(100); −ESIMS m/z 359.2 [M+Cl]−, 369.1 [M+HCOO]−; and
−ESIMS2 (369.1→) m/z 323.0 (48), 262.9 (26), 218.8 (34), 190.8
(12), 176.8 (100), and 144.9 (27).
Buergeriside C1 isomer (11):+ESIMS m/z 307.1
[M−H2O+H]+, 347.1 [M+Na]+; +ESIMS2 (307.1 →)
m/z 161.0 (100); +ESIMS3 (307.1 → 161.0 →) m/z 133.0
(100); −ESIMS m/z 359.3 [M+Cl]−, 369.1 [M+HCOO]−; and
−ESIMS2 (369.1→) m/z 323.9 (22), 323.0 (74), 236.8 (12), 219.7
(15), 218.8 (28), 190.8 (36), 176.9 (43), 145.9 (11), 144.8 (100),
and 126.9 (7).
6-O-(2′′-Acetyl-3′′,4′′-O-di-trans-cinnamoyl-α-L-rhamnop-
yranosyl-catalpol (12):+ESIMS m/z 833.3 [M+Na]+;+ESIMS2
(833.3 →) m/z 803.2 (11), 773.2 (35), 751.3 (100), 495.1 (30);
−ESIMS m/z 845.5 [M+Cl]−, 855.3 [M+HCOO]−; −ESIMS2
(855.3 →) m/z 810.2 (65), 809.3 (100), and 533.2 (14); and
−ESIMS3 (855.3→ 809.3→) m/z 767.2 (36), 750.2 (28), 749.2
(37), 662.1 (39), 661.2 (100), 648.1 (41), 647.2 (36), 629.2 (11),
620.2 (16), 619.2 (21), 618.3 (12), 617.0 (17), 533.1 (16), 353.0
(11), 311.0 (18), and 293.0 (11).
Koelzioside (13): whitish amorphous powder;1H-NMR and
13C-NMR shifts: see Supplementary Material;+ESIMS m/z 828.4
[M+NH4]+; +ESIMS2 (828.4 →) m/z 449.1 (100); +ESIMS3
(828.4 → 449.1 →) m/z 389.0 (11), 301.0 (47), 241.0 (25),
and 131.0 (100); and −ESIMS m/z 845.3 [M+Cl]−, 855.3
[M+HCOO]−.
Scrovalentinoside (14): whitish amorphous powder;1H-NMR
and 13C-NMR shifts: see Supplementary Material; +ESIMS m/z
770.3 [M+NH4]+; +ESIMS2 (770.3 →) m/z 770.3 (14), 591.2
(5), 573.1 (4), and 391.1 (100); +ESIMS3 (770.3 → 391.1 →)
m/z 391.1 (28), 271.1 (6), 213.0 (21), 161.0 (100), 153.0 (71),
133.0 (7), and 111.1 (19); and−ESIMS m/z 787.3 [M+Cl]−, 797.3
[M+HCOO]−.
Cell Culture
Cultivation of human MCF-7 breast cancer cells was carried
out in MEM medium supplemented with 10% FCS, 1%
penicillin/streptomycin, and 1% NEAA (all from Invitrogen
Life Technologies, Karlsruhe, Germany) and of telomerase
immortalized human LECs in EGM2 MV medium (Clonetics
CC-4147, Allendale, NJ, United States) at 37◦C in a humidified
atmosphere containing 5% CO2.
3-D Co-cultivation of MCF-7 Cancer
Cells With LECs
MCF-7 cells were transferred to 30 mL MEM medium
containing 6 mL of a 1.6% methylcellulose solution (0.3% final
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FIGURE 3 | Structures of compounds 1–14. Glcp, glucopyranosyl; Rhap, rhamnopyranosyl; Ac, acetyl.
concentration; cat. no. M-512, 4000 centipoises; Sigma–Aldrich,
Munich, Germany). To each well of a 96-well plate (Greiner Bio-
one, Cellstar 650185, Kremsmünster, Austria), 150 µL of the cell
suspension was transferred for spheroid formation within 48 h.
Then, MCF-7 spheroids were washed in PBS and transferred to
CellTrackerTM green (Invitrogen Life Technologies, Karlsruhe,
Germany) stained LEC monolayers that had been seeded into
24-well plates (Costar 3524, Sigma) in 2 mL EGM2 MV medium
(Vonach et al., 2011).
Circular Chemorepellent-Induced Defect
(CCID) Assay
After 4 h of incubation of the co-cultures of MCF-7 spheroids
(3,000 cells/spheroid) and the LEC monolayer, the size of
CCIDs in the LEC monolayer underneath the MCF-7 spheroids
was photographed with an Axiovert (Zeiss, Jena, Germany)
fluorescence microscope to visualize CellTrackerTM (green)
stained LECs underneath the spheroids (Madlener et al., 2010).
CCID areas were calculated with the Axiovision Re. 4.5 software
(Zeiss, Jena, Germany). MCF-7 spheroids were treated with
solvent (ethanol) as negative control. The CCID areas of at least
15 spheroids per experiment were measured.
RESULTS AND DISCUSSION
From the methanolic extract of the aerial parts from S. lucida,
apolar compounds were depleted by extraction with petroleum
ether. After subsequent partition with chloroform and ethyl
acetate, the two organic fractions and the residue of the aqueous
phase were tested in the CCID assay. The crude methanol extract
significantly and linearly inhibited CCID formation between
concentrations of 0.25–1 mg/mL (Figure 1). At a concentration
of 0.25 mg/mL, the CF seemed to be even more effective than
0.25 mg/mL of the methanol extract; however, this difference
was not significant. The EF was only active at 1 mg/mL and the
AF was inactive at the tested concentrations. Therefore, the CF
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was chosen for further separation by CC on silica and five of
the resulting sub-fractions (A–E) were active in the CCID assay
with sub-fraction A exhibiting the strongest inhibition (Figure 2).
The EF was separated by size exclusion chromatography followed
by solid phase extraction or another subsequent size exclusion
chromatography. Due to the lower activity of the EF in the
CCID assay, these sub-fractions were submitted to chemical
investigations only.
The processes resulted in the elucidation of 14 compounds,
one of which is a new natural product (Figure 3). The 13
known compounds were identified by chromatographic, mass
spectrometric and/or spectroscopic dereplication with authentic
samples or data from literature. This led to the elucidation of
seven flavonoids. The widespread natural compounds astragalin
(1), luteolin-7-O-glucoside (8), kaempferol-3-O-rutinoside (6),
and rutin (7) were confirmed by TLC- and LC-DAD comparison
with the authentic substances. To the best of our knowledge,
only the two latter have been reported in the genus Scrophularia
until now, namely, in Scrophularia ilwensis C. Koch (Calis et al.,
1993). Two further, less prevalent flavonoids, nepitrin (4) and
homoplantaginin (2), had been isolated from S. ningpoensis (Li
et al., 2009) and nepitrin also from S. striata (Monsef-Esfahani
et al., 2010) before. 1H-NMR- and 13C-NMR data of 2 correlated
excellently with the data published earlier for homoplantaginin
(Wang et al., 1998; Dawa et al., 2009). Hispidulin (9) was detected
for the first time in a Scrophularia species and elucidated by
LC-DAD comparison and LC–MS data.
A new flavonoid (3) was identified by thorough MS and NMR
experiments: a molecular formula of C24H24O12 was determined
from the HRESIMS data. Fragmentation of the [M+H]+ ion
at m/z 505.0 showed the loss of a 204 Da to yield a Y0 ion
at m/z 301.3, which again lost a CH•3 in MS3, typical for a
methoxy group bound to an aromatic system. The MS2, MS3, and
MS4 spectra were nearly identical to those of homoplantaginin.
Fragmentation of the [M−H]− ion at m/z 503.0 confirmed this
information. In addition, the loss of 60 Da (CH3COOH) in
MS2 indicated acetylation of the glucose of homoplantaginin.
The signals of 3 in the 1H-NMR spectrum excellently correlated
with those of compound 2 (Table 1), despite a large downfield
shift of the proton at C-2′′ in the sugar for 1.55 ppm. The
signals of the protons at C-1′′ and C-3′′ were shifted downfield
for 0.24 and 0.22 ppm, respectively, as well. Additionally, from
the singlet at δ = 2.038 ppm, linkage of an acetyl group was
deduced. The connection of an additional acetyl group in position
2′′ of homoplantaginin was confirmed by the 13C-NMR data.
The signals of C-1′′ and C-3′′ were shifted upfield for 2.28 and
TABLE 1 | 1H NMR and 13C NMR data of compounds 2 and 3 in DMSO-d6.
Compound 2 Compound 3
Position 1H (ppm) JH.H (Hz) 13C (ppm) 1H (ppm) JH.H (Hz) 13C (ppm)
2 C – – 164.3 – – 164.4
3 CH 6.86 s 102.7 6.87 s 102.7
4 C – – 182.3 – – 182.3
4a C – – 105.7 – – 106.1
5 C – – 152.5 – – 152.6
OH 12.96 s – 12.97 s –
6 C – – 132.5 – – 132.5
CH3 3.77 s 60.3 3.65 s 60.2
7 C – – 156.5 – – 155.9
8 CH 7.02 94.3 7.03 s 94.7
8a C – – 152.1 – – 152.0
1′ C – – 121.0 – – 120.9
2′/6′ CH 7.95 d 8.8 128.6 7.94 d 8.9 128.6
3′/5′ CH 6.94 d 8.8 116.0 6.94 d 8.9 116.0
4′ C – – 161.4 – – 161.5
1′′ CH 5.11 d 7.1 100.2 5.35 d 8.1 97.9
2′′ CH 3.34 dd 7.1/9.6 73.2 4.89 dd 8.1/9.6 73.3
C – – – – 169.3
CH3 – – 2.04 s 20.8
3′′ CH 3.32 dd 9.6/9.2 76.7 3.54 dd 9.6/9.1 73.8
4′′ CH 3.21 dd 9.2/9.6 69.5 3.31 dd 9.1/9.7 69.6
5′′ CH 3.47 ddd 9.6/ 6.0/2.1 77.3 3.58 ddd 9.7/6.0/2.1 77.5
6′′a CH2 3.73 dd 2.1/11.6 60.6 3.77 dd 2.1/11.8 60.4
b 3.49 dd 6.0/11.6 3.53 dd 6.0/11.8
Further OH signals 10.40
5.43
5.12
4.63
10.43
5.39
4.77
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2.95 ppm, respectively. Signals of an acetyl group occurred at
δ = 169.26 ppm (quarternary C) and δ = 20.82 ppm (methyl C).
An HMBC crosspeak from the CH3 protons to the C-2′′ finally
proofed the connectivity. Thus, compound 3 was unambiguously
identified as 2′′-O-acetyl-homoplantaginin.
The phenylpropanoid verbascoside, which had been detected
in many species of the Scrophulariaceae family (see, e.g., Zhang
et al., 2013; Pasdaran et al., 2016, 2017; Venditti et al., 2016), was
isolated from S. lucida as well and identified by HPLC-DAD and
MS.
The genus is well-known for synthesizing a broad range
of iridoids (De Santos Galíndez et al., 2002) and two such
compounds were isolated from and two further ones tentatively
identified in the CF.
The major iridoid was scrovalentinoside (14). The compound
was elucidated by MS and NMR experiments (see Supplementary
Material). The spectroscopic data were in excellent accordance
with those published after isolation of the compound from
S. auriculata L. ssp. pseudoauriculata (Senn.) Bolós et Vigo
(Giner et al., 1998) and from S. nodosa L. (Miyase and Mimatsu,
1999). A second iridoid was unambiguously elucidated as
koelzioside (13) based on MS experiments and the analogy
of the 1H-NMR and 13C-NMR data as reported for the
compound, until now only known from Scrophularia koelzii
L. (Bhandari et al., 1992) and Scrophularia deserti Del.
(Ahmed et al., 2003). Tentatively identified by thorough LC–MS
experiments were two isomers of buergeriside C1 (10 and 11),
known from Scrophularia buergeriana (Miquel) (Kim and
Kim, 2000), and 6-O-(2′′-acetyl-3′′,4′′-di-O-trans-cinnamoyl)-
α-L-rhamnopyranosyl-catalpol (scropolioside B, 12), reported
in Scrophularia scopolii [Hoppe ex] Pers. var. scopolii (Calis
et al., 1988). Compounds 10 and 11 both showed a UV
spectrum typical for a para-substituted cinnamic acid derivative
and yielded identical fragment ions, although the relative
intensities were different in the MS2 spectra of the [M+COOH]−
ion of 10 and 11. Fragmentation of the [M−H2O+H]+
ion yielded the acylium ion of methoxycinnamic acid (Z0),
while CID of the [M+COOH]− ion produced deprotonated
methoxycinnamic acid (Y0), dehydrated deoxyhexose (B1),
and typical cross-ring cleavage of the deoxyhexose. From
the compounds described for the genus Scrophularia, this
pattern only fits to buergeriside C1, why we have tentatively
identified 10 and 11 as buergeriside C1 isomers. The UV
spectrum of 12 points toward cinnamic acid. Fragmentation
of the [M−H]− ion (resulting from CID of the [M+COOH]−
ion) yielded the neutral loss of 60, 148, and 162 Da, fitting
to an acetylated, cinnamoylated, and hexosylated compound.
Scropolioside B is the only previously described compound
in the genus Scrophularia being in accordance with these
data. All iridoids detected in S. lucida are very rare natural
compounds.
The quantitative determination by HPLC of the
major compounds in the methanolic extract revealed 3%
homoplantaginin, 1.4% scrovalentinoside, and 0.7% koelzioside.
In an earlier study, 20 µg/mL of the methanolic extract of
S. lucida was reported to induce 70% apoptosis and to almost
completely inhibit proliferation of HL-60 cells in S-phase within
48 and 72 h, respectively (Giessrigl et al., 2012). Here, we
demonstrate that 250 µg/mL of the methanolic extract inhibits
60% CCID formation in the MCF-7/LEC model within 4 h
and the CF of the methanolic extract inhibited CCIDs almost
similarly (with insignificant difference; Figure 1). Sub-fraction
A of the CF was the most active one and other four fractions
(B–E) also exhibited significant CCID-inhibitory properties
(Figure 2).
Hispidulin turned out to be the major component in sub-
fraction A, whereas koelzioside and scrovalentinoside, the main
components in sub-fractions C and D, respectively, showed
significantly less activity. To evaluate the potential of hispidulin
in suppressing CCID formation, the pure compound was
tested as well-demonstrating an IC50 of 88.7 µM confirming
a contribution of hispidulin to the effects of the methanolic
extract. This further implicated that other components present
in sub-fraction A must have synergized strongly with hispidulin
as only 250 µg/mL of sub-fraction A inhibited ∼90% CCID
formation (compared to 26.6 mg/mL of purified hispidulin,
which inhibited just 50%). Conceivably, residual amounts of
sub-fraction B still been present in sub-fraction A caused this
synergy. Hispidulin, in vitro and in vivo, had been shown
to inhibit proliferation and to induce apoptosis of various
cancer lines (Yu et al., 2013; Gao et al., 2015; Wang et al.,
2015). The compound exhibited cytotoxicity toward HepG2
liver cancer cells but not normal liver cells (Gao et al., 2014).
It also inhibited pancreas cancer cell mobility and invasion
in vitro as well as neovascularization in C57/BL6 mice (He
et al., 2011). Additionally, colon cancer cell intravasation through
blood endothelial barriers was hindered in vitro (Holzner et al.,
2017).
CONCLUSION
In the activity-guided search for components of S. lucida
inhibitory in the CCID assay, we showed that intravasation of
breast cancer cells through the lymph endothelial wall, which is
the major route of breast cancer dissemination, is significantly
inhibited by hispidulin and other compounds present in the CF
of S. lucida methanolic extract.
In addition, this is the first study characterizing the chemical
composition of S. lucida. It resulted in the proof or tentative
identification of several rare iridoids and flavonoids for the first
time in the genus Scrophularia and a new compound, 2′′-O-
acetyl-homoplantaginin, was unambiguously elucidated.
For a more profound assessment of the potential of S. lucida
to inhibit metastasis in breast cancer, testing in an appropriate
animal model is necessary as a next step.
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Flavonoids, present in fruits, vegetables and traditional medicinal plants, show
anticancer effects in experimental systems and are reportedly non-toxic. This is a
favorable property for long term strategies for the attenuation of lymph node metastasis,
which may effectively improve the prognostic states in breast cancer. Hence, we
studied two flavonoids, apigenin and luteolin exhibiting strong bio-activity in various
test systems in cancer research and are readily available on the market. This study
has further advanced the mechanistic understanding of breast cancer intravasation
through the lymphatic barrier. Apigenin and luteolin were tested in a three-dimensional
(3-D) assay consisting of MDA-MB231 breast cancer spheroids and immortalized
lymph endothelial cell (LEC) monolayers. The 3-D model faithfully resembles the
intravasation of breast cancer emboli through the lymphatic vasculature. Western blot
analysis, intracellular Ca2+ determination, EROD assay and siRNA transfection revealed
insights into mechanisms of intravasation as well as the anti-intravasative outcome
of flavonoid action. Both flavonoids suppressed pro-intravasative trigger factors in
MDA-MB231 breast cancer cells, specifically MMP1 expression and CYP1A1 activity.
A pro-intravasative contribution of FAK expression in LECs was established as FAK
supported the retraction of the LEC monolayer upon contact with cancer cells thereby
enabling them to cross the endothelial barrier. As mechanistic basis, MMP1 caused the
phosphorylation (activation) of FAK at Tyr397 in LECs. Apigenin and luteolin prevented
MMP1-induced FAK activation, but not constitutive FAK phosphorylation. Luteolin,
unlike apigenin, inhibited MMP1-induced Ca2+ release. Free intracellular Ca2+ is a
central signal amplifier triggering LEC retraction through activation of the mobility protein
MLC2, thereby enhancing intravasation. FAK activity and Ca2+ levels did not correlate.
This implicates that the pro-intravasative contribution of FAK and of Ca2+ release in
LECs was independent of each other and explains the better anti-intravasative effects
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of luteolin in vitro. In specific formulations, flavonoid concentrations causing significant
anti-intravasative effects, can certainly be achieved in vivo. As the therapeutic strategy
has to be based on permanent flavonoid treatment both the beneficial and adverse
effects have to be investigated in future studies.
Keywords: intravasation, 3D model, flavonoids, FAK, MMP1, CYP1A1, Ca2+ release
INTRODUCTION
Species of the Scrophularia family are used in ethno-medicine
since ancient times (Galindez et al., 2002). In the search for
anti-metastatic natural compounds, extracts of six Scrophularia
species were tested. For a methanolic extract from S. lucida a
significant anti-intravasative activity was discovered (Giessrigl
et al., 2012). The chloroform fraction of the methanolic extract
inhibited in vitro intravasation of breast cancer spheroids most
effectively. The major compound of the most active sub-fraction
was hispidulin which, as pure compound, attenuated this early
stage of the metastatic process significantly (Lewenhofer et al.,
2018, same issue). Therefore, we decided to test two structurally
related flavonoids, luteolin and apigenin, in in-depth mechanistic
studies. These flavonoids are present in many medicinal plants
used in the traditional medicine of Central and Eastern Europe.
One of the oldest references to a healing plant in occidental
literature can be found in Homer’s Iliad (book XI, line 822
et seq.; Murray, 1924). There is said that ’Aχιλλευ´ς used a
bitter, astringent root to treat wounds. This background in
mythology led to the name of a very important medicinal plant:
Achillea. In fact, this plant is used to treat, among other ailments,
bleeding disorders and bruises (Akram, 2013). Later, Achillea sp.
(“Achilleios”) was also listed in De Materia Medica; Dioscurides,
1st century A.D. and used by Classical Greeks, in the Roman
Empire, the Byzantium, and the Middle Ages up until our
present day. A. millefolium is very rich in glycosides of luteolin
and apigenin, which are easily metabolized into the respective
genins (Benedek et al., 2007; Benetis et al., 2008). Many other
apigenin- and luteolin-rich plant genera are also listed in De
Materia Medica: Cynara, Apium, Allium, Petroselinum, Punica,
Thymus, Solidago, Chamaemelum, Viola, and Vitis (the entire 5th
book is dedicated to Vitis).
Triple negative breast cancer (TNBC) comprises about 15%
of all breast cancer types. In general, TNBC responds well
to chemotherapy as long it has not disseminated to other
organs. However, as soon as TNBC metastasizes the success of
drug treatment is very limited. This implicates that TNBC, in
addition to conventional therapy, needs a metastasis-preventive
approach to maintain a tumor state associated with a better
prognosis. At an early stage of metastasis breast cancer cells
intravasate the lymphatic vasculature and colonize lymph nodes.
Importantly, the “lymph node status” is a prognostic breast
tumor marker (Sobin et al., 2009). Hence, we hypothesized
that compounds which prevent intravasation may interfere with
tumor progression such as lymph node- and distant organ
metastasis. As such a preventive concept for TNCB has to be
based on long term drug administration, the therapeutic regimen
has to be mild and rather free of side effects to allow continuous
treatment. Luteolin inhibited proliferation and induced apoptosis
of the highly metastatic TNBC cell line MDA-MB231 (Attoub
et al., 2011). Anti-invasive/anti-metastatic activities of luteolin
(Tsai et al., 2016; Lin et al., 2017) and the structurally related
analog apigenin (Lindenmeyer et al., 2001; Qin et al., 2016;
Zhao et al., 2017) have also been demonstrated in various
cancer cell lines. As these flavonoids are also wide-spread
constituents in fruits and vegetables they are considered free
of adverse effects. This tempted us to investigate luteolin
and apigenin in terms of their anti-intravasative properties.
In the daily diet, the concentration of flavonoids is too low
to show tumor preventive effects (Vogiatzoglou et al., 2015).
However, apigenin and luteolin are also commercially available
as food supplements with rather high concentrations (40–200 mg
apigenin/capsule; 50 mg luteolin/capsule) and may provide a
preventive option.
The TNCB cell line MDA-MB231 over-expresses the
pro-metastatic matrix metalloprotease 1 (MMP1), and inhibition
of MMP1 attenuates tumor intravasation (Nguyen et al., 2015).
Furthermore, MDA-MB231 cells secrete the pro-intravasative
arachidonic acid metabolite 12(S)-HETE (Nguyen et al., 2016a),
which is synthesized by CYP1A1. Therefore, we investigated
whether luteolin and apigenin interfered with MMP1 expression
and CYP1A1 activity in MDA-MB231 cells.
MMP1 and 12(S)-HETE activate the PAR1 and the
12(S)-HETE receptor, respectively, in LECs, which both trigger
the release of Ca2+, causing the rapid retraction of LECs. This
opens gaps in the monolayer [circular chemorepellent-induced
defects (CCIDs)] through which tumor cells cross the endothelial
barrier (Nguyen et al., 2015, 2016b). Hence, the influence of
apigenin and luteolin on levels of intracellular Ca2+ in LECs
was investigated. The expression of FAK in LECs seems to be
crucial for rapid cell movement (Desai et al., 2009) as observed
during CCID formation. Thus, FAK expression and activity were
studied as well.
MATERIALS AND METHODS
Antibodies and Reagents
Polyclonal rabbit anti-focal adhesion kinase (FAK) and
polyclonal rabbit anti-phospho-Tyr397-FAK were purchased
from Cell Signaling (Danvers, MA, United States), polyclonal
rabbit anti-MMP1 from Abcam (Cambridge, United Kingdom)
and monoclonal anti-β-actin from Sigma (Munich, Germany).
Polyclonal rabbit anti-mouse, anti-goat and anti-rabbit IgGs
were acquired from Dako (Glostrup, Denmark). Apigenin and
luteolin were purchased from Sigma (Munich, Germany) and
human recombinant MMP1 from Sigma-Aldrich (SRP3117,
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FIGURE 1 | Effects of flavonoid combinations on CCID formation. Chemical structures of (A) apigenin and (B) luteolin. (C) MDA-MB231 spheroids were placed on
LEC monolayers and treated with solvent (DMSO, Co), or with 10, 20, and 40 µM apigenin (A) or luteolin (L), or combinations of 10 and 20 µM A and L (solvent was
kept constant) for 4 h, after which CCID areas were measured using an Axiovert microscope and Zen little 2012 software. Three independent experiments with at
least five replicates were analyzed. Error bars indicate means ± SEM and asterisks and hash significances (p < 0.05; t-test).
St. Louis, MO, United States). U73122 was obtained from
Calbiochem (Darmstadt, Germany), BAPTA-AM was from Santa
Cruz Biotechnology (Heidelberg, Germany).
siRNAs targeting human MLC2 (MYL2; SMART pool,
ON-TARGET PLUS, Cat. No.: L-011087000005, siRNAs
targeting human FAK (SMART pool, ON-TARGET PLUS, Cat.
No.: L-003164000005) were ordered from Dharmacon (Gene
Expression and Gene Editing, GE Healthcare, Lafayette, CO,
United States). Non-targeting (n.t.) control siRNA (Silencer R©
Select Negative Control No. 1 siRNA, Cat. No.: 4390843) was
purchased from Ambion (Life Technologies, Carlsbad, CA,
United States). All siRNAs were re-suspended in RNAse-free
water to yield a stock concentration of 20 µM.
Cell Culture
Human MDA-MB231 breast cancer cells from the American
Type Culture Collection (ATCC, Rockville, MD, United States)
were grown in MEM medium supplemented with 10% fetal
calf serum (FCS), 1% penicillin/streptomycin (PS) and 1%
non-essential amino acids (Gibco, Invitrogen, Karlsruhe,
Germany). Telomerase immortalized human lymph endothelial
cells (LECs) were grown in EGM2 MV (Clonetics CC-4147,
Allendale, NJ, United States). The cells were kept at 37◦C in a
humidified atmosphere containing 5% CO2. For CCID formation
assays, LECs were stained with CellTrackerTM green purchased
from Invitrogen (Karlsruhe, Germany).
Spheroid Formation
MDA-MB231 cells (input of 6.000 cells per spheroid) were
transferred to 30 mL serum free MEM medium containing 6 mL
of a 1.6% methylcellulose solution (0.3% final concentration;
Cat. No.: M-512, 4000 centipoises; Sigma-Aldrich, Munich,
Germany). 150 µL of cell suspension were transferred to
each well of a 96-well plate (Greiner Bio-one, Cellstar
650185, Kremsmünster, Austria) to allow spheroid formation
within 48 h.
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CCID (Circular Chemorepellent Induced
Defect) Assay
In this assay, the sizes of the cell free areas (CCIDs) formed
in the endothelial monolayer underneath the tumor spheroids,
were measured. MDA-MB231 spheroids were washed in PBS and
transferred to CellTrackerTM (green)-stained LEC monolayers
seeded into 24-well plates (Costar 3524, Sigma-Aldrich, Munich,
Germany) in 1 mL EGM2 MV medium. After 4 h of incubation,
the CCID areas in the LEC monolayers underneath the
MDA-MB231 spheroids were photographed using an Axiovert
(Zeiss, Jena, Germany) fluorescence microscope. CCID areas
were calculated using the Zen Little 2012 (Zeiss, Jena, Germany).
For each treatment and control the CCID size of at least 25
spheroids (unless otherwise specified) was measured.
SDS Gel Electrophoresis and Western
Blotting
MDA-MB231 cells and LECs were grown in T-25 tissue culture
flasks (Nunc, Roskilde, Denmark) to 80% confluence and
then pre-treated with the flavonoids for 0.5, 1, 2, and 4 h.
Then, cells were processed for SDS gel electrophoresis and
Western blotting as described before (Nguyen et al., 2015).
Chemo-luminescence was developed by Amersham ECL prime
Kit (GE Healthcare, Freiburg, Germany) and detected using
a Lumi-Imager F1 Workstation (Roche, Basel, Switzerland).
Densitometry of the Western blots was analyzed with the
Image-J software (National Institutes of Health, Bethesda, MD,
United States).
Ethoxyresorufin-O-Deethylase (EROD)
Assay Selective for CYP1A1/A2 Activity
MDA-MB231 cells were grown in phenol red-free DMEM/F12
medium (Gibco, Karlsruhe, Germany) containing 10% FCS and
1% PS (Invitrogen, Karlsruhe, Germany). Before treatment, the
cells were transferred to DMEM/F12 medium supplemented with
10% charcoal-stripped FCS (PAN Biotech, Aldenbach, Germany)
and 1% PS. After 4 h of treatment with apigenin and luteolin
CYP1A1 activity was measured with minor modifications
as previously described (Teichmann et al., 2014). Briefly,
ethoxyresorufin (final concentration 5.0 µM, Sigma-Aldrich,
Munich, Germany) was added, 0.4 mL aliquots of the medium
were collected after 180 min and the formation of resorufin was
analyzed by spectro-fluorometry (PerkinElmer LS50B, Waltham,
MA, United States) at an excitation wavelength of 530 nm and an
emission wavelength of 585 nm.
Intracellular Ca2+ Assay
Free intracellular Ca2+ levels were measured using the
FluoForteTM Calcium Assay Kit (Enzo Life Sciences, Ann Arbor,
MI, United States). 8 × 103 LECs/well/100 µL EGM2 medium
were seeded into 96-well black-wall clear-bottom plates (Nunc,
Thermo Fisher Scientific, Rochester, NY, United States) and after
24 h LECs were pre-treated with apigenin, luteolin or DMSO
for 1 h. Then, medium was removed and 100 µL FluoForteTM
Dye-loading (containing apigenin, luteolin, or DMSO) were
added to each well. Cells were further incubated for 45 min at
FIGURE 2 | Inhibition of MMP1 expression upon flavonoid treatment.
MDA-MB231 cells were grown to ∼80% confluence and then treated with
solvent (0), or (A) 20 µM apigenin, or (B) 20 µM luteolin for 0.5, 1, 2, and 4 h.
Then, cells were lysed, proteins separated by SDS gel electrophoresis and
subjected to Western blotting using the indicated antibodies. Staining with
Ponceau S and immunoblotting with anti-β-actin antibody controlled equal
sample loading. Relative protein expression levels (Prot. expr.) are shown to
the right of the blots. Densitometries are means ± SEM from at least three
experiments (asterisks indicate significances, p < 0.05; t-test) and the
Western blot images are representatives for illustration.
FIGURE 3 | Inhibition of CYP1A1 activity in MDA-MB231 cells by flavonoids.
MDA-MB231 cells were treated with solvent (DMSO, Co), or the indicated
concentrations of apigenin and luteolin. Ethoxyresorufin (5 µM) was added
after 4 h and the formation of resorufin was measured. Three independent
experiments with at least three replicates were analyzed. Error bars indicate
means ± SEM and asterisks significances (∗p < 0.05; ANOVA together with
Tukey’s post-test).
37◦C followed by 15 min at room temperature. Then, cells were
stimulated with 1 µM 12(S)-HETE for 5 min, and fluorescence
was measured with a fluorescence plate reader at 490/525 nm.
Transfection of LEC Monolayer
Lymph endothelial cells were seeded in 24-well plates (1 mL/well)
and grown in EGM2 medium. Transfections were performed
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FIGURE 4 | Modulation of MMP1-induced Ca2+ release by flavonoids in LECs. LECs (8 × 103 cells/well) were pre-treated with solvent (DMSO, Co), or (A) 20 µM
luteolin, or (B) 20 µM apigenin and then charged with FluoForte Dye-loading for 45 min at 37◦C and 15 min at room temperature when cells were stimulated with
100 ng/mL activated recombinant MMP1 for 5 min. Intracellular free calcium was measured with a fluorescence plate reader at 490/525 nm. Three independent
experiments with at least two replicates were analyzed. Error bars indicate means ± SEM, and asterisks and hash significances (p < 0.05; t-test).
at a confluence of 70–80%. 0.75 µg siRNA and 6 µL
HiPerFect Transfection Reagent (Cat. No.: 301705; Qiagen,
Hilden, Germany) were mixed in 100µL serum-free medium and
incubated for 30 min at room temperature to allow the formation
of transfection complexes. Cell culture medium was discarded
and 500 µL of fresh EGM2 medium were added into each well.
Then, the transfection complexes were added drop-wise to the
cells (to a final siRNA concentration of 100 nM) and incubated
for 24 h at 37◦C. After 24 h, the medium was replaced and
cells were incubated for another 24 h to recover. The LEC
monolayers were used for CCID assays or isolated RNA for
qPCR.
Statistical Analysis
For statistical analyses Excel 2013 software and Prism 6 software
packages (GraphPad, San Diego, CA, United States) were used.
The values were expressed as mean ± SEM, and the Student’s
t-test and ANOVA with Tukey’s post-test was used to compare
differences between control samples and treatment groups as
well as differences among treatment groups. The statistical
significance level was set to p< 0.05.
RESULTS
Apigenin/Luteolin Inhibit CCID Formation
Induced by MDA-MB231 Spheroids
Breast cancer cells have to intravasate the lymphatic barrier to
colonize lymph nodes, and the CCID in vitro assay realistically
resembles the intravasation of tumor spheroids through the
lymphatic vasculature (Kerjaschki et al., 2011). Treatment of
the three-dimensional MDA-MB231/LEC model with apigenin
(Figure 1A) and luteolin (Figure 1B) dose dependently inhibited
CCID formation in the LEC monolayer, with luteolin showing
a stronger effect than apigenin. Simultaneous treatment with
20 µM luteolin and 20 µM apigenin synergized and inhibited
CCID formation significantly stronger than 40 µM luteolin or
40 µM apigenin, respectively, thus suggesting that luteolin and
apigenin interfered with distinct pro-intravasative mechanisms
(Figure 1C).
Apigenin/Luteolin Inhibit MMP1
Expression and CYP1A1 Activity in
MDA-MB231 Cells
MDA-MB231 cell spheroids express MMP1, which is one
mechanism causing CCIDs in the adjacent LEC monolayer
(Nguyen et al., 2015). Thus, the expression of MMP1 was
investigated after treatment of MDA-MB231 cells with apigenin
and luteolin. 20 µM apigenin and 20 µM luteolin caused
a significant and time-dependent down-regulation of MMP1
protein (Figures 2A,B).
Another mechanism of breast cancer emboli to cross the
endothelial barrier is the secretion of 12(S)-HETE which, in
MDA-MB231 cells, is produced by CYP1A1 (Nguyen et al.,
2016a). Hence, the activity of CYP1A1 in MDA-MB231 cells
was analyzed by EROD assay after treatment with increasing
concentrations of apigenin and luteolin. 5–20 µM apigenin
and luteolin inhibited CYP1A1 activity significantly within 4 h
(Figure 3).
The results proved that apigenin and luteolin inhibited MMP1
expression and CYP1A1 activity, which trigger the retraction of
the adjacent LEC barrier thereby enabling MDA-MB231 tumor
spheroid intravasation.
Influence of Apigenin and Luteolin on
Intracellular Ca2+ Release in LEC
The intravasation of breast cancer cells relies on an interplay
between cancer emboli and the LEC barrier (Vonach et al., 2011;
Viola et al., 2013). Therefore, it was investigated whether apigenin
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FIGURE 5 | Analysis of drug combinations on CCID formation. MDA-MB231 spheroids were placed on LEC monolayers and treated with solvent (DMSO, Co), or
(A,B) 20 µM apigenin, or (C,D) 20 µM luteolin, alone, or together with (A,C) 5 µM BAPTA-AM, or together with (B,D) 2.5 µM U73122 for 4 h, after which CCID
areas were measured using an Axiovert microscope and Zen little 2012 software. Three independent experiments with at least five replicates were analyzed. Error
bars indicate means ± SEM and asterisks and hash significances (∗p < 0.05; t-test).
or luteolin would also inhibit the pro-intravasative response of
LECs.
The release of Ca2+ from intracellular stores plays a central
role in MMP1- and 12(S)-HETE-induced CCID formation
(Nguyen et al., 2016b; Stadler et al., 2017). Hence, it was tested
whether apigenin and luteolin affected intracellular Ca2+ release.
Luteolin prevented MMP1-induced Ca2+ increase (Figure 4A),
which is consistent with previous reports (Jiang et al., 2005). In
contrast, apigenin did not reduce MMP1-induced Ca2+ levels
in LECs, but in contrast increased Ca2+ release (Figure 4B).
This is in agreement with data that apigenin activates potassium
channels leading to their hyper-polarization and causing
the release of Ca2+ (Erdogan et al., 2007). Accordingly,
treating the MDA-MB231/LEC model with apigenin and
BAPTA-AM (intracellular Ca2+ inhibitor) caused a significantly
stronger inhibition of CCID formation than apigenin alone,
or BAPTA-AM alone (Figure 5A). Ca2+ release is dependent
on PLCβ activity and, therefore, also the co-treatment with
apigenin and U73122 (PLC inhibitor) attenuated CCID
formation significantly stronger than the treatment with
just apigenin or U73122 (Figure 5B). Luteolin ameliorated
the CCID-inhibitory effect of BAPTA-AM (Figure 5C) or
U73122 (Figure 5D) even more efficiently than apigenin.
Overall, these data support the notion that an additional
intravasative mechanism, which was independent of Ca2+
signaling, must have been inhibited by apigenin and luteolin as
well.
Luteolin/Apigenin Inhibit
Phosphorylation of Tyr397-FAK in LEC
The FAK controls cell-matrix interactions and mobility (Schwock
et al., 2010) as observed in CCID formation (Nguyen et al.,
2015). Recombinant MMP1 induced the phosphorylation of
FAK at Tyr397 indicative for its activation. Pre-treatment
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FIGURE 6 | MMP1 activates focal adhesion kinase (FAK) in LECs. LECs were grown to ∼70–80% confluence and then pre-treated with solvent (DMSO), or (A)
20 µM apigenin, or (B) 20 µM luteolin and then stimulated with 100 ng/mL activated recombinant MMP1 for 4 h. Cells were lysed, proteins were separated by SDS
gel electrophoresis and analyzed by Western blotting using the indicated antibodies. Equal sample loading was controlled by Ponceau S staining and β-actin
immunoblotting. The relative protein expression (Prot. expr.) was quantified by densitometry facilitating the comparison with β-actin control, which was set to a value
of “1.” The calculated FAK protein expression levels are shown in the bar graphs next to the FAK Western blots. The relative phosphorylation of FAK (p-FAK;
corresponding to FAK activity) was quantified by densitometry facilitating the comparison with FAK protein expression, which was set to a value of “1.” The
calculated FAK protein activity levels (Prot. Act.) are shown in the bar graphs next to the p-FAK Western blots. The numbers below the bar graphs refer to the
respective treatment conditions indicated in the blot lanes. Densitometries are means ± SEM from at least three experiments (asterisks indicate significances,
p < 0.05; t-test) and the Western blot images are representatives for illustration. Hashes (#; rhomboids) indicate significance.
FIGURE 7 | Inhibition of focal adhesion kinase (FAK) expression in LECs by specific siRNA. LECs were transiently transfected with either non-targeting siRNA (n.t.co)
or siRNA inhibiting the expression of FAK. (A) MDA-MB231 spheroids were placed on confluent LEC monolayers and co-incubated for 4 h when the areas of CCIDs
were analyzed using an Axiovert microscope and Zen Little 2012 software. Three independent experiments with at least five replicates were analyzed. (B) After 24 h
cells were lysed, total protein was isolated, separated by SDS-PAGE and transferred to PVDF membranes for Western blotting using FAK antibody. β-Actin was used
to control equal sample loading. Relative protein expression levels (Prot. expr.) are shown to the right of the blots and the numbers below the bar graphs refer to the
respective treatment conditions shown below the lanes. Densitometries are means ± SEM from at least three experiments (asterisks indicate significances, p < 0.05;
t-test) and the Western blot images are representatives for illustration.
with apigenin or luteolin prevented MMP1-induced, but not
constitutive FAK phosphorylation (Figures 6A,B). The inhibition
of Tyr397-FAK phosphorylation by apigenin did not correlate
with the inhibition of Ca2+ release. Therefore, the relevance
of FAK for CCID formation was studied by siRNA-mediated
knock-down of FAK (siFAK). In fact, siFAK transfection of LECs
suppressed MDA-MB231-induced CCID formation by ∼50%
(Figure 7A). The knock-down of FAK was confirmed by Western
blotting (Figure 7B). Hence, FAK significantly contributed to
intravasation in vitro and apigenin and luteolin inhibited this
mechanism.
Earlier work demonstrated that CCID formation through
MLC2 depends on intracellular Ca2+ release (Nguyen et al.,
2015). Our results show that FAK-dependent CCID formation
did not correlate with intracellular Ca2+ levels. Although
both pathways were induced by MMP1, they, obviously,
are independent of each other. Thus, we hypothesized that
simultaneous inhibition of MLC2 (Ca2+-dependent) and
FAK (Ca2+-independent) by respective siRNAs, should
bring about a greater reduction in CCID formation than
inhibition of either FAK or MLC2 alone, which was
actually confirmed (Figure 8). This supports former data
(Figure 1C) showing that luteolin (inhibiting FAK and
Ca2+ release) and apigenin (inhibiting FAK but not Ca2+
release) synergize in CCID attenuation via distinct signaling
pathways.
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FIGURE 8 | Inhibition of focal adhesion kinase (FAK) and myosin light chain 2
(MLC2) protein expression in LECs by specific siRNAs. LECs were transiently
transfected with either non-targeting siRNA (n.t.co), or siRNAs inhibiting the
expression of FAK and MLC2. Then, MDA-MB231 spheroids were placed on
confluent LEC monolayers and co-incubated for 4 h, after which the areas of
CCIDs were analyzed using an Axiovert microscope and Zen Little 2012
software. Three independent experiments with at least five replicates were
analyzed. Error bars indicate means ± SEM, asterisks and hash significances
(p < 0.05; t-test).
DISCUSSION
We show for the first time that luteolin and apigenin attenuate
the intravasation of breast cancer cells in vitro. At the tested
concentrations, luteolin and apigenin inhibited CYP1A1 activity
in MDA-MB231 cells. CYP1A1 synthesizes the pro-metastatic
arachidonic acid metabolite 12(S)-HETE and is induced, e.g., by
the activated aryl hydrocarbon receptor, the expression of which
is high in many cancer entities (Murray et al., 2014) and also
in MDA-MB231 cells (Nguyen et al., 2016a). In HepG2 cells
with a luciferase reporter fused to the CYP1A1-regulator region,
5 µM apigenin increased reporter gene expression by threefold.
In contrast, the higher concentration of 20 µM apigenin
inhibited the expression by 50% (Allen et al., 2001). In cell-free
assays luteolin inhibited CYP1A1 more potently than apigenin,
whereas CYP1A2 was inhibited more efficiently by apigenin
(Kim et al., 2005). CYP1A2 mediates the formation of flavonoid
metabolites with different properties to the genuin compounds.
The comparability of flavonoid effects is rather difficult among
different cell lines, which depend on the expression and activity
profiles of the various CYP isoforms converting these flavonoids
to other (more or less active) products (Androutsopoulos et al.,
2009). Based on the very different individual expression levels
of CYP1A2 in humans, Breinholt et al. (2002) conclude that this
may result in different individual sensitivity.
Apigenin and luteolin inhibited also MMP1 expression in
MDA-MB231 cells. MMP1 expression is induced by NF-κB
(Lee et al., 2011), which is activated not only in inflamed- but
also in cancerous tissue (Karin and Greten, 2005; Karin, 2006).
Recently, we provided evidence that specific inhibition of
NF-κB (by siRELA, siNFKB1, siNEMO) down-regulated MMP1
expression and attenuated CCID formation (Nguyen et al., 2015).
Flavones such as apigenin and luteolin inhibited NF-κB activity
and consequently the expression of its target MMP9 (Amrutha
et al., 2014). Hence, the inhibition of NF-κB by apigenin and
luteolin may have been the reason for suppressed MMP1 levels
in MDA-MB231 cells.
As shown here, recombinant MMP1 significantly induced
the phosphorylation of FAK at Tyr397 in LECs. FAK activity
contributes to cancer cell migration by establishing loose
cell-matrix interactions necessary for rapid cell movement
(Desai et al., 2009; Schwock et al., 2010), as described in
CCID formation (Kerjaschki et al., 2011). In our experiments
suppression of FAK significantly inhibited CCID formation.
The activation of FAK (through phosphorylation of Tyr397)
is mediated through Kv2.1 channels (Wei et al., 2008). Since
FAK as well as potassium channel activity contribute to LEC
retraction and CCID formation (Nguyen et al., 2017), the
reduction of Tyr397-FAK phosphorylation by apigenin may
have been due to the inhibition of potassium channels. This
was supported by reports demonstrating that trimethyl-apigenin
interfered with cardiac potassium currents (Liu et al., 2012) and
the inhibition of potassium channel activity by the flavonoids
acacetin, scutellarin, genistein, and naringenin (Teisseyre and
Michalak, 2005; Zhu et al., 2008; Wu et al., 2011; Gasiorowska
et al., 2012). However, quite to the contrary, apigenin and
luteolin exhibited vasodilatory effects, which are discussed to
be due to activation (rather than inactivation) of potassium
channels (Calderone et al., 2004; Jiang et al., 2005). A more
recent research concluded that the vasodilatory properties of
apigenin and luteolin were independent of potassium channel
inhibition, but due to extracellular calcium influx (Roberts
et al., 2013). Therefore, the mechanism by which apigenin
and luteolin inhibit FAK phosphorylation remains to be
established.
MMP1 also activates the mobility protein MLC2 in LECs,
which contributes to CCID formation as well (Nguyen et al., 2015,
2016c). MMP1 binds to PAR1, activates PLCβ, triggers Ca2+
release and activates the Ca2+-calmodulin kinase MYLK, which
phosphorylates MLC2. MMP1 was also shown to cause migration
by binding to PAR1 in breast cancer cells (Boire et al., 2005)
and blood endothelial cells (Juncker-Jensen et al., 2013). Whereas
MMP1-induced MLC2 activation depends on Ca2+ release,
FAK activation was not found to correlate with intracellular
Ca2+ levels. This implicates that the pathway activating FAK
represents a pro-intravasative mechanism independent of the
one activating MLC2. Therefore, the inhibition both of FAK
(either by siFAK or apigenin) and of MLC2 (by siMLC2, or
BAPTA-AM, or U73122) reduced CCID formation in LEC
monolayers to a greater extent than the inhibition of just one
pathway.
Summing up, luteolin and apigenin inhibited
pro-intravasative mechanisms in MDA-MB231 breast cancer
cells at the levels of CYP1A1 activity and MMP1 expression. In
LECs, apigenin and luteolin inhibited MMP1-induced, aberrant
FAK activity but not constitutive, normal FAK phosphorylation.
Only luteolin inhibited Ca2+ signaling in LEC, which contributed
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to CCID formation (Nguyen et al., 2016b). This may explain why
luteolin affected CCID formation more potently than apigenin as
well as the synergism between apigenin and luteolin.
The results implicate that luteolin and apigenin maintained
the resilience of the endothelial barrier whilst attacking cancer
cells and additionally, inhibited the malignant armamentarium
of the tumor. Luteolin and apigenin exerted their effects at low
µM concentrations which usually cannot be reached by daily
dietary intake (Vogiatzoglou et al., 2015). Nevertheless, the daily
intake of particular flavonoid subclasses (flavonols, flavan-3-ols,
anthocyanidins) significantly correlates inversely with the risk
of colorectal cancer (Woo and Kim, 2013). However, no other
flavonoid subclasses or total flavonoids are associated with a
lower risk of breast cancer in post-menopausal women (Hui
et al., 2013). Intake of highly enriched apigenin and luteolin
formulations achieved flavonoid concentrations in blood plasma
which are comparable to those described herein in vitro. In detail,
a single oral dose of apigenin delivered via a carbon nanopowder
solid dispersion carrier (60 mg/kg) to rats resulted in peak plasma
concentrations of up to 3.2µg/mL which corresponds to 11.8µM
(Ding et al., 2014). Similarly, a single oral dose luteolin in a
peanut hull extract (14.3 mg/kg) to rats resulted in peak plasma
concentrations of up to 8.3 µg/mL (29.1 µM) (Zhou et al., 2008).
The evaluation as to whether these concentrations are free of
negative side effects throughout long term treatment requires
controlled phase I studies.
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In the Romanian folk medicine, aerial parts of Ajuga laxmannii (“nobleman’s beard,”
Romanian – “barba boierului” or “avra˘measca˘” or “cres¸tineasca˘”) are traditionally
used as galactagogue and anti-inflammatory agents. The present study aimed to
evaluate the chemical composition (polyphenols, iridoids, and phytosterols), antioxidant,
antimicrobial and in vivo anti-inflammatory activity of different extracts of A. laxmannii
aerial parts. The major identified bioactive compounds were rutin, 8-O-acetylharpagide
and β-sitosterol. The antioxidant activity of A. laxmannii extracts was evaluated using
several methods, and the results showed good antiradical effects. Moreover, the
antimicrobial evaluation showed a potent antifungal activity against C. albicans and
P. funiculosum. Furthermore, the anti-inflammatory effect was determined by monitoring
some parameters involved in the inflammatory process. The results obtained showed
differences between the analyzed extracts; and therefore the importance of choosing
the best solvent in order to extract the appropriate amount of bioactive compounds.
A. laxmannii ethanol extract showed an anti-inflammatory effect by reducing total
leukocytes, PMN, phagocytosis, and oxidative stress. Compared to diclofenac, only the
50 mg/mL A. laxmannii extract had better anti-inflammatory and anti-oxidative stress
effects, and this could justify the importance of a correlation between the activity and
the used concentration. These findings strongly suggest that A. laxmannii could be
considered as a valuable source of bioactive compounds, which could be further valued
as anti-inflammatory agents in the composition of several herbal drugs.
Keywords: Ajuga laxmannii, polyphenols, iridoids, sterols, anti-inflammatory, antimicrobial
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INTRODUCTION
Medicinal plants have proven their value as sources of molecules
with therapeutic potential, and still represent an important
pool for the identification of novel drug leads (Atanasov et al.,
2015). Moreover, nowadays herbal medicines have received
great scientific interest because they provide both important
biomolecules which are used in the treatment of several
diseases, as well as a broad spectrum of long-term use and
safety. Nevertheless, plant secondary metabolites are excellent
candidates for developing new phytopharmaceuticals with
various biological activities, including antioxidant, antimicrobial,
and anti-inflammatory (Shahidi and Ambigaipalan, 2015; Liao
et al., 2017; Zhang et al., 2017).
In many parts of the world such as Europe, Asia, Africa,
South America, plants and/or plant compounds are used to
cure or prevent different diseases, being in the same time part
of the cultural inheritage of different nations or ethnicities.
Still, herbal medicines were used and applied only based on
traditional knowledge and empirical observations of “indigenous
healers,” without elucidating the chemical composition of the
used extracts or mechanistic knowledge of their pharmacological
activities and main bioactive compounds (Atanasov et al.,
2015). Often, the empirical value of medicinal plants is seen
as a proof of effectiveness and safety, and still many plant
preparations are traditionally used without having a certain
scientific proof of their pharmacological effects or long-term
safety and efficacy.
Phytochemicals are biomolecules that occur in herbal drugs
or phytopharmaceuticals, and possess the ability to modulate one
or more metabolic processes or pathways in the human organism
resulting in health benefits and promotion of well-being (Abuajah
et al., 2014; Ferrante et al., 2017; Locatelli et al., 2017). Within this
frame, new studies on uninvestigated traditionally used medicinal
plants or plant products provide remarkable interest for the
development of novel herbal drugs or herbal formulations.
The genus Ajuga part of the Lamiaceae family comprises 50
species, and about 300 taxa (including subspecies and varieties),
distributed in Asia, Africa, Australia, North America, and Europe
(Riaz et al., 2007; Atay et al., 2016). Some Ajuga species are used
in folk medicine for the treatment of diabetes, inflammation,
malaria, high blood pressure, pain, fever, and as antihelmintic
(Cocquyt et al., 2011). Moreover, several studies have been carried
out on Ajuga species indicating pharmacological activities such as
antimalarial (Njoroge and Bussmann, 2006; Cocquyt et al., 2011),
hypoglycemic (El-Hilaly et al., 2006), anti-inflammatory (Gautam
et al., 2011), anti-arthritis, antipyretic, anabolic, antibacterial,
hepatoprotective, antifungal, antioxidant, cardiotonic (Israili and
Lyoussi, 2009), and analgesic properties (Ono et al., 2008).
Additionally, several phytochemical studies on Ajuga species
have shown the presence of iridoids, diterpenes, phytoecdy-
steroids, flavonoids, sterol glycosides and phenylethanoid
glycosides as the main secondary metabolites of the genus
(Manguro et al., 2006, 2011; Ono et al., 2011; Atay et al., 2016).
Ajuga laxmannii (Murray) Benth. is an erect rhizomatous
pubescent herb that belongs to the genus Ajuga, growing in the
grasslands of Romania and other parts of Europe. In Romania,
the local name for this species is “nobleman’s beard” (Romanian –
“barba boierului” or “avra˘measca˘” or “cres¸tineasca˘”), and it is
used as a galactogogue and anti-inflammatory agent. To the
best of our knowledge, there is only one study on A. laxmannii
(Murray) Benth. regarding its antiprotozoal activity (Atay et al.,
2016).
Within this frame, the aim of this study was to perform
a phytochemical analysis of A. laxmannii aerial parts extracts,
particularly polyphenolic compounds, iridoids and phytosterols,
and to investigate the antioxidant, antimicrobial and anti-
inflammatory activities.
MATERIALS AND METHODS
Chemicals
The standards used were chlorogenic acid, p-coumaric acid,
caffeic acid, rutin, apigenin, quercetin, isoquercitrin, hyperoside,
kaempferol, quercetol, myricetol, fisetin, gallic acid, aucubin,
catalpol, harpagoside, β-sitosterol, brassicasterol, stigmasterol,
campesterol and ergosterol from Sigma–Aldrich (Germany),
ferulic acid, sinapic acid, gentisic acid, patuletin, luteolin from
Roth (Germany), caftaric acid from Dalton (United States),
harpagide, 8-O-acetyl-harpagide from PhytoLab GmbH & Co.
(Germany). Methanol of HPLC analytical-grade, acetonitrile
of HPLC analytical-grade, ammonium acetate of HPLC
analytical-grade, silver nitrate of HPLC analytical-grade,
chloroform, petroleum ether, n-hexane, potassium hydroxide
of analytical-grade and hydrochloric acid of analytical-grade,
acetic acid of analytical-grade, Folin–Ciocâlteu reagent were
purchased from Merck (Germany). Sodium carbonate, Copper
(II) sulfate pentahydrate, sodium acetate trihydrate and
anhydrous aluminum chloride were acquired from Sigma–
Aldrich (Germany). The DPPH (2,2-diphenyl-1-picrylhydrazyl),
Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic
acid) were obtained from Alfa-Aesar (Karlsruhe, Germany),
HRP (horseradish peroxidase), Fremy’s salt were purchased from
Sigma–Aldrich (Germany).
Methanolic stock solutions (100 mg/mL) of the flavonoid
standards were prepared and stored at 4◦C, protected from
daylight. They were appropriately diluted with double distilled
water before being used as working solutions. Methanolic stock
solutions of iridoids (1 mg/mL) were prepared and stored at 4◦C,
protected from daylight. They were appropriately diluted with
double distilled water before being used as working solutions.
Chloroform stock solutions (1 mg/mL) of the phytosterol
standards were prepared and stored at 4◦C, protected from
daylight. Before being used as working solutions, they were
appropriately diluted with acetonitrile. Distilled, deionised water
was produced by a Direct Q-5 Millipore (Millipore SA, Molsheim,
France) water system.
Plant Sample and Extraction Procedure
Ajuga laxmannii aerial parts were collected from Cluj County
(Romania) spontaneous flora during flowering stage in June
2015. The air-dried powder of herbal material was extracted with
different solvents. The methanol extract was obtained from 5 g
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herbal material and 50 mL 70% methanol for 30 min on a water
bath at 60◦C (Methanol Extract, ME). The 10% tincture was
prepared at room temperature from 100 g of herbal material
and 1000 mL 70% ethanol by maceration at room temperature
for 7 days (Ethanol Extract, EE) as previously described by
Toiu et al. (2017). In order to evaluate the anti-inflammatory
activity of A. laxmannii aerial parts, three extracts were used:
A. laxmannii ethanol extract 100% (100 mg dry weight herbal
material/mL), A. laxmannii ethanol extract 50% (50 mg dw herbal
material/mL), and A. laxmannii ethanol extract 25% (25 mg dw
herbal material/mL).
For identification and quantification of phytosterols, and for
determination of antifungal properties, chloroform (CE) and
petroleum ether extracts (PEE) were also prepared. Thus, 2.5 g of
herbal material were extracted with 25 mL chloroform and 25 mL
petroleum ether, respectively, for 30 min in a sonication bath at
60◦C. The extracts were cooled down, and then centrifuged at
4500 rpm for 15 min, and the supernatant was recovered (Mocan
et al., 2014).
Quantitative Determinations of Total
Bioactive Compounds
Total Phenolic Content (TPC)
The total phenolic content (TPC) of the A. laxmannii extracts
was determined photometrically, by Folin-Ciocâlteu method with
slight modifications (Ta˘mas¸ et al., 2009). Briefly, 2 mL of each
ethanolic and methanolic extracts were diluted 25 times, then
mixed with Folin-Ciocâlteu reagent (1 mL) and distilled water
(10.0 mL), and further diluted to 25 mL with a 290 g/L solution
of sodium carbonate. The samples were incubated in the dark
for 30 min. The absorbance was measured at 760 nm, using
a JASCO V-530 (Jasco International Co., Ltd., Tokyo, Japan)
UV-VIS spectrophotometer. TPC values were expressed as gallic
acid equivalents (R2 = 0.999), mg gallic acid/g dry weight herbal
material (mg GAE/g dw herbal material). Assay was performed
in triplicate.
Total Flavonoid Content (TFC)
The total flavonoid content (TFC) of the A. laxmannii extracts
was calculated and expressed as rutin equivalents after the
method previously described (Mocan et al., 2014). Briefly, each
extract (EE and ME) (5 mL) was mixed with sodium acetate
(5.0 mL, 100 g/L), aluminum chloride (3.0 mL, 25 g/L), and
mixed up to 25 mL in a calibrated flask with methanol. The
absorbance was measured at 430 nm. The TFC was expressed
as rutin equivalents (R2 = 0.999), mg rutin equivalents/g dry
weight herbal material (mg RE/g dw herbal material). Assay was
performed in triplicate.
Total Iridoid Content (TIC)
The total iridoid content (TIC) of the A. laxmannii extracts
was determined by a photometric method based on a Trim-Hill
reaction and the results were expressed as aucubin equivalents
(mg AE/g dw herbal material). Each extract (0.4 mL) was
mixed with 4 mL of Trim-Hill reagent (acetic acid –0.2%
CuSO4 - conc. HCl, 10:1:0.5), afterwards the absorbance was
measured at 609 nm, and the blue color indicated the presence of
iridoids. The amount of iridoids was calculated using an aucubin
(0.1–1 mg/mL) calibration curve (R2 = 0.999) (Erdenechimeg
et al., 2017). Assay was performed in triplicate.
Antioxidant Capacity Assays
For testing the antioxidant capacity, the A. laxmannii extracts
were further tested using three different assays.
DPPH Radical Scavenging Activity
The effect of the A. laxmannii extracts against the 2,2-
diphenyl-1-picrylhydrazyl (DPPH) radical was tested according
to Savran et al. (2016). Two milliliters of sample solution
(2 mL, 3.75–30 µg/mL) was added to 2 mL of a 0.1 mg/mL
DPPH methanol solution. After 30 min of incubation at room
temperature in the dark, the absorbance was read at 517 nm.
The DPPH radical scavenging activity was expressed as IC50
(µg/mL). The percentage of DPPH consumption was converted
to trolox equivalents (TE) using a calibration curve (R2 = 0.985)
of Trolox standard solutions (0.5–5 µg/mL). Considering the
results, an IC50 < 50 µg TE/mL shows a very good antioxidant
potential; an IC50 of 50–100 µg TE/mL displays a good
antioxidant potential; an IC50 of 100–200 µg TE/mL reveals a
weak antioxidant potential; an IC50 > 200 µg TE/mL means no
antioxidant potential (Araniciu et al., 2014). Assay was performed
in triplicate.
ABTS Radical Cation Scavenging Activity
The scavenging activity of the A. laxmannii ethanol extract
against the ABTS radical cation (2,2′-azino-bis(3-ethyl-
benzothiazoline)-6-sulphonic acid) was measured according to
Zengin et al. (2014). ABTS
r+ was produced directly by reacting
7 mM ABTS solution with 2.45 mM potassium persulfate and
allowing the mixture to stand for 12–16 h in the dark at room
temperature. Prior to beginning the assay, ABTS solution was
diluted with methanol to an absorbance of 0.700 ± 0.02 at
734 nm. Sample solution was added to ABTS solution (2 mL)
and mixed. After 30 min incubation at room temperature,
the sample absorbance was read at 734 nm. The ABTS radical
cation scavenging activity was expressed as milligrams of
TE per gram of extract (mg TE/g). Assay was performed in
triplicate.
Electron Paramagnetic Resonance (EPR)
Spectroscopy
In order to compare with the results of the spectrophotometric
measurements, the radical scavenging activity of the A. laxmannii
ethanol extract was additionally measured with EPR
spectrometry using the stable synthetic radical Fremy’s salt
as reported previously (Barakat and Rohn, 2014; Moussa-
Ayoub et al., 2014). A mixture of 25 mL of the diluted extract
and a 25 mL of a 1 mM Fremy’s salt solution [potassium
nitrosodisulfonate, K2NO(SO3)2] in phosphate buffer (pH 7.4)
were filled into a 50 mL capillary. After a reaction time of
30 min, the EPR spectrum of Fremy’s salt radical was recorded
and intensity was obtained by integration of the signal. The
antioxidant activity of the extract, expressed as milligrams
of Fremy’s salt equivalents per gram dry weight (mg FSE/g
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dw), was calculated in comparison to a control reaction with
the solvent. Spectra were recorded at 21◦C on a Miniscope
MS 200 X-band spectrometer (Magnettech GmbH, Berlin,
Germany) with the microwave power set to 10 dB and using
modulation amplitude of 1500 mG. Assay was performed in
triplicate.
Identification and Quantification of
Polyphenolic Compounds
General Apparatus and Chromatographic Conditions
An Agilent 1100 HPLC Series system was used (Agilent
Technologies, Darmstadt, Germany), coupled with an Agilent
Ion Trap SL mass spectrometer equipped with an electrospray or
APCI ion source.
Chromatographic Conditions for the Analysis of
Polyphenolic Compounds
The experiment was carried out using an Agilent 1100 HPLC
Series system (Agilent, United States) equipped with degasser,
binary gradient pump, column thermostat, autosampler and
UV detector. The HPLC system was coupled with an Agilent
1100 mass spectrometer (LC/MSD Ion Trap VL). For the
separation, a reverse-phase analytical column was employed
(Zorbax SB-C18 100 mm × 3.0 mm i.d., 3.5 µm particle); the
work temperature was 48◦C. The detection of the compounds
was performed on both UV and MS mode. The UV detector
was set at 330 nm until 17.5 min, then at 370 nm. The
MS system operated using an electrospray ion source in
negative mode. The chromatographic data were processed
using ChemStation and Data Analysis software from Agilent,
United States.
The mobile phase was a binary gradient prepared from
methanol and solution of 0.1% acetic acid (v/v). The elution
started with a linear gradient, beginning with 5% methanol and
ending at 42% methanol, for 35 min; isocratic elution followed for
the next 3 min with 42% methanol. The flow rate was 1 mL/min
and the injection volume was 5 µL.
The MS signal was used only for qualitative analysis
based on specific mass spectra of each compound. The MS
spectra obtained from a standard solution of polyphenols
were integrated in a mass spectra library. Later, the MS
traces/spectra of the compounds from analyzed samples were
compared to spectra from library, which allows positive
identification of each substance, based on spectral match.
The UV trace was used for quantification of identified
compounds from MS detection. Using the chromatographic
conditions described above, the polyphenols eluted in less than
35 min. Four polyphenols cannot be quantified in current
chromatographic conditions due overlapping (caftaric acid
with gentisic acid and caffeic acid with chlorogenic acid).
However, all four compounds can be selectively identified in
MS detection (qualitative analysis) based on differences between
their molecular mass and MS spectra. The detection limits were
calculated as minimal concentration producing a reproductive
peak with a signal-to-noise ratio greater than three. Quantitative
determinations were performed using an external standard
method. Calibration curves in the range of 0.5–50 µg/mL range
with good linearity (R2 > 0.999) for a five point plot were
used to determine the concentration of polyphenols in plant
samples.
Mass Spectrometry Analyses
The detection and quantification of polyphenols was made
in UV assisted by mass spectrometry. Due peak overlapping,
four polyphenol-carboxylic acids (caftaric, gentisic, caffeic, and
chlorogenic) were determined only based on MS spectra, whereas
for the rest of compounds the linearity of calibration curves was
very good (R2 > 0.998), with detection limits in the range of 18
to 92 ng/mL. The detection limits were calculated as minimal
concentration producing a reproductive peak with a signal-
to-noise ratio greater than three. Quantitative determinations
were performed using an external standard method; retention
times were determined with a standard deviation ranging from
0.04 to 0.19 min. Accuracy was checked by spiking samples
with a solution containing each polyphenol in a concentration
of 10 µg/mL. In all analyzed samples, the compounds were
identified by comparison of their retention times and the
recorded electrospray mass spectra with those of standards
in the same chromatographic conditions (Vlase et al., 2013;
Andriamadio et al., 2015).
Identification and Quantification of
Phytosterols
Chromatographic Conditions for the Analysis of
Phytosterols
Compounds were separated using a Zorbax SB-C18 reversed-
phase analytical column (100 mm × 3.0 mm i.d., 5 µm particle)
fitted with a guard column Zorbax SB-C18, both operated
at 40◦C. Sterols were separated under isocratic conditions
using a mobile phase consisting of 10:90 (v/v) methanol and
acetonitrile. The flow rate was 1 mL/min and the injection volume
was 5 µL. Mass spectrometry analysis was performed on an
Agilent Ion Trap 1100 VL mass spectrometer with atmospheric
pressure chemical ionization (APCI) interface. The instrument
was operated in positive ion mode. Operating conditions were
optimized in order to achieve maximum sensitivity values: gas
temperature (nitrogen) 325◦C at a flow rate of 7 L/min, nebulizer
pressure 60 psi and capillary voltage−4000 V.
The identification of sterols was performed by comparing
the retention times and mass spectra with those of standards
in the same chromatographic conditions. To avoid or limit the
interference from background, the multiple reactions monitoring
analysis mode was used instead of single ion monitoring
(e.g., MS/MS instead of MS). Linearity of calibration curves
was very good (R2 > 0.998), with detection limits in the
range of 69 to 3312 ng/mL for ergosterol, 62 to 2952 ng/mL
for brassicasterol, 59 to 2808 ng/mL for campesterol, 136 to
6528 ng/mL for stigmasterol, and 132 to 6336 ng/mL for
β-sitosterol. The results are expressed as µg per mL of extract
(µg/mL).
The software ChemStation (vA09.03) and DataAnalysis (v5.3)
from Agilent, United States were used for the acquisition and
analysis of chromatographic data (Vlase et al., 2013).
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Identification and Quantification of
Iridoids
Targeted A. laxmannii iridoids (aucubin, catalpol, harpagide,
harpagoside, and 8-O-acetylharpagide) were analyzed by HPLC-
MS on a Agilent 1100 liquid chromatography system equipped
with a binary pump, autosampler, thermostat and detector (all
1100 Series from Agilent Inc., United States). The system was
controlled with Data Analysis software (version B01.03, Agilent
Inc., United States). The separation was carried out on an
Atlantis HILIC 3.5 µm (100 mm × 3.0 mm i.d.) (Waters Inc.,
United States) column equipped with an online 0.2 µm filter
(Agilent Inc.), at a working temperature of 40◦C, a flow rate of
0.75 mL/min and an injection volume of 8 µL. A binary gradient
system with eluent (A) 0.1% acetic acid (v/v) and 20 µM sodium
acetate in water, and eluent (B) 0.1% acetic acid (v/v) and 20 µM
sodium acetate in acetonitrile was used for the analyzed samples
with the following gradient: 95–80% B (0–5 min). The HPLC
system was coupled with an Agilent Ion Trap 1100 SL mass
spectrometer equipped with an electrospray ionisation (ESI)
source and operated in the positive mode with a scan range
between 360 and 680 m/z. The newly developed LC-ESI-MS/MS
method was used to identify the targeted compounds based on
their sodium adducts (M+23 m/z): aucubin (369 m/z), catalpol
(385 m/z), harpagide (387.2 m/z), harpagoside (517.4 m/z)
and 8-O-acetylharpagide (429.3 m/z), and by comparison with
standards in the same chromatographic conditions. The capillary
voltage was set to 4 kV and the capillary temperature to 300◦C.
Nitrogen (N2) was used as dry gas with a dry flow of 12 L/min
and a pressure of 60 psi for the nebulizer. For quantification of
the iridoids, stock solutions of the five commercially available
standards substances were prepared in acetonitrile, and different
concentrations of each standard were used. All calibration curves
yielded a coefficient of determination of R2 ≥ 0.990. The results
are expressed asµg per mL of extract (µg/mL). All phytochemical
assays were performed in triplicate.
Antibacterial Activity
Microorganisms and Culture Conditions
For the bioassay, five aerobic bacterial strains were used,
two Gram positive: Staphylococcus aureus (ATCC 49444),
Listeria monocytogenes (ATCC 19114) and three gram
negative: Pseudomonas aeruginosa (ATCC 27853), Salmonella
typhimurium (ATCC 14028) and Escherichia coli (ATCC 25922).
All of the tested microorganisms were obtained from Food
Biotechnology Laboratory, Life Sciences Institute, University
of Agricultural Sciences and Veterinary Medicine Cluj Napoca,
Romania. The bacteria were cultured on Muller-Hinton Agar
and cultures were stored at 4◦C and subcultured once a month.
Microdilution Method
The modified microdilution technique was used to evaluate
antimicrobial activity. Bacterial species were cultured overnight
at 37◦C in Tryptic Soy Broth (TSB) medium at 37◦C. The
bacterial cell suspensions were adjusted with sterile saline to a
concentration of approximately 2.5 × 105 CFU/mL in a final
volume of 100 µL per well. The inoculum was stored at +4◦C
for further use. Dilutions of the inoculum were cultured on solid
Muller–Hinton (MH) for bacteria in order to verify the absence
of contamination and to check the validity of the inoculum.
Determinations of minimum inhibitory concentrations (MICs)
were performed by a serial dilution technique using 96-well
microtitre plates. Different A. laxmannii ethanol extract dilutions
were carried out over the wells containing 100 µL of TSB and
afterwards, 10 µL of inoculum was added to all the wells. The
microplates were incubated for 24–48 h at 37◦C. The MIC
of the samples was detected following the addition of 20 µL
(0.2 mg/mL) of resazurin solution to each well, and the plates
were incubated 2 h at 37◦C. A change from blue to pink indicates
reduction of resazurin, therefore, the bacterial growth. The MIC
was defined as the lowest drug concentration that prevented
this color change. The minimum bactericidal concentrations
(MBCs) were determined by serial subcultivation of a 2 µL
into microtitre plates containing 100 µL of broth per well and
further incubation for 48 h at 37◦C. The lowest concentration,
with no visible growth, was defined as MBC, indicating 99.5%
killing of the original inoculum. Gentamycin (25 µL/well at
concentration of 4 µg/mL) was used as positive control for
bacterial growth. A 50% solution of ethanol in water was used as
negative control. All determinations were performed in triplicate,
and values are the averages of three replicates (Mocan et al.,
2014).
Antifungal Activity
To investigate the antifungal activities of A. laxmannii extracts,
the following fungi were used: Aspergillus flavus (ATCC 9643),
Aspergillus niger (ATCC 6275), Candida albicans (ATCC 10231),
Candida parapsilosis (ATCC 22019) and Penicillium funiculosum
(ATCC 56755). These fungi were obtained from the Food
Biotechnology Laboratory, Life Sciences Institute, University of
Agricultural Sciences and Veterinary Medicine Cluj-Napoca,
Romania. Cultures were maintained on malt agar at 4◦C
and subcultured every month. Spore suspension (1.0 × 105
CFU/mL) was obtained by washing agar plates with sterile
solution containing [0.85% saline, 0.10% Tween 80 (v/v)], then
added to each well to a final volume of 100 µL. Inocula were
screened for contamination by culturing on a solid medium.
The minimum inhibitory (MIC) and minimum fungicidal (MFC)
concentrations assays were determined using the microdilution
method by preparing a serial of dilutions in 96-well microtiter
plates. The extracts (EE, PEE, CE) were diluted in 0.85% saline
(10 mg/mL), then added to microplates containing Broth Malt
medium with inoculum and incubated for 72 h at 28◦C on a
rotary shaker. The lowest concentrations without visible growth
(at the binocular microscope) were defined as MICs. The MFCs
were determined by serial sub-cultivation of 2 µL of tested
extracts dissolved in medium and inoculated for 72 h, into
microtiter plates containing 100 µL of broth per well and further
incubation 72 h at 28◦C. The lowest concentration with no
visible growth was defined as MFC indicating 99.5% killing
of the original inoculum. The fungicide fluconazole was used
as positive control (1–3500 µg/mL). All the experiments were
performed in duplicate and repeated three times (Stana et al.,
2017).
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In Vivo Anti-inflammatory Effects
Experimental Design
All procedures that involved the use of life animals followed the
European guidelines and rules as established by the EU Directive
2010/63/EU. The study protocol was approved by the Research
Ethics Committee of the Iuliu Hat¸ieganu University of Medicine
and Pharmacy Cluj-Napoca (No. 382/2017).
The experiments were performed on adult male Wistar (strain
Crl:WI) albino rats (Charles River Laboratories, United States),
weighing 200–250 g, that were bred in the Animal Facility of Iuliu
Hat¸ieganu University of Medicine and Pharmacy. The animals
were randomly assigned to six groups (n = 8). Rats from group
I were injected intramuscularly (i.m.) with 0.9% saline solution
as a negative control. Inflammation was induced by i.m. injection
of turpentine oil (6 mL/kg BW) in groups II–VI. Animals were
housed under controlled conditions (12 h light/dark cycle, at
an average temperature of 21–22◦C and humidity of 50–55%),
and had free access to standard pellet (Cantacuzino Institute,
Bucharest, Romania) basal diet and water ad libitum. After the
i.m. injection, the animals received the following intraperitoneal
(i.p.) injections: groups I and II received 1 mL of a 0.9% saline
solution; groups III–V received 5 mL/kg BW of A. laxmannii
ethanol extract diluted in distilled water to concentrations
of 25% (25 mg dw/mL), 50% (50 mg dw/mL) and 100%
(100 mg dw/mL), respectively; group VI received 20 mg/kg BW
diclofenac (Araniciu et al., 2014).
In previous studies on anti-inflammatory activity of
A. bracteosa, the evaluated dose was 200 mg/kg BW (Kayani
et al., 2016), therefore in this research the animals received
400 mg/kg BW (100%), 200 mg/kg BW (50%), and 100 mg/kg
BW (25%) of A. laxmannii ethanol extract.
Twenty-four hours after the incubation of inflammation, the
rats were anesthetized using a combination of 50 mg/kg BW
ketamine and 20 mg/kg BW xylazine (Parvu et al., 2014), and
blood was withdrawn by retro-orbital puncture. Blood collected
for use in the phagocytosis test and for white blood cells
count (WBC) was collected on ethylenediaminetetraacetic acid
(EDTA), while blood collected for use in the nitro-oxidative stress
tests was collected without anticoagulant. Coagulated blood was
centrifuged and the separated serum was stored in −80◦C until
use. The total nitrites and nitrates (NOx), total oxidative status
(TOS), total antioxidant response (TAR) and oxidative stress
index (OSI) calculation was measured in the serum.
The experiments were performed in triplicate. At the end
of the experiments under anesthesia using a combination
of ketamine (60 mg/kg BW) and xylazine (15 mg/kg BW)
(Francischi et al., 2017) animals were killed by cervical
dislocation.
In Vitro Phagocytosis Test
Phagocytic activity (PA) was determined as previously described
with minor modifications (Moldovan et al., 2011). The blood
samples that were harvested on EDTA were incubated with an
E. coli suspension (4 × 106 bacteria/mL, in 0.9% saline solution
in the ratio of 0.2 mL of blood/20 µL E. coli suspension) in a
silicon tube at 37◦C for 30 min. May-Grünwald-Giemsa stained
smears were then prepared and counted by light microscopy
using an Olympus microscope. We used two parameters to
assess phagocytic capacity: the PA which was the number of the
E. coli bacteria that were phagocytized by 100 leukocytes, and the
phagocytic index (PI) which was the percentage of leukocytes that
phagocytized at least one bacterium.
WBC Count
For the WBC count, a blood sample dilution 1:10 in Türk
solution was prepared in a Potain leukocyte-dropper. The count
was performed with an optical microscope (Olympus), using
a Bürcker-Türk counting chamber. The differential leukocyte
count was expressed as a percentage and carried out on May-
Grünwald-Giemsa stained smears.
Oxidative Stress Evaluation
First serum samples were passed through 10-kDd filters
(Sartorius AG, Goettingen, Germany) and contaminant proteins
were removed by extraction with a 3:1 (v:v) solution of
methanol/diethyl ether. The sample methanol/diethyl ether ratio
was 1:9 (v:v) (Harma et al., 2003). The Griess reaction was used
to indirectly determine NO synthesis (NOx). In brief, 100 µL of
8 mg/mL VCl3 was added to 100 µL of filtered and extracted
serum supernatant in order to reduce nitrate to nitrite, followed
by the addition of the Griess reagents, 50 µL of SULF (2%)
and 50 µL of NEDD (0.1%). After 30 min incubation at 37◦C,
the sample absorbance was read at 540 nm. The concentration
of serum NOx was determined using a sodium nitrite-based
curve, and expressed as nitrite µmol/L (Miranda et al., 2001).
The TOS of the serum was measured using a colorimetric assay
(Erel, 2005). This assay measures the oxidation of ferrous ions
to ferric ions in the presence of various reactive oxygen species
in an acidic medium. The ferric ions are detected by reaction
with xylenol orange. Assay measurements were standardized
using hydrogen peroxide (H2O2) as the oxidative species, and
the obtained results were expressed in µmol H2O2 equivalents/L.
The TAR was measured in serum using a colorimetric assay (Erel,
2004). In this assay, the rate of hydroxyl radical producion by
the Fenton reaction was monitored by following the changes
in the absorbance of colored dianisidyl radicals. Upon addition
of a serum sample, the hydroxyl radical initiated oxidative
reactions are suppressed by antioxidant present in the serum.
Inhibition of dianisidyl oxidation prevents the subsequent color
change, thereby effectively measuring the total antioxidant
capacity of the serum. This assay is calibrated using trolox
and results are expressed as micromol TE/L. The ratio of
the TOS to the TAR represents the OSI, an indicator of the
degree of oxidative stress (Harma et al., 2003): OSI (Arbitrary
Unit) = TOS (micromol H2O2 equivalents/L)/TAR (micromol
TE/L).
All of the spectroscopic measurements were performed using a
Jasco V-530 UV-Vis spectrophotometer (Jasco International Co.,
Ltd., Tokyo, Japan).
Statistical Analysis
All results were expressed as the mean ± SD. Otherwise,
the median and first quartile (Q1) and third quartile (Q3)
were reported. Statistical comparisons between two independent
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groups were performed using the Student’s t-test (with equal and
unequal variances, depending upon to the results of the F-test)
for normally distributed data. Mann–Whitney’s test was used
for non-parametric data. Pearson and Spearman’s correlation
analyses were used to calculate statistical relationships between
parameters. A p-value < 0.05 was considered as statistically
significant. Analyses were performed using SPSS 16.0 for
Windows (SPSS Inc., United States).
RESULTS AND DISCUSSION
Quantitative Determinations of Total
Bioactive Compounds
Various studies showed that phenolic compounds are widely
distributed in the Ajuga species and these compounds could
contribute to their antioxidant activity. In this part, a preliminary
comparative overview of the total phenolic, flavonoid and iridoid
contents of the different extracts of the A. laxmannii is presented.
The TPC is presented in Table 1 and was 67.68 ± 1.57 mg
GAE/g dw for ethanol extract, and 56.76 ± 0.92 mg GAE/g dw
for methanol extract. The TPC values of analyzed A. laxmannii
aerial parts extracts were higher than those obtained previously
for A. reptans flower extracts (20.86 ± 0.53 and 24.11 ± 0.57 mg
GAE/g dw, for methanol and ethanol extracts, respectively) by
Toiu et al. (2017). Another study performed by Movahhedin
et al. (2016) revealed that ethanol extract of Ajuga chamaecistus
subsp. scoparia (Boiss.) Rech.f. aerial parts (6.5 g extract obtained
from 50 g plant material) had a TPC value of 20.32 ± 0.39 mg
GAE/g extract (representing 2.64 mg GAE/g dw), and the
water extract had TPC values of 18.94 ± 0.13 mg GAEs/g
extract, which is lower than both previously considered Ajuga
species.
The TFC for ethanol extract of A. laxmannii (36.14± 0.53 mg
RE/g dw), was lower than the one reported for the ethyl acetate,
methanol and acetone extract of A. chamaepitys (L.) Schreb
(91.76 ± 0.81, 63.87 ± 0.66, and 61.77 ± 0.51 mg RE/g,
respectively), and considerably higher than the water extract from
same species (9.32± 0.33 mg RE/g) (Jakovljevic´, 2015). However,
a clear comparison between the results of the present study is
rather impossible, due to different extraction protocols and ways
of expressing results.
In previous studies, Toiu et al. (2017) found a TFC value of
12.38 ± 0.22 mg RE/g dw for a methanol extract of A. reptans
flowers.
Concerning the TIC of different species of Ajuga, the available
data is limited. In a former research on A. reptans flowers, Toiu
TABLE 1 | TPC, TFC and TIC in A. laxmannii extracts (±SD).
Extract TPC
(mg GAE/g dw)
TFC
(mg RE/g dw)
TIC
(mg AE/g dw)
Methanol extract (ME) 56.76 ± 0.92 31.22 ± 0.39 15.37 ± 0.77
Ethanol extract (EE) 67.68 ± 1.57 36.14 ± 0.53 16.28 ± 0.85
Values are the mean ± SD (n = 3).
et al. (2017) revealed that the methanol extract content in iridoids
is lower than ethanol extract from the same species (22.17± 0.89
vs. 27.49 ± 0.94 mg AE/g dw). The same trend was observed
in this study for the A. laxmannii, the TIC being 15.37 ± 0.77
and 16.28 ± 0.85 mg AE/g dw for methanol and ethanol extract,
respectively.
Identification and Quantification of
Polyphenolic Compounds
In order to determine the polyphenolic compounds from
A. laxmannii extracts, an optimized HPLC/MS method for
the identification and quantification of 18 polyphenols was
employed. The A. laxmannii extracts contain one caffeic acid
derivative (chlorogenic acid), corresponding to peak 1, with
m/z 353, three flavonoid glycosides (isoquercitrin, rutin, and
quercitrin), corresponding to peaks 2, 3, and 4, with m/z 463, 609,
and 447, respectively. Additionally, two free aglycones (luteolin
and apigenin), with m/z 285 and 279, corresponding to peaks 5
and 6 were identified.
The HPLC chromatogram of A. laxmannii ethanol extract
(Figure 1), and the amounts of polyphenols identified in the
analyzed extracts expressed as µg/g dw are presented (Table 2).
Rutin, an important flavonoid glycoside, was the major
compound found in a significant quantity, both in ethanol and
methanol extract (6883.48 ± 9.12 and 6721.49 ± 8.92 µg/g
dw, respectively). Various studies showed the effectiveness
of rutin in various diseases such as inflammatory bowel
disease and Alzheimer’s disease (Kim et al., 2005; Xu
et al., 2014). Another flavonoid glycoside compound
which was found and quantified in ethanol and methanol
A. laxmannii extracts was isoquercitrin, which is known to
have good anti-inflammatory effects (Rogerio et al., 2007).
The quantities obtained are significant lower than those
obtained for rutin, but still important (685.35 ± 5.72 and
636.1 ± 5.44 µg/g dw), for ethanol and methanol extracts,
respectively.
Considering the correlation between the type of the extract
and the quantity of a particular compound, with one exception,
all extracts showed similar values. Only in case of luteolin, the
methanol extract showed a lower value than the ethanol extract
(88.24± 1.09 vs. 122.27± 1.14 µg/g dw).
Identification and Quantification of
Phytosterols
Under the proposed chromatographic conditions, retention
times of the five analyzed sterols were: 3.2 min for ergosterol,
3.9 min for brassicasterol, 4.9 min for stigmasterol and
campesterol (co-elution) and 5.7 min for β-sitosterol. The ions
monitorized in the MS method are presented in Table 3. In
the ionization conditions all sterols have lost a water molecule,
therefore the ions detected by the mass spectrometer are always
in the form [M-H2O+H]+.
The pseudo-molecular ions of sterols (379 for ergosterol,
381 for brassicasterol, 395 for stigmasterol, 383 for campesterol,
and 397 for β-sitosterol) have been fragmented, and based
on their daughter ions from the MS spectrum the extracted
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FIGURE 1 | HPLC chromatogram of polyphenols from A. laxmannii aerial parts extract. The identified compounds: chlorogenic acid (1), isoquercitrin (2), rutin (3),
quercitrin (4), luteolin (5), apigenin (6).
TABLE 2 | The content of polyphenolic compounds in A. laxmannii extracts by HPLC (µg/g dw).
Polyphenolic compounds m/z value RT ± SD (min) A. laxmannii EE (µg/g dw) A. laxmannii ME (µg/g dw)
Chlorogenic acid (1) 353 5.6 ± 0.05 23.27 ± 1.72 19.33 ± 1.57
Isoquercitrin (2) 463 19.60 ± 0.10 685.35 ± 5.72 636.1 ± 5.44
Rutin (3) 609 20.20 ± 0.15 6883.48 ± 9.12 6721.49 ± 8.92
Quercitrin (4) 447 23.64 ± 0.13 41.13 ± 1.87 36.5 ± 1.68
Luteolin (5) 285 29.64 ± 0.15 122.27 ± 1.14 88.24 ± 1.09
Apigenin (6) 279 33.10 ± 0.17 129.32 ± 2.49 126.53 ± 2.31
Values are the mean ± SD (n = 3).
TABLE 3 | Characteristic ions of standard sterols in full scan mode by LC-MS/MS.
Compound RT (min) M M-H2O+H+ Specific ions for identification Ion [M-H2O+H+] > Ions from spectrum
Ergosterol 3.2 396 379 379 > 158.9; 184.9; 199; 213; 225; 239; 253; 295; 309; 323
Brassicasterol 3.9 398 381 381 > 201.3; 203.3; 215.2; 217.3; 241.2; 255.3; 257.4; 271.1; 297.3; 299.3
Stigmasterol 4.9 412 395 395 > 255; 297; 283; 311; 241; 201
Campesterol 4.9 400 383 383 > 147; 149; 161; 175; 189; 203; 215; 229; 243; 257
β-Sitosterol 5.7 414 397 397 > 160.9; 174.9; 188.9; 202.9; 214.9; 243; 257; 287.1; 315.2
TABLE 4 | The content in sterols in A. laxmannii extracts (µg/mL extract).
Phytosterol A. laxmannii EE A. laxmannii PEE A. laxmannii CE
β-Sitosterol 367.24 ± 2.97 – 11589.96 ± 8.66
Campesterol – 598.04 ± 4.22 1717.28 ± 5.25
Stigmasterol 55.49 ± 2.01 55.49 ± 1.99 55.5 ± 2.09
Ergosterol 1.88 ± 0.09 1.88 ± 0.11 1.88 ± 0.13
Brassicasterol 47.65 ± 2.79 47.65 ± 2.71 47.66 ± 2.39
Not found, below the limit of detection. Values are the mean ± SD (n = 3).
chromatograms of each compound were constructed. The
method can also be applied for quantitative determination
because the intensity of ions in the mass spectrum is proportional
to the concentration of the substance in the sample.
In order to quantify the five sterols from A. laxmannii extracts
(EE, PEE, CE), we have constructed the extracted chromatograms
for each compound, taking into account the intensity of major
ions in the mass spectrum (Table 3).
Calibration curves were obtained from standard solutions at
different concentration levels, selected as representative of the
range of concentration in the sample. Regression analysis of
various concentrations of standard solutions (0.08–8 µg/mL)
gave good correlation coefficients for the calibration curves
of sterols. Concentrations of phytosterols in A. laxmannii
extracts are presented in Table 4. Significant differences
between the three A. laxmannii extracts were observed: all
five sterols were identified in CE, whereas the EE contains
β-sitosterol, stigmasterol, ergosterol and brassicasterol and PEE
contains campesterol, stigmasterol, ergosterol and brassicasterol.
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The A. laxmannii CE was the richest in phytosterols, with
β-sitosterol as major compound in very high concentration
(11589.96 ± 8.66 µg/mL), while in EE it was found in smaller
quantities (367.24 ± 2.97 µg/mL), and in PEE campesterol was
the main sterol (598.04 ± 4.22 µg/mL). The concentrations of
stigmasterol, ergosterol, and brassicasterol were comparable in all
three extracts. To the best of our knowledge, this is the first report
on phytosterols from A. laxmannii aerial parts extracts. Previous
studies showed the presence of stigmasterol and β-sitosterol in
other Ajuga species, such as A. bracteosa, A. relicta, A. taiwanensis
(Israili and Lyoussi, 2009).
Identification and Quantification of
Iridoids
Iridoids are important compounds for the genus Ajuga, and
many Ajuga species contain the iridoid glycoside harpagide
(Manguro et al., 2011; Mamadalieva et al., 2013). The main
known ethnopharmacological indications for Ajuga species are
oedema, hypertension, fever, intestinal and biliary disorders,
ulcer, they are used as antipyretic, diuretic, and astringent
(Toiu et al., 2017), and several studies have shown that iridoid
glycosides in Ajuga species are linked to this therapeutic effects
(Makni et al., 2013; Hailu and Engidawork, 2014). The HPLC-MS
results from the present study show the characterization of Ajuga
laxmannii aerial parts in five commercially available iridoid
glycosides, namely aucubin, catalpol, harpagide, harpagoside,
and 8-O-acetylharpagide. From a pharmaceutical point of
view, the concentrations of the compounds determined in
plant extract cannot be neglected as they are directly linked
to their pharmaceutical efficacy and effectiveness. 8-O-
acetylharpagide was the major compound found in ethanol
extract (266.3 ± 3.92 µg/mL extract), followed by harpagide
(87.4 ± 2.39 µg/mL extract). The concentrations of aucubin
and catalpol (7.2 ± 0.41 and 3.1 ± 0.23 µg/mL ethanol extract,
respectively) were significantly lower than the other iridoids.
We observed that A. laxmannii aerial parts ethanol extract
contains higher amounts of iridoids than methanol extract
(Table 5). As far as one can tell, this is the first report of a
rapid, simple and highly accurate HPLC-MS/MS method for the
identification and quantification of iridoids from A. laxmannii
extracts.
Antioxidant Activity
DPPH and ABTS Radical Scavenging Activity
Several studies showed that the number and position of
the substituents on the aromatic ring affects the antioxidant
properties of phenolics; different substituents affect the reactivity
and thus, the antioxidant capacity of the phenolic compounds
(Shahidi and Ambigaipalan, 2015).
The DPPH and ABTS radical scavenging assays are reliable
and commonly used methods for evaluation of the radical
scavenging activity. These measurements are based on the
reduction of radical species by electron-transferring or hydrogen-
donating radical scavengers. DPPH
r
method is used for anion
radicals and ABTS
r+ is used for cation radicals. DPPH r is a
stable free radical, the largest absorbance occurs at 517 nm,
and when it reacts with antioxidants free radicals its absorbance
decreases.
TABLE 5 | The quantification of iridoids in A. laxmannii extracts (µg/mL extract).
Extract Harpagide Aucubin Catalpol Harpagoside 8-O-acetyl-harpagide
A. laxmannii EE 87.4 ± 2.39 7.2 ± 0.41 3.1 ± 0.23 37.2 ± 2.35 266.3 ± 3.92
A. laxmannii ME 76.5 ± 2.01 6.9 ± 0.37 2.7 ± 0.19 29.1 ± 1.98 241.4 ± 3.65
Values are the mean ± SD (n = 3).
TABLE 6 | DPPH, TEAC, EPR activity of A. laxmannii (mean ± SD).
Sample DPPH IC50 (µg/mL) EE DPPH IC50 (µg/mL) ME TEAC mg TE/g dw EPR mg FS/25µL EPR mg FS/g dw
A. laxmannii 22.64 ± 0.88 24.89 ± 0.83 71.07 ± 2.40 0.266 98.073 ± 1.23
Trolox 11.2 ± 0.21
Values are the mean ± SD (n = 3).
TABLE 7 | Antibacterial activity of A. laxmannii extracts (MIC, MBC).
Bacterial strains MIC (mg/mL) MBC (mg/mL) Gentamycin (µg/mL)
ME EE ME EE
S. aureus 1.56 0.78 3.12 1.56 0.038
P. aeruginosa 3.12 3.12 6.25 6.25 1.2
L. monocytogenes 6.25 6.25 12.5 12.5 0.076
E. coli 6.25 6.25 12.5 12.5 1.2
S. typhimurium 6.25 6.25 12.5 12.5 2.4
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TABLE 8 | Antifungal activity of A. laxmannii extracts (MIC, MFC).
Bacterial Strains MIC (mg/mL) MFC (mg/mL) Fluconazole (µg/mL)
EE PEE CE EE PEE CE MIC (µg/mL) MFC (µg/mL)
Aspergillus flavus 0.05 0.025 0.12 0.1 0.05 0.025 0.15 0.3
Aspergillus niger 0.05 0.05 0.025 0.1 0.1 0.05 0.15 0.3
Candida albicans 0.025 0.1 0.012 0.05 0.2 0.025 0.1 0.2
Candida parapsilosis 0.012 0.025 0.025 0.025 0.5 0.05 0.1 0.2
Penicillium funiculosum 0.1 0.025 0.012 0.2 0.05 0.025 0.15 0.3
TABLE 9 | Anti-inflammatory activity of A. laxmannii extracts (WBC, PMN, Monocytes, PA, PI, TAR, TOS, NO, OSI).
Parameter A.l. 100% (100 mg dw/mL) A.l. 50% (50 mg dw/mL) A.l. 25% (25 mg dw/mL) Inflam Diclo
WBC 10444 5103.6 5634 11602 4866.8
PMN 68.2 62 68.6 79.6 54.4
Monocytes 3 2.4 2.4 2.8 2.4
PA 42.4 23.6 35.2 50.4 23.8
PI 54.2 31.2 41.2 86.8 37.2
TAR 1.088668 1.086654 1.08674 1.087136 1.089406
TOS 22.36506 16.70665 18.16688 22.46936 16.20834
NO 42.56259 44.77172 57.1134 59.29308 33.23183
OSI 20.539 15.37416 16.71447 20.66744 14.87844
A.l. 100% – the animals received 5 mL/kg BW A. laxmannii ethanol extract 100% (100 mg dw/mL), A.l. 50% – the animals received 5 mL/kg BW A. laxmannii ethanol
extract 50% (50 mg dw/mL), A.l. 25% – the animals received 5 mL/kg BW A. laxmannii ethanol extract 25% (25 mg dw/mL), Inflam – inflammation was induced by i.m.
injection of turpentine oil (6 mL/kg BW), Diclo – the animals received 20 mg/kg BW diclofenac.
FIGURE 2 | White blood cells (WBC) count. A.l. 100% – the animals received
5 mL/kg BW A. laxmannii ethanol extract 100% (100 mg dw/mL), A.l. 50% –
the animals received 5 mL/kg BW A. laxmannii ethanol extract 50%
(50 mg dw/mL), A.l. 25% – the animals received 5 mL/kg BW A. laxmannii
ethanol extract 25% (25 mg dw/mL), Inflam – inflammation was induced by
i.m. injection of turpentine oil (6 mL/kg BW), Diclo – the animals received
20 mg/kg BW diclofenac (p < 0.001).
The antioxidant activity of A. laxmannii was investigated
for the first time and the IC50 values were determined:
22.64 ± 0.88 and 24.89 ± 0.83 µg/mL for ethanol and methanol
extract, respectively, while for Trolox 11.2 ± 0.21 µg/mL
(Table 6). In comparison with other research, A. laxmannii
showed a higher antiradical capacity. For example, a study
concerning antioxidant capacity of A. turkestanica reported
a value of 57.84 ± 4.19 µg/mL (Mamadalieva et al., 2013),
whereas a similar study concerning A. reptans reported a
slightly higher value (65.7 ± 3.82 µg/mL) (Ono et al., 2011).
A similar antiradical activity was reported by Movahhedin
et al. (2016) for A. chamaecistus subsp. scoparia (Boiss.) Rech.f.
(22.69± 1.30 µg/mL).
2,2′-Azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid)
(ABTS) is another free radical used for evaluation of antioxidant
capacity. In the ABTS
r+ (TEAC) scavenging assay, the value
of antiradical capacity of A. laxmannii ethanol extract was
71.07 ± 2.40 mg TE/g extract (Table 6), which is higher
than the one reported by Movahhedin et al. (2016) for
A. chamaecistus subsp. scoparia (Boiss.) Rech.f. (53.87± 2.11 mg
TE/g extract).
Electron Paramagnetic Resonance (EPR)
Spectroscopy
To support the results from the TEAC assay, the Ajuga laxmannii
ethanol extract was additionally analyzed using EPR with Fremy’s
salt as a stable radical. EPR is a very common method to
assess the antioxidant activity of different samples. The main
advantage of this assay is the matrix-independent measurement
of the reaction between potential antioxidants and radicals in
an electro-magnetic field instead of the absorbance of light
(Yu and Cheng, 2008). The degraded amount of Fremy’s salt
after 30 min incubation time was 98.07 ± 1.23 mg FS/g
extract (Table 6). The EPR is a common, well-characterized,
established methodology for detecting radicals and their kinetics.
Unfortunately, it is not so frequently used in combination
with other assays to detect the overall antioxidant activity.
Therefore, in this case, a comparison with the results of
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FIGURE 3 | Polymorphonuclear leukocytes (PMN). A.l. 100% – the animals
received 5 mL/kg BW A. laxmannii ethanol extract 100% (100 mg dw/mL), A.l.
50% – the animals received 5 mL/kg BW A. laxmannii ethanol extract 50%
(50 mg dw/mL), A.l. 25% – the animals received 5 mL/kg BW A. laxmannii
ethanol extract 25% (25 mg dw/mL), Inflam – Inflammation was induced by
i.m. injection of turpentine oil (6 mL/kg BW), Diclo – the animals received
20 mg/kg BW diclofenac (p < 0.001).
FIGURE 4 | Total number of monocytes. A.l. 100% – the animals received
5 mL/kg BW A. laxmannii ethanol extract 100% (100 mg dw/mL), A.l. 50% –
the animals received 5 mL/kg BW A. laxmannii ethanol extract 50%
(50 mg dw/mL), A.l. 25% – the animals received 5 mL/kg BW A. laxmannii
ethanol extract 25% (25 mg dw/mL), Inflam – Inflammation was induced by
i.m. injection of turpentine oil (6 mL/kg BW), Diclo – the animals received
20 mg/kg BW diclofenac (p < 0.001).
other researchers with regard to other Ajuga species is
lacking.
Antibacterial Activity
The obtained results for the antibacterial activity of A. laxmannii
extracts and gentamicin against Gram+ and Gram− bacteria are
presented in Table 7. The antimicrobial effect was measured by
microdilution assay, and the determination of MIC (mg/mL) and
MBC (mg/mL) was assessed.
The MIC values obtained for the ethanol extract ranged
from 0.78 to 6.25 mg/mL, and from 1.56 to 6.25 mg/mL for
the methanol extract of A. laxmannii. Against some bacterial
strains, such as Pseudomonas aeruginosa, Listeria monocytogenes,
Escherichia coli and Salmonella typhimurium, both extracts
FIGURE 5 | Phagocytic activity (PA) of A. laxmannii extract. A.l. 100% – the
animals received 5 mL/kg BW A. laxmannii ethanol extract 100%
(100 mg dw/mL), A.l. 50% – the animals received 5 mL/kg BW A. laxmannii
ethanol extract 50% (50 mg dw/mL), A.l. 25% – the animals received 5 mL/kg
BW A. laxmannii ethanol extract 25% (25 mg dw/mL), Inflam – Inflammation
was induced by i.m. injection of turpentine oil (6 mL/kg BW), Diclo – the
animals received 20 mg/kg BW diclofenac (p < 0.001).
FIGURE 6 | Phagocytic index (PI) of A. laxmannii extract. A.l. 100% – the
animals received 5 mL/kg BW A. laxmannii ethanol extract 100%
(100 mg dw/mL), A.l. 50% – the animals received 5 mL/kg BW A. laxmannii
ethanol extract 50% (50 mg dw/mL), A.l. 25% – the animals received 5 mL/kg
BW A. laxmannii ethanol extract 25% (25 mg dw/mL), Inflam – Inflammation
was induced by i.m. injection of turpentine oil (6 mL/kg BW), Diclo – the
animals received 20 mg/kg BW diclofenac (p < 0.001).
showed comparable activities. The best antimicrobial activity
against S. aureus is associated with A. laxmannii ethanol extract
(MIC value = 0.78 mg/mL and MBC value = 1.56 mg/mL). The
less susceptible strains were: Listeria monocytogenes, Escherichia
coli and Salmonella typhimurium, for both methanol and ethanol
extracts. Previous studies showed a similar trend in terms of
MIC and MBC for A. reptans (Toiu et al., 2017). According
to Salvat et al. (2004), herbal extracts with MIC values less
than/around 0.50 mg/mL indicate good antimicrobial effect.
Consequently, the results presented herein showed moderate
antibacterial activity.
Generally, the bacterial strains were more sensitive to ethanol
extract of A. laxmannii. Considering HPLC–MS results presented
in this study, we can derive some assumptions regarding
antibacterial activity of A. laxmannii aerial parts. The content
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FIGURE 7 | Total oxidative status (TOS). A.l. 100% – the animals received
5 mL/kg BW A. laxmannii ethanol extract 100% (100 mg dw/mL), A.l. 50% –
the animals received 5 mL/kg BW A. laxmannii ethanol extract 50%
(50 mg dw/mL) (p < 0.001), A.l. 25% – the animals received 5 mL/kg BW
A. laxmannii ethanol extract 25% (25 mg dw/mL) (p < 0.01), Inflam –
Inflammation was induced by i.m. injection of turpentine oil (6 mL/kg BW),
Diclo – the animals received 20 mg/kg BW diclofenac (p < 0.001).
FIGURE 8 | Total antioxidant response (TAR). A.l. 100% – the animals
received 5 mL/kg BW A. laxmannii ethanol extract 100% (100 mg dw/mL), A.l.
50% – the animals received 5 mL/kg BW A. laxmannii ethanol extract 50%
(50 mg dw/mL), A.l. 25% – the animals received 5 mL/kg BW A. laxmannii
ethanol extract 25% (25 mg dw/mL), Inflam – Inflammation was induced by
i.m. injection of turpentine oil (6 mL/kg BW), Diclo – the animals received
20 mg/kg BW diclofenac (p > 0.05).
of polyphenolic compounds in ethanol extract of A. laxmannii
was higher than in methanol extract. Many recent investigations
confirmed antibacterial and antifungal properties of phenolic
compounds from plant origin, among which are the main
constituents of examined extracts (rutin and isoquercitrin) (Alves
et al., 2013; Stojkovic´ et al., 2013). The exerted antibacterial
potential of A. laxmannii could be associated with higher level
of mentioned phenolic compounds in ethanol extract.
Antifungal Activity
The antifungal activity of the A. laxmannii extracts (EE, PEE,
and CE) was tested against a panel of five fungi, selected
on the basis of their relevance for public health. The results
obtained for the antifungal efficacy of A. laxmannii extracts
and fluconazole against tested strains are presented in Table 8.
FIGURE 9 | Oxidative stress index (OSI). A.l. 100% – the animals received
5 mL/kg BW A. laxmannii ethanol extract 100% (100 mg dw/mL), A.l. 50% –
the animals received 5 mL/kg BW A. laxmannii ethanol extract 50%
(50 mg dw/mL), A.l. 25% – the animals received 5 mL/kg BW A. laxmannii
ethanol extract 25% (25 mg dw/mL), Inflam – Inflammation was induced by
i.m. injection of turpentine oil (6 mL/kg BW), Diclo – the animals received
20 mg/kg BW diclofenac (p < 0.001).
FIGURE 10 | NO synthesis. A.l. 100% – the animals received 5 mL/kg BW
A. laxmannii ethanol extract 100% (100 mg dw/mL), A.l. 50% – the animals
received 5 mL/kg BW A. laxmannii ethanol extract 50% (50 mg dw/mL), A.l.
25% – the animals received 5 mL/kg BW A. laxmannii ethanol extract 25%
(25 mg dw/mL), Inflam – Inflammation was induced by i.m. injection of
turpentine oil (6 mL/kg BW), Diclo – the animals received 20 mg/kg BW
diclofenac (p < 0.001).
Candida parapsilosis possessed the highest sensitivity to the
ethanolic extract of A. laxmannii, with MIC = 0.012 mg/mL
and MFC = 0.025 mg/mL. Moreover, Candida albicans and
Penicillium funiculosum were similarly susceptible to the
inhibitory (MICs = 0.012 mg/mL) and fungicidal effects
(MFCs = 0.025 mg/mL) of the chloroform extract. Nonetheless,
the most resistant fungal strains were Candida parapsilosis and
Candida albicans, toward petroleum ether extract with MFCs 0.5
and 0.2 mg/mL, respectively. According to Kawamura and Ohara
(2005), the antifungal activity of plant extracts might be ascribed
to the high level of iridoids. Both methanol and ethanol extracts
from A. laxmannii aerial parts showed high values for iridoid
glycosides, especially for 8-O-acetylharpagide. These results are
in accordance to previous studies performed by Makni et al.
(2013), who similarly demonstrated the antifungal effect of A. iva
extracts.
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Anti-inflammatory Activity
The anti-inflammatory effects of three A. laxmannii ethanol
extract concentrations (25 mg dw/mL, 50 mg dw/mL, and
100 mg dw/mL) were evaluated in vivo on a model turpentine
oil-induced inflammation in rats by determining WBC count,
differential WBC count, serum total nitrites and nitrates, TOS,
TAR and OSI. These three extract dilutions were also evaluated
in vitro for the ability to inhibit phagocytosis. The 50 mg dw/mL
diluted extract had the best inhibitory activity on phagocytosis
and oxidative stress. In conclusion, these results support the
hypothesis that extracts from A. laxmannii aerial parts exert anti-
inflammatory activities by inhibiting phagocytosis through the
reduction of oxidative stress (Table 9).
Compared to the inflammation group, A. laxmannii ethanol
extracts significantly reduced (p < 0.001) total WBC count
(Figure 2) by lowering PMN% (Figures 3, 4). That was associated
with an important decrease of the phagocytosis indices PA
(Figure 5) and PI (Figure 6) (p < 0.001). Extracts 50 mg dw/mL
and 25 mg dw/mL had the best inhibitory effects (p < 0.001) and
this was comparable to diclofenac activity (p > 0.05).
Turpentine-induced inflammation significantly increased
(p < 0.001) and treatment with diclofenac significantly reduced
(p < 0.001) the TOS (Figure 7). Importantly, the TOS
was also reduced by the treatment with all dilutions of the
A. laxmannii extract. The inhibitory effects were strongest for
the 50 mg dw/mL (p < 0.001) and 25 mg dw/mL (p < 0.01)
plant extracts. Diclofenac treatment had a similar effect on TOS
inhibition (p < 0.01) compared to treatment with either the
25 mg dw/mL (p < 0.01) or the 50 mg dw/mL (p < 0.01)
extract. The A. laxmannii extract had no important effect on TAR
(Figure 8) (p > 0.05).
In the inflammation group, the OSI was significantly elevated
(p < 0.001), and diclofenac treatment decreased the OSI
(p < 0.001) (Figure 9). The 25 mg dw/mL and 50 mg dw/mL
extracts of A. laxmannii aerial parts induced a significant decline
in OSI (p < 0.001). The 50 mg dw/mL extract was the best
OSI inhibitor (p < 0.001). The 50 mg dw/mL (p < 0.001)
and 25 mg dw/mL (p < 0.01) A. laxmannii extract dilutions
significantly reduced NOx (Figure 10). The OSI correlated with
the TOS (r = 0.92) and NOx (r = 0.81).
Compared to diclofenac treatment, A. laxmannii extract had
a lower anti-inflammatory and anti-nitro-oxidative stress effect
upon all measured parameters (p < 0.001). Among the three
extracts, the 50 mg dw/mL A. laxmannii one had the best effect in
comparison with diclofenac.
CONCLUSION
In the present study, the chemical composition, antioxidant,
antimicrobial, and anti-inflammatory properties of different
A. laxmannii (from Romania) extracts were evaluated for the
first time. The major identified compounds were rutin, 8-O-
acetylharpagide and β-sitosterol. The content in polyphenolic
compounds, iridoids and phytosterols could be correlated
with the evaluated pharmacological effects. The antioxidant
activity of A. laxmannii extracts was assessed using several
methods, and results showed good antiradical effects. The results
of the antimicrobial evaluation showed a potent antifungal
activity against C. albicans and P. funiculosum. The anti-
inflammatory effect was determined by monitoring some
parameters involved in the inflammatory process, and these
findings could indicate a possible mechanism of action. The
obtained results showed differences between the analyzed
extracts; and therefore the importance of choosing the best
solvent in order to extract the appropriate amounts of
bioactive compounds. A. laxmannii ethanol extract possessed
anti-inflammatory effect by reducing total leukocytes, PMN,
phagocytosis, and oxidative stress. Compared to diclofenac,
only the 50 mg/mL A. laxmannii extract showed better anti-
inflammatory and anti-oxidative stress effects, and this could
justify the importance of the correlation between the activity
and the dose. The results confirm the use of A. laxmannii
in traditional medicine as an anti-inflammatory agent. Further
research is needed in order to deeply comprehend the
bioavailability and how processes are involved in the metabolic
pathways.
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Historically Russia can be regarded as a “herbophilious” society. For centuries the
multinational population of Russia has used plants in daily diet and for self-medication.
The specificity of dietary uptake of medicinal plants (especially those in the unique
and highly developed Russian herbal medical tradition) has remained mostly unknown
in other regions. Based on 11th edition of the State Pharmacopoeia of the USSR,
we selected 70 wild plant species which have been used in food by local Russian
populations. Empirical searches were conducted via the Russian-wide applied online
database E-library.ru, library catalogs of public libraries in St-Petersburg, the databases
Scopus, Web of Science, PubMed, and search engine Google Scholar. The large majority
of species included in Russian Pharmacopoeia are used as food by local population,
however, aerial parts are more widely used for food. In this review, we summarize data
on medicinal species published in Russia and other countries that are included in the
Russian Pharmacopoeia and have being used in food for a long time. Consequently,
the Russian Pharmacopoeia is an important source of information on plant species
used traditionally at the interface of food and medicine. At the same time, there are
the so-called “functional foods”, which denotes foods that not only serves to provide
nutrition but also can be a source for prevention and cure of various diseases. This review
highlights the potential of wild species of Russia monographed in its pharmacopeia for
further developing new functional foods and—through the lens of their incorporation into
the pharmacopeia—showcases the species’ importance in Russia.
Keywords: medicinal plants, traditional use, functional food, health benefits, Russian Federation
INTRODUCTION
Until today over 7000 species have been recorded to be edible (Lim, 2012) and for many of these
specific health benefits have been claimed, with, however, generally only limited pharmacological
evidence for such claims. Only a small share of these is used on a large, extensive scale.
Wild and cultivated food plants may have medicinal, nutraceutical, pharmaceutical, and health
benefits. Plants are excellent sources of active phytochemicals with importance in the prevention
of different diseases. Herbal medicinal products are going recognition for the treatment and
prophylaxis of different diseases. Direct nutritional benefits of such plants are often known
267
Shikov et al. Food, Wild Plants, Russian Pharmacopoeia
only to a limited extend. Herbal infusions will add small
quantities of essential micronutrients and vitamins to the daily
intake. For sick or malnourished individuals this may contribute
to restoring the balance between nutrients and thereby improve
or sustain health (Lim, 2012).
Blurring of the food and medicine interface is a common
theme across multiple contexts and cultures (Heinrich, 2016).
The association between food and disease is widely recognized
as the bedrock of preventive nutrition. Throughout the ages, and
at least since the proclamation “let food be your medicine, let
medicine be your food” which has been attributed toHippocrates’
(ca. 480–377 BC), physicians recognized the impact of food on
human health. The question of the continuum between food and
medicine is of great interest to (ethno-)pharmacologists (Etkin
and Ross, 1982; Leonti, 2012; Valussi and Scire, 2012; Jennings
et al., 2014; Alarcón et al., 2015).
In many countries medicinal plants are widely used as dietary
supplements, in daily foods and as functional foods, with the aim
of promoting health. In Eastern cultures food and medicine are
seen to come from the same source. Their use is based on the
same fundamental theories, and they are equally important in
maintaining and improving health and for preventing and curing
diseases, as well as facilitating rehabilitation. In China, Japan,
Korea, and Southeast Asia, medicinal plants are widely used both
daily foods (cereals, vegetables, and fruits) and functional foods,
for replacement and medical purposes (Shi et al., 2011). The
last few decades has seen the introduction to Europe of a wide
range of species used in other continents, including from South
Africa e.g. rooibos (Aspalathus linearis (Burm.f.) R.Dahlgren)
and to a lesser extent honey bush tea (Cyclopia sp.) or Hoodia
gordonii (Masson) Sweet ex Decne. to regulate the appetite. Also
some exotic fruits, such as acerola (Malpighia glabra L.) from
South America, rich in vitamin C are now marketed as food
supplements (Franz et al., 2011).
In the early history of Western biomedicine, diet figured
prominently in the prevention of diseases and therapeutics.
The history of biomedicine customarily is traced to Greece and
the Hyppocratic Corpus, some 60 medical texts dating to the
fifth to fourth centuries BCE. Diet regulation was the most
prominent element in all the Hippocratic texts (Etkin, 2006).
Due to its location between East and West Russian tradition of
medicine and diet has accumulated and adopted approaches that
originated in Europe and Asia. The Greek influence on Russian
medicine is of particular relevance in this context (Shikov et al.,
2014a).
Russia in the past and present can be regarded as a
“herbophilious” society. The term “herbophilia” was used
by Łuczaj (2008) for such cultures, in which medicinal
and food plant species are often used and highly prized.
Approximately 58% of the Russian population was reported to
use phytopharmaceuticals as a form of treatment (Shikov et al.,
2011) including wild plants. Plants are an integral part of Russian
everyday life. A large number of species of green vegetables are
used in agricultural communities, particularly those in which
food shortages are frequent. Due to the harsh climatic conditions
coupled with poor crop harvests Russian peasants were educated
on how to survive by relying on wild plants (Kovaleva, 1972).
Wild food plants became highest priority in the USSR
during the Second World War most notably during the siege
of Leningrad (1941–1944). In 1942 a special manual about
most important wild food plants of the Leningrad region
was published and distributed to the army and civilians. The
scientists from V.L. Komarov Botanical Institute described thirty
seven common herbs and two edible lichens, their nutritional
and functional properties, specificity of harvesting, and food
processing (Tikhomirov, 1942).
As a result of socio-economic changes after the SecondWorld
War, the active role of wild plants gradually diminished in regular
diet. However, some species are still gathered and made into
food products by small companies. Wild berry harvesting is very
popular especial among of rural populations. The practice of
preparing jam, compotes, and home made liqueurs from wild
berries has been passed down by housewives from generation to
generation (Grigorieva, 2008).
A wide choice of herbal medicines or botanicals has
provided increasing opportunities for both the development and
marketing of herbal food products, dietary supplements, and
functional foods.
Wild species were selected for food application by humans
not only because of their pleasant taste and aroma, but some
pharmacological effects were considered as well (Gammerman
and Grom, 1976). Herbal medicine products have become
popular over the past decade and they are widely used for
the treatment and prevention of various diseases. However,
safety and efficacy of herbal medicine should be confirmed.
Utilization of knowledge about positive pharmacological effects
of edible plants included in in a pharmacopeia is one
of probably safe and effective way for development of
functional products with new beneficial effects (Kunakova et al.,
2011).
Searching for new food supplements is essential. Systematic
explorations of pharmacopoeial plants are one particularly
relevant opportunity in Eastern Europe, especially in those
areas which, for historical reasons, remain relatively isolated.
The use and importance of Russian medicinal plants remains
largely unknown in the West. The aim of this review is to
summarize data about species that are referenced in the Russian
Pharmacopoeia and about their health food value with a primary
focus on literature published in Russian.
OVERVIEW OF SPECIES FROM THE
RUSSIAN PHARMACOPOEIA USED AS
FOODS
For centuries the multinational population of Russia has used
plants in daily diet and for self-medication. The beneficial effects
of plants were carefully collected by “knowledgeable experts”
(znahar = “знахарь”in Russian) and recorded in chronicles
and manuscripts. In 1778, Russia was among the first countries
to implement a national pharmacopeia: The Pharmacopoeia
Rossica in St. Petersburg. This work contains 770 monographs,
of which 316 texts are on herbal medicinal preparations (Shikov
et al., 2014a).
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Since 1990, the Russian Federation has followed the
State Pharmacopoeia of the USSR (1990) 11th edition.
This Pharmacopeia includes 83 individual monographs
for plants describing 119 species. There are 26 Rosaceae,
12 Compositae (syn. Asteraceae), eight Lamiaceae, six
Polygonaceae, four each of the Apiaceae, Betulaceae, Ericaceae,
and Malvaceae species, three representatives each of the
Solanaceae, Leguminosae (Fabaceae), and Plantaginaceae,
two species each of the Adoxaceae (Caprifoliaceae),
Asparagaceae (Liliaceae, s.l), Araliaceae Fagaceae, Gentianaceae,
Hypericaceae, Laminariaceae, Pinaceae, Rhamnaceae, and
Violaceae, and one member each of the Acoraceae (Araceae),
Brassicaceae, Caprifoliaceae (Valerianaceae), Crassulaceae,
Cucurbitaceae, Cupressaceae, Equisetaceae, Hymenochaetaceae,
Linaceae, Menyanthaceae, Myrtaceae, Papaveraceae, poaceae,
Polemoniaceae, Ranunculaceae, Rubiaceae, Saxifragaceae,
Schisandraceae, and Urticaceae, respectively.
In the most of monographs, just one species is described as
a source of plant material. However, 13 species are approved
for Fructus rosae, 11 species are approved for Fructus crataegi,
two species are approved for Herba hyperici, Fructus alni, Herba
violae etc. Different parts are described for Viburnum opulus L.
(Cortex viburni as diuretic and Fructus viburni as diaphoretic
and anti-inflammatory) and Crataegus (Flos crataegi−13 species
and Fructus crataegi−11 species for cardiovascular problems).
The large majority of species included in the Russian
Pharmacopoeia (98 out of 119) are known to have been used
as food by local population in Russia. For a majority of species,
the part of plant used in food and as a medicine is the same.
For example, the aerial parts of Origanum vulgare L., Thymus
serpyllum L., Leonurus cardiaca L., are used as a medicine and
as a food. Acorns and leaves of Quercus robur L. and Q. petraea
(Matt.) Liebl. are used in food, while oak bark is used as a
medicine. Fruits and bark of Viburnum opulus L. are used as
medicine, with only the fruits being edible. Roots and rhizomes
of Acorus calamus L., Taraxacum campylodes G.E.Haglund (syn.
Taraxacum officinale L.), and Aralia elata (Miq.) Seem. are used
as a medicine while young sprouts, leaves, flowers and fruits are
used in food. The aerial parts of Equisetum arvense L. are used
in medicine, while its cone-bearing shoots and black nodules
attached to the roots are eaten raw in spring.
In general, considering all 98 edible plant species in the
Russian Pharmacopoeia 11th edition, a higher number of plant
parts are used in nutrition as compared to medicine. In the
context of this article, the term “wild medicinal plants” referrings
mainly to non-cultivated species. Twenty one plants including
Calendula officinalis L., Eucalyptus viminalis Labill., Pimpinella
anisum L., Zea mays L., and some others do not occur in
Russia outside of cultivation and are excluded from this review.
All poisonous and toxic species are not used in food as such
as the species belonging to the Solanaceae (Atropa belladonna
L., Datura stramonium L., Hyoscyamus niger L.), Asparagaceae
(Convallaria majalis L., Convallaria keiskei Miq.), Rhamnaceae
(Frangula alnus Mill., Rhamnus cathartica L.), Ranunculaceae
(Adonis vernalis L.), Papaveraceae (Chelidonium majus L.) and
some species from the newly circumscribed Plantaginaceae
(Digitalis purpurea L., Digitalis grandifloraMill.).
Consumer andmarketing studies invariably showed that taste,
as opposed to perceived nutrition or health value is the key
influence on food selection (Drewnowski and Gomez-Carneros,
2000). Sensitized to the astringent taste of tannins or some bitter
poisons, humans reject foods that are perceived to be excessively
astringent or bitter. Polemonium caeruleum L. (Polemoniaceae),
Rubia tinctorum L. (Rubiaceae), Alnus incana (L.) Moench and
Alnus glutinosa (L.) Gaertn. (Betulaceae) are not considered to
be edible due to their taste, as well as Gnaphalium uliginosum L.
and Bidens tripartita L. (Asteraceae) which, however, are without
any strong taste.
Edible wild species included in the Russian Pharmacopoeia
have a wide range of uses: expectorant, diuretic, astringent,
haemostatic, bitterness and choleretic, anti-inflammatory,
diaphoretic, tonic, sedative, spasmolytic, polyvitamin,
cardiovascular, and antihelminthic (Table 1).
Plants with expectorant properties alleviate the symptoms of
patients in certain stages of bronchitis or tracheitis. Beneficial
expectorant effects are mentioned for nine edible wild species.
Certain edible species (nine species) are natural diuretics.
Astringent species (eight species) provide not only specific
taste for wine, tea, and other beverages due to high tannins
content, but are effective in stopping the flow of blood or other
secretions, and resolve diarrhea. Bitterness and choleretic herbs
(seven species) are useful for development of functional foods
with digestion-enhancing properties. The haemostatic effects
of herbs (six species) are often due to mechanisms such as
tannin astringency rather than enhancement of coagulation,
although there are a few haemostatic herbs have been shown
to reduce clotting times and have inhibitory effects on the
Platelet Aggregation Factor. Four species included in the Russian
Pharmacopoeia are used for their anti-inflammatory action.
In the last decades, so-called natural anti-inflammatory diets
have gained popularity (Sears, 2015). Diaphoretic herbs (four
species) induce involuntary perspiration and thus reduce fever,
promote circulation, relieve muscle tension, aching joints, and
inflammatory skin conditions. These herbs are used as well
to relieve diarrhea, dysentery, kidney nephritis, liver, urinary,
and gall bladder. Tonic herbs (four species) as supplement to
food are consumed throughout the world on a daily basis to
promote radiant health and are included in many beverages.
Motherwort and valerian provide mild sedative effects. The
species with spasmolytic effects (two species) are noticeable
as components of diets for treatment of gastro-intestinal
ailments.
Hawthorn berries and flowers are useful for the creation
of functional products with cardiovascular properties.
Antihelmintic properties of tansy are complementary to its
choleretic effects. The well documented anxiolytic effect of L.
cardiaca L. may lead to the development of antistress functional
food products. Increased access to information through
systematic evaluation of medicinal plants and its nutritional
properties will support the generation of ideas for functional
food with new value added properties.
Underground parts like roots, shoots and leafy greens, berries
and other fleshy fruits, seeds, and other species commonly yield
wild-harvested foods, a practice which is based on specialized
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cultural knowledge of their harvesting, preparation, cooking and
other forms of processing.
EDIBLE WILD PLANTS–APPROACHES
AND METHODS FOR ASSESSING USES
AND EVIDENCE
Based on the State Pharmacopoeia of the USSR, we selected
seventy wild species that are used as food in Russia and
systematically searched the scientific literature (published
between 1878-2016) for data using the Russia-wide applied
online database E-library.ru, library catalogs of public libraries
in St-Petersburg, the databases Scopus, Web of Science, PubMed,
and search engine Google Scholar. The primary search criterion
was a food application of medicinal plants.
Edible wild plants include food categories familiar to
everyone: green vegetables and potherbs, wild berries and fruits,
beverages, tea and coffee substitutes, seasonings and spices,
sweets, bread surrogates, plants used for preserves. Family names
of the species are based onwww.theplantlist.org database with the
names in the Russian Pharmacopoeia given in brackets (Table 1).
Also included are the applications in food.
Green Vegetables and Potherbs
This category includes the majority of examined plants.
Especially in the spring or at the beginning of their growing
season, many wild species produce tender, edible leaves and
shoots, and flowers at the beginning of flowering. Some,
like shepherd’s-purse (Capsella bursa-pastoris (L.) Medik.),
cornflower (Cyanus segetum Hill., syn. Centaurea cyanus L.), and
broadleaf plantain (Plantago major L.) can be eaten raw, after
being peeled from soil (Sokolov, 1985, 1990; Tcherepnin, 1987;
Grisjuk et al., 1989; Budantsev and Lesiovskaya, 2001; Turner
et al., 2011), whereas others, like stinging nettles (Urtica dioica
L.) must be steamed or cooked in some way (Litvintsev and
Koscheev, 1988; Fedorov, 1984; Toren, 1996). These plants are
used for salads, added to soups, borsch, omelets, cooked and used
as a garnish.
Many edible greens emerging right after the melting of snow
are particularly important for their vitamin C content in the
spring and traditionally have been used to prevent and alleviate
scurvy. In particularly, soup and borsch with nettles are popular
not only among rural but also many urban people (Gubanov
et al., 1976; Koscheev, 1981; Tcherepnin, 1987; Litvintsev and
Koscheev, 1988).
Tonic properties of shoots of aralia (Aralia elata (Miq.)Seem.)
were recognized by Ussuri aborigines (Far East). Young shots no
more than 20 cm are cooked and served as garnish (Izmodenov,
1989).
Wild Berries and Fruits
Presumably, wild berries and fruits are the most favored group of
edible medicinal plants in Russia, and today probably used most
frequently. The wild fruits most commonly collected in Russia
include bilberry (Vaccinium myrtillus L.), hawthorn (Crataegus
spp.), and rose hips (Rosa spp.) (Gubanov et al., 1976; Koscheev,
1981; Sokolov, 1987; Tcherepnin, 1987; Grisjuk et al., 1989;
Efremova, 1992; Budantsev and Lesiovskaya, 2001; Soenov, 2002;
Łuczaj et al., 2012; Sõukand et al., 2013; Novruzov, 2014). All
of them are consumed fresh, but some are also preserved for
the winter by making jams, marmalade or pasteurized compotes
(Turova and Sapozhnikova, 1989). Furthermore, they are used
to make beverages. Some berries are popular among all groups
of the population (like bilberry), other species that once were
used as a valuable food source in some regions of Russia have
seen that food use diminished because of the bitter or astringent
taste as such as guelder rose (Viburnum opulus L.), bird cherry
(Prunus padus L.), and rowan (Sorbus aucuparia L.) (Baikov,
1968; Rubtsov, 1971; Gubanov et al., 1976; Sokolov, 1985, 1990;
Tcherepnin, 1987; Grisjuk et al., 1989; Toren, 1996; Smertina
et al., 2011). The berries and seeds of Schisandra chinensis
(Turcz.) Bail. were eaten by Nanai (Goldes or Samagir) hunters
from Far Eastern Russia since “it gives forces to follow a sable
all the day without food” and were acclaimed as a tonic, to
improve night vision and to reduce hunger, thirst and exhaustion
(Panossian and Wikman, 2008).
Beverage
Aerial parts, leaves or flowers are used mainly for making
beverages, while the underground parts are used rarely. Aromatic
plants belonging to the Asteraceae and Lamiaceae are used
to sweeten or to flavor alcoholic and non-alcoholic beverages:
yarrow (Achillea millefolium L.), tansy (Tanacetum vulgare
L.), and oregano (Origanum vulgare L.) (Timoshenko, 1940;
Wustenfeld and Gesler, 1959; Koscheev, 1981; Berson, 1991;
Sokolov, 1991; Budantsev and Lesiovskaya, 2001; Soenov, 2002;
Kalle and Sõukand, 2012; Sõukand et al., 2013). Juicy fruits of
species belonging to the Rosaceae (rowan and bird cherry) are
used often for coloring of alcoholic beverages and giving a more
pronounced flavor. The fruits of these plants are used both in
home made alcoholic beverages as well as in wine- and brewing
industry for the production of liqueurs, bitters, wines, and beers
(Wustenfeld and Gesler, 1959; Gubanov et al., 1976; Koscheev,
1981; Tcherepnin, 1987; Toren, 1996; Budantsev and Lesiovskaya,
2001). Making liqueurs out of rowan berries seems to be an old
habit that has been in vogue in Russia (Timoshenko, 1940). The
aroma is an important attribute of refreshing soft drinks (kvass,
lemonade, and fruit morse), which are popular in the summer
season.
Tonic properties of ginseng and aralia were recorded in the Far
Eastern Russia by hunters and their roots were regularly added to
alcoholic and nonalcoholic beverages, and balsams (Grushvitsky,
1961; Zhuravlev and Kolyada, 1996; Budantsev and Lesiovskaya,
2001; Palagina et al., 2011; Palagina and Bogoutdinova, 2012).
Birch (Betula pendula Roth., and B. pubescens Ehrh.) sap
has been gathered all over Russia and was usually seen as a
refreshing drink (Fedorov, 1984; Tcherepnin, 1987; Budantsev
and Lesiovskaya, 2001). Today, Russia, Estonia, Latvia, Lithuania,
Ukraine and Belarus are the only countries where the gathering
and use of birch sap has remained an important. Large birch
forests, low population density and the incorporation of sap
into the former Soviet economic system facilitated this (Svanberg
et al., 2012). Birch sap was utilized the diverse ways as described
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by the Russian ethnographer Zelenin (1927). It was drunk fresh,
but also fermented by adding malt, wax, beans or rye bread.
Tea and Coffee Substitutes
After water, tea is the second most-consumed beverage
worldwide (Keating et al., 2015). Although the English term “tea”
generally denotes an infusion made of the leaves of Camellia
sinensis (L.) Kuntze, many herbal teas, which usually are mono-
or polyherbal formulations made from (medicinal) plant(s), are
available worldwide. Historically in Russia such herbal teas often
made from local species were widespread. Samovar and tea-
drinking are an indispensable element of Russian culture. With
C. sinensis not being available or affordable to the vast majority
of population, local surrogates/substitutes of tea have been used
for centuries. The best known tea surrogates were prepared
from fireweed (Epilobium angustifolium L.) and, in Siberia -
Bergenia spp. (Tcherepnin, 1987; Pohlebkin, 1998; Shikov et al.,
2006, 2014b; Sõukand et al., 2013). Prior to the introduction
of oriental (black or green) tea in Europe, E. angustifolium
was esteemed as the “original Russian tea” and used widely
throughout Russia and beyond (Litvintsev and Koscheev, 1988;
Sõukand et al., 2013). However, this botanical drug is not in
the Russian Pharmacopoeia. Extracts of black and fermented
leaves of B. crassifolia are reported as appetite and energy intake
suppressants (Shikov et al., 2012). Other species that are used
as substitutes for tea in Russia belong to different families. First
of all they are expected to bring delicious flavor, taste and nice
color to the tea. Marsh Labrador tea (Ledum palustre L.), thyme
(Thymus serpyllum L.), wormwood (Artemisia absinthium L.), are
highly aromatic. Aerial parts of Saint John’s wort (Hypericum
perforatum L.), oregano, thyme, leaves of lingonberry (Vaccinium
vitis-idaea L.), flowers of linden (Tilia cordata Mill. and T.
platyphyllos Scop.) are among the most popular components of
herbal teas in Russia (Krylov, 1972; Koscheev, 1981; Sokolov,
1985; Grisjuk et al., 1989; Efremova, 1992; Kalle and Sõukand,
2012). Dry fruits of rose hips, hawthorn, and rowan are used
as substitutes of tea (Gubanov et al., 1976; Tcherepnin, 1987;
Budantsev and Lesiovskaya, 2001). Ethnobotanical data also
lists dried and roasted rhizomes of dandelion (Taraxacum
campylodes G.E. Haglund), dry seeds of guelder rose, roasted
fruits of hawthorn, and fruits of R. canina L.as coffee substitutes
(Klobukova-Alisova, 1958; Vul’f and Maleeva, 1969; Koscheev,
1981; Sokolov, 1990, 1993).
Seasoning, Spices
Aromatic herbs are very important part of local gastronomy,
especial for seasoning and as spices in southern Russia. In
particular, sweet flag (A. calamus L.), valerian (Valeriana
officinalis L.), elecampane (Inula helenium L.) roots and
rhizomes, juniper (Juniperus communis L.), and caraway (Carum
carvi L.) fruits, dwarf everlast (Helichrysum arenarium (L.)
Moench) and tansy flowers, yarrow, oregano, thyme, and
artemisia aerial parts are normally used as aroma and flavor
enhancer or digestives (Sokolov, 1988, 1994; Berson, 1991;
Mashanov and Pokrovsky, 1991). These species are used both
in culinary preparations at home: they are added to the soups
and main dishes, salads, meats, bakery, as well as in the food
industry in the production of sausages, confectionery and bakery
products.
Sweets
The Russian make a kind of sweet flag and elecampane candied
peel by boiling the transverse root slices in syrup, and drying
(Gubanov et al., 1976; Koscheev, 1981; Berson, 1991). Candied
fruits of hawthorn, bird cherry, guelder rose are used as
sweetness (Gubanov et al., 1976; Koscheev, 1981; Tcherepnin,
1987; Budantsev and Lesiovskaya, 2001).
Bread Surrogates
In the eighteenth and the first half of the nineteenth century
flour and products like bread derived from it were the main
foods for Russian peasants. Consequently, every an extended
period of bad weather resulting in crop failure resulted in large-
scale famines. This explains why a vast variety of plant parts
was used for filling bread, including roots, fruits, leaves, and
barks. Roots and rhizomes of some plants are known to be good
sources of starch and carbohydrates. Powdered roots of Persicaria
bistorta (L.) Samp. were added to the rye flour for baking bread
(Rubtsov, 1971; Fedorov, 1984; Tcherepnin, 1987). Bergenia
rhizomes were eaten as a substitute for bread (Vereschagin et al.,
1959; Tcherepnin, 1987). Flour from black leaves of bergenia
is used for cookies (Bugdaeva et al., 2005). Roots of sweet flag
were used as source of starch (Berson, 1991). Whole or crushed
caraway seeds, dried and ground into flour fruits of hawthorn,
bird cherry, rowan, guelder rose were added to the pastry when
baking bread and sweet bakery (cakes and pancakes) (Gubanov
et al., 1976; Koscheev, 1981; Tcherepnin, 1987; Budantsev and
Lesiovskaya, 2001).
In the middle of nineteenth century, fruits of guelder rose
(Viburnum opulus) were popular in Tver province of Russia as
ingredients for making “kulaga,” a porridge based on malt flour.
Guelder rose fruits tenderized with flour and honey were “a tasty
cuisine and refined taste for urban residents, not excluding the
nobility” (Toren, 1996). Residents of Pskov province received the
nickname “kalinniki” because they cooked a delicious porridge
with guelder rose (“kalina” in Russian) berries and licorice flour,
which was sold at the bazaar (Toren, 1996).
Despite the fact that today wild bread additives have almost
completely disappeared from the European diet (Łuczaj et al.,
2012), in Russia some local bakeries produce bread and buns with
nettle, hawthorn, and dog rose.
Species Used in Preserves
Home made preserves have a long tradition in Russia because of
the long and severe cold season. There are many canning recipes
in every household for foods which have been handed down from
generation to generation. Plants used for preserves can be divided
into two large groups. Fresh juicy berries of rose hips, guelder
rose, rowan, bird cherry, and bilberry are widely used in jam,
comfiture, and marmalade. All these berries are useful for filling
pies (Klobukova-Alisova, 1958; Baikov, 1968; Gubanov et al.,
1976; Sokolov, 1985, 1990; Budantsev and Lesiovskaya, 2001;
Soenov, 2002). The second group includes species used as spices
and condiments for pickling and salting of cabbage, cucumbers,
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tomatoes and other vegetables, as well as mushrooms: caraway,
juniper, and thyme (Rubtsov, 1971; Gubanov et al., 1976;
Koscheev, 1981; Tcherepnin, 1987; Litvintsev and Koscheev,
1988; Grisjuk et al., 1989; Sõukand et al., 2013).
CONCLUSIONS
This review focuses on botanical drugs with a monograph in
the Russian Pharmacopoeia 11th edition and their potential
as untapped resources beyond their strictly medical uses. In
general, the Soviet period was characterized by the country
being closed not only from a political point of view, but
also scientifically. Most commonly, research output was only
available in Russian and not translated into English dramatically
restricting its availability to the international community. Here
such information published in Russian was evaluated focusing
on medicinal species from the Russian (Soviet) Pharmacopoeia
and used as a food. This highlights the importance of the Russian
Pharmacopoeia as a source of information on plant species used
traditionally at the interface of food and medicine.
Clearly our approach has the limitation of only focusing on
species included in the pharmacopeia and, consequently, local
or endemic species are mostly excluded. However, in the context
of developing high value products with potential health benefits
priority needs to be given to species which are widely available
and not at risk of being overexploited if the demand increases.
The evidence for the individual species varies, and while we
do not claim that their use could be, based on the current data,
evidence-based, the review provides a basis for further research
and development.
“Functional food” are foods that not only serve to provide
nutrition but also can be a source for prevention and cure of
various diseases. This review highlights the potential of wild
Russian species monographed in its pharmacopeia for further
developing new functional foods and—through the lens of their
incorporation into the pharmacopeia—showcases the species’
importance in Russia.
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Flower extracts of Prunus spinosa L. (blackthorn)—a traditional medicinal plant of Central
and Eastern Europe indicated for the treatment of urinary tract disorders, inflammation,
and adjunctive therapy of cardiovascular diseases—were evaluated in terms of chemical
composition, antioxidant activity, potential anti-inflammatory effects, and cellular safety
in function of fractionated extraction. The UHPLC-PDA-ESI-MS3 fingerprinting led to
full or partial identification of 57 marker constituents (36 new for the flowers), mostly
flavonoids, A-type proanthocyanidins, and phenolic acids, and provided the basis for
authentication and standardization of the flower extracts. With the contents up to 584.07
mg/g dry weight (dw), 490.63, 109.43, and 66.77 mg/g dw of total phenolics (TPC),
flavonoids, proanthocyanidins, and phenolic acids, respectively, the extracts were proven
to be rich sources of polyphenols. In chemical in vitro tests of antioxidant (DPPH, FRAP,
TBARS) and enzyme (lipoxygenase and hyaluronidase) inhibitory activity, the extracts
effects were profound, dose-, phenolic-, and extraction solvent-dependent. Moreover, at
in vivo-relevant levels (1–5µg/mL) the extracts effectively protected the human plasma
components against peroxynitrite-induced damage (reduced the levels of oxidative
stress biomarkers: 3-nitrotyrosine, lipid hydroperoxides, and thiobarbituric acid-reactive
substances) and enhanced the total antioxidant status of plasma. The effects observed
in biological models were in general dose- and TPC-dependent; only for protein nitration
the relationships were not significant. Furthermore, in cytotoxicity tests, the extracts did
not affect the viability of human peripheral blood mononuclear cells (PBMC), and might
be regarded as safe. Among extracts, the defatted methanol-water (7:3, v/v) extract
and its diethyl ether and ethyl acetate fractions appear to be the most advantageous
for biological applications. As compared to the positive controls, activity of the extracts
was favorable, which might be attributed to some synergic effects of their constituents.
In conclusion, this research proves that the antioxidant and enzyme inhibitory capacity
of phenolic fractions should be counted as one of the mechanisms behind the activity
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of the flowers reported by traditional medicine and demonstrates the potential of the
extracts as alternative ingredients for functional products supporting the treatment of
oxidative stress-related pathologies cross-linked with inflammatory changes, especially
in cardiovascular protection.
Keywords: Prunus spinosa, oxidative stress, antioxidants, human plasma, lipoxygenase, hyaluronidase,
polyphenols, LC-MS
INTRODUCTION
Medicinal plants as primary sources of natural bioactive
compounds are attracting growing interest as constituents of
functional products active in prevention and adjunctive therapy
of numerous chronic diseases, including cardiovascular disorders
(CVD), the leading cause of mortality in the world today. In the
search of new candidates for closer investigation, ethnobotanical
knowledge constitutes an important guideline indicating species
with the relevant activity (Franz et al., 2011).
One of such plants might be Prunus spinosa L. (blackthorn
or sloe)—a wild plume tree native to Europe, western Asia,
north-western Africa, and naturalized in New Zealand and
North America (Tutin et al., 1968). In European tradition it
has been known for over 7,000 years, at first as a source
of edible fruit and then also as a medicinal plant (Poonam
et al., 2011; Zohary et al., 2012), used i.a. in the treatment of
various circulatory system disorders. For medicinal applications
the plant has been used throughout Europe with the flowers
being the most popular in central and eastern parts of
the continent (Hoppe, 1981). Ethnopharmacological sources
indicate vasoprotective, anti-inflammatory, diuretic, detoxifying
(blood purifying), and spasmolytic activities for the flowers,
and document their use as ingredients of compound herbal
prescriptions traditionally applied, e.g., to treat intestinal and
respiratory tract disorders, but also various cardiac complaints,
such as myocarditis, cardiac neurosis and atherosclerosis
(Berger, 1949; Hoppe, 1981; Wawrzyniak, 1992; Blumenthal and
Busse, 1998). The fruits, according to German Commission
E, have been indicated mainly in mild inflammation of
the oral and pharyngeal mucosa, as well as an astringent
(Blumenthal and Busse, 1998); however, local European sources
report their use also as a heart-strengthening remedy (Kültür,
2007; Jaric´ et al., 2015). Branches, on the other hand, have
been more popular in the south of Europe and suggested
to possess anti-hypertensive properties (Calvo and Cavero,
2014).
Active components of the plant are believed to be polyphenols,
including flavonoids, A-type proanthocyanidins, anthocyanins,
coumarins, and phenolic acids, forming unique and diversified
profiles in particular organs, among which the flowers are the
least characterized (Kolodziej et al., 1991; Sakar and Kolodziej,
1993; Olszewska and Wolbis´, 2001, 2002a,b; Guimarães
et al., 2013; Pinacho et al., 2015; Owczarek et al., 2017).
Some blackthorn constituents, such as flavonoid pentosides
(arabinosides, xylosides, rhamnosides) and A-type procyanidin
dimers with twice-bonded structures are quite rare in nature
and their distribution is generally limited to selected species and
plant families (Pinacho et al., 2015). This unique composition
may correspond to the distinctive activity profile of P. spinosa
reported by traditional medicine. Indeed, the earliest studies
suggested that the flavonoid fraction of blackthorn flowers
significantly reduces capillary permeability and shows anti-
inflammatory effects in animal internal organs, normalizes
the blood cholesterol and cholesterol/phospholipid ratio in
atherogenic rabbits, exhibits spasmolytic effects on isolated
intestinal segments from different animals, and increases the
amplitude of heart contractions in perfusion of isolated frog
hearts (Lisevitskaya et al., 1968; Makarov, 1968, 1972; Makarov
and Khadzhaiˇ, 1969). However, despite these promising in vivo
and ex vivo results, the potential of blackthorn, especially the
blackthorn flowers, as a source of biologically active extracts
(that means standardized dry extracts—more effective than
unprocessed plant materials and recommended in modern
phytotherapy) remains unexplored, and the plant materials are
still used mostly in the form of traditional herbal teas, partly due
to the lacking molecular background for their activity and safety.
Recently, special attention has been given to the antioxidant
activity of the extracts from the branches, leaves, and fruits,
as one of the possible mechanism of action of the blackthorn
polyphenols (Barros et al., 2010; Guimarães et al., 2014; Pinacho
et al., 2015). Nevertheless, as these studies were based only on
simple, mostly chemical tests, and did not cover the flower
extracts, the subject requires more detailed investigations.
Polyphenols, including flavonoids, are specialized plant
metabolites, the beneficial effects of which in CVD is commonly
linked with their ability to influence two interdependent
pathological processes of oxidative/nitrative stress and
inflammation (Biswas, 2016). As free radical scavengers,
metal chelators, inhibitors of pro-inflammatory enzymes, and
modifiers of cell signaling pathways, polyphenols may protect
cellular and functional elements of the circulatory system against
lipid peroxidation, protein nitration, chronic inflammation, and
oxidative damage to DNA, which results i.a. in vasodilatory,
vasoprotective, anti-atherogenic, antithrombotic, and anti-
apoptotic effects (Alissa and Ferns, 2012; Quiñones et al., 2013).
Moreover, the reducing polyphenols and their metabolites can
increase the total antioxidant capacity of blood plasma and
thus the tolerance of body tissues against ischemic/reperfusion
injuries (Pandey and Rizvi, 2009).
Therefore, the aim of this project was a comprehensive
characteristic of the flowers of P. spinosa in a function of
fractionated extraction with respect to the chemical composition
and biological activity of the dry extracts obtained with solvents
of different polarity. Phenolic profiles of the extracts were
investigated by UHPLC-PDA-ESI-MS3, HPLC-PDA, and UV-
spectrophotometric methods, while their biological effects were
studied in vitro by nine complementary tests (both chemical and
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human plasma models) covering some of the main mechanisms
of the beneficial action of polyphenols in CVD, including
direct scavenging of free radicals, inhibition of pro-inflammatory
enzymes, enhancement of the total antioxidant capacity of
blood plasma and protection against oxidative and nitrative
damage of its lipid and protein components. Moreover, the
relationship between activity of the extracts and the presence
of different groups of polyphenolic constituents was explored
statistically. Additionally, cellular safety of the extracts was
evaluated in vitro in cytotoxicity tests against human peripheral
blood mononuclear cells (PBMCs).
MATERIALS AND METHODS
General
HPLC grade reagents and standards, such as 2,2-diphenyl-
1-picrylhydrazyl (DPPH); 2,2′-azobis-(2-amidinopropane)
dihydrochloride (AAPH); 2,4,6-tris-(2-pyridyl)-s-triazine
(TPTZ); (±)-6-hydroxy-2,2,7,8-tetramethylchroman-2-
carboxylic acid (Trolox R©); gallic acid monohydrate; chlorogenic
acid hemihydrate; caffeic acid; kaempferol; quercetin trihydrate;
isorhamnetin; rutin trihydrate; cyanidin chloride; indomethacin;
bovine testis hyaluronidase; lipoxygenase from soybean; linoleic
acid; 2-thiobarbituric acid; were purchased from Sigma-Aldrich
(Seelze, Germany/St. Louis, MO, USA), as were analytical
grade butylated hydroxyanisole (BHA); 2,6-di-tert-butyl-4-
methylphenol (BHT); Tween R© 40; xylenol orange disodium
salt; and Histopaque R©-1077 medium. HPLC grade solvents
(acetonitrile and methanol) used for UHPLC and HPLC analyses
were obtained from Avantor Performance Materials (Gliwice,
Poland). A (Ca2+)-free phosphate buffered saline (PBS) was
purchased from Biomed (Lublin, Poland). Peroxynitrite was
synthesized according to Pryor et al. (1995). All immunoreagents
for 3-nitrotyrosine detection were purchased from Abcam
(Cambridge, UK). Pierce BCA Protein Assay Kit was obtained
from Thermo Scientific (Waltham, MA, USA). All other
chemicals and solvents were of analytical grade and obtained
from Avantor (Poland). In all analyses redistilled water
was used. For chemical tests samples were incubated in
a constant temperature using a BD 23 incubator (Binder,
Tuttlingen, Germany) and measured using a UV-1601 Rayleigh
spectrophotometer (Beijing, China), in 10mm quartz cuvettes.
Activity tests in blood plasma models and enzyme inhibitory
assays were done using 96-well plates and a microplate reader,
SPECTROStar Nano (BMG LabTech, Ortenberg, Germany).
Plant Material and Extracts Preparation
Commercial samples of Prunus spinosa L. flowers were purchased
in 2015 (harvest in April 2015) from Dary Natury (Koryciny,
Poland). According to the manufacturer, the raw material was
collected in the district Rudka, Malopolska province (50◦02′N,
20◦52′E). The raw material was powdered with an electric
grinder, and sieved through a 0.315-mm sieve. A portion (100 g)
was extracted with chloroform (3 L, 30 h) in a Soxhlet apparatus
and the pellet was next four times refluxed with methanol-
water (7:3, v/v; 4 × 1 L) to give the defatted methanol extract
(MED, 27.3 g dw). The extraction solvent was selected from
methanol-water mixtures of different alcohol concentration after
optimization performed in terms of extracts yield and total
phenolic content (results not shown). The MED (25.0 g) was
suspended in water (1 L) and subjected to sequential liquid-
liquid extraction with organic solvents (8 × 100 mL each)
to yield diethyl ether fraction (DEF, 1.23 g dw), ethyl acetate
fraction (EAF, 4.00 g dw), n-butanol fraction (BF, 4.86 g dw) and
water residue (WR, 13.08 g dw). The organic solvent extracts
were evaporated in vacuo, and the water-containing fractions
were lyophilized using an Alpha 1–2/LD Plus freeze dryer
(Christ, Osterode amHarz, Germany) before weighing. In further
analyses freshly prepared solutions of the extracts in methanol-
water (7:3, v/v) were used. All quantitative results were calculated
per dry weight (dw) of the extracts.
Phytochemical Profiling
Qualitative LC-MS Study
The UHPLC-PDA-ESI-MS3 analysis was performed on UHPLC-
3000 RS system (Dionex, Dreieich, Germany) equipped with
a dual low-pressure gradient pump, an autosampler, a column
compartment, a diode array detector, and an AmaZon SL ion
trap mass spectrometer with an ESI interface (Bruker Daltonik,
Bremen, Germany). Separations were carried out on a Kinetex
XB-C18 column (1.7 µm, 150mm × 2.1mm i.d.; Phenomenex,
Torrance, CA, USA) at 25◦C. The mobile phase consisted
of solvent A (water/formic acid, 100:0.1, v/v), and solvent B
(acetonitrile/formic acid, 100:0.1, v/v) with the elution profile as
follows: 0–10 min, 6–13% B (v/v); 10–15 min, 13% B (v/v); 15–19
min, 13–15% B (v/v); 19–24 min, 15% B (v/v); 24–40 min, 15–
23% B (v/v); 40–55 min, 23–40% B (v/v); 55–60 min, 40% B (v/v);
60–63 min, 40–6% B (v/v); 63-70 min, 6% B (equilibration). The
flow rate was 0.3 mL/min. Before injection, sample solutions of
the extracts (3.0 mg/mL) were filtered through a PTFE syringe
filter (13mm, 0.2 µm, Whatman, Pittsburgh, PA, USA). UV-
Vis spectra were recorded over a range of 200–600 nm, and
chromatograms were acquired at 254, 280, and 350 nm. The
LC eluate was introduced directly into the ESI interface without
splitting and analyzed in both negative and positive ion modes.
ESI parameters: the nebulizer pressure was 40 psi; dry gas flow 9
L/min; dry temperature 300◦C; and capillary voltage 4.5 kV. MS2
and MS3 fragmentations were obtained in Auto MS/MS mode
for the most abundant ions at the time. Analysis was carried out
using scan from m/z 200–2,200.
Quantitative Standardization
The total phenolic contents (TPC) and total proanthocyanidin
contents (TPA) were quantified by the Folin-Ciocalteu and
n-butanol-HCl methods, respectively, as described previously
(Olszewska et al., 2012). Results were expressed as equivalents
of gallic acid (GAE) and cyanidin chloride (CYE), respectively.
The total flavonoid contents (TFA) were determined by HPLC-
PDA as the total content of flavonoid aglycones after acid
hydrolysis. Samples of the extracts (1–5 mg) were heated under
reflux for 30 min with methanol-water (9:1, v/v; 30 mL) and
25% (w/v) hydrochloric acid (9 mL). The hydrolysates were
diluted with methanol-water (7:3, v/v) to 50 mL, filtered through
a PTFE syringe filter (as above) and injected (5 µL) into
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the HPLC system. The HPLC-PDA assays were carried out
according to Olszewska (2012) with quercetin, kaempferol and
isorhamnetin used for external calibration. Results were re-
calculated for total contents of glycosides with the molecular
masses of avicularin, juglanin, and isorhamnetin diglucoside,
correspondingly. The total contents of phenolic acids (TAC) were
assayed by HPLC-PDA according to Olszewska et al. (2012) with
caffeic acid and chlorogenic acid used as calibration standards for
quantification of simple hydroxycinnamic acids and quinic acid
pseudodepsides, respectively.
Antioxidant Activity in Chemical Models
The DPPH free-radical scavenging activity was determined
according to the method optimized previously (Olszewska
et al., 2012) and expressed as normalized EC50 values
calculated from concentration-inhibition curves. The FRAP
(Ferric Reducing Antioxidant Power) was determined according
to Olszewska et al. (2012) and expressed in µmol of ferrous
ions (Fe2+) produced by 1 g of the dry extract or standard,
which was calculated from the calibration curve of ferrous
sulfate. The ability of the extracts to inhibit AAPH-induced
peroxidation of linoleic acid (LA) was assayed as described
previously (Olszewska et al., 2012) with peroxidation monitored
by quantification of thiobarbituric acid-reactive substances
(TBARS) according to the method of Kljak and Grbeša (2015)
with some changes. Briefly, before and after the samples
were incubated for 3 h at 50.0 ± 0.1◦C in the dark, the
reaction solution (0.5 mL) was mixed with 0.67% (w/w)
aqueous thiobarbituric acid (1 mL), 0.05M HCl (0.5 mL),
Tween R©40 (1 mL), and then heated for 30 min in the
water bath at 95◦C. The absorbance was measured at 535
nm vs. the control with methanol-water (7:3, v/v) instead
of the reaction mixture. The inhibition ratio (I%) of the
LA-peroxidation was calculated as follows: I% = (1Acontrol
− 1Asample)/1Acontrol, where 1A is the difference between
the absorbance measured before and after incubation. Finally,
antioxidant activity was expressed as IC50 values calculated from
concentration-inhibition curves.
Antioxidant Activity in Human Plasma
Models
Isolation of Blood Plasma and Preparation of
Samples
Blood from five healthy, non-smoking volunteers was
obtained from the Regional Centre of Blood Donation
and Blood Treatment in Lodz (Poland), collected on CPD
(citrate/phosphate/dextrose) solution in the Fresenius-Kabi
Compoflex bags, and next plasma was isolated by differential
centrifugation of blood (Kolodziejczyk-Czepas et al., 2013). All
experiments were approved by the committee on the Ethics of
Research at the University of Lodz 8/KBBN-UŁ/II/2015. For
the FRAP assay and measurements of 3-nitrotyrosine, plasma
samples were diluted with a (Ca2+)-free PBS buffer (1:4, v/v),
whereas for hydroperoxide and TBARS assays plasma was
diluted with (Ca2+)-free PBS in a volume ratio 1:1. For all tests,
samples were pre-incubated for 5 min at 37◦C with the examined
extracts added to the final concentration range of 1–50µg/mL,
and then exposed to 100 µM peroxynitrite (ONOO−). Control
samples were prepared with plasma untreated with the extracts
and/or peroxynitrite. In the experiments with blood plasma and
the extracts only (without adding ONOO−) no pro-oxidative
effect was found. Protein concentration in blood plasma was
estimated using bicinchoninic acid (BCA) assay (according to
protocol provided by the manufacturer).
Determination of 3-Nitrotyrosine in Human Plasma
Proteins
Detection of nitrotyrosine-containing proteins by the
competitive ELISA (C-ELISA) method in plasma samples
(control or antioxidants and ONOO−-treated plasma) was
performed according to Kolodziejczyk-Czepas et al. (2013). The
concentrations of nitrated proteins were estimated from the
standard curve and are expressed as the 3NT-Fg equivalents (in
nmol/mg of plasma protein).
Ferric-Xylenol Orange Hydroperoxide Assay
Concentration of hydroperoxides in plasma samples (control
or antioxidants and ONOO−-treated plasma) was determined
by a ferric-xylenol orange (FOX-1) protocol (Kolodziejczyk-
Czepas et al., 2013). The FOX-1 reagent contained 125 µM
xylenol orange and 100mM sorbitol in 25mM sulfuric acid, and
was freshly prepared each time before use by the addition of
ammonium ferrous sulfate to the final concentration of 250 µM.
To perform FOX-1 assay, blood plasma samples were mixed with
the reagent in a volume ratio 1:9 and incubated for 30 min in
the dark (25◦C). Absorbance of the sample was measured at
560 nm against blank (water instead of plasma). The amount of
lipid hydroperoxides was calculated from the standard curve of
hydrogen peroxide and expressed in nmol/mg of plasma proteins.
TBARS Test
Determination of thiobarbituric acid reactive substances
(TBARS) in plasma samples (control or antioxidants and
ONOO−-treated plasma) was performed according to
Kolodziejczyk et al. (2011). Results were expressed in µmol
TBARS/mL of plasma.
Ferric Reducing Ability of Plasma (FRAP) Assay
The influence of the extracts on the total antioxidant activity
of plasma (dependent on non-enzymatic antioxidants) was
determined according to Kolodziejczyk-Czepas et al. (2014) with
some modifications. The freshly collected plasma samples were
diluted with a (Ca2+)-free PBS buffer in a volume ratio of 1:4,
prepared as described above, and then added to the reagent
mixture in a volume ratio of 1:10:1:1 for plasma, acetate buffer
(300mM, pH 3.6), TPTZ (10mM, in 0.04M hydrochloric acid),
and ferric chloride (20mM), respectively. After incubation for 15
min at 37◦C, the measured FRAPs of plasma samples (control
or antioxidants and ONOO−-treated plasma) were expressed in
mM Fe2+ in plasma.
Inhibition of Pro-Inflammatory Enzymes
The ability of the extracts to inhibit lipoxygenase (LOX) and
hyaluronidase (HYAL) was examined as described by Michel
et al. (2017) with some changes. Briefly, in the LOX tests the
reagents were used in a volume ratio of 1:2:1 for working
solutions of the tested analyte, linoleic acid, and enzyme. Results
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of the both assays were expressed as IC50 values calculated from
concentration-inhibition curves.
Cell Viability Assay
PBMCs were isolated from human blood (obtained and collected
as described above) using the Histopaque R©-1077 medium (a
sterile solution of polysucrose, 57 g/L, and sodium diatrizoate,
90 g/L, with a density of 1.077 g/mL). From each of eight
donors, two independent PBMCs isolations and incubations
with the extracts were performed. Blood was carefully layered
(in a volume ratio of 1:1) onto the medium, and centrifuged
for 30 min (400 × g, at room temperature). Then, the pellet
was washed two times with 0.02M PBS buffer. The obtained
fraction of PBMCs was suspended in PBS. Cell suspensions (1
× 106 PBMCs/mL) were incubated with plant extracts, added
to the final concentration of 5µg/mL. Cell viability (%) was
determined during a spectrofluorimetric analysis, involving the
use of propidium iodide as a fluorescent dye. Measurements were
conducted using a microchip-type automatic cell counter Adam-
MC DigitalBio (NanoEnTek Inc., Seoul, Korea), after 60 and
120 min of incubation of PBMCs with the examined substances
(at 37◦C). The procedure was carried out according to the
manufacturer’s protocol.
Statistical Analysis
Normality of the distribution of the results was verified using the
Shapiro-Wilk test, and the homogeneity of variances using the
Levene’s test. The results are reported as means ± SD (standard
deviation) or ± SE (standard error) for the indicated number of
experiments. The significance of differences between samples and
controls was determined with one-way ANOVA (for chemical
tests) or one-way ANOVA for repeated measures (for human
plasma model), followed by the post-hoc Tukey’s test for multiple
comparisons. The correlations were evaluated using F-test. All
calculations were performed using the Satistica12Pl software for
Windows (StatSoft Inc., Krakow, Poland) with p-values less than
0.05 regarded as significant.
RESULTS
LC-MS Metabolite Profiling
Phytochemical profiling of the dry extracts revealed significant
differences in their chemical composition depending on the
extraction solvent (Figure 1, Tables 1, 2). The qualitative
UHPLC-PDA-ESI-MS3 analysis resulted in full or partial
identification of over fifty phenolic constituents (Figure 1,
Table 1, peaks 1–59) belonging to three main classes of
phytochemicals—flavonols (thirty eight analytes), flavan-3-ol
derivatives (catechins and proanthocyanidins, seven peaks)
and phenolic acids (twelve compounds). The analytes were
structurally characterized based on the comparison of their
chromatographic behavior and ESI-MS3 fragmentation patterns
(in positive and negative ionization modes) with the literature
data or reference standards, both commercial and isolated
FIGURE 1 | Representative UHPLC chromatograms of the P. spinosa flower dry extracts at 280 nm: (A) MED, defatted methanol-water (7:3, v/v) extract; (B) DEF,
diethyl ether fraction. Peak numbers refer to those implemented in Table 1.
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TABLE 2 | Quantitative standardization data for P. spinosa flower dry extracts.
Extract Total phenolicsa
TPC (mg GAE/g dw)
Total flavonoids (mg/g dw)b Total
proanthocyanidins
TPA (mg CYE/g
dw)c
Total phenolic acids
TAC (mg/g dw)d
Kaempferol Quercetin Isorhamnetin TFC
MED 206.07 ± 10.86B 62.47 ± 0.17B 19.30 ± 0.39B 1.47 ± 0.13B 125.12 ± 0.55B 45.13 ± 2.38B 29.24 ± 0.76C
DEF 464.57 ± 20.57D 259.68 ± 3.30E 61.14 ± 2.22E 5.16 ± 0.01D 490.63 ± 8.16E 49.5 ± 2.23B 8.76 ± 0.27A
EAF 584.07 ± 12.98E 158.69 ± 1.32D 53.21 ± 1.15D 4.57 ± 0.29C 325.53 ± 4.23D 109.43 ± 3.71C 17.20 ± 0.47B
BF 296.57 ± 3.28C 123.05 ± 1.99C 32.06 ± 1.26C 4.58 ± 0.03C 241.27 ± 4.74C 46.6 ± 1.14B 66.77 ± 2.86D
WR 64.6 ± 1.93A 0.80 ± 0.01A 0.38 ± 0.02A 0.06 ± 0.01A 1.88 ± 0.04A 12.43 ± 0.25A 17.71 ± 0.30B
Results are presented as mean values ± SD (n = 3) calculated per dry weight (dw) of the extract. For extract codes see Table 1. Different superscripts (capitals) in each column indicate
significant differences in the means at p < 0.05.
aValues expressed in gallic acid equivalents.
bValues expressed as the levels of individual aglycones released after acid hydrolysis, and TFC, total glycosides.
cValues expressed in cyanidine chloride equivalents.
dValues calculated as a sum of caffeic acid and chlorogenic acid equivalents.
previously in our laboratory from flowers and leaves of P. spinosa
(Olszewska and Wolbis´, 2001, 2002a,b; Owczarek et al., 2017).
The greatest chemical diversity was observed for the defatted
methanol-water (7:3, v/v) extract (MED), while its fractions
of diethyl ether (DEF), ethyl acetate (EAF), n-butanol (BF),
and water residue (WR) obtained after sequential liquid-liquid
partitioning were enriched in selected analytes, depending on the
fractionation solvent.
Compounds 1–4, 6–10, and 12–14 displayed absorption
maxima at 325 or 310 nm and UV-Vis spectra characteristic
of caffeic acid or p-coumaric acid derivatives, respectively.
According to the spectral profiles and hierarchical discrimination
key proposed by Clifford et al. (2003), the peaks showing
parent [M–H]− ions at m/z 353, 337, and 367 were identified
as isomeric caffeoylquinic acids (chlorogenic acids; 1, 4, 8),
p-coumaroylquinic acids (3, 10, 12), and feruloylquinic acids
(6, 14), correspondingly. The identity of chlorogenic acids was
additionally confirmed by experiments with standards, as was the
presence of simple caffeic (7) and p-coumaric acids (13) giving
the typical [M–H]− ions at m/z 179 and 163, respectively. The
same ions were found in MS2 spectra of compounds 2 and 9
after neutral losses of sugar moieties (–162 Da each), which led to
the tentative identification of hexosides of caffeic acid and ferulic
acid, respectively.
Peaks 5, 11, 16, 18, 28, 30, and 37 with UV maxima at
280 nm were classified as flavan-3-ols and proanthocyanidins.
Based on standard spiking and literature data, compounds
5 and 11 were characterized as (+)-catechin and (−)-
epicatechin, respectively. Compounds 16, 18, and 28 with
parent ions [M+H]+ at m/z 577 were classified as dimeric
A-type procyanidins. These compounds gave secondary ions
in MS2 spectra at m/z 559, 425, and 287. The ions at
m/z 425, arising from retro-Diels-Alder (RDA) fission of the
[M+H]+ (577–152 Da), and the ions at m/z 287 (577–290
Da) resulting from quinone methide (QM) fission, confirmed
the presence of two (epi)catechin units in the structures (Li
and Deinzer, 2008; Hamed et al., 2014). Compounds 16, 18,
and 28 were thus tentatively identified as (epi)catechin-A-
(epi)catechins. Two A-type proanthocyanidins of that kind
have already been isolated from the flowers of P. spinosa
and identified as ent-epicatechin-(4α→8;2α→O→7)-catechin
and ent-epicatechin-(4α→8;2α→O→7)-epicatechin (Kolodziej
et al., 1991). Compounds 30 and 37 with pseudomolecular
[M+H]+ ions at m/z 561 and ions in MS2 spectra at m/z 543,
409 and 271 were classified as dimeric A-type proanthocyanidins.
The mass difference between compounds 16, 18, 28, and 30,
37 was 16 Da, which indicated that in the latter molecules one
(epi)catechin unit is probably replaced by (epi)afzelechin, the
flavan-3-ol reported to occur in blackthorn flowers (Kolodziej
et al., 1991) and branches (Pinacho et al., 2015). m/z 409
(561–152 Da) arising from RDA fission of the [M+H]+ ion,
confirmed the presence of (epi)catechin in both compounds.
On the other hand, the product ions at m/z 271 (561–290
Da) resulting from QM fission of the [M+H]+ ions, showed
that the upper unit in both cases was (epi)afzelechin, and
hence the terminal unit must be (epi)catechin, m/z 287 (Li
and Deinzer, 2008; Hamed et al., 2014). The structures of
compounds 30 and 37 were thus tentatively identified as
(epi)afzelechin-A-(epi)catechin. Two proanthocyanidins of that
type, i.e., ent-epiafzelechin-(4α→8;2α→O→7)-epicatechin and
ent-epiafzelechin-(4α→8;2α→O→7)-catechin have previously
been isolated from blackthorn flowers (Kolodziej et al., 1991).
Peaks 15, 17, 19–21, 23–27, 29, 31–36, 38–54, and 56–59with
two UV-Vis maxima at 250–268 and 355–365 nm were classified
as flavonoids. Compounds 52 and 56 showed parent [M–H]−
ions at m/z 301 and 285, respectively, and were identified with
standards as free aglycones quercetin and kaempferol. Peaks 23,
26, 35, 36, 44, 47–49, 54, 57, and 59 with fragment ions in MS2
m/z 285 (typical for kaempferol) were identified with authentic
standards of kaempferol glycosides (Table 1). Compounds 15,
32, 33, 38, 42, 43, 45, and 46 were tentatively characterized
based on their fragmentation pattern as kaempferol mono- and
diglycosides. Peak 53 with parent [M–H]− ion at m/z 635 and
fragment ions at m/z 593, 285 in MS spectra was tentatively
identified as kaempferol acetyl hexoside-rhamnoside due to the
neutral loss of an acetyl moiety (−42 Da), hexose (−162 Da)
and rhamnose (−146 Da). Peaks 24, 25, 27, 31, 34, 39–41, and
50 with fragment ions in MS3 spectra at m/z 301 (typical for
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quercetin) were identified with standards of quercetin glycosides
(Table 1). Compound 21 with pseudomolecular [M–H]− ion at
m/z 595 and fragment ion at m/z 301 was tentatively assigned
to quercetin hexoside-pentoside. Peak 51 with parent ion at m/z
651 and fragment ions at m/z 609, 447, and 301 was determined
as a quercetin analog of 53, i.e., quercetin acetyl hexoside-
rhamnoside. Similarly, compound 58was tentatively identified as
an analog of 59, i.e., quercetin p-coumaroyl-pentoside, probably
quercetin 3-O-(2′′-E-p-coumaroyl)-α-L-arabinofuranoside, due
to the additional UV-Vis absorptionmaximum at 316 nm (typical
for an aromatic acyl unit), and the neutral loss of p-coumaroyl
moiety (−146 Da) and a pentose (−132 Da). Peak 17 gave the
parent ion at m/z 639 and its MS spectra revealed the cleavage of
two hexoses (−162 amu twice) and the aglycone signal consistent
with isorhamnetin, which enabled tentative identification of
isorhamnetin dihexoside.
Quantitative Standardization
According to the LC-MS findings, total contents of polyphenols
(TPC), flavonoids (TFC), proanthocyanidins (TPA), and
phenolic acids (TAC) were selected as standardization targets
(Table 2). The TPC levels assayed by the standard Folin-
Ciocalteu method and expressed in gallic acid equivalents (GAE)
varied in the range of 64.6–584.07 mg GAE/g dw of the extracts
with the highest values found for EAF (584.07 mg GAE/g dw)
and DEF (464.57 mg GAE/g dw). The total flavonoid content
(TFC) was determined by HPLC-PDA as a sum of flavonoid
aglycones released after acid hydrolysis of native extracts,
and recalculated on the dominant glycosides. With the levels
constituting 55.7–105.5% of the TPC values, flavonoids were the
dominant phenolic components of all extracts except WR, in
which phenolic acids prevailed. The highest TFC contents were
observed for DEF (490.63 mg/g dw) and EAF (325.53 mg/g dw).
As regards individual aglycones, kaempferol was the dominant
one and constituted 64.4–79.7% of the total aglycones. The
contents of quercetin and isorhamnetin were much lower and
constituted 18.8–30.9% and 1.6–4.7% of the sum of aglycones,
respectively. The total TPA, determined by the n-butanol-HCl
assay and expressed as cyanidin chloride equivalents (CYE),
ranged from 12.43 to 109.43 mg CYE/g dw, with the peak value
found again for EAF. Contrastingly, the highest level of phenolic
acids (TAC), assayed by HPLC-PDA, was observed for BF (66.77
mg/g dw), while in other extracts the TAC contents varied in the
range of 8.76–29.24 mg/g dw.
Antioxidative Effects in Chemical Models
All of the extracts showed significant and dose-dependent
antioxidant activity and ability to scavenge free radicals (DPPH,
a stable synthetic radical), directly reduce transition metal
ions (Fe3+, FRAP), and inhibit AAPH-induced linoleic acid
peroxidation (chemical model of lipid peroxidation) significantly
diminishing levels of thiobarbituric acid-reactive substances
(TBARS), with the final parameters strongly influenced by the
extraction solvent (Table 3). Regardless of the test, activity
of the extracts decreased in similar order, i.e., EAF ≥ DEF
> BF > MED > WR, and correlated with the amounts
of polyphenols (TPC) and flavonoids (TFC) in the samples
(Table 4). The strongest relationships were observed for the
FRAP test, whereas for the DPPH and TBARS assays, the
correlation coefficients were negatively influenced by WR, a
virtually flavonoid-free extract. If WR was excluded from the
data matrix, the impact of TPC (|r| > 0.91, p < 0.05) on the
antioxidant parameters of the other extracts was evident for
all tests (results not shown). In a comparison to the positive
standards, the antioxidant capacity of the most active extracts
EAF and DEF was higher (p < 0.05) or not statistically
different (p > 0.05) than that of an industrial antioxidant
BHT (DPPH and TBARS tests), and Trolox, a synthetic analog
of vitamin E (FRAP and TBARS tests). Moreover, if activity
parameters of the native extracts were recalculated to GAE
(Table 3) using the TPC values, the obtained antioxidant
capacities of the phenolic fractions constituting the dry extracts
were comparable to all of the positive standards except
quercetin.
Protective Effects on Human Plasma
Components
After demonstrating the promising antioxidant capacity in
chemical assays, the extracts were examined in terms of their
effects on human plasma exposed to oxidative stress induced
by peroxynitrite (ONOO−; 100 µM). In comparison to the
control (untreated) samples, the peroxynitrite-stimulated plasma
exhibited a considerably enhanced level (Figure 2A; p < 0.001)
of 3-nitrotyrosine in plasma proteins (3-NT-Fg, a marker of
protein nitration), a strong increase of lipid hydroperoxides
(ferric-xylenol orange assay, FOX-1) and thiobarbituric acid-
reactive substances (TBARS)—markers of lipid peroxidation
(Figures 2B,C; p < 0.001), as well as a noticeable decrease
(Figure 2D; p < 0.001) in ferric reducing ability (FRAP, a
marker of total antioxidant status of plasma). In plasma
samples incubated with ONOO− in the presence of the extracts
(at 1–50µg/mL), the rate of oxidative/nitrative damage was
significantly reduced (Figures 2A–C; p < 0.05). All tested
extracts effectively diminished the nitration of tyrosine residues
(Figure 2A; p < 0.001)—by about 15–50% and 36–54% at 1
and 50µg/mL, respectively. The impact of extraction solvent
on the anti-nitrative activity was less pronounced than that
observed in chemical tests; still, WR was again the least
effective at each concentration level (p < 0.05). Among the
other extracts, MED displayed the strongest activity (50–58%
decrease in tyrosine nitration); however, only the effects of
EAF, BF, and WR were dose-dependent (Figure 2A; p <
0.05). In consequence, the correlation between the percentage
inhibition of tyrosine nitration and the phenolic contents
(TPC, TFC, TPA, TAC) was not significant (Table 4). All of
the tested extracts exhibited also protective properties against
peroxynitrite-induced lipid peroxidation (Figures 2B,C; p <
0.001), regardless of the concentration level. In samples pre-
incubated with the medium extracts concentration (5µg/mL),
the levels of hydroperoxides and TBARS decreased by about
47–53% and 21–34%, respectively. The solvent effects were
negligible, although EAF at 50µg/mL was the most effective
antioxidant, able to reduce the peroxidation parameters by
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TABLE 3 | Antioxidant activity of P. spinosa flower dry extracts and standard antioxidants in DPPH, FRAP, and TBARS tests.
Analyte DPPH-Radical scavenging activity Ferric reducing antioxidant power LA-Peroxidation TBARS
EC50 (µg/mL)
a EC50 (µg GAE/mL)
b FRAP (mmol Fe2+/g)c FRAP (mmol Fe2+/g GAE)d IC50 (µg/mL)
e IC50 (µg GAE/mL)
d, f
MED 15.46 ± 0.38F 3.19 4.40 ± 0.10B 21.35 20.02 ± 1.95F 4.13
DEF 6.91 ± 0.22D 3.42 9.46 ± 0.04D,E 19.12 6.87 ± 0.59C,D 3.40
EAF 6.04 ± 0.07D 3.53 9.02 ± 0.11D 15.44 5.81 ± 0.40B,C 3.40
BF 11.79 ± 0.50E 3.50 6.15 ± 0.23C 20.75 11.34 ± 0.76E 3.36
WR 51.32 ± 0.93G 3.32 1.31 ± 0.04A 20.33 49.73 ± 2.05G 3.21
QU 1.63 ± 0.07A – 36.02 ± 1.1H – 1.85 ± 0.12A –
TX 4.34 ± 0.22C – 10.83 ± 0.32E – 8.47 ± 0.45C,D,E –
BHA 2.90 ± 0.14B – 16.13 ± 0.83F – 3.16 ± 0.22A,B –
BHT 6.54 ± 0.28D – 18.89 ± 0.42G – 9.31 ± 0.16D,E –
Results are presented as mean values (± SD for replicates, n= 3) calculated per dry weight of the extract or positive control (QU, quercetin; TX, Trolox; BHA; BHT). For extract codes see
Table 1. Different superscripts (capitals) in each column indicate significant differences in the means at p < 0.05. a,bScavenging efficiency (amount of antioxidant needed to decrease
the initial DPPH concentration by 50%) expressed as follows: a in µg of the dry extract or standard/mL of the DPPH solution; b in µg of phenolics/mL of the DPPH solution (values
obtained by converting the original EC50 values using the TPC levels).
cValues expressed per g of the dry extract or standard. dValues expressed per g of the phenolics (obtained by
converting the original FRAP values using the TPC levels). e,fLinoleic Acid (LA) Peroxidation test; inhibition concentration (amount of antioxidant needed to decrease the LA-peroxidation
by 50%) expressed as follows: e in µg of the dry extract or standard/mL of the LA solution; f in µg of phenolics/mL of the LA solution (values obtained by converting the original IC50
values using the TPC levels).
TABLE 4 | Correlation coefficients (r) and probability (p) values of linear relationships between antioxidant activity parameters and phenolic contents.
r (p) for: Antioxidant activity (chemical models) Antioxidant activity (human plasma model)
DPPH FRAP TBARS 3NT-Fg TBARS FOX-1 FRAP
TPC −0.8277 (0.084) 0.9721 (0.006)** −0.8696 (0.055) 0.5094 (0.052) 0.8657 (0.000)*** 0.7567 (0.001)*** 0.9877 (0.000)***
TFC −0.8122 (0.095) 0.9606 (0.009)** −0.8536 (0.066) 0.4733 (0.075) 0.7335 (0.002)** 0.6273 (0.012)* 0.9284 (0.000)***
TPA −0.7273 (0.164) 0.7586 (0.137) −0.7453 (0.148) 0.5084 (0.053) 0.9018 (0.000)*** 0.8001 (0.000)*** 0.9535 (0.000)***
TAC −0.1415 (0.820) −0.1517 (0.808) −0.1417 (0.820) 0.2173 (0.437) 0.4021 (0.134) 0.2125 (0.447) 0.5691 (0.021)*
Activity and concentration parameters according to Tables 2, 3, and Figure 2. Asterisks mean statistical significance of the estimated linear relationships (*p < 0.05, **p < 0.01,
***p < 0.001).
about 70% in FOX-1 and 45% in TBARS tests. The inhibitory
activity on lipid peroxidation was dose-dependent for all extracts
if measured by TBARS (Figure 2C; p < 0.05); however, in
the FOX-1 assay only some dose-effects for MED, DEF and
EAF were significant, i.e., differences observed between the two
lowest concentration levels (1–5µg/mL) and the highest dose
of 50µg/mL (Figure 2B; p < 0.05). Consequently, relatively
strong correlations (|r| > 0.73, p < 0.01) were observed between
the percentage of lipid peroxidation assayed by TBARS and
the phenolic contents (TPC, TFC, TPA), whereas the analog
relationships for FOX-1 test were weaker (|r| > 0.62, p <
0.01) (Table 4). All of the extracts were also able to normalize
and/or enhance the total antioxidant status of ONOO−-
treated plasma (FRAP), depending on the concentration used,
and only MED at 1µg/mL did not change significantly the
FRAP value of the oxidized plasma (Figure 2D; p > 0.05).
For all other extracts, a significant improvement in the
plasma reducing ability was observed with the increase up
to about 190% vs. the ONOO−-stimulated plasma and 140%
vs. the control sample for EAF at 50µg/mL (Figure 2D; p
< 0.001). Strong dose-dependency of the analytical response
was found, and thus strong relationships (|r| > 0.92, p <
0.001) between the percentage increase in the FRAP values
of the oxidized plasma and the TPC, TFC, and TPA levels
(Table 4).
Simultaneously, the ONOO−-treated plasma was incubated
with 5µg/mL of standard phenolics (Figures 2A–D). In contrast
to results of the chemical tests, in the plasma model the
pure compounds were merely comparable or inferior to the
blackthorn extracts in terms of the antioxidant activity. For
instance, the range of percentage inhibition of tyrosine nitration
achieved for the standards (ca. 11–34%) was lower than for
the extracts (ca. 19–58%) applied at the same concentration
of 5µg/mL (Figure 2A). Moreover, the activity of MED and
EAF at 5µg/mL was significantly higher (p < 0.001) than
that of all standards. Furthermore, quercetin—the strongest
antioxidant in chemical models—counteracted the plasma
nitration significantly less effectively than all extracts (Figure 2A;
p < 0.001). Similar trend was observed for ONOO−-induced
lipid peroxidation, both with FOX-1 detection—only rutin
exhibited protective activity comparable to that of the extracts
at 5µg/mL (Figure 2B; p > 0.05), and with TBARS test—
overlapped ranges of percentage inhibition of peroxidation were
found for the standards (ca. 26–32%) and the extracts (21–34%)
at 5µg/mL (Figure 2C; p > 0.05). Only in the FRAP assay, two
of the standards—quercetin and chlorogenic acid—enhanced the
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FIGURE 2 | Effects of P. spinosa flower dry extracts on human plasma exposed to oxidative stress: (A) effects on the nitration of tyrosine residues in plasma proteins
and formation of 3-nirotyrosine, 3-NT-Fg; effects on the peroxidation of plasma lipids including formation of lipid hydroperoxides, LOOH (B), and thiobarbituric
acid-reactive substances, TBARS (C); (D) effects on ferric reducing ability of plasma, FRAP. Results are presented as means ± SE (n = 10) for repeated measures:
###p < 0.001 for control plasma vs. ONOO−-treated plasma (without the extracts); **p < 0.01, ***p < 0.001 for ONOO−-treated plasma in the presence of the
extracts (1, 5, or 50µg/mL) or standards (5µg/mL) vs. ONOO−-treated plasma in the absence of the extracts. Standards: RT, rutin; QU, quercetin; TX, Trolox; CHA,
chlorogenic acid.
reducing ability of plasma more strongly than the extracts at the
corresponding concentration (Figure 2D; p< 0.001).
Inhibitory Effects on Pro-Inflammatory
Enzymes
The extracts inhibited the activity of lipoxygenase (LOX)
and hyaluronidase (HYAL) in a dose-dependent manner, but
with different responses toward particular enzyme (Table 5).
Considering the IC50 values expressed in µg/U, the extracts
were stronger inhibitors of LOX than HYAL. In both tests the
strongest effects observed for EAF and DEF were intermediate
between those of phenolic standards and indomethacin, a strong
nonsteroidal anti-inflammatory drug. The inhibitory activity
toward both enzymes was strongly correlated with the TPC levels
(|r| > 0.88, p < 0.05). The responses in the LOX test were also
strongly TFC-dependent (r = −0.8868, p < 0.05), while in the
HYAL assay this relationship was noticeable (r = −0.8691) but
not significant (p= 0.056).
Influence on Cells Viability
The potential cytotoxicity of the extracts was evaluated in a
model of PBMCs after 60 and 120 min of incubation with the
extracts at 5µg/mL. Cellular safety of the extracts was evidenced
by the lack of significant differences (p > 0.05) in cell viability
observed between PBMCs incubated with the extracts (85.6–
90.5% viability) and the control (untreated) samples (87.85–90.85
viability), regardless of the incubation time and extraction solvent
(Figure 3).
DISCUSSION
As beneficial for human health, including prevention of CVD,
polyphenol-rich extracts are widely used in the preparation of
dietary supplements and pharmaceuticals (Franz et al., 2011).
Extraction from natural matrices is thus the crucial step in
their utilization as it affects extract composition, activity, and
yield. Generally, alcohol and alcohol-water mixtures are the
best extractants for low-molecular-weight polyphenols of high
antioxidant potential and good bioavailability (Manach et al.,
2005). The crude extracts are often fractionated to remove fat-
soluble ballast substances (chlorophylls and waxes) and thereby
purify and concentrate the phenolic fractions (Rana et al.,
2016). The results from the present study confirmed these
observations: the defatted methanol-water (7:3, v/v) extract from
the blackthorn flowers (MED), demonstrated to be a rich source
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TABLE 5 | Inhibitory activity of P. spinosa flower dry extracts on lipoxygenase
(LOX) and hyaluronidase (HYAL).
Analyte LOX HYAL
IC50 (µg/mL)
a IC50 (µg/U)
b IC50 (µg/mL)
a IC50 (µg/U)
b
MED 327.36 ± 5.93F 7.85 51.74 ± 2.16E 23.00
DEF 150.36 ± 4.47C 3.60 21.40 ± 0.76B 9.51
EAF 135.36 ± 5.55B 3.25 21.27 ± 0.16B 9.45
BF 171.10 ± 1.36E 4.11 42.23 ± 0.99D 18.77
WR 479.50 ± 3.38G 11.50 121.72 ± 5.73F 54.10
QU 89.23 ± 2.13A 2.14 30.78 ± 1.84C 13.65
RT 162.70 ± 3.70D 3.90 54.63 ± 2.61E 24.23
CHA 166.83 ± 7.15D,E 4.00 28.59 ± 1.21C 12.68
IND 92.60 ± 3.71A 2.22 12.77 ± 0.91A 5.66
Results are presented asmean values± SD (n= 3) calculated per dry weight of the extract
or positive control (QU, quercetin; RT, rutin; CHA, chlorogenic acid; IND, indomethacin).
For extract codes see Table 1. Different superscripts (capitals) in each column indicate
significant differences in the means at p < 0.05. a,b Inhibition concentration (amount of
analyte needed for 50% inhibition of enzyme activity) expressed as follows: a in µg of the
dry extract or standard/mL of the enzyme solution; b in µg of the extracts/enzyme unit (U).
FIGURE 3 | Viability of peripheral blood mononuclear cells (PMBCs) after 60
and 120 min of incubation with P. spinosa flower dry extracts at 5µg/mL.
of phenolic compounds, could be further enriched by liquid-
liquid partitioning with organic solvents (Table 2). The TPC in
the richest fractions EAF and DEF, as determined by the Folin-
Ciocalteu (FC) assay, were comparable to those found in the
extracts considered important in CVD prevention, for instance
in commercial ethanol extracts of grape seed (ca. 630–670 mg
GAE/g dw) (Baydara et al., 2004) or in ethyl acetate fractions
of green tea and green mate (ca. 480–580 mg GAE/g dw) (Erol
et al., 2009). The previous literature data referring to P. spinosa
are limited to studies on fruits, branches, and leaves. According
to Pinacho et al. (2015), the highest TPC level quantified by
the Prussian Blue method (PB) was found for ethanol fraction
from branches (732.34 mg GAE/g dw), followed by those from
fruits (359.11 mg GAE/g dw) and leaves (228.56 mg GAE/g
dw). Despite some differences in chemistry of the PB assay
in comparison to the standardized FC test, in the preliminary
studies focused on selection of the plant material for the present
work, we have observed the magnitude of phenolic levels to some
extent similar, which enables ordering of the blackthorn tissues in
respect to the TPC values as follows: branches > flowers > fruits
≥ leaves. Therefore, the flowers were found promising for further
studies.
The present paper is the first presenting comprehensive LC-
MS profile of P. spinosa flowers (Figure 1, Table 1). The previous
studies aimed at isolation and resulted in structure elucidation
of 16 flavonoids (Sakar and Kolodziej, 1993; Olszewska and
Wolbis´, 2001, 2002a) and five proanthocyanidins (Kolodziej
et al., 1991), the presence of which was now confirmed in
the flower dry extracts. In addition, 36 constituents, mainly
flavonoids, and phenolic acids, were reported here for the
first time for the blackthorn flowers (Table 1). With nearly
60 components detected, in contrast to only 25 observed in
the leaves (Owczarek et al., 2017), 26 in branches (Pinacho
et al., 2015), and 29 in fruits (Guimarães et al., 2013), the
phenolic matrix of the flowers is obviously the most complex.
A distinctive qualitative feature of the flower extracts is a vast
diversity of the flavonoid fraction (thirty seven peaks). While
according to Owczarek et al. (2017) flavonoids prevail also in
the leaf samples, only 14 structures have been detected in this
organ. The branches and fruits of P. spinosa may be in turn
distinguished by the presence of numerous proanthocyanidins
(twelve peaks in branches) and anthocyanins (eight peaks in
fruits), respectively (Guimarães et al., 2013; Pinacho et al., 2015).
In phytotherapy, the blackthorn flowers are indeed recognized as
a flavonoid herbal product (Hoppe, 1981; Poonam et al., 2011).
High content of flavonoids found in the present study and their
prevalence in flower dry extracts (Table 2), were in agreement
with these findings. In addition to flavonoids, the analyzed
extracts contained moderate levels of proanthocyanidins and
phenolic acids (Table 2). The TPA level of MED is in accordance
with the results reported recently by Ropiak et al. (2016) for
aqueous acetone extracts of blackthorn flowers (40 mg/g dw). As
indicated in the latter paper, the average degree of polymerization
of flower procyanidins is 2.9, which means that the majority
of TPA fraction is within the bioavailable range of molecular
masses (Manach et al., 2005). Thus, the composition of the
flower extracts of blackthorn appears promising in the context
of CVD and potential industrial application. Regular intake
of flavonoids with the diet or supplements is associated with
reduced risk of cardiovascular episodes and mortality (Alissa
and Ferns, 2012). In in vivo studies, they have been shown
to improve antioxidant status, exert anti-atherosclerotic and
anti-atherothrombotic effects in early stages of atherosclerosis
development (e.g., decrease LDL oxidation), modulate lipid
metabolism (e.g., normalize LDL/HDL profile), improve capillary
permeability (vasoprotective effects) and endothelial function,
and increase nitric oxide release (vasodilatory effects) (Middleton
et al., 2000; Alissa and Ferns, 2012). As the most common
group of polyphenols in the human diet, flavonoids are also
regarded as safe in internal applications. Like flavonoids, both
low-molecular-mass proanthocyanidins and phenolic acids have
been shown to modulate lipid metabolism, increase plasma
antioxidant capacity, improve vascular functions, and reduce
platelet activity in humans (Manach et al., 2005).
As antioxidant activity of polyphenols is one of the most
important aspects of their beneficial effects in CVD (Middleton
et al., 2000; Alissa and Ferns, 2012; Quiñones et al., 2013;
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Santilli et al., 2015) we decided to verify it in complementary
chemical and biological models that reflect various direct and
complex mechanisms. Although simple chemical in vitro assays
are hardly relevant to in vivo conditions, they enable preliminary
screening for potential mechanisms and comparison with the
literature data. In the present study, we employed three the most
frequently used tests of both single electron transfer (DPPH,
FRAP) and hydrogen atom transfer basic mechanisms (TBARS)
to explore direct interactions of the extracts with free-radicals
and transition metal ions as well as to study some of these effects
in a model of lipid peroxidation. The results demonstrated that
the flower extracts are potent and universal antioxidants, and
that their dose-dependent activity is determined by the contents
of phenolics, primarily flavonoids, and strongly influenced
by the fractionation solvent (Tables 3, 4). Also the extracts
produced from other organs of P. spinosa have recently been
reported effective DPPH scavengers, as well as inhibitors of
lipid peroxidation (Guimarães et al., 2014; Pinacho et al., 2015).
Comparing our results to those of Pinacho et al. (2015) and in
terms of capacity of BHA after 60 min of incubation, it seems that
the activity of flower extracts (EAF, DEF) is comparable to that of
branches, and superior to those of leaves and fruits. Moreover,
the comparison of our results from TBARS assay and the results
obtained by Guimarães et al. (2014) in terms of activity of Trolox,
shows that the lipid peroxidation inhibitory activity of flower
extracts (EAF, DEF) is higher than that of phenolic-enriched
extracts from wild fruits. On the other hand, the outcomes from
DPPH test suggest similar scavenging activity for flower and fruit
extracts.
To give a more accurate approximation of the possible in
vivo effects of the flower extracts, we extended the in vitro
study to the model of human plasma exposed to oxidative
stress. The stress conditions were induced by peroxynitrite
(ONOO−), a powerful oxidative and nitrative species, generated
in vivo by the reaction of nitric oxide (NO) and superoxide
anion (O•−2 ), and involved in the pathophysiology of various
inflammatory, neurodegenerative, and especially cardiovascular
disorders including atherosclerosis, myocardial infarction and
chronic heart failure (Ronson et al., 1999). The concentration of
ONOO− used in our in vitro study (100µM) enables quantitative
measurements of the changes induced in plasma components
and corresponds to its levels in vivo, that can be reached in
local compartments in the conditions of accelerated production
of NO and O•−2 , e.g., during a serious inflammation of blood
vessels, when its synthesis can increase up to 50–100 µM/min
(Szabo et al., 2007). During the study, the plasma samples were
pre-incubated with the extracts at the levels of 1–50µg/mL,
equivalent to 0.06–29.2 µg GAE/mL, depending on the extract.
From the physiological point of view, the concentrations of
phenolic substances that are likely to occur in blood plasma
in vivo after oral supplementation can reach up to 5–7 µM,
depending on the foodmatrix (Manach et al., 2005). For example,
it has been reported that 100-mg dose of quercetin from onions
and 150-mg dose of pure isoquercitrin (quercetin-3-glucoside)
resulted in the concentrations up to 7.6 and 5 µM in plasma,
respectively, which is an equivalent of 1.5–2.3µg/mL of quercetin
(Hollmann, 2004; Manach et al., 2005). It has also been suggested
that the bioavailability of kaempferol and its glycosides, the
dominant flavonoids of blackthorn flowers according to our
results, is higher than that of quercetin (DuPont et al., 2004).
Therefore, the lower levels of the extracts (1–5µg/mL) used in the
study appear to closely correspond to the range of physiological
level of plant-derived phenolic compounds available after oral
administration. In accordance with the common practice of in
vitro studies (Kolodziejczyk et al., 2011; Kolodziejczyk-Czepas
et al., 2013, 2014), the extracts were studied also at 50µg/mL
to enable that of observation of all possible effects of their
interaction with peroxynitrite.
The results from biological model confirmed our hypothesis
that antioxidant activity of the P. spinosa flower extracts may be
crucial in understanding their beneficial effects in CVD in vivo.
The analyzed extracts not only enhanced the total antioxidant
status of the ONOO−-treated plasma but also effectively reduced
the levels of well-known oxidative stress biomarkers—products
of protein nitration (3-nitrotyrosine) and lipid peroxidation
(hydroperoxides and TBARS) (Figure 3). In CVD patients, the
increased levels of these biomarkers are good predictors of
cardiovascular events and are correlated with prothrombotic,
proatherogenic, and pro-inflammatory intravascular effects,
plaque instability, and endothelial dysfunctions (Lee et al., 2012;
Thomson, 2015). The mechanism of action of the blackthorn
extracts in the protection of plasma proteins and lipids probably
involves a direct scavenging of peroxynitrite or/and secondary
radicals formed in the induced chain reactions. It is consistent
with the noticeable scavenging potential of the extracts toward
the model radical (DPPH), and with the accumulating evidence
of anti-radical effects of polyphenols against ONOO− and
ONOO−-related radicals operating in plasma, such as O•−2 , NO,
•NO2,
•OH, etc. (Heijnen et al., 2001). Despite some arguments
being presented for the impact of blackthorn polyphenols
on the target activity in plasma, the differences between the
examined extracts were not as evident as in the case of chemical
tests. The discrepancies may be an effect of complexity and
ontogenetic diversity of blood plasma, as well as differences
in the sensitivity to ONOO− between the plasma samples.
Some interactions between endogenous plasma constituents and
blackthorn phenolics could also be the reason. On the other
hand, the complexity of the extracts and synergic effects of their
individual components are probably behind the superior activity
profile revealed by the extracts comparing to the pure standards.
Finally, it is of note that all beneficial effects of the extracts
on plasma were measurable at physiological concentrations (1–
5µg/mL), which do not deteriorate the viability of PBMCs and
may be regarded as safe.
Pathogenesis of CVD covers, apart from oxidative stress,
also a closely related process of inflammation (Biswas, 2016).
To evaluate the potential anti-inflammatory effects of the
blackthorn extracts, we decided to study their impact on two
model pro-inflammatory enzymes. The first belongs to the
family of lipoxygenases, enzymes catalyzing dioxygenation of
polyenoic fatty acids in biological membranes and lipoproteins,
and producing key chemokines and ROS, such as leukotrienes
and O•−2 , associated with the development of oxidative
stress-related inflammatory pathologies of CVD, e.g., myocardial
infarction/reperfusion injury (Schneider and Bucar, 2005). The
second one—hyaluronidase—is a spreading factor increasing
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tissues (i.a. vascular) permeability during the inflammatory
processes by degrading hyaluronan, an anti-inflammatory
extracellular matrix component (Girish et al., 2009). Both
enzymes are targets of many synthetic drugs used in anti-
inflammatory therapies, but it has been shown that plant extracts,
especially those containing phenolics, can also significantly
inhibit their activity (Schneider and Bucar, 2005; Piwowarski
et al., 2011). Indeed, the investigated extracts, rich in polyphenols,
were found to be inhibitors of both enzymes (Table 5).
The activity of the most active fractions was between those
of the commercial agents—indomethacin (nonsteroidal anti-
inflammatory drug) and rutin (flavonoid vasoprotective agent),
while the basic methanol-water extract was slightly less
active. However, with the results of antioxidant activity tests,
these findings suggest that the extracts might influence both
interdependent processes of oxidative stress and inflammation.
CONCLUSIONS
This work is the first comprehensive phytochemical and activity
study of the flower extracts of P. spinosa. The detailed LC-MS
patterns presented here can be recommended as reference
fingerprints useful in authentication and standardization
studies of blackthorn flowers and flower extracts. Distinct
phenolic profiles, significant antioxidant effects comparable to
or surpassing the activity of pure phenolics in both chemical
and biological models, noticeable inhibitory effects on pro-
inflammatory enzymes, and cellular safety suggest that
the investigated extracts may be promising candidates for
the production of pharma- and nutraceuticals effective in
cardiovascular protection. Considering both the yield and the
activity, the defatted methanol-water (7:3, v/v) extract and
its diethyl ether and ethyl acetate fractions appear to be the
most advantageous for biological applications. As the observed
capacities might be considered as some of the mechanisms
behind the activity of blackthorn phenolics within the circulatory
system, the present study forms a basis for their further studies
in the context of CVD. For instance, the demonstrated protective
effects of the extracts against ONOO−-induced changes in
plasma components and ability to inhibit pro-inflammatory
enzymes might be cross-linked with their possible anti-
atherogenic, anticoagulant, and antiplatelet functions or ability
to influence endothelium, which should be addressed in future
research.
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Modern treatment strategies provide better overall survival in cancer patients, primarily
by controlling tumor growth. However, off-target and systemic toxicity, tumor recurrence,
and resistance to therapy are still inadvertent hurdles in current treatment regimens.
Similarly, metastasis is another deadly threat to patients suffering from cancer. This has
created an urgent demand to come up with new drugs having anti-metastatic potential
and minimum side effects. Thus, this study was aimed at exploring the anti-proliferative
and anti-metastatic potential of colocynth medicinal plant. Results from MTT assay,
morphological visualization of cells and scratch assay indicated a role of ethanol and
acetone extracts of fruit pulp of the colocynth plant in inhibiting cell viability, enhancing
cell cytotoxicity and preventing cell migration in various cancer cell types, including
breast cancer cell lines MCF-7 and MDA-MB-231, and cervical cancer cell line SiHa,
subsequently having a low cytotoxic effect on mononuclear PBMC and macrophage
J774A cells. Our study in metastatic MDA-MB-231 cells showed that both ethanol and
acetone pulp extracts decreased transcript levels of the anti-apoptotic genes BCL2
and BCLXL, and a reverse effect was observed for the pro-apoptotic genes BAX and
caspase 3. Additionally, enhanced caspase 3 activity and downregulated BCL2 protein
were seen, indicating a role of these extracts in inducing apoptotic activity. Moreover,
MDA-MB-231 cells treated with both these extracts demonstrated up-regulation of the
epithelial gene keratin 19 and down-regulation of the mesenchymal genes, vimentin,
N-cadherin, Zeb1 and Zeb2 compared to control, suggesting a suppressive impact of
these extracts in epithelial to mesenchymal transition (EMT). In addition, these extracts
inhibited colony and sphere formation with simultaneous reduction in the transcript
level of the stemness associated genes, BMI-1 and CD44. It was also found that
both the plant extracts exhibited synergistic potential with the chemotherapeutic drug
doxorubicin to inhibit cancer viability. Furthermore, GC-MS/MS analysis revealed the
presence of certain novel compounds in both the extracts that are responsible for the
anti-cancer role of the extracts. Overall, the results of this report suggest, for the first
time, that colocynth fruit pulp extracts may block the proliferative as well as metastatic
activity of breast cancer cells.
Keywords: cancer, colocynth, cell death, apoptosis, cell viability, epithelial to mesenchymal transition, metastasis
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INTRODUCTION
Cancer constitutes a group of deadly diseases that is not only
the second leading cause of death worldwide, but also largely
contributes to the global health economic burden. The World
Health Organization (WHO) has estimated over 14.1 million
cancer cases and 8.2 million cancer-induced deaths worldwide
in 2012, and this number is expected to rise catastrophically
in the coming decades (Torre et al., 2015). Breast and cervical
cancers are the most frequently diagnosed cancers in females
nationwide, accounting for about 1.7 million new cases and
521,900 breast cancer deaths in 2008 (Torre et al., 2015). India
infamously boasts of a surmounting 27 and 23% breast and
cervical cancer incidence respectively1. Cervical cancer is the
second most diagnosed cancer and third leading cause of deaths
in females, accounting for about 527600 new cases and 265700
deaths (Torre et al., 2015).
Cancer is predominantly caused due to abnormalities in the
genome (Balmain et al., 2003) and epigenome (Feinberg and
Tycko, 2004) due to exposure to various damaging agents. This
set of accumulated cells that has escaped the normal regulatory
control mechanisms undergoes unchecked proliferation to
form tumors. Despite several advancements in recent years,
contemporary anticancer therapy suffers from several limitations
owing to their associated toxicity and off-target effects. This
provokes an urgent need to design novel drugs with high efficacy
specific for cancer cells and less toxicity to off-target cells.
Phytochemicals have shown promise in this regard as they fit
the above criteria, and their usage in anticancer therapy is an
emerging trend.
Citrullus colocynth (L.) is a valuable cucurbit plant, widely
distributed in the desert areas of the world, including India,
known to possess nutritional values and diverse medicinal
activities, including antibacterial, antifungal, larvicidal and
anti-inflammatory properties (Sawaya et al., 1986; Marzouk et al.,
2010; Chawech et al., 2017). Literature documents the presence
of many bioactive compounds, such as cucurbitacin, phenolic
acids, flavonoids, pyridine and quinolone type alkaloids and
fatty acids in fruits of these herbal plants (Hussain et al., 2013,
2014; Jeon and Lee, 2014). This plant is traditionally used to
control diabetes (Shi et al., 2014). Recent clinical trial studies have
witnessed a fall in fasting blood glucose and Hb1Ac, triglyceride
and cholesterol in case of colocynth users (Rahbar and Nabipour,
2010; Barghamdi et al., 2016). Intriguingly, a study by Tannin-
Spitz et al. (2007) documented cancer specific apoptotic activity
of the isolate cucurbitacin, extracted from this plant. However,
no study has yet been conducted to explore the effect of colocynth
extract in cancer metastasis. Thus, this study was primarily aimed
at investigating the unexplored anti-metastatic potential of this
plant extract.
This study testified that ethanol and acetone fruit pulp
extracts exhibited impressive inhibition of cell viability and
cell migration of various cancer cell types, including breast
and cervical cancer cells with considerably less effect on
mononuclear cells and macrophage cells. Moreover, these pulp
1breastcancerindia.net
extracts noticeably hindered colony and sphere formation
and epithelial to mesenchymal transition (EMT) of metastatic
breast cancer MDA-MB-231 cells. Our GC-MS analysis also
reveals some unique compounds, which may account for the
anticancer activity of the extracts. The current study is the
first report advocating that fruit pulp extracts containing the
novel compounds may have anti-metastatic potential along with
apoptotic activity.
MATERIALS AND METHODS
Materials
Verso cDNA synthesis kit (AB1453A, Thermo Scientific), TRIzol
Reagent (T9424, Sigma Aldrich), Taq Polymerase (MBT060A,
Himedia), ready Mix dNTP (MBT078, Himedia), caspase-3
antibody (#9661, Cell signaling), BCL-2 antibody (SC-7382,
Santa Cruz Technology), actin antibody (A02066, Sigma
Aldrich), WesternSure-Premium Chemiluminescent substrate
(WesternSure-Li-COR-Part No: 926-95000).
Cell Lines
The human breast cancer MDA-MB-231 (metastatic) and MCF-7
(non-metastatic) cell lines, and cervical cancer SiHa cell line
were procured from NCCS cell repository, Pune, India. J774A
cell (Macrophage cell line) was obtained from Dr. Vijay Kumar
Prajapati, Department of Biochemistry, Central University of
Rajasthan, India. All cells were cultured in Dulbecco’s Modified
Eagles Medium (DMEM), supplemented with 10% fetal bovine
serum (FBS) (RM1112, Himedia) and maintained at 37◦C in a
humidified incubator with 5% CO2.
Isolation of Human Mononuclear Cells
(PBMC)
Mononuclear cells were isolated from human peripheral blood
by using a simple and rapid density gradient centrifugation
technique using Ficoll-Paque (Sigma-F5414-50ML) methodology
established by Boyum (1968) and Boyum (1976). The isolation
was done according to the manufacturer’s protocol. Cells
(0.5 × 105 cells) were seeded in 96 well culture plate in DMEM
supplemented with 10% FBS and incubated for overnight at
5% CO2, and treated with increasing concentration (mentioned
in other cell lines ) by ethanolic and acetone plant extracts
respectively for 24 h. Blood samples from two healthy volunteers
were taken and mixed before isolation of PBMC. Written consent
was obtained from the participants, and they were informed
about the use of blood in this study. Moreover, the work related
to blood samples had been conducted by following the regulation
of Institutional Ethical Committee at Central University of
Rajasthan and, this study was approved by Institutional Ethical
Committee.
Plant Extracts
The plant Citrullus colocynth was obtained from a rural area of
India [Jaisalmer (26.9157◦ N, 70.9083◦ E), Rajasthan, India]. The
taxonomic name of this plant had been confirmed by Dr. Amit
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Kotia, Department of Botany, University of Rajasthan, India. The
pulp was isolated from fruits, dried and crushed, using a mixer
grinder. One gram of dried pulp powder was suspended in 10 ml
of ethanol and acetone, followed by solvent extraction at 50◦C
for 72 h. The solvent fractions were evaporated using a rotary-
evaporator at 42◦C to get the crude products. The crude extracts
obtained were then dissolved in ethanol and acetone and kept at
−20◦C for further use.
MTT Cell Viability Assay
Cell viability was measured by MTT assay (MB186, Himedia)
described earlier (Ghosh-Choudhury et al., 2010; Mehta et al.,
2015). In brief, cancer cells (5000 cells/well) were seeded in 96
well tissue culture plate in DMEM supplemented with 10% FBS
at an atmosphere of 5% CO2 at 37◦C. After 24 h of seeding,
cells were separately incubated with different concentrations
[25, 100, and 250 µg/ml; equivalent to 1, 4, and 10 µl of
solvents (ethanol/acetone)] of fruit pulp ethanol extract (PEE)
and pulp acetone extract (PAE) for 24 h. Control cells were
similarly incubated with equal volume of the solvents as in the
experimental wells. At the end of the incubation period, 10 µl of
MTT solution (5 mg/ml) was added to each well and the plate
was incubated at 37◦C for 1 h. The formazan crystals formed
were solubilized by adding DMSO, and subsequently, absorbance
was measured at a wavelength of 530 nm (Studzinski, 1995;
Moongkarndi et al., 2004; Ghosh-Choudhury et al., 2010; Mehta
et al., 2015). The effective absorbance was calculated for the
experimental wells with respect to corresponding control wells.
LC50 (Lethal concentration at which 50% cells are killed) at 24 h
duration was calculated using MTT data set for different cancer
cell lines (Zhang et al., 2007).
Scratch Assay
Cell migration was determined by scratch assay as described
earlier (Mandal et al., 2010b, 2011b). In brief, cells (2 × 105
cells/plate) were seeded in 35 mm tissue culture plates and
allowed to grow till they reach 95% confluency. A cell scratch-
wound was generated using a micropipette tip, and washed once
with PBS buffer to remove the floating cells. Cells were then
separately treated with PEE and PAE (25 µg/ml) for 24 h in
experimental plates, and equal volume of respective solvents
was added in control plates. Cells were visualized under an
inverted microscope (Carl-Zeiss), and cell migration was assessed
by measuring gap sizes in multiple fields and the relative area
calculated using ImageJ, and statistically analyzed (Hirsch et al.,
2009).
RT-PCR Analysis
Transcript levels of several genes were measured by
semi-quantitative RT-PCR analysis as described previously
(Mandal et al., 2010a; Chowdhury et al., 2017). In brief, breast
cancer cells (2 × 105 cells/plate) were plated in 35 mm tissue
culture plates in DMEM supplemented with 10% FBS at an
atmosphere of 5% CO2 at 37◦C. After 90-100% cell confluency
is reached, the cells were treated with different test factors
(such as PEE and PAE (50 µg/ml)) for 24 h. Total RNA was
extracted using TRIzol reagent as described earlier (Mandal
et al., 2010a, 2011a, 2016a; Ghosh-Choudhury et al., 2013). First
stand cDNA synthesis was performed using 1 µg of total RNAs
using the Verso cDNA synthesis kit, according to manufacturer’s
instruction. Semi-quantitative PCR was performed using this
cDNA as template and gene specific primers in a ProFlex PCR
system (Applied Biosystem by Life Technologies). The list of
primers used in this study is given in Supplementary Table S1.
Densitometric analysis of the PCR bands was done using
ScnImage (Chowdhury et al., 2017).
Western Blot Analysis
Methodology of western blotting has been described previously
(Chowdhury et al., 2017). In brief, cells were seeded at a density
of 2 × 105 cells/plate in 35 mm tissue culture plates. Cells were
treated with different test factors and harvested after 24 h of
treatment. Protein extraction was carried out in RIPA buffer and
subsequently, cell lysates were centrifuged at 12,000 × g at 4◦C
for 20 min. The protein concentration was measured by Bradford
reagent (BIORAD), according to manufacturer’s instruction.
Equal amounts of whole cell lysates were resolved by 12%
SDS-PAGE, and transferred to PVDF membrane. This PVDF
membrane was incubated with primary antibody (Anti-caspase-3
antibody (#9661, Cell signaling), Anti-BCL-2 antibody (SC-7382,
Santa Cruz Technology), Anti-actin antibody (A02066, Sigma
Aldrich) used at 1:1000 dilution) overnight at 4◦C. After
washing, the PVDF membrane was further incubated with
HRP-conjugated secondary antibody (used at 1:10000 dilution)
for 1 h at room temperature. The washed membrane was further
incubated with chemiluminescent substrate and subsequently,
the blot was scanned by C-DIGIT Blot Scanner (Li-COR-Model:
3600).
Colony Formation Assay
Cells were seeded at a density of 500 cells/well in a 12 well tissue
culture plate in DMEM with 10% FBS at 37◦C incubator with
5% CO2 for 24 h. Cells were then treated with PEE and PAE
extracts (25 µg/ml), and incubated under same conditions for
5 days. Next, colonies were fixed with methanol and were stained
with crystal violet solution (Hirsch et al., 2009). Photographs
of stained plate were taken by a camera. Photographs of
colonies were also taken by a bright field inverted microscope
(Carl-Zeiss).
Soft Agar Sphere Formation Assay
For performing soft agar assay (Sebolt-Leopold et al., 1999),
MDA-MB-231 cells (10,000 cells/plate) were mixed with 2X
DMEM containing 0.6% (w/v) agar and layered with 2X DMEM
containing 1.2% base agar medium in 35 mm culture plates.
25 µg/ml of PEE and PAE was added in 300 µl of DMEM to the
top agar and cells were allowed to grow for 8 days. The top 300 µl
medium was replaced with fresh medium with or without test
factors at intervals of every 3 days. The morphology and size of
the spheres were visualized using bright field inverted microscope
(Carl-Zeiss) and photographed. Subsequently, spheres were
manually counted under the microscope.
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FIGURE 1 | Effect of fruit pulp ethanol extract of colocynth on cell viability and cytotoxicity of breast and cervical cancer cell lines. Cell viability was measured by MTT
assay after 24 h of treatment of breast cancer MDA-MB-231 (A) and MCF-7 (B), and cervical SiHa (C) cell lines with pulp ethanol extract (PEE) with different
concentrations (25–250 µg/ml). Values represent mean ± SE of triplicate measurements, ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 vs. control. (D–F) Morphologic
visualization (cytotoxicity) was recorded after 24 hr of treatment of breast cancer MDA-MB-231 (D) and MCF-7 (E), and cervical SiHa (F) cell lines with PEE
(100 µg/ml). Photographs were taken at 10X magnification.
GC-MS/MS Analysis
Solvent Extraction of Citrullus colocynthis fruit pulp was done by
ethanol and acetone. Dried extracts were dissolved in methanol
followed by GC-MS/MS analysis using Thermo GC 1300 and
“TSQ 8000” Triple quadrupole GC-MS/MS SYSTEM with auto
sampler Al 1310. The Gas Chromatography 1300 was used with
a fused GC column TG-5MS AMINE. The column length was of
30 m with an internal diameter coated film of 0.25 µm, with the
flow rate of 10 ml/min and the condition kept were as follows:
PTV Temp. Program: 70◦C, hold 2.00 min, 10◦C/min to 270◦C,
hold 8 min. Carrier gas helium flow rate was 1 ml/min and split
ratio of 1:50. GC was equipped with an auto sampler AI 1300
and sample volume loaded was 1 µl. Eluates were automatically
passed into the mass spectrometer. Mass Spectrum analysis was
conducted using TSQ-8000 with a transfer line temperature
of 280◦C and ion source temperature of 230◦C in EI mode.
Mass scan time was 4 min with feature of full Scan MS. The
mass spectrum was also equipped with a computer fed NIST mass
Spectra data library.
Component Identification
Chemical constituents of the extracts were identified by matching
the peaks with Computer NIST MS libraries and confirmed by
comparing mass spectra of the peaks and those from literature.
List of 50 compounds isolated from the extracts are listed in
Supplementary Tables S2, S3. Scifinder was used to analyze
the compounds and thus interpret the literature available for
them.
Statistical Analysis
Statistical analysis was done by GraphPad Prism (Ghosh-
Choudhury et al., 2010; Mandal et al., 2011a,b, 2016b). A p-value
of < 0.05 was considered to be statistically significant. All values
were represented as mean ± standard error mean of three
measurements.
RESULTS
Effect of Colocynth Fruit Pulp Extracts
on Viability of Breast and Cervical
Cancer Cells
To test the anticancer potential of colocynth fruit pulp extracts
(prepared separately by solvent ethanol and acetone), cell viability
was measured by MTT assay. For this, different cancer cells,
including breast cancer cell lines, MCF-7 and MDA-MB-231,
and cervical cancer cell line, SiHa, were separately treated with
increasing concentrations (range 25–250 µg/ml) of PEE and
PAE for 24 h (Figures 1A–C, 2A–C). MTT assay result showed
noteworthy reduction in the number of viable cells in a dose
dependent manner for both PEE and PAE treatment when
compared to their respective solvent controls. To determine the
effectiveness of the pulp extracts in these cancer cells, LC50 values
(using MTT data) were also calculated. In case of ethanol extract,
LC50 (µg /ml) values were 142± 16, 105± 8.3 and 157± 4.3 for
MDA-MB-231, MCF-7 and SiHa cell lines respectively (Table 1).
For acetone extract, these values were 140 ± 0.8, 94 ± 6.4
and 121 ± 4.6 respectively. These findings indicated relatively
higher efficacy of PAE in cancer cell lines compared to PEE.
Moreover, MCF-7 cells showed higher sensitivity to both PAE
and PEE as compared to MDA-MB-231 cells. LC50 values of both
the extracts in PBMC and J774A cell line were >300 µg /ml
(Table 1). Furthermore, microscopic visualization indicated a
cytotoxic effect of the extracts upon these cancer cell lines
(Figures 1D–F, 2D–F). All these findings suggested that the
fruit pulp extracts induced reduced viability of cells that is
presumably caused by inhibiting cell proliferation and inducing
cytotoxicity.
To examine the influence of these pulp extracts on cell
apoptosis, RT-PCR analysis was performed to compare the
transcript levels of anti-apoptotic BCL2 and BCLXL and
apoptotic BAX genes, using total RNA of MDA-MB-231
Frontiers in Pharmacology | www.frontiersin.org September 2017 | Volume 8 | Article 593300
fphar-08-00593 September 1, 2017 Time: 16:33 # 5
Chowdhury et al. Colocynth Extracts: EMT and Stemness
TABLE 1 | Cytotoxic effect [LC50 (µg/ml)] of Citrullus colocynthis pulp extracts against two breast cancer (MDA-MB-231 and MCF-7), a cervical cancer (SiHa) cell lines, a
human mononuclear cell PBMC and a macrophage cell J774A.
LC50 (µg/ml) ± SEM
Cancer cell lines Normal cell lines
Solvents (extraction) MDA-MB-231 MCF-7 SiHa PBMC J774A
Colocynth fruit pulp Ethanol 142 ± 16 105 ± 8.3 157 ± 4.3 >300 >300
Acetone 140 ± 0.8 94 ± 6.4 121 ± 4.6 >300 >300
Values represent mean ± SEM of three independent experiments.
FIGURE 2 | Effect of fruit pulp acetone extract of colocynth on cell viability and cytotoxicity of breast and cervical cancer cell lines. MTT assay was performed to
measure cell viability by after 24 h of treatment of breast cancer MDA-MB-231 (A) and MCF-7 (B), and cervical SiHa (C) cell lines with pulp acetone extract (PAE)
with different concentrations (25–250 µg/ml). Values represent mean ± SE of triplicate measurements, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001, vs. control.
(D–F) Morphologic visualization (cytotoxicity) was recorded after 24 h of treatment of breast cancer MDA-MB-231 (D) and MCF-7 (E), and cervical SiHa (F) cell lines
with PAE (100 µg/ml). Photographs were taken at 10X magnification.
cells with or without treatment with ethanol and acetone
extracts (50 µg/ml). Both PEE and PAE considerably impeded
BCL2 and BCLXL expression with simultaneous upsurge in
BAX expression (Figures 3A–D and Supplementary Figures
S1A–C,E–G). Moreover, expression of apoptotic caspase 3
gene was augmented upon treatment with both PAE and
PEE (Figures 3E,F and Supplementary Figures S1D,H).
Furthermore, western blot results demonstrated increased
level of cleaved caspase 3 (Figures 3G,H) with a concomitant
decrease in the protein level of anti-apoptotic gene BCL2
(Figures 3I,J) for both ethanol and acetone extract treated cells
compared to control. These observations led us to propose
an apoptotic activity of fruit pulp extracts in breast cancer
cells.
Inhibitory Effect of Colocynth Pulp
Extracts on Cancer Cell Migration
A common problem faced by a large percentage of cancer patients
is development of metastasis if cancers are not detected in
early and/or not treated with a suitable therapy. Migration of
cancer cells is a critical step in the metastatic cascade (Chaffer
and Weinberg, 2011). Thus, we investigated the effect of pulp
ethanol and acetone extracts on the migratory property of
cancer cells by performing scratch assay. Scratches were made
on cell monolayer by a small pipet tip, and subsequently, cells
were incubated with or without pulp extracts. Microscopic
photos indicated migration of cells to close the induced scratch
after 24 h in control MDA-MB-231, MCF-7 and SiHa cells
(Figures 4A–C, 5A–C). Cells treated with both ethanol and
acetone extracts (25 µg/ml) showed substantial prevention of
cell migration as evident from the unfilled gap areas between
the two ends of the scratches that were larger in cases of
pulp extracts as compared to control. The data displayed in
Figures 4D–F, 5D–F denoted a significant inhibition of cell
migration in response to treatment with both ethanol and acetone
extracts.
Effect of Colocynth Pulp Extracts on
EMT
Transition from epithelial to mesenchymal phenotype is a critical
step for metastasis (Chaffer and Weinberg, 2011). To examine the
effect of fruit pulp extracts on prevention of EMT of metastatic
MDA-MB-231 cells, we analyzed mRNA levels of several EMT
markers by RT-PCR. Interestingly, we observed a decline in
expression of mesenchymal markers, Vimentin and N-cadherin,
with a concurrent increase in the expression of epithelial marker
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FIGURE 3 | Effect of fruit pulp extracts on anti-apoptotic and apoptotic genes in MDA-MB-231 cells. (A) Cells were separately treated with pulp ethanol extract
(PEE) (A,C,E,G) and pulp acetone extract (PAE) (B,D,F,H) for 24 h, and subsequently expression of anti-apoptotic genes (A,B) BCL2 and BCLXL, and pro-apoptotic
genes BAX (C,D) and Caspase 3 (E,F) were measured by RT-PCR analysis, using total RNA isolated from cells with or without PEE and PAE treatment, and gene
specific primers. Here, GAPDH was used as an internal loading control. Densitometric analysis data are given in Supplementary Figure S1. (G,H) Level of cleaved
caspase 3 and (I,J) BCL-2 was measured by western blotting using equal amount of cellular protein isolated from cells with or without treatment with PEE or PAE.
B-actin serves as an internal loading control.
keratin-19 in treated samples (Figures 6A,B and Supplementary
Figures S2A–C,F–H). Moreover, both PEE and PAE treatment
strongly inhibited expression of the mesenchymal phenotype
inducing transcription factors, Zeb1 and Zeb2 (Figures 6A,B
and Supplementary Figures S2D,E,I,J). These observations clearly
indicate a restraining impact of these pulp extracts on EMT of
breast cancer cells.
Colocynth Pulp Extracts Inhibited
Stemness Property of Breast Cancer
Cells
Accumulating evidences suggest that cancers develop from
cancer initiating cells or cancer stem cells (CSCs) (Reya et al.,
2001; Singh and Settleman, 2010). Although CSCs comprise of
a small percentage of the tumor population, their resistance
to contemporary chemo- and radiation- therapy is a leading
cause for tumor recurrence and metastasis (Li et al., 2007;
Singh and Settleman, 2010). Thus, we investigated the effect of
colocynth pulp extracts on the stemness property of metastatic
MDA-MB-231 cells by colony formation assay. In agreement
with previous observations, the number of colony formed was
markedly reduced when cells were treated with pulp extracts
(25 µg/ml) as compared to control, indicating an inhibitory
role of both PEE and PAE on cancer stemness (Figures 7A–D).
To further support these results, we carried out soft agar
sphere formation assay. Microscopic visualization documented
formation of a great number of spheres with large size after
8 days of cell culture in the control plates. The number
as well as the size of such spheres was, however, greatly
diminished when cells were incubated with both PAE and PEE
(25 µg/ml) as compared to control (Figures 8A–D). These
results show that fruit pulp extracts might attenuate stemness
property of cancer cells. To verify these findings, we further
examined the effect of these pulp extracts on the expression of
stemness associated genes CD44 and BMI-1. RT-PCR analysis
documented that transcript levels of both CD44 and BMI-
1 genes (Al-Hajj et al., 2003; Liu et al., 2006) were significantly
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FIGURE 4 | Pulp ethanol extract inhibited migration of breast and cervical cancer cells. Breast cancer MDA-MB-231 (A), MCF-7 (B) and cervical cancer (SiHa) (C)
cells were treated with pulp ethanol extract (PEE) for 24 h. Photos of cells at the starting time point and after 24 h of treatment were captured by inverted bright field
microscope. The unfilled gap areas between two ends of the scratch were measured and subsequently plotted. Significant inhibition of cell migration was observed
in case of PEE treated plates wells as compared to control in MDA-MB-231 (D), MCF-7 (E) and SiHa (F) cancer cell lines. Percent inhibition by PEE after 24 h was
calculated with the 0 h being the control. Values represent mean ± SE of triplicate measurements. In (D) ∗∗∗∗p < 0.0001; control (ethanol) 24 h vs. control (ethanol)
0 h and ∗∗∗∗p < 0.0001; PEE 24 h vs. control 24 h. In (E) ∗∗∗∗p < 0.0001; control (ethanol) 24 h vs. control (ethanol) 0 h and ∗∗∗∗p < 0.0001; PEE 24 h vs. control
(ethanol) 24 h. In (F) ∗∗p < 0.01; control (ethanol) 24 h vs. control (ethanol) 0 h and ∗∗p < 0.01; PEE 24 h vs. control (ethanol) 24 h.
FIGURE 5 | Pulp acetone extract inhibited migration of breast and cervical cancer cells. Breast cancer MDA-MB-231 (A), MCF-7 (B) and cervical cancer (SiHa) (C)
cells were treated with pulp acetone extract (PAE) for 24 h. Photos of cells at the starting timepoint and after 24 h of treatment were captured by inverted bright field
microscope. The unfilled gap areas between two ends of the scratch were measured and subsequently plotted. Significant inhibition of cell migration was observed
in case of PAE treated plates wells as compared to control in MDA-MB-231 (D), MCF-7 (E) and SiHa (F) cancer cell lines. Percent inhibition by PAE after 24 h was
calculated with the 0 h being the control. Values represent mean ± SE of triplicate measurements. In (D) ∗∗∗∗p < 0.0001; control (acetone) 24 h vs. control (acetone)
0 h and ∗∗∗p < 0.001; PAE 24 h vs. control (acetone) 24 h. In (E) ∗∗∗∗p < 0.0001; control (acetone) 24 h vs. control (acetone) 0 h and ∗∗∗∗p < 0.0001; PAE 24 h vs.
control (acetone) 24 h. In (F) ∗∗p < 0.01; control (acetone) 24 h vs. control (acetone) 0 h. and ∗∗p < 0.01; PAE 24 h vs. control (acetone) 24 h.
lowered in MDA-MB-231 cells when treated with both PAE and
PEE as compared to control (Figures 8E,F and Supplementary
Figures S3A–D). Together, these data clearly suggested that fruit
pulp extracts (PEE and PAE) obliterate the stemness property of
breast cancer cells.
DISCUSSION
Considering the current status of diagnostic and treatment
options available, cancer associated deaths are on the rise.
In India, carcinoma of the breast and cervix contributes to
Frontiers in Pharmacology | www.frontiersin.org September 2017 | Volume 8 | Article 593303
fphar-08-00593 September 1, 2017 Time: 16:33 # 8
Chowdhury et al. Colocynth Extracts: EMT and Stemness
FIGURE 6 | Effect of colocynth pulp extracts on expression of EMT associated genes in breast cancer cells. Breast cancer MDA-MB-231 cells were either treated
with pulp ethanol extract (PEE) (A) or pulp acetone extract (PAE) (B) for 24 h, and subsequently the expression of EMT associated genes was measured by RT-PCR
analysis using total RNA isolated from cells. GAPDH was used an internal loading control. Densitometric data is given in Supplementary Figure S2.
FIGURE 7 | Effect of colocynth pulp extracts on colony formation of breast cancer cell. MDA-MB-231 cells were treated with pulp ethanol extract (PEE) (A,C) and
pulp acetone extract (B,D). After 5 days of cell seeding, photos of the wells were taken by a camera (A,B), and colonies were also visualized by inverted bright field
microscope (C,D).
50% of total cancer incidences2. However, surgical removal,
radiation-, chemo-, endocrine-, and other targeted- therapies
are continuously being improvised to improve the overall
survival and quality of life of cancer patients. Although
modern treatment modalities are capable of taking care of
the primary tumors, tumor recurrence and metastasis are the
major limitations in the limelight at present. Furthermore,
2breastcancerindia.net
chemotherapeutic drugs often show significant off-target effects
along with systemic toxicity, such as cardiovascular, liver and
nephrotoxicity (King and Perry, 2001; Schimmel et al., 2004).
Thus, finding novel anticancer drugs, which prevent both tumor
growth and metastasis while circumventing the known side
effects, is an active area of research. In this area, application
of natural products like secondary metabolites with effective
tumor suppressive ability has shown promise in recent years
as they are found to be effective even at sufficiently lower
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FIGURE 8 | Inhibitory activity of colocynth pulp extract on spheroid formation and stemness of breast cancer cell. (A) Soft agar assay was performed on
MDA-MB-231 cells by treating cells with pulp ethanol extract (PEE; A,C) and pulp acetone extract (PAE; B,D) and allowing cells to grow for 8 days. Spheroid
colonies were visualized by inverted bright field microscope (A,B). Number of spheroids of all plates was counted and analyzed with respect to control plates (C,D),
in (C) ∗∗p < 0.01; PEE vs. control (ethanol) after 8 days, and in (D) ∗∗p < 0.01; PAE vs. control (acetone) after 8 days. (E,F) MDA-MB-231 cells were treated with
PEE (E) and PAE (F) for 24 h and subsequently, expression of CD44 and BMI-1 was compared by RT-PCR analysis using total RNA isolated from cells and CD44
and BMI-1 gene specific primers. GAPDH was used as an internal loading control. Densitometric data is given in Supplementary Figure S3.
doses and due to their safety profile (Koehn and Carter,
2005).
Thus, this study was aimed at exploring the anti-cancer
properties of extracts from Citrullus colocynth plant of the
cucurbitaceae family that has been used as a traditional medicine
to control diabetes (Zaini et al., 2011; Shi et al., 2014). Reports
about the nutritional and medicinal values of this plant and
presence of many bioactive molecules had initially attracted our
attention (Sawaya et al., 1983, 1986; Asyaz et al., 2010; Marzouk
et al., 2010; Hussain et al., 2013, 2014; Jeon and Lee, 2014;
Chawech et al., 2017). Moreover, Tannin-Spitz et al. (2007)
found that an isolate (cucurbitacin glucosides) extracted from
the leaves of this plant exhibits apoptotic activity in cancer cells.
Nevertheless, no detailed study was done regarding the anti-
cancer effects of this plant extract. Our study found that both
ethanol and acetone extracts of fruit pulp of the colocynth plant
showed a significant inhibition of cell viability of various cancer
cell lines, including breast cancer MCF-7 and MDA-MB-231,
and cervical cancer SiHa cell lines (Figures 1, 2 and Table 1).
Correspondingly, both extracts had reverse cytotoxic effect on
mononuclear cells PBMC and macrophage cell line J774A. Breast
cancer MCF-7 cells showed more sensitivity to both ethanol
and acetone pulp extracts as compared to other cancer cells.
This was in agreement with previous reports that too claim
higher sensitivity of MCF-7 cells to colocynth fruit extract at
relatively lower concentrations (Mukherjee and Patil, 2012). The
probable explanation may be either use of alkaloid rich extracts
or longer exposure in MCF-7 cells (Mukherjee and Patil, 2012).
Our study also found that both ethanol and acetone extracts
exhibited synergistic potential with the chemotherapeutic drug
doxorubicin to inhibit viability in the breast cancer cells
(Supplementary Figure S4).
Moreover, on molecular analysis, we found suppression of
transcripts of anti-apoptotic genes BCL2 and BCLXL, and an
induction of apoptotic gene BAX and caspase 3 mRNA in
metastatic breast cancer MDA-MB-231 cells following treatment
with ethanol and acetone pulp extracts (Figure 3). In addition,
these pulp extracts displayed a higher level of cleaved caspase
3 protein and a lower level of BCL-2 protein as compared to
control, implying an enhancement of active caspase 3 upon
treatment with these extracts (Figure 3). Thus, this study
indicated that colocynth fruit pulp extracts exhibit an anticancer
potential presumably by promoting apoptosis.
As stated earlier, metastasis remains one of the major threats
to cancer patients. However, no study has yet been conducted
to investigate the anti-metastatic potential of this plant extract.
Our study indicated, for the first time, a preventive role of
these pulp extracts in cancer cell migration, a key step in the
metastatic process (Figures 4, 5) (Chaffer and Weinberg, 2011).
These pulp extracts also block EMT (Chaffer and Weinberg,
2011), another vital step in the metastatic cascade, since both
PEE and PAE treatment significantly enhanced epithelial gene
expression with simultaneous inhibition of mesenchymal marker
expression in breast cancer MDA-MB-231 cells (Figure 6).
Additionally, treatment of cancer cells with these ethanol and
acetone pulp extracts showed a noticeable reduction in colony
and sphere formation with concomitant inhibition of cancer
stemness associated genes CD44 and BMI-1 at their transcript
levels, suggesting a preventive role of these pulp extracts
in cancer stemness (Monteiro and Fodde, 2010), a pivotal
property responsible for metastasis, therapy resistance and tumor
recurrence (Figures 7, 8).
All these findings summarized a role of the ethanol and
acetone fruit pulp extracts of colocynth in prevention of cell
proliferation, induction of cell apoptosis, prevention of cell
migration, reduction of EMT, and inhibition of cancer stemness
property in breast cancer cells.
However, further study is required to identify the bioactive
molecule(s) present in fruit pulp, liable for the observed
anticancer potential. Subsequent GC-MS/MS analysis of both the
extracts revealed about fifty compounds (Supplementary Figures
S5A,B and Tables S2, S3) out of which, we analyzed the top 20
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TABLE 2 | Top 20 compounds isolated from GC-MS/MS analysis of ethanol and acetone crude extract.
S. No RT Compound name Area % Molecular formula Molecular weight Biological study
Ethanol
1 20.64 Naphtho[1,2-d]oxazol-2(1H)-one, 3a,4,5,9b-tetrahydro-
3a,5,5,9b-tetramethyl-1-(phenylmethyl)-
31.32 C22H25NO2 335 Not reported
2 21.64 1,5-Diphenylhex-3-ene 14.72 C18H20 236 Anti-microbial
3 28.56 Benzenesulfonic acid, 4-methoxy-,
[(4-methylphenyl)sulfonyl]methyl ester
5.56 C15H16O6S2 356 Not reported
4 24.6 Heptyl methyl methylphosphonate 4.55 C8H19O3P 194 Not reported
5 7.58 DL-4,5-Octanediol 3.28 C8H18O2 146 Not reported
6 16.99 Oxalic acid, allyl dodecyl ester 3.23 C17H30O4 298 Yes
7 21.97 10-Pentadecen-5-yn-1-ol, (E)- 3.22 C15H26O 222 Not reported
8 29.33 (E,E,E)-(5-Phenylsulfonylgeranyl)geraniol 2.71 C26H38O3S 430 Not reported
9 18.71 cis,cis,cis-7,10,13-Hexadecatrienal 2.46 C16H26O 234 Yes, anti-microbial
10 26.46 2-Isopropyl-5-methylcyclohexyl
3-(1-(4-chlorophenyl)-3-oxobutyl)-coumarin-4-yl carbonate
2.26 C30H33ClO6 524 Not reported
11 22.52 Cyclopenta[c]pyran-1,3-dione,
4,4a,5,6-tetrahydro-4,7-dimethyl-
2 C10H12O3 180 Yes, anti-insecticidal
12 26.51 2-Isopropyl-5-methylcyclohexyl
3-(1-(4-chlorophenyl)-3-oxobutyl)-coumarin-4-yl carbonate
1.98 C30H33CLO6 524 Not reported
13 13.04 2,2-Dimethyl-propyl 2,2-dimethyl-propanesulfinyl sulfone 1.7 C10H22O3S2 254 Yes
14 14.43 á-l-Arabinopyranoside, methyl 1.59 C6H12O5 164 Yes
15 8.78 Cycloheptatrienylium, iodide 1.46 C7H7I 218 Not reported
16 18.62 Cyclohexanemethyl propanoate 1.41 C10H18O2 170 Yes
17 20.47 2,2-Dimethyl-propyl 2,2-dimethyl-propanesulfinyl sulfone 1.36 C10H22O3S2 254 Yes
18 23.01 Benzenesulfonic acid, 4-methoxy-,
[(4-methylphenyl)sulfonyl]methyl ester
1.33 C15H16O6S2 356 Not reported
19 28.31 Dimethylsilyl tert-buthylperoxide 1.24 C6H16O2Si 148 Not reported
20 23.9 Heptyl methyl methylphosphonate 1.02 C9H21O3P 208 Not reported
Acetone
1 18.91 Oxalic acid, cyclobutyl octadecyl ester 24.73 C24H44O4 396 Yes
2 21.02 9,12,15-Octadecatrienal 16.98 C18H30O 262 Yes
3 14 2,2-Dimethyl-propyl 2,2-dimethyl-propanesulfinyl sulfone 14.46 C10H22O3S2 254 Yes
4 20.91 Z-4-Dodecenol 10.32 C12H24O 184 Yes
5 28.95 Carbonic acid, 3-hexenyl methyl ester, (Z)- 5.24 C8H14O3 158 Yes
6 23.61 Naphtho[1,2-d]oxazol-2(1H)-one, 3a,4,5,9b-tetrahydro-
3a,5,5,9b-tetramethyl-1-(phenylmethyl)-
4.79 C22H25O2 335 Not reported
7 24.74 17-Octadecene-9,11-diynoic acid, 8-hydroxy-, methyl ester 3.36 C19H28O3 304 Not reported
8 21.13 1-Cyclohexylnonene 2.84 C15H28 208 Not reported
9 8.71 Cycloheptatrienylium, iodide 1.24 C7H7I 218 Not reported
10 24.64 Cyclohexanemethyl propanoate 1.2 C10H18O2 170 Yes
11 10.1 3-Selenetanol, 3-(4-methoxyphenyl)- 1.12 C10H12O2Se 244 Not reported
12 7.71 Cyclobutanecarboxylic acid, but-3-yn-2-yl ester 1.1 C10H14O2 166 Not reported
13 23.85 1-Benzylbenzimidazole 3-oxide 0.85 C14H12N2O 224 Yes
14 25.86 Sucrose 0.75 C12H22O11 342 Yes
15 29.4 9-Azabicyclo[6.1.0]nonane, 9,9′-azobis-,
[1à,8à,9[E(1’R∗,8’S∗)]]-
0.75 C16H28N4 276 Not reported
16 7.77 N,N′-Bis(2,6-dimethyl-6-nitrosohept-2-en-4-one) 0.7 C18H30N2O4 338 Not reported
17 15.63 Z-2-Dodecenol 0.69 C12H24O 184 Yes
18 27.46 2-(4-Bromobutyl)-furan 0.59 C8H11BrO 202 Not reported
19 18.58 2,2-Dimethyl-propyl 2,2-dimethyl-propanesulfinyl sulfone 0.58 C10H22OS2 254 Yes
20 24.84 5,10-Pentadecadiyn-1-ol 0.55 C15H24O 220 Yes
Compounds were selected on the basis of top twenty peak area extracted from the ethanol crude extract of fruit from the plant Citrullus colocynthis. Interpretation of the
compound activity was done, and thus a comparative analysis is given with their reported molecular formula.
compounds on the basis of abundance in the extracts (Table 2).
More in-depth study narrowed the list to those compounds that
are novel to the extracts, with no previous reports of biological
study (Table 3). We have also noticed that some compounds
are common both in ethanolic and acetone extracts. Thus,
purification and more detailed investigation of these compounds
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TABLE 3 | List of extracted novel compounds.
S. No RT Compound name Area % Molecular formula Biological study
Ethanol plant extract
1 23.84 Phosphonic acid, methyl-, 2,2-dimethylcyclohexyl methyl
ester
0.73 C10H21O3P NA
2 16.34 2-Trimethylsiloxy-6-hexadecenoic acid, methyl ester 0.25 C20H40O3Si NA
3 21.05 Manganese(1+), dicarbonyl[(1,2,3,4,5-ü)-1-methyl-2,4-
cyclopentadienyl]nitrosyl-
0.24 C8H8MnNO3 NA
1 20.64 Naphtho[1,2-d]oxazol-2(1H)-one, 3a,4,5,9b-tetrahydro-
3a,5,5,9b-tetramethyl-1-(phenylmethyl)-
31.32 C22H25NO2 NA
2 21.64 2-Cyclohexene-6-carboxylic acid,
3-methyl-1-(5-oxo-3,4-dihydro-2H-pyrrolyl)-, ethyl ester
14.72 C14H21NO3 NA
3 28.56 Naphtho[1,2-d]oxazol-2(1H)-one, 3a,4,5,9b-tetrahydro-
3a,5,5,9b-tetramethyl-1-(phenylmethyl)-
5.56 C22H25NO2 NA
4 18.71 Acrylic acid, 5,7-octadien-1-yl ester 2.46 C11H16O2 NA
5 26.46 2-Isopropyl-5-methylcyclohexyl
3-(1-(4-chlorophenyl)-3-oxobutyl)-coumarin-4-yl carbonate
2.26 C30H33ClO6 NA
6 26.51 4-Chloro-4-methylhexane-2,3-dione 1.98 C7H11ClO2 NA
7 29.1 Cyanomethyl 2-chloroethyl disulfide 0.26 C4H6ClNS2 NA
8 9.83 2-Methyl-2-(methoxy-ethoxy)amino-propan-1-ol 0.2 C7H17NO3 NA
9 25.25 5-[2-(1,3-Dioxolan-2-yl)-ethyl]-2-methyl-1-cyclopentene-1-
carboxaldehyde
0.13 C12H18O3 NA
Acetone plant extract
1 7.36 Propanamide, 3-(3,4-dimethylphenylsulfonyl)- 0.31 C11H15NO3S NA
2 7.77 Cyclobutanecarboxylic acid, 4-nitrophenyl ester 0.7 C11H11NO4 NA
3 26.12 Bicyclo[3.2.1]octane, 2-bromo-4-iodo- 0.22 C8H12BrI NA
1 23.61 Naphtho[1,2-d]oxazol-2(1H)-one, 3a,4,5,9b-tetrahydro-
3a,5,5,9b-tetramethyl-1-(phenylmethyl)-
4.79 C22H25NO2 NA
2 24.74 4,5-Dihydroxy-6-hydroxymethyl-oxepan-3-one 3.36 C7H12O5 NA
3 21.13 2-Methyl-2-chloro-3-nitroso-4-cyclohexyloxy-butane 2.84 C11H20ClNO2 NA
4 7.71 Cyclobutanecarboxylic acid, but-3-yn-2-yl ester 1.1 C10H14O2 NA
5 7.71 Cyclobutanecarboxylic acid, pent-2-en-4-ynyl ester 1.1 C10H12O2 NA
6 25.86 6-Chloro-2,2,9,9-tetramethyl-3,7-decadiyn-5-ol 0.75 C14H21ClO NA
7 7.77 Cyclobutanecarboxylic acid, but-3-yn-2-yl ester 0.7 C10H14O2 NA
8 26.43 5-[2-(1,3-Dioxolan-2-yl)-ethyl]-2-methyl-1-cyclopentene-1-
carboxaldehyde
0.4 C12H18O3 NA
9 24.22 2-Bromoethyl vinyl sulfide 0.15 C4H7BrS NA
10 27.59 N-Difluorophosphoxy-O-trimethylsilylhydroxylamine 0.15 C3H10F2NO2PSi NA
Compounds were isolated by GC-MS/MS analysis from ethanol and acetone pulp extract and tabulated on the basis of non-reported data.
will enable identification of the potent constituents in the extracts
that are accountable for retarded cell growth and metastasis of
cancer cells. Further mechanistic studies will prove extremely
useful for their utility in future therapeutic interventions.
In brief, using cell culture based in vitro study and GC-MS/MS
analysis, we report, for the first time, some novel compounds in
the fruit pulp extracts of colocynth plant, that show promising
potential as anti-cancer therapeutics for their tumor suppressive
properties.
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We report increased cholesterol efflux from macrophages in the presence of
falcarindiol, an important dietary constituent present in commonly used vegetables and
medicinal plants. Falcarindiol (3–20 µM) increased cholesterol efflux from THP-1-derived
macrophages. Western blot analysis showed an increased protein level of ABCA1
upon falcarindiol exposure. Quantitative real-time PCR revealed that also ABCA1 mRNA
level rise with falcarindiol (10 µM) treatment. The effect of falcarindiol on ABCA1
protein as well as mRNA level were counteracted by co-treatment with BADGE, an
antagonist of PPARγ. Furthermore, falcarindiol significantly inhibited ABCA1 protein
degradation in the presence of cycloheximide. This post-translational regulation of
ABCA1 by falcarindiol occurs most likely by inhibition of lysosomal cathepsins, resulting
in decreased proteolysis and extended protein half-life of ABCA1. Taken together,
falcarindiol increases ABCA1 protein level by two complementary mechanisms, i.e.,
promoting ABCA1 gene expression and inhibiting ABCA1 protein degradation, which
lead to enhanced cholesterol efflux.
Keywords: falcarindiol, cholesterol efflux, ABCA1, protein degradation, PPARγ
INTRODUCTION
Cardiovascular disease (CVD) associated with atherosclerosis is a leading cause of mortality in
the world. Cholesterol metabolism has been considered as a major player in the pathogenesis of
CVD. Excessive cholesterol deposition resulting in plaques is a critical cause of atherosclerosis.
Reverse cholesterol transport (RTC) is a complex multi-step process overall resulting in the
relocation of cholesterol from peripheral tissues to the liver for excretion into the bile and
ultimately the feces. Cholesterol eﬄux, the initial step of RTC, is known to enhance the export
of excessive cholesterol from peripheral tissues, in particular macrophages, and thereby to
inhibit the accumulation of cholesterol in the wall of arteries (Fielding and Fielding, 1995).
There is strong evidence that the cholesterol eﬄux capacity is inversely associated with the
310
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Graphical Abstract: The dietary constituent falcarindiol promotes macrophage cholesterol efflux by increasing ABCA1 transporter gene transcription (via PPARγ
activation) and protein stability (via inhibition of lysosomal proteolysis).
incidence of CVD (Rohatgi et al., 2014). Therefore, the
enhancement of cholesterol eﬄux from macrophages might
prevent CVD, making it a potential strategy for pharmacological
interventions. Key determinant of cholesterol eﬄux is the
expression level and activity of transmembrane transporter
proteins such as the ATP-binding cassette transporter A1
(ABCA1) and G1 (ABCG1) and the scavenger receptor class
B member 1 (SR-B1) (Duffy and Rader, 2006). Among them,
ABCA1 is the predominant one and it contributes to most of the
cholesterol transport in macrophages (Rosenson et al., 2012; Du
et al., 2015). ABCA1 mediates mostly transfer of cholesterol to
lipid–poor apolipoprotein A1 (apo A1), but it can also mediate
cholesterol transport using high density lipoproteins (HDL) as
an acceptor (Du et al., 2015). Modulation of the ABCA1 protein
level is considered an important regulator for cholesterol eﬄux.
In general, the level of ABCA1 protein is determined by de
novo synthesis and protein degradation. Several nuclear receptors
are implicated in the regulation of ABCA1 gene transcription.
Thus, the activation of the ligand-dependent nuclear receptors
peroxisome proliferator-activated receptor gamma (PPARγ) and
subsequently the liver X receptor (LXR), can lead to increased
ABCA1 gene transcription (Chawla et al., 2001; Chinetti et al.,
2001; Ozasa et al., 2011). The ABCA1 protein half-life is largely
regulated via the proteolytic activity of calpain-, lysosome-, and
ubiquitin-degradation pathways (Wang et al., 2003;Mizuno et al.,
2011; Liu and Tang, 2012; Yokoyama et al., 2012). Cathepsins
represent key lysosomal proteases (Turk et al., 2012) and diverse
cathepsin isoforms (e.g., cathepsin B, D, K, L, S) are known to
be expressed in macrophages (Punturieri et al., 2000; Beers et al.,
2003; Bracke et al., 2005; Vasiljeva et al., 2006).
Natural products have proven to be an excellent source of
molecules with promising pharmacological activities and novel
mechanisms of action (Atanasov et al., 2015). Here, we report
the identification and characterization of the natural product
falcarindiol (Figure 1A) as a novel enhancer of macrophage
cholesterol eﬄux. Falcarindiol is a C(17)-polyacetylene and a
typical constituent of roots and rhizomes of Apiaceae plants
used worldwide, including in Europe, such as the commonly
used vegetables and herbs carrot (Daucus carota L.) (Garrod
et al., 1978), celery (Apium graveolens L.) (Zidorn et al., 2005),
Notopterygium incisum K.C.Ting ex H.T.Chang (Zschocke et al.,
1997), and Aegopodium podagraria L. (Kemp, 1978), among
others. Taking the important role of PPARγ in the regulation
of macrophage cholesterol eﬄux into consideration, we have
chosen this natural product as a study subject in the context
of cholesterol eﬄux because falcarindiol, extracted from the
rhizomes and roots of Notopterygium incisum K.C.Ting ex
H.T.Chang, was recently identified as a partial PPARγ agonist
in HEK-293 cells transfected with a PPARγ-responsive luciferase
reporter (Atanasov et al., 2013).
MATERIALS AND METHODS
Chemical Reagents
Roswell Park Memorial Institute 1640 (RPMI-1640) medium
was obtained from Lonza (Basel, Switzerland). Fetal bovine
serum (FBS) was purchased from Gibco via Invitrogen (Lofer,
Austria). [3H]-Cholesterol was bought from Perkin Elmer Life
Sciences (Vienna, Austria) and pioglitazone was from Molekula
(Munich, Germany). Albumin faction V, fatty acid free BSA
was obtained from Carl Roth (Graz, Austria). Bisphenol A
diglycidyl ether (BADGE), resazurin sodium salt, water soluble
unesterified cholesterol, apolipoprotein (apo) A1, phorbol 12-
myristate 13-acetate (PMA), lactacystin, calpeptin, chloroquine,
and cycloheximide were provided by Sigma-Aldrich (Vienna,
Austria). Falcarindiol was isolated from the roots and rhizomes
of the traditional Chinese herbal drug Radix Notopterygii, with
a purity over 95% as determined by High Performance Liquid
Chromatography (HPLC) (Zschocke et al., 1997; Liu et al.,
2014). Cathepsin B, L, D, and K Activity Fluorometric kits were
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FIGURE 1 | Chemical structure of falcarindiol (A), its effect on cell viability (B), and cholesterol efflux in THP-1-derived macrophages (C,D). (B) Differentiated THP-1
macrophages were incubated with solvent vehicle control (DMSO), 50 µg/mL digitonin, or the indicated concentrations (10–20 µM) of falcarindiol. After 24 h, the
increased fluorescent signal from resazurin conversion was detected and calculated as the percentage of cell viability. (C,D) THP-1-derived macrophages were loaded
with [3H]-cholesterol together with the indicated treatments for 24 h. On the next day, macrophages were washed twice with pre-warmed PBS and incubated with the
same compounds [solvent vehicle (DMSO), falcarindiol (1–20 µM for apo A1-mediated cholesterol efflux, or 10 µM for human plasma-mediated cholesterol efflux), or
the PPARγ agonist pioglitazone (10 µM) as positive control] with or without 10 µg/mL apo A1 (C) or 1% human plasma (D) dissolved in serum-free medium for 6 h.
Extracellular as well as intracellular radioactivity were quantified with a scintillation counter. All values are means ± SD (n = 3) and vs. solvent vehicle control (DMSO):
*p < 0.05, **p < 0.01, ***p < 0.001, n.s, not significant (ANOVA/Bonferroni).
purchased from BioVision via THP Medical Products GmbH
(Vienna, Austria). Cathepsin S activity assay kit (fluorometric)
was bought from Abcam (Cambridge, UK). Antibodies were
obtained from the following companies: ABCA1, ABCG1, SR-
B1 from Novus Biologicals via THP Medical Products GmbH
(Vienna, Austria), anti-actin antibody from MP biologicals
(Illkirch, France), horseradish peroxidase-conjugated goat anti-
rabbit secondary antibody fromNew England Biolabs (Frankfurt,
Germany), horseradish peroxidase conjugated goat anti-mouse
secondary antibody from Upstate (Millipore, Vienna, Austria).
Cell Culture
Human monocytic THP-1 cells were acquired from ATCC R©
and grown in suspension in RPMI-1640 medium supplemented
with 2 mM glutamine, 100 U/mL benzylpenicillin, 100 mg/mL
streptomycin, and 10% FBS in T175 flasks. For experiments,
differentiation was induced by seeding THP-1 monocytes in 96-,
24-, or 6- well plates under treatment of 200 nM PMA for 72 h
(seeding cell density of 0.2 × 106 cells per mL). All of the tested
compounds were dissolved in dimethyl sulfoxide (DMSO) and
stored at −20◦C. Control cells were always treated with an equal
volume of solvent (DMSO) and its final concentrations did not
exceed 0.1%.
Cholesterol Efflux Assay
The cholesterol eﬄux assay (Wang et al., 2015) was adapted
from previous studies (Chawla et al., 2001; Chinetti et al., 2001).
Briefly, THP-1-derived macrophages were incubated for 24 h
with the compounds at the indicated concentrations [solvent
vehicle (DMSO), falcarindiol (1–20 µM), the PPARγ agonist
pioglitazone (10 µM) as positive control] together with [3H]-
cholesterol in serum free medium supplemented with 0.1% BSA
and 10 µg/mL unesterified cholesterol. On the next day, cells
were washed twice with pre-warmed PBS and incubated with
the same compounds with or without 10 µg/mL apo A1 or
1% human plasma dissolved in serum-free medium for 6 h.
Extracellular as well as intracellular radioactivity were quantified
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with scintillation counting. The apo A1- as well as human
plasma-mediated cholesterol eﬄux was calculated as follows:
Apo A1mediated cholesterol eﬄux % =
((
extracellular cpm
)
apo A1(
total cpm
)
apo A1
−
(
extracellular cpm
)
no apo A1(
total cpm
)
no apo A1
)
× 100
Human plasma mediated cholesterol eﬄux % =
((
extracellular cpm
)
plasma(
total cpm
)
plasma
−
(
extracellular cpm
)
no plasma(
total cpm
)
no plasma
)
× 100
Resazurin Conversion Assay
The viability of THP-1-derived macrophages was assessed by
resazurin conversion. The assay was performed as previously
described (Wang et al., 2015) by quantification of the conversion
of the low fluorescent resazurin to high fluorescent resorufin.
Gel Electrophoresis and Immunoblot
Analysis
THP-1 cells were seeded in 6-well plates and differentiated into
macrophages with 200 nM PMA for 72 h. The macrophages
were treated with the indicated compounds at the corresponding
time points, as described in detail in each figure legend.
Cellular proteins were extracted using NP40 buffer (150
mM NaCl; 50 mM HEPES (pH 7.4); 1% NP40; 1% protease
inhibitor CompleteTM (Roche); 1% phenylmethylsulfonyl
fluoride (PMSF); 0.5% Na3VO4; 0.5% NaF) and quantified
with the Bradford method. For western blot analysis, an equal
amount of protein (20 µg) was separated via SDS-PAGE and
transferred onto a PVDF membrane. The membrane was
blocked for 1 h at room temperature with 5% non-fat milk,
and then incubated at 4◦C overnight with primary polyclonal
antibody against ABCA1, ABCG1 or SR-B1 (1:500) or actin
(1:10,000). After being washed for three times (15 min each
time), the membranes were incubated with a secondary antibody
[horseradish peroxidase-conjugated goat anti-rabbit (1:500) or
anti-mouse (1:10,000)] for 1 h at room temperature. The signals
were detected and visualized using a LAS-3000 luminescent
image analyzer (Fujifilm, Düsseldorf, Germany) using AIDA
image analyzer 4.06 software (Raytest, Sprockhövel, Germany).
The indicated protein band intensity was normalized to that of
actin.
RNA Extraction and Analysis
THP-1 cells were seeded in 6-well plates and differentiated
into macrophages with a 200 nM PMA treatment for 72 h.
The macrophages were treated with the indicated compounds
at the indicated time points, which are described in detail
in the figure legends. Total cellular RNA was extracted from
the treated THP-1 macrophages using peqGOLD Total RNA
kits (PeqLab, Linz, Austria) according to the manufacturer’s
instructions. One microgram of total RNA was used for cDNA
synthesis according to the protocol of the High Capacity
cDNA Reverse Transcription Kit together with RNase Inhibitor
(Applied Biosystems). LightCycler R© 480 SYBR Green I Master
kit (Roche) was used for quantitative real-time PCR (qRT-
PCR) with 40 ng cDNA from each sample for triplicate
measurements. Amplification cycles were detected using the
LightCycler 480 system (Roche). ABCA1 (HS_ABCA1_1_SG
QuantiTect primer assay, Cat.no.: #QT00064869, QIAGEN)
and 18S (Hs_RRN18S_1_SG QuantiTect Primer assay,
Cat.no.: #QT00199367, QIAGEN) primers were used, and
the quantification was performed with the1CT method.
Determination of Cathepsin Activity
The cathepsin activity assays were performed according to
the manufacturer’s instructions. In general, THP-1-derived
macrophages were cultured for 24 hwith solvent control (DMSO)
or falcarindiol (10µM). After incubation, cells were washed once
with cold PBS and lysed with chilled cell lysis buffer. Protein
concentration was determined using the Bradford method.
Hundredmicrograms of protein per reaction in 50µL of cell lysis
buffer was used for the activity measurement. Fifty microliters
of reaction buffer and 2 µL of the respective cathepsin substrate
were added to 50 µL cell lysates. The assay plate was incubated
at 37◦C for 1 h protected from light. The fluorescence was
quantified with Tecan Infinite 200 R© Pro plate reader (Vienna,
Austria).
Statistical Methods
Statistical analysis was performedwith data acquired from at least
three independent experiments using GraphPad Prism software
version 4.03 (GraphPad Software Inc., La Jolla, CA, USA). Figures
with bar graphs represent mean ± SD. To determine statistical
significance, one- or two- way analysis of variance (ANOVA)
were performed and p< 0.05 was considered significant.
RESULTS
Falcarindiol Promotes Cholesterol Efflux in
Thp-1-Derived Macrophages
In a previous study, we showed that falcarindiol activates
PPARγ in HEK-293 cells transfected with a PPARγ-responsive
luciferase reporter (Atanasov et al., 2013). Considering that
PPARγ is a known regulator of cholesterol eﬄux (Chawla
et al., 2001; Chinetti et al., 2001), we aimed to investigate
whether falcarindiol can promote cholesterol eﬄux in THP-1-
derived macrophages. Since apo A1, the nascent and lipid free
form of HDL, is the most significant acceptor for cholesterol
eﬄuxed from macrophages (Du et al., 2015), we first studied
cholesterol eﬄux mediated by apo A1. Falcarindiol enhanced
apo A1-mediated cholesterol eﬄux in a concentration-dependent
manner when applied at 1–20µM(without effect on cell viability;
Figure 1B) with a half maximal effective concentration (EC50)
of 5.8 µM (Figure 1C). Moreover, 10 µM falcarindiol also
significantly enhanced 1% human plasma-mediated cholesterol
eﬄux (Figure 1D) as plasma containing HDL particles served
as cholesterol acceptors in the process of cholesterol eﬄux.
Pioglitazone, a PPARγ agonist known to upregulate cholesterol
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eﬄux (Ozasa et al., 2011), was used as positive control both in
presence of apo A1 and human plasma (Figures 1C,D).
Falcarindiol Enhances ABCA1 Protein
Expression
The transmembrane proteins ABCA1, ABCG1, and SR-B1 are
transporters mediating cholesterol eﬄux (Duffy and Rader,
2006). Therefore, we investigated protein expression of these
three transporters upon treatment with falcarindiol in THP-1-
derived macrophages. As evident in Figure 2A, ABCA1 protein
level significantly increased in response to falcarindiol (10 µM).
At the same time, there was no significant upregulation of
ABCG1 (Figure 2B) or the bi-directional transporter SR-B1
(Figure 2C; Stangl et al., 1999). Next, we investigated whether
increased ABCA1 protein level is associated with an increase in
ABCA1 mRNA level. ABCA1 mRNA level indeed significantly
increased upon falcarindiol (10 µM) treatment (Figure 3B, left).
In macrophages, enhanced ABCA1 mRNA level might result
from PPARγ and subsequent LXR activation (Chawla et al., 2001;
Chinetti et al., 2001). We, therefore, asked whether the increased
ABCA1 mRNA level induced by falcarindiol might be due to
PPARγ-activation. To check this possibility, we used the PPARγ
antagonist, BADGE (50 µM), to block the activity of PPARγ in
THP-1-derived macrophages (Hinz et al., 2003). Indeed, BADGE
blocked the falcarindiol-mediated increase of ABCA1 protein as
well as mRNA level (Figures 3A,B).
Falcarindiol Inhibits ABCA1 Protein
Degradation
Interestingly, the ABCA1 mRNA up-regulation by falcarindiol
was significantly lower than the mRNA induction caused
by the PPARγ agonist pioglitazone (Figure 3B, on the left),
while the induction of ABCA1 protein level by falcarindiol
and pioglitazone was equally potent (Figure 3A, on the left).
This inconsistency indicated that an additional effect of
falcarindiol might exist, which could enhance ABCA1 protein
level besides the increase of ABCA1 mRNA level. To explore
this possibility, we measured the rate of ABCA1 protein
degradation in the presence and absence of falcarindiol. THP-1-
derived macrophages were incubated with falcarindiol or solvent
vehicle (DMSO) for 24 h and were then further treated with
cycloheximide (140 µM) to block de novo protein synthesis
(Arakawa et al., 2009). As evident in Figure 4, ABCA1 protein
degradation was significantly inhibited in the presence of
falcarindiol showing that the compound interferes with the
ABCA1 protein turnover rate.
Falcarindiol Inhibits Lysosomal
Cathepsin-Dependent ABCA1 Degradation
To further explore how falcarindiol inhibits ABCA1 protein
degradation, we first investigated, which protein degradation
pathway could be affected by falcarindiol in THP-1-derived
macrophages. As presented in Figure 5A, the application of
lactacystin, an ubiquitin proteasome inhibitor, failed to affect
ABCA1 protein level in our experimental setting. However, the
application of calpeptin (a calpain inhibitor) and chloroquine
(a lysosome inhibitor) (Figures 5B,C) increased ABCA1 protein
level, similarly to falcarindiol. Falcarindiol had an additive effect
on ABCA1 protein level upon co-treatment with calpeptin,
indicating that its mechanism of action is likely different
from the calpain inhibitor calpeptin. However, there was no
difference observed with or without chloroquine in the presence
of falcarindiol, suggesting that falcarindiol might interfere with
protein degradation in the lysosome, mimicking the effect of
chloroquine (Figure 5C).
The lysosomal degradation pathway is a well-known regulator
of ABCA1 protein turnover (Neufeld et al., 2001; Santamarina-
Fojo et al., 2001; Mizuno et al., 2011) and cathepsins are well
established proteases mediating the lysosomal proteolysis in
general (Turk et al., 2012; Appelqvist et al., 2013). Therefore,
FIGURE 2 | Falcarindiol increases ABCA1 protein level. Differentiated THP-1 macrophages were treated with solvent vehicle control (DMSO), falcarindiol (Fal, 10 µM),
or the PPARγ agonist pioglitazone (Pio, 10 µM). After 24 h, cells were lysed and 20 µg protein was resolved via SDS-PAGE. Immunoblotting was performed with
antibodies against the indicated proteins, ABCA1 (A), ABCG1 (B), and SR-B1 (C) as well as actin as loading control. All experiments were performed four times and
values are presented as means ± SD and vs. solvent vehicle control (DMSO): **p < 0.01, n.s. not significant (ANOVA/Bonferroni).
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FIGURE 3 | The PPARγ antagonist, BADGE, blocks falcarindiol-mediated ABCA1 protein and mRNA induction. Differentiated THP-1 macrophages were incubated
for 24 h with falcarindiol (Fal, 10µM) or pioglitazone (Pio, 10 µM) with or without 50 µM BADGE. ABCA1 protein (A) and mRNA (B) level were analyzed by western
blotting and qPCR, respectively. All data are mean ± SD (n = 3), *p < 0.05, **p < 0.01, ***p < 0.001, n.s. not significant vs. solvent vehicle control (DMSO)
(ANOVA/Bonferroni).
FIGURE 4 | Falcarindiol inhibits ABCA1 protein degradation. Differentiated
THP-1 macrophages were stimulated with 10 µM falcarindiol (black circles) or
an equal amount of the solvent vehicle control (DMSO; white circles). After 24
h incubation, cells were treated with cycloheximide (140 µM) and lysed at
different time points (0, 10, 20, 40 min). Western blotting was used to monitor
the decline of ABCA1 protein level upon cycloheximide treatment in the
presence or absence of falcarindiol. All data are mean ± SD (n = 3) and vs.
solvent vehicle control (DMSO): *p < 0.05, **p < 0.01, n.s. not significant
(two-way ANOVA/Bonferroni).
we investigated whether the proteolytic activity of lysosomal
cathepsins is affected by falcarindiol. Figures 6A–E shows that
among the tested cathepsins (B, D, K, L, S) the activity of
cathepsin B, S, and K were significantly suppressed by 35, 14,
and 8%, respectively. Overall, these data indicate that falcarindiol
leads to the suppression of ABCA1 degradation and inhibits
lysosomal cathepsins.
DISCUSSION
In this study, we describe for the first time that falcarindiol, a
typical constituent of Apiaceae vegetables, stimulates cholesterol
eﬄux by promoting ABCA1 gene expression in THP-1-derived
macrophages. In addition, we show that falcarindiol increases
ABCA1 protein stability and inhibits the proteolytic activity of
lysosomal cathepsins.
Macrophage cholesterol eﬄux is a process counteracting
the transformation of macrophages into pro-atherogenic foam
cells. Thus, the study of this process and molecules that can
regulate it is of significance for potential approaches to combat
CVD (Rosenson et al., 2012; Du et al., 2015). ABCA1 is the
most important membrane transporter for cholesterol eﬄux
from macrophages (Du et al., 2015). Treatment of THP-1-
derived macrophages with falcarindiol increased ABCA1 protein
expression (Figure 2). In contrast, the expression level of the
other two cholesterol transmembrane transporters, SR-B1 and
ABCG1, remained unchanged. In THP-1 macrophages, SR-B1
was shown to be co-expressed with caveolin-1 and to enhance
selectively cholesterol ester uptake rather than cholesterol
eﬄux (Matveev et al., 1999). Interestingly, both ABCA1 and
ABCG1 proteins seem to be tightly regulated by PPARγ as
shown in studies using full agonists of PPARγ (Chawla et al.,
2001; Ozasa et al., 2011). Falcarindiol, in contrast, works as
a partial PPARγ agonist in HEK-293 cells (Atanasov et al.,
2013). Thus, the fact that the abundance of ABCG1 protein
did not significantly increase in response to falcarindiol might
be explained by the partial agonism of the compound. The
contribution of PPARγ to falcarindiol-induced ABCA1 protein
expression was demonstrated by co-treatment experiment with
BADGE, a PPARγ antagonist (Figure 3). Numerous reports
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FIGURE 5 | Effect of specific inhibitors of the proteasome (A) calpain (B), and lysosomal (C) protein degradation pathways on ABCA1 protein level in the presence or
absence of falcarindiol. Differentiated THP-1 macrophages were pre-treated with or without falcarindiol (Fal) at 10 µM for 24 h and incubated for another 3 h with the
proteasome inhibitor lactacystin (Lact) at 10 µM (A), the calpain inhibitor calpeptin (Calp) at 30 µg/mL (B), or the lysosomal inhibitor chloroquine (Chlq) at 100 µM (C).
Cells were lysed and protein was resolved via SDS-PAGE. Western blot analysis was used to monitor ABCA1 protein level under the indicated treatment conditions.
All data are mean ± SD (n = 4) and vs. solvent vehicle control (DMSO): *p < 0.05, ***p < 0.001, n.s. not significant (one-way ANOVA/Bonferroni).
FIGURE 6 | Falcarindiol inhibits several lysosomal cathepsins. (A–E) Differentiated THP-1 macrophages were incubated for 24 h with or without falcarindiol (10 µM).
Cells were lysed and cathepsin activity (S, B, L, K, and D) was determined by fluorescence measurements. Irreversible inhibitors of cathepsin B, S, L, and K
(Z-FF-FMK; 1 µM) and cathepsin D (pepstatin A; 10 µM) were used as positive controls and directly added to the control lysates. All data are mean ± SD (n = 3) and
vs. solvent vehicle control (DMSO): *p < 0.05, **p < 0.01, ***p < 0.001, n.s. not significant (one way-ANOVA/Bonferroni).
suggest a synergistic effect between ABCA1 and ABCG1 in the
context of cholesterol eﬄux (Gelissen et al., 2006; Hsieh et al.,
2014). Although they exhibited a similar degradation rate in
CHO cells, ABCG1 degradation seems to work by different
degradation mechanisms than that of ABCA1. In addition, there
are differences in the protein stability of two ABCG1 isoforms
(Gelissen et al., 2010).
We also demonstrate that falcarindiol inhibits protein
degradation of ABCA1 in the presence of cycloheximide, a de
novo protein synthesis inhibitor (Figure 4). Several proteolytic
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pathways have been described to mediate ABCA1 degradation
in different cell types, particularly the calpain-, lysosome-, and
proteasome-mediated pathways (Wang et al., 2003; Mizuno et al.,
2011; Liu and Tang, 2012; Yokoyama et al., 2012). Applying
specific inhibitors of these three proteolytic pathways, we found
that falcarindiol mimics the effect of lysosomal proteolysis
inhibitor chloroquine on ABCA1 levels (Figure 5).
Cathepsins are well-established lysosomal proteases (Turk
et al., 2012). A variety of cathepsins (e.g., cathepsin B, D,
K, L, S) are known to be expressed and to serve important
regulatory functions in macrophages (Punturieri et al., 2000;
Beers et al., 2003; Bracke et al., 2005; Vasiljeva et al.,
2006). Measuring the activity of lysosomal cathepsins known
to be expressed in macrophages revealed that falcarindiol
simultaneously suppresses the activity of cathepsin B, S, and K.
Among these three cathepsins, cathepsin S and K were proposed
to reduce cholesterol eﬄux from macrophages (Lindstedt et al.,
2003; Lutgens et al., 2007) and knockout of cathepsin S or K genes
was shown to lead to decreased atherosclerosis in mice (Sukhova
et al., 2003; Lutgens et al., 2006). Cathepsin B was also found to
be highly expressed and active in murine atherosclerotic lesions
(Chen et al., 2002; Lutgens et al., 2007). The potential of cathepsin
B, S, and K to influence ABCA1 protein level regulation further
supports the concept for their implication in atherosclerosis.
To the best of our knowledge, interference of falcarindiol with
cathepsins or with lysosomal function was never reported before.
In summary, our results demonstrate for the first time that
falcarindiol is able to increase macrophage cholesterol eﬄux.
Falcarindiol upregulates ABCA1 protein level by promoting its
PPARγ-driven gene expression and by extending its protein half-
life. Moreover, our findings reveal the inhibition of lysosomal
proteases as a new possiblemechanism of action of this important
dietary constituent. These data advance our knowledge for
the molecular mechanisms, by which small molecules regulate
macrophage cholesterol eﬄux, and might have implication for
the development of novel therapeutics or dietary supplements for
the prevention or treatment of CVD.
CONCLUSION
In the present study, we demonstrated that falcarindiol enhances
cholesterol eﬄux and increases ABCA1 protein level by two
complementary mechanisms, i.e., promoting ABCA1 gene
expression and inhibiting ABCA1 protein degradation.
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The genus Ononis has important value as traditional drugs and foods. In the present
work, we aimed to assess the chemical profiles and biological effects of Ononis natrix
subsp. hispanica extracts (ethyl acetate, methanol, and water). For chemical profile, total
and individual phenolic components were detected. For biological effects, antioxidant
(DPPH, ABTS, CUPRAC, FRAP, phosphomolybdenum, and metal chelating assays),
enzyme inhibitory (against cholinesterase, tyrosinase, α-amylase and α-glucosidase),
antimicrobial, DNA protection and cytotoxic abilities were tested. The predominant
phenolics were apigenin, luteolin, and quercetin in the tested extracts. Generally, the
ethyl acetate and methanol extracts were noted as the most active in the antioxidant
and enzyme inhibitory assays. Water extract with different concentrations indicated high
level of DNA protection activity. Methanol and ethyl acetate extracts showed antibacterial
effect against to Staphylococcus aureus and Staphylococcus epidermidis strains. The
cytotoxic effects of O. natrix subsp. hispanica extracts on the survival of HeLa and
PC3 cells were determined by MTT cell viability assay. Water and methanol extracts
caused initiation of apoptosis for PC3 cell line. Furthermore, molecular docking was
performed to better understand interactions between dominant phenolic compounds
and selected enzymes. Our results clearly indicate that O. natrix subsp. hispanica
could be considered a potential candidate for designing novel pharmaceuticals,
cosmeceuticals and nutraceuticals.
Keywords: Ononis, bioactive compounds, natural agents, pharmaceuticals, molecular docking
INTRODUCTION
In the twenty first century, the usage of plant or plant products are undergoing a revolution
as sources of prominent (functional and bioactive) compounds. For example, artemisinin
was awarded as an anti-malarial compound in Nobel Prize for Medicine 2015 (Omura and
Campbell, 2015). From this point, to better combat the lifestyle, communicable or infectious
diseases, many phytochemicals have been suggested as antioxidant, antimicrobial, anticancer
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and anti-mutagenic agents (Fernandes et al., 2017; Losada-
Barreiro and Bravo-Díaz, 2017; Meeran et al., 2017; Yin et al.,
2017). These facts provide encouragement for designing
further studies on the plants. Within these perspectives,
the term of functional products has emerged and it is
defined as any products which provide health benefits
including treatment of afore-mentioned diseases. In this
framework, uninvestigated wild plants could be considered as a
springboard for designing novel functional products with low
toxicity.
The genus Ononis (Fabaceae) is represented by 75 species
in the world especially Europe and Central Asia (Wollenweber
et al., 2003). The genus comprises of 23 taxa in Tukey and
known as “semisk” and “kayıs¸kıran” in Turkish name (Baytop,
1999; Sohretoglu, 2007; Mükemre et al., 2015). In the literature,
several studies were reported that member of the genus Ononis
exhibited significant biological activities, such as antimicrobial
effect (Mhamdi et al., 2015; Sayari et al., 2016), antioxidant
(Mhamdi et al., 2015; Mezrag et al., 2017), wound healing
(Süntar et al., 2011), cytotoxic (Kuete et al., 2013; Ghribi et al.,
2016), and analgesic (Yõlmaz et al., 2006). In addition, the
decoctions from Ononis species is used for treating urinary
problems, skin disorders as well as gout (Baytop, 1999; Erdemgil
et al., 2002; Liebezeit, 2008). With this in mind, Ononis species
have been sold as herbal tea on the market as single or
combined with other diuretic plants (Gampe et al., 2016). Several
publications have appeared in recent years documenting on
biological activities of some Ononis species along with their
phytochemicals profiles (Daruházi et al., 2008; Al-Rehaily et al.,
2014; Ghribi et al., 2015; Yousaf et al., 2015; Gampe et al., 2016;
Casiglia et al., 2017; Mezrag et al., 2017). However, to the best
of our knowledge, there is no report on the chemical profile and
biological ability of Ononis natrix subsp. hispanica. Thus, the
present study aims to provide more details about chemical and
biological properties of O. natrix subsp. hispanica. The observed
findings could be provide new insights for O. natrix subsp.
hispanica.
MATERIALS AND METHODS
Plant Material and Preparation of the
Extracts
Ononis natrix subsp. hispanica was collected from Antalya-
Turkey during of flowering season (June 2015). Taxonomic
identification of the plant material was confirmed by the senior
taxonomist Dr. Murad Aydin Sanda, from the Department of
Biology, Selcuk University. The voucher specimen has been
deposited at the Herbarium of the Department of Biology, Selcuk
University, Konya-Turkey.
To obtain ethyl acetate and methanol extracts, the air-dried
aerial parts (10 g) were macerated with 200mL of these solvents
at room temperature (25◦ ± 1◦C) for 24 h. The extracts were
concentrated under vacuum at 40◦C by using a rotary evaporator.
To obtain water extract, the powdered samples were boiled with
250mL of distilled water for 30min. The aqueous extract was
filtered, lyophilized (−80◦C, 48 h), and all extracts stored at +
4◦C in the dark until use.
Total Phenolics, Flavonoids, and Phenolic
Composition
The total phenolics content was determined by Folin-Ciocalteu
method (Slinkard and Singleton, 1977) with slight modification
and expressed as gallic acid equivalents (GAE/g extract), while
total flavonoids content was determined using AlCl3 method
(Zengin et al., 2014) with slight modification and expressed as
rutin equivalents (RE/g extract).
Phenolic compounds were evaluated by RP-HPLC
(Shimadzu Scientific Instruments, Tokyo, Japan). Detection
and quantification were carried out with a LC-10ADvp pump, a
Diode Array Detector, a CTO-10Avp column heater, SCL-10Avp
system controller, DGU-14A degasser and SIL-10ADvp auto
sampler (Shimadzu Scientific Instruments, Columbia, MD).
Separations were conducted at 30◦C on Agilent R© Eclipse
XDB C-18 reversed-phase column (250 × 4.6 mm length, 5
µm particle size). Phenolic compositions of the extracts were
determined by a modified method of Zengin et al. (2014). Gallic
acid, protocatechuic acid, (+)-catechin, p-hydroxybenzoic acid,
chlorogenic acid, caffeic acid, (−)-epicatechin, syringic acid,
vanillin, p-coumaric acid, ferulic acid, sinapic acid, benzoic acid,
o-coumaric acid, rutin, hesperidin, rosmarinic acid, eriodictyol,
trans-cinnamic acid, quercetin, luteolin, kaempferol, and
apigenin were used as standards. Identification and quantitative
analysis were done by comparison with standards. The amount
of each phenolic compound was expressed as microgram per
gram of extract using external calibration curves, which were
obtained for each phenolic standard.
Antioxidant and Enzyme Inhibitory Assays
Antioxidant [DPPH, ABTS radical scavenging, reducing power
(CUPRAC and FRAP), phosphomolybdenum and metal
chelating (ferrozine method) and enzyme inhibitory assays
(cholinesterase (Elmann’s method), tyrosinase (dopachrome
method), α-amylase (iodine/potassium iodide method) and
α-glucosidase (chromogenic PNPG method)] were performed
according to our previous researches (Zengin et al., 2014; Zengin,
2016). Antioxidant capacities were expressed as equivalents of
trolox and EDTA (for metal chelating). In addition, the enzyme
inhibitory activities of the extracts were evaluated as equivalents
of standard inhibitors per gram of the plant extract (galantamine
for AChE and BChE, kojic acid for tyrosinase, and acarbose for
α-amylase and α-glucosidase inhibition assays).
Molecular Modelling
Receptors Preparation
The crystalline structure of the selected enzymes together
with their inhibitors have been downloaded from the Protein
Databank RCSB PDB (Berman et al., 2000): acetylcholinesterase
(pdb:4X3C) (Pesaresi and Lamba, in press) in complex
with tacrine-nicotinamide hybrid inhibitor, butyrilcholinesterase
(pdb:4BDS) (Nachon et al., 2013) in complex with tacrine,
amylase (pdb:1VAH) (Zhuo et al., 2004) in complex with r-
nitrophenyl-α-D-maltoside, glucosidase (pdb:3AXI) (Yamamoto
et al., 2011) in complex with maltose and tyrosinase (pdb:2Y9X)
(Ismaya et al., 2011) in complex with tropolone. The raw
crystal structures were prepared for the docking experiments as
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previously reported (Mocan et al., 2016; Uysal et al., 2016). Non-
catalytic water molecules, inhibitors and all the other molecules
present in the pdb files were removed by using UCSF Chimera
(DeLano, 2002) and the proteins alone were neutralized at pH
7.4 by PropKa implemented in Maestro 10.2 suite (Maestro,
2015). Seleno-cysteines and seleno-methionines, if present, were
converted to cysteines and methionines, respectively. All the
missing fragments and other errors present in the crystal
structures were automatically solved by the Wizard Protein
Preparation implemented in Maestro 10.2 suite (Maestro, 2015).
Ligands Preparation
(+)-Epicatechin, apigenin, luteolin, quercetin and rosmarinic
acid were selected as representative compounds to carry out
molecular docking study, as these compounds were present
in abundance in the herbs extracts. The chemical structure
the selected compounds are reported in Figure 1. The three
dimensional structures have been downloaded from Zinc
databases (Irwin et al., 2012) and used for molecular modeling
experiments after preparation. The ligands were prepared by the
LigPrep tool embedded in Maestro 10.2, neutralized at pH 7.4 by
Ionizer and minimized by OPLS3 force field (Shelley et al., 2007).
Molecular Docking
Dockings of the representative substances have been performed
for each selected enzyme employed for the in vitro enzymatic
inhibition tests in this work. Glide embedded in the maestro suite
10.2 has been employed for the docking calculations by using
the “eXtra Precision” scoring function for all the enzymes and
the mm-GBSA binding energy has been calculated by the use
of Prime embedded in maestro 10.2 (Table 1; Jones et al., 1997).
In all cases, the binding pocket was determined automatically by
centering the grid on the crystallographic inhibitor, extended in
a radius of 10 Angstroms from the center. The best pose for each
compound docked to the selected enzymes was the best ranked
among the 10,000 generated.
DNA Protection
DNA protection activity of the studied extracts was analyzed
using pUC19 plasmid DNA (pDNA). Plasmid isolation was
performed by Thermo Scientific Genejet Plasmid Miniprep Kit.
The reaction mixture contained 5µL of Fenton’s reagent (30mM
H2O2, 50mM ascorbic acid, and 80mM FeCI3), 5 µL of these
extracts at two different concentrations (5 and 10 mg/mL) and
3 µL of pDNA (300 µg/µL). Final volume of reaction mixture
was brought up to 20 µL using double-distilled water. Positive
control was composed of 12µL of distilled water, 5µL of Fenton’s
reagent and 3µL of pDNA. Negative control involved only 17µL
of distilled water and 3 µL of pDNA. Samples were incubated for
30min at 37◦C and 4 µL loading dye (Thermo Scientific, USA)
was added to the all mixtures. The DNA mixtures were run on
0.8% agarose gel and then visualized under ultraviolet light cabin.
Biological replication of test was carried out at three times and
band density was determined by the gel image analysis software
(Quantum, Vision-Capt., Vilber Lourmat SAS, France) (Ozkan
et al., 2015).
Cytotoxic Evaluation
Cell Culture Materials
HeLa and PC3 cancer cell lines were obtained from Selcuk
University, Faculty of Science, and Department of Biochemistry.
Penicillin/Streptomycin, EMEM cell culture media, Ham’s F-
12 cell culture media, Fetal bovine serum (FBS), trypsin, MTT,
ethanol, 2-prophanol, 60 × 15 mm corning plates and 75 cm2
FIGURE 1 | Chemical structure of apigenin, luteolin and quercetin.
TABLE 1 | Binding energy and glide XP docking scores.
Compounds AChE* BChE* α-amylase* α-glucosidase* Tyrosinase*
XP 1G XP 1G XP 1G XP 1G XP 1G
Apigenin −9.6 −60.6 −9.4 −52.5 −5.98 −35.2 −5.7 −17.2 −5.7 −26.1
Benzoic A. −4.0 −14.2 −4.9 −22.3 −3.88 −0.03 −2.3 +71.8 −5.1 +41.7
(−)-Epicat. −9.3 −41.5 −7.3 −41.0 −7.03 −38.1 −6.9 −21.8 −5.5 −20.9
Luteolin −9.6 −52.9 −8.0 −53.3 −6.54 −54.0 −6.7 −30.3 −5.1 −29.3
Quercetin −10.3 −62.9 −7.9 −43.5 −8.79 −52.9 −6.9 −31.2 −5.4 −28.3
Rosmarinic A. −11.3 −64.5 −10.9 −42.8 −8.26 −46.8 −6.5 −22.6 −6.3 −12.2
*1G values (Binding energy) are expressed in Kcal/mol.
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corning flasks were purchased from Sigma-Aldrich (Sigma-
Aldrich, USA).
Cell Culture Maintenance
Culture media were prepared with 10% fetal bovine serum (FBS)
and 1% penicillin-streptomycin (Pen-Strep) solution. Prepared
medium was kept at +4◦C and warmed at 37◦C before using.
Cells (HeLa, PC3) were proliferated in incubator (37◦C including
5% CO2). Stock cells were proliferated in 75 cm
2 sterile corning
flasks and experiment cell cultures were proliferated in 60 × 15
mm sterile petri dishes. In the logarithmic phase of the growth
(when reached to∼80% cell confluency), cells were sub-cultured
(Karakurt and Adali, 2016).
Preparation of Plant Extraction
Dilutions weremade to obtain extract concentration of 10mg/ml.
The water extract was suspended in PBS and other extracts were
suspended in DMSO (Dimethylsulfoxide)/water (1:5) and the
diluted extracts were centrifuged at 10,000× g during 2 min, and
supernatants were filtrated (having the diameter of 0.22 µm pore
size) and they were kept in−20◦C.
MTT Cell Viability Test
A total of 10.000 PC3 and HeLa cells were seeded in 96-well
plates and allowed to fasten on the wells for 24 h. After 24 h,
cells were treated with different doses of the tested extracts (0.1,
1, 2.5, 5, and 10mg for water) (0.1, 1, 10, 100, and 1,000 µg
for ethyl acetate and methanol) for 24 h. After exposure time
completed, the medium was changed with EMEM and Ham’s
F12 medium supplemented with 0.5% FBS + 0.5 mg/ml MTT
for HeLa and PC3 cancer cells, respectively. Then, they were
incubated at 37◦C with 5% CO2, for 4 h. After that time, the cells
were treated with 3% SDS+ 40 mMHCl/isopropanol for 15min
in order to dissolve the MTT-formazan crystals (Yerlikaya et al.,
2016). The absorbance of each sample was recorded at 570 nm.
Cell survival rate was calculated by using GraphPad Prism 3.03
software (GraphPad Software, Inc., La Jolla, CA, USA).
Antimicrobial Activity
Antimicrobial activity test was performed by disc diffusion
method. Nutrient agar mediumwas used for test microorganisms
and microorganisms were refreshed in 100 mm sterile petri
dishes. Single colony of bacterial strain was inoculated in
20ml nutrient broth medium for 24 h at 37◦C incubator. After
bacteria concentration was made visible in %9 sterile NaCI
and its turbidity was standardized to 0.5 McFarland by adding
bacterial suspension. Bacterial suspension seeded to 100mm
petri dishes. After the tested extracts were dissolved in DMSO
and saturated on discs, they were incubated at room temperature
for drying. They were placed on the inoculated petri plates
with microorganisms for 24 h at 37◦C incubator. Test was
replicated at least three times and results were analyzed by
measuring inhibition zone. Microorganisms were illustrated on
Table 2.
Statistical Analysis
All the assays were carried out in triplicate. The results were
expressed as mean value and standard deviation (mean ±
TABLE 2 | Microorganisms used for antimicrobial activity test.
Microorganisms Gram (+) Gram (−)
Klebsiella pneumonia X
Staphylococcus aureus ATCC 25923 X
Staphylococcus hominis X
Proteus vulgaris X
Escherichia coli X
Serratia marcescens X
Staphylococcus epidermidis X
Alfa streptococcus haemolyticua X
Enterococcus faecium X
Pseudomonas aeruginosa X
Listeria monocytogenes ATCC 7644 X
Enterococcus durans X
Salmonella kentucky X
Enterobacter aerogenes ATCC 13048 X
SD). Statistical differences between the extracts were analyzed
by using one-way analysis of variance (ANOVA) followed
by Tukey’s honestly significant difference post-hoc test (α =
0.05). All the analysis was carried out using SPSS v22.0
software.
RESULTS AND DISCUSSION
Phytochemical Composition
In the last decades, many studies highlighted biological
activities of phenolic compounds, such as antioxidant, anticancer,
antimicrobial, and anti-inflammatory. Flavonoids are the most
abundant group of phenolics and considered as natural bioactive
agents for designing novel functional products. In this sense,
the amounts of total phenolics and flavonoids contents in O.
natrix extracts were determined by Folin-Ciocalteu and AlCl3
methods. The greatest content of total phenolics was noticed in
the ethyl acetate extract (60.19 mgGAE/g extract), followed by
methanol (59.22 mgGAE/g extract) and water (35.12 mgGAE/g
extract) extracts. Similar results were observed for flavonoid
as well (Table 3). These findings were confirmed by several
researchers who reported the higher concentration of total
phenolics in ethyl acetate and methanol extracts (Do et al.,
2014; Murugan and Parimelazhagan, 2014). In a previous study
(Mhamdi et al., 2015), the total phenolic content of O. natrix
in Tunisia was reported as 51 mgGAE/g, which was lower than
that found in the present study. Moreover, some researchers
were found to be different levels of total phenolics in several
Ononis species, such as O. spinosa (3.09 mgGAE/g extract)
(Orhan et al., 2012), O. pubescens (17.23 mgGAE/g extract), and
O. ornithopodioides (20.96 mgGAE/g extract) (Sarikürkcü et al.,
2016).
Individual phenolic constituents in the tested extracts were
analyzed by HPLC-DAD and the results are given in Table 4.
A total of 23 standard phenolics were used and 21 of them
were identified in these extracts. Two compounds (rutin and
hesperidin) were not detected in the extracts. Apigenin was
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TABLE 3 | Total phenolic and flavonoid contents, and free radical scavenging (DPPH and ABTS) activities of the extracts.
Extracts Total phenolic content (mgGAE/g extract) Total flavonoid content (mgRE/g extract) DPPH (mgTE/g extract) ABTS (mgTE/g extract)
Ethyl acetate 60.19 ± 1.67* 30.07 ± 0.39 56.60 ± 1.46 530.37 ± 0.40
Methanol 59.22 ± 0.09 28.40 ± 0.27 63.95 ± 1.45 521.80 ± 2.90
Water 35.12 ± 0.07 10.25 ± 0.23 63.38 ± 1.10 457.92 ± 2.29
GAE, gallic acid equivalents; RE, rutin equivalents; TE, trolox equivalents.
*Values expressed are means ± S.D. of three parallel measurements.
TABLE 4 | Quantitative analysis for determination of phenolic components in the extracts (µg/g extract).
No. Phenolic compounds Extracts Analytical characteristics
Ethyl acetate Methanol Water Linear range (ppm) r2 LOD (ppm) LOQ (ppm)
1 Gallic acid 8 ± 0.4 100 ± 0.8 58 ± 0.8 0.20–25.0 0.9993 0.075 0.227
2 Protocatechuic acid 10 ± 0.4 80 ± 0.6 234 ± 8 0.20–25.0 0.9991 0.086 0.260
3 (+)-Catechin nd 152 ± 2 492 ± 20 0.90–113 0.9988 0.172 0.522
4 p-Hydroxybenzoic acid 44 ± 4 106 ± 4 200 ± 4 0.20–25.0 0.9994 0.007 0.020
5 Chlorogenic acid 210 ± 2 nd 166 ± 2 0.35–45.0 0.9988 0.080 0.241
6 Caffeic acid 42 ± 4 34 ± 4 90 ± 4 0.16–21.0 0.9993 0.054 0.162
7 (-)-Epicatechin 310 ± 16 950 ± 24 nd 0.50–66.0 0.9990 0.170 0.514
8 Syringic acid 22 ± 0.2 66 ± 4 86 ± 4 0.05–12.0 0.9995 0.030 0.090
9 Vanillin 2 ± 0.1 10 ± 0.2 nd 0.08–10.0 0.9995 0.020 0.060
10 p-coumaric acid 8 ± 0.6 34 ± 2 64 ± 2 0.04–6.0 0.9996 0.066 0.199
11 Ferulic acid 8 ± 0.4 90 ± 0.4 130 ± 6 0.12–17.0 0.9993 0.004 0.011
12 Sinapic acid nd nd 54 ± 2 0.12–17.0 0.9993 0.017 0.053
13 Benzoic acid 50 ± 0.6 50 ± 0.6 1386 ± 26 0.85–55.0 0.9998 0.111 0.335
14 o-Coumaric acid 82 ± 2 82 ± 2 nd 0.24–32.0 0.9988 0.023 0.069
15 Rutin nd nd nd 0.40–56.0 0.9989 1.113 3.373
16 Hesperidin nd nd nd 0.43–55.0 0.9992 1.080 3.280
17 Rosmarinic acid 76 ± 2 1960 ± 22 nd 0.02–7.0 0.9998 0.148 0.447
18 Eriodictyol nd nd 116 ± 4 0.33–21.0 0.9998 0.140 0.410
19 trans-Cinnamic acid 18 ± 1 66 ± 1.2 10 ± 1 0.02–7.0 0.9998 0.148 0.447
20 Quercetin nd nd 1356 ± 42 0.40–55.0 0.9999 0.013 0.040
21 Luteolin 756 ± 56 908 ± 56 1006 ± 56 0.13–17.0 0.9999 0.020 0.060
22 Kaempferol nd 288 ± 6 222 ± 4 0.05–15.0 0.9996 0.021 0.062
23 Apigenin 4136 ± 94 3314 ± 86 850 ± 24 0.17–11.0 0.9997 0.034 0.104
nd, not detected.
quantified as the dominant phenolic in the ethyl acetate and
methanol extracts. Other dominant phenolics were luteolin,
epicatechin, and rosmarinic acid in these extracts. However,
the most abundant phenolics in the water extract were benzoic
acid and quercetin. In recent studies, the detected phenolics in
O. natrix extracts possess a broad range of biological activities
including antioxidant, anticancer, antimicrobial and enzyme
inhibitory (López-Lázaro, 2009; Amoah et al., 2016; David et al.,
2016). In this framework, the observed biological activities for
O. natrix extracts might be explained with the presence of these
phenolic components. To the best of our knowledge, this study
is the first report which indicates comprehensive analysis of
phenolic constituents of O. natrix. In this sense, the present
findings could be opened new horizons for the genus Ononis and
it’ usages.
Antioxidant Capacity
In order to evaluate antioxidant ability of O. natrix extracts,
several methods were performed: free radical scavenging
(DPPH and ABTS), reducing power (CUPRAC and FRAP),
phosphomolybdenum and metal chelating assays. DPPH and
ABTS assays are widely utilized to examine radical scavenging
activities of plant extracts or synthetics. These assays are based
on the reduction of ABTS+ and DPPH· in the presence of
antioxidants and the changes (from blue to white in ABTS;
from purple to yellow in DPPH) can spectrophotometrically be
recorded. In addition, the assays reflect to hydrogen donating
abilities of antioxidants. As shown in Table 3, the methanol and
water extracts had similar DPPH scavenging abilities whereas the
lowest ability was observed in the ethyl acetate extract. However,
ABTS radical scavenging abilities can be ranked as ethyl acetate>
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methanol>water. The apparent differences can be attributed
to nature of these radicals (ABTS assay is considered as both
hydrophilic and lipophilic antioxidant systems, while DPPH is
only hydrophobic systems). Our findings are consistent with
previous results, which were reported different results for DPPH
and ABTS (Kim et al., 2002; Zengin et al., 2015, 2017; Bouhlali
et al., 2017).
Reducing power is an important way in the antioxidant
mechanisms and it reflects electron-donating abilities of
antioxidants. From this point, CUPRAC and FRAP assays were
performed to detect reducing abilities of O. natrix extracts
(Table 5). By using CUPRAC assay (from Cu2+ to Cu), the ethyl
acetate extract showed the strongest reducing ability, followed
by methanol and water extracts. These results are in line with
the total phenolic and flavonoid contents. Nevertheless, the
FRAP (from Fe3+ to Fe2+) abilities decreased in that order
water (106.12 mgTE/g extract)>ethyl acetate (90.71 mgTE/g
extract)>methanol (79.73 mgTE/g extract). This finding for
water extract in FRAP assay might be related to complex
interactions of phytochemical (antagonistic etc.) described as
Peña-Cerda et al. (2017) and (Hmid et al., 2017).
Phosphomolybdenum assays is proposed by Prieto et al.
(1999), which is based on the reduction of Mo (VI) to Mo (V)
by the antioxidants and then a green phosphate/Mo (V) complex
occurs at the acidic pH. The assay is also considered as one of
total antioxidant capacity assays. Within O. natrix extracts, the
methanol extract (1.53 mmolTE/g extract) exerted the strongest
ability in phosphomolybdenum assay, followed by ethyl acetate
(1.27 mmolTE/g extract) and water (1.13 mmolTE/g extract)
extracts (Table 4). In the literature, several researchers reported
different approaches for a correlation between total phenolic and
the reduction of Mo (VI) to Mo (V) (Albayrak et al., 2010; Kocak
et al., 2016; Amessis-Ouchemoukh et al., 2017). At this point, this
activity for the methanol extract may be related to the presence of
other antioxidants as well as phenolics.
Transition metal ions, such as iron and copper are involved in
the production of hydroxyl radical via Fenton and Haber-Weiss
reactions. In this sense, the metal chelating ability is considered
as an important way in the antioxidant mechanisms. Contrary
to expectations, the metal chelating ability significantly differs
from other antioxidant assays and the strongest activity was
observed in water extract with 14.49 mgEDTAE/g, while the ethyl
acetate extract had the lowest ability (Table 5). These findings are
consistent with previous studies, which reported no correlation
between total phenolic and metal chelating ability (Silva et al.,
2011; Hatami et al., 2014; Khorasani Esmaeili et al., 2015). In
fact, the metal chelating abilities of phenolics were described as
a minor way in theirs antioxidant properties by Rice-Evans et al.
(1996).
Enzyme Inhibitory Effect
Alzheimer’s diseases (AD) and diabetes mellitus (DM) are
considered as major public health problems and their incidence
tends to increase at an alarming rate (more than 35.6 million
AD patients in worldwide and is expected to be more than
100 million AD patients by 2050). The development of new
therapeutic approaches (also in terms of non-pharmacological
therapy supplement) for these diseases has become a pressing
issue. Among the therapeutic approaches, the inhibition of
key enzymes is considered as one of most effective strategy
(Wimo and Prince, 2010). Cholinesterase inhibitors are currently
used as a drug for the treatment of AD. The inhibitors
increase brain acetylcholine (ACh) levels by preventing the
breakdown of ACh and this case is very important to
cognitive function (Menichini et al., 2014). Again, α-amylase
and α-glucosidase release glucose from larger carbohydrates
(especially starch) and are key enzymes in DM glucose level
control (Kubinova et al., 2014). In this direction, both α-
amylase and α-glucosidase inhibitors are promising drugs in
the treatment of DM. In addition, tyrosinase is a main enzyme
in the synthesis of melanin and thus tyrosinase inhibitors
are useful for controlling hyperpigmentation problems. Within
the framework of these information’s, many enzyme inhibitors
are synthetically produced. However, most of them show
limited effectiveness especially related to side effects, such as
gastrointestinal disturbances, and toxic properties (Kumar et al.,
2011). Therefore, many scientists have focused on naturally
occurring compounds from plants as potential sources of either
new or safe effective inhibitors.
Thus, we tested enzyme inhibitory effects of Ononis extracts
against to cholinesterases, tyrosinase, amylase and glucosidase.
The results are represented in Table 6. The ethyl acetate extract
exhibited the strongest cholinesterase inhibitory effect on both
AChE (1.46 mgGALAE/g extract) and BChE (0.93 mgGALAE/g
extract). However, the water extract was not active on BChE.
The observed activity for ethyl acetate extract may be linked
to higher level of phenolics in the extracts. Our findings were
confirmed by several researchers (Kennedy andWightman, 2011;
Roseiro et al., 2012; Mazlan et al., 2013; Hlila et al., 2015),
who reported a linear correlation between phenolic content
and anti-cholinesterase abilities. Interestingly, the ethyl acetate
extract did not have any inhibitory effect on tyrosinase and the
TABLE 5 | Total antioxidant capacity (phosphomolybdenum assay), reducing power (CUPRAC and FRAP assays) and metal chelating activities of the extracts.
Extracts Phosphomolybdenum (mmolTE/g extract) CUPRAC (mgTE/g extract) FRAP (mgTE/g extract) Metal chelating (mgEDTAE/g extract)
Ethyl acetate 1.27 ± 0.07* 183.37 ± 0.02 90.71 ± 1.79 9.16 ± 0.17
Methanol 1.53 ± 0.08 170.51 ± 0.57 79.73 ± 1.17 12.02 ± 1.40
Water 1.13 ± 0.03 94.16 ± 0.99 106.12 ± 0.44 14.49 ± 0.64
TE, trolox equivalents; EDTAE, EDTA equivalents.
*Values expressed are means ± S.D. of three parallel measurements.
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water extract had remarkable anti-tyrosinase effect with 52.81
mgKAE/g extract. As for amylase and glucosidase inhibition, the
ethyl acetate (0.74 mmolACAE/g and 17.52 mmolACAE/g) and
methanol extracts (0.59 mmolACAE/g and 19.94 mmolACAE/g)
had the greatest abilities compared to water extract. The higher
concentrations of phenolics in these extracts may be responsible
for their anti-diabetic effects. In accordance with our findings,
some phenolic components were reported as anti-diabetic agents
(Tundis et al., 2010; Etxeberria et al., 2012; Ríos et al., 2015).
From this point, molecular approaches could be valuable to
understand interactions of enzymes and phenolics. To the best
of our knowledge, this study is the first report on Ononis natrix
TABLE 6 | Enzyme inhibitory effects of the extracts.
Extracts AChE ınhibition
(mgGALAE/g
extract)
BChE ınhibition
(mgGALAE/g
extract)
Tyrosinase ınhibition
(mgKAE/g extract)
α-amylase ınhibition
(mmolACAE/g
extract)
α-glucosidase
ınhibition (mmolACAE/g
extract)
Ethyl acetate 1.46 ± 0.07* 0.93 ± 0.01 na 0.74 ± 0.02 17.52 ± 0.28
Methanol 1.29 ± 0.05 0.64 ± 0.06 11.20 ± 2.30 0.59 ± 0.01 19.94 ± 0.11
Water 0.02 ± 0.01 na 52.81 ± 5.15 0.17 ± 0.01 3.69 ± 0.17
GALAE, galanthamine equivalents; ACAE, acarbose equivalents; KAE, kojic acid equivalents; na, not active.
*Values expressed are means ± S.D. of three parallel measurements.
FIGURE 2 | (A) Best pose of apigenin docked to AChE and (B) to BChE.
FIGURE 3 | (A) Best pose of apigenin docked to α-amylase and (B) to α-glucosidase.
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subsp. hispanica. Taken together, this study could provide a
starting point on this species and could open new perspectives
for designing novel functional products.
Molecular Docking
Evidence from the literature supports the inhibitory action of
apigenin on AChE and BChE (Katalinic´ et al., 2010; Xie et al.,
2014). Apigenin was also reported to induce moderate inhibitory
effect on α-amylase (Li et al., 2014; Wulan et al., 2014) and on
α-glucosidase. On the other hand, we have found that the water
extract possesses good inhibition activity toward tyrosinase. This
may be attributed to the presence of luteolin and quercetin.
In light of the observed inhibitory activity, in silico molecular
docking simulation was used to investigate the interactions
between apigenin to AChE, BChE, amylase and glucosidase,
whereas luteolin and quercetin have been selected as principal
FIGURE 4 | Best pose of (A) luteolin and (B) quercetin docked to tyrosinase.
FIGURE 5 | percentage of DNA protection analysis and gel view of plasmid DNA protection test for each Ononis natrix extracts. A,B: (+) control, H: (−) control, C:
5mg methanol extract, D: 10mg methanol extract, E: 5mg ethyl acetate extract, F: 10mg ethyl acetate extract, I-G: 5mg water extract, K-J: 10mg water extract.
Striped bars indicate significantly different applications.
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inhibitors of tyrosinase. The most representative enzyme-ligand
complexes were reported in Figures 2–4.
Apigenin has been previously reported to inhibit both AChE
and BChE by IC50 of 7.72 micro/Mol (Balkis et al., 2015) and
37.4 micro/Mol (Katalinic´ et al., 2010), respectively. The best
docked pose interacts with AChE in the binding pocked by
establishing two hydrogen bonds to Glu199 and Ser122 and
two pi-pi stacks to Phe330 and Trp 84 with a docking score
of −9.607 and a binding energy of −60.64 Kcal/Mol. Apigenin
also interacts with several residues present in the binding pocket
of BChE forming two hydrogen bonds to Thr120 and Glu197
with a docking score of −9.459 and a binding energy of −52.54
kcal/Mol. Also, considering the abundance in the ethyl acetate
and methanol extracts, apigenin could be also responsible for the
amylase and glucosidase inhibiting activity. Indeed, it has been
previously reported that apigenin was an efficacious inhibitor of
α-glucosidase with a IC50 of and a moderate α-amylase inhibitor
with a IC50 of 10.5 µ/Mol (Zeng et al., 2016).
Apigenin interacts with α-glucosidase by forming two
hydrogen bonds to Asp215 and Gln353 and with the enzymatic
cavity of α-amylase by forming three hydrogen bonds to Gln63,
His299, and Glu233. The aqueous extract has shown a strong
activity toward tyrosinase. Themost abundant substances present
in the extracts are benzoic acid, luteolin and quercetin. All of
these substances have been demonstrated to have an tyrosinase
inhibitory activity in in vitro experiments (IC50= quercetin 0.13
mM) (Chen and Kubo, 2002). However, benzoic acid reported
a scarce docking score (−5.1) and a positive binding energy
(+41.7 Kcal/Mol) which indicate none or very little affinity for
the binding pocket of the enzyme, whereas the luteolin and
quercetin have obtained the best binding energy. (−28 Kcal/Mol
and−29.31 Kcal/Mol, respectively).
However, it is noteworthy to highlight that the plant extracts
contain several phenolic compounds which in less extent are
able to inhibit the tested enzymes all with non-competitive
mechanism as demonstrated in our previous paper (Picot et al.,
2017). Inhibitory action of the plant extracts on AChE, BChE,
tyrosinase, α-amylase, and α-glucosidase might be due to the
concerted action of several phenolic compounds rather than a
single molecule.
DNA Protective Effects
Various stress factors, such as oxidative stress, acid, alkaline,
UV, and heavy metals can damage DNA. ROS formed by
hydroxyl radicals cause DNA strand breakage that is brought
about carcinogenesis, mutagenesis and cytotoxicity (Golla and
Bhimathati, 2014). Here, we targeted to measure the DNA
damage by Fenton reaction-mediated oxidative stress. Fenton’s
reagent (Fe2+ + H2O2 → Fe
3+ + OH− + .OH) produces the
highly deleterious hydroxyl radicals that damage the cellular
components, such as DNA, lipid and proteins. The scavenging
effect of extract was tested in plasmid nicking assay. Figure 5
illustrates the DNA protection activity of theOnonis extracts with
two different concentrations (5 and 10 mg/ml). Ononis extracted
in water (10 mg/ml) had the most effective on protection
of DNA with 78%, followed by water (5 mg/ml) (70%) and
methanol extract with 5mg/ml (53%). Except for the ethyl acetate
extract (5 and 10 mg/ml), water and methanol extracts protected
supercoiled form of pDNA and indicated DNA protection
activity.
FIGURE 6 | Cells morphology of HeLA and PC3 cancer cell lines after application of different extracts of Ononis natrix. Control and different concentrations of extracts
were tested in HeLA or PC3 cancer cell lines and indicated for each figures.
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In the present study, the water extract had the most protection
activity on DNA. This can be arisen from availability of different
metabolites in water extract. Quercetin and sinapic acid are
only metabolites which found in this extract. So, it can be
concluded that these chemicals may be responsible for protection
of DNA from Fenton reagent. Like water extract, the methanol
extract also contained specific metabolite, such as rosmarinic
acid. In this sense, the observed DNA protection ability for the
methanol extract can be arisen from presence of higher amount
of rosmarinic acid. Therefore, it seems that different ingredients
of the extracts may cause formation of DNA protection property
for the tested extracts. According to DNA protection assay
results, water extract ofOnonis natrix showed themost protective
activity for DNA. This result may be explained by determination
of phenolic components in the extracts using HPLC analysis. As
indicated inTable 4, rosmarinic acid and quercetin were themost
dissolved components in methanol and water extracts of Ononis
natrix, respectively. So, it can be concluded that rosmarinic
acid and quercetin can be considered as potential chemicals
for protection of DNA from free radicals, hydroxyl radicals
and mutagens. Quercetin is a well-investigated antioxidant
known as promising molecule for pharmacological studies. In a
comprehensive research for DNA protection ability of quercetin,
its supplementation indicated protection of nuclear DNA from
oxidative damage and significant genoprotective activity on
mitochondrial DNA (Potenza et al., 2008). In a different study,
three polyphenolic compounds including luteolin, quercetin
and rosmarinic acid, were investigated for their protective
effects against oxidative DNA damage (Silva et al., 2008).
They found that all of these phenolics were protection agents
against oxidative stress-induced DNA damage. In another search,
protective activity of pure rosmarinic acid and elagic acid were
evaluated. It has been found that they have equal effect on
declining AAPH-induced oxidative DNA damage (Vattem et al.,
2006). These results are in accord with our study indicating that
methanol and water extracts of Ononis natrix can be considered
FIGURE 7 | Cell viability assay (MTT) analysis of HeLA and PC3 cancer cell lines after application of different extracts of Ononis natrix. White bars and striped bars
indicate controls and significantly different applications, respectively.
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as valuable DNA protectors because of presence of rosmarinic
acid and quercetin.
Cytotoxic Effects
The cytotoxic effects of Ononis natrix on the survival of HeLa
and PC3 cells were determined by MTT cell viability assay. HeLa
cervical cancer cell line and PC3 prostate cancer cell line were
treated with these extracts with different concentrations for 24 h.
Cells morphology was observed under inverted microscope and
illustrated in Figure 6. According to morphological appearance,
there was no significant apoptotic effect onOnonis natrix extracts
for HeLa cell line. However, the water and methanol extracts
caused initiation of apoptosis for PC3 cell line. To indicate effect
of three extracts on cancer cell lines, cell viability assay (MTT)
was also conducted. Although there was a cytotoxic activity for
HeLa cells after application of the water extract, no significant
decline was observed in cancer cell numbers compared to
control (Figure 7). On the other hand, 2.5mg water extract,
1mg methanol extract and 0.1 µg ethyl acetate extract caused a
significant cell number reduction on PC3 cancer line (Figure 7).
Ethyl acetate extract indicated cytotoxic activity with the smallest
concertation (0.1 µg) among all extracts. 2.5mg of the water
extract showed dose-independent cytotoxic effect on PC3 cell line
since there was no effect for 5mg and 10mg water extracts. It
has been considered that concentration of water extract more
than 2.5mg may be toxic against healthy or normal viable cells.
Thus, it can be concluded that 2.5mg is amoderate concentration
for cytotoxicity on PC3 cancer cell line. It was also monitored
that other treatments had cytotoxic effect whereas, they were not
significantly different from control sample anymore.
According to reports, about 60% of anticancer drugs are
isolated from plant-derived natural compounds. These medicinal
plants highly contain polyphenolic compounds which are
actually inhibitors for cancer development (Sukumaran et al.,
2016). Cytotoxic and apoptotic effects of the studied extracts
on HeLa and PC3 cell lines were investigated. Although there
was no significant variation on HeLa cells, 2.5mg of water and
1mg methanol extracts leaded to cytotoxic activity compared
to control in PC3. Some of phenolic compounds show anti-
proliferative effect which depends on polarity of compounds.
Cytotoxic effect of methanol extract can be explained with
the presence of rosmarinic acid, apigenin, and epicatechin.
Effect of anti-carcinogenic and scavenging of reactive oxygen
radicals of rosmaniric acid were particularly searched in Perilla
frutescens (Osakabe et al., 2004). The body’s response to cancer
showed parallel effects with the inflammatory response. Since,
inflammatory cytokine networks may affect survival, growth,
mutation, proliferation, differentiation and relocation of tumor
and stromal cells (David, 1988; Balkwill and Mantovani, 2001;
Osakabe et al., 2004). Rosmaniric acid is a water-soluble
polyphenolic compound and has function on inhibition of
angiogenesis (Huang and Zheng, 2006). There was a potential
evidence that ROS acts as initiating angiogenesis and onset
of cancer mechanism. It was proved that hydrogen peroxide
stimulated angiogenesis in vitro condition (Shono et al., 1996;
Yasuda et al., 1999; Huang and Zheng, 2006). Rosmaniric acid
reduced ROS expression, hydrogen peroxide level and VEGF
(Vascular Endothelial Growth Factor) level that are important
on cancer development (Huang and Zheng, 2006). Furthermore,
the previous report which indicated effect of methanolic extract
of plant species on antioxidant activity and examination of level
of rosmaniric acid (Tepe, 2008). In addition, in our previous
study, three extracts (ethyl acetate, methanol and water) of two
Potentilla species (Potentilla reptans and P. speciosa) showed
cytotoxic activity against A549 andMCF-7 due to some phenolic
compounds (Uysal et al., 2017). The findings of this analysis
suggest that one or more than one phenolic compounds and
their interaction may cause initiation of apoptosis in cancer cell
lines. However, further investigation should be performed in in
vivo test to arrive at a definite judgment for inhibition of cancer
development.
Antimicrobial Effects
Antimicrobial activity of the extracts from O. natrix subsp.
hispanica were searched against to 13 bacteria and 1 fungus
by the disk diffusion method. The extracts were loaded the
disks at the concentration of 10, 50, and 100 mg. According to
results, 50 and 100mg of methanol and ethyl acetate extracts
showed the best antibacterial effect against to Staphylococcus
aureus ATCC 25923 and Staphylococcus epidermidis strains
(Figure 8). In addition, 100mg water extracts had a small effect
on Salmonella kentucky. It was realized that extracts possessed
more protective effect against to gram positive bacteria strains. In
addition, concentration-dependent effect was also observed. For
example, S. epidermis stain was more sensitive against to 100mg
of methanol and ethyl acetate extracts than 50mg ones. Methanol
and ethyl acetate extracts ofO. natrix subsp. hispanica were more
effective than water extract for antimicrobial analysis. The results
of this analysis support the idea that because of higher total
phenolic and flavonoid contents of methanol and ethyl acetate
FIGURE 8 | Antimicrobial activity of methanol, ethyl acetate and water extracts
of Ononis natrix against to S. aureus ATCC 25923, S. epidermidis and
S. kentucky.
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extracts, they indicated more antimicrobial activity than water
one.
Staphylococcus aureus (ATCC 25923) is a gram positive
bacterium and causes several human infections and leads to
sanitary problems. S. aureus also shows resistance to some
antibiotics and drugs particularly to methicillin (Hannan et al.,
2008). Resistance problems induced to researchers to tend for
seeking novel therapy. S. epidermidis together with S. aureus
lead to severe infectious diseases (Otto, 2009). S. epidermidis is
more being tend to cause infectious diseases due to developing
persistent infection on human skin (Otto, 2009). Researchers
are seeking the mechanisms by which S. epidermidis promotes
diseases (Otto, 2009). In a study of Sayari et al. (2016)
Ononis natrix leaves extracts were tested against to 9 bacterial
strains (5 gram-negative and 4 gram-positive). Consistently
with our study, S. aureus were the most susceptible against
to Ononis natrix leaves extracts. In another study, S. aureus
(ATCC 25923), and E. coli (ATCC 25922) were found to have
more sensitivity against the Ononis natrix essential oils with
inhibition zone as 27 and 25, respectively (Elamrani and Benaissa,
2010).
CONCLUSION
In recent years, pharmaceuticals and functional ingredients from
plant sources have been of paramount interest. In this sense,
chemical profile and biological abilities of O. natrix subsp.
hispanica were investigated in the current work. As far as
we aware, this work is the first report on this species. The
tested extracts, especially ethyl acetate and methanol, exhibited
notable biological effects correlated with higher levels of bioactive
compounds. The results obtained from the present work provide
a new framework for utilization of the genus Ononis and as a
result, O. natrix subp. hispanica could be suggested as a natural
source of bioactive agents, such as antioxidant, antimicrobial and
anticancer. We hope that our research will serve a base for future
studies for in vivo and bioavailability studies on O. natrix subsp.
hispanica.
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Studying herbal products derived from local and traditional knowledge and their value
chains is one of the main challenges in ethnopharmacology. The majority of these
products have a long history of use, but non-harmonized trade and differences in
regulatory policies between countries impact their value chains and lead to concerns
over product efficacy, safety and quality. Veronica officinalis L. (common speedwell),
a member of Plantaginaceae family, has a long history of use in European traditional
medicine, mainly in central eastern Europe and the Balkans. However, no specified
control tests are available either to establish the quality of derived herbal products or
for the discrimination of its most common substitute, V. chamaedrys L. (germander
speedwell). In this study, we use DNA metabarcoding and high performance liquid
chromatography coupled with mass spectrometry (HPLC-MS) to authenticate sixteen
V. officinalis herbal products and compare the potential of the two approaches to
detect substitution, adulteration and the use of unreported constituents. HPLC-MS
showed high resolution in detecting phytochemical target compounds, but did not
enable detection of specific plant species in the products. DNA metabarcoding detected
V. officinalis in only 15% of the products, whereas it detected V. chamaedrys in 62% of
the products. The results confirm that DNA metabarcoding can be used to test for
the presence of Veronica species, and detect substitution and/or admixture of other
Veronica species, as well as simultaneously detect all other species present. Our results
confirm that none of the herbal products contained exactly the species listed on the
label, and all included substitutes, contaminants or fillers. This study highlights the
need for authentication of raw herbals along the value chain of these products. An
integrative methodology can assess both the quality of herbal products in terms of
target compound concentrations and species composition, as well as admixture and
substitution with other chemical compounds and plants.
Keywords: adulteration, DNA metabarcoding, herbal products, HPLC-MS, Veronica chamaedrys, Veronica
officinalis
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INTRODUCTION
Traditional herbal medicines play an important role in meeting
healthcare needs around the world, and complementary and
alternative medicines based on these are gaining in importance in
many industrialized countries as a perceived healthy alternative
to synthetic pharmaceuticals (World Health Organization, 2013).
The commercialization of such products is undergoing a
transition process from unregulated locally traded products to
internationally traded mass produced herbal pharmaceuticals
and food supplements (Heinrich, 2010; Leonti and Casu,
2013). A challenge in ethnopharmacology is to study such
novel herbal products and their value chains (Heinrich,
2010; Atanasov et al., 2015), as these are impacted by non-
harmonized regulatory and trade policies (Booker et al., 2012,
2016).
The regulation of herbal products varies globally and
between EU member countries, these falling under specific
legislation depending on their intended use, for instance, as food,
food supplements, herbal medicines, or homeopathic products.
Similar to the United States and Canada, the EU currently does
not have a centralized marketing authorization procedure for
herbal products, but instead provides relevant methodological
specifications to guarantee manufacturing quality. The EU also
lacks a central public institution for pharmacovigilance of the
herbal products, and the primary legal responsibility for safety of
the marketed herbal products is delegated to the pharmaceutical
industry, whereas national pharmacovigilance agencies monitor
drug safety.
A lack of standards for studies of medicinal plants has been
previously identified (cf. Ríos and Recio, 2005; Gertsch, 2009)
and several authors have advocated a stronger guidance of value
chains to mitigate this shortcoming (Rios et al., 1988; Cos et al.,
2006; Verpoorte, 2008). Current quality assessment methods rely
mainly on morphology and analytical chemistry based methods
detailed in national or EU pharmacopoeias (EDQM - Council
of Europe, 2014). However, the resolution of these methods is
highly influenced by factors such as the phenotypic plasticity,
morphological cryptic taxa, species-specific chemical markers,
growing conditions, harvesting process, storage condition, or the
extraction procedure (Barnes, 2003; Bickford et al., 2007; Jiang
et al., 2010; Shaw et al., 2012).
In addition to ensuring that herbal products contain the
intended ingredients in the right quantities, an important
problem is the use of substitutes and undeclared fillers (Coghlan
et al., 2012, 2015; Newmaster et al., 2013). Misidentification
(Saslis-Lagoudakis et al., 2015) or incongruences in the
vernacular names of the raw material (Farah et al., 2006;
Ouarghidi et al., 2012; Walker and Applequist, 2012; De Boer
et al., 2015) can lead to accidental substitution, but rising prices
of raw materials and the high demand for such products also
provide an incentive for deliberate adulteration. The use of
unlabelled ingredients presents a serious safety challenge as
adverse drug reactions cannot be associated to the product label
and ingredients (Heubl, 2010; Gilbert, 2011). Recent studies of
herbal medicine and herbal food supplement value chains using a
combination of phytochemical and metabolomics analyses have
found that adulteration of these products often occurs in the
first stages of their value chains (Booker et al., 2012, 2014,
2016).
Veronica officinalis L. (common speedwell) is a popular
medicinal plant in several European countries, especially in
central eastern Europe and the Balkans, and used in herbal
medicine both traditionally and increasingly in commercial
herbal products. Veronica L. (Plantaginaceae) is a genus
of about 450 species (Albach and Meudt, 2010) occurring
over most of the Northern Hemisphere and in many parts
of the Southern Hemisphere (Mabberley, 2008). Modern
systematic studies of the genus have focused on molecular
phylogenies of several nuclear and plastid markers: the nuclear
ribosomal internal transcribed spacer, nrITS (Wagstaff and
Garnock-Jones, 1998; Albach and Chase, 2001; Albach et al.,
2004; Buhk et al., 2015), the plastid regions trnL-F (Albach
et al., 2004, 2006; Buhk et al., 2015), ndhF-rpl32 (Sonibare
et al., 2014; Albach and Al-Gharaibeh, 2015; Buhk et al.,
2015), trnH-psbA (Sonibare et al., 2014; Albach and Al-
Gharaibeh, 2015), rps16 intron (Albach and Chase, 2004),
rps16–trnK (Sonibare et al., 2014; Albach and Al-Gharaibeh,
2015).
Ethnopharmacological Importance of
Veronica Species
Several Veronica species are used in European traditional
medicine to treat respiratory affections, as an expectorant,
an antiscorbutic, a diuretic, and for wound healing (Baytop,
1984; Harput et al., 2002a). In Turkey, the aerial parts of
Veronica anagallis-aquatica L. are boiled in milk to obtain
a poultice used to alleviate abdominal pain (Küpeli et al.,
2005), or used as a bath cure to relieve rheumatic pain
(Fujita et al., 1995). In the Valdesi valley of Italy, in the
poorer villages Veronica species are traditionally used as an
inexpensive substitute for imported teas and this has been
posed as an explanation of the modern use of Veronica
species in recreational teas (Bellia and Pieroni, 2015). In
traditional Chinese medicine V. anagallis-aquatica is used for
the treatment of influenza, hemoptysis, laryngopharyngitis,
and hernia (Su et al., 1999). In Europe, V. officinalis is
the best-known and most commonly used species (Table 1).
The main ethnopharmacological indications for V. officinalis
are inflammatory conditions, rheumatism, stomach ulcers,
respiratory ailments (Scarlat et al., 1985; Mocan et al., 2015b), and
nervous, cardiovascular and metabolism system disorders (Vogl
et al., 2013).
Phytochemical and Pharmacological
Studies
Veronica species are rich in iridoid glucosides, mainly aucubin,
catalpol and benzoic and cinnamic acid esters of catalpol, all
compounds that have previously been investigated for their
bioactivities (Harput et al., 2002a,b, 2014; Saracoglu et al., 2002).
Saracoglu and Harput (2012) showed that some iridoid glucosides
of V. anagallis-aquatica, V. persica Poir, and V. thymoides
P.H.Davis subsp. pseudocinerea M.A.Fisch. exhibited cytostatic
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TABLE 1 | Traditional uses of Veronica officinalis in different European countries.
Country Use Reference
Austria Cardiovascular system Vogl et al., 2013
Metabolism
Nervous system
Respiratory tract
Bulgaria Appetizer Ivancheva and Stantcheva,
2000; Leporatti and Ivancheva,
2003
Anti-inflammatory
Antitussive
Asthma
Coughs
Expectorant
Pharyngitis
Tonsillitis
Italy Recreational tea Bellia and Pieroni, 2015
Montenegro Bronchitis Menkovic´ et al., 2011
Rheumatic complaints
Skin diseases
Wounds
Romania Antiulcerous activity
Catarrh
Cough
Hepatoprotective activity
Hypocholesterolemic effect
Tamas et al., 1984; Scarlat
et al., 1985; Cris¸an et al., 2007;
Gründemann et al., 2013
Kidney diseases
Lung diseases
Wound healing properties
Serbia Against anemia Zlatkovic´ et al., 2014
Hypolipemic
Treatment of skin diseases
Sweden Recreational tea Sõukand et al., 2013
and cytotoxic activities on human and murine cancer cell
lines, with verminoside being the most cytotoxic compound
and Harput et al. (2002a) showed that V. cymbalaria Bodard,
V. hederifolia L., V. pectinata L. var. glandulosa, V. persica and
V. polita Fr. possess anti-inflammatory, cytotoxic and radical
scavenging activities. Vogl et al. (2013) showed for the first
time in vitro anti-inflammatory activity of the extracts prepared
from V. officinalis. Nikolova (2011) found that V. bellidioides
L., V. kellereri Degen & Urum., V. vindobonensis (M.A.Fisch.)
M.A.Fisch., V. beccabunga L., V. rhodopea Degen ex Stoj.
& Stef. and V. austriaca L. showed significant antioxidant
properties.
Quality Issues of Veronica officinalis
Herbal Products
As a folk remedy, V. officinalis is used mostly in traditional
medicine, and no current national pharmacopeia monographs
include standards for quality control or authentication of
Veronica herbal products. Identification tests currently available
to detect substitutes and adulterants rely on chromatographic
methods, usually as a combination of separate approaches (e.g.,
HPLC with TLC-densitometry) or a combination of different
approaches into a single procedure (e.g., HPLC-UV, HPLC-MS
or GC-MC) (European Medicine Agency [EMA], 2006; EDQM -
Council of Europe, 2014).
All raw materials of V. officinalis used in the marketed herbal
products are harvested from the spontaneous flora, and sourced
from several countries in central eastern Europe and the Balkans.
Kathe et al. (2003) and Ichim et al. (2011) cite that the exploitation
pressure of wild-harvesting could potentially threaten the species.
The limited availability of V. officinalis is a likely driver behind
the widespread substitution with V. chamaedrys L. (germander
speedwell), an abundant herb of grassland and forest edges,
with no proven therapeutic uses Cris¸an et al. (2007, 2011).
Furthermore, even though their vegetative morphology is clearly
distinct, the flowers of V. officinalis and V. chamaedrys can
easily be confused (Leyel, 1937). Cris¸an et al. (2001, 2011)
report histological, anatomical and phytochemical characters
that distinguish V. officinalis and V. chamaedrys and propose a
rapid differentiation method using thin-layer chromatography
(TLC) of species-specific phenyl-propanoic compounds. These
analytical methods enable chemical identification of some target
compounds, but cannot rule out that other Veronica species,
or mixtures thereof, might be present in the investigated
products. Marketed herbal products are complex formulations
that are usually highly processed and consist of numerous
ingredients.
DNA Barcoding and Metabarcoding
Rapid advances in DNA sequencing have enabled cost-effective
use of DNA sequences for species identification. Hebert et al.
(2003) coined the concept of DNA barcoding as a rapid and
accurate way of species-level identifications using short standard
DNA regions. Different combinations of plastid markers (e.g.,
rbcL, matK, and trnH-psbA) and the nuclear ribosomal internal
transcribed spacer (nrITS) have been proposed as the primary
barcodes for plants, and the current core barcodes are rbcL
and matK, supplemented by nrITS (Kress and Erickson, 2007;
CBOL Plant Working Group, 2009; China Plant BOL Group,
2011; Hollingsworth et al., 2011). Several studies have shown
that about 75–85%, and in some floras over 90%, of plant
species can be identified to species level using DNA barcoding
(Lahaye et al., 2008; Kress et al., 2009, 2010; Chen et al.,
2010; Burgess et al., 2011). In taxonomically difficult plant
groups, where hybridization is frequent, or in lineages of
relatively young age the use of traditional barcodes may not
be reliable (Kress and Erickson, 2007; Fazekas et al., 2009).
In such groups the use of low-coverage shotgun sequencing
of genomic DNA could resolve relationships and augment
current plant barcodes (Coissac et al., 2016; Hollingsworth et al.,
2016).
Techen et al. (2014) reviewed the progress made in DNA
barcoding of medicinal plants. DNA barcoding of herbal products
has revealed alarming levels of substitution within marketed
herbal products, for instance, 6% in saw palmetto herbal
dietary supplements (Little and Jeanson, 2013), 16% in ginkgo
products (Little, 2014), 25% in black cohosh (Baker et al., 2012),
33% in herbal teas (Stoeckle et al., 2011), 50% in ginseng
(Wallace et al., 2012), 37% in Senna and 50% in Cassia market
products (Seethapathy et al., 2014). Newmaster et al. (2013)
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tested 44 herbal products sold in North America using DNA
barcoding and found that 59% contained species not listed
on the label, and only 2 out of 12 screened companies had
products free of substitution, contamination or unreported
fillers. DNA metabarcoding, a combination of high-throughput
sequencing (HTS) and polymerase chain reaction based DNA
amplification, provides simultaneous taxonomic identification
of taxa from samples containing DNA from different origins
(Taberlet et al., 2012). DNA metabarcoding studies are providing
insights into species composition of complex mixtures of DNA
such as processed herbal products. For example, Coghlan
et al. (2012) evaluated the species composition of fifteen
highly processed traditional Chinese medicines (TCM) and
found that these contained species and genera included on
CITES appendices I and II. Similarly, Cheng et al. (2014)
found a high level of contamination within 27 investigated
herbal preparations, Ivanova et al. (2016) found that all 15
tested herbal supplements contained species not listed on the
product label, and Raclariu et al. (2017) authenticated 78
Hypericum perforatum herbal products and found the target
species in only 68% products while detecting incongruence
between constituent species and those listed on the label in all
products.
In this study we test the hypothesis that dwindling availability
of wild V. officinalis has resulted in admixture of V. chamaedrys
and other Veronica species in Veronica herbal products.
Substitution of V. officinalis with V. chamaedrys would not
only be fraudulent from a commercial perspective, but would
also leave anticipating consumers with a herbal product without
proven therapeutic activity. We approach this hypothesis using
DNA metabarcoding and HPLC-MS to authenticate and detect
species diversity in European Veronica herbal products, and aim
to answer the following research questions: (1) Can HPLC-MS
be used to distinguish V. officinalis from V. chamaedrys and to
identify exclusive presence of V. officinalis in herbal products?;
(2) Can DNA metabarcoding be used to test for the presence
of V. officinalis in herbal products, to detect substitution and
adulteration for other Veronica species and/or presence of other
off label plant species?
MATERIALS AND METHODS
Sample Collection
Sixteen single and multi-ingredient herbal products including
V. officinalis on the label were purchased from retail stores and
pharmacies (14) and via e-commerce (2). The products included
herbal teas (12), extracts (2), capsules (1), and candies (1).
An overview of the samples is included in the Supplementary
Table S1, but identifying information on the producer/importer,
product name, lot number, expiration date is withheld for
anonymity. The herbal products were imported to Norway under
Norwegian Medicines Agency license no. 16/04551–2.
For DNA barcoding, nrITS reference sequences of 118
accessions belonging to 56 Veronica species were compiled into
a barcode reference database, consisting partly of sequences
mined from NCBI/GenBank and partly of sequences generated
within the project from specimens collected in 2014 and 2015
(Supplementary Table S2). For the phytochemical analyses, aerial
parts of V. officinalis and V. chamaedrys (samples marked with
an asterisk in Supplementary Table S2) were used as references
for the identification and quantification of the main compounds.
Voucher specimens of the plant material used in this study are
deposited in the Herbarium of the Alexandru Borza Botanical
Garden (CL) of Babes-Bolyai University, Cluj-Napoca, Romania
(Supplementary Table S2).
Phytochemical Analysis
High-Performance Liquid
Chromatography-Mass Spectrometry
(HPLC-MS)
Extracts were prepared from plant material and herbal products
following established procedures (Cris¸an et al., 2010; Mocan et al.,
2015a,b), with slight modifications. One gram of each sample
was extracted with 10 ml of 70% ethanol (HPLC grade) at room
temperature for 1 h in a sonication bath (Polsonic 3, Polsonic
Inc., Poland). The extracts were filtered through MN 615 filter
paper (Macherey-Nagel GmbH, Germany) and stored at 4◦C
until further analysis. Prior to HPLC-MS analysis the extracts
were syringe filtered with a 0.45 µm nylon membrane (Whatman
Inc., United States).
Target Veronica iridoids (aucubin, catalpol, catalposide, and
veronicoside) from all sixteen herbal products as well as aerial
plant parts were analyzed by HPLC-MS on a Agilent 1100
liquid chromatography system equipped with a binary pump,
autosampler, thermostat and detector (all 1100 Series from
Agilent Inc., United States). The system was controlled with
Data Analysis software (version B01.03, Agilent Inc., United
States). The separation was carried out on an Atlantis HILIC
3.5 µm (100 mm × 3.0 mm i.d.) (Waters Inc., United
States) column equipped with an online 0.2 µm filter (Agilent
Inc.), at a working temperature of 40◦C, a flow rate of
0.75 ml/min and an injection volume of 6 µl. A binary
gradient system with eluent (A) 0.1% acetic acid and 20 µM
sodium acetate in water, and eluent (B) 0.1% acetic acid
and 20 µM sodium acetate in acetonitrile was used for the
analyzed samples with the following gradient: 95–80% B (1–
5 min). The HPLC system was coupled with an Agilent Ion
Trap 1100 SL mass spectrometer equipped with an electrospray
ionisation (ESI) source and operated in the positive mode
with a scan range between 360 and 680 m/z, to identify the
target compounds based on their sodium adducts (M+23 m/z):
aucubin (369 m/z), catalpol (385 m/z), catalposide (505 m/z)
and veronicoside (489 m/z), and by comparison with analytical
standards in the same chromatographic conditions. The capillary
voltage was set to 4 kV and the capillary temperature to
325◦C. Nitrogen (N2) was used as dry gas with a dry flow
of 12 l/min and a pressure of 60 psi for the nebulizer.
For quantitation of the iridoids, stock solutions of the four
commercially available standards substances (Sigma–Aldrich, St.
Louis, Missouri, United States) were prepared in acetonitrile,
and different concentrations of each standard were used. All
calibration curves yielded a coefficient of determination of
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R2 ≥ 0.99. The results are expressed as µg per g of dry weight
material (µg/g dw).
Genetic Analysis
DNA Extraction, PCR Amplification and DNA
Sequencing
The total DNA was extracted from 300 mg of each homogenized
herbal product or silica gel dried leaves, using a modified
CTAB extraction protocol (Doyle and Doyle, 1987; Kool et al.,
2012). Two extraction negative controls were included to
screen for contamination and cross-contamination. Total DNA
extracts of the herbal products were quantified and assessed for
fragmentation with a Fragment Analyzer (Advanced Analytical
Technologies, Inc., Ankeny, IA, United States) using the DNF-
488-33 HS (High Sensitivity) genomic DNA Reagent Kit (50 –
40000 bp). Total DNA extracts of silica gel dried leaves were
quantified with a Qubit 2.0 fluorometer (Life Technologies,
Carlsbad, CA, United States) using the dsDNA BR (Broad-
Range) kit. PCR amplification using nrITS primers, ITS-4
and ITS-5 (White et al., 1990), was done on purified total
DNA from the dried leaves, using a final reaction volume of
25 µl, including 2.5 µl 10X reaction buffer II (supplied with
the polymerase), 2.5 µl 25 mM MgCl2 (supplied with the
polymerase), 0.2 µl 5 U/ml AmpliTaq DNA Polymerase (Applied
Biosystems, Foster City, CA, United States), 2.5 µl 10 µM dNTPs
(Applied Biosystems, Foster City, CA, United States), 2.5 µl
10 µM of each primer (Sigma–Aldrich, St. Louis, Mo, United
States), 2.5 µl 1 mg/ml bovine serum albumen (BSA) (Roche
Diagnostic GmbH, Mannheim, Germany), 9.3 µl of Milli-Q
ultrapure water and 0.5 µl of template DNA solution (1 ng/µl).
The PCR cycling protocol consisted of initial denaturation at
94◦C for 2.5 min, followed by 32 cycles of denaturation at 94◦C
for 30 s, annealing at 53◦C for 30 s, and elongation at 72◦C
for 50 s, followed by a final elongation step at 72◦C for 4 min.
Three PCR negative controls were included per amplification
to control for external and cross-sample contamination. 6 µl
of each PCR products was purified using 2 µl 10 times diluted
ExoSAP-IT (USB Corporation, Cleveland, OH, United States)
by incubation at 37◦C for 45 min followed by 15 min at 80◦C.
Sequencing was performed using the ABI BigDye Terminator
sequencing buffer and the v3.1 Cycle Sequencing kit (Applied
Biosystems, Foster City, CA, United States) on an ABI3130XL
automated sequencer (Applied Biosystems, Foster City, CA,
United States). The sequences were edited, and the forward and
reverse sequences assembled using SeqTrace (Stucky, 2012). The
sequences were submitted to NCBI/GenBank and their accession
numbers are listed in the Supplementary Table S2.
Barcode Gap Analysis
The reference sequences of 118 accessions belonging to 56
Veronica species were aligned using AliView (Larsson, 2014),
and pairwise genetic distances between the accessions were
calculated using MEGA 6.0 (Tamura et al., 2013) for each of
the following regions: nrITS1, nrITS2, and the entire nrITS.
Automatic Barcode Gap Discovery (ABGD) (Puillandre et al.,
2012) was used to determine the genetic distance threshold
and automatically define species delimitation hypotheses. ABGD
determines the number of groups (hypothetical species) within
a dataset using pairwise sequence distances and two input
variables, prior intraspecific diversity (P) and minimum gap
width (X) (Puillandre et al., 2012). Based on this information
ABGD makes an initial partition of the supplied sequences
into candidate species groups based on a statistically inferred
barcode gap and then applies recursive partitions to each group
to generate subsequent partitions into candidate species until no
further splitting occurs (Puillandre et al., 2012). The minimum
gap width (X) was set to X = 1.0, the prior intraspecific diversity
(P) was set to range from 0.001 to 0.1, and the p-distance, Jukes-
Cantor (JC) and Kimura 2 Parameter (K2P) distance metrics were
used in the ABGD analyses (Jukes and Cantor, 1969; Kimura,
1980), resulting in 18 analyses (6 per dataset). Default values were
used for all other parameters (steps: 10 and Nb bins: 20). The
total numbers of groups corresponding to the prior intraspecific
divergence (P) values, ranging from 0.001 to 0.1, were recorded
(Supplementary Table S3).
To determine whether V. officinalis can be unambiguously
differentiated from its main adulterant, V. chamaedrys, using
molecular operational taxonomic units (MOTUs), the intra- and
interspecific variation of all reference sequences of these species,
respectively, 16 accessions belonging to V. officinalis and 9 to
V. chamaedrys, were analyzed based on pairwise comparison
of nrITS genetic distances using Taxon DNA/SpeciesIdentifier v
1.7.8 (Meier et al., 2006).
DNA Metabarcoding
Fusion primers of the internal transcribed spacers nrITS1 and
nrITS2, based on primers 17SE and 5.8I1, and 5.8I2 and 26SE
(Sun et al., 1994) (Biolegio B.V., the Netherlands), were used
to generate PCR based amplicons. Forward primers were fused
with a unique 10 bp multiplex identifier (MID) tags and the
reverse primers with a truncated version of adapter P1 (trP1)
tags. Expected amplicon sizes were 300–350 bp. PCR reactions
on DNA extracted from the herbal products were carried out
in final reaction volumes of 25 µl including 0.5 µl of template
DNA solution (ranging from 0.5 to 2 ng/µl), 5 µl 5X Q5
reaction buffer (New England Biolabs Inc., United Kingdom),
1.5 µl 10 µM of each primer (Biolegio B.V., the Netherlands),
0.5 µl 10 mM dNTPs, 0.25 µl 20 U/µl Q5 High-Fidelity DNA
Polymerase (New England Biolabs Inc., United Kingdom), 5 µl
5X Q5 High GC enhancer and 10.75 µl of Milli-Q ultrapure
water. The PCR cycling protocol consisted of initial denaturation
at 98◦C for 30s, followed by 35 cycles of denaturation at 98◦C
for 10s, annealing at 56◦C for nrITS1 or 71◦C for nrITS2 for
30 s, and elongation at 72◦C for 30 s, followed by a final
elongation step at 72◦C for 2 min. Eight PCR negative controls
were included per amplification to control for external and cross-
sample contamination.
Agencourt AMPure XP PCR purification (Beckman Coulter
Inc., United States) was used for high-throughput purification
of PCR amplicons. The size, purity and the molar concentration
(nmol/l) of each amplicon library was measured using a
Fragment AnalyzerTM (Advanced Analytical Technologies Inc.,
United States) with a DNF-910 dsDNA Reagent Kit (35–
1,500 bp), equimolar pools (2 ng/µl/library) were prepared
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from the amplicon libraries using a Biomek 4000 Laboratory
Automation Workstation (Beckman Coulter Inc., United States).
To identify the optimum bead-to-template ratio for template
preparation, the concentration of the purified pooled amplicon
libraries was analyzed with a Fragment AnalyzerTM (Advanced
Analytical Technologies, Inc., United States) using a DNF-488
High Sensitivity Genomic DNA Analysis Kit. The pooled Ion
AmpliSeq libraries (Life Technologies, Thermo Fisher Scientific
Inc., United States) for emulsion PCR and sequencing chip
loading were prepared using an Ion Chef (LT). The DNA template
concentration was adjusted to the number of Ion Sphere Particles
(ISPs) and added to the emulsion PCR master mix. The template-
positive ISPs were enriched and sequenced on an Ion Torrent
Personal Genome Machine (LT) using Ion 318 v2 chips (LT) and
the Ion PGM Sequencing 400 kit (LT). Sequencing read data was
initially processed and demultiplexed based on MIDs into FASTQ
files using Ion Torrent Suite Software version 5.0.4 (LT).
Bioinformatics Analysis
Sequencing reads were processed using the HTS barcode-checker
pipeline freely available at https://github.com/naturalis/HTS-
barcode-checker (Lammers et al., 2014). The nrITS1 and nrITS2
primer sequences were used to split the reads based on the
primer sequence. Read lengths and Phred quality scores were
assessed using PRINSEQ (Schmieder and Edwards, 2011), and
based on these values reads with a mean Phred quality score of
less than 26 and a length of less than 300 bp were filtered out.
The remaining reads were trimmed to a maximum length of
350 bp. Reads were clustered into MOTUs using three different
sequence similarity thresholds during clustering, respectively, 97,
99 and 100%, with a minimum of 10 reads per cluster using CD-
HIT-EST (Li and Godzik, 2006). A representative sequence from
each MOTU was taxonomically assigned using local Basic Local
Alignment Search Tool (local BLAST) (Altschul et al., 1990),
with a maximum e-value of 0.05 and a minimum hit length of
100 bp, against a reference database consisting of a local copy of
the NCBI nucleotide database (Benson et al., 2013). Species level
identifications were assigned when similarity to the reference
barcode matched at>99%.
RESULTS AND DISCUSSION
Phyotochemical Analysis
High-Performance Liquid Chromatography-Mass
Spectrometry (HPLC-MS)
Iridoids and iridoid glycosides are specific chemotaxonomic
markers for the genus Veronica, and most Veronica species
contain the iridoid glycosides aucubin and/or catalpol as well as
one or more 6-O-esters of catalpol (i.e., veronicoside, catalposide)
(Afifi-Yazar and Sticher, 1980; Taskova et al., 2002, 2004; Jensen
et al., 2005). The main known ethnopharmacological indication
for Veronica species are inflammatory diseases (rheumatism,
stomach ulcer) or respiratory ailments (Scarlat et al., 1985;
Mocan et al., 2015a), and several studies have shown that
iridoid glycosides in Veronica are linked to this therapeutic
effects (Scarlat et al., 1985; Gründemann et al., 2013; Ignjatovic´,
2015). Although regulatory guidelines to establish quality control
or authentication of Veronica herbal products are lacking, the
presence and concentration of specific iridoid glycosides has
been shown to enable authentication of Veronica herbal products
(Cris¸an et al., 2010; Gründemann et al., 2013).
The HPLC-MS results from the present study show the
characterization of Veronica herbal products against four
commercially available iridoid glycosides, namely aucubin,
catalpol, veronicoside and catalposide (Table 2). The two
most commonly identified compounds in the examined herbal
products and reference plant material were aucubin and catalpol.
From a pharmaceutical point of view, the concentrations of
the compounds present in different herbal remedies or plant
materials cannot be neglected as they are directly linked to their
pharmaceutical efficacy and effectiveness. Aucubin was found in
fifteen herbal products samples as well as in the reference plant
material of both species (V. officinalis and V. chamaedrys), with
the highest concentration in sample 9. Aucubin concentrations
in the herbal products and reference plant material show a large
variation with concentrations ranging from 0.33 to 39.73 µg/g.
Catalpol was found in 13 herbal products, with the highest
concentration in sample 11, but was missing in two of the
reference plant samples (V. off 4 and V. cha 1). No iridoid
glycosides were identified in sample 14, a lozenge with nineteen
ingredients listed on the label. Jensen et al. (2005) concludes that
aucubin and/or catalpol is/are present in all Veronica species,
implying that if sample 14 contains any material of Veronica this
would be below the level of detection of the HPLC-MS platform
we used in this study, and consequently unlikely to exert any
pharmacological activity. Concerning the other two 6-O-esters
of catalpol, veronicoside was present in five herbal products and
in all V. officinalis reference material, with highest concentration
in sample V. off 1, while catalposide was present in nine herbal
products, with the highest concentration in sample 8, but none of
the investigated reference plant materials contained catalposide.
Jensen et al. (2005) states that although aucubin and/or catalpol
are present in all Veronica species, V. micrantha is the only species
in Veronica subgenus Chamaedrys, to which V. chamaedrys
belongs, that contains aucubin. However, this assumption was
later rejected by Cris¸an et al. (2010) that identified both aucubin
and catalpol in V. chamaedrys, and as well as by the results of this
study.
Genetic Analyses
Barcode Gap Analysis
Species-level identification using DNA barcoding and
metabarcoding requires that the level of intraspecific genetic
divergence is lower than the interspecific genetic divergence
(Meyer and Paulay, 2005), and several identification approaches
are based on setting a cut-off threshold above which a query
sequence is considered to be distinct from a reference sequence.
Defining an optimal threshold is a controversial debate (Hebert
et al., 2004; Meyer and Paulay, 2005; Smith et al., 2005; Wiemers
and Fiedler, 2007; Chen et al., 2013). Previous studies proposed
different thresholds of genetic distances, for instance, 1%
(Ratnasingham and Hebert, 2013), 3% (Smith et al., 2005) or the
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TABLE 2 | Concentrations of the four main iridoid glycosides in the analyzed herbal products and the Veronica reference plant material (details about the herbal products
can be found in Supplementary Table S1).
Product no. Concentrations (in µg/g)
Veronicoside Catalposide Aucubin Catalpol
1 n/c 0.48 ± 0.02 1.19 ± 0.03 0.28 ± 0.01
2 n/c n/c 1.58 ± 0.02 1.05 ± 0.04
3 n/c 3.38 ± 0.11 13.77 ± 0.52 1.52 ± 0.04
4 0.24 ± 0.01 2.10 ± 0.08 29.17 ± 1.03 5.42 ± 0.18
5 n/c n/c 0.33 ± 0.01 0.56 ± 0.02
6 n/c n/c 20.79 ± 0.73 n/c
7 n/c n/c 6.01 ± 0.13 n/c
8 n/c 4.56 ± 0.16 18.24 ± 0.71 5.82 ± 0.12
9 n/c 0.22 ± 0.01 39.73 ± 1.17 2.33 ± 0.09
10 n/c n/c 26.88 ± 0.95 3.97 ± 0.13
11 8.81 ± 0.39 0.77 ± 0.02 11.78 ± 0.43 11.46 ± 0.37
12 9.06 ± 0.41 2.01 ± 0.08 7.31 ± 0.29 9.63 ± 0.38
13 2.74 ± 0.11 2.08 ± 0.07 4.16 ± 0.17 1.92 ± 0.08
14 n/c n/c n/c n/c
15 n/c n/c 0.64 ± 0.02 0.43 ± 0.01
16 1.01 ± 0.03 0.37 ± 0.01 1.11 ± 0.04 1.12 ± 0.02
V. off 1 36.07 ± 1.8 n/c 11.32 ± 0.55 10.04 ± 0.45
V. off 2 0.29 ± 0.01 n/c 1.94 ± 0.07 3.32 ± 0.15
V. off 3 1.72 ± 0.03 n/c 1.53 ± 0.06 0.48 ± 0.01
V. off 4 0.27 ± 0.01 n/c 0.41 ± 0.02 n/c
V. cha 1 n/c n/c 3.39 ± 0.11 n/c
V. cha 2 n/c n/c 6.12 ± 0.29 0.87 ± 0.03
V. cha 3 n/c n/c 7.44 ± 0.32 0.93 ± 0.02
V. cha 4 n/c n/c 7.52 ± 0.27 2.38 ± 0.10
10X rule where the interspecific distances are considered to be
10 times greater than intraspecific distances (Hebert et al., 2004),
but each has shortcomings for general application (Meier et al.,
2008; Rach et al., 2008; Bertolazzi et al., 2009).
In this study we used ABGD to assess the ‘barcode gap’ for the
Veronica genus, with the specific aim of evaluating if nrITS has
sufficient discriminatory power to differentiate V. officinalis from
its main adulterant, V. chamaedrys. The three distance metrics
used for the analyses produced identical initial partitions within
each dataset and for all the values of prior intraspecific diversity
(P), but with a slight difference between the datasets, respectively,
14 groups for nrITS and nrITS2 and 13 for nrITS1. The recursive
partitions resulted in a variable number of groups within each
dataset depending on P, respectively, with 18, 22, 37, and 53
groups for nrITS dataset, 14, 19, and 37 groups for nrITS1, and
16, 23, 31, and 54 groups for nrITS2 data set.
Infra- and interspecific divergence based on pairwise
comparison of nrITS genetic distances of V. officinalis and
V. chamaedrys (Supplementary Table S4) helped to identify an
optimal clustering threshold for analysis of high-throughput
sequence data and accurate molecular identification and
discrimination of the two species. Pairwise intraspecific genetic
distances did not exceed 1.5%, and furthermore 93.8% of
the pairwise intraspecific distances were below 1%. Pairwise
interspecific genetic distances, on the other hand, ranged from
18 to 22%. The pairwise comparisons showed that applying
97% or more similarity as a clustering threshold will confidently
discriminate V. officinalis and V. chamaedrys. These results
are consistent with the ABGD analysis in which the sequences
belonging to V. officinalis and V. chamaedrys were assigned
to well defined independent groups using an a priori defined
genetic threshold of 1%.
DNA Metabarcoding
The quantity of the total DNA extracted from the sixteen herbal
products varied between samples. Total DNA concentration
measurement gave detectable results for 15 of the samples
(93.7%), with DNA concentrations ranging from 0.06 to
87.32 ng/µl, and nrITS1 and nrITS2 amplicons were obtained
for all these samples. One sample, marketed as a lozenge,
did not yield a measurable DNA concentration and no
amplicons of nrITS1 and nrITS2 were obtained from this sample
(Supplementary Table S5).
The raw data before demultiplexing consisted of 2,638,101
sequences, with an average of 82,440 sequences per sample
for each marker. Sequencing was successful for thirteen herbal
products (81.3%) for both nrITS1 and nrITS2 and they were
used for further analysis (Table 3). Three products, two herbal
teas (5, 16) and the lozenge (14), did not yield reads or MOTUs
after applying the quality filtering criteria and were excluded from
further analyses. A total of 63,929 sequences passed our trimming
and filtering quality criteria (2.4% of reads), including 19,788
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TABLE 3 | Overview of the results of three clustering thresholds (97, 99, and 100%).
Sample # nrITS1+nrITS2 # reads
before demultiplexing
nrITS21 #
reads
nrITS2 #
reads
97% 99% 100%
# MOTUs # Species # MOTUs # Species # MOTUs # Species
1 163443 80255 78683 15 6 75 11 108 12
2 180106 104096 67500 17 11 71 17 79 16
3 158877 85618 69168 19 7 53 13 188 12
4 440956 299997 114335 47 12 142 23 191 16
5∗ 34 8 18 0 0 0 0 0 0
6 217323 131223 74700 16 7 27 7 47 7
7 400607 174347 192110 49 25 99 32 191 26
8 309978 73352 213401 30 16 107 23 303 19
9 80179 58175 16627 25 14 36 13 49 12
10 62198 45321 15903 12 5 47 7 49 4
11 254965 186423 47991 33 14 64 16 77 10
12 122393 63939 55331 14 7 33 5 108 4
13 26001 16464 7830 0 0 4 2 12 2
14∗ 19 10 6 0 0 0 0 0 0
15 220984 70947 131918 10 4 66 4 170 4
16∗ 38 12 18 0 0 0 0 0 0
Total 2638101 1390187 1085539 287 91 824 109 1572 80
∗Samples excluded from subsequent data analysis.
nrITS1 reads and 44,141 nrITS2 reads (Supplementary Table
S6). The metabarcoding data is used for qualitative evaluation
only, to determine presence of identified taxa, and not for
quantitative assessment of relative species abundance based on
read numbers, as too many variables impact the values, such as
the availability of DNA that can be removed or degraded during
the harvesting, drying, storage, transportation and processing
(Bombardelli, 1991; Novak et al., 2007), as well as variation in
nrITS copy numbers, primer annealing and PCR amplification
biases (Pawluczyk et al., 2015). Furthermore, incomplete
reference databases and incorrectly identified sequences in
GenBank can impact taxonomic assignments.
The choice of similarity clustering thresholds (>97, >99,
and 100%) impacted the number and size of assigned MOTUs
(Table 3). Setting the clustering threshold to 100% yielded
1572 MOTUs, 99% yielded 824 MOTUs, and 97% yielded only
287 MOTUs. The low number of MOTUs obtained using the
97% clustering threshold is likely the result of multiple species
being grouped together into the same MOTU as 3% divergence
far exceeds interspecific variation in many genera (Yang and
Rannala, 2017). Setting the clustering threshold to 100%, on
the other hand, likely resulted in more than one MOTU being
formed for a single taxonomic species as a result of infraspecific
variation and/or sequencing errors between reads. Here we
followed previous studies in using a 99% clustering threshold
(Ghorbani et al., 2016; Raclariu et al., 2017; Veldman et al.,
2017). Furthermore, to limit the impact of sequencing errors,
which are known to affect the Ion Torrent sequencing platform
(Loman et al., 2012; Salipante et al., 2014) and which could lead
to the formation of false MOTUs, we used only the clusters that
contained a minimum 10 reads.
The 824 MOTUs that were retained using a 99% similarity
clustering threshold were further identified using BLAST as
109 different species (Table 3 and Supplementary Table S6).
Based on only nrITS1 we detected a total of 64 different species
and on only nrITS2 61 species (Supplementary Table S6).
Based on both markers, the number of species detected per
sample ranged from 2 to 32, with an average of 8 species
per sample. Only two of the seven (28.6%) single ingredient
samples (those listing V. officinalis as the only ingredient)
contained V. officinalis, three others contained V. chamaedrys
and one contained other Veronica species, and all products
contained additional species, ranging from 1 to 21 species
per product. None of the nine retained multiple ingredient
samples (i.e., those listing V. officinalis and other species on the
label) contained only the listed ingredients, and none contained
V. officinalis (Figure 1). The overall ingredient fidelity (detected
species from product label/total number of species on label)
was 9.5% for the multiple ingredient products, and 17% for all
products. The target species V. officinalis was detected in only
2 products (15%), whereas V. chamaedrys was detected in eight
(62%) of the retained samples. These results are supported by
the pairwise comparison of the genetic distances that showed
that V. officinalis could be unambiguously differentiated from
V. chamaedrys using standard arbitrary clustering thresholds
(Supplementary Table S4). In sample 10 a mixture of several
Veronica species was detected, including V. bombycina Boiss.
& Kotschy, V. filiformis Sm., V. pectinata, V. tenuifolia Asso,
V. krumovii (Peev) Peev and V. chamaedrys. The presence of
these species can be explained as substitutes, admixtures or
contaminants. It should be noted that the general monograph
number 1433 on ‘Herbal drugs’ of the European Pharmacopoeia
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FIGURE 1 | Veronica and other species detected in the herbal products using DNA metabarcoding. Each numbered circle represents a product (more information
about these products can be found in Supplementary Table S1). The size of circles corresponds to the relative abundance of the reads.
allows up to 2% foreign matter, unless this is differently indicated
in a specific herb monograph (EDQM - Council of Europe,
2014). Presence of these other Veronica species might not be
in breach of the European Pharmacopoeia but it does indicate
a lapse in the value chain of this product. The same applies
to the 62% products that contained V. chamaedrys instead of
V. officinalis.
CONCLUSION
This study used HPLC-MS and DNA metabarcoding to
authenticate and detect adulteration or admixture of V. officinalis
with V. chamaedrys in Veronica herbal products. HPLC-MS is
useful for qualitative and quantitative analysis of constituents in
medicinal plants and herbal products and its use has increased in
recent years (Steinmann and Ganzera, 2011; Bansal et al., 2014),
but constraints are the expensive chemical reference standards
(some of which are still unavailable for biologically active
target components), sensitivity to the type of raw material and
manufacturing process, and lack of resolution in distinguishing
plant species (Bansal et al., 2014). Our HPLC-MS results show
that distinction of V. officinalis from other Veronica species
based on the targeted iridoid glycosides, aucubin, catalpol,
veronicoside, and catalposide is difficult in pure products, and
impossible in multiple ingredient products. General application
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of HPLC-MS to detect substitution and/or adulteration of highly
processed and multi-ingredient herbal products is challenging,
and this is corroborated by our findings.
Several authors have advocated the use of DNA barcoding
and metabarcoding in herbal product authentication and
pharmacovigilance (Coghlan et al., 2012; Newmaster et al.,
2013; Cheng et al., 2014; De Boer et al., 2015; Palhares et al.,
2015; Ivanova et al., 2016), due to its cost effectiveness and
ability to disclose plant species diversity within products. Our
DNA metabarcoding results corroborate previous research
that used metabarcoding to authenticate herbal products
(Coghlan et al., 2012, 2015; Cheng et al., 2014; Ivanova
et al., 2016; Veldman et al., 2017). In this study we confirm
its applicability to test for presence of V. officinalis and
simultaneously to detect substitution, adulteration and/or
admixture of other Veronica species. Using DNA metabarcoding
we found that only 15% of the products contained V. officinalis,
whereas 62% of the products contained V. chamaedrys.
Furthermore, we found that all the investigated herbal
products contained other species not listed on the label.
Limitations of DNA metabarcoding are its susceptibility
to various factors, such as quality, processing state and
product type of the extracted material, as well as several
variables related to the methodological framework, such as
DNA extraction procedures, primers, markers, amplification
protocols for the library preparation sequencing platform,
filtering, quality thresholds and chimera removal, and clustering
thresholds.
Despite limitations of the methodology, our DNA
metabarcoding results show that there is a need to study herbal
products derived from traditional medicine, and to increase
consumer confidence by advocating and promoting a higher
standard of quality in herbal products. In recent years, the
scientific community has been showing an increasing interest
in finding adequate and comprehensive methodologies to
investigate such complex products, focusing on their entire
value chain, from the raw material to the product on the
shelf.
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Lavender essential oil is traditionally used and approved by the European Medicines
Agency (EMA) as herbal medicine to relieve stress and anxiety. Some animal and clinical
studies reveal positive results in models of anxiety and depression although very little
research has been done on molecular mechanisms. Our work consisted of evaluating
the effects of lavender (Lavandula angustifolia) essential oil on central nervous system
well-established targets, such as MAO-A, SERT, GABAAand NMDA receptors as well
as in vitro models of neurotoxicity. The results showed that lavender essential oil and its
main components exert affinity for the glutamate NMDA-receptor in a dose-dependent
manner with an IC50 value of 0.04µl/mL for lavender oil. In addition, lavender and linalool
were also able to bind the serotonin transporter (SERT) whereas they did not show affinity
for GABAA-benzodiazepine receptor. In three different models of neurotoxicity, lavender
did not enhance the neurotoxic insult and improved viability of SH-SY5Y cells treated with
hydrogen peroxide. According to our data, the anxiolytic and antidepressant-like effects
attributed to lavender may be due to an antagonism on the NMDA-receptor and inhibition
of SERT. This study suggests that lavender essential oil may exert pharmacological
properties via modulating the NMDA receptor, the SERT as well as neurotoxicity induced
by hydrogen peroxide.
Keywords: essential oils, central nervous system, lavender, Lavandula angustifolia, Lavandula officinalis, SH-SY5Y
cells, glutamate receptor
INTRODUCTION
Essential oils have a long tradition in pharmaceutical sciences as natural products with
pharmacological, cosmetic, agrochemical and nutritional applications (Bakkali et al., 2008). The
use of EO in form of aromatherapy or phytotherapy is widely extended, some of them being
used as agents to relieve anxiety and stress (Setzer, 2009). Phytotherapy consists of the use of
medicinal plants in order to prevent, cure or threat illnesses. Aromatherapy can be understood as
a subdivision of phytotherapy and defined as the use of essential oils regarding therapeutic effects.
Abbreviations: CNS, central nervous system; LEO, lavender essential oil; GABA, γ-aminobutyric acid; iGLURs, ionotropic
glutamate receptors; MAO-A, monoamine oxidase A; NMDA, n-methyl-D-aspartate; SERT, serotonin transporter; SSRI,
selective serotonin reuptake inhibitor.
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These products have been used for centuries and are accepted in
traditional or modern healthcare systems of medicine. Medicinal
plants are widely used for the treatment of central nervous system
disorders (Wheatley, 2005) but in some cases there is still lack of
preclinical and clinical studies.
Central nervous system disorders have a great impact in
society due to a general aging process of the population as well
as lifestyle. Stress is one of the most prevalent psychological
disorders in developed countries leading to other clinical
features, such as anxiety, insomnia or depression.
Benzodiazepines (BZD) and selective serotonin reuptake
inhibitors (SSRIs) are highly prescribed as anxiolytic and
antidepressant drugs, respectively. BZD, such as diazepam,
lorazepam or alprazolam produce calming effects via binding
to GABAA receptors, but they may also produce somnolence
and cognitive impairment as adverse drug reactions. SSRIs
(e.g., fluoxetin, paroxetin, citalopram) are prescribed as
antidepressants because they are able to selectively block the
serotonin transporter (SERT), but side effects include sexual
dysfunction and neuropsychiatric disorders, such as suicide
tendencies and sleep disorders. Both groups of medicines are
also involved in withdrawal and “rebound effects” as a result of
discontinuing their administration.
Certain EO are being used as anxiolytic remedies and the
administration mode can be orally but also by inhalation or
combined with massage. One of the most popular essential
oils for mental disorders and anxiety is lavender (Lavandula
angustifolia Miller or Lavandula officinalis Chaix). Lavender
essential oil can be considered as one of the best-seller over
the counter herbal remedies for anxiety, stress and depression.
Studies reveal high content of linalool and linalyl acetate (Da
Porto et al., 2009) and international organizations, such as the
World Health Organization (WHO), the European Scientific
Cooperative on Phytotherapy (ESCOP) or the European
Medicines Agency (EMA) approve this medicinal plant to relieve
stress, restlessness and anxiety (Community)1.
The growing awareness of the adverse effects of central
nervous system drugs has led to develop new strategies and
safer pharmacological agents in mental health. Enzymes, such
as monoamine oxidase (MAO), proteins, such as the SERT and
ligand-gated ion channels, such as GABAA and NMDA receptors
are therapeutic targets in neuropharmacology. With the aim to
contribute to evidence-based herbal medicine we have studied
the effects of lavender essential oil on pharmacological targets
involved in anxiolytic and antidepressive properties as well as
in vitromodels of neurotoxicity.
METHODS
Lavender Essential Oil (LEO) and
Chemicals
Pure lavender (L. angustifolia) essential oil was kindly supplied
by Pranarom International (Belgium). Isolated monoterpenes
(linalool, linalyl acetate) were purchased from Fluka. Enzymes,
1 Community herbal monograph on Lavandula angustifolia Mill., aetheroleum.,
EMA/HMPC/143181/2010 (http://www.ema.europa.eu/ema/).
proteins and reagents were acquired from Sigma. Linalool and
linalyl acetate were also tested when lavender essential oil had a
clear and significant activity in the assays.
Chemical Profile by GC-MS
Although the essential oils are chemically characterized by
Pranarom International, LEO was analyzed in the laboratory by
GC-MS on an Agilent 6890N Network GC system coupled to
a 5973 Network Mass Selective Detector, accelerating voltage -
69.9 eV, recodingmasses of 35.00–400.00. GC conditions: injector
temperature: 150◦C; temperature programme: start 50◦C,
20◦C/min to 300◦C; column: HP5MS (5% phenylmethylsiloxane)
capillary, 30.0m × 250µl × 0.25µm nominal. Carrier gas:
helium at 1.0ml/min. A NIST library was used for comparison
of MS data.
Animals and Brain Membrane
Homogenates
Adult male Sprague Dawley rats were obtained from Taconic
(Denmark). Ethical permission for the studies was granted by the
AnimalWelfare Committee, appointed by the DanishMinistry of
Justice, and all animal procedures were carried out in compliance
with the ECDirective 86/609/EEC and theDanish laws regulating
experiments on animals. Rats were put down by competent staff,
the heads were separated from the body and the brains were
removed whereas cerebellum was discarded. The cortex were
weighed and homogenized with an Ultra-Turrax using different
buffers at 4◦C and the tissue preparation in each case was carried
out as earlier described (Ransom and Stec, 1988). The tissue
homogenates were resuspended and stored in aliquots at −80◦C
until use.
Bioassays Regarding Serotonergic Targets
Monoamine Oxidase-A Inhibition (MAO-A Assay)
The bioassay was performed in a 96-well microplate (Saaby
et al., 2009). Each well contained 50µl of essential oil dilution
or DMSO as blank (making a final concentration in the
wells of 0.002, 0.01, 0.02, and 0.1%), 50µl of chromogenic
solution (0.8mM vanillic acid, 417mM 4-aminoantipyrine and
4 U/ml horseradish peroxidase in potassium phosphate buffer
pH 7.6), 100µl of 3mM tyramine and 50µl of 8 U/ml MAO-
A. Absorbance was read at 490 nm every 5min for 30min.
Background interferences were deducted in the same way
described above but without MAO enzyme. Data was analyzed
usingGraphPad Prism. IC50 values could not be obtained because
the higest tested concentration did not reach 50% of MAO
inhibition. Clorgyline was used as positive control.
Serotonin Transporter Assay ([3H]-Citalopram
Binding Assay)
The assay was performed on the basis of themethod fromNielsen
et al. (2004). 25µl of three different essential oil concentrations
were mixed with 50µl of 4 nM [3H]-Citalopram and 225µl
of rat cortex suspension making a final concentration of the
essential oils in the assay of 0.08, 0.4, and 0.8%. All components
were previously dissolved in buffer (50mM Tris-base; 120mM
NaCl: 5mM KCl at pH 7.5). Plastic tubes were placed on an
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ice bath, the reagents were added and the tubes were mixed
and then left at room temperature (approximately 22◦C) for
2 h. After incubation, 5ml of ice cold buffer were added to
the samples and they were filtered through GC-50 Advantec
glass filters under vacuum and immediately washed once with
additional 5ml of ice cold buffer. Control test tubes (with
buffer instead of EO) and blind tubes (with 25µl of 120µM
paroxetine instead of EO) were done in every run in order
to determine total and unspecific binding. The amount of
radioactivity was determined transferring the glass filters into
scintillation tubes and adding 4ml of Ultimo Gold XR. The
scintillation tubes were placed in the dark for 30min before
they were measured on a Tri-CARB 2100 TR analyzer. Three
independent experiments were performed in triplicates. Non-
radioactive citalopram was used as reference. Linalool and linalyl
acetate were tested. The specific binding of [3H]-citalopram was
determined using the formula: % binding = [dpm(essential oil)-
dpm(unspecific binding)/dpm(total binding)-dpm(unspeficic binding)] ×
100.
Bioassays on Ionotropic Receptors
Affinity for GABAA Receptor ([
3H]-Ro 15-1788
Binding Assay)
The membrane preparation was washed with ice-cold buffer
(50mM Tris-citrate pH 7.1). The suspension was centrifuged at
0–4◦C for 10min at 27,000 × g. The pellet was resuspended in
Tris-citrate buffer (2mg original tissue per ml) and used for the
assay. 25µl of 3H-Ro 15-1788 (flumazenil) was added to 25µl
of test solutions (10, 1, and 0.1mg/ml) and 500µl of membrane
preparation. Total and unspecific binding was measured using
buffer or diazepam (1µM assay final concentration). After
incubation for 40min in an ice bath, 5ml of ice-cold buffer was
added to the samples and poured onto Adventic glass fiber filters
(GC-50) under vacuum, and immediately washed with another
5ml of ice-cold buffer. The amount of radioactivity of the filters
was measured by conventional liquid scintillation counting using
Ultimo Gold XR as scintillation fluid. Clonazepam was used as
positive control.
Affinity for NMDA Receptor ([3H]-CGP39653 Binding
Assay)
Affinity for native NMDA receptors was determined using 2 nM
[3H]-CGP 39653 (Sills et al., 1991) with some modification. On
the day of the assay, frozen membranes were quickly thawed
and homogenized in 30 volumes of ice-cold Tris-HCl buffer,
pH 7.4 (50mM containing 2.5mM CaCl2), and centrifuged
(48,000 × g for 10min). This step was repeated three times. The
final pellet was re-suspended in ice-cold buffer, corresponding
to approximately 0.4–0.5mg protein/ml. Binding was carried
out in aliquots consisting of 25µL [3H]-CGP 39653, 25µL test
solution, and 200µL membrane suspension and incubated at 0◦
for 60min. Non-specific binding was determined using 1mM
(S)-Glu. Binding was terminated by filtration through Whatman
GF/C filters using a 96-well Packard Filter-Mate Cell Harvester
and filters were washed with 3× 250 µL of ice-cold buffer. After
drying, 30µL Microscint 0 (Perkin-Elmer) per well was added
and the filter was counted on a Topcounter (Perkin-Elmer).
Linalool and linalyl acetate were also tested in this assay.
Neuroprotection on SH-SY5Y Cells
SH-SY5Y Neuroblastoma Cell Culture
Cells were cultured in DMEM (Gibco, ref. 41966-029) containing
phenol red (PR), L-Glutamine (1mM) and sodium pyruvate
(1mM) and was supplemented with 10% FBS (Gibco), penicillin
(100 U/mL, Gibco) and streptomycin (100 U/mL, Gibco). Cells
were maintained at 37◦C in saturated humidity (5% CO2). Non-
differentiated cells were plated on 48-well plates (Corning), at a
density of 5× 104 cells per well and were used 48 h after seeding.
Aβ25–35SolubleSpecies Preparation
Aβ25–35fragment was purchased from Sigma-Aldrich
laboratories (ref. A4559-1MG). 1mg of Aβ25–35 fragment
was dissolved in 1mL of type II water and was frozen at -20◦C
until further use. Different concentrations of Aβ25–35 (5, 10
and 15µM) were incubated in DMEM phenol red free (Gibco,
31053-028) at 37◦C for 3 days to obtain the oligomeric forms.
Cell Treatment and MTT Cell Viability Assay
SH-SY5Y cells were treated with either different LEO
concentration (0.05, 0.1, 0.5, and1µL/mL) or incubation
time (0, 2, and 24 h), followed by hydrogen peroxide (100, 200,
400, 800, and 1,600µM), malonate (0 or 50mM) or Aβ25–35(5,
10, and 15µM).
Cell viability was examined by the 3,4,5-dimethylthiazol-2-
yl-2,5-diphenyltetrazolium bromide (MTT) assay. MTT assay
is a colorimetric assay for measuring the activity of cellular
enzymes in living cells in response to potential toxic. After the
cell treatment, culture medium was replaced by a solution of
5 mg/mL MTT (Sigma-Aldrich) in DMEM (Gibco, 31053-028).
Cells were incubated with MTT solution for 2 h in the cell
incubator (5% CO2 and 37
◦C). Then, the MTT solution was
discarded and DMSO was added to the wells. Aliquots were
transferred to a 96-well plate, and absorbance was measured at
595 nm in a plate reader. Results were expressed as percentages
of non-treated control cells.
Statistical Analyses
Data are expressed as mean ± SE (figures) or as mean ±SD
(tables) of at least three independent experiments performed in
different days and in triplicates. GraphPad Prism was used to
calculate IC50 values and to detect significant differences. Student
t-test or ANOVA was performed for data analysis.
RESULTS
Chemical Profile by GC-MS
According to the GC-MS analyses, lavender essential oil mainly
contained the following monoterpenes: linalyl acetate (52.1%),
linalool (37.4%), geranyl acetate (5.4%), and β-caryophyllene
(5.1%).
Monoamine Oxidase-A Inhibition (MAO-A
Assay)
Inhibition of MAO A was not detected (data not shown).
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TABLE 1 | Activity of lavender essential oil (LEO) on the serotonin
transporter (SERT) and GABAA ionotropic receptor.
Samples SERT (% 3H-Citalopram binding)
0.8µl/ml 4µl/ml 8µl/ml
LEO 105.4 ± 0.9 77.6 ± 2.7* 37.8 ± 16.0***
GABAA (%
3H-Flumazenil binding)
0.045µl/ml 0.45µl/ml 4.5µl/ml
LEO 100.3 ± 9.5 100.1 ± 0.8 105.2 ± 9.3
*p< 0.05; ***p< 0.001 vs. the lowest concentration tested (0.8µl/ml in the SERT assay or
0.045µl/ml in the GABA assay). Data are mean ± SD of three independent experiments
performed in triplicates.
FIGURE 1 | Percentage of 3H-Citalopram binding induced by different
concentrations of linalool on the SERT assay. Linalyl acetate did not
show affinity to the serotonin transporter (data not shown). ***p < 0.0001 vs.
the lowest concentration tested.
Serotonin Transporter Assay
([3H]-Citalopram Binding Assay)
The effects of LEO on the SERT are displayed in Table 1,
showing moderate activity in this assay (citalopram IC50
value was 1.3 nM). LEO significantly displaced 3H-citalopram
from binding to the SERT in a dose-dependent manner,
which means that LEO might have an antidepressant-
like effect via this specific transporter. This effect was
also detected for linalool, one of the main constituents
of lavender essential oil (Figure 1), but not for linalyl
acetate.
Affinity for GABAA Receptor ([
3H]-Ro
15-1788 Binding Assay)
The affinity for the GABAA-benzodiazepine receptor, which
may lead to a nerve calming effect, was not detected (Table 1).
LEO had no effect in binding this ionotropic receptor.
Clonazepam (IC500.002 nM) was used as positive control
drug.
FIGURE 2 | Affinity of lavender essential oil (A) and linalool and linalyl
acetate (B) for the glutamate NMDA receptor. The displacement studies of
[3H]CGP39653 were performed on membranes obtained from rat brain
homogenates.
TABLE 2 | IC50 and Ki values of lavender essential oil (LEO) and
monoterpenes in the [3H]CGP39653 binding assay.
Essential oil IC50 (µl/ml) Ki (µl/ml)
LEO 0.04 ± 0.09 0.026 [0.022;0.030]
Monoterpenes IC50 (mM) Ki (mM)
Linalyl acetate 0.74 ± 0.18** 0.54 [0.47;0.62]
Linalool 2.97 ± 0.63 2.3 [2.1; 2.6]
**p < 0.01 vs. linalool; each IC50 value, determined from the “dose-response” curve, has
been converted into the Ki value using the Cheng Prusoff equation: (Ki = IC50 × [1/([L]/KD )
+ 1)]. (S)-Glu has a Ki value of 0.02µM.
Affinity for NMDA Receptor (CGP39653
Binding Assay)
Lavender Essential Oil (LEO) was found to be active
in the CGP39653 binding assay. Figure 2 shows the
profile of the affinities for the NMDA receptor and
Table 2 presents results in terms of IC50 and Ki values.
It can be observed that lavender was significantly active
showing a clear dose-response activity (Figure 2A). In
this case, linalool and linalyl acetate were also tested,
showing binding properties to the NMDA receptor
(Figure 2B).
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FIGURE 3 | Effect of 1µl/ml lavender essential oil (LEO) on hydrogen
peroxide induced toxicity on SH-SY5Y cells at 0 (A), 2 (B),and 24 h (C).
*p < 0.05 vs. medium only.
Effects of Lavender Oil against Hydrogen
Peroxide in SH-SY5Y Cells
As depicted in Figure 3A, when 1µl/ml lavender oil was
incubated 0 h before the addition of hydrogen peroxide
(H2O2), lavender oil only produced a significance difference
(∗p < 0.05, Two-way ANOVA) at 1,600µM of H2O2.
Same result was obtained when lavender oil was incubated
2 h prior the addition of H2O2 (
∗p < 0.05, Two-way
ANOVA) (Figure 3B). As shown in Figure 3C, when
lavender oil was incubated 24 h prior the addition of
H2O2 a significant reversion of cell death was obtained at
400, 800, and 1,600µM of H2O2 (
∗p < 0.05, Two-way
ANOVA).
Effects of Lavender Oil against Malonate in
SH-SY5Y Cells
Lavender oil did not protect from malonate induced
toxicity in any of the concentrations (0.05, 0.1, 0.5,
and 1µL/mL) or incubation times tested (0, 2, or 24 h;
Figure 4).
FIGURE 4 | Effect of lavender essential oil on malonate induced
toxicity on SH-SY5Y cells at 0 (A), 2 (B), and 24 h (C). ****p < 0.0001 vs.
0mM malonate in the respective lavender concentration.
Effects of Lavender Oil against Aβ25–35 in
SH-SY5Y Cells
As observed in Figure 5, lavender oil only produced a significant
effect against Aβ25–3515µM induced toxicity when it was
incubated 2 h before toxin addition (∗∗p < 0.01, Two-way
ANOVA; Figure 5B).
DISCUSSION
Lavender is used in pharmacy, phytotherapy and aromatherapy
to treat central nervous system disorders, such as anxiety,
stress, and sleep disorders. This essential oil is one of the best-
selling natural remedies and a common therapeutic tool for
physiotherapists and chiropractors.
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FIGURE 5 | Effect of 1µl/ml lavender essential oil (LEO) on
beta-amyloid induced toxicity on SH-SY5Y cells at 0 (A), 2 (B), and 24 h
(C). **p < 0.01 vs. 15µM beta-amyloid (medium only).
There has recently been an increase in the use of natural
therapies due to well-known side effects of common CNS drugs,
such as (BZD) and selective serotonin re-uptake inhibitors
(SSRI). Although BZD and SSRI have been widely used
in neuropharmacology, there is a need of developing new
therapeutic tools that play a role both in prevention and
treatment of mild CNS disorders.
In this sense, aromatherapy and some essentials oils have been
used for decades to induce nerve-calming effects and mood-
enhancing properties (Dobetsberger and Buchbauer, 2011).
Aromatherapy is a form of complementary and alternative
medicine (CAM) that uses plant essentials oils to affect the mood
or health of the patient (Wheatley, 2005) and some clinical
studies suggest that inhaled or topically applied essential oils
like lavender exert psychological and central nervous system
effects (Perry and Perry, 2006). It has also recently been stated
that essential oils may behave as antidepressants due to playing
an important role on neurotransmitter pathways, mainly in the
serotonin system (Lv et al., 2013).
Certain studies have reported pharmacological properties
of essential oils but there is little research on the molecular
mechanisms underlying the CNS effects. The ability of lavender
essential oil to interact with neuropharmacological targets, such
as MAO-A, the SERT and ionotropic receptors (GABAA and
NMDA) has been tested, as well as the protective potential against
neurotoxic agents, such as hydrogen peroxide, malonate and
amyloid peptide.
It was surprising that LEO had the capacity to bind
to the NMDA receptor, which was measured through the
CGP39653 binding assay. CGP39653 is a competitive antagonist,
being currently the ligand of choice for labeling NMDA
receptors. NMDA receptors are neurochemically classified as
ionotropic glutamate receptors (iGLURs) and are involved in
certain neurological and psychiatric disorders, such as epilepsy,
sustained-seizure damage, Parkinsonism, etc. For this reason
iGLURs are considered pharmacological targets in drug research
and development. LEO was able to displace CGP39653 binding
in a dose-dependent mode, which means that this oil may exert
nerve-calming effects via modulating NMDA receptors. This is
the first time that this affinity is reported and this fact could
explain the anti-agitation properties that have been found for
these products in animal and some clinical studies (Bradley et al.,
2009; Faturi et al., 2010; Kasper et al., 2010; Tsang and Ho,
2010; Woelk and Schlaefke, 2010; Chioca et al., 2011; Goes et al.,
2012; Hritcu et al., 2012; Schuwald et al., 2013). NMDA-receptor
activation by glutamate is also involved in neurotoxicity so our
essential oil might exert neuroprotection through the blockade of
this ionotropic receptor.
According to our data, these results are in the range of other
natural products that have been reported to show activity in this
target (Cho et al., 2001; Pedersen et al., 2008; Marchetti et al.,
2011).
Lavender essential oil has shown activity in animal and
human studies but according to Koulivand et al. (2013), due to
methodological inadequacies, small sample sizes, variations on
administration methods or the absence of placebos or control
groups in the studies, more standard experiments are needed to
confirm the benefits of lavender in CNS disorders. The molecular
mechanisms involved in lavender effects have been suggested
in other studies. For example, Huang et al. (2009) suggest
that lavender essential oil reversibly inhibited GABA-induced
currents in a concentration-dependent manner (0.01–1 mg/mL),
whereas no inhibition of NMDA- or AMPA-induced currents
was noted. In a recent study, Schuwald et al. (2013) identified a
standarized lavender essential oil (Silexan) as a potent anxiolytic
inhibiting voltage dependent calcium channels in synaptosomes,
primary hippocampal neurons and stably overexpressing cell
lines, in the same range as pregabaline.
Lavender essential oil is known to contain monoterpenes like
linalool and linalyl acetate, which seem to be responsible for the
activity according to our data and previous works (Cline et al.,
2008; Linck et al., 2010; Souto-Maior et al., 2011). The capacity of
linalool to interact with the glutamatergic system and the NMDA
receptor is not new as it has been previously described by other
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authors (Elisabetsky et al., 1995, 1999; Silva Brum et al., 2001;
Aprotosoaie et al., 2014); however, the ability of linalyl acetate
to bind the NMDA receptor has not been found to be reported
in previous works. It seems that lavender essential oil anxiolytic
effects is due to the fact that its main monoterpenes, linalool and
linalyl acetate, interact with the NMDA receptor.
It is very difficult to establish structure activity relationships
because linalyl acetate was inactive in the SERT assay, whereas the
activity of this compound was slightly higher than linalool in the
NMDA binding receptor assay. Linalool and linalyl acetate are
secondary metabolites classified as monoterpenes with a similar
structure consisting of a linear hydrocarbon chain of 10 carbons
(linalool) or 11 (linalyl acetate), being linalyl acetate the ester
of linalool. The free hydroxyl group in linalool seems to be
determinant for the activity in the SERT. On the contrary, the
activity on the NMDA receptor is increased when the acetate
group exists in the compound named linalyl acetate; limonene,
another monoterpenic compound found at high concentration
in Citrus essential oils, has also shown anxiolytic-like activity
with other targets involved (de Almeida et al., 2012; Lima et al.,
2013).
Other essential oils have been demonstrated to produce
changes in brain neurotransmitters which could explain its anti-
agitation properties. For example, ylang-ylang (Cananga odorata)
essential oil has shown anxiolytic effects in male mice decreasing
the dopamine concentration in the striatum and increasing the
serotonin concentration in the hippocampus (Zhang et al., 2016).
Surprisingly, linalool is one of the main components of this
essential oil. The essential oils obtained from Eugenia uniflora has
also demonstrated antidepressant-like activities in animal models
with the serotonergic and adrenergic systems being involved
(Victoria et al., 2013). Melissa officinalis essential oil, which is
also used as a natural sedative, has demonstrated a depressant
effect on neurotransmission but no inhibition of NMDA- or
AMPA-induced currents was detected (Abuhamdah et al., 2008).
Citrus aurantifolia (bitter orange) essential oil has also exhibited
anxiolytic-like effects mediated by 5-HT(1A)-receptors (Costa
et al., 2013). All these works put forward the idea that the
serotonergic system is involved in the nerve calming effects of
essential oils.
We have also observed that lavender and linalool inhibits
serotonergic targets, such as the SERT, which might explain why
lavender has shown antidepressant-like effects in animal and
human models (Cavanagh and Wilkinson, 2002; Akhondzadesh
et al., 2003; Hritcu et al., 2012). However, we did not observe
effects on the GABAA-receptor, which is in accordance with
results from a recent study (Chioca et al., 2013).
This study has been completed using neuroblasts from neural
human tissue (SH-SY5Y) exposed to different neurotoxic agents.
Lavender was able to protect the cells from the toxic insult
generated by hydrogen peroxide although it was not capable
to reduce malonate toxicity. Results from amyloid-β peptide
induced toxicity are not conclusive. However, this activity seems
to be in accordance with a previous study where lavender
essential oil showed neuroprotective properties against hydrogen
peroxide induced toxicity in PC12 cells (Xu et al., 2016). The
authors conclude that lavender protected the cells reducing LDH,
NO release, intracellular ROS accumulation and MMP loss.
CONCLUSION
Our study reveals for the first time that lavender exerts receptor
binding affinities with a relevant activity on the NMDA receptor.
According to our data, we can state that the anti-agitation and
antidepressant activities of lavender may be attributed at least in
part to the NMDA receptor modulation as well as an inhibition
of the SERT. Lavender essential oil also protected SH-SY5Y cells
from hydrogen peroxide induced neurotoxicity.
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